<SEC-DOCUMENT>0000939767-18-000023.txt : 20180226
<SEC-HEADER>0000939767-18-000023.hdr.sgml : 20180226
<ACCEPTANCE-DATETIME>20180226161133
ACCESSION NUMBER:		0000939767-18-000023
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20171229
FILED AS OF DATE:		20180226
DATE AS OF CHANGE:		20180226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		18640637

	BUSINESS ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>exel2017123110-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0FD9D4EE7E28618375C7B6B5E4967694"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM 10-K</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For the fiscal year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">or</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo2017a.jpg" alt="exellogo2017a.jpg" style="height:64px;width:192px;"></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><font style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">04-3257395</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">210 East Grand Ave.</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">South San Francisco, CA 94080</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(650) 837-7000</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Securities Registered Pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Common Stock $.001 Par Value per Share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Securities Registered Pursuant to Section&#160;12(g) of the Act:</font></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168; </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253; </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.  </font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:21%;"></td><td style="width:40%;"></td><td style="width:15%;"></td><td style="width:21%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  </font><font style="font-family:Wingdings;font-size:9pt;">&#168;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#168; </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">No&#160;</font><font style="font-family:Wingdings;font-size:9pt;">&#253;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter: </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">$7,116,352,282</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#32;(based on the closing sales price of the registrant&#8217;s common stock on </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">. Excludes an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">4,797,371</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#32;shares of the registrant&#8217;s common stock held by persons who were directors and/or executive officers of the registrant at</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">June&#160;30, 2017</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#32;on the basis that such persons may be deemed to have been affiliates of the registrant at such date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">As of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">February&#160;12, 2018</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">, there were </font><font style="font-family:Calibri,sans-serif;font-size:9pt;">296,307,278</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#32;shares of the registrant&#8217;s common stock outstanding.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-top:4px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Certain portions of the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than April 30, 2018, in connection with the registrant&#8217;s 2018 Annual Meeting of Stockholders are incorporated herein by reference into Part III of this Annual Report on Form 10-K. </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7F0290BFF8720281375AB6B62C06CEC5"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:77%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s48DC0592C44E21D4B712B6B62C261929"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE7DCF47D7937C7B195AAB6B5FABC222B"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE7DCF47D7937C7B195AAB6B5FABC222B">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s84027E596EA4FBE8C988B6B62DDB7E07"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s84027E596EA4FBE8C988B6B62DDB7E07">33</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1B.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sFC7296A2A6563E3EF82CB6B62E779D29"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sFC7296A2A6563E3EF82CB6B62E779D29">54</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s62F0349472B7D74FBABFB6B62EF388A9"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s62F0349472B7D74FBABFB6B62EF388A9">54</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s10CCCBFFC89E5DDF245BB6B62F1399E4"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s10CCCBFFC89E5DDF245BB6B62F1399E4">54</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA911878BDCDBD0431202B6B62F42563B"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA911878BDCDBD0431202B6B62F42563B">55</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s797A2BD1C2AAC6B9241CB6B630286A20"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6BEDD47E90A2A61BA997B6B63048627D"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6BEDD47E90A2A61BA997B6B63048627D">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s42F6166B50FB7B1E43A9B6B5F88763DA"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s42F6166B50FB7B1E43A9B6B5F88763DA">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;7.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s26F786427B5CBCA2ED7BB6B6D64D261E"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9B41A51773DB0223A1C6B6B630E4655E">58</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;7A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0A7F756E017C820EE403B6B5FBE521E3"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0A7F756E017C820EE403B6B5FBE521E3">73</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;8.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA5E8C1DD373EBD5E1799B6B5E4A5AD09"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA5E8C1DD373EBD5E1799B6B5E4A5AD09">74</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s55752E216BEC51A5AA06B6B63A940855"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s55752E216BEC51A5AA06B6B63A940855">112</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s19A492D68354AAE321A2B6B63AB3BDB2"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s19A492D68354AAE321A2B6B63AB3BDB2">112</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;9B.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAEABB55CCAB04D04CB31B6B63AD23D19"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sAEABB55CCAB04D04CB31B6B63AD23D19">114</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s135207A531F1ED06F61DB6B63AF19E79"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;10.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s27C80F5D5F56FB841600B6B63B118475"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s27C80F5D5F56FB841600B6B63B118475">114</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;11.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3C3CB975BD1ECAB3E241B6B63B4FF8D4"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3C3CB975BD1ECAB3E241B6B63B4FF8D4">114</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;12.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2310583CE13DA2FB1278B6B5FEB47879"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2310583CE13DA2FB1278B6B5FEB47879">114</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;13.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2310583CE13DA2FB1278B6B5FEB47879"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE0C1A29EB7DA22337C23B6B63B650CD8">115</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;14.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF13851D7B2DA56890090B6B63BB5CA23"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF13851D7B2DA56890090B6B63BB5CA23">115</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sCA04D21DC6BF99A67709B6B63BE5441B"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART IV</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;15.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5299B27509BEA9D19B7DB6B5ED78CF6D"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5299B27509BEA9D19B7DB6B5ED78CF6D">116</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;16.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9166F73531D0483F109BB6B63C24555B"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s9166F73531D0483F109BB6B63C24555B">121</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA580A848D6E176407C61B6B63C53C9FC"><font style="font-family:Calibri,sans-serif;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA580A848D6E176407C61B6B63C53C9FC">122</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1</font></div></div><hr style="page-break-after:always"><div><a name="s48DC0592C44E21D4B712B6B62C261929"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Some of the statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221; and elsewhere in this Annual Report on Form&#160;10-K are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;focus,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;encouraging&#8221; or the negative of such terms or other similar expressions identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font></div><div><a name="sE7DCF47D7937C7B195AAB6B5FABC222B"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Business</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma, or RCC, and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC&#174; (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc. (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown the potential to advance the treatment of patients with various forms of cancer and are the subject of broad clinical development programs for multiple potential oncology indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following is a summary of important information about our internally-discovered, marketed products:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:36%;"></td><td style="width:64%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="cabo01a.gif" alt="cabo01a.gif" style="height:78px;width:226px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">CABOMETYX&#160;(cabozantinib) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">was first approved by the U.S. Food and Drug Administration, or FDA, on April 25, 2016, for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy and by the European Com</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">mission, or EC, on September 9, 2016, similarly for the treatment of advanced RCC in adults following prior VEGF targeted therapy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. On December 19, 2017, the FDA approved the expanded indication for CABOMETYX to include previously untreated patients with advanced RCC, and o</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">n September 8, 2017, the European Medicines Agency, or EMA, validated the regulatory dossier for cabozantinib as a treatment for patients with previously untreated advanced RCC in the European Union, or EU. Outside the U.S. and Japan, CABOMETYX is marketed by our collaboration partner Ipsen Pharma SAS, or Ipsen. Should CABOMETYX be approved in Japan, it would be marketed by our collaboration partner Takeda Pharmaceutical Company Limited, or Takeda. In 2017, we generated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">$323.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in net product revenues from sales of CABOMETYX in the U.S. </font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:36%;"></td><td style="width:64%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="cometriq.jpg" alt="cometriq.jpg" style="height:54px;width:229px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">COMETRIQ&#160;(cabozantinib)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, our first marketed product, was approved by the FDA on November 29, 2012, for the treatment of patients with progressive, metastatic MTC. In March 2014, the EC granted COMETRIQ a similar, conditional marketing authorization for the treatment of adult patients with progressive, unresectable locally advanced or metastatic MTC. COMETRIQ is commercialized in the EU by Ipsen. In 2017, we generated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;in net product revenues from sales of COMETRIQ in the U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="cotellic.jpg" alt="cotellic.jpg" style="height:73px;width:208px;"></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">COTELLIC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#160;(cobimetinib)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;was approved by the FDA on November 10, 2015, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the U.S. It has also been approved in combination with vemurafenib in multiple other territories including the EU, Switzerland, Canada, Australia and Brazil. In 2017, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">$6.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;royalties on ex-U.S. sales of COTELLIC and recorded a net loss of $2.1 million related to our profit share from sales of COTELLIC in the U.S. under our collaboration agreement with Genentech. Cobimetinib is being evaluated in a broad development program consisting of more than 50 trials by Genentech. For additional information on the cobimetinib development program, see &#8220;Cobimetinib Development Program</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In support of our effort to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers, we are focused on maximizing the opportunity for our two internally discovered compounds, cabozantinib and cobimetinib. Over the course of 2017, the revenues generated from the sale of these products and from our collaboration agreements, coupled with disciplined expense management and elimination of the debt on our balance sheet, have created a capital structure upon which we believe we can continue to grow in a sustainable manner. As a result, we believe we are well positioned to drive the expansion and depth of our product offerings through the continued development of cabozantinib both alone and in combination with other therapies, Genentech&#8217;s cobimetinib development program, the resumption of our internal drug discovery activities, and the evaluation and execution of in-licensing and acquisition opportunities that align with our oncology drug development expertise.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Key Developments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2017, we achieved numerous commercial, regulatory, financial and business development milestones. We also continued to build the infrastructure necessary to support anticipated corporate growth and product development beyond our current pipeline. The key developments impacting our business in 2017 include: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Commercialization of CABOMETYX for Previously Treated Advanced RCC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In 2017, we continued to execute on the commercial launch of CABOMETYX for previously treated patients with advanced RCC. When the FDA approved our novel tyrosine kinase inhibitor, or TKI, for this indication based on the results of the phase 3 METEOR trial in April 2016, we were prepared to bring CABOMETYX to market with field sales, medical affairs and market access personnel of the highest caliber, experience and professionalism. Following the initial success of the CABOMETYX launch in 2016 and in an effort to provide patients with greater access to CABOMETYX, during 2017, we expanded our distribution channel. Meanwhile our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">promotional and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">medical affairs teams have continued to focus on educating physicians on CABOMETYX&#8217;s unique product profile. CABOMETYX is distinct from other approved treatment options for previously treated patients with advanced RCC because it is the first single agent therapy approved for this indication to demonstrate statistically significant and clinically meaningful improvements in three key efficacy parameters</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;overall survival, or OS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;progression-free survival, or PFS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and objective response rate, or ORR--in a global pivotal trial. This profile translated into strong product demand in 2017 as certain physicians prescribed CABOMETYX as a preferred new therapeutic option despite numerous competing products approved to treat advanced RCC. For additional information about CABOMETYX&#8217;s profile as expressed in METEOR, see &#8220;Cabozantinib Development Program</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;- Exelixis Sponsored Trials - RCC - METEOR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In markets outside the U.S. and Japan in 2017, we worked closely with our partner Ipsen in support of its regulatory strategy and commercialization efforts for CABOMETYX. Utilizing its established international oncology marketing expertise, Ipsen </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">continues to execute its commercialization plans, most recently receiving regulatory approval in Australia, Switzerland </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and South Korea, and having launched in France, Germany, Italy, Spain and the United Kingdom. Pricing and reimbursement negotiations have been completed or are actively ongoing in the majority of EU member states</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Expansion of CABOMETYX Label as a Treatment for Previously Untreated Advanced RCC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 19, 2017, approximately two months ahead of the assigned </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prescription Drug User Fee Act, or PDUFA, action date, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDA approved CABOMETYX for an expanded indication to include previously untreated patients with advanced RCC, the most common form of advanced kidney cancer in adults. Published studies indicate that there are a</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pproximately 30,000 patients in the U.S. and 68,000 patients globally with advanced kidney cancer who are drug-eligible, with an estimated 14,000 patients in the U.S. in the first-line setting. Utilizing our existing commercial and medical affairs organizations and established distribution network, we were prepared to bring CABOMETYX to all eligible patients in the U.S. who may benefit from this treatment option immediately upon approval of the expanded indication.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA&#8217;s priority review and early approval of CABOMETYX for this indication was based on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOSUN, a randomized phase 2 trial of cabozantinib versus sunitinib in patients with previously untreated advanced RCC, which was conducted by The Alliance for Clinical Trials in Oncology, or The Alliance, as part of our Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program, or NCI-CTEP. Cabozantinib met the study&#8217;s primary endpoint of improving PFS, as compared to sunitinib in patients with intermediate- or poor-risk disease. For additional information on the results of CABOSUN, see &#8220;Cabozantinib Development Program </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">- Clinical Trials Supporting Regulatory Approvals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Initiating the regulatory approval process outside of the U.S., Ipsen submitted to&#160;the EMA the regulatory dossier for CABOMETYX as a treatment for previously untreated, advanced or metastatic RCC in the&#160;EU&#160;on&#160;August 28, 2017 based on the CABOSUN trial results; the filing was subsequently validated on&#160;September 8, 2017.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Positive Results from the CELESTIAL Trial in Previously Treated Advanced HCC following Second Interim Analysis</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On October 16, 2017, we announced that CELESTIAL, our company-sponsored, global phase 3 trial comparing cabozantinib to placebo in patients with advanced hepatocellular carcinoma, or HCC, who had previously progressed on or were intolerant to sorafenib and up to one additional therapy, met its primary endpoint, with cabozantinib providing a statistically significant and clinically meaningful improvement in OS compared to placebo. Based on the results of CELESTIAL, we plan to submit a supplemental New Drug Application, or sNDA, to the FDA in the first quarter of 2018, for CABOMETYX as a treatment for patients with previously treated advanced HCC. Ipsen has informed us that it intends to submit the regulatory application in the EU for CABOMETYX as a treatment for patients with previously treated advanced HCC in the first half of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Published studies indicate that an estimated 800,000 new cases of HCC present each year worldwide, with 41,000 of these cases in the U.S. While patients with localized disease may be candidates for surgery or other therapies such as embolization, treatment options for advanced disease are limited. Currently, sorafenib is the only approved agent for the first-line treatment of advanced, unresectable HCC. Despite sorafenib treatment, however, patients with HCC typically progress, and only regorafenib and nivolumab are approved as treatment options for sorafenib-pretreated patients. Thus, previously treated advanced HCC still represents an area of substantial unmet medical need.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Evaluation of Cabozantinib in Combination with Multiple Immune Checkpoint Inhibitors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib has shown clinical anti-tumor activity in more than 20 forms of cancer; therefore, we are focused on advancing a broad cabozantinib clinical development program in order to fully investigate its therapeutic potential both alone and in combination with other therapies and potentially serve additional patient populations. In particular, given that clinical observations from an ongoing phase 1 trial evaluating cabozantinib in combination with Bristol-Meyers Squibb Company&#8217;s, or BMS&#8217;s, nivolumab, with or without ipilimumab, in patients with previously treated genitourinary tumors suggest treatment with cabozantinib results in a more immune-permissive tumor environment, we are interested in exploring the therapeutic potential of cabozantinib in combination with immune checkpoint inhibitors to treat a variety of types of cancer. Data from this trial showed that cabozantinib in combination with nivolumab demonstrated promising efficacy across a diverse range of genitourinary tumors, and also that patients can tolerate these drug combinations. We believe these promising early-stage clinical findings support continued, broad investigation of cabozantinib in combination with nivolumab and other immune checkpoint inhibitors. To that end, in collaboration with BMS, in July 2017, we initiated a phase 3 pivotal trial in previously untreated, advanced or metastatic RCC, which, pursuant to its amended protocol, is evaluating the combination of cabozantinib with BMS&#8217;s immune checkpoint inhibitor, nivolumab. We also initiated a phase 1/2 trial in collaboration with BMS in patients with both previously treated and previously untreated advanced HCC, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab, and there is strong rationale to evaluate the combination of checkpoint inhibitors and cabozantinib in various other tumor types, including bladder cancer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have not limited our clinical investigations to a single checkpoint inhibitor. In June 2017, we initiated a phase 1b trial with various expansion cohorts evaluating cabozantinib and atezolizumab, Roche&#8217;s PD-L1 checkpoint inhibitor, in patients with advanced genitourinary malignancies, including RCC and urothelial carcinoma, or UC. We subsequently amended the protocol in January 2018 to add four new expansion cohorts to this trial, which will now also include patients with non-small cell lung cancer, or NSCLC, and castration-resistant prostate cancer, or CRPC, in addition to previously included patients with RCC and UC. For additional information on our clinical collaboration agreements with BMS and Roche, see &#8220;Cabozantinib Development Program - </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Trials Conducted Under our Clinical Collaboration Agreements.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Expansion of Global Partnership for Cabozantinib to Japan</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 30, 2017, we continued to advance the global development and commercialization of cabozantinib by entering into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of this collaboration agreement, Takeda has exclusive commercialization rights for currently developed and potential future cabozantinib indications in Japan, and has also agreed to collaborate on cabozantinib&#8217;s future clinical development. In December 2017, Takeda confirmed that the first patient was enrolled in its bridging study evaluating cabozantinib in second-line advanced RCC in Japan. For additional information on our collaboration with Takeda, see &#8220;Collaborations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;- Cabozantinib Collaborations - Takeda Collaboration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Continued Development of COTELLIC and Resolution of Genentech Arbitration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Genentech continues to advance the development program for cobimetinib, with three phase 3 pivotal trials currently underway exploring the combination of cobimetinib with atezolizumab or atezolizumab alone in colorectal carcinoma, or CRC, (IMblaze370) and BRAF wild type melanoma&#160;(IMspire170), and the combination of cobimetinib with atezolizumab and vemurafenib in BRAF V600 mutant melanoma (IMspire150). Enrollment for IMblaze370 was completed in the first quarter of 2017, and Genentech has announced that top-line results for the trial are expected during the first half of 2018. For additional information on the cobimetinib development program, see &#8220;Cobimetinib Development Program</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2017, we amended our collaboration agreement with Genentech in connection with the final resolution of claims&#160;asserted in an arbitration proceeding by us against Genentech related to the development, pricing and commercialization of COTELLIC. The amendment provides for a favorably revised revenue and cost-sharing arrangement, that became effective as of July 1, 2017, and that is applicable to current and all potential future commercial uses of COTELLIC. Should the ongoing IMblaze370, IMspire170 and IMspire150 clinical trials prove positive and Genentech obtain regulatory approvals based on such positive results, we believe that with the revised revenue and cost-sharing arrangement, cobimetinib could provide us with another meaningful source of revenue.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Extinguishment of All Outstanding Indebtedness</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2017, we retired all of our outstanding debt, beginning with the repayment of our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$80.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;term loan with Silicon Valley Bank in March 2017. This repayment was followed by the June 2017 retirement of the Secured Convertible Notes due 2018 held by entities associated with Deerfield Management Company, L.P., or the Deerfield Notes, in consideration for a payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$123.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The Deerfield Notes were retired one year ahead of their July 2018 maturity date providing us with a savings of approximately $12.2 million in interest expense, net of the termination fee. As a result of the elimination of this indebtedness and increasing cash flow, we began to fund our ongoing business and growth primarily from business operations. For additional information on the repayment of our term loan with Silicon Valley Bank and the retirement of the Deerfield Notes, see &#8220;Note 6. Debt&#8221; to our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib inhibits the activity of tyrosine kinases, including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance and maintenance of the tumor microenvironment. Objective tumor responses have been observed in patients treated with cabozantinib in more than 20 individual tumor types investigated in phase 1 and 2 clinical trials to date, reflecting the medicine&#8217;s broad clinical potential. We are currently evaluating cabozantinib, both as a single agent and in combination with immune checkpoint inhibitors, in a broad development program comprising over 70 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial collaboration partners, sponsor some of those trials, while the remaining trials are conducted through our CRADA with NCI-CTEP or our investigator sponsored trial, or IST program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two summary tables of select cabozantinib clinical development activities, one listing studies evaluating the potential of cabozantinib as a single-agent, and another listing studies evaluating the potential of cabozantinib in combination with one or more immune checkpoint inhibitors, are below:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, SINGLE-AGENT</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Thyroid Cancer</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Progressive, metastatic medullary thyroid cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (EXAM)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Progressive, metastatic medullary thyroid cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Post-marketing study (EXAMINER)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Differentiated thyroid cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Renal Cell Carcinoma (RCC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line advanced RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. and EU (METEOR)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced RCC (including previously untreated RCC)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S. on December 19, 2017; filing accepted in EU, currently under regulatory review (CABOSUN)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First- or second-line papillary RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Randomized phase 2&#8224; (PAPMET)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Hepatocellular Carcinoma (HCC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line advanced HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (CELESTIAL) positive results; sNDA filing planned for Q1 2018 and EMA filing planned for 1H 2018 (Ipsen)</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Small Cell Lung Cancer (NSCLC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EGFR wild-type</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Molecular alterations in RET, ROS1, MET, AXL, or NTRK1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Trials </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic urothelial cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2 *</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Breast cancer with brain metastases</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Colorectal cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">High-grade uterine sarcomas</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2 &#167;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic gastrointestinal stromal tumor</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2 (CABOGIST)&#167;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pancreatic neuroendocrine tumors and carcinoid tumors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Plexiform neurofibromas (pediatric and adult cohorts)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Relapsed osteosarcoma or Ewing sarcoma</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Soft-tissue sarcomas</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through our IST program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8224; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through collaboration with NCI-CTEP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#167; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial sponsored by the European Organization for Research and Treatment of Cancer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CLINICAL DEVELOPMENT PROGRAM FOR CABOZANTINIB, IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combination Regimen</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#40aeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RCC</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First-line advanced RCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 pivotal trial (CheckMate 9ER)</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">HCC</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second- and later-line advanced HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1/2 (Checkmate 040)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Neoadjuvant locally advanced HCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#177; nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b*</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NSCLC</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced solid tumors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b started in 2017, eight planned expansion cohorts including NSCLC</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Trials in Genitourinary Tumors, including RCC, Urothelial Carcinoma (UC), and Castration-Resistant Prostate Cancer (CRPC)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Genitourinary tumors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab &#177; ipilimumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Advanced solid tumors</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 1b started in 2017, eight planned expansion cohorts including RCC, UC, and CRPC</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Clinical Trials</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Endometrial cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2&#8224;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Metastatic, triple negative breast cancer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ nivolumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 2*</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through our IST program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#8224; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial conducted through collaboration with NCI-CTEP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#167; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Trial sponsored by the European Organization for Research and Treatment of Cancer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trials Supporting Regulatory Approvals</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">MTC - EXAM</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">COMETRIQ&#8217;s safety and efficacy were assessed in an international, multi-center, randomized double-blinded controlled trial of 330 patients with progressive, metastatic MTC, known as EXAM. Patients were required to have evidence of progressive disease within 14 months prior to study entry. This assessment was performed by an independent radiology review committee, or IRRC, in 89% of patients and by the treating physicians in 11% of patients. Patients were randomized 2:1 to receive COMETRIQ 140 mg (n = 219) or placebo (n = 111) orally, once daily until disease progression determined by the treating physician or until intolerable toxicity. Randomization was stratified by age (&#8804; 65 years vs. &gt; 65 years) and prior use of a TKI. No cross-over was allowed at the time of progression. The primary endpoint was to compare PFS in patients receiving COMETRIQ versus patients receiving placebo. Secondary endpoints included ORR and OS. The main efficacy outcome measures of PFS, ORR and response duration were based on IRRC-confirmed events using modified Response Evaluation Criteria in Solid Tumors, or RECIST, which is a widely used set of rules that defines when cancer patients improve (&#8220;respond&#8221;), stay the same (&#8220;stabilize&#8221;) or worsen (&#8220;progress&#8221;) during treatments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EXAM served as the basis for the regulatory approval of COMETRIQ in the U.S. and EU. A statistically significant and clinically meaningful prolongation in PFS was demonstrated among COMETRIQ-treated patients compared to those receiving placebo (hazard ratio, or HR, 0.28; 95% confidence interval, or CI, 0.19-0.40; p&lt;0.0001), with median PFS of 11.2 months in the COMETRIQ arm and 4.0&#160;months in the placebo arm. Partial responses, or PRs, were observed only among patients in the COMETRIQ arm (27% vs. 0%; p&lt;0.0001). The median duration of objective response was 14.7 months (95% CI 11.1-19.3) for patients treated with COMETRIQ. The most commonly reported adverse drug reactions occurring in at least 25% of patients were diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome, or PPES, decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. In November 2014, we announced completion of the OS analysis, the secondary endpoint of the study. Consistent with an earlier interim analysis, there was no statistically significant difference in OS between the treatment arms. The median OS was 26.6 months for the COMETRIQ arm and 21.1 months for the placebo arm (HR 0.85; 95% CI 0.64-1.12; p = 0.2409). The subgroup analysis by RET M918T mutation status, a known negative prognostic factor in MTC, revealed an improvement in OS of 25.4 months for COMETRIQ-treated patients positive for the RET M918T mutation; the median OS was 44.3 months for the COMETRIQ arm and 18.9 months for the placebo arm (HR 0.60; 95% CI 0.38-0.95; p = </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">0.026, not adjusted for multiple subgroup testing). We presented the final results at the American Society of Clinical Oncology, or ASCO, 2015 Annual Meeting and submitted the results to regulatory authorities to satisfy post-marketing commitments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with the approval of COMETRIQ for the treatment of progressive, metastatic MTC, we were subject to post-marketing requirements, all of which have been satisfied, other than a requirement to conduct a clinical study comparing a lower dose of COMETRIQ with the labeled dose of 140 mg. This study is evaluating safety and PFS in progressive, metastatic MTC patients and is ongoing.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">RCC - METEOR</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2015, we announced positive results of METEOR, a phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with advanced RCC who have experienced disease progression following treatment with at least one prior VEGF receptor inhibitor. METEOR was initiated in May 2013. The trial was designed to enroll 650 patients at approximately 200 sites. Patients were stratified based on the number of prior VEGF receptor inhibitors received, and on commonly applied RCC risk criteria. Patients were randomized 1:1 to receive 60 mg of CABOMETYX daily or 10 mg of everolimus daily and no cross-over was allowed between the study arms. The METEOR trial was designed to provide adequate power to assess both the primary endpoint of PFS, and the secondary endpoint of OS. The trial protocol specified that the primary analysis of PFS would be conducted among the first 375 patients randomized while the secondary endpoint of OS would be conducted among all 650 patients randomized. This design was employed to ensure sufficient follow-up and a PFS profile that would not be primarily weighted toward early events. Such disproportionate weighting of events was a potential risk if the entire study population required for the secondary endpoint analysis of OS had also served as the population for the primary analysis of PFS. On September 26, 2015,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">The New England Journal of Medicine</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;published the complete, detailed positive results from the primary analysis of METEOR, and these results were also presented during the Presidential Session I at the European Cancer Congress 2015. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful increase in PFS for CABOMETYX, as determined by an IRRC among the first 375 patients enrolled. The median PFS was 7.4 months for the CABOMETYX arm versus 3.8 months for the everolimus arm, and the HR was 0.58 (95% CI 0.45-0.75; p&lt;001), corresponding to a 42% reduction in the rate of disease progression or death for CABOMETYX compared to everolimus. The trial also showed that CABOMETYX significantly improved the ORR. The most commonly reported adverse drug reactions occurring in at least 25% of patients were diarrhea, fatigue, nausea, decreased appetite, PPES, hypertension, vomiting, weight decreased, and constipation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of adverse events, or AEs, demonstrated that the frequency of AEs of any grade regardless of causality was approximately balanced between study arms, and the rate of treatment discontinuation due to AEs was 9% and 10% for CABOMETYX and everolimus, respectively. With additional follow-up for OS, the study also met its secondary endpoint of OS as presented in June 2016 at the ASCO 2016 Annual Meeting and published in Lancet Oncology. Compared with everolimus, CABOMETYX was associated with a 34% reduction in the rate of death and median OS was 21.4 months for patients receiving CABOMETYX versus 16.5 months for those receiving everolimus (HR 0.66; 95% CI 0.53-0.83; p=0.0003). </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2016, an analysis of PFS among all 658 patients enrolled was presented at the 2016 ASCO Genitourinary Cancers Symposium, and revealed consistent results with the primary analysis showing a median PFS of 7.4 months for the CABOMETYX arm versus 3.9 months for the everolimus arm, and the HR was 0.52 (95% CI 0.43-0.64; p&lt;0.001), corresponding to a 48% reduction in the rate of disease progression or death for CABOMETYX as compared to everolimus. In addition, subgroup analyses for PFS showed consistent beneficial effect of CABOMETYX versus everolimus; subgroups included: ECOG performance status; commonly applied RCC risk groups as described by Motzer et al.; organ involvement, including bone and visceral metastases and overall tumor burden; extent and type of prior VEGF receptor inhibitor therapy; and prior PD-1/PD-L1 therapy. For patients without prior PD-1/PD-L1 therapy, median PFS was 7.4 months for CABOMETYX and 3.9 months for everolimus (HR 0.54; 95% CI 0.44-0.66). For patients who had received prior PD-1/PD-L1 therapy, the median PFS for CABOMETYX was not reached, and the median PFS for everolimus was 4.1 months (HR 0.22; 95% CI 0.07-0.65). Subgroup analyses for ORR also showed consistent benefit for CABOMETYX as compared to everolimus.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the METEOR trial, the FDA approved CABOMETYX for the treatment of patients with advanced RCC following prior antiangiogenic therapy, and the EMA approved CABOMETYX for the treatment of advanced RCC in adults following prior VEGF targeted therapy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">RCC - CABOSUN</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2016, we announced detailed results from CABOSUN, a randomized phase 2 trial of cabozantinib in patients with previously untreated advanced RCC with intermediate- or poor-risk disease conducted by The Alliance under </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our CRADA with NCI-CTEP. CABOSUN was a randomized, open-label, active-controlled phase 2 trial that enrolled 157 patients with advanced RCC. Patients were randomized 1:1 to receive cabozantinib (60 mg once daily) or sunitinib (50 mg once daily, 4 weeks on followed by 2 weeks off). The primary endpoint was PFS. Secondary endpoints included OS and ORR. Eligible patients were required to have locally advanced or metastatic clear-cell RCC, ECOG performance status 0-2, and had to be intermediate or poor risk per the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">International Metastatic Renal Cell Carcinoma Database Consortium, or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">IMDC criteria (Heng,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Journal of Clinical Oncology</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, 2009). </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOSUN met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in investigator-assessed PFS compared with sunitinib.&#160;With a median follow-up of 21.4 months, cabozantinib demonstrated a 34% reduction in the rate of disease progression or death (HR 0.66; 95% CI 0.46-0.95; one-sided p=0.012). The median PFS for cabozantinib was 8.2 months versus 5.6 months for sunitinib, corresponding to a 2.6 months (46%) improvement favoring cabozantinib over sunitinib. PFS benefits were independent of the IMDC&#160;risk group (intermediate or poor risk) and presence or absence of bone metastases at baseline. The results for sunitinib were in line with a previously published retrospective analysis of 1,174 intermediate- and poor-risk RCC patients from the IMDC database, which documented a median PFS of 5.6 months with a first-line targeted therapy, mainly sunitinib, in this patient population. Investigator-assessed</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ORR was also significantly improved, at 33% (95% CI 23% - 44%) for cabozantinib versus 12% (95% CI 5.4% - 21%) for sunitinib. With a median follow-up of 22.8 months, median OS was 30.3 months for cabozantinib versus 21.8 months for sunitinib (HR 0.80; 95% CI 0.50 - 1.26). The most common grade 3 or 4 AEs with cabozantinib were hypertension (28%), diarrhea (10%), PPES (8%), and fatigue (6%); with sunitinib, they were hypertension (22%), fatigue (15%), diarrhea (11%), and thrombocytopenia (11%). Grade 5 AEs occurred in four patients (5%) in the cabozantinib group and five patients (7%) in the sunitinib group. Treatment-related grade 5 events occurred in three patients in the cabozantinib group (acute kidney injury, sepsis, and jejunal perforation) and three patients in the sunitinib group (sepsis, respiratory failure, and vascular disorders). The rate of treatment discontinuation because of AEs was 20% (n = 16) and 21% (n = 16) in the cabozantinib and sunitinib groups, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On September 19, 2017, updated results from CABOSUN were presented at the European Society for Medical Oncology, or ESMO, 2017&#160;Congress. The results included the analysis from a blinded IRC, which confirmed the primary efficacy endpoint results of investigator-assessed PFS, as well as an updated investigator-assessed analysis. Per the IRC analysis, cabozantinib demonstrated a statistically significant and clinically meaningful 52% reduction in the rate of disease progression or death (HR 0.48; 95% CI 0.31-0.74; two-sided p=0.0008). The median PFS for cabozantinib was 8.6 months versus 5.3 months for sunitinib, corresponding to a 3.3 month (62%) improvement favoring cabozantinib over sunitinib. The updated data sets and methods differ from the initial investigator analyses presented in 2016. The comprehensive image collection for IRC review used a later cut-off point (5 months) than the initial investigator analysis and followed a rigorous IRC review process. The analysis of IRC data applied&#160;FDA guidance for PFS analyses in oncology studies, including recommended censoring rules.&#160;Both the updated investigator assessment and IRC analysis demonstrated consistent and statistically significant improvement of PFS with cabozantinib as compared to sunitinib. The updated OS analysis had a data cut-off of&#160;July 1, 2017, and showed a favorable trend for patients randomized to cabozantinib compared to sunitinib that was not statistically significant. Median OS was 26.6 months for patients receiving cabozantinib versus 21.2 months for those receiving sunitinib (HR 0.80; 95% CI 0.53-1.21; two-sided p=0.29). The most common all-causality grade 3 or 4 AEs in more than 5% of patients for cabozantinib (N=78) and sunitinib (N=72), respectively, were diarrhea (10% vs. 11%), hypertension (28% vs. 21%), fatigue (6% vs. 17%), increased alanine aminotransferase (5% vs. 0%), decreased appetite (5% vs. 1%), PPES (8% vs. 4%), decreased platelet count (1% vs. 11%) and stomatitis (5% vs. 6%). 21% of patients in the cabozantinib arm and 22% of patients in the sunitinib arm discontinued treatment due to AEs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On the basis of the data from the CABOSUN trial, the FDA approved CABOMETYX for the treatment of patients with previously untreated, advanced or metastatic RCC on December 19, 2017, and we commenced our commercial launch of CABOMETYX for this new indication upon such approval. Additionally, o</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">n September 8, 2017, the EMA validated the regulatory dossier for cabozantinib as a treatment for previously untreated, advanced or metastatic RCC in the EU.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Exelixis Sponsored Trials</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">HCC - CELESTIAL</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, we announced positive results of CELESTIAL, our phase 3 pivotal trial comparing cabozantinib to placebo in patients with advanced HCC who had received previous treatment with sorafenib. The CELESTIAL trial, which we initiated in September 2013, was designed to enroll 760 patients who were intolerant to or who had received prior systemic therapy with sorafenib, could have received up to two prior systemic cancer therapies for advanced HCC, and must have progressed following at least one prior therapy. The CELESTIAL trial was conducted at more than 100 sites globally in 19 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">countries and enrollment was completed in September 2017. Patients were randomized 2:1 to receive 60 mg of cabozantinib daily or placebo and were stratified based on etiology of the disease (hepatitis C, hepatitis B or other), geographic region (Asia&#160;versus other regions) and presence of extrahepatic spread and/or macrovascular invasion (yes or no). No cross-over was allowed between the study arms. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The primary endpoint for the trial was OS, and secondary endpoints included ORR and PFS. Exploratory endpoints include patient-reported outcomes, biomarkers and safety. A total of 621 events provided the study with 90% power to detect a 32% increase in median OS (HR 0.76) at the final analysis. Two interim analyses were planned to be conducted at 50% and 75% of the planned 621 events. Following the first interim analysis, on September 6, 2016, we announced that CELESTIAL&#8217;s independent data monitoring committee, or IDMC, determined that the study should continue without modifications per the study protocol for a second interim analysis to take place once 75% of events had been observed. Subsequently, on October 16, 2017, following the second interim analysis, the IDMC, recommended that CELESTIAL be stopped for efficacy, providing a statistically significant and clinically meaningful improvement versus placebo in OS. On January 19, 2018,&#160;statistically significant and clinically meaningful positive results from the second interim analysis of CELESTIAL were presented during an oral session at the 2018 American Society of Clinical Oncology&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gastrointestinal Cancers Symposium. In the total population of second- and third-line patients, m</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">edian OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76; 95% CI 0.63-0.92; p=0.0049). Median PFS was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44; 95% CI 0.36-0.52; p&lt;0.0001). ORR was 4% with cabozantinib and 0.4% with placebo (p=0.0086). Disease control (PR or stable disease, or SD) was achieved by 64% of the cabozantinib group compared with 33% of the placebo group. In a subgroup analysis of patients whose only prior therapy for advanced HCC was sorafenib (70% of patients in the study), median OS was 11.3 months with cabozantinib versus 7.2 months with placebo (HR 0.70; 95% CI 0.55-0.88). PFS in the subgroup was 5.5 months with cabozantinib versus 1.9 months with placebo (HR 0.40; 95% CI 0.32-0.50). The most commonly reported grade 3 or 4 AEs occurring in at least 10% of the patients were PPES, hypertension, increased aspartate aminotransferase, fatigue and diarrhea. Treatment-related grade 5 AEs occurred in six patients in the cabozantinib group and included, hepatic failure, esophagobronchial fistula, portal vein thrombosis, upper gastrointestinal hemorrhage, pulmonary embolism and hepatorenal syndrome and in one patient in the placebo group (hepatic failure).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on the results of CELESTIAL, we plan to submit a sNDA to the FDA in the first quarter of 2018, for CABOMETYX as a treatment for patients with previously treated advanced HCC. Our partner, Ipsen, has informed us that it intends to submit a regulatory dossier for CABOMETYX as a treatment for patients with previously treated advanced HCC to the EMA in the first half of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trials Conducted Under our Clinical Collaboration Agreements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical observations from an ongoing phase 1 trial evaluating cabozantinib in combination with nivolumab, with or without ipilimumab, in patients with previously treated genitourinary tumors suggest that when cabozantinib is given with immune checkpoint inhibitors, the combination may result in a more immune-permissive tumor environment. In consideration of those results, in February 2017, we entered into individual clinical collaboration agreements with BMS and Roche, for the purpose of conducting clinical studies combining cabozantinib with BMS&#8217;s PD-1 and CTLA-4 immune checkpoint inhibitors and Roche&#8217;s anti-PD-L1 immune checkpoint inhibitor. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Combination Studies with BMS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We entered into a clinical trial collaboration agreement with BMS in February 2017 for the purpose of exploring the therapeutic potential of cabozantinib in combination with BMS&#8217;s immune checkpoint inhibitors, nivolumab and/or ipilimumab, to treat a variety of types of cancer. As part of the collaboration, we are evaluating various forms of these combinations in a phase 3 pivotal trial in previously untreated or metastatic advanced RCC and in a phase 1/2 trial in both previously treated and previously untreated advanced HCC. We also intend to evaluate these combinations in various other tumor types, including bladder cancer. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the terms of the collaboration agreement with BMS, each party granted to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug, or IND, application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial and unless otherwise agreed between the parties, costs for each such trial will be shared equally between the parties, unless two BMS compounds will </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">be utilized in such trial, in which case BMS will bear two-thirds of the costs for such study treatment arms and we will bear one-third of the costs. Unless earlier terminated, the collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. Upon termination by either party, the licenses granted to each party to conduct a combined therapy trial will terminate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">RCC - CheckMate 9ER</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 9ER is an open-label, randomized, multi-national phase 3 pivotal trial evaluating nivolumab in combination with cabozantinib or nivolumab and ipilimumab in combination with cabozantinib versus sunitinib in patients with previously untreated, advanced or metastatic RCC. The original trial protocol required patients to be randomized 1:1:1 to one of three arms: cabozantinib and nivolumab; cabozantinib, nivolumab and ipilimumab; or sunitinib. However, following the positive results of CheckMate 214, BMS&#8217;s phase 3 trial evaluating nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic RCC and in an effort to accelerate the development of the cabozantinib and nivolumab combination, the trial protocol was amended to remove the triplet combination.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The triplet combination continues to be evaluated in an ongoing phase 1b trial in patients with advanced genitourinary malignancies and a separate phase 3 trial evaluating the triplet combination versus nivolumab and ipilimumab is under evaluation. The modified protocol for the trial aims to enroll approximately 580 patients with previously untreated, advanced or metastatic RCC of all risk groups. Patients are being randomized 1:1 to receive 40 mg of cabozantinib daily and 240 mg of nivolumab every 2 weeks or 50 mg of sunitinib daily on a 4 week/2 week off schedule. The primary endpoint for the trial is PFS and the secondary endpoint is OS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">HCC - Checkmate 040</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CheckMate 040 is a phase 1/2 trial evaluating treatment regimens including cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab versus sorafenib in patients with previously treated and previously untreated advanced HCC. The protocol for the trial aims to enroll approximately 30 patients each to cohorts that will receive either 40 mg of cabozantinib daily and 3 mg of nivolumab every two weeks or 40 mg of cabozantinib daily, 3 mg of nivolumab every two weeks, and 1 mg ipilimumab every 3 weeks for a total of 4 administrations. The primary objectives for the cohorts are safety and tolerability, ORR and duration of response, or DOR, and the secondary objectives include time to progression, PFS and OS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Combination Study with Roche - Locally Advanced or Metastatic Solid Tumors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a master clinical supply agreement with Roche for the purpose of evaluating cabozantinib and atezolizumab in locally advanced or metastatic solid tumors. Pursuant to the terms of this agreement with Roche, in June 2017, we initiated a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. We are the trial sponsor, and Roche is providing atezolizumab free of charge.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The study is divided into two parts: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase of the trial is enrolling up to 36 patients either with advanced RCC with or without prior systemic therapy or with inoperable, locally advanced, metastatic or recurrent UC (including renal, pelvis, ureter, urinary bladder and urethra) after prior platinum-based therapy. The primary objective is to determine the optimal dose and schedule of daily oral administration of cabozantinib when given in combination with atezolizumab to inform the trial&#8217;s subsequent expansion stage. Cabozantinib doses of 40 mg daily and 60 mg daily are being evaluated. All patients will receive the standard atezolizumab dosing regimen of 1200 mg infusion once every 3 weeks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we amended the protocol to add four new expansion cohorts to the trial, which will now also include patients with NSCLC and CRPC, in addition to previously included patients with RCC and UC. The primary objective in the expansion stage of this trial remains to determine the ORR in each cohort. Once the recommended dose and schedule are determined, which is anticipated to occur in the first half of 2018, the trial will begin to enroll the eight expansion cohorts, which are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with advanced non-squamous NSCLC without a defined tumor genetic alteration (EGFR, ALK, ROS1, or BRAF) who have not received prior therapy with an immune checkpoint inhibitor;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with NSCLC without a defined tumor genetic alteration who have progressed following treatment with an immune checkpoint inhibitor;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who have progressed following treatment with an immune checkpoint inhibitor;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with CRPC who have previously received enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with RCC with clear cell histology who have not had prior systemic anticancer therapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who have progressed on or after platinum-containing chemotherapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced or metastatic disease; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patients with UC who are eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy for inoperable, locally advanced or metastatic disease.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Each expansion cohort will initially enroll approximately 30 patients, although the cohorts of patients with UC or NSCLC who have been previously treated with an immune checkpoint inhibitor may enroll up to 80 each, for a total of up to 340 patients. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trials Conducted through our CRADA with NCI-CTEP and our IST Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2011, we entered into a CRADA with NCI-CTEP for the clinical development of cabozantinib. Through our CRADA with NCI-CTEP and our IST program we have been able to expand the cabozantinib development program while avoiding over-burdening our internal development resources. Our CRADA reflects a major commitment by NCI-CTEP to support the broad exploration of cabozantinib&#8217;s potential in a wide variety of cancers, each representing a substantial unmet medical need. Through this mechanism, NCI-CTEP provides funding for as many as 20 active clinical trials of cabozantinib each year for a five-year period. The term of the CRADA was extended in October 2016 for an additional five-year period through October 2021, provided that both parties maintain the right to terminate the CRADA for any reason upon sixty days&#8217; notice, for an uncured material breach upon thirty days&#8217; notice and immediately for safety concerns. IND applications for trials under the CRADA are held by NCI-CTEP. NCI-CTEP also retains rights to any inventions made in whole or in part by NCI-CTEP investigators.&#160;However, for inventions that claim the use and/or the composition of cabozantinib, we have an automatic option to elect a worldwide, non-exclusive license to cabozantinib inventions for commercial purposes, with the right to sublicense to affiliates or collaborators working on our behalf, as well as an additional, separate option to negotiate an exclusive license to cabozantinib inventions.&#160;Further, before any trial proposed under the CRADA may commence, the protocol is subject to our review and approval, and the satisfaction of certain other conditions. We believe our CRADA with NCI-CTEP has and will enable us to continue to expand the cabozantinib development program broadly in a cost-efficient manner.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Advanced Genitourinary Tumors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Results from a phase 1 trial evaluating cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors being conducted under our CRADA with NCI-CTEP were first presented at the ESMO 2016 Congress in October 2016 and most recently updated at the 2018 ASCO Genitourinary Cancers Symposium in February 2018. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The primary endpoint of the trial is to determine the dose-limiting toxicity and recommended doses of the doublet and triplet combinations for later stage clinical studies. The secondary endpoint is clinical response rate as assessed by RECIST 1.1.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The updated data reported results from 78 patients treated with either cabozantinib and nivolumab with or without ipilimumab. The initial part of the study determined the recommended dose for each treatment at four dose levels. In all, 49 patients were treated with the doublet combination of cabozantinib and nivolumab and 29 patients were treated with the triplet combination of cabozantinib, nivolumab and ipilimumab. Nineteen patients with metastatic UC were evaluable for response with a median follow up of 15.7 months. Thirteen patients with previously treated metastatic RCC were evaluable for response.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For the metastatic UC cohort, the ORR across all treatment groups was 42% (2 complete responses, or CRs, and 6 PRs of 19 patients) and the disease control rate, or DCR, (DCR = CR, PR and SD) was 84%. Seven of eight (88%) metastatic UC patients with an objective response had not progressed at the time of the data cut-off. Median PFS in this patient population was 12.8 months and the OS rate at 12 months was 77%. Among the 13 patients with metastatic RCC who were evaluable for response, ORR was 54 percent (7 PRs of 13 patients) and the DCR was 100 percent. In the overall study the ORR in 64 evaluable patients was 36% (3 CRs and 20 PRs) with a median DOR of 24 months. 78 patients were included in the safety analysis. Expected immune-related events including colitis, meningitis, hepatitis, pneumonitis, and endocrine disorders occurred at a low frequency. No dose-limiting toxicity was observed in the study. Based on general tolerability, the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recommended cabozantinib dose for the expanded dose cohorts and for future late stage evaluation has been determined as cabozantinib at 40 mg daily oral dose combined with nivolumab at 3 mg/kg every 2 weeks and ipilimumab at 1 mg/kg every 3 weeks for 4 doses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Treatment-related grade 3 or 4 AEs (&gt;5% of patients) observed in the doublet combination included lipase increased (16%), hypophosphatemia (14%), neutrophil count decreased (12%), hypertension (8%) and fatigue (6%). Grade 3 or 4 AEs (&gt;5% of patients) observed in the triplet combination included hypophosphatemia (21%), lymphocyte count decreased (14%), ALT increased (14%), lipase increased (14%), AST increased (10%), hypertension (10%), diarrhea (10%), hypokalemia (10%), fatigue (7%), hyponatremia (7%) and amylase increased (7%). Grade 3 or 4 immune-related AEs for the doublet combination included colitis, aseptic meningitis, and hepatitis (one patient each) and for the triplet combination colitis (one patient) and hepatitis (two patients). There were no treatment-related deaths.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe these promising early stage clinical findings support further investigation of cabozantinib in combination with nivolumab and other immune checkpoint inhibitors in a number of genitourinary tumors. Based on these phase 1 trial results, we initiated CheckMate 9ER, a phase 3 pivotal trial in patients with previously untreated, advanced or metastatic RCC, which, pursuant to its amended protocol, is evaluating the combination of cabozantinib with BMS&#8217;s nivolumab.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">NSCLC</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2014, we announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type NSCLC. This trial (Study E1512) was sponsored through our CRADA with NCI-CTEP and was conducted by the ECOG-ACRIN Cancer Research Group. It enrolled 125 patients with EGFR wild-type metastatic NSCLC who had received at least one or two prior chemotherapy regimens; of these, 111 patients were evaluable for efficacy and 118 patients were evaluable for safety. Patients were randomized 1:1:1 to receive erlotinib (150 mg daily), cabozantinib (60 mg daily), or the combination of erlotinib plus cabozantinib (150 mg plus 40 mg daily).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The positive results from this trial were reported at the ASCO 2015 Annual Meeting on May 31, 2015, and subsequently published online in Lancet Oncology on November 4, 2016. The study met its primary endpoint, demonstrating significant increases in PFS for cabozantinib and the combination of cabozantinib plus erlotinib when individually compared to the erlotinib arm. The median PFS for the combination of cabozantinib and erlotinib was 4.7 months versus 1.8 months for erlotinib alone, a more than two-fold increase. The HR was 0.37 (80% CI 0.25-0.53, p=0.0003), which corresponds to a 63% reduction in the rate of disease worsening. The median PFS for cabozantinib monotherapy was 4.3 months versus 1.8 months for erlotinib alone, and the HR was 0.39 (80% CI 0.27-0.55, p=0.0003), corresponding to a 61% reduction in the rate of disease worsening. OS was a secondary endpoint of the trial. Median OS was 13.3 months for the combination of cabozantinib and erlotinib, and 9.2 months for cabozantinib alone, as compared to 5.1 months for erlotinib alone. When individually compared to the erlotinib arm, HR for OS was 0.51 (p=0.011), corresponding to a 49% reduction in the rate of death for the combination of cabozantinib plus erlotinib, and 0.68 (p=0.071), corresponding to a 32% reduction in the rate of death for the cabozantinib monotherapy arm. ORR, another secondary endpoint, was 3% for the combination arm (1 PR), 11% (4 PRs) for the cabozantinib monotherapy arm, and 3% (1 PR) for the erlotinib arm. SD as a best response was observed in 46% of patients in the combination arm and 50% in the cabozantinib monotherapy arm, compared with 16% in the erlotinib arm. 119 patients were evaluable for safety. The most common treatment-related AEs grade 3 or higher, for the combination arm (n=39) were: diarrhea (28%), fatigue (15%), and anorexia (8%). For the cabozantinib monotherapy arm, the most common AEs, grade 3 or higher, were: hypertension (25%), fatigue (15%), mucositis (10%), diarrhea (8%), and thromboembolic events (8%). The most common AEs, grade 3 or higher, for the erlotinib arm were fatigue (13%) and diarrhea (8%). Overall, the rate of grade 3 or higher AEs was 72% in the combination arm, 70% in the cabozantinib monotherapy arm, and 33% in the erlotinib arm.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Informed by these clinical results, we are working with clinical collaborators to explore cabozantinib&#8217;s further development in NSCLC, including potential combination approaches with immune checkpoint inhibitors, such as within one of the expansion cohorts of our phase 1b study with Roche evaluating the combination of cabozantinib and atezolizumab.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other Cancer Indications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are 31 ongoing and 29 planned externally sponsored trials evaluating the clinical and therapeutic potential of cabozantinib, including those administered through our CRADA with NCI-CTEP and our IST program.&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Like our CRADA with NCI-CTEP, our IST program helps us to continue to evaluate cabozantinib across a broad range of tumor types. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These externally sponsored trials include signal seeking studies of single-agent cabozantinib, novel combinations, and randomized trials.&#160;The monotherapy trials are focused on solid tumors including genitourinary neoplasms, gastrointestinal malignancies, lung cancer and a variety of less common tumor types.&#160;The combination studies include trials combining cabozantinib with several different immune checkpoint inhibitors, as well as studies adding cabozantinib to monoclonal antibodies and small molecules which target specific cellular pathways.&#160;Randomized trials within the CRADA include a phase 3 study in neuroendocrine tumors and phase 2 trials in both endometrial cancer in combination with checkpoint inhibitors and in prostate cancer in combination with docetaxel.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A complete listing of all ongoing cabozantinib trials can be found at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:underline;">www.ClinicalTrials.gov</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cobimetinib Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to the advances made under our cabozantinib development program, significant progress continues to be made with respect to the clinical development, regulatory status and commercial potential of cobimetinib. Cobimetinib is a reversible inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors.&#160; Cobimetinib is being evaluated in a broad development program consisting of more than 50 clinical trials by Genentech or through Genentech&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">investigator sponsored trial program</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A summary table of Genentech&#8217;s ongoing phase 3 cobimetinib development activities, all of which are sponsored by Genentech, is provided below:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Combination Regimen</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Status Update</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Metastatic or Unresectable Locally Advanced Melanoma</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">BRAF mutation-positive</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ vemurafenib</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approved in U.S., EU and other territories</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First-line BRAF mutation-positive</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab + vemurafenib</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 (IMspire150)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First-line BRAF wild-type</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 (IMspire170) </font></div></td></tr><tr><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Colorectal Cancer</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third-line advanced or metastatic disease</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">+ atezolizumab</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phase 3 (IMblaze370); data expected in H1 2018 (per Genentech guidance)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Melanoma - coBRIM</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2014, we announced positive top-line results from coBRIM, the phase 3 pivotal trial conducted by Genentech evaluating cobimetinib in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600E or V600K mutation. Data were subsequently presented at ESMO in September 2014. The trial met its primary endpoint of demonstrating a statistically significant increase in investigator-determined PFS. The median PFS was 9.9 months for the combination of cobimetinib and vemurafenib versus 6.2 months for vemurafenib alone (HR 0.51; 95 percent CI 0.39-0.68; p&lt;0.0001), demonstrating the combination reduced the risk of the disease worsening by half (49 percent). The median PFS as established by an IRRC, a secondary endpoint, was 11.3 months for the combination arm compared to 6.0 months for the control arm (HR 0.60; 95 percent CI 0.45-0.79; p=0.0003). ORR, another secondary endpoint, was 68% for the combination versus 45% for vemurafenib alone (p&lt;0.0001). Updated results for PFS and ORR from coBRIM were presented at the ASCO 2015 Annual Meeting and showed a median PFS of 12.3 months for vemurafenib plus cobimetinib versus 7.2 months for vemurafenib alone (HR 0.58; 95 percent CI 0.46-0.72) and an ORR of 70% for the combination of vemurafenib and cobimetinib versus 50% for vemurafenib alone. In November 2015, we announced that the coBRIM trial also met its OS secondary endpoint, demonstrating a statistically significant increase in OS for the combination of cobimetinib and vemurafenib compared to vemurafenib monotherapy. The median OS was 22.3 months for the combination of cobimetinib and vemurafenib versus 17.4 months for vemurafenib alone, corresponding to a 30% reduction in the rate of death for the combination as compared to vemurafenib alone (HR 0.70; 95 percent CI 0.55-0.90; p= 0.005). The safety profile of the combination was consistent with that observed in a previous study. The most common adverse drug reactions for COTELLIC occurring in at least 20% of patients were diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CoBRIM served as the basis for the regulatory approval of COTELLIC in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma in the U.S., Switzerland, the EU, Canada, Australia, Brazil and other countries.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">CRC - IMblaze370</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, Genentech initiated IMblaze370, a phase 3 pivotal trial evaluating the combination of cobimetinib and atezolizumab, an anti-PD-L1 antibody, or atezolizumab alone versus regorafenib, in unresectable locally advanced or metastatic CRC patients who have received at least two lines of prior cytotoxic chemotherapy. IMblaze370 was informed by results from Genentech&#8217;s ongoing phase 1b trial of the same combination in advanced CRC. The trial is designed to enroll 360 patients who have received at least two prior chemotherapies in the metastatic disease setting. Enrollment for IMblaze370 was completed in the first quarter of 2017, and Genentech has announced that top-line results for the trial are expected during the first half of 2018. The primary endpoint of the trial is OS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Melanoma - IMspire150</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, Genentech initiated IMspire150, a phase 3 pivotal trial evaluating the combination of cobimetinib, vemurafenib and atezolizumab vs. cobimetinib plus vemurafenib in previously untreated BRAF V600 mutation positive patients with metastatic or unresectable locally advanced melanoma. This trial was based on the results of Genentech&#8217;s ongoing phase 1b trial in the same patient population. The trial is designed to enroll 500 patients, and the primary endpoint is PFS. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Melanoma - IMspire170</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, Genentech initiated IMspire170, a phase 3 trial comparing cobimetinib plus atezolizumab to pembrolizumab in previously untreated BRAF WT patients with metastatic or unresectable locally advanced melanoma. IMspire170 was based on the results of Genentech&#8217;s ongoing phase 1b trial in the same patient population. The trial is designed to enroll 500 patients with primary endpoints of PFS and OS, and the first patient was enrolled in December 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other Cancer Indications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to coBRIM, IMblaze370, IMspire150 and IMspire170, additional earlier-stage clinical trials are ongoing studying the combination of cobimetinib with a variety of agents in multiple tumor types. These include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the combination of cobimetinib and vemurafenib in additional melanoma patient populations and settings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a phase 2 trial of cobimetinib in combination with taxanes, with or without atezolizumab in first-line triple negative breast cancer (COLET);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 2 studies of cobimetinib in combination with atezolizumab in RCC, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">head and neck squamous cell carcinoma, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">UC and hormone receptor positive, HER2 negative breast cancer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 1/2 studies of cobimetinib in combination with atezolizumab in melanoma and NSCLC, in combination with vemurafenib and atezolizumab in melanoma, and in combination with venetoclax in relapsed or refractory acute myeloid leukemia and multiple myeloma;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a phase 1b study evaluating the safety, tolerability and pharmacokinetics of cobimetinib in combination with atezolizumab and bevacizumab in patients with metastatic CRC; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a phase 1b/2 study of cobimetinib in combination with atezolizumab (one arm of a randomized umbrella study) in metastatic pancreatic ductal adenocarcinoma.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A complete listing of all ongoing cobimetinib trials can be found at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:underline;">www.ClinicalTrials.gov</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">XL888 Development Program</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XL888 is an Exelixis-discovered highly potent small molecule oral inhibitor of Heat Shock Protein 90, a molecular chaperone protein that affects the activity and stability of a range of key regulatory proteins, including kinases such as BRAF, MET and VEGFR2, which are implicated in cancer cell proliferation and survival. Based on clinical data, investigators at the H. Lee Moffitt Cancer Center initiated an investigator-sponsored phase 1 trial, evaluating the safety and activity of XL888 in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma. In November 2014, we announced positive preliminary results from this phase 1 trial. The primary endpoint of the trial was to determine the safety and tolerability of the combination, including determination of a maximum tolerated dose, or MTD, for XL888. Secondary endpoints included ORR (RECIST-1 criteria), estimates of PFS and OS, and analysis of pharmacodynamic biomarkers. The trial had enrolled fifteen subjects, and at the time of data cut-off, objective tumor regression was observed in 11 of 12 response-evaluable patients (two CRs and nine PRs), for an ORR of 92%. Safety data for the combination identified tolerable dose levels of XL888 with full dose vemurafenib.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on these results, as well as findings from coBRIM, the phase 3 pivotal trial of cobimetinib, an Exelixis-discovered MEK inhibitor, and vemurafenib in previously untreated metastatic melanoma patients with a BRAF V600E or V600K mutation, investigators at the Moffitt Cancer Center initiated a phase 1b IST of the triple combination of vemurafenib, cobimetinib, and XL888 in a similar patient population during the second quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Drug Discovery and Business Development Programs</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are actively focused on expanding our pipeline through internal drug discovery and targeted business development activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Drug Discovery</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In 2016, we resumed internal drug discovery efforts with the goal of identifying novel and promising therapeutic candidates to advance into clinical trials. From 2000 until 2012, we had an active Discovery group that advanced 22 compounds to the IND stage, either independently or with collaboration partners, including cabozantinib and cobimetinib. We built significant infrastructure, including a library of 4.6 million compounds, and gained extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our new discovery organization is leveraging that history in a focused and measured manner. We are concentrating our in-house work on the most demanding aspects of lead optimization and use contract research organizations to support more routine activities, thereby minimizing our internal footprint while still maintaining an agile, competitive approach. We are and will continue to be judicious in the selection of targets, focusing on those with robust preclinical validation datasets. We anticipate that our experience and ability to identify high quality lead compounds through use of our propriety compound library will permit us to prosecute competitive and productive discovery programs in areas of high potential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Business Development</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Building upon our existing collaborative relationships, we are focused on entering into additional partnerships or licensing agreements for attractive oncology assets that would augment our development pipeline thereby utilizing our established and validated clinical development infrastructure. In addition we are seeking external partnerships around assets and new technologies that complement our in house drug discovery efforts. These partnerships are aimed at expanding our ability to discover, develop and commercialize novel therapies with the aim of providing new treatment options for cancer patients and their physicians.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2018, we entered into an exclusive collaboration and license agreement with&#160;StemSynergy Therapeutics, Inc. for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha, or CK1&#945;, a component of the Wnt signaling pathway implicated in key oncogenic processes. Activation of &#946;-catenin, a key downstream component of the pathway, is increased in multiple tumors, including a majority of colorectal cancers, where mutations in the APC gene that result in &#946;-catenin stabilization are prevalent. Compounds targeting CK1&#945; have also been shown to induce degradation of &#946;-catenin and pygopus, another member of the pathway, in preclinical CRC models, and to inhibit the growth of tumors. Importantly, their GI-sparing qualities may help overcome limitations of other approaches targeting the Wnt pathway. Under the terms of the agreement,&#160;we&#160;will partner with StemSynergy to conduct preclinical and clinical studies with compounds targeting CK1&#945;.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with Ipsen and Takeda for cabozantinib, Genentech for cobimetinib, and other collaborations with leading pharmaceutical companies including, Daiichi Sankyo Company Limited, or Daiichi Sankyo, Merck (known as MSD outside of the U.S. and Canada), BMS, and Sanofi for compounds and programs in our portfolio. Under each of our collaborations, we are entitled to receive milestones and royalties or, in the case of cobimetinib, royalties from sales outside the U.S. and a share of profits (or losses) from commercialization in the U.S. For information on our collaboration agreements focused solely on the clinical development of cabozantinib in combination with immune checkpoint inhibitors, see &#8220;Cabozantinib Development Program - </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Trials Conducted Under our Clinical Collaboration Agreements.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cabozantinib Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Ipsen Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of $210.0 million. As of December 31, 2017, we achieved aggregate milestone payments of $125.0 million related to regulatory and commercial progress by Ipsen since the inception of the collaboration agreement. We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$209.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including milestone payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$40.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upon EMA filing and the approval of cabozantinib as a treatment for patients with previously treated advanced HCC and additional milestone payments for other future indications and/or jurisdictions. The collaboration agreement also provides that we will be eligible to receive contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$546.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with the achievement of specified levels of Ipsen sales to end users. We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. Excluding Ipsen sales in Canada, we received a 2% royalty on the first $50.0 million of net sales</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was achieved in the fourth quarter of 2017, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and are entitled to receive a 12% royalty on the next $100.0 million of net sales, and following this initial $150.0 million of net sales, we are then entitled to receive a tiered royalty of 22% to 26% on annual net sales. These tiers will reset each calendar year. In Canada, we are entitled to receive a tiered royalty of 22% </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of annual net sales and a tiered royalty thereafter to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;26% on annual net sales; these tiers will also reset each calendar year. As of December 31, 2017, we have earned royalties of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on net sales of cabozantinib by Ipsen since the inception of the collaboration agreement. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for 35% of such costs, provided Ipsen chooses to opt into such trials. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In accordance with the collaboration agreement, Ipsen has opted into and is co-funding: CheckMate 9ER, subject to re-confirmation following the protocol amendment; CheckMate 040 (except for the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen in February 2016, which, pursuant to its amended terms, effective October 2017, we will supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan, indefinitely.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) ten years after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the FDA or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen terminated only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;$50.0 million upfront nonrefundable payment from Takeda. We are eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$95.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestones payments for potential future indications. The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with potential sales milestones. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;15%&#160;to&#160;24%&#160;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, and following this initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, we are then entitled to receive a tiered royalty of 20%&#160;to&#160;30%&#160;on annual net sales. These tiers will reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for 20% of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and 100% of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the manufacture and supply of cabozantinib to Takeda. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) two years after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first six years of the collaboration will constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application, or MAA, in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cobimetinib Collaboration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we were responsible for developing cobimetinib through the determination of the MTD in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, which Genentech could exercise after receipt of certain phase 1 data from us. In March&#160;2008, Genentech exercised its option to co-develop cobimetinib, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. We received aggregate upfront and milestone payments of&#160;$50.0&#160;million under our collaboration agreement with Genentech and are not eligible for any additional milestone payments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allows for us to provide up to 25% of the total sales force for approved cobimetinib indications in the U.S. Between November 2015 and December 2017, we fielded 25%&#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">positive advanced melanoma in the U.S. However, following a recent commercial review, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive 50% of profits and losses from the first $200.0 million of U.S. actual sales, decreasing to 30% of profits and losses from U.S. actual sales in excess of $400.0 million. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These tiers will reset each calendar year. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement, or the Genentech Collaboration P&amp;L, is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to the commercialization of our first product, COMETRIQ, our primary business strategy was focused on the development and out-license of compounds to pharmaceutical and biotechnology companies under collaboration agreements that allowed us to retain economic participation in compounds and support additional development of our proprietary products.&#160;Our collaboration agreements with Daiichi Sankyo, Merck, BMS and Sanofi described below are representative of this historical strategy. We have since evolved and are now a fully-integrated biopharmaceutical company focused on maximizing the opportunity for our two internally discovered compounds, cabozantinib and cobimetinib, to improve care and outcomes for people with cancer around the world. While our historical collaboration agreements described below have the potential to provide meaningful future revenue in the aggregate, we do not expect to receive substantial revenues from these historical collaboration agreements unless and until our partnered compounds enter late-stage clinical development and/or receive marketing approval from the FDA, if ever, when the milestone payments, royalties or other rights and benefits under our historical collaboration agreements become more substantial and material to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to our partnered compounds, other than cabozantinib and cobimetinib, we are eligible to receive potential contingent payments totaling approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.9 billion</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate on a non-risk adjusted basis, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are related to clinical development milestones, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are related to regulatory milestones and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are related to commercial milestones, all to be achieved by the various collaborators, which may not be paid, if at all, until certain conditions are met. Since we do not control the research, development or commercialization of any of our other partnered compounds that would generate these milestones, we are not able to reasonably estimate when, if at all, any milestone payments or royalties may be payable by our collaborators. In addition, most of the collaborations for our other partnered compounds are at early stages of development. Successfully developing a product candidate, obtaining regulatory approval and ultimately commercializing it is a significantly lengthy and highly uncertain process which entails a significant risk of failure. In addition, business combinations, changes in a collaborator&#8217;s business strategy and financial difficulties or other factors could result in a collaborator abandoning or delaying development of a partnered compound. As such, the remaining potential contingent payments associated with our historical collaboration agreements involve a substantial degree of risk to achieve and may never be received. Accordingly, we do not expect, and investors should not assume, that we will receive all of the potential contingent payments described above and it is possible that we may never receive any additional significant milestone or other payments under these historical collaboration agreements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Daiichi Sankyo</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the mineralocorticoid receptor, or MR, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including CS-3150/esaxerenone (a specific rotational isomer of XL550). Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the research term, which concluded in November 2007, we jointly identified drug candidates with Daiichi Sankyo for further development. For each product from the collaboration, we are entitled to receive payments upon attainment of pre-specified development, regulatory and commercialization milestones. As of December 31, 2017, we have received an aggregate of $25.5 million in development milestone payments related to CS-3150, an oral, non-steroidal, selective MR antagonist over there life of the collaboration agreement. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2017, Daiichi Sankyo reported positive top-line results from the phase 3 pivotal trial of CS-3150/esaxerenone and communicated its intention to submit a Japanese regulatory application for CS-3150/esaxerenone for an essential hypertension indication in the first quarter of 2018. We are eligible to receive additional development, regulatory and commercialization milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$130.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. In addition, we are entitled to receive royalties on any sales of certain products commercialized under the collaboration. Daiichi Sankyo may terminate the agreement upon ninety days&#8217; written notice in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Merck</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December&#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta, or PI3K-d, program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-d program. In July 2015 we received a $3.0 million milestone payment from Merck in connection with Merck&#8217;s selection of a compound from our PI3K-d program to advance into clinical trials and in April 2016, we received a milestone payment of $5.0 million in connection with the initiation of a phase 1 clinical trial for the compound. We will be eligible to receive additional payments associated with the successful achievement of potential development and regulatory milestones for multiple indications of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$231.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will also be eligible to receive payments for combined sales performance milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$375.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and royalties on net-sales of products emerging from the agreement. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Merck may at any time, upon specified prior notice to us, terminate the license. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by Merck at will or by us for Merck&#8217;s uncured material breach, the license granted to Merck would terminate. In the event of a termination by us for Merck&#8217;s uncured material breach, we would receive a royalty-free license from Merck to develop and commercialize certain joint products. In the event of termination by Merck for our uncured material breach, Merck would retain the licenses from us, and we would receive reduced royalties from Merck on commercial sales of products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">BMS - ROR Collaboration Agreement </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Under the terms of the collaboration agreement, we were responsible for activities related to the discovery, optimization and characterization of the ROR antagonists during the collaborative research period which began on October&#160;8, 2010 and ended on&#160;July 8, 2013. Since the end of the collaborative research period, BMS has and will continue to have sole responsibility for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each product developed by BMS under the collaboration, we will be eligible to receive payments upon the achievement by BMS of development and regulatory milestones. As of December 31, 2017, we have earned aggregate development and regulatory milestones of $12.5 million, including a $2.5 million development milestone payment in February 2017 in connection with the achievement of certain preclinical milestones set forth in the collaboration agreement and a $10.0 million regulatory milestone payment in October 2017 in connection with BMS&#8217;s filing of a Clinical Trial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Authorization in Europe for a first in-human study of an </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ROR&#947;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;inverse agonist. We are eligible for additional development and regulatory milestone payment of up to $240.0 million in the aggregate and commercialization milestones of up to $150.0 million in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement was amended and restated in April 2011 in connection with an assignment of patents to a wholly-owned subsidiary. BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Sanofi</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2009, we entered into a global license agreement with Sanofi for SAR245408 (XL147) and SAR245409 (XL765), leading inhibitors of phosphoinositide-3 kinase, or PI3K, and a broad collaboration for the discovery of inhibitors of PI3K for the treatment of cancer. The license agreement and collaboration agreement became effective on July&#160;7, 2009. Under the license agreement, Sanofi received a worldwide exclusive license to SAR245408 (XL147) and SAR245409 (XL765), which entered into a series of phase 1, phase 1b/2 or phase 2 clinical trials, and has sole responsibility, including funding, for all subsequent clinical, regulatory, commercial and manufacturing activities. We were notified by Sanofi that the initial clinical trials involving XL147 or XL765 have been terminated or are in the process of concluding, and that Sanofi is still considering whether to initiate any further trials. We will be eligible to receive contingent payments associated with development, regulatory and commercial milestones under the license agreement of $745.0 million in the aggregate, as well as royalties on sales of any products commercialized under the license. Sanofi may, upon certain prior notice to us, terminate the license as to products containing SAR245408 (XL147) and SAR245409 (XL765). In the event of such termination election, Sanofi&#8217;s license relating to such product would terminate and revert to us, and we would receive, subject to certain terms, conditions and potential payment obligations, licenses from Sanofi to research, develop and commercialize such products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December&#160;2011, we entered into an agreement with Sanofi pursuant to which the parties terminated the discovery collaboration agreement and released each other from any potential liabilities arising under the collaboration agreement prior to effectiveness of the termination in December 2011. Each party retains ownership of the intellectual property that it generated under the collaboration agreement, and we granted Sanofi covenants not-to-enforce with respect to certain of our intellectual property rights. If either party or its affiliate or licensee develops and commercializes a therapeutic product containing an isoform-selective PI3K inhibitor that arose from such party&#8217;s work (or was derived from such work) under the collaboration agreement, then such party will be obligated to pay royalties to the other party based upon the net sales of such products. The termination agreement provides that Sanofi will make a one-time payment to us upon the first receipt by Sanofi or its affiliate or licensee of marketing approval for the first therapeutic product containing an isoform-selective PI3K inhibitor that arose from Sanofi&#8217;s work (or was derived from such work) under the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Manufacturing and Product Supply</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing or distribution facilities or resources for clinical or commercial production and distribution of CABOMETYX and COMETRIQ. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations who, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. This will continue in the foreseeable future for both our current and future commercial products. We have selected well-established and reputable global third-party contract manufacturers for our drug substance and drug product manufacturing that have good regulatory standing, large manufacturing capacities and multiple manufacturing sites within their business footprint. These third parties must comply with applicable regulatory requirements, including the FDA&#8217;s Current Good Manufacturing Practices the EC&#8217;s Guidelines on Good Distribution Practice, as well as other stringent regulatory requirements enforced by the FDA or foreign regulatory agencies, as applicable, and are subject to routine inspections by such regulatory agencies. We monitor and evaluate the performance of our third-party contract manufacturers on an ongoing basis to ensure compliance with these requirements and to affirm their continuing capabilities to meet both our commercial and clinical needs. We also have contracted with a third-party logistics provider, with multiple distribution locations, to provide shipping and warehousing services for our commercial supply of both </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX and COMETRIQ in the U.S. We employ highly skilled personnel with both technical and manufacturing experience to diligently manage the activities at our third-party contract manufacturers, and our quality department audits them on a periodic basis. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We source raw materials that are used to manufacture our drug substance from multiple third-party suppliers in Asia and Europe. We stock sufficient quantities of these materials and provide them to our third-party drug substance contract manufacturers to ensure they can manufacture adequate drug substance quantities per our requirements, for both clinical and commercial purposes. We then store drug substance at third-party facilities and provide appropriate amounts to our third-party drug product contract manufacturers, who then manufacture, package and label our specified quantities of finished goods for COMETRIQ and CABOMETYX, respectively. In addition, we rely on our third-party contract manufacturers to source materials such as excipients, components and reagents, which are required to manufacture our drug substance and finished drug product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Within our supply chain, we have established safety stock amounts for both our drug substance and drug products, and store these quantities in multiple locations. The quantities that we store are based on our business needs and take into account scenarios for market demand, production lead times, potential supply interruptions and shelf life for our drug substance and drug products. In parallel, for business continuity reasons, we are in the process of evaluating and expect to establish additional suppliers for our drug substance and drug product manufacturers soon. We believe that our current manufacturing network has the appropriate capacity to produce sufficient commercial quantities of CABOMETYX to support the currently approved advanced RCC indications, as well as potential indications, including previously treated HCC, if those indications prove to be successful and gain regulatory approval in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Marketing, Sales and Distribution</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our sales team promotes CABOMETYX and COMETRIQ in the U.S. In addition, although we currently do not co-promote COTELLIC alongside Genentech, we have the right to do so and will do so if we, in consultation with Genentech, deem it useful and appropriate to realize COTELLIC&#8217;s commercial objectives. We use customary pharmaceutical company practices to market our products in the U.S. and concentrate our efforts on oncologists, oncology nurses and pharmacists.&#160;Our finished products of CABOMETYX and COMETRIQ are sold initially through wholesale distribution and specialty pharmacy channels and then, if applicable, resold to hospitals and other organizations that provide CABOMETYX and COMETRIQ to end-user patients. To facilitate our commercial activities in the U.S., we also employ various third-party vendors, such as advertising agencies, market research firms and other sales-support related services as needed. We believe that our commercial team and distribution practices are sufficient to ensure our marketing efforts reach our target audience and deliver our products to patients in a timely and compliant fashion.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we rely on Ipsen and Takeda for the commercialization and distribution of CABOMETYX in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs or similar programs with the effect of introducing earlier patient access to CABOMETYX, and we also rely on Ipsen for these same activities with respect to the commercialization and distribution of COMETRIQ outside of the U.S. For COTELLIC, we rely on Genentech, as our collaboration partner, for all current and future commercialization and marketing activities, with the exception of the limited co-promotion activities highlighted above.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help ensure that all eligible patients in the U.S. have appropriate access to CABOMETYX and COMETRIQ, we have established a comprehensive reimbursement and patient support program called Exelixis Access Services, or EASE. Through EASE, we provide co-pay assistance to qualified, commercially insured patients to help minimize out-of-pocket costs and provide free drug to uninsured or under-insured patients who meet certain clinical and financial criteria. In addition, EASE is designed to provide comprehensive reimbursement support services, such as prior authorization support, benefits investigation and, if needed, appeals support.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Seasonal Operations and Backlog</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Sales of our marketed products do not reflect any significant degree of seasonality.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The markets in which we operate are characterized by short lead times and the absence of significant backlogs. We do not believe that backlog information is material to our business as a whole.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Environment, Health and Safety</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In support of the development and expansion of our product pipeline, we have resumed discovery activities. Our research and development processes involve the controlled use of certain hazardous materials and chemicals. We are subject to federal, state and local environmental, health and workplace safety laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials. While we have incurred, and may continue to incur, expenditures to ensure we are in compliance with these laws and regulations, we do not expect the cost of complying with these laws and regulations to be material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Government Regulation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, export, import, record keeping, approval, advertising and promotion of our products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The process required by the FDA before product candidates may be marketed in the U.S. generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">preclinical laboratory and animal tests that must be conducted in accordance with Good Laboratory Practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">submission of an IND, which must become effective before clinical trials may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug candidate for its intended use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">submission of a New Drug Application, or NDA, to FDA for commercial marketing, or of a sNDA, for approval of a new indication if the product is already approved for another indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with Good Manufacturing Practices, or GMP, and Good Clinical Practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if FDA convenes an advisory committee, satisfactory completion of the advisory committee review; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDA approval of the NDA or sNDA.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The testing and approval process requires substantial time, effort and financial resources. Prior to commencing the first clinical trial with a product candidate, we must submit an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development. Further, an independent institutional review board for each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial and provide its informed consent form before the trial commences at that center. Regulatory authorities or an institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 1 - Studi</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">es, which involve the initial introduction of an IND into humans, are initially conducted in a limited number of subjects to test the product candidate for safety, dosage tolerance, absorption, metabolism, distribution and excretion in healthy humans or patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 2 - Studies are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, optimal dosages and expanded evidence of safety. Multiple phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive phase 3 clinical trials. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. In some cases, a sponsor may decide to run what is referred to as a &#8220;phase 2b&#8221; evaluation, which is a second, confirmatory phase 2 trial that could, if positive, serve as a pivotal trial in the approval of a product candidate.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Phase 3 - When phase 2 evaluations demonstrate that a dosage range of the product is effective and has an acceptable safety profile, p</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">hase 3 trials are performed to gather the additional information about effectiveness </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 trials are undertaken in large patient populations to further evaluate dosage, to provide replicate statistically significant evidence of clinical efficacy and to further test for safety in an expanded patient population at multiple clinical trial sites.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called phase 4 studies may be made a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval. The results of phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety information to augment the FDA&#8217;s adverse drug reaction reporting system. The results of product development, preclinical studies and clinical trials are submitted to the FDA as part of an NDA, or as part of an sNDA. The submission of an NDA or sNDA requires payment of a substantial user fee to the FDA. The FDA may convene an advisory committee to provide clinical insight on NDA review questions. Although the FDA is not required to follow the recommendations of an advisory committee, the agency usually does so. The FDA may deny approval of an NDA or sNDA by way of a Complete Response letter if the applicable regulatory criteria are not satisfied, or it may require additional clinical data and/or an additional phase 3 pivotal clinical trial. Even if such data are submitted, the FDA may ultimately decide that the NDA or sNDA does not satisfy the criteria for approval. An NDA may be approved with significant restrictions on its labeling, marketing and distribution under a Risk Evaluation and Mitigation Strategy. Once issued, the FDA may withdraw product approval if ongoing regulatory standards are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Satisfaction of FDA requirements or similar requirements of state, local and foreign regulatory agencies typically takes several years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Government regulation may delay or prevent marketing of product candidates or new diseases for a considerable period of time and impose costly procedures upon our activities. The FDA or any other regulatory agency may not grant approvals for new indications for our product candidates on a timely basis, if at all. Success in early stage clinical trials does not ensure success in later stage clinical trials. Targets and pathways identified in vitro may be determined to be less relevant in clinical studies and results in animal model studies may not be predictive of human clinical results. Data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. Even if a product candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse experiences with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA closely regulates the marketing and promotion of drugs, including restricting the promotion of uses for which a drug is not approved by the agency. Not only must a company have appropriate substantiation to support claims made about a drug, under the FDA&#8217;s current interpretation of the relevant laws, a company can make only those claims relating to safety and efficacy that are for indications for which FDA has approved the drug and that are otherwise consistent with the FDA-approved label for the drug. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may, in their independent medical judgment, prescribe legally available drugs for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturers&#8217; communications on the subject of off-label use. Additionally, a significant number of pharmaceutical companies have been the target of inquiries and investigations by various U.S. federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for off-label uses and other sales practices. These investigations have alleged violations of various U.S. federal and state laws and regulations, including claims asserting antitrust violations, violations of the Food, Drug and Cosmetic Act, false claims laws, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the Orphan Drug Act of 1983, as amended, is intended to incentivize the development of drugs and biological products for rare diseases or conditions that affect fewer than 200,000 people in the U.S. (or that affects more than 200,000 persons in the U.S. and for which there is no reasonable expectation that the cost of developing and making available the drug in the U.S. for such disease or condition will be recovered from sales of the drug in the U.S.). If a drug is being developed for a rare disease of condition, to be eligible for designation as an orphan drug, the FDA must not have previously approved a drug considered the &#8220;same drug,&#8221; as defined in the FDA&#8217;s orphan drug regulations, for the same orphan-designated indication. If the FDA has previously approved another same drug for the same indication, to obtain orphan drug designation, the sponsor of the subsequent drug would be required to provide a plausible hypothesis of clinical superiority over the previously approved drug to obtain an orphan designation. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Upon FDA receipt of Orphan Drug Designation, the sponsor is eligible for tax credits of up to 50% for qualified clinical trial expenses, the ability to apply for grant funding, and waiver of the PDUFA application fee. Following the passage of the Tax Cuts and Jobs Act of 2017, for clinical trial expenses incurred in tax years 2018 and going forward, the tax credit is reduced to 25%. In addition, upon marketing approval, an orphan-designated drug could be eligible for seven years of market exclusivity for the approved orphan-designated indication. Such orphan drug exclusivity, if awarded, would only block the approval of any drug considered the same drug for the same orphan indication. Moreover, a subsequent same drug could break a previously approved drug&#8217;s orphan exclusivity through a demonstration of clinical superiority over the previously approved drug.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA has various programs, including Fast Track, priority review and accelerated approval, which are intended to expedite or simplify the process for developing and reviewing promising drugs, or to provide for the approval of a drug on the basis of a surrogate endpoint. Generally, drugs that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions and fill unmet medical needs. Priority review is designed to give drugs that treat serious conditions and that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months of NDA filing as compared to a standard review time of 10 months from NDA filing. Certain other types of drug applications are also eligible for priority review. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the application for a drug designated for priority review. Accelerated approval provides for an earlier approval for a new drug that is intended to treat a serious or life-threatening disease or condition and that fills an unmet medical need based on a surrogate endpoint. As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform post-marketing clinical trials to confirm the clinically meaningful outcome as predicted by the surrogate marker trial. In addition to the Fast Track, accelerated approval and priority review programs, the FDA also designates Breakthrough Therapy status to drugs that are intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives: intensive guidance on an efficient drug development program; intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review; and rolling review.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additional programs intended to expedite the development of drug products were included in the recently enacted 21</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Century Cures Act, or the Cures Act. Signed into law on December 13, 2016, the Cures Act includes various provisions to accelerate the development and delivery of new treatments, such as those intended to expand the types of evidence manufacturers may bring to the FDA to support drug approval, to encourage patient-centered drug development, to liberalize the communication of healthcare economic information, or HCEI, to payers, and to create greater transparency with regard to manufacturer expanded access programs. Central to the Cures Act are provisions that enhance and accelerate the FDA&#8217;s processes for reviewing and approving new drugs and supplements to approved NDAs, including provisions that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">require the FDA t</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">o establish a program to evaluate the potential use of real world evidence to help to support the approval of a new indication for an approved drug and to help to support or satisfy post-approval study requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">provide that the FDA may rely upon qualified data summaries to support the approval of a supplemental application with respect to a qualified indication for an already approved drug; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">require FDA to issue guidance for purposes of assisting sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs; and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">require FDA to establish a process for the qualification of drug development tools for use in supporting or obtaining FDA approval for or investigational</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;use of a drug. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As to dissemination of HCEI, the Cures Act amends Section 114 of the Food and Drug Administration Modernization Act of 1997 to help clarify and facilitate the dissemination of HCEI, including by broadening the definition of HCEI, expressly extending the dissemination of HCEI to payors, and clarifying that HCEI must only &#8220;relate&#8221; to an FDA-approved indication rather than &#8220;directly&#8221; relate to the indication.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">The Hatch-Waxman Act </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, established two abbreviated approval pathways for drug products in which potential competitors may rely upon the FDA&#8217;s prior approval of the same or similar drug product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">ANDA.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;An Abbreviated New Drug Application, or ANDA, may be approved by the FDA if the applicant demonstrates that the proposed generic product is the same as the approved drug, which is referred to as the Reference Listed Drug, or RLD.&#160;Generally, an ANDA must contain data and information showing that the proposed generic product and RLD (1)&#160;have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of administration, (2)&#160;are intended for the same uses, and (3)&#160;are bioequivalent.&#160;This is instead of independently demonstrating the proposed product&#8217;s safety and effectiveness, which are inferred from the fact that the product is the same as the RLD, which the FDA previously found to be safe and effective. Furthermore, conducting bioequivalence testing is generally less time consuming and costly than conducting a full set of clinical trials in humans.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">505(b)(2)&#160;NDAs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;A 505(b)(2) application is one for which one or more of the investigations relied upon by the applicant for approval were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. Under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, or FDCA, an applicant may rely, in part, on the FDA&#8217;s previous approval of a similar product, or published literature, in support of its application. If the 505(b)(2) applicant establishes that reliance on FDA&#8217;s prior findings of safety and efficacy for an approved product is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies. The FDA may require additional studies or measurements, including comparability studies.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unlike a full NDA for which the sponsor has conducted or obtained a right of reference to all the data essential to approval, the filing of both an ANDA application and a 505(b)(2) application may be delayed due to patent or exclusivity protections covering an approved product. The Hatch-Waxman Act provides five years of data exclusivity for the first approval of a new chemical entity, and three years of data exclusivity for supplemental applications containing clinical studies essential to the approval of the sNDA.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book Listing.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is referred to as the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the RLD that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. Filing such a lawsuit within 45 days of the receipt of the Paragraph IV certification notice prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the RLD has expired. We intend to defend vigorously any patents for our approved products. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Regulation Outside of the United States </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical trials and the manufacturing, commercial sales and distribution of our products outside of the U.S. Whether or not we obtain FDA </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The way clinical trials are conducted in the EU will undergo a major change when Regulation (EU) 536/2014 governing clinical trials in the EU, repealing the existing Directive 2001/20/EC comes into application in 2019. This regulation harmonizes the assessment and supervision processes for clinical trials throughout the EU, via an EU portal and database. The EMA will set up and maintain the portal and database, in collaboration with the Member States and the EC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under EU regulatory systems, a company may submit MAAs either under a centralized or decentralized procedure. Under the centralized procedure, MAAs are submitted to the EMA whose Committee for Medicinal Products for Human Use reviews the application and issues an opinion on it. The opinion is considered by the EC which is responsible for deciding applications. If the application is approved, the EC grants a single marketing authorization that is valid for all EU member states as well as Iceland, Liechtenstein and Norway, collectively the European Economic Area, or the EEA. The national authorization procedures, the decentralized and mutual recognition procedures, as well as national applications, are available for products for which the centralized procedure is not compulsory. The mutual recognition procedure provides for the EU member states selected by the applicant to mutually recognize a national marketing authorization that has already been granted by the competent authority of another member state, referred to as the Reference Member State, or RMS. The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any member state. Under this procedure the applicant can select the member state that will act as the RMS. In both the mutual recognition and decentralized procedures, the RMS reviews the application and submits its assessment of the application to the member states where marketing authorizations are being sought, referred to as Concerned Member States or CMS. Within 90 days of receiving the application and assessment report, each CMS must decide whether to recognize the RMS assessment. If a member state does not agree with the assessment, and the disputed points cannot be resolved the matter is eventually referred to the Coordination Group on Mutual Recognition and Decentralised procedures in the first instance to reach an agreement and failing to reach such an agreement, a referral to the EMA and the Committee for Medicinal Products for Human Use for arbitration that will result in an opinion to form the basis of a decision to be issued by the EC binding on all member states. If the application is successful national marketing authorizations will be granted by the competent authorities in each of the member states chosen by the applicant.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Conditional marketing authorizations may be granted for a limited number of medicinal products for human use referenced in EU law applicable to conditional marketing authorizations where the clinical dataset is not comprehensive, if (1) the risk-benefit balance of the product is positive, (2) it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) unmet medical needs will be fulfilled and (4) the benefit to public health of the immediate availability on the market of the medicinal product outweighs the risk inherent in the fact that additional data are still required. Specific obligations, such as the completion of ongoing or new studies and obligations relating to the collection of pharmacovigilance data, may be amongst the conditions stipulated in the marketing authorization. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a product as an Orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. In the EU orphan designation is available for products in development which are either: (a) intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU, or (b) intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the Community and when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. Additionally, the sponsor of an application for orphan drug designation must establish that there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition or even if such treatment exists, the product will be of significant benefit to those affected by that condition. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product. The period of market exclusivity may be reduced to six years if at the end of the fifth year it is established that the criteria for orphan designation are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Healthcare Regulation </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, also apply to our business. If we fail to comply with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The laws that may affect our ability to operate include, but are not limited to: the federal Anti&#8209;Kickback Statute, which prohibits. among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; and federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third&#8209;party payers that are false or fraudulent. Additionally, we are subject to state law equivalents of each of the above federal laws, which may be broader in scope and apply regardless of whether the payer is a federal healthcare program, and many of which differ from each other in significant ways and may not have the same effect, further complicate compliance efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information, are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act, or HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we obtain and/or disclose individually identifiable health information from a HIPAA-covered entity, including healthcare providers, in a manner that is not authorized or permitted by HIPAA. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including recently enacted laws in a majority of states requiring security breach notification. These laws could create liability for us or increase our cost of doing business. International laws, such as the EU Data Privacy Directive (95/46/EC) and Swiss Federal Act on Data Protection, regulate the processing of personal data within the EU and between countries in the EU and countries outside of the EU, including the U.S. On April 27, 2016, the EU legislature adopted Regulation (EU) 2016/679, the General Data Protection Regulation, or GDPR. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The GDPR will replace Directive 95/46/EC when it takes effect on May 25, 2018, and it will apply in all Member States without the need for implementing national legislation, as well as extra-territorially outside the EU. Furthermore, in October 2015, the Court of Justice of the EU declared the previous framework, the International Safe Harbor Privacy Principles, or Safe Harbor, invalid for data transfer between the U.S. and the EU. The Safe Harbor has now been replaced by the EU-U.S. Privacy Shield, a framework for transatlantic exchanges of personal data for commercial purposes between the EU and the U.S. in accordance with the principles of the GDPR.&#160; Accordingly, there may be an immediate impact on companies located in the U.S. as they devote resources to comply with these new obligations. &#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The GDPR establishes a tiered approach to penalties for breach which enables the data protection authorities of the various Member States to impose fines for certain infringements, including the breach of requirements relating to international transfers or the basic principles for processing of personal data (such as conditions for obtaining consent from that individual whose data is being transferred). The severity of these fines may be up to the higher of 4% of annual worldwide revenue or &#8364;20 million.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, created a federal requirement under the federal Open Payments program, that requires certain manufacturers to track and report to the Centers for Medicare and Medicaid Services annually certain payments and other transfers of value provided to physicians and teaching hospitals made in the previous calendar year. In addition, there are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state and federal authorities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For those marketed products which are covered in the U.S. by the Medicaid programs, we have various obligations, including government price reporting and rebate requirements, which generally require products be offered at substantial rebates/discounts to Medicaid and certain purchasers (including &#8220;covered entities&#8221; purchasing under the 340B Drug Discount Program). We are also required to discount such products to authorized users of the Federal Supply Schedule of the General Services Administration, under which additional laws and requirements apply. These programs require submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations, and the guidance governing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">such calculations is not always clear. Compliance with such requirements can require significant investment in personnel, systems and resources, but failure to properly calculate prices, or offer required discounts or rebates could subject us to substantial penalties.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Subject to the application in the EU of the Transparency Directive 89/105/EEC, which aims to ensure the transparency of measures adopted to control pricing and reimbursement, pricing and reimbursement in the EU/EEA is governed by national rules and policy and may vary from Member State to Member State.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Reimbursement </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Sales of our approved products and any future products of ours will depend, in part, on the extent to which their costs will be covered by third-party payers, such as government health programs, commercial insurance and managed healthcare organizations. Patients may be less likely to use our products if coverage is not provided and reimbursement is inadequate to cover a significant portion of the cost of our products. In addition, although to date qualified patients who would not otherwise be able to afford our products have been able to receive financial support from us in some cases, and from independent patient support foundations in other cases, these programs have recently been subject to significant government scrutiny, and in the future these patients may no longer be able to use our products. Third-party payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a third-party payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Additionally, a third-party payer&#8217;s decision to cover a particular drug product does not ensure that other payers will also provide coverage for the drug product, or will provide coverage at an adequate reimbursement rate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S. and other potentially significant markets for our products, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">products and therapies, which may result in lower average selling prices. In some cases, for example, third-party payers try to encourage the use of less expensive generic products through their prescription benefits coverage and reimbursement and co-pay policies. Further, the increased emphasis on managed healthcare in the U.S. and on country-specific and national pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing coverage and/or reimbursement controls and measures, could have a material adverse impact on our net product revenues and results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering proposals or have enacted legislative and regulatory changes the healthcare system that could affect our ability to sell our products profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. There has been particular and increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. At the federal level, there have been several U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. In the U.S., the pharmaceutical industry has already been significantly affected by major legislative initiatives, including, for example, the PPACA. Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the PPACA recently have been enacted. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on January 23, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain PPACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and the medical device excise tax on non-exempt medical devices. It is expected that Congress will continue to consider legislation to repeal and replace some or all elements of the PPACA. We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing, which could have a negative impact on our revenue or sales of any products or future approved products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other legislative changes have also been proposed and adopted since the PPACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to 2%&#160;per fiscal year, starting in 2013, and the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding. In the future, there will likely continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of drug products, including our approved products and any future approved products. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before its cost may be funded within the respective national healthcare system. The requirements governing drug pricing vary widely from country to country. For example, EU member states may restrict the range of medicinal products for which their national healthcare systems provide reimbursement and may control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profits the medicinal product generates for the company placing it on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products on cost-effectiveness grounds. Historically, products launched in countries in the EU do not follow the price structures of the U.S. and they generally tend to be priced significantly lower.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Competition </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are many companies focused on the development of small molecules and antibodies for cancer. Our competitors and potential competitors include major pharmaceutical and biotechnology companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition for Cabozantinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that our ability to successfully compete will depend on, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">efficacy, safety and reliab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ility of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">timing and scope of regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the speed at which we develop cabozantinib for the treatment of additional tumor types beyond its approved indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to complete clinical development and obtain regulatory approvals for cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to manufacture and sell commercial quantities of cabozantinib product to the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to successfully commercialize cabozantinib and secure coverage and adequate reimbursement in approved indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product acceptance by physicians and other health care providers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our collaboration partners&#8217; investments in the resources necessary to successfully commercialize cabozantinib in&#160;territories where it is approved outside of the U.S.;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">skills of our employees and our ability to recruit and retain skilled employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">protection of our intellectual property; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the availability of subs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tantial capital resources to fund development and commercialization activities.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that the quality and breadth of activity observed with cabozantinib, the skill of our employees and our ability to recruit and retain skilled employees, our patent portfolio and our capabilities for research and drug development are competitive strengths. However, many large pharmaceutical and biotechnology companies have significantly larger intellectual property estates than we do, more substantial capital resources than we have, and greater capabilities and experience than we do in preclinical and clinical development, sales, marketing, manufacturing and regulatory affairs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The markets for which we intend to pursue regulatory approval of cabozantinib are highly competitive. We are aware of products in research or development by our competitors that are intended to treat all of the tumor types we are targeting, and should they demonstrate suitable clinical evidence, any of these products may compete with cabozantinib. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. CABOMETYX in particular may become less marketable if we are unable to successfully adapt our development strategy to address the fact that this recent approach to treating cancer with immune checkpoint inhibitors has and will continue to become more prevalent in indications for which CABOMETYX is approved, most notably advanced RCC, and in additional indications where we intend to seek regulatory approval, such as previously treated advanced HCC. Furthermore, the complexities of such a strategy has and may continue to require collaboration with some of our competitors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">CABOMETYX:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;We believe the principal competition for CABOMETYX in advanced RCC includes: BMS&#8217;s nivolumab; Pfizer&#8217;s axitinib, sunitinib and temsirolimus; Novartis&#8217; everolimus and pazopanib; Bayer&#8217;s and Onyx Pharmaceuticals&#8217; (a wholly-owned subsidiary of Amgen) sorafenib; Genentech&#8217;s bevacizumab and atezolizumab; Eisai&#8217;s lenvatinib; and AVEO Pharmaceutical&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">tivozanib</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Additionally, there are a variety of combination therapies being developed for RCC, including, Roche&#8217;s bevacizumab and atezolizumab, BMS&#8217;s ipilimumab and nivolumab, Merck&#8217;s pembrolizumab and Eisai&#8217;s lenvatinib, Merck&#8217;s pembrolizumab and Pfizer&#8217;s axitinib, Pfizer&#8217;s avelumab and axitinib, Merck&#8217;s pembrolizumab and Roche&#8217;s bevacizumab, Merck&#8217;s pembrolizumab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and Incyte&#8217;s epacadostat and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Eisai&#8217;s </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lenvatinib and Novartis&#8217; everolimus. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The competition we currently face from BMS&#8217;s nivolumab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in previously treated advanced RCC </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">is particularly significant. Nivolumab was approved as a second-line treatment of advanced RCC on November 23, 2015, following a rapid review by the FDA. That approval was based in large part on the results of BMS&#8217;s phase&#160;3 trial comparing nivolumab to everolimus in patients who had received previous antiangiogenic therapy for advanced RCC (CheckMate-025), in which nivolumab met its primary endpoint of showing a statistically-significant improvement in OS over everolimus, a current standard of care for the treatment of second-line RCC patients. While nivolumab failed to demonstrate a statistically-significant PFS benefit over everolimus, it demonstrated an acceptable safety profile. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For previously untreated, advanced or metastatic RCC, we expect to face significant competition from BMS&#8217;s combination of nivolumab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ipilimumab, if approved by the FDA. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2017, BMS announced that its phase 3 study evaluating </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nivolumab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ipilimumab in patients with previously untreated advanced or metastatic RCC (CheckMate-214) met its co-primary endpoint, demonstrating OS compared to sunitinib, the current standard of care, in intermediate-and poor-risk patients. The combination also met a secondary endpoint of improved OS versus sunitinib in all randomized patients. On the basis of this data, BMS filed a supplemental Biologics License Application, or sBLA, for use of the combination of nivolumab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ipilimumab as a first-line treatment for intermediate-and poor-risk patients with advanced RCC, and in</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;December 2017, the FDA granted a priority review to the sBLA. The FDA is scheduled to make its final decision on the sBLA on or before April 16, 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">COMETRIQ:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;We believe that the principal competing anti-cancer therapy&#160;to COMETRIQ in progressive, metastatic MTC is Genzyme&#8217;s RET, VEGFR and EGFR inhibitor vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease. In addition, we believe that COMETRIQ also faces competition as a treatment for progressive, metastatic MTC from off-label use of Bayer&#8217;s and Onyx Pharmaceuticals&#8217; (a wholly-owned subsidiary of Amgen) multikinase inhibitor sorafenib, Pfizer&#8217;s multikinase inhibitor sunitinib, Takeda&#8217;s multikinase inhibitor ponatinib, Novartis&#8217; multikinase inhibitor pazopanib, and Eisai&#8217;s multikinase inhibitor lenvatinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Potential Cabozantinib Indications Beyond RCC and MTC, Including Advanced HCC:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Based on the results of CELESTIAL, we plan to submit a sNDA to the FDA in the first quarter of 2018, for CABOMETYX as a treatment for patients with</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;previously treated</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;advanced HCC. However, we face a rapidly evolving treatment landscape for the treatment of advanced HCC, as other</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;therapies have recently received regulatory approval or are in advanced stages of clinical development, which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">may impair the relative value of CABOMETYX for this indication</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Should cabozantinib be approved for the treatment of patients with previously treated advanced HCC, we believe its principal competition may include Bayer&#8217;s regorafenib, BMS&#8217;s nivolumab, Eisai&#8217;s lenvatinib, Merck&#8217;s pembrolizumab, Lilly&#8217;s ramucirumab and AstraZeneca&#8217;s durvalumab </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and tremelimumab. Examples of potential competition for cabozantinib in other cancer indications include: other VEGF pathway inhibitors, including Genentech&#8217;s bevacizumab; other RET inhibitors including Eisai&#8217;s lenvatinib and Takeda&#8217;s ponatinib; and other MET inhibitors, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Astra Zeneca&#8217;s savolitinib,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Pfizer&#8217;s crizotinib and Mirati&#8217;s glesatinib; and immunotherapies such as BMS&#8217;s ipilimumab and nivolumab, Merck&#8217;s pembrolizumab and Roche&#8217;s atezolizumab.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition for Cobimetinib</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that cobimetinib&#8217;s principal competition amongst targeted agents includes Novartis&#8217; trametinib and dabrafenib, and Array&#8217;s encorafenib and binimetinib; and within the class of immunotherapies, BMS&#8217;s ipilimumab and nivolumab and Merck&#8217;s pembrolizumab. The second category, immunotherapies, are of particular competitive importance vis-a-vis cobimetinib in advanced melanoma as they are already FDA approved in melanoma patient populations that overlap with those that may be eligible for cobimetinib, they have been rapidly incorporated into the National Comprehensive Cancer Network treatment guidelines, and they are viewed with a high degree of enthusiasm by physicians and key opinion leaders. Ongoing and future trials incorporating immune checkpoint inhibitors, including combination trials, may further impact usage of cobimetinib in melanoma and potentially in additional tumor types in which cobimetinib may ultimately gain approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Should cobimetinib in combination with atezolizumab be approved for the treatment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unresectable locally advanced or metastatic </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CRC, we believe its principal competition may include </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Bayer&#8217;s regorafenib, Taihio Oncology&#8217;s trifluridine&#160;and&#160;tipiracil</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, Lilly&#8217;s cetuximab and Amgen&#8217;s panitumumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Financial Information and Significant Customers</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate as a single business segment and have operations solely in the U.S. During the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we derived approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues from Diplomat Specialty Pharmacy, approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues from Caremark L.L.C. and approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues from each of Accredo Health, Incorporated and affiliates of McKesson Corporation, all of which are located in the U.S. and approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our revenues in connection with our collaboration with Ipsen which is located in Europe. Information regarding total revenues, including geographic regions in which they are earned, net loss, total assets and the location of our long-lived assets for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;is set forth in &#8220;Note 13. Segment Information&#8221; in our &#8220;Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$112.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;for the year ended&#160;December&#160;31, 2017, compared to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$96.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;for the year ended&#160;December&#160;31, 2016&#160;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$96.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;for the year ended&#160;December&#160;31, 2015. Additional information about our research and development expenses in each of the last three fiscal years is set forth in Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Patents and Proprietary Rights </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We actively seek patent protection in the U.S., Europe and selected other foreign countries to cover our drug candidates and related technologies. Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country. We have numerous patents and pending patent applications that relate to methods of screening drug targets, compounds that modulate drug targets, as well as methods of making and using such compounds.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">While many patent applications have been filed relating to the drug candidates that we have developed, the majority of these are not yet issued or allowed. We own all global patents associated with cabozantinib and cobimetinib that are referenced below.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cabozantinib is covered by 10 issued patents in the U.S., including U.S. Pat. No.&#160;7,579,473, for the composition-of-matter of cabozantinib and pharmaceutical compositions thereof. U.S.&#160;Pat. No.&#160;7,579,473 would normally expire in September 2024, but we have been granted a patent term extension to extend the term to August 2026. The additional issued U.S. patents will expire between 2024 and 2033. Cabozantinib is also covered by an issued patent in Europe (covering the composition-of-matter of cabozantinib and certain methods of use) and an issued patent in Japan (covering the composition-of-matter of cabozantinib). These issued patents would normally expire in September 2024, but we have applied for and are obtaining Supplementary Protection Certificates in Europe to extend the term to 2029. We intend to apply for patent term extension in Japan to extend the term to 2029. Foreign counterparts of the issued U.S. and European patents are issued in Australia and Canada, which are anticipated to expire in 2024. We have patent applications pending in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the U.S., Europe, Australia, Japan and Canada covering certain synthetic methods related to making cabozantinib, which, if issued, are anticipated to expire in 2024. We have filed patent applications in the U.S. and other selected countries covering certain salts, polymorphs and formulations of cabozantinib that, if issued, are anticipated to expire in approximately 2035. We have filed several patent applications in the U.S. and other selected countries relating to combinations of cabozantinib with certain other anti-cancer agents that, if issued, are anticipated to expire in approximately 2035. Cabozantinib is licensed to Takeda in Japan and elsewhere, except the U.S., to Ipsen, in accordance with our collaboration agreements with Takeda and Ipsen.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cobimetinib is covered by three issued patents in the U.S., including U.S. Pat. No 7,803,839 for the composition of matter of cobimetinib and pharmaceutical compositions thereof. U.S. Pat. No 7,803,839 would normally expire in February 2027, but we have applied for a patent term extension to extend the term to November 2029. Cobimetinib is also covered by an issued patent in Europe (covering the composition-of-matter of cobimetinib and certain methods of use), which would normally expire in October 2026, but we have applied for and are obtaining Supplementary Protection Certificates to extend the term to November 2030. Foreign counterparts of the issued U.S. and European patents are issued or pending in Australia, Brazil, Canada, China, Colombia, the Eurasian Patent Organization, Georgia, Hong Kong, India, Indonesia, Israel, Japan, Mexico, Malaysia, New Zealand, Philippines, Singapore, South Africa, South Korea, and Ukraine. We have filed patent applications in the U.S. and other selected countries covering certain salts and polymorphs of cobimetinib that, if issued, are anticipated to expire in approximately 2036. We have filed patent applications in the U.S. and other selected countries covering certain synthetic methods related to making cobimetinib that, if issued, are anticipated to expire in approximately 2033. Cobimetinib is licensed to Genentech in the U.S. and to Roche outside of the U.S.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have pending patent applications in the U.S. and Europe covering the composition-of-matter of our other drug candidates in clinical or preclinical development that, if issued, are anticipated to expire between 2023 and 2030.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have obtained licenses from various parties that give us rights to technologies that we deem to be necessary or desirable for our research and development. These licenses (both exclusive and non-exclusive) may require us to pay royalties as well as upfront and milestone payments. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Employees</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had 372 full-time equivalent employees, all of which are located in the U.S. None of our employees are represented by a labor union, and we consider our employee relations to be good.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We were incorporated in Delaware in November 1994 as Exelixis Pharmaceuticals, Inc. and changed our name to Exelixis, Inc. in February 2000. Our principal executive offices are located at 210 East Grand Ave., South San Francisco, California 94080. Our telephone number is (650) 837-7000. We maintain a site on the worldwide web at www.exelixis.com; however, information found on our website is not incorporated by reference into this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We make available free of charge on or through our website our Securities and Exchange Commission, or SEC, filings, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Further, copies of our filings with the SEC are available at the SEC&#8217;s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.</font></div><div><a name="s84027E596EA4FBE8C988B6B62DDB7E07"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the factors discussed elsewhere in this report, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our future prospects are critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our mission is to maximize the clinical and commercial potential of cabozantinib and cobimetinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline. We anticipate that for the foreseeable future our ability to generate meaningful unrestricted cash flow to fund our commercial operations and our development and discovery programs is dependent upon the successful commercialization of CABOMETYX for the treatment of advanced RCC in territories where it has been or may soon be approved and in potential other indications for which we are in late-stage development or we otherwise intend to seek regulatory review. The commercial opportunity for CABOMETYX as a treatment for advanced RCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of advanced RCC.&#160;If revenue from CABOMETYX decreases or remains flat, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plan, which may have a material adverse effect on our business and financial condition, results of operations and growth prospects. Furthermore, as a consequence of our collaboration agreements with Ipsen and Takeda, we rely heavily upon their regulatory, commercial, medical affairs, and other expertise and resources for commercialization of CABOMETYX in territories outside of the U.S. If our collaborators are unable to, or do not invest the resources necessary to successfully commercialize CABOMETYX in the EU and other international territories where it may be approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even following the approval of CABOMETYX for the treatment of advanced RCC in the U.S. and EU, our success remains contingent upon, among other things, successful clinical development, regulatory approval and market acceptance of cabozantinib, the compound from which CABOMETYX is derived, in potential additional indications, such as advanced HCC. We cannot be certain that that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in clinical testing to receive regulatory approval. Should we prove unsuccessful in advancing the further clinical development and commercialization of cabozantinib beyond its approved indications, we may be unable to execute our business plan and our financial results and condition could be materially adversely affected. Even if we and our partners receive the required regulatory approvals to market cabozantinib for any additional indications or in additional jurisdictions, we and our partners may not be able to effectively commercialize CABOMETYX. Our ability to grow CABOMETYX product sales in future periods is also dependent on price increases and we periodically increase the price of CABOMETYX. Price increases on CABOMETYX and negative publicity regarding drug pricing and price increases generally, whether on CABOMETYX or products distributed by other pharmaceutical companies, could negatively affect market acceptance of, and sales of, CABOMETYX. In any event, we cannot assure you that price increases we have taken or may take in the future will not in the future negatively affect CABOMETYX sales. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The commercial success of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent to which CABOMETYX gains market acceptance among physicians, patients, government health care payers such as Medicare and Medicaid, commercial health care plans and the medical community. If CABOMETYX does not achieve an adequate level of acceptance, we may not generate significant future product revenues. The degree of market acceptance of CABOMETYX will depend upon a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the effectiveness, or perceived effectiveness, of CABOMETYX in comparison to competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the safety of CABOMETYX, including the existence of serious side effects of CABOMETYX and their severity in comparison to those of competing products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#8217;s relative convenience and ease of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">potential unexpected results connected with analysis of data from future or ongoing clinical trials of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of CABOMETYX label expansions for additional indications, if any, relative to competitive treatments;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the price of CABOMETYX relative to competitive therapies and any new government initiatives affecting pharmaceutical pricing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the strength of CABOMETYX sales efforts, marketing, medical affairs and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the sufficiency of commercial and government insurance coverage and reimbursement for CABOMETYX; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights with respect to CABOMETYX.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The pharmaceutical, biopharmaceutical and biotechnology industries are competitive, highly diversified and are characterized by rapid technological change, particularly in the area of novel oncology therapies. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage. Further, our competitors may be more effective at using their technologies to develop commercial products. As a result, our competitors may be able to more easily develop technologies and products that would render our technologies and products, and those of our collaborators, obsolete and noncompetitive. There may also be drug candidates that we are not aware of at an earlier stage of development that may compete with our marketed products and product candidates. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Delays in the development of cabozantinib or cobimetinib for the treatment of additional tumor types, for example, could allow our competitors to bring products to market before us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, the advanced RCC indications, for which CABOMETYX is approved, are highly competitive, and several novel therapies and combinations of therapies are in advanced stages of clinical development or under expedited regulatory review in these indications, and are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of immunotherapy. CABOMETYX in particular may become less marketable if we are unable to successfully adapt our development strategy to address the fact that this recent approach to treating cancer with immune checkpoint inhibitors has and will continue to become more prevalent in indications for which our products are approved, most notably advanced RCC, and in additional indications where we intend to seek regulatory approval, such as previously treated advanced HCC. Furthermore, the complexities of such a strategy has and may continue to require collaboration with some of our competitors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also may in the future face competition from manufacturers of generic versions of our marketed products. In this regard, in February 2018, the FDA published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active ingredient in CABOMETYX and COMETRIQ. The FDA regularly issues product specific bioequivalence guidance for products following their approval. The February 2018 draft guidance for drug products containing cabozantinib could have been issued by the FDA as a matter of its own standard practice; it could also indicate that a generic drug manufacturer is investigating whether to submit an ANDA for cabozantinib. The ANDA process is discussed in more detail above under the heading "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Government Regulation-The Hatch-Waxman Act&#8221;. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Generic competition often results in decreases in the prices at which branded products can be sold.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or scale adequate sales, marketing, market access and distribution capabilities for CABOMETYX or enter into or maintain agreements with third parties to do so, we may be unable to maximize product revenues and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access, medical affairs and product distribution capabilities requires significant resources, and there are numerous risks involved with managing such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial-stage oncology-focused biotech companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded, and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access, medical affairs and product distribution capabilities, we may be unable to maximize the commercial potential of CABOMETYX and COMETRIQ in their approved indications. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly judge the requisite size and experience of the commercialization teams </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or the scale of distribution necessary to market and sell CABOMETYX successfully. If we are unable to maintain or scale our organization appropriately, we may not be able to maximize product revenues and our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize CABOMETYX and COMETRIQ will depend, in part, on the extent to which we are able to adequately distribute the products to eligible patients. We currently rely on third-party providers to handle storage and distribution for our commercial supply of both CABOMETYX and COMETRIQ in the U.S. Furthermore, we rely on our collaboration partners for the commercialization and distribution of CABOMETYX and COMETRIQ in territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs) with the effect of introducing earlier patient access to COMETRIQ and CABOMETYX. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply cabozantinib to the marketplace on a timely and competitive basis. These third parties may not provide services in the time required to meet our commercial timelines and objectives or to meet regulatory requirements. We may not be able to maintain or renew our arrangements with third parties, or enter into new arrangements, on acceptable terms, or at all. Third parties could terminate or decline to renew our arrangements based on their own business priorities. If we are unable to contract for these third-party services related to the distribution of cabozantinib on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper conduct, the laws that may affect our ability to operate include, without limitation:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, or AKS, which governs our business activities, including our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The AKS has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Among other things, this statute prohibits persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. Remuneration is not defined in the AKS and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the FDCA and its regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HIPAA and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Foreign Corrupt Practices Act, a U.S. law, which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals) and its foreign equivalents;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs, as well as certain state and municipal government price reporting laws that require us to provide justifications where drug prices exceed a certain price increase threshold (and participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and could potentially affect our ability to offer certain marketplace discounts); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state financial and drug pricing transparency laws, which generally require certain types of expenditures in the U.S. to be tracked and reported (and compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships with healthcare providers and healthcare entities, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">T</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">hese federal and state healthcare fraud and abuse laws, FDA rules and regulations, as well as false claims laws, including the civil False Claims Act, govern certain mar</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">keting practices, including off-label promotion. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. Such individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially then share in amounts paid by the entity to the government in fines or settlement. The filing of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend civil False Claims Act actions. When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect our business, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, that govern the collection, use and disclosure of personal information. In addition, most healthcare providers who are expected to prescribe our products and from whom we obtain patient health information are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly obtain individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU Data Privacy Directive (95/46/EC) and implementing legislation in the various national Member States of the EU, which will be replaced on May 25, 2018 by the more restrictive GDPR (Regulation (EU) 2016/679) and the Swiss Federal Act on Data Protection, regulate the processing of personal data within the EU and between countries in the EU and countries outside of the EU, including the U.S. We are currently reviewing all privacy and other regulations in connection with these new laws to assess whether additional procedural safeguards are warranted, including compliance with the EU-U.S. Privacy Shield framework, which will replace the previous safe harbor mechanism. Failure to provide adequate privacy protections and maintain compliance with these laws and regulations could jeopardize business transactions across borders, create liability for us, including the imposition of sanctions or other penalties, and/or could increase our cost of doing business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain both adequate coverage and adequate reimbursement from third-party payers for CABOMETYX or COMETRIQ, our revenues and prospects for profitability will suffer.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize CABOMETYX or COMETRIQ successfully is highly dependent on the extent to which coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Patients may not be capable of paying for CABOMETYX or COMETRIQ </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">themselves and may rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and prospects for profitability will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ. Third-party payers continue to scrutinize and manage the prices charged for pharmaceutical products and services and many also limit reimbursement for newly-approved products and indications. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There has been negative publicity regarding, and increasing legislative and enforcement interest in the U.S. with respect to, drug pricing, the use of specialty pharmacies, and the effect of free drug programs and programs designed to help patients afford and defray the cost of their medications, which may result in physicians being less willing to participate in these programs and thereby limit our ability to increase patient access and adoption of CABOMETYX. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, and reform government program reimbursement methodologies for drugs. There have also been similar laws enacted at the state level, including legislation signed by California Governor Jerry Brown in October 2017, currently being challenged in court, which requires pharmaceutical manufacturers to disclose information and justifications with respect to certain price increases. If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in some foreign countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control under the respective national health system. In these countries, price negotiations with governmental authorities or payers can take six to twelve months or longer after marketing authorization is granted for a product, which has the potential to substantially delay broad availability of the product in some of those countries. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner, Ipsen, may be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies to support health technology appraisal. The conduct of such a study could result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives could decrease the price we and our collaboration partner, Ipsen, might establish for CABOMETYX, which would result in lower license revenues to us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may affect our ability to sell CABOMETYX and COMETRIQ profitably.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell CABOMETYX and COMETRIQ profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since its enactment, there have been judicial and Congressional challenges to numerous provisions of the PPACA,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as well as recent efforts by the Trump administration and Congress to repeal or replace certain aspects of the PPACA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the PPACA have been enacted. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on January 23, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain PPACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. It is expected that Congress will continue to consider legislation to repeal and replace some or all elements of the PPACA. Moreover, certain politicians, including the President, have announced plans to regulate the prices of pharmaceutical products. Congress has also signaled an intent to address pharmaceutical pricing, with Senate hearings to examine the cost of prescription drugs held on June 13 and October 17, 2017. Federal legislators previously proposed legislation that would require pharmaceutical manufacturers to report price </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increases and provide a public justification for increases that exceed given benchmarks and authorize the U.S. Department of Health and Human Services to negotiate the price of Part D prescription drugs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk. We cannot know what form any such measures may take or the market&#8217;s perception of how such proposals and provisions would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may limit our ability to generate revenue or commercialize our current products and/or those for which we may receive regulatory approval in the future.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which will reauthorize the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which manufacturers of such products partially pay for the FDA&#8217;s pre-market review of their product candidates. The legislation includes, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; health care costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs. In January 2018, the FDA took steps to implement the Drug Competition Action Plan and released guidance to streamline aspects of the submission and review of ANDAs for generic drugs. We cannot currently predict the specific outcome or impact on our business of such regulatory actions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the overall trend towards cost-effectiveness criteria and managed healthcare in the U.S., third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. These entities could refuse or limit coverage for CABOMETYX and COMETRIQ, such as by using tiered reimbursement, which would adversely affect demand for CABOMETYX and COMETRIQ. They may also refuse to provide coverage for uses of CABOMETYX and COMETRIQ for medical indications other than those for which the FDA has granted market approval. As a result, significant uncertainty exists as to whether and how much third-party payers will cover newly approved drugs, which in turn will put pressure on the pricing of drugs. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, third-party payer or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on our revenues and prospects for profitability.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for pharmaceutical products has come under increasing scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many companies in our industry have received a governmental request for documents and information relating to drug pricing and patient support programs. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, such findings could further harm our business, reputation and/or prospects. It is possible that such inquiries could result in: negative publicity or other negative actions that could harm our reputation; changes in our product pricing and distribution strategies; reduced demand for our approved products; and/or reduced reimbursement of approved products, including by federal health care programs such as Medicare and Medicaid and state health care programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, the Trump Administration has indicated interest in taking regulatory and other policy actions pertaining to drug pricing, including potential proposals relating to Medicare price negotiations, importation of drugs from other countries and facilitating value-based arrangements between manufacturers and payers. At this time, it is unclear whether any of these proposals will be pursued and how they would impact our products or our future product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">State and local governments continue to consider prescription drug pricing transparency proposals. In October 2017, California Governor Jerry Brown signed legislation requiring pharmaceutical manufacturers to disclose and provide justification for certain price increases; however, the regulations under which we will be required to operate have not yet been promulgated. While we have taken and will continue to take appropriate actions to ensure compliance with this new law, without knowing the final regulations applicable to us, we cannot comprehensively assess the potential impact on our business. Additionally, Ohio voters considered, but rejected, a ballot initiative in November 2017, which would have required state agencies to pay no more for prescription drugs than the price paid by the U.S. Department of Veterans </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Affairs. While this particular initiative in Ohio failed to become law, additional legislation or ballot initiatives may be proposed by various states and municipalities in the future, and we cannot predict the outcome of any future proposals, the market&#8217;s perception of them or their potential impact on us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are heavily dependent on our partner, Genentech (a member of the Roche group), for the successful development, regulatory approval and commercialization of cobimetinib, marketed as COTELLIC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The terms of our collaboration agreement with Genentech provide Genentech with exclusive authority over the global development and commercialization plans for cobimetinib and the execution of those plans. We have limited effective influence over those plans and are heavily dependent on Genentech&#8217;s decision making. Any significant changes to Genentech&#8217;s business strategy and priorities, over which we have no control, could adversely affect Genentech&#8217;s willingness or ability to complete their obligations under our collaboration agreement and result in harm to our business and operations.&#160;Subject to contractual diligence obligations, Genentech has complete control over and financial responsibility for cobimetinib&#8217;s development program, as well as over regulatory and commercial strategy and execution, and we are not able to control the amount or timing of resources that Genentech will devote to the product.&#160;Of particular significance are Genentech&#8217;s development efforts with respect to the combination of cobimetinib with immune checkpoint inhibitors, a competitive area of clinical research. Regardless of Genentech&#8217;s efforts and expenditures for the further development of cobimetinib, the results of such additional clinical investigation may not prove positive and may not produce label expansions or approval in additional indications, which could have a material adverse impact on our long-term revenue prospects. For instance, top-line results from IMblaze370, Genentech&#8217;s phase 3 pivotal trial evaluating the combination of cobimetinib and atezolizumab or atezolizumab alone versus regorafenib, in unresectable locally advanced or metastatic CRC patients who have received at least two lines of prior cytotoxic chemotherapy, are expected in the first half of 2018; should Genentech obtain negative or inconclusive results in this trial, cobimetinib&#8217;s prospects, and its ability to contribute meaningfully to our business, will be substantially impaired.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;&#160; </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. In this regard, in February 2018, the FDA published draft guidance containing product-specific bioequivalence recommendations for drug products containing cabozantinib, the active ingredient in CABOMETYX and COMETRIQ. The FDA regularly issues product specific bioequivalence guidance for products following their approval. The February 2018 draft guidance for drug products containing cabozantinib could have been issued by the FDA as a matter of its own standard practice; it could also indicate that a generic drug manufacturer is investigating whether to submit an ANDA for cabozantinib. The FDA can also approve a 505(b)(2) NDA that relies on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. In either case, we will have to engage in litigation with a potential generic competitor to protect our patent rights, which would require us to incur significant expense and result in distraction for our management team, and could also have an adverse impact on our stock price</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Moreover</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, if any such ANDAs or 505(b)(2) NDAs were to be approved and the patents covering cabozantinib were not upheld in litigation, or if a generic competitor is found not to infringe these patents, the resulting generic competition would negatively affect our business, financial condition and results of operations. In this regard, generic equivalents, which must meet the same quality standards as the branded drugs, would be significantly less costly than ours to bring to market. Companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, regardless of the regulatory approval pathway, the introduction of a generic version of any of our marketed products could result in a significant decrease in the sales of these marketed products and materially harm our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of product candidates is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that a product candidate, even if it is approved for other indications, is ineffective or has an unacceptable safety profile that may significantly decrease the likelihood of regulatory approval in a new indication. The results of preliminary studies do not necessarily predict clinical or commercial success, and later-stage clinical trials may fail to confirm the results observed in earlier-stage trials or preliminary studies. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we have established timelines for manufacturing and clinical development of our product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">timelines. We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of such product candidates, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of efficacy or harmful side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results may require us to conduct further testing or to abandon projects that we had expected to be promising;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our competitors may discover or commercialize other compounds or therapies that show significantly improved safety or efficacy compared to our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">patient registration or enrollment in our clinical testing may be lower than we anticipate, resulting in the delay or cancellation of clinical testing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaborators to provide us on a timely basis with an adequate supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organization or investigators to satisfy their contractual obligations, including deviating from trial protocol; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulators or institutional review boards may withhold authorization to commence or conduct clinical trials of a product candidate, or delay, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their determination that participating patients are being exposed to unacceptable health risks.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we were to have significant delays in or termination of our clinical testing of our product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our clinical and commercial collaboration partners to fund a significant portion of the clinical development of cabozantinib and our product candidates. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for the financial obligations associated with the further development of such product candidates, and as a result, we may be unable to execute our business plan, and our financial results could be materially adversely affected. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to rapidly or effectively continue the further development of our product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions, including those identified based on our discussions with the FDA or such other regulatory authorities. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Completion of clinical trials may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of the product candidate. The duration and the cost of clinical trials may vary significantly over the life of a project as a result of factors relating to the clinical trial, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of patients who ultimately participate in the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of clinical sites included in the trials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the length of time required to enroll suitable patient subjects.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain, and may not result in regulatory approvals for our product candidates, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of our products and product candidates, are subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. We have only limited experience in preparing and filing the applications necessary to gain regulatory approvals. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a MAA to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual, additional indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for our product candidates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more indications beyond advanced RCC and MTC, or one of our other product candidates, the approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, advertising, promotion, marketing and/or production of the product and could impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. For example, in connection with the FDA&#8217;s approval of COMETRIQ for the treatment of progressive, metastatic MTC, we are subject to a post-marketing requirement to conduct a clinical study comparing a lower dose of cabozantinib to the approved dose of 140 mg daily cabozantinib in progressive, metastatic MTC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or eliminate the commercialization of cabozantinib. Further, these agencies may also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we are pursuing internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including where the research methodology used may not be successful in identifying potential product candidates, or where potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profile or other characteristics suggesting that they are unlikely to be effective products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive.&#160;Established companies, in particular, may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160; We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to develop suitable product candidates through internal discovery effort or if we are unable to successfully obtain rights to suitable product candidates, our business, financial condition and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements and Financial Results</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to maintain or increase profitability.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$154.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to accurately predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones and the amount of royalties, if any, from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; our share of the net profits and losses for the commercialization of COTELLIC in the U.S. under our collaboration with Genentech; the amount of royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech; other license and contract revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We have limited commercialization experience and expect to continue to spend significant additional amounts to fund the continued development and commercialization of cabozantinib. In addition, we will continue to expand our product pipeline through our drug discovery efforts and the evaluation of in-licensing and acquisition opportunities that align with our oncology drug expertise, which efforts could involve substantial costs. If we are unable to maintain or increase profitability, the market value of our common stock may decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be forced to limit the expansion of our product development programs or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$452.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;available for operations. Our business operations grew substantially during 2017. To maintain business growth and maximize the clinical and commercial opportunities for cabozantinib, we plan to continue to execute on the U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib, both alone and in combination with other therapies, research and development activities, as well as through in-licensing and acquisition efforts. Our ability to execute on these business objectives will depend on many factors including but not limited to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, medical affairs and distribution capabilities for CABOMETYX and COMETRIQ;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones under our collaboration agreements with Ipsen and Takeda; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of COTELLIC and the revenues generated through our share of related profits and losses for the commercialization of COTELLIC in the U.S. and royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to timely prepare and submit an sNDA for cabozantinib as a treatment for patients with previously treated advanced HCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and corporate development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to control costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the cost of clinical drug supply for our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib, increasing drug discovery activities as well as through in-licensing and acquisition efforts, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations, licensing arrangements, and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets.&#160;Economic conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160; Accordingly, we do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to limit the expansion of our product development programs or commercialization efforts, which could have a material adverse effect on our business and growth prospects.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. The preparation of our financial statements requires us to make significant estimates, assumptions and judgments that affect the amounts of assets, liabilities, revenues and expenses and related disclosures. Significant estimates that may be made by us include assumptions used in the determination of revenue recognition, discounts and allowances from gross revenue, inventory and stock-based compensation. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future, and as a result we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, prospects for profitability or financial position. For example, in May 2014, the Financial Accounting Standards </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Board, or FASB, issued an Accounting Standards Update entitled Accounting Standards Update No. 2014-09,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or ASU 2014-09, which will replace existing revenue recognition guidance in U.S. generally accepted accounting pronouncements when it becomes effective for us in the first quarter of fiscal year 2018. ASU 2014-09 will not have a material impact on the recognition of revenue from product sales; however, ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration agreements with Ipsen and Takeda. We will record a net adjustment of approximately $260 million to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accumulated deficit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(a concept known as &#8220;lost revenue&#8221;) for amounts associated with these collaboration agreements upon recording our transition adjustment in the first quarter of 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration agreements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. For a more detailed description of the impact that ASU 2014-09 and other new accounting standards will have on our reported results, see &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies - Recent Accounting Pronouncements&#8221; to</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;our&#160;&#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The application of existing or future financial accounting standards, particularly those relating to the way we account for revenues and costs, could have a significant impact on our reported results. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subjects us to a number of risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading pharmaceutical and biotechnology companies, including, Ipsen, Takeda, Genentech, Daiichi Sankyo, Merck (known as MSD outside of the U.S. and Canada), BMS and Sanofi for the development and ultimate commercialization of certain compounds generated from our research and development efforts. Our dependence on our relationships with collaborators for the development and commercialization of compounds subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we are not able to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we are not able to control the U.S. commercial resourcing decisions made and resulting costs incurred by Genentech for cobimetinib, which costs we are obligated to share, in part, under our collaboration agreement with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may experience financial difficulties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may not be successful in their efforts to obtain regulatory approvals in a timely manner, or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborators may not comply with applicable healthcare regulatory laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we may be precluded from entering into additional collaboration arrangements with other parties in an area or field of exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of development of our drug candidates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, our product development efforts could be delayed and our business, operating results and financial condition could be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib for the treatment of additional indications beyond advanced RCC and MTC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib independently, including our post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond its approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our drug discovery efforts, which would impede our ability to identify, develop and commercialize our product candidates. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce cabozantinib for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing or distribution facilities for clinical or commercial production and distribution of CABOMETYX and COMETRIQ. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. We expect that this will continue for the foreseeable future for both our current and future commercial products. To establish and manage this supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to ensure compliance with applicable regulatory requirements. Although we maintain significant resources to directly oversee the activities and relationships with the companies in our supply chain effectively, we do not have direct control over their operations. Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach, and their failure to supply us could impair or preclude our ability to meet our commercial supply requirements, or our supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and our business, operating results and financial condition could be adversely affected. Additionally, as part of our collaboration agreements with Ipsen and Takeda, we are responsible for the manufacturing and supply of cabozantinib products for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our collaborators&#8217; ability to successfully develop and commercialize cabozantinib and generate revenues to which we are entitled under the collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our collaborations with outside scientific advisors and collaborators may be subject to restriction and change.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts. These advisors and collaborators are not our employees and may have other commitments that limit their availability to us. Although these advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. In such a circumstance, we may lose work performed by them, and our development efforts with respect to the matters on which they were working may be significantly delayed or otherwise adversely affected. In addition, although </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners. We have also outsourced significant elements of our information technology infrastructure and, as a result, third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced our cyber-security efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. We believe that companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access. In fact, although the aggregate impact on our operations and financial condition has not been material to date, we have been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack and motive (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks continue to become more prevalent and much harder to detect and defend against. Our network and storage applications and those of our vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees and others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant legal and financial exposure. Cyber-attacks could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. Our network security and data recovery measures and those of our vendors may not be adequate to protect against such security breaches and disruptions. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. Notwithstanding our patents, it is possible that a third party that receives FDA approval of an ANDA for a generic version of cabozantinib or an 505(b)(2) NDA with </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">respect to cabozantinib could introduce a generic version of cabozantinib or other such 505(b)(2) product before our patents expire. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical personnel, in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, independent contractors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to commercialize certain product candidates, which could severely harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We plan to move our headquarters and may face disruption and turnover of employees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the first half of 2018, we plan to move our corporate headquarters from South San Francisco, California to Alameda, California. As a result, we expect to incur additional expenses, including those related to tenant improvements, furniture and equipment for the new corporate headquarters, as well as moving and exit costs, and may encounter disruption of operations related to the move, all of which could have an adverse effect on our financial condition and results of operations. In addition, relocation of our corporate headquarters may make it more difficult to retain certain employees, and any resulting loss of talent and need to recruit and train new employees could be disruptive to our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. In addition, the physical expansion of our operations and change of location of our corporate headquarters may lead to significant costs and may divert our management and capital resources. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, our business, financial condition, results of operations and prospects may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plan. Retaining and, where necessary, recruiting qualified clinical, commercial and scientific personnel will be critical to support activities related to advancing the development program for cabozantinib and our other compounds, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial and scientific personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our headquarters are located near known earthquake fault zones, and the occurrence of an earthquake or other disaster could damage our facilities and equipment, which could harm our operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current headquarters in South San Francisco and the planned headquarters in Alameda are located in the San Francisco Bay Area, California and, therefore our facilities are vulnerable to damage from earthquakes. We have limited earthquake insurance, which may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, terrorism and similar events since any insurance we may maintain may not be adequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired. In addition, the unique nature of our research activities could cause significant delays in our programs and make it difficult for us to recover from a disaster. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, could subject us to liability and have a material adverse impact on our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, any hazardous materials used by these parties. Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaborators develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical, biopharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline, causing investor losses.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">customer ordering patterns for CABOMETYX and COMETRIQ, which may vary significantly from period to period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the overall level of demand for CABOMETYX and COMETRIQ, including the impact of any competitive products and the duration of therapy for patients receiving CABOMETYX or COMETRIQ;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of COTELLIC and the revenues generated through our share of related profits and losses for the commercialization of COTELLIC in the U.S. and royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in the amount of deductions from gross sales, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">including changes to the discount percentage of rebates and chargebacks mandated by the government programs in which we participate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government rebates and chargebacks and changes in patient demographics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our sales, marketing, medical affairs and distribution capabilities for CABOMETYX, COMETRIQ and COTELLIC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to timely prepare and submit an sNDA for cabozantinib as a treatment for patients with previously treated advanced HCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones, under our collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the progress and scope of other development and commercialization activities for cabozantinib and our other compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through drug discovery and corporate development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognition of upfront licensing or other fees or revenues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the introduction of new technologies or products by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and willingness of collaborators to further develop or, if approved, commercialize our product candidates out-licensed to them;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the termination or non-renewal of existing collaborations or third-party vendor relationships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adjustments to expenses accrued in prior periods based on management&#8217;s estimates after the actual level of activity relating to such expenses becomes more certain;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general and industry-specific economic conditions that may affect our or our collaborators&#8217; research and development expenditures; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">other factors described in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance. As a result, in some future quarters, our operating results may not meet the expectations of securities analysts and investors, which could result in a decline in the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse results or delays in our or our collaborators&#8217; clinical trials;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaborators&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for cabozantinib or any of our other programs or compounds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates at earlier stages of clinical development or with lesser developed data sets and the speed with which the FDA is conducting regulatory reviews</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products by our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications seeking a path to U.S. approval of generic versions of our marketed products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in our relationships with our collaborators, including the termination or modification of our agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">conflicts or litigation with our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure to achieve operating results projected by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">departures of key personnel or board members;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the extent to which coverage and reimbursement is available for both CABOMETYX and COMETRIQ from government and health administration authorities, private health insurers, managed care programs and other third-party payers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disposition of any of our technologies or compounds; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of the United Kingdom&#8217;s pending withdrawal from the EU and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and health care spending and delivery, including the repeal of the individual mandate and the potential repeal and/or replacement of other portions or all of the PPACA, or greater restrictions on free trade stemming from Trump Administration policies, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material and adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Future sales of our common stock or the perception that such sales or conversions may occur, may depress our stock price.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A substantial number of shares of our common stock are reserved for issuance upon the exercise of stock options, upon vesting of restricted stock unit awards and upon a purchase under our employee stock purchase plan. The issuance and sale of substantial amounts of our common stock or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity or equity-related securities in the future at a time and price that we deem appropriate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a classified Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability of our stockholders to call special meetings of stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">limitations on the removal of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017 that significantly reforms the Internal Revenue Code of 1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction of future net operating losses to 80% of current year taxable income and elimination of net operating loss carry-backs, one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new capital investments instead of deductions for depreciation expense over time, and modifying, reducing or repealing many business deductions and credits (including reducing the business tax credit for certain clinical trial expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Cuts and Jobs Act is uncertain and our business and financial condition could be adversely affected. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2017, or are expected to be recorded in future periods.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, further guidance may be forthcoming from the FASB and SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including the passage of the Tax Cuts and Jobs Act, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, our utilization of federal and state net operating losses, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2017, we had federal and state net operating loss carry-forwards of approximately $1,529 million. The federal and state net operating loss carry-forwards will begin to expire, if not utilized, beginning in 2024 for federal income tax purposes and 2028 for California state income tax purposes. These net operating loss carry-forwards could expire unused and be unavailable to offset future income tax liabilities. While the Tax Cuts and Jobs Act allows for federal </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">n</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">et operating losses incurred in 2018 and in future years to be carried forward indefinitely, the deductibility of such federal net operating losses incurred in 2018 and in future years will be limited.&#160; In addition, u</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nder the Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carry-forwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carry-forwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2017, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses other than the net operating losses expected to be utilized to offset income in 2017, is conditioned upon our maintaining profitability and generating U.S. federal taxable income. We do not know whether or when we will generate the U.S. federal taxable income necessary to utilize our remaining net operating losses. A full valuation allowance has been provided for the entire amount of our remaining net operating losses.</font></div><div><a name="sFC7296A2A6563E3EF82CB6B62E779D29"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1B. Unresolved Staff Comments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">None.</font></div><div><a name="s62F0349472B7D74FBABFB6B62EF388A9"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Properties</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We lease a total of 246,624 square feet of office and research facilities in the San Francisco Bay Area. The leased premises comprise five buildings and are covered by two lease agreements, as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The first lease covers two buildings in South San Francisco, California with a total area of 116,063 square feet and expires in July 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The second lease covers three buildings in Alameda, California with a total area of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">130,561</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet and expires in January 2028. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri;font-size:10pt;color:#000000;">five</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year options to extend the lease and a </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-time option to terminate the lease without cause on the last day of the 8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year of the initial term. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We entered into the Alameda lease in order to replace the facilities in South San Francisco prior to the expiration of the lease for those facilities. We believe that our leased facilities have sufficient space to accommodate our current needs.</font></div><div><a name="s10CCCBFFC89E5DDF245BB6B62F1399E4"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are not a party to any material legal proceedings. We may from time to time become a party or subject to various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><a name="sA911878BDCDBD0431202B6B62F42563B"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s797A2BD1C2AAC6B9241CB6B630286A20"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II</font></div><div><a name="s6BEDD47E90A2A61BA997B6B63048627D"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;EXEL&#8221; since April&#160;11, 2000. The following table sets forth, for the periods indicated, the high and low intraday sales prices for our common stock as reported by the Nasdaq Global Select Market:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Common&#160;Stock Price</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Year ended December 29, 2017:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended September&#160;29, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended December 29, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Year ended December 30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended April 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended July 1, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Quarter ended December 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Holders</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">February&#160;12, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were 420 holders of record of our common stock. The number of record holders is based upon the actual number of holders registered on our books at such date and does not include holders of shares in &#8220;street names&#8221; or persons, partnerships, associations, corporations or other entities identified in security position listings maintained by depository trust companies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dividends</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since inception, we have not paid dividends on our common stock. We currently intend to retain all future earnings, if any, for use in our business and currently do not plan to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board of Directors.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of ours under the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following graph compares, for the five year period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the cumulative total stockholder return for our common stock, the Nasdaq Stock Market (U.S. companies) Index, or the Nasdaq Market Index, and the Nasdaq Biotechnology Index. The graph assumes that $100 was invested on December&#160;31, 2012 in each of our common stock, the Nasdaq Market Index and the Nasdaq Biotechnology Index and assumes reinvestment of any dividends. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;"><img src="fiveyearchart2017a.jpg" alt="fiveyearchart2017a.jpg" style="height:253px;width:470px;"></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:29%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Nasdaq Market Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Nasdaq Biotechnology Index</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div><a name="s42F6166B50FB7B1E43A9B6B5F88763DA"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Selected Financial Data</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following Selected Financial Data has been derived from our audited Consolidated Financial Statements and should be read in conjunction with Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Part II, Item 8. &#8220;Financial Statements and Supplementary Data&#8221; contained in this Annual Report on Form 10-K. The consolidated financial information as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and for the years ended, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are derived from audited Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K. The consolidated financial information as of December&#160;31, 2015, 2014 and 2013, and for each of the years ended December&#160;31, 2014 and 2013, are derived from audited Consolidated Financial Statements not included in this Annual Report on Form 10-K. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;font-weight:bold;">(In thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,895</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">189,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">178,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">57,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,829</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,958</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restructuring (recovery) charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,231</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,567</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">219,578</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">249,569</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">232,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(28,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(121,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(224,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(200,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expenses), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(7,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(42,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(37,021</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(37,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,479</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(238,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax provision (benefit) </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(182</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,297</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(238,192</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1.29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1.29</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, basic </font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">194,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">184,062</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, diluted</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">194,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">184,062</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Calibri,sans-serif;font-size:7pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">457,176</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">479,554</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">253,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">242,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">415,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Working capital (deficit) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">369,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">200,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">178,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">332,223</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">323,256</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">497,940</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">255,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">420,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">395,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,983,147</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,912,925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,751,181</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,489,884</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(140,806</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(159,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div><a name="s9B41A51773DB0223A1C6B6B630E4655E"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Some of the statements under in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;focus,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;will,&#8221; &#8220;may&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of such terms or other similar expressions identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Item&#160;1A. Risk&#160;Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX approved for advanced RCC and COMETRIQ approved for progressive, metastatic MTC. The third product, COTELLIC, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subject of broad clinical development programs for multiple potential oncology indications.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have and continue to be highly focused on the execution of the commercial launch of CABOMETYX for previously treated patients with advanced RCC, originally approved by the FDA in April 2016. On December 19, 2017, approximately two months ahead of the assigned PDUFA action date, the FDA approved CABOMETYX for an expanded indication to include previously untreated patients with advanced RCC. Utilizing our existing commercial and medical affairs organizations and established distribution network, we were prepared to bring CABOMETYX to all eligible patients in the U.S. who may benefit from this treatment option immediately upon approval of the expanded indication.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">While our commercialization efforts for CABOMETYX and COMETRIQ are focused in the U.S. we have licensed development and commercialization rights to cabozantinib outside of the U.S. to Ipsen and Takeda. Ipsen has been granted rights to cabozantinib outside of the U.S. and Japan, and Takeda has been granted rights to cabozantinib in Japan. Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we are working closely with them on these activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Beyond our currently approved indications for advanced RCC and for MTC, we are pursuing other indications that have the potential to expand the number of cancer patients that could benefit from cabozantinib. Most advanced in the cabozantinib development program is our evaluation of CABOMETYX as a treatment for patients with advanced HCC who have previously been treated with sorafenib. On October 16, 2017, we announced that, at the time of the second planned interim analysis, the study&#8217;s IDMC had recommended that CELESTIAL, our company-sponsored, global phase 3 trial comparing cabozantinib to placebo in patients with advanced HCC who had previously progressed on or were intolerant to sorafenib and up to one additional therapy, be stopped because it had met its primary endpoint, with cabozantinib providing a statistically significant and clinically meaningful improvement in OS compared to placebo. Safety data from the study were consistent with the established profile of cabozantinib. Based on the results of CELESTIAL, we plan to submit a sNDA to the FDA in the first quarter of 2018, for CABOMETYX as a treatment for patients with previously treated advanced </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC. Our partner, Ipsen, has informed us that it intends to submit a regulatory dossier for CABOMETYX as a treatment for patients with previously treated advanced HCC to the EMA in the first half of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe that the available clinical data demonstrate that cabozantinib has the potential to be a broadly active anti-cancer agent that can make a meaningful difference in the lives of patients.&#160;Accordingly, we are currently evaluating cabozantinib, both as a single agent and in combination with immune checkpoint inhibitors, in a broad development program comprising over&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial collaboration partners, sponsor some of the trials, while the remaining trials are conducted through our CRADA with NCI-CTEP or our IST program. We are particularly interested in examining cabozantinib&#8217;s potential in combination with immunotherapies to determine if such combinations further improve outcomes for patients. Building on clinical observations that cabozantinib creates a more immune-permissive tumor environment potentially resulting in the cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of immune checkpoint inhibitors in multiple clinical trials. The most advanced of these combination studies includes a phase 3 pivotal trial evaluating cabozantinib in combination with nivolumab in previously untreated, advanced or metastatic advanced RCC and a phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with both previously treated and previously untreated advanced HCC, each in collaboration with BMS. As a further part of our clinical collaboration with BMS, we also plan to evaluate cabozantinib and nivolumab with or without ipilimumab in various other tumor types, including in bladder cancer. Diversifying our exploration of immunotherapy combinations, we have also initiated a phase 1b dose escalation study that is evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Significant progress also continues to be made under our&#160;December 2006 worldwide collaboration agreement with Genentech with respect to the phase 3 clinical development program for our second approved cancer agent, cobimetinib. Genentech is now conducting three phase 3 pivotal trials exploring the combination of cobimetinib with atezolizumab or atezolizumab alone in CRC (IMblaze370) and BRAF wild type melanoma population&#160;(IMspire170), and the combination of cobimetinib with atezolizumab and vemurafenib in BRAF V600 mutant melanoma (IMspire150). Enrollment for IMblaze370 was completed in the first quarter of 2017, and Genentech has announced that top line results for the trial are expected during the first half of 2018. Additionally, the first patient for IMspire170 was enrolled in December 2017. Should these trials prove positive and Genentech obtain regulatory approvals based on such positive results, we believe that cobimetinib could provide us with another meaningful source of revenue.&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As we continue to work to maximize the clinical, therapeutic and commercial potential of cabozantinib and cobimetinib, we remain committed to discovering and developing new cancer therapies for patients. In this regard, we have resumed internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Notably, these efforts are led by some of the same experienced scientists responsible for the discovery of cabozantinib and cobimetinib, which have been approved for commercialization by regulatory authorities, as well as other promising Exelixis compounds, many of which are in earlier stages of clinical and regulatory development, pursuant to our collaborations with Daiichi Sankyo, Merck, BMS and Sanofi.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additional information regarding our business is included in Part I, Item&#160;1, &#8220;Business,&#8221; included in this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2017, we executed on our commercial, development and financial objectives, generating significant revenue from operations and positioning the business to be able to maximize the clinical and commercial potential of CABOMETYX, COMETRIQ and COTELLIC and to expand the product pipeline. Below is a summary of our significant business developments and financial highlights for 2017:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Development Updates</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda received exclusive commercialization rights for current and potential future cabozantinib indications in Japan. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of examining cabozantinib&#8217;s potential in combination with immunotherapies. Pursuant to this collaboration, in July 2017, we initiated CheckMate 9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab in previously untreated, advanced or metastatic RCC. We also initiated CheckMate 040 in July 2017, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluating the same combination and also cabozantinib with both nivolumab and ipilimumab in a phase 1/2 trial in both previously treated and previously untreated advanced HCC. Ipsen has opted in to participate in CheckMate 9ER and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at its choosing.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration with Roche pursuant to which are evaluating cabozantinib and atezolizumab in locally advanced or metastatic solid tumors and in June 2017, we initiated a phase 1b trial evaluating this combination in patients with advanced genitorurinary malignancies, including RCC and UC. The trial is divided in two parts: a dose-escalation phase and an expansion cohort phase. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The primary objective is to determine </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the optimal dose and schedule of daily oral administration of cabozantinib when given in combination with atezolizumab to inform the trial&#8217;s subsequent expansion stage. We subsequently amended the protocol in January 2018 to add four new expansion cohorts to the trial, which will now also include patients with NSCLC and CRPC in addition to previously included patients with RCC and UC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a lease agreement&#160;for an aggregate of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of space in office and research facilities in Alameda, California, which will become our corporate headquarters in 2018. The lease agreement was amended in October 2017 to include an additional </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">19,778</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2017, we entered into an amendment to our collaboration agreement with Genentech in connection with the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">final resolution of claims&#160;asserted in an arbitration proceeding by us against Genentech related to the development, pricing and commercialization of COTELLIC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The amendment provides for a favorably revised revenue and cost-sharing arrangement, that became effective as of July 1, 2017, and that is applicable to current and all potential future commercial uses of COTELLIC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2017, Ipsen received validation from the EMA for the application for variation to the CABOMETYX marketing authorization for the addition of a new indication in previously untreated, advanced or metastatic RCC in adults.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2017, we announced that our partner Daiichi Sankyo reported positive top-line results from&#160;ESAX-HTN,&#160;a phase 3 pivotal trial of esaxerenone, a product of the companies&#8217; prior research collaboration, in patients with essential hypertension in&#160;Japan. With the trial achieving its primary endpoint,&#160;Daiichi Sankyo&#160;communicated its intention to submit a Japanese regulatory application for esaxerenone for an essential hypertension indication in the first quarter of 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, we announced that BMS filed a Clinical Trial Authorization in Europe for a first-in-human study of a ROR&#947; inverse agonist.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2017, we announced that CELESTIAL met its primary endpoint of OS, with cabozantinib providing a statistically significant and clinically meaningful improvement in OS compared to placebo in patients with previously treated advanced HCC. Median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76; 95% CI 0.63-0.92; p=0.0049). </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on these results, we plan to submit an sNDA to the FDA in the first quarter of 2018 for CABOMETYX as a treatment for patients with previously treated advanced HCC. Ipsen has informed us that it intends to submit a regulatory dossier for CABOMETYX as a treatment for patients with previously treated advanced HCC to the EMA in the first half of 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2017, following a priority review and approximately two months ahead of the assigned PDUFA target action date, the FDA approved CABOMETYX for the expanded indication of patients with previously untreated advanced RCC, the most common form of kidney cancer </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in adults. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The FDA&#8217;s priority review and early approval of CABOMETYX was based on results from the randomized phase 2 CABOSUN trial in patients with previously untreated RCC, which demonstrated a statistically significant and clinically meaningful improvement in PFS versus sunitinib, a current standard of care.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2018, we announced updated results from the NCI-CTEP-sponsored phase 1 trial of cabozantinib in combination with nivolumab, with or without ipilimumab, in patients with refractory genitourinary tumors. The updated results demonstrated an acceptable tolerability profile and high rates of durable responses in the previously treated metastatic UC and metastatic RCC cohorts.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2018, updated data from a phase 2 IST of cabozantinib in patients with previously untreated radioiodine-refractory differentiated thyroid carcinoma, or DTC,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Based on the encouraging efficacy results and manageable safety profile in this phase 2 trial and other prior phase 2 trials in previously treated DTC, we plan to initiate a phase 3 pivotal trial evaluating cabozantinib as a treatment for patients with advanced DTC in 2018.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2017 Financial Highlights</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Our net product revenues increased by&#160;</font><font style="font-family:Calibri;font-size:10pt;">$213.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, or </font><font style="font-family:Calibri;font-size:10pt;">158%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to </font><font style="font-family:Calibri;font-size:10pt;">$349.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in 2017 compared to 2016, which primarily </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the growth in product sales of CABOMETYX since the product&#8217;s launch in late April 2016 and an increase in market share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Our collaboration revenues increased by&#160;</font><font style="font-family:Calibri;font-size:10pt;">$47.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, or </font><font style="font-family:Calibri;font-size:10pt;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,&#160;to </font><font style="font-family:Calibri;font-size:10pt;">$103.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in 2017 compared to 2016, primarily due to increases in milestone, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">license, development, royalty and product supply revenues recognized under our collaboration agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Between March 2017 and June 2017, we repaid our $80.0 million term loan with Silicon Valley Bank and retired the Deerfield Notes in consideration for a payment of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$123.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. For additional information on the repayment of our term loan with Silicon Valley Bank and the retirement of the Deerfield Notes, see &#8220;Note 6. Debt&#8221; to our &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments decreased to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as compared to </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">$479.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">primarily due to the payoff of in debt, described above, offset by the increase in product and collaboration revenue</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">2018 Outlook</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In 2018, our key objective remains to maximize the clinical and commercial opportunities for cabozantinib and cobimetinib as oncology franchises. On the commercial front, we are executing on the U.S. launch of CABOMETYX for the expanded indication of previously untreated advanced RCC and working to ensure launch readiness should CABOMETYX be approved by the FDA for previously treated advanced HCC, while also supporting our collaboration partners on the execution of their commercial plans. From the research and development perspective, we intend to continue to invest in our cabozantinib development program, while driving toward the expansion of our product pipeline through drug discovery activities and the evaluation and execution of potential additional in-licensing and acquisition opportunities that align with our oncology drug development expertise.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We anticipate that we will continue to face a number of challenges and risks to our business that may impact our ability to execute on our 2018 business objectives. In particular, we anticipate that for the foreseeable future our ability to generate meaningful unrestricted cash to fund our commercial operations and our development and discovery programs is dependent upon the successful commercialization of CABOMETYX for the treatment of advanced RCC in territories where it has been or may soon be approved </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and in potential other indications for which we are in late-stage development or intend to seek regulatory review</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The commercial opportunity for CABOMETYX as a treatment for advanced RCC remains subject to a variety of factors, most importantly, CABOMETYX&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or currently in development for the treatment of advanced RCC. Our ability to generate meaningful product revenues from CABOMETYX is also affected by a number of other factors, including, the highly competitive markets for which we intend to pursue regulatory approval of cabozantinib and the prospect for new competitive therapies and generic competition, and the extent to which coverage and reimbursement for CABOMETYX is available from government and other third-party payers. Obtaining and maintaining appropriate coverage and reimbursement for CABOMETYX is increasingly challenging due to, among other things, the attention being paid to healthcare cost containment and other potential austerity measures being discussed in the U.S. and worldwide, as well as increasing policy interest in the U.S. with respect to pharmaceutical drug pricing practices. Our ability to fulfill the commercial potential of cabozantinib also depends on our ability to expand the compound&#8217;s use by generating data in clinical development that will support regulatory approval of cabozantinib in additional indications. Achievement of our 2018 business objectives will also depend on our ability to adapt our development and commercialization strategy to navigate the increasing prevalence of immunotherapy competition, as well as the use of combination therapy to treat cancer. Furthermore, our research and development objectives may be curtailed as a result of operational challenges related to organizational growth as we expand drug discovery activities, and we may be unable to successfully identify appropriate candidates for in-licensing or acquisition.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the pharmaceutical industry with development and commercial operations. For a complete discussion of challenges and risks we face, see in Part I, Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><a name="sE76D3F9983D1CCA3F54EB6B5F9BF9884"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">402,569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,499</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(53,561</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,124</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,492</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">57,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;</sup></font><font style="font-family:Calibri,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty and product supply revenues, net </font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">261,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,282</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">136</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">415</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes milestone payments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes amortization of upfront payments.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">213,633</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101,217</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, net product revenues increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">158%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Net product revenues for CABOMETYX increased 247% during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to a 228% increase in the number of units of CABOMETYX sold, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and to a lesser extent,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;an increase in the average selling price of the product. The increase in CABOMETYX sales volume </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the growth in product sales of CABOMETYX since the product&#8217;s launch in late April 2016 and an increase in market share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Net product revenues for COMETRIQ decreased 40% during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to a 53% decrease in the number of units of COMETRIQ sold, partially offset by an increase in the average selling price of the product. The decrease in COMETRIQ sales volume was primarily driven by the adoption of CABOMETYX by our U.S. customers and the change in how our product was distributed outside the U.S., which resulted in a shift from earning product revenues </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during most of 2016 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">under our former </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">distribution </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreement with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Swedish Orphan Biovitrum to earning royalty and other collaboration revenues during 2017 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">under our current collaboration agreement with Ipsen. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have completed our analysis of the adoption of ASU 2014-09, which we will adopt using the modified retrospective method in the first quarter of fiscal year 2018, and we have determined the adoption will not have a material impact on our recognition of net product revenues. For information on our adoption of ASU 2014-09, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, net product revenues increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">296%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increase in CABOMETYX sales volume was primarily due to the impact of the commercial launch of the product in late April 2016. Net </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenues for CABOMETYX during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;were also favorably impacted by the build of channel inventory by the specialty pharmacies and distributors to whom we sell CABOMETYX in connection with its initial launch. Net product revenues for COMETRIQ increased 23% during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to a 15% increase in the number of COMETRIQ units sold as a result of an increase in demand for COMETRIQ, and to a lesser extent, an increase in the average selling price of the product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances. Reserves for chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Rebates and fees due to customers on the accompanying Consolidated Balance Sheets. Total reserve balances were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, 2016 and 2015, respectively. See &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K for a description and a summary of activities for each significant category of discount and allowance. The increase in the reserve balances from </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was the result of an increase in product sales volume, and to a lesser extent, additional reserves for goods in the channel expected to have higher discounts during early 2018, as well as a higher volume in government programs. Those increases were partially offset by payments, the issuance of customer credits and the prior period adjustments for chargebacks and certain rebates. We expect our discounts and allowances as a percentage of gross product revenues to increase during 2018 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as our business evolves and the number of patients participating in government programs increases, the discounts or rebates to government payers increase, and our engagement in commercial contracting which will result in additional discounts or rebates. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in the reserve balances from December&#160;31, 2015 to December&#160;31, 2016 resulted from the increase in discounts and allowances on increased product sales through an expanded distribution network, which included five specialty pharmacies and three specialty distributors during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we implemented following the launch of CABOMETYX and the continued distribution of COMETRIQ through one specialty pharmacy and one specialty distributor. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contract revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;reflect recognition of two milestones totaling </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;resulting from Ipsen&#8217;s receipt of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the validation </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from the EMA for the application for variation to the CABOMETYX marketing authorization for the addition of a new indication in previously untreated, advanced or metastatic RCC in adults</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Payment of the first milestone of $20.0 million was received in the fourth quarter of 2017 and payment of the second milestone of $25.0 million was received in January 2018.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Contract revenues also reflect recognition of two milestones totaling </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;earned from BMS related to the ROR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;collaboration agreement with BMS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Contract revenues for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;reflect recognition of two milestones totaling $20.0 million earned for the first commercial sales of CABOMETYX by Ipsen in Germany and the United Kingdom, a $15.0 million milestone earned from Daiichi Sankyo related to its worldwide license of our compounds that modulate MR, including CS-3150/esaxerenone (a specific rotational isomer of XL550) and a $5.0 million milestone earned from Merck related to its worldwide license of our PI3K-d program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">License revenues consist of the recognition of a portion of the upfront payments and the non-substantive milestone received in connection with our February 2016 collaboration agreement with Ipsen and the upfront payment received in connection with our January 2017 collaboration agreement with Takeda. The </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aggregate </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upfront payments and non-substantive milestone for the Ipsen collaboration agreement has been recognized ratably over the term of the collaboration agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the EU. The upfront payment for the Takeda collaboration agreement has been recognized ratably over the development period of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. For the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of such revenue in connection with the Ipsen collaboration agreement and the Takeda collaboration agreement, respectively. For the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of such revenue in connection with the Ipsen collaboration agreement. No such revenue was recognized in connection with the Takeda collaboration agreement during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or in connection with either agreement during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increase in such revenues is due to the timing of the execution of those agreements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration arrangements with Ipsen and Takeda. For information on our adoption of ASU 2014-09, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;consisted of reimbursements pursuant to our collaboration and license agreements, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;under the Ipsen collaboration agreement and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.3 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;under the Takeda collaboration agreement. There were no such development cost reimbursements during 2016 or 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalty and product supply revenues, net, primarily consisted of royalties on ex-U.S. net sales of COTELLIC under our collaboration agreement with Genentech and royalties on sales of cabozantinib under our collaboration agreement with Ipsen. Under the terms of our supply agreement with Ipsen, we supply product at our cost, as defined in the agreement, and therefore product supply revenues did not have a significant impact on collaboration revenues.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues by significant customer were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,746</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,662</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of total revenues for all periods presented</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">126,327</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">46,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,316</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold and our gross margins were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty payable to GlaxoSmithKline, or GSK, on net sales of any product incorporating cabozantinib, indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, and other third-party logistics and distribution costs for our product. A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and therefore was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. The sale of products containing previously expensed materials resulted in a 3%, 7% and 6% reduction in the Cost of goods sold during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, of materials that were previously expensed and will not be charged to Costs of goods sold in future periods. Write-downs related to excess and expiring inventory were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in Cost of goods sold primarily </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the growth in product sales of CABOMETYX since the product&#8217;s launch in late April 2016 and an increase in market share.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;The increase in gross margin during </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was related to the change in product mix as CABOMETYX sales volumes have increased while COMETRIQ volumes have decreased. CABOMETYX tablets have a lower manufacturing cost than COMETRIQ capsules as the capsules have additional packaging requirements and are produced in smaller quantities due to lower market demand. In addition, during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, write-downs related to excess and expiring inventory had a more significant impact on gross margin than in subsequent periods. We do not expect our gross margin to change significantly during 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total research and development expenses were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(384</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">less than 1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial expenses, personnel expenses, consulting and outside services, stock-based compensation, the allocation of general corporate costs, and temporary personnel expenses. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in research and development expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily related to an increase in personnel expenses, clinical trial costs, and consulting and outside services. The increase in personnel expenses of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a result of increases in headcount associated with our development efforts, our internal discovery program, and our medical affairs organization.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;The increase in clinical trial costs was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Clinical trial costs includes services performed by third-party contract research organizations and other vendors who support our clinical trials. The increase in clinical trial costs was primarily due to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">start-up costs associated with CheckMate 9ER </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and start-up costs associated with our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">phase 1b trial of cabozantinib and atezolizumab in locally advanced or metastatic solid tumors, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partially offset by decreases in costs related to METEOR, our completed phase 3 pivotal trial comparing CABOMETYX to everolimus in patients with previously treated advanced RCC. The increase in consulting and outside services was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and was primarily in support of our discovery and medical affairs organizations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The nominal decrease in research and development expenses for the year ended December&#160;31, 2016, as compared to 2015, was primarily related to clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials. The decrease in clinical trial costs was $8.9 million for the year ended December&#160;31, 2016, as compared to 2015. The decrease in clinical trial costs was primarily due to decreases in costs related to METEOR, partially offset by increases in costs related to CELESTIAL, our phase 3 pivotal trial in previously treated advanced HCC. The decrease in research and development expenses for the year ended December&#160;31, 2016, as compared to 2015, was also related to a decrease in the allocation of general corporate costs and stock-based compensation. The allocation of general corporate costs decreased $4.2 million for the year ended December&#160;31, 2016 as compared to 2015, primarily due to headcount growth in the selling, general and administrative functions. Stock-based compensation decreased $2.3 million for the year ended December&#160;31, 2016 as compared to 2015, primarily due to the 2015 recognition of stock-based compensation expenses for performance-based stock-options tied to the positive top-line data received from the METEOR trial and the anticipated acceptance of our NDA filing with the FDA, partially offset by a bonus to our employees in the form of fully-vested restricted stock units, or RSUs, during 2016. These decreases were almost entirely offset by increases in personnel expenses and consulting and outside services. Personnel and related expenses increased $12.8 million for the year ended December&#160;31, 2016 as compared to 2015 primarily due to the hiring of medical science liaisons as a result of the launch of CABOMETYX and an increase in the accrual for corporate bonuses. Consulting and outside services increased $2.1 million for the year ended December&#160;31, 2016 as compared to 2015 primarily due to increases in activities related to medical affairs and drug safety. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened research and development expenses on a project-by-project basis.&#160;We group our research and development expenses into three categories: development, drug discovery and other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Research and development expenses by category were as follows (in thousands):</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,947</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">44,859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,936</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,655</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">78,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">73,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,334</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,220</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,711</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,351</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes primarily personnel expenses, consulting and outside services, and laboratory supplies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation and the allocation of general corporate costs to research and development. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, the results of and data from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy, which includes the pursuit of commercial collaborations with major pharmaceutical and biotechnology companies for the development of our drug candidates. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development and commercialization efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound, and as a result, we expect our near-term research and development expenses to primarily relate to the clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising over </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ongoing or planned clinical trials across multiple indications. Notable studies of this program include CheckMate 9ER and CheckMate 040, each in collaboration with BMS, as well as the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with Roche</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result, we expect our research and development expenses to increase in 2018 as we continue to expand the cabozantinib development program and our product pipeline. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications, and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know how many of those indications we will ultimately pursue regulatory approval for. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any of our other research and development projects. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total selling, general and administrative expenses were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">57,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">43,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58,840</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation, travel and entertainment, facility costs, legal and accounting costs, marketing costs and charitable contribution expenses. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in selling, general and administrative expenses for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016, was primarily related to increases in personnel expenses, consulting and outside services, marketing costs, charitable contribution expenses and legal and accounting costs. Personnel expenses increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016, primarily due to an increase in general and administrative headcount to support our commercial and research and development organizations. Consulting and outside services increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016, primarily due to increases in consulting for marketing activities. Marketing costs increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016, primarily due to an increase in losses recognized under our collaboration agreement with Genentech. In December 2016, Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay certain disputed costs that had been accrued by us; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the year ended December 31, 2016, we offset Selling, general and administrative expenses with a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;recovery of disputed losses that we had recognized and recorded prior to 2016. Marketing costs also included a loss of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for activities during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;under our collaboration agreement with Genentech, as compared to a loss of $4.5 million for activities during 2016. Charitable contribution expenses increased $5.2 million for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016. Legal and accounting expenses increased </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to 2016, primarily due to increases in costs related to our dispute with Genentech which was resolved during 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in selling, general and administrative expenses for the year ended December&#160;31, 2016, as compared to 2015, was primarily related to increases in personnel expenses, consulting and outside services, travel and entertainment, the allocation of general corporate costs and stock-based compensation. Personnel expenses increased $44.1 million for the year ended December&#160;31, 2016, as compared to 2015, primarily due to an increase in headcount connected with the build-out of our U.S. commercial organization as a result of the launch of CABOMETYX, as well as an increase in incentive compensation and the accrual for corporate bonuses. Consulting and outside services increased $16.0 million for the year ended December&#160;31, 2016, as compared to 2015, primarily due to costs incurred supporting the commercialization and launch of CABOMETYX. Travel and entertainment increased $5.5 million for the year ended December&#160;31, 2016, as compared to 2015, primarily due to travel incurred by our U.S. commercial organization. The allocation of general corporate costs to research and development and cost of goods sold decreased $3.9 million for the year ended December&#160;31, 2016, as compared to 2015, primarily due to headcount growth in the selling, general and administrative functions. Stock-based compensation increased $3.3 million for the year ended December&#160;31, 2016, as compared to 2015, primarily due to headcount growth and a bonus paid to our employees in the form of fully-vested RSUs, which was further offset by the 2015 recognition of expenses for performance-based stock-options described above. These </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increases were partially offset by a decrease in marketing expenses primarily due a decrease in losses recognized under our collaboration agreement with Genentech.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our Selling, general and administrative expenses in 2018 will increase as we continue to support our commercial and research and development organizations. Those expenses may increase further commensurate with potential expanded commercial opportunities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Expenses, net</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other expenses, net, were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(33,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(381</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other expenses, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(7,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(42,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dollar change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Percentage change</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increase in interest income during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to both 2016 and 2015, was a result of both an increase in our investment balances and an increase in the yield earned on those investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decrease in interest expense during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to both 2016 and 2015, was due to the repayment of the Deerfield Notes, in June 2017, the repayment of the Silicon Valley Bank term loan in March 2017, and the conversions and the redemption of the 4.25% convertible senior subordinated notes due 2019, or the 2019 Notes, during the third and fourth quarters of 2016. See &#8220;Note 6 - Debt&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K for more information on the repayment and conversion of our debt.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The change in Other, net during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to both 2016 and 2015, was primarily due to losses on extinguishment of debt. During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we recognized a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;loss on extinguishment of debt, respectively, due to the repayment of the Deerfield Notes in June 2017 and the conversions and the redemption of the 2019 Notes during the third and fourth quarters of 2016. Other, net also included gains of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, related to the August 2016 sale of our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;interest in Akarna Therapeutics, Ltd., or Akarna, to Allergan Holdco UK Limited, or Allergan. We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income Tax Expense</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Income tax expense was as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Income tax expense for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;primarily related to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset any federal taxable income.</font></div><div><a name="sECC014AD80D0E04EB178B6B5FF61AA36"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$154.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to accurately predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones and the amount of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties, if any, from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; our share of the net profits and losses for the commercialization of COTELLIC in the U.S. under our collaboration with Genentech; the amount of royalties from COTELLIC sales outside the U.S. under our collaboration with Genentech; other license and contract revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We have limited commercialization experience and expect to continue to spend significant additional amounts to fund the continued development and commercialization of cabozantinib. In addition, we will continue to expand our product pipeline through our drug discovery efforts and the evaluation of in-licensing and acquisition opportunities that align with our oncology drug expertise, which efforts could involve substantial costs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash and investments, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$452.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;available for operations. We anticipate that </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report. The sufficiency of our cash resources depends on numerous assumptions, including assumptions related to product sales and operating expenses, as well as the other factors set forth in &#8220;Risk Factors&#8221; under the headings &#8220;Risks Related to our Capital Requirements and Financial Results,&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K.&#160;Our assumptions may prove to be wrong or other factors may adversely affect our sources of cash, and as a result we may not have the cash resources to fund our operations as currently planned, which would have a material adverse effect on our business. In addition, we may choose to raise additional funds through the issuance of equity or debt due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current and future operating plans. For example, we may choose to raise additional capital to fund in-licensing or product acquisition opportunities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes our cash flow activities (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,330</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,359</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">46,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in operating assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,946</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">227,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25,845</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,611</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">210,404</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(141,051</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(216,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(169,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents at beginning of year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">141,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">141,634</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our operating activities provided cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$165.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$210.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$141.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash used in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income (loss) for: non-cash operating items such as depreciation and amortization, non-cash interest expense and share-based compensation charges; and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Consolidated Results of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Significant factors that contributed to the decrease in cash provided by operating activities for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, include the upfront nonrefundable payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;received from Ipsen in 2016 in consideration for the exclusive license and other rights contained in our collaboration agreement with Ipsen along with a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$67.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in operating expenses. These were offset by a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$213.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in net product revenues and the upfront nonrefundable payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;received from Takeda in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in consideration for the exclusive license and other rights contained in our collaboration agreement with Takeda.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Significant factors that contributed to the increase in cash provided by operating activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, include the upfront nonrefundable payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;received from Ipsen in the year ended December 31, 2016 and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$101.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in net product revenues, which were partially offset by a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$61.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase in operating expenses in 2016. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our investing activities provided cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$35.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$216.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash used for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$50.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by investing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily due to unrestricted and restricted investment purchases of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$334.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash from the sale and maturity of unrestricted and restricted investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$388.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During 2017 we also invested </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$21.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in property and equipment, primarily related to our new corporate headquarters and research facilities in Alameda, California.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used by investing activities for the year ended December&#160;31, 2016 was primarily due to unrestricted and restricted investment purchases of $377.8 million, less cash from the maturity of unrestricted and restricted investments of $158.6 million.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by investing activities for the year ended December&#160;31, 2015 was primarily due to the maturity of unrestricted and restricted investments of $198.7 million, less unrestricted and restricted investment purchases of $149.6 million.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our financing activities used cash of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$169.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the year ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$15.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$152.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of cash provided for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in financing activities for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was primarily a result of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$185.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;paid for all amounts outstanding under the Deerfield Notes and our term loan with Silicon Valley Bank. Those payments were partially offset by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in proceeds from the issuance of common stock under our equity incentive plans, net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">taxes paid related to net share settlements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the year ended December&#160;31, 2016 was primarily the result of the issuance of common stock under our equity incentive plans, net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">taxes paid related to net share settlements, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">totaling </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$23.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Those proceeds were partially offset by cash payments from the conversion and redemption of the 2019 Notes totaling $7.7 million.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by our financing activities for the year ended December&#160;31, 2015 was primarily due to the issuance of 28,750,000 shares of common stock in July 2015 for net proceeds of $145.6 million and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in proceeds from the issuance of common stock under our equity incentive plans, net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">taxes paid related to net share settlements. Those proceeds were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partially offset by principal payments on debt of $4.4 million.</font></div><div><a name="sE002AD2707286D21835CB6B5FABC2A15"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have contractual obligations in the form of leases and purchase obligations. The following chart details our contractual obligations as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual Obligations </font><font style="font-family:Calibri,sans-serif;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">1-3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">More than 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other financing obligations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,493</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,034</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Purchase and other long-term obligations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total contractual cash obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">60,164</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,787</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">This table does not include potential future royalty obligations to GSK as the amount of such royalty obligations are not estimable.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other financing obligations are related to our build-to-suit lease of office and research facilities located in Alameda, California. For a description of our obligations under our leases, see &#8220;Note 12. Commitments&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Purchase obligations due in 2018 include an obligation, which was capped at $20.9 million, for additional construction costs at our new office and research facilities in Alameda, California. We anticipate entering into additional contractual agreements related to the construction and furnishing of those facilities in 2018. At December&#160;31, 2017, we also had firm purchase commitments related to manufacturing and maintenance of inventory.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</font></div><div><a name="s107D90EBB432F8CF320AB6B63296ABA3"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Estimates </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, share based compensation and inventory reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a complete description of our significant accounting policies, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Net Product Revenues and Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize net product revenues when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. Discounts and allowances are complex and require significant judgment by management. Estimates are assessed each period and updated to reflect current information.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We initially record estimates for these deductions at the time we recognize the gross revenue. Our estimates for the expected utilization are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. For a further description of our discounts and allowance, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues from collaboration agreements primarily consist of upfront license fees, milestone, royalty and/or product supply payments. These arrangements have multiple elements, and our deliverables may include intellectual property rights, distribution rights, delivery of manufactured product, commercial and development activities and participation on joint steering, commercial and development committees. In order to account for these arrangements, we identify the deliverables and evaluate whether the delivered elements have value to our collaboration partner on a stand-alone basis and represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver future goods or services, a right or license to use an asset, or another performance obligation. If we determine that multiple deliverables exist, the consideration is allocated to one or more units of accounting based upon the best estimate of the selling price of each deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement will be combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue then will be determined for those combined deliverables as a single unit of accounting. For a combined unit of accounting, non-refundable upfront fees are recognized in a manner consistent with the final deliverable, which has generally been ratably over the period of our continued involvement. Amounts received in advance of performance are recorded as deferred revenue. The determination of deliverables and the allocation of consideration using selling prices and the period of our continued involvement may involve significant judgments and estimates that will impact revenue recognition. Often, the term of our continued involvement is not contractually defined, and an estimate of the term of our total obligation must be made. Therefore, any changes in the expected term of our continued involvement will impact revenue recognition for the given period. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues and U.S. profits and losses under the collaboration agreement with Genentech based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical activity, adjusted for any changes in facts and circumstances, as appropriate. We base our estimates on the best information available at the time provided to us by our collaboration partners. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases are generally considered to be changes in estimates and will be reflected in our Consolidated Statements of Operations in the period they become known. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets in the Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Trial Accruals</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our clinical trials have been executed with support from contract research organizations and other vendors. We accrue costs for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the activities to be performed for each patient, the number of active clinical sites and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us, which may allow us to make a more accurate estimate in future periods. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Stock Option Valuation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our estimate of compensation expense requires us to determine the appropriate fair value model and a number of complex and subjective assumptions including our stock price volatility, employee exercise patterns and related tax effects. The most significant assumptions are our estimates of the expected volatility and the expected term of the stock option. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The value of a stock option is derived from its potential for appreciation. The more volatile the stock, the more valuable the option becomes because of the greater possibility of significant changes in stock price. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical volatilities when developing an estimate of expected volatility. The expected option term also has a significant effect on the value of the option. The longer the term, the more time the option holder has to allow the stock price to increase without a cash investment and thus, the more valuable the option. Further, lengthier option terms provide more opportunity to exploit market highs. However, empirical data show that employees typically do not wait until the end of the contractual term of a nontransferable option to exercise. Accordingly, we are required to estimate the expected term of the option for input to an option-pricing model. As required under generally accepted accounting principles, we review our valuation assumptions at each grant date and, as a result, from time to time we change the valuation assumptions we use to value stock options granted. The assumptions used in calculating the fair value of stock options represent management&#8217;s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our stock-based compensation could be materially different in the future. For additional description of our stock-based compensation, see &#8220;Note&#160;8. Stock-based Compensation&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;contained in Part II, Item 8 of this Annual Report on Form 10-K .</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221; contained in Part II, Item 8 of this Annual Report on Form 10-K.</font></div><div><a name="s0A7F756E017C820EE403B6B5FBE521E3"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, our exposure to market risk for changes in interest rates relates primarily to our investment portfolio, and as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, this also included our long-term debt. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had cash and investments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$457.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$479.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Our investments are subject to interest rate risk, and our interest income may fluctuate due to changes in interest rates. We manage market risk through diversification requirements mandated by our investment policy, which limits the amount of our portfolio that can be invested in a single issuer. We limit our credit risk by limiting purchases to high-quality issuers. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had debt outstanding of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$189.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Our payment commitments associated with these debt instruments were primarily fixed and consist of interest and principal payments. The fair value of our investments will fluctuate with movements of interest rates. We have estimated the effects on our interest rate sensitive assets and liabilities based on a one percentage point hypothetical adverse change in interest rates as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. For our investments, the estimated effects of hypothetical interest rate changes are obtained from the same third-party pricing sources we use to value our investments. For debt instruments, we determined the estimated effects of hypothetical interest rate changes using the same present value model we use to determine the fair of value of those instruments. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, an increase in the interest rates of one percentage point would have had a net adverse change in the fair value of interest rate sensitive assets and liabilities of ($1.6) million as compared to a net positive change in the fair value of interest rate sensitive assets and liabilities of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">73</font></div></div><hr style="page-break-after:always"><div><a name="sA5E8C1DD373EBD5E1799B6B5E4A5AD09"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 8. Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:86%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDF61B049541ADABB0A10B6B633033C1F"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDF61B049541ADABB0A10B6B633033C1F">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s77CAB85B1C624E75828CB6B5E448DC45"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s77CAB85B1C624E75828CB6B5E448DC45">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD612E4B821B7DBD98B29B6B5E10DBF5A"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD612E4B821B7DBD98B29B6B5E10DBF5A">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA39B25B7E10E4D7FF533B6B5E1CB9AED"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income (Loss)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA39B25B7E10E4D7FF533B6B5E1CB9AED">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s51B79CED94DDB039978FB6B5E11E7188"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s51B79CED94DDB039978FB6B5E11E7188">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4083E2AF5E64105D86ABB6B5E35E3BD3"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4083E2AF5E64105D86ABB6B5E35E3BD3">79</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC4694EA8390D35D971BCB6B635752776"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC4694EA8390D35D971BCB6B635752776">81</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">74</font></div></div><hr style="page-break-after:always"><div><a name="sDF61B049541ADABB0A10B6B633033C1F"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of Exelixis, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Exelixis, Inc. (the &#8220;Company&#8221;) as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;30, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity (deficit) and cash flows for each of the three fiscal years in the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;30, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, and the results of its operations and its cash flows for each of the three fiscal years in the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We have served as the Company&#8217;s auditor since 2002.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">75</font></div></div><hr style="page-break-after:always"><div><a name="s77CAB85B1C624E75828CB6B5E448DC45"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">151,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">204,607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">268,117</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Trade and other receivables, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,192</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">484,874</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">469,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,601</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,575</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,565</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,849</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,565</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,150</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,503</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">115,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">268,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">238,520</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">237,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,643</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">370,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">506,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments (Note 12)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,114,184</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,072,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(347</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(416</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,983,147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">655,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">76</font></div></div><hr style="page-break-after:always"><div><a name="sD612E4B821B7DBD98B29B6B5E10DBF5A"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share data)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">103,469</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">56,079</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">452,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">191,454</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,066</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,552</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,895</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">112,171</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">95,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">96,351</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">116,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">57,305</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restructuring (recovery) charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">914</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">286,567</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">219,578</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,593</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,910</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(28,124</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(121,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other expenses, net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(33,060</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,616</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(381</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total other expenses, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(7,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(42,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(40,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, basic </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income (loss) per share, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><a name="sA39B25B7E10E4D7FF533B6B5E1CB9AED"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities and there was </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;income tax expense related to other comprehensive income (loss) during the periods presented. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">77</font></div></div><hr style="page-break-after:always"><div><a name="s51B79CED94DDB039978FB6B5E11E7188"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:38%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Additional<br>Paid-in<br>Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated<br>Other<br>Comprehensive<br>Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated<br>Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total<br>Stockholders&#8217;<br>Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195,895,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,591,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,751,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(159,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Sale of shares of common stock, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,750,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">145,649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,315,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Warrants transferred from other long-term liabilities </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,470</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">227,960,943</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">228</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,772,123</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(232</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,912,925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(140,806</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock in settlement of convertible notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,009,279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">253,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">253,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,953,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,530</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">289,923,798</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,072,591</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(416</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,983,147</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Accounting Standards Update No. 2016-09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,408,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,404</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,409</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock on warrant exercise</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">877,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296,209,426</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,114,184</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(347</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,829,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">284,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">78</font></div></div><hr style="page-break-after:always"><div><a name="s4083E2AF5E64105D86ABB6B5E35E3BD3"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">154,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(161,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">23,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">22,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">21,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">6,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">13,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Amortization of debt discounts and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">8,432</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">17,041</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Interest paid in kind</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(11,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">8,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3,817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Gain on other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(2,980</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(2,494</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Changes in warrant fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">548</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,589</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,598</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,861</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Trade and other receivables</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(40,839</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(35,318</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(540</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Inventory, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(3,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(3,268</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(1,610</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(325</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">3,010</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">164</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accrued compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">16,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">279</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accrued clinical trial liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5,718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(3,940</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(23,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Accrued collaboration liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">6,928</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(10,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">10,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">13,745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">256,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(2,582</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Other current and long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">9,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">5,090</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(10,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Net cash provided by (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">165,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">210,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(141,051</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(21,143</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(1,703</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(447</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">1,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(319,090</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(369,187</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(143,992</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">336,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">151,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">178,936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from sale of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">37,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,266</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Purchase of restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(15,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(8,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(5,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from maturities of restricted cash and investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">14,650</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">7,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">19,789</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from other equity investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">95</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">35,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(216,048</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">50,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Principal repayments of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(185,788</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(575</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(4,381</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Payments on conversion of convertible notes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(7,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from issuance of common stock, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">145,649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">17,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">25,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">10,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Proceeds from employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">4,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">2,187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">568</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Taxes paid related to net share settlement of equity awards</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(6,563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(4,108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(534</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Net cash (used in) provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(169,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">15,696</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">152,213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">31,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">10,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">61,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash and cash equivalents at beginning of year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">151,686</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">141,634</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">80,395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash and cash equivalents at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">183,164</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">151,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">141,634</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;text-indent:0px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">(Continued on next page)</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Supplemental cash flow disclosure:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">20,460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">21,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">19,822</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Cash paid for taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Non-cash investing and financing activity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Construction in progress deemed to have been acquired under build-to-suit lease</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">14,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Issuance of common stock in settlement of convertible notes</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">286,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Consolidated Financial Statements</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</font></div></div><hr style="page-break-after:always"><div><a name="sC4694EA8390D35D971BCB6B635752776"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="s2FF550550022815CEFFAB6B5E1EB859A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX&#174;&#160;(cabozantinib) tablets approved for advanced renal cell carcinoma (&#8220;RCC&#8221;) and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&#174; (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc. (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts on the accompanying Consolidated Financial Statements have been reclassified to conform to current period presentation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net on the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments on the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were insignificant. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory related costs are recognized as Cost of goods sold on the accompanying Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets on the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">development costs. Only once regulatory approval is obtained, would we begin capitalization of these inventory related costs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:200px;"></td><td style="width:5px;"></td><td style="width:200px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value. We continue to operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018. For information on our adoption of ASU 2014-09, see &#8220;- Recent Accounting Pronouncements,&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;below</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and title has transferred or services have been performed; the price is fixed or determinable; and collectability of the resulting receivable is reasonably assured. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize net product revenues upon delivery of the product and when there are no remaining customer acceptance requirements which is frequently referred to as the &#8220;sell-in&#8221; revenue recognition model. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations generally purchase the product at a discounted price. The specialty pharmacy or distributor, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The specialty pharmacies and distributors in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for prompt payment. We expect the specialty pharmacies and distributors will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;pay fees to our customers for account management, data management and other administrative services.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty pharmacies and distributors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarter&#8217;s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also includes the Medicare Part&#160;D Coverage Gap</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap are based in part on historical utilization rates, specialty pharmacy and distributor customer and payer data and third-party market research data. We also estimate when eligible patients who are prescribed our product enter and exit the insurance coverage gap. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarters&#8217; shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and discounts for prompt payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other customer credits/fees and co-pay assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Rebates and fees due to customers on the accompanying Consolidated Balance Sheets. Balances as of December 31, 2016 have been reclassified to reflect that presentation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration agreements under which we may obtain upfront license fees, milestone, royalty, development cost reimbursements, and/or product supply payments. These arrangements have multiple elements, and our deliverables may include intellectual property rights, distribution rights, delivery of manufactured product, commercial and development activities and participation on joint steering, commercial and development committees. In order to account for these arrangements, we identify the deliverables and evaluate whether the delivered elements have value to our collaboration partner on a stand-alone basis and represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver future goods or services, a right or license to use an asset, or another performance obligation. If we determine that multiple deliverables exist, the consideration is allocated to one or more units of accounting based upon the best estimate of the selling price of each deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement will be combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue then will be determined for those combined deliverables as a single unit of accounting. For a combined unit of accounting, non-refundable upfront fees are recognized in a manner consistent with the final deliverable, which has generally been ratably over the period of our continued involvement. Amounts received in advance of performance are recorded as deferred revenue.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Historically, adjustments have not been material when compared to actual amounts paid by licensees. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases in revenue are generally considered to be changes in estimates and will be reflected in the period they become known. If we are unable to reasonably estimate royalty revenue, we record royalty revenues when they are received. We consider sales-based contingent payments to be royalty revenue which is generally recognized at the date the contingency is achieved. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our product supply revenues are recognized upon delivery of the product. See &#8220;Note 2. Collaboration Agreements&#8221; for a description of our product supply agreements with our collaboration partners.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For certain milestone payments under collaboration agreements, we have made a policy election to recognize revenue using the milestone method. A milestone is an event: (i)&#160;that can be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&#160;that would result in additional payments being due to us. The determination that a milestone is substantive requires estimation and judgment and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is: (i)&#160;commensurate with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from our performance to achieve the milestone, (ii)&#160;relates solely to past performance and (iii)&#160;reasonable relative to all deliverables and payment terms in the arrangement. In making the determination as to whether a milestone is substantive or not, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. A substantive milestone is recognized as revenue in its entirety in the period in which the milestone is achieved. A non-substantive milestone is recognized as revenues over the estimated period of our continued involvement. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are also entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are entitled to low double-digit royalties on ex-U.S. net sales. See &#8220;Note 2. Collaboration Agreements&#8221; for additional information about our collaboration agreement with Genentech. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. As of December 31, 2017, we have not recognized a profit for any year to date period from the commercialization of cobimetinib in the U.S. Until we have recognized a profit under the agreement, losses are recognized as Selling, general and administrative expenses on the accompanying Consolidated Statements of Operations. In connection with our agreement to co-promote with Genentech, we were responsible for providing up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the sales force necessary to assist with the promotion of cobimetinib. Genentech reimburses us for these costs which we include as a reduction of our Selling, general and administrative costs when the obligations are incurred or we become entitled to the cost recovery.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patient Assistance Programs</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We provide CABOMETYX and COMETRIQ at no cost to eligible patients who have no insurance and meet certain financial and clinical criteria through our patient assistance programs. We record the cost of the product as a selling, general and administrative expense at the time the product is shipped to the specialty pharmacy for patient assistance use.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty on sales of any product incorporating cabozantinib payable to GlaxoSmithKline (&#8220;GSK&#8221;), indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. A portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ and CABOMETYX and therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. See &#8220;Note 2. Collaboration Agreements&#8221; for additional information on the royalty payable to GSK on sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other expenses, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The expense for stock-based compensation is based on the grant date fair value of the award; the grant date fair value of Restricted Stock Units (&#8220;RSUs&#8221;) is estimated as the value of the underlying shares of our common stock and the grant date fair value of stock-options is estimated using the Black-Scholes Merton option pricing model. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on a straight-line basis over the requisite service period. Compensation expense relating to awards subject to performance conditions is recognized if it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-09&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences and classification on the statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, with a cumulative adjustment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to accumulated deficit and additional paid-in capital as of January 1, 2017. No prior periods were restated as a result of this change in accounting principle. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on the accompanying Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in operating cash flows of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;along with a corresponding decrease in financing cash flows on the accompanying Consolidated Statement of Cash Flows for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax provision is computed under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">together with assessing carry-forwards </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an unrecognized tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2014-09,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2014-09&#8221;).&#160;In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which delayed the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, which is when we will adopt the standard. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of net product revenues. ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration agreements with Ipsen Pharma SAS (&#8220;Ipsen&#8221;) and Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;). We will record a net adjustment of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$260 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accumulated deficit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(a concept known as &#8220;lost revenue&#8221;) for amounts associated with these collaboration agreements upon recording our transition adjustment in the first quarter of 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration agreements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No.&#160;2016-02,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Leases (Topic 842),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-02&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require both types of leases to be recognized on the balance sheet. The ASU also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 is effective for us for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. We are in the process of assessing the impact of ASU No. 2016-02 on our Consolidated Financial Statements and are considering early adoption of this standard in the first half of 2018. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU No.&#160;2016-15,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-15&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2016-15 addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing and contingent consideration payments made after a business combination. ASU 2016-15 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-15 to have a material impact on our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2016, the FASB issued ASU No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2016-18&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-18 to have a material impact on our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2017-04&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU No.&#160;2017-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#32;Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;(&#8220;ASU 2017-09&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;ASU 2017-09 streamlines the application of modification accounting by stating that when making a change to the terms or conditions of a share-based payment award, a company should apply modification accounting to the award, unless each of the following conditions is met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, and 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2017-09 to have a material impact on our Consolidated Financial Statements.</font></div><div><a name="s43A91C60D949ECD10A05B6B5E11DAA75"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Ipsen for all development and commercial activities, research and development services, and participation on the joint steering, development and commercialization committees (as defined in the collaboration agreement). We determined that these deliverables do not have stand-alone value and accordingly, combined these deliverables into a single unit of accounting and allocated the entire arrangement consideration to that combined unit of accounting. As a result, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aggregate </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;has been recognized ratably over the term of the collaboration agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the European Union (&#8220;EU&#8221;). At the time we entered into the collaboration agreement, we determined that the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;milestone we achieved in September 2016 upon the approval of cabozantinib by the European Commission in previously treated advanced RCC was not substantive due to the relatively low degree of uncertainty and relatively low amount of effort required on our part to achieve the milestone as of the date of the collaboration agreement; the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was deferred and has been recognized ratably over the remainder of the term of the Ipsen collaboration agreement. We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018, which will materially impact the timing of recognition of revenue for our collaboration </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;with Ipsen. For information on our adoption of ASU 2014-09, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the time we entered into the collaboration agreement we determined that the remaining development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We have achieved additional milestones of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$209.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including milestone payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$40.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upon </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">European Medicines Agency (&#8220;EMA&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">filing and the approval of cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced hepatocellular carcinoma (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC&#8221;) and additional milestone payments for other future indications and/or jurisdictions. The collaboration agreement also provides that we will be eligible to receive contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$546.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with the achievement of specified levels of Ipsen sales to end users. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider the contingent payments due to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">us upon the achievement of specified sales volumes to be similar to royalty payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Excluding Ipsen sales in Canada, we </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">received a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was achieved in the fourth quarter of 2017, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and are entitled to receive a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty on the next </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">following this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales. These tiers will reset each calendar year. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In Canada, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of annual net sales and a tiered royalty thereafter, up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on annual net sales; these tiers will also reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with Bristol-Myers Squibb Company (&#8220;BMS&#8221;); CheckMate 040, the phase 1/2 study evaluating the combination of cabozantinib with nivolumab in patients with both previously treated and previously untreated advanced HCC being conducted in collaboration with BMS (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with Roche. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">s a result of a change in operational responsibilities for certain clinical programs, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in March </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017, we reclassified </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of deferred revenue to Accrued collaboration liabilities and accordingly adjusted our amortization of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aggregate </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had paid </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;toward the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of reimbursements due to Ipsen for these clinical programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen in February 2016,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which, pursuant to its amended terms, effective October 2017, we will supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan, indefinitely. The product will be supplied</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">at our cost, as defined in the agreement, which excludes the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty we are required to pay GSK on Ipsen&#8217;s net sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">U.S. Food and Drug Administration (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDA&#8221;) or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen terminated only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestones achieved</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of upfront payments and deferred milestone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,284</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,417</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of supplied product</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,390</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty payable to GSK on net sales by Ipsen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues under the collaboration agreement with Ipsen</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;such revenues for the year ended December 31, 2015. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the collaboration agreement was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$19.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upfront nonrefundable payment from Takeda. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Takeda for all development and commercial activities, research and development services, and participation on the joint executive, development and commercialization committees (as defined in the collaboration agreement). We determined that these deliverables, other than the commercial supply and joint commercialization committee participation, are non-contingent in nature. The commercial supply deliverable was deemed contingent, primarily due to the fact that there is uncertainty around approval in Japan, which is dependent on successful clinical trial results from a study in Japanese patients. We also determined that the non-contingent deliverables do not have stand-alone value, because each one of them has value only if we meet our obligation as a whole to provide Takeda with research and development services, including clinical supply of cabozantinib under the collaboration agreement. Accordingly, we combined the non-contingent deliverables into a single unit of accounting and allocated the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;upfront fee to that combined unit of accounting. We also determined that the level of effort required of us to meet our obligations under the collaboration agreement is not expected to vary significantly over the development period of the collaboration agreement. As a result, the upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, received in the first quarter of 2017, has been recognized ratably over the development period of the collaboration agreement of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018, which will materially impact the timing of recognition of revenue for our collaboration </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;with Takeda. For information on our adoption of ASU 2014-09, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$95.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestones payments for potential future indications. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determined that the development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;associated with potential sales milestones. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, and after the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales. These tiers will reset each calendar year. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the manufacture and supply of cabozantinib to Takeda, as well as a quality agreement setting forth, in detail, the quality assurance arrangements and procedures for our manufacture of cabozantinib. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;years of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of upfront payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues under the collaboration agreement with Takeda</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;such revenues for the year ended December 31, 2016 or 2015. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the collaboration agreement was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$28.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cobimetinib Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genentech Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we were responsible for developing cobimetinib through the determination of the maximum-tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, which Genentech could exercise after receipt of certain phase 1 data from us. In March&#160;2008, Genentech exercised its option to co-develop cobimetinib, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allowed us to provide up to 25% of the total sales force for approved cobimentinib indications in the U.S. Between November 2015 and December 2017, we fielded </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a recent commercial review, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. This decision is not indicative of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of profits and losses from the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of U.S. actual sales, decreasing to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of profits and losses from U.S. actual sales in excess of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$400.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These tiers will reset each calendar year. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (the &#8220;Genentech Collaboration P&amp;L&#8221;) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales of COTELLIC</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,771</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2016 Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay certain disputed costs that had been accrued by us; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the year ended December 31, 2016, we offset Selling, general and administrative expenses with a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;recovery of disputed losses that we had recognized and recorded prior to 2016 and also recognized a loss under the collaboration agreement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for 2016 activities, resulting in a net cost recovery of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with other leading pharmaceutical and biotechnology companies, including BMS, Daiichi Sankyo Company Limited (&#8220;Daiichi Sankyo&#8221;), Roche, Merck (known as MSD outside of the U.S. and Canada) and Sanofi, for various compounds and programs in our portfolio. Pursuant to these collaborations, we have fully out-licensed compounds or programs to a partner for further development and commercialization.&#160;Under each of our collaborations, we are entitled to receive milestones and royalties. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to our partnered compounds, other than cabozantinib and cobimetinib, we are eligible to receive potential contingent payments totaling approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.9 billion</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate on a non-risk adjusted basis, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are related to clinical development milestones, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are related to regulatory milestones and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;are related to commercial milestones, all to be achieved by the various licensees, which may not be paid, if at all, until certain conditions are met.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Daiichi Sankyo</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the mineralocorticoid receptor (&#8220;MR&#8221;), a nuclear hormone receptor </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including CS-3150/esaxerenone (a specific rotational isomer of XL550). Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below. In September 2017, Daiichi Sankyo reported positive top-line results from the phase 3 pivotal trial of CS-3150/esaxerenone and communicated its intention to submit a Japanese regulatory application for CS-3150/esaxerenone for an essential hypertension indication in the first quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive additional development, regulatory and commercialization milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$130.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. In addition, we are entitled to receive royalties on any sales of certain products commercialized under the collaboration. Daiichi Sankyo may terminate the agreement upon ninety days&#8217; written notice in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognized contract revenues of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for milestone payments during the year ended December 31, 2016 under our collaboration agreement with Daiichi Sankyo. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any such revenue during the years ended December 31, 2017 or 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">The Roche Group Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we established a clinical trial collaboration with The Roche Group (&#8220;Roche&#8221;) for the purpose of evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Each party is responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the clinical supply agreement entered into by the parties in February 2017. Based on the dose-escalation results, the trial has the potential to enroll up to four expansion cohorts, including a cohort of patients with previously untreated advanced clear cell RCC and three cohorts of urothelial carcinoma, namely platinum eligible first-line patients, first or second-line platinum ineligible patients and patients previously treated with platinum-containing chemotherapy. The trial was initiated in June 2017 and is open for enrollment. We are the sponsor of the trial, and Roche is responsible for supplying atezolizumab to us. Ipsen has opted to participate in the study and will have access to the results to support potential future development in its territories.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Merck</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December&#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta (&#8220;PI3K-d&#8221;) program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-d program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive additional payments associated with the successful achievement of potential development and regulatory milestones for multiple indications of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$231.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will also be eligible to receive payments for combined sales performance milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$375.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and royalties on net-sales of products emerging from the agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Merck may at any time, upon specified prior notice to us, terminate the license. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by Merck at will or by us for Merck&#8217;s uncured material breach, the license granted to Merck would terminate. In the event of a termination by us for Merck&#8217;s uncured material breach, we would receive a royalty-free license from Merck to develop and commercialize certain joint products. In the event of termination by Merck for our uncured material breach, Merck would retain the licenses from us, and we would receive reduced royalties from Merck on commercial sales of products. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognized contract revenues of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for milestone payments during the years ended December 31, 2016 and 2015, respectively, under our collaboration agreement with Merck. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any such revenue during the year ended December 31, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Bristol-Myers Squibb</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Previously Untreated Advanced RCC, Bladder Cancer and Previously Treated HCC Combination Studies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of evaluating the combination of cabozantinib and nivolumab with or without ipilimumab in various tumor types, including, in RCC, HCC and bladder cancer. To date, CheckMate 9ER, a phase 3 pivotal trial in previously untreated, advanced or metastatic RCC, and CheckMate 040, a phase 1/2 trial in both previously treated and previously untreated advanced HCC evaluating these combinations has been initiated. Pursuant to the terms of the collaboration agreement, each party will grant to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug Application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the supply agreement entered into between the parties in April 2017, and costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two-thirds</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the costs and we will bear </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one-third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the costs for such study treatment arms. Unless earlier terminated, the BMS collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. Ipsen has opted in to participate in both trials (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab) and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at its choosing.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">ROR Collaboration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Under the terms of the collaboration agreement, we were responsible for activities related to the discovery, optimization and characterization of the ROR antagonists during the collaborative research period which began on October&#160;8, 2010 and ended on&#160;July 8, 2013. Since the end of the collaborative research period, BMS has and will continue to have sole responsibility for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible for additional development and regulatory milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$240.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate and commercialization milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement was amended and restated in April 2011 in connection with an assignment of patents to a wholly-owned subsidiary. BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognized contract revenues of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for milestone payments during the year ended December 31, 2017 under our collaboration agreement with BMS. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any such revenue during the years ended December 31, 2016 or 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sanofi</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2009, we entered into a global license agreement with Sanofi for SAR245408 (XL147) and SAR245409 (XL765), leading inhibitors of phosphoinositide-3 kinase (&#8220;PI3K&#8221;), and a broad collaboration for the discovery of inhibitors of PI3K for the treatment of cancer. The license agreement and collaboration agreement became effective on July&#160;7, 2009. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Under the license agreement, Sanofi received a worldwide exclusive license to SAR245408 (XL147) and SAR245409 (XL765), which entered into a series of phase 1, phase 1b/2 or phase 2 clinical trials, and has sole responsibility, including </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">funding, for all subsequent clinical, regulatory, commercial and manufacturing activities. We were notified by Sanofi that the initial clinical trials involving XL147 or XL765 have been terminated or are in the process of concluding, and that Sanofi is still considering whether to initiate any further trials. We are eligible to receive contingent payments associated with development, regulatory and commercial milestones under the license agreement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$745.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in the aggregate, as well as royalties on sales of any products commercialized under the license. Sanofi may, upon certain prior notice to us, terminate the license as to products containing SAR245408 (XL147) and SAR245409 (XL765). In the event of such termination election, Sanofi&#8217;s license relating to such product would terminate and revert to us, and we would receive, subject to certain terms, conditions and potential payment obligations, licenses from Sanofi to research, develop and commercialize such products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any revenue under our collaboration agreement with Sanofi during the three years ended December 31, 2017, 2016 and 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GlaxoSmithKline</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a collaboration with GSK to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under the terms of the product development and commercialization agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. As a result, we retained the rights to develop, commercialize, and license cabozantinib, subject to payment to GSK of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty on net sales of any product incorporating cabozantinib. The product development and commercialization agreement was terminated during 2014, although GSK will continue to be entitled to a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;royalty on net sales by us or our collaboration partners of any product incorporating cabozantinib, including COMETRIQ and CABOMETYX. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Consolidated Statements of Operations. </font></div><div><a name="sA883FC020A1DD417C8CBB6B5E11DADAD"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. INVESTMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investments Available-for-Sale</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash equivalents and investments by security type were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">460,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were nominal or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">zero</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses of investments available-for-sale in an unrealized loss position were as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br>Unrealized<br>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">169,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">172,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross unrealized losses on commercial paper were less than </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$1</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;thousand.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">86</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;investments in an unrealized loss position as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">404,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash is excluded from the table above. The classification of certain restricted investments was dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. As a result, certain investments with contractual maturities within one year were classified as long-term restricted cash and investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we were required to maintain compensating balances of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$81.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in connection with our term loan payable to Silicon Valley Bank, which was included in short-term investments on the accompanying Consolidated Balance Sheet; as a result of our repayment of the term loan, the compensating balance requirement was terminated in March 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Cost Method Equity Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;we recognized gains of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, related to the August 2016 sale of our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;interest in Akarna Therapeutics, Ltd. (&#8220;Akarna&#8221;) to Allergan Holdco UK Limited (&#8220;Allergan&#8221;). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. The gain on sale was included in Other expenses, net on the accompanying Consolidated Statements of Operations. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. The gain on sale of other cost method equity investments was nominal during the year ended December&#160;31, 2015.</font></div><div><a name="s0FBB769DE1989437DE75B6B5E17D01F3"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and therefore was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and 2015, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory expected to be used or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Consolidated Balance Sheets. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the non-current portion of inventory consisted of finished goods. As of December 31, 2016, the non-current portion of inventory consisted of raw materials and a portion of the active pharmaceutical ingredient that was included in work in process inventories. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">98</font></div></div><hr style="page-break-after:always"><div><a name="sB1D08885B5DE6D19D24CB6B5E1BC7EB9"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,310</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,953</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(24,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Build-to-Suit Lease </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with Ascentris 105, LLC (&#8220;Ascentris&#8221;), to lease </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of space in office and research facilities located at 1751, 1801, and 1851 Harbor Bay Parkway, Alameda, California (the &#8220;Premises&#8221;). On October 16, 2017, we executed an amendment to the Lease for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19,778</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of additional space located at the Premises with terms consistent with the original Lease. See &#8220;Note 12. Commitments&#8221; for a description of the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with the Lease, we received a tenant improvement allowance of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;from Ascentris, for the costs associated with the design, development and construction of tenant improvements for the Premises. We are obligated to fund all costs incurred in excess of the tenant improvement allowance and to certain indemnification obligations related to the construction activities. We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises including the building shells did not qualify as &#8220;normal tenant improvements&#8221; under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 840, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Accordingly, for accounting purposes, we are the deemed owner of such portions of the Premises during the construction period. As such, we will capitalize the construction costs as a build-to-suit property within property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. The capitalized construction costs will also include the estimated tenant improvements incurred by Ascentris. Accordingly, we capitalized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of costs related to the Lease in construction in progress as of May 2, 2017, with a corresponding build-to-suit lease obligation in Other long-term liabilities. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have capitalized an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of construction in progress for tenant improvements related to the Premises. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have also prepaid an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for future constructions costs which is included in Other long-term assets on the accompanying Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Once the construction is complete, we will consider the requirements for sale-leaseback accounting treatment, including evaluating whether all risks of ownership have been transferred back to Ascentris, as evidenced by a lack of continuing involvement in the leased property. If the arrangement does not qualify for sale-leaseback accounting treatment, the building assets will remain on the accompanying Consolidated Balance Sheets at their historical cost. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">99</font></div></div><hr style="page-break-after:always"><div><a name="sAE778CACC4223A466879B6B5E0CF22CD"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. DEBT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The amortized carrying amount of our debt was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">189,122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance of unamortized fees and costs was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was recorded as a reduction of the carrying amount of the Convertible notes on the accompanying Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Convertible notes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Secured Convertible Notes due 2018 (&#8220;Deerfield Notes&#8221;)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. The repayment amount totaled </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$123.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which comprised </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$113.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in principal, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of interest paid in kind paid through the repayment date, a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;prepayment penalty associated with the early repayment of the notes and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in accrued and unpaid interest. As a result of the early repayment, there was a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;loss on the extinguishment of the debt which comprised the prepayment penalty and the unamortized fees and costs on the date of the repayment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to our early repayment of the Deerfield Notes, the outstanding principal amount of the notes bore interest at the rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per annum to be paid in cash, quarterly in arrears, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per annum to be paid in kind, quarterly in arrears, for a total interest rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per annum.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">4.25% Convertible Senior Subordinated Notes due 2019 (&#8220;2019 Notes&#8221;)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Between August and November 2016, all </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$287.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;aggregate principal amount outstanding under the 2019 Notes was either converted into </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54,009,279</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of common stock or redeemed for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in cash. In addition, certain holders received inducements of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which included an aggregate cash payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in accrued interest payments which would have been payable if the notes had not been exchanged. Under the terms of the indenture for the 2019 Notes, certain holders who exchanged their notes on August 9, 2016 would have been required to repay the interest payment they received as holders of record on August 1. The exchange transactions were structured such that the holders were not required to repay this interest. We have included those payments as an additional inducement and as financing activities on the accompanying Consolidated Statement of Cash Flows. A summary of loss on extinguishment of debt for the conversion and redemption of the 2019 Notes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash inducements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Waiver of requirement to repay interest, described above</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unamortized discount on redeemed notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third-party costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The stock issuance on the conversion of the notes resulted in an increase to common stock and additional paid-in capital of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$592.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. A portion of the settlement consideration transferred to the holders of the notes was allocated to the reacquisition of the conversion option embedded in the notes, which resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$342.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;reduction of additional paid-in capital. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to the extinguishment of the 2019 Notes, the outstanding principal amount of the notes bore interest at a rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;per annum, payable semi-annually in arrears on February&#160;15 and August&#160;15 of each year. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term loan payable</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On March 29, 2017, we repaid all amounts outstanding under our term loan payable to Silicon Valley Bank. The repayment included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$80.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in principal plus </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in accrued and unpaid interest. There was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;gain or loss on the extinguishment of debt as a result of the repayment of the term loan. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to our early repayment of the term loan payable, the outstanding principal amount of the loan bore interest at the rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;per annum, which was due and payable monthly. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we were required to maintain compensating balances of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$81.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in connection with our term loan payable to Silicon Valley Bank, which was included in short-term investments on the accompanying Consolidated Balance Sheet; as a result of our repayment of the term loan, the compensating balance requirement was terminated in March 2017.</font></div><div><a name="sDB307D61ED39987ED599B6B5E13F8C7B"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. COMMON STOCK AND WARRANTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Conversion of Debt into Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Between August and November 2016, we issued </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54,009,279</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of our common stock pursuant to the conversion of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$286.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of aggregate principal amount of the 2019 Notes. The conversions resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$253.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;increase to shareholder&#8217;s equity and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;loss on extinguishment of debt. See &#8220;Note 6. Debt&#8221; for more information on the conversion of the 2019 Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Sale of Shares of Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2015, we completed a registered underwritten public offering of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28,750,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of our common stock, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3,750,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares issued under the underwriters&#8217; 30-day option to buy shares, at a price of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.40</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission, which was filed and automatically became effective on July 1, 2015. We received </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$145.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;in net proceeds from the offering after deducting the underwriting discount and other expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2014 Warrants</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with an amendment to the note purchase agreement for the Secured Convertible Notes due 2015, (the &#8220;Original Deerfield Notes&#8221;), in January 2014 we issued </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year warrants to purchase an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of our common stock at an exercise price of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.70</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share (the &#8220;2014 Warrants&#8221;). Subsequent to our March 2015 notification of our election to extend the maturity date of the Deerfield Notes, the exercise price of the 2014 Warrants was reset to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.445</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;per share, the term was extended by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;to January 22, 2018, and the 2014 Warrants were transferred to Additional paid-in capital as of that date at their then estimated fair value of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;as their terms had become fixed.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On September 11, 2017, we issued an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">877,451</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares of common stock pursuant to the cashless exercises of the 2014 Warrants issued to an accredited investor transferee. The number of shares issued upon exercise was net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">122,549</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares withheld to effect the cashless exercise of the 2014 Warrants in accordance with their terms. As of December 31, 2017, there are </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;remaining warrants outstanding.</font></div><div><a name="sF22530A302A5ED78B341B6B5E11D70F7"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The allocation of stock-based compensation for our equity incentive plans and our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was as</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and RSUs to employees, directors and consultants. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">20,328,545</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;shares were available for grant under our equity incentive </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">plans. The Board of Directors or a designated Committee of the Board is responsible for administration of our equity incentive plans and determines the term, exercise price and vesting terms of each grant. Stock options have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term, an exercise price equal to the fair market value on the date of grant, and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seven</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year life from the date of grant. Stock options issued prior to May 2011 have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year life from the date of grant. RSUs granted to our employees generally vest annually over a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year term.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Change in Control and Severance Benefit Plan for executives and certain non-executives. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one month</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;before and ending </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">thirteen months</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all of such participant&#8217;s stock options accelerated with the exercise period being extended to no more than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one year</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the beginning of the offering period or</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the end of each</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">month purchase period. Compensation expense related to our ESPP was</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">for the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, we had</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">5,052,500</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares available for issuance under our ESPP. Pursuant to the ESPP, we issued</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">434,523</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">559,936</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">324,315</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares of common stock at an average price per share of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$11.20</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$3.91</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.75</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">during the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. Cash received</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from purchases under the ESPP in the years ended December 31, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options. The weighted average grant-date fair value of our stock option grants and ESPP purchases were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered implied volatility as well as our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">102</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock option activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,999,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,166,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,469,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(229,793</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(258,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.05 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">523,448</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,158,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.46 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$39.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of unrecognized compensation expense related to stock options will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.57 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and the exercise prices, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total intrinsic value of options exercised was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$85.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Cash received from option exercises during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The total estimated fair value of employee options vested and recorded as expense during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2016, March 2016 and July 2015, the Compensation Committee of the Board of Directors of Exelixis convened to determine we had met certain performance objectives for performance-based stock options granted to employees in 2013, 2014 and 2015. As a result of these determinations, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5,870,303</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6,982,613</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;performance-based stock options vested during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">we recognized</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$13.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">in stock-based compensation for those</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock option grants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">. We did</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">t have any</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock options outstanding during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and therefore, did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">stock-based compensation for</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">options during the year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was determined based on the value of the underlying common stock on the date of grant. The expenses relating to RSUs are recognized over their vesting period. A summary of all RSU activity were as follows (dollars in thousands, except per share amounts):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,469,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,137,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(708,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(136,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.95 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">114,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$61.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of unrecognized compensation expense related to employee RSUs will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.20 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">401(k) Retirement Plan</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sponsor the Exelixis, Inc. 401(k) Plan (the &#8220;401(k) Plan&#8221;) whereby eligible employees may elect to contribute up to the lesser of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. We make matching contributions in the form of our common stock of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of each participant&#8217;s contributions into the 401(k) Plan. We recorded compensation expense related to the stock match of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">231,090</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares were available for issuance under the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">401(k) Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</font></div><div><a name="sB13CF98CF6653BDD0B0DB6B5E1BC0D20"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was based on the following income (loss) before income taxes (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(150,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,843</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes for the year ended December&#160;31, 2017 primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset any federal taxable income. The Provision for income taxes for the year ended December 31, 2016 related to state minimum and franchise taxes and were nominal. The Provision for income taxes for the year ended December 31, 2015 relates to state minimum and franchise tax expenses as well as true ups related to prior year tax returns. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of income taxes at the statutory federal income tax rate to our Provision for income taxes included on the accompanying Consolidated Statements of Operations was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax provision (benefit) at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,421</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Debt extinguishment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,726</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(20,548</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">104</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carry-forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carry-forwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">471,327</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Book over tax depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit and charitable contribution carry-forwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,367</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of deferred stock compensation &#8211; non-qualified</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,780</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">629,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(629,062</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unrealized gains on derivatives and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law. The Tax Cuts and Jobs Act contains significant changes to corporate taxation, including among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. As a result of the signing of the Tax Cuts and Jobs Act, we recorded a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$184.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;reduction of our deferred tax assets along with a corresponding reduction of our valuation allowance. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2017, or are expected to be recorded in future periods.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, further guidance may be forthcoming from the FASB and the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Securities and Exchange Commission</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC Topic 740 (&#8220;ASC 740&#8221;) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely (as defined in ASC 740) to be realized and, accordingly, has provided a valuation allowance. The valuation allowance decreased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during 2017 and increased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$92.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;during 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At December&#160;31, 2017, we had federal net operating loss carry-forwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1,105 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2024</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and federal business tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$83 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2037</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also had state net operating loss carry-forwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$424 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2028</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and California research and development tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$28 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which have no expiration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carry-forwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carry-forwards before utilization. We completed a Section 382 study through December 31, 2017, and concluded that an ownership change, as defined under Section 382, had not occurred. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">105</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC 740 clarifies the accounting for uncertainty in income taxes by prescribing the recognition threshold a tax position is required to meet before being recognized in the financial statements. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(29,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,696</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2017 will significantly decrease over the next 12 months.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2016 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods. </font></div><div><a name="sEF2A95DAFD0E508DB4B3B6B5E2D147AE"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,860</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The 2014 Warrants were participating securities and the warrant holders did not have a contractual obligation to share in our losses. See &#8220;Note 7. Common Stock and Warrants&#8221; for a description of the 2014 Warrants.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">106</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potentially dilutive shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deerfield Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2014 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">117,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Deerfield Notes were repaid in June 2017. The 2014 Warrants were exercised in September 2017. The 2019 Notes were converted or redeemed between August and November 2016.</font></div><div><a name="s5CA14C35191BAB723587B6B5E0CFDD08"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. FAIR VALUE MEASUREMENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">388,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and there were no transfers of financial assets or liabilities classified as Level 3 during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;or 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The estimated fair value of our financial instruments that are carried at amortized cost was as follows (in thousands)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">121,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,784</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying amounts of cash, trade and other receivables, accounts payable, accrued collaboration liability, accrued compensation and benefits, accrued clinical trial liabilities, rebates fees due customers, and other liabilities approximate their fair values and are excluded from the tables above. We had no additional financial instruments carried at amortized cost as of December 31, 2017. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">107</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following methods and assumptions were used to estimate the fair value of each class of financial instrument: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We estimated the fair value of our debt instruments using the net present value of estimated future cash flows through maturity. For the Deerfield Notes, we used a discount rate of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we estimated as our current borrowing rate for similar debt as of December&#160;31, 2016, which is a Level 3 input.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For the term loan payable, we used an interest rate that is consistent with money-market rates that would have been earned on our non-interest-bearing compensating balances as our discount rate, which is a Level 2 input.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Financial Assets, Liabilities and Equity Measured on a Nonrecurring Basis</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with the conversions of our 2019 Notes during 2016, we were required to determine the fair value of the settlement consideration received by the holders and the fair value of the liability component of the 2019 Notes, as of the various settlement dates of the conversions. The following methods and assumptions were used to estimate the fair value of those financial instruments:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The settlement consideration comprises, in part, shares of our Common Stock. The fair value of our Common Stock was determined based on the closing market price of our Common Stock on the various settlement dates of the conversions, which are level 1 inputs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of the remaining settlement consideration, which includes cash and the forgiveness of the repayment of certain prior interest payments, approximates fair value; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We estimated the fair value of the liability component of the 2019 Notes using the net present value of estimated future cash flows through maturity. We used a discount rate of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we estimated as our current borrowing rate for straight debt as of September 30, 2016, which is a Level 3 input. </font></div></td></tr></table><div><a name="sF79C9ACBCF81C10199B8B6B5E17DAB5B"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. COMMITMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease with Ascentris for an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of space in office and research facilities located at the Premises in Alameda, California. We also have the right to make certain tenant improvements to the space leased on the Premises. The Lease has an initial term of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;with a target commencement date of February 1, 2018, and, subject to a partial twelve-month rent abatement period, rent payments will begin upon the target commencement date. We have </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">five</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year options to extend the Lease and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-time option to terminate the Lease without cause on the last day of the 8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;year of the initial term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">170,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of space, as that additional space becomes available over the remainder of the initial term at 1601, 1701, 1751, and 1801 Harbor Bay Parkway, Alameda, California at a market rate determined according to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are deemed, for accounting purposes only, to be the owner of portions of the Premises, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;building shells, even though we are not the legal owner. See &#8220;Note 5. Property and Equipment - Build-to-Suit Lease&#8221; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for a further description of the accounting for that portion of the Premises.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On May 2, 2017, we also entered into an Agreement for Conditional Option to Amend Lease (the &#8220;Optional Amendment Agreement&#8221;) with Ascentris. Under the terms of the Optional Amendment Agreement, a current tenant (the &#8220;Tenant&#8221;) occupying approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16,343</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of the facility located at 1801 Harbor Bay Parkway was given the option to relocate to another building on the premises or terminate their current lease early, requiring them to relocate within </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;from the termination date. Under the terms of the Optional Amendment Agreement, we would reimburse Ascentris for the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of costs incurred to induce the Tenant to relocate. In August 2017, the Tenant communicated to Ascentris that they were terminating their lease early. During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recorded a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;expense for our anticipated reimbursement of costs to Ascentris for the Tenant&#8217;s relocation of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;remains payable as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. On October 16, 2017, we executed an amendment to the Lease for an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19,778</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet of space located on the Premises, which includes the space vacated by the Tenant, with terms consistent with the original Lease. Including the amendment, we are obligated to make lease payments totaling $</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;over the Lease term. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">108</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also lease </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;buildings in South San Francisco, California with a total area of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116,063</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;square feet, the lease for which expires in July 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the aggregate future minimum lease payments under our leases were as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:72%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other financing obligations</font><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Year ending December&#160;31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,864</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,129</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,282</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other financing obligations includes payments related to our build-to-suit lease.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Rent expense and sublease income were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross rental expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">less: Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,553</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,205</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net rental expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Letters of Credit and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We obtained a standby letter of credit related to our South San Francisco lease with a credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We obtained two standby letters of credit related to a workers compensation insurance policy with a combined credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We obtained </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;standby letters of credit related to the Lease with Ascentris for a combined credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. All of the letters of credit are fully collateralized by certificates of deposit. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">none</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of our letters of credit have been drawn upon. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of a purchasing card program we initiated during 2007, we were required to provide collateral in the form of certificates of deposit. The collateral requirement at both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The certificate of deposit used to collateralize the standby letter of credit related to our South San Francisco lease was included in short-term restricted cash and investments. The certificates of deposit used to collateralize all other letters of credit and the purchase card program were included in long-term restricted cash and investments.</font></div><div><a name="sE1D49A13ED30CB91B15BB6B5E14FC735"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 13. SEGMENT INFORMATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;business segment which focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Enterprise-wide disclosures about product sales, revenues from major customers, revenues and long-lived assets by geographic area are presented below.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">109</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues earned by geographic region were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">367,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,303</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to regions based on ship-to location and Collaboration revenues are attributed to regions based on the location of the collaboration partner.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;loss, a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;loss and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;gain relating to foreign exchange fluctuations for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110</font></div></div><hr style="page-break-after:always"><div><a name="s204545F8F2FC93FB0C3BB6B5E0DE5DD1"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 14. QUARTERLY FINANCIAL DATA (UNAUDITED)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2017:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120,072</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,510</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">84,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,287</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,058</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,414</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(59,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as Net product revenues less Cost of goods sold. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2016 Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of disputed costs that had been accrued by us as of September 30, 2016; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the quarter ended December 31, 2016, we offset Selling, general and administrative expenses for a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$23.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;recovery of net losses which had been recorded from 2013 through September 30, 2016, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;of losses that we had recognized and recorded during the three quarters ended September 30, 2016. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">111</font></div></div><hr style="page-break-after:always"><div><a name="s55752E216BEC51A5AA06B6B63A940855"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s19A492D68354AAE321A2B6B63AB3BDB2"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9A. Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the Effectiveness of Controls.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S.&#160;generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of the end of our 2017 fiscal year, management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework established in the original </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Internal Control&#160;&#8211; Integrated Framework</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on this assessment, management has determined that our internal control over financial reporting as of December 29, 2017 was effective. There were no material weaknesses in internal control over financial reporting identified by management.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The independent registered public accounting firm Ernst&#160;&amp; Young LLP has issued an audit report on our internal control over financial reporting, which is included on the following page.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in Internal Control Over Financial Reporting.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#32;There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">112</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the Stockholders and the Board of Directors of Exelixis, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We have audited Exelixis, Inc.&#8217;s internal control over financial reporting as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Exelixis, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, based on the COSO criteria. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and December 30, 2016, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity (deficit) and cash flows for each of the three fiscal years in the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and the related notes </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">and our report dated </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;expressed an unqualified opinion thereon. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basis for Opinion</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">113</font></div></div><hr style="page-break-after:always"><div><a name="sAEABB55CCAB04D04CB31B6B63AD23D19"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9B. Other Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable</font></div><div><a name="s135207A531F1ED06F61DB6B63AF19E79"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART III</font></div><div><a name="s27C80F5D5F56FB841600B6B63B118475"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our board of directors, is incorporated by reference to the section entitled &#8220;Proposal&#160;1&#160;&#8211; Election of Class I Directors&#8221; appearing in our Proxy Statement for our 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission, or SEC, within 120 days after </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we refer to as our 2018 Proxy Statement. The information required by this item regarding our executive officers is incorporated by reference to the section entitled &#8220;Executive Officers&#8221; appearing in our 2018 Proxy Statement. The information required by this item regarding compliance with Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference to the section entitled &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; appearing in our 2018 Proxy Statement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Code of Ethics</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Corporate Code of Conduct that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. The Corporate Code of Conduct is posted on our website at www.exelixis.com under the caption &#8220;Investors &amp; Media -- Corporate Governance - </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Corporate Governance Documents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.&#8221;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Corporate Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of the Nasdaq Stock Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</font></div><div><a name="s3C3CB975BD1ECAB3E241B6B63B4FF8D4"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 11. Executive Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the sections entitled &#8220;Compensation of Executive Officers,&#8221; &#8220;Compensation of Directors,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; appearing in our 2018 Proxy Statement.</font></div><div><a name="s2310583CE13DA2FB1278B6B5FEB47879"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item relating to security ownership of certain beneficial owners and management is incorporated by reference to the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in our 2018 Proxy Statement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">114</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Equity Compensation Plan Information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table provides certain information about our common stock that may be issued upon the exercise of stock options and other rights under all of our existing equity compensation plans as of December&#160;31, 2017, which consists of our 2000 Equity Incentive Plan, or the 2000 Plan, our 2000 Non-Employee Directors&#8217; Stock Option Plan, or the Director Plan, our 2000 Employee Stock Purchase Plan, or the ESPP, our 2011 Equity Incentive Plan, or the 2011 Plan, our 2014 Equity Incentive Plan, or the 2014 Plan, our 2016 Inducement Award Plan, or the 2016 Plan, our 2017 Equity Incentive Plan, or the 2017 Plan, and our 401(k) Plan:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Plan Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">securities to&#160;be issued upon exercise of outstanding&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">options, warrants and rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted-average exercise&#160;price of outstanding&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">options, warrants&#160;and&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(c)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Equity compensation plans approved by stockholders</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,576,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup>&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,381,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Equity compensation plans not approved by stockholders</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">395,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup>&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">231,090</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,971,436</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,612,135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1 )</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Equity plans approved by our shareholders are the 2000 Plan, the 2011 Plan, the 2014 Plan, the Director Plan, the 2017 Plan and the ESPP. As of December&#160;31, 2017, a total of </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">5,052,500</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#32;shares of our common stock remained available for issuance under the ESPP, and up to a maximum of 437,237 shares of our common stock may be purchased in the current purchase period. The shares issuable pursuant to our ESPP are not included in the number of shares to be issued pursuant to rights outstanding or and the weighted-average exercise&#160;price of such rights as of December 29, 2017, as those numbers are not known.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The weighted-average exercise price takes into account the shares subject to outstanding restricted stock units, or RSUs, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $6.68.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents shares of our common stock issuable pursuant to the 2016 Plan and 401(k) Plan.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">As of December&#160;31, 2017, no shares of our common stock remained available for issuance under the 2016 Plan. In November 2016, the Board adopted the 2016 Plan pursuant to which we reserved 1,500,000 shares of our common stock for issuance under the 2016 Plan. The only persons eligible to receive grants of Awards under the 2016 Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 - that is, generally, a person not previously an employee or director of Exelixis, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Exelixis. An &#8220;Award&#8221; is any right to receive Exelixis common stock pursuant to the 2016 Plan, consisting of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, or any other stock award.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">We sponsor the 401(k) Plan whereby eligible employees may elect to contribute up to the lesser of 50% of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. The 401(k) Plan permits us to make matching contributions on behalf of all participants. During the year ended December 31, 2017, we matched 100% of the first 3% of participant contributions into the 401(k) Plan in the form of our common stock.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">The weighted-average exercise price takes into account the shares subject to outstanding RSUs, which have no exercise price. The weighted-average exercise price, excluding such outstanding RSUs, is $19.44.</font></div></td></tr></table><div><a name="sE0C1A29EB7DA22337C23B6B63B650CD8"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 13. Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the sections entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Proposal 1 &#8211; Election of Class I Directors&#8221; appearing in our 2018 Proxy Statement.</font></div><div><a name="sF13851D7B2DA56890090B6B63BB5CA23"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 14. Principal Accounting Fees and Services</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The information required by this item is incorporated by reference to the section entitled &#8220;Proposal 2&#160;&#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; appearing in our 2018 Proxy Statement. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">115</font></div></div><hr style="page-break-after:always"><div><a name="sCA04D21DC6BF99A67709B6B63BE5441B"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART IV</font></div><div><a name="s5299B27509BEA9D19B7DB6B5ED78CF6D"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 15. Exhibits, Financial Statement Schedules</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following documents are being filed as part of this report:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following financial statements and the Report of Independent Registered Public Accounting Firm are included in Part II, Item&#160;8:</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:72px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:84%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDF61B049541ADABB0A10B6B633033C1F"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDF61B049541ADABB0A10B6B633033C1F">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s77CAB85B1C624E75828CB6B5E448DC45"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s77CAB85B1C624E75828CB6B5E448DC45">76</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD612E4B821B7DBD98B29B6B5E10DBF5A"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD612E4B821B7DBD98B29B6B5E10DBF5A">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA39B25B7E10E4D7FF533B6B5E1CB9AED"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income (Loss)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA39B25B7E10E4D7FF533B6B5E1CB9AED">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s51B79CED94DDB039978FB6B5E11E7188"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s51B79CED94DDB039978FB6B5E11E7188">78</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4083E2AF5E64105D86ABB6B5E35E3BD3"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4083E2AF5E64105D86ABB6B5E35E3BD3">79</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC4694EA8390D35D971BCB6B635752776"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC4694EA8390D35D971BCB6B635752776">81</a></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">All financial statement schedules are omitted because the information is inapplicable or presented in the Notes to Consolidated Financial Statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following Exhibits are filed as part of this report.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3/10/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/25/2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511330584/d265434dex31.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amended and Restated Bylaws of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12/5/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Specimen Common Stock Certificate.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;vertical-align:top;">S-1,</font></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;vertical-align:top;">as amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">333-96335</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4/7/2000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001409/0001012870-00-001409.txt"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Indemnity Agreement</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;">S-1,</font></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;">as&#160;amended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">333-96335</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3/17/2000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;">10.2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312507101304/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/3/2007</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;">10.3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904034294/a04-12880_1ex10d2.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Equity Incentive Plan (early exercise permissible)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/8/2004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;">10.4</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-align:center;vertical-align:top;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904039592/a04-14803_1ex10d1.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Equity Incentive Plan (early exercise may be restricted)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12/15/2004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000009/exel20131231exhibit106.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/20/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511042330/dex107.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/22/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.7</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000170/def14a-20160413xproxy.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2000 Employee Stock Purchase Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Schedule 14A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4/13/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511149147/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2011 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/24/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.9</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511210303/dex103.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2011 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/4/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.10</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312511210303/dex104.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2011 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/4/2011</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312514217441/d735542dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/29/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.12</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.13</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit103.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (International) under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.14</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit104.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.15</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000026/exel20140630exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/31/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.16</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000042/exel20141014exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2014 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10/16/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.17</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2016 Inducement Award Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.18</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the 2016 Inducement Award Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.19</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000278/exel201611218-kexhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the 2016 Inducement Award Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/22/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.20</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1020.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.21</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1021.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.22</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1022.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.23</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1023.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">117</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1024.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.25</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1025.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-Employee Director Equity Compensation Policy</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.26</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000110465904022709/a04-8650_1ex10d43.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated February 3, 2000, between Exelixis, Inc. and Michael Morrissey, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/5/2004</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.27</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976715000102/exel20150930exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated June 30, 2015, between Exelixis, Inc. and Christopher Senner</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/10/2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.28</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312506135893/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated June&#160;20, 2006, between Exelixis, Inc. and Gisela M. Schwab,&#160;M.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6/26/2006</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.29</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000018/exel20140331exhibit104.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated February 10, 2014, between Exelixis, Inc. and Jeffrey J. Hessekiel.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.30</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000149/exel20151231exhibit1024.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated August 11, 2000, between Exelixis, Inc. and Peter Lamb.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/29/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.31</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1026.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Offer Letter Agreement, dated August 19, 2010, between Exelixis, Inc. and Patrick J. Haley</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.32</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510248047/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Resignation Agreement dated July&#160;22, 2010, by and between Exelixis, Inc. and George A. Scangos</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/4/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.33</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/form8-kannualexecutivecash.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Compensation Information for Named Executive Officers (2017 Bonus Payments and 2018 Base Salaries and Target Bonus Percentages)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Item 5.02 disclosure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/16/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.34</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976718000013/exel20180212exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Annual Cash Bonus Compensation Plan for Executives</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/16/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.35</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1035.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash Compensation Information for Non-Employee Directors.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.36</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000183/exel20170930exhibit104.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.37</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312505116685/dex101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Lease Agreement, dated May&#160;27, 2005, between Exelixis, Inc. and Britannia Pointe Grand Limited Partnership.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/27/2005</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1039.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment to Lease Agreement dated October 16, 2017 to Lease Agreement dated May 2, 2017 between Ascentris 105, LLC and Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">118</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.40*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1045.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.45</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1046.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #1 dated April 16, 2013, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.46</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1047.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment #2 dated July 18, 2016, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the National Institutes of Health and Exelixis, Inc. dated October 5, 2011</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.47</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.43*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit103-ame.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.44*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1049.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.49</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.45*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000183/exel20170930exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.46**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1046.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.47*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976716000260/exel20160331exhibit104-ame.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9/30/2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">119</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.48**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit1048.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.49*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1051.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration Agreement dated December&#160;22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.50*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000019/exel20161231exhibit1052.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment, dated March&#160;13, 2008, to the Collaboration Agreement dated December&#160;22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2/27/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510179304/dex105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment, dated April&#160;30, 2010, to the Collaboration Agreement dated December 22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/5/2010</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.52*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000137/exel20170630exhibit105.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment, dated July 19, 2017, to the Collaboration Agreement dated December 22, 2006, by and between Exelixis, Inc. and Genentech, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.53*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000126/exel2017033110-qaexhibit101.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7/14/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.54*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000069/exel20170331exhibit102.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.55*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976717000069/exel20170331exhibit103.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Ipsen Pharma SAS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5/1/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit121.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Statement Re Computation of Earnings to Fixed Charges</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit211.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subsidiaries of Exelixis, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit231.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Consent of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA580A848D6E176407C61B6B63C53C9FC"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Power of Attorney (contained on signature page)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit311.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit312.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">32.1&#8225;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20171231exhibit321.htm"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">120</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Number</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Incorporation by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Filed</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Herewith</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">File Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Exhibit/</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Appendix</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;text-align:center;">Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Instance Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Labels Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#8224;</sup></font><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Management contract or compensatory plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Confidential treatment granted for certain portions of this exhibit.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Confidential treatment requested for certain portions of this exhibit.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8225;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This certification accompanies this Annual Report on Form 10-K, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div></td></tr></table></div></div><div><a name="s9166F73531D0483F109BB6B63C24555B"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;None provided.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">121</font></div></div><hr style="page-break-after:always"><div><a name="sA580A848D6E176407C61B6B63C53C9FC"></a></div><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</font></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">E</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, I</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">NC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">KNOW ALL PERSONS BY THESE PRESENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, that each person whose signature appears below constitutes and appoints </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">MICHAEL M. MORRISSEY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">CHRISTOPHER J. SENNER </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#32;JEFFREY J. HESSEKIEL </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Signatures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director, President and</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Chief&#160;Executive&#160;Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Executive&#160;Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Chief&#160;Financial&#160;Officer </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;(Principal&#160;Financial and</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accounting&#160;Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">TELIOS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">APADOPOULOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Chairman of the Board</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Stelios Papadopoulos, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HARLES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">OHEN&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Charles Cohen, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;B. F</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ELDBAUM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Carl B. Feldbaum, Esq.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;A</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">LAN</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. G</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARBER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Alan M. Garber, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">122</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:0px;font-size:9pt;"><a style="font-family:Calibri,sans-serif;font-size:9pt;" href="#s7F0290BFF8720281375AB6B62C06CEC5"><font style="font-family:Calibri,sans-serif;font-size:9pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:4%;"></td><td style="width:33%;"></td><td style="width:4%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Signatures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;V</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">INCENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;T. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ARCHESI&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Vincent T. Marchesi, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;G</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">EORGE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">OSTE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">George Poste, D.V.M., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;G</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">EORGE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">CANGOS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">George A. Scangos, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ULIE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">MITH&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Julie A. Smith</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;L</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;W</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ILLSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Lance Willsey, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ACK</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;L. W</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">YSZOMIERSKI&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Jack L. Wyszomierski</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">123</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>2
<FILENAME>exel20171231exhibit1020.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8E08D2FC50665E14AA1D5A1C7AAA30AE"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.20</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2017 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  FEBRUARY 23, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE:  MARCH 22, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;APPROVED BY THE STOCKHOLDERS:  MAY 24, 2017</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY:  DECEMBER 18, 2017</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Successor to and Continuation of 2014 Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan is intended as the successor to and continuation of the Exelixis, Inc. 2014 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Following the Effective Date, no additional stock awards may be granted under the 2014 Plan.  Any unallocated shares remaining available for grant under the 2014 Plan as of 12:01 a.m. Pacific time on the Effective Date (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan&#8217;s Available Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will cease to be available under the 2014 Plan at such time and will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan.  In addition, from and after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date, all outstanding stock awards granted under the 2014 Plan, the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Non-Employee Directors&#8217; Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), the Exelixis, Inc. 2011 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2011 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and the Exelixis, Inc. 2016 Inducement Award Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2016 Inducement Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will remain subject to the terms of the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan, as applicable; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any shares subject to outstanding stock awards granted under the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan that (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding options and stock appreciation rights granted under the 2014 Plan, the 2000 Plan, the 2000 Nonemployee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Appreciation Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder.  All Awards granted on or after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date will be subject to the terms of this Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Employees, Directors and Consultants are eligible to receive Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  However, if required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E) materially expands the types of Awards available for issuance under the Plan.  Except as provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Section 162(m) and Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Delegation to an Officer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.  Any such Stock Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority.  The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Repricing; Cancellation and Re-Grant of Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Minimum Vesting Requirements.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Award will vest until at least twelve (12) months following the date of grant of the Award; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that up to five percent (5%) of the Share Reserve (as defined in Section 3(a)) may be subject to Awards which do not meet such vesting requirement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Dividends and Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and contained in the applicable Award Agreement; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Award Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 24,453,064 shares (which number is the sum of (i) the number of shares (453,064) subject to the 2014 Plan&#8217;s Available Reserve and (ii) an additional 24,000,000 new shares), </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">plus</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(B) the Prior Plans&#8217; Returning Shares, if any, which become available for grant under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A) one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B) 1.5 shares for each share of Common Stock issued pursuant to a Full Value Award.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If (A) any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2017 Plan Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  For each (1) 2017 Plan Returning Share subject to a Full Value Award or (2) Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by 1.5 shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award will no longer </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">be available for issuance under the Plan, including any shares subject to a Stock Award that are not delivered to a Participant because such Stock Award is exercised through a reduction of shares subject to such Stock Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;).  In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Incentive Stock Option Limit.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 50,000,000 shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Section 162(m) Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code, the following limitations will apply.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date any such Stock Award is granted may be granted to any one Participant during any one calendar year.  Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is granted are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards will not satisfy the requirements to be considered &#8220;qualified performance-based compensation&#8221; under Section 162(m) of the Code unless such additional Stock Award is approved by the Company&#8217;s stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of $10,000,000 subject to Performance Cash Awards may be granted to any one Participant during any one calendar year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Limitation on Grants to Non-Employee Directors.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">The (i) maximum number of shares of Common Stock subject to Stock Awards granted under the Plan or otherwise during any one calendar year (beginning with the 2017 calendar year) to any Non-Employee Director, taken together with the (ii) cash fees paid by the Company to such Non-Employee Director during such calendar year, and in both cases for service on the Board, will not exceed $750,000 in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to the  calendar year in which a Non-Employee Director is first appointed or elected to the Board, $1,500,000.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligibility for Specific Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code).  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Ten Percent Stockholders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option.  If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option.  The provisions of separate Options or SARs need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section 5(e) on the transferability of Options and SARs will apply.  Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws.  Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2).  If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to Section 2(g) and any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Non-Exempt Employees.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 2(g), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.  Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Performance Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Performance Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d)(ii)) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Performance Cash Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d)(iii)) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Cash Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Committee and Board Discretion.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.  </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Section 162(m) Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless otherwise permitted in compliance with Section 162(m) of the Code with respect to an Award intended to qualify as &#8220;performance-based compensation&#8221; thereunder, the Committee will establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (A) the date 90 days after the commencement of the applicable Performance Period, and (B) the date on which 25% of the Performance Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain.  Prior to the payment of any compensation under an Award intended to qualify as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where the Performance Goals relate solely to the increase in the value of the Common Stock).  Notwithstanding satisfaction or any completion of any Performance Goals, shares subject to Options, cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of any further considerations as the Committee, in its sole discretion, will determine.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Other Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Corporate Action Constituting Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Change in Time Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Incentive Stock Option Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Electronic Delivery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Compliance with Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code.  To the extent that the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and, to the extent applicable, the Plan and Award Agreements will be interpreted in accordance with the requirements of Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Clawback/Recovery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Capitalization Adjustments.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Section 3(d), and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Dissolution or Liquidation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(c) will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Stock Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Stock Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Payment for Stock Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Stock Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(d) will apply to Stock Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Stock Awards as if such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">280G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then any such 280G Payment (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Pro Rata Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest  economic benefit for the Participant as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Participant receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Board may suspend or terminate the Plan at any time.  No Incentive Stock Option will be granted after</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;No Impairment of Rights.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suspension or termination of the Plan will not materially impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan will become effective on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award or a Performance Cash Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Control Acquisition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;);</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the terms Corporate Transaction and Control Acquisition will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Covered Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; will have the meaning provided in Section 162(m)(3) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant,  the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2017, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Full Value Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if: (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an option granted pursuant to Section 5 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 that does not qualify as an Incentive Stock Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Outside Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Director who either (i) is not a current employee of the Company or an &#8220;affiliated corporation&#8221; (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an &#8220;affiliated corporation&#8221; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an &#8220;affiliated corporation,&#8221; and does not receive remuneration from the Company or an &#8220;affiliated corporation,&#8221; either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an &#8220;outside director&#8221; for purposes of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Cash Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Criteria</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the one or more criteria that the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee (or Board, if applicable): (1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, depreciation and amortization; (4) total stockholder return; (5) return on equity or average stockholder&#8217;s equity; (6) return on assets, investment, or capital employed; (7) stock price; (8) </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">margin (including gross margin); (9) income (before or after taxes); (10) operating income; (11) operating income after taxes; (12) pre-tax profit; (13) operating cash flow; (14) sales or revenue targets; (15) increases in revenue or product revenue; (16) expenses and cost reduction goals; (17) improvement in or attainment of working capital levels; (18) economic value added (or an equivalent metric); (19) market share; (20) cash flow; (21) cash flow per share; (22) share price performance; (23) debt reduction; (24) implementation or completion of projects or processes; (25) customer satisfaction; (26) stockholders&#8217; equity; (27) capital expenditures; (28) debt levels; (29) operating profit or net operating profit; (30) workforce diversity; (31) growth of net income or operating income; (32) billings; and (33) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Committee or Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Goals</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, for a Performance Period, the one or more goals established by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Committee (or Board, if applicable) will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of any items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles.    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the period of time selected by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Stock Award or a Performance Cash Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Committee (or Board, if applicable).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2017 Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(tt)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(uu)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ww)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 405</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(xx)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(yy)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(zz)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aaa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bbb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ccc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ddd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ten Percent Stockholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>3
<FILENAME>exel20171231exhibit1021.htm
<DESCRIPTION>EXHIBIT 10.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3BEF8773D56A5B8AA972D10FE4989AD3"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.21</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><a name="s90823A972AA656BFAC25B61AB59A3EB4"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2017 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">OPTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to your Notice of Grant of Stock Option (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Option Agreement and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has granted you an option under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Your option is granted to you effective as of the Date of Grant set forth in the Grant Notice. This Option Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Grant Notice to which it is attached. Capitalized terms not explicitly defined in this Option Agreement shall have the same meanings given to them in the Plan. In the event of any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan shall control. The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;NUMBER OF SHARES AND EXERCISE PRICE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for Capitalization Adjustments. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (i.e., a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Exempt Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified in your Grant Notice, notwithstanding any other provision of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;METHOD OF PAYMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or by any of the following methods</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;unless prohibited by your Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by such delivery in cash or other permitted form of payment. Notwithstanding the foregoing, you may not exercise your option by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;WHOLE SHARES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You may exercise your option only for whole shares of Common Stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;TERM</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. You may not exercise your option before the commencement or after the expiration of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">immediately upon the termination of your Continuous Service for Cause; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">three (3) months after the termination of your Continuous Service for any reason other than Cause, Disability or death, provided that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above relating to &#8220;Securities Law Compliance,&#8221; your option shall not expire until the earlier of the expiration date indicated in your Grant Notice (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; and provided further that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant specified in your Grant Notice, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option shall not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant specified in your Grant Notice or (B) the date that is three (3) months after the termination of your Continuous Service, or (y) the Expiration Date; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">twelve (12) months after the termination of your Continuous Service due to your Disability; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">eighteen (18) months after your death if you die during your Continuous Service; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Expiration Date indicated in your Grant Notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, if you die during the period provided in Section 7(b) or 7(c) above, the term of your option shall not expire until the earlier of eighteen (18) months after your death or the Expiration Date indicated in your Grant Notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;EXERCISE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You may exercise the vested portion of your option during its term by delivering a notice (in a form designated by the Company) or taking such other action as the Company may require together with delivering the exercise price to the Secretary of the Company, or to such other person as the Company may designate (such as any broker designated by the Company to effect option exercises) during regular business hours, together with such additional documents as the Company may then require. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company or any Affiliate of any tax withholding obligation of the Company or any Affiliate arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;TRANSFERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Certain Trusts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Domestic Relations Orders</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Beneficiary Designation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect option exercises, you may designate a third party who, in the event of your death, shall thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate shall be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;OPTION NOT A SERVICE CONTRACT. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice. Nothing in this Option Agreement (including, but not limited to, the vesting of your option pursuant to the schedule set forth in Section 1 herein or the issuance of the shares upon exercise of your option), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Option Agreement or the Plan shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Option Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Option Agreement or Plan; or (iv) deprive the Company or an Affiliate of the right to terminate you at will and without regard to any future vesting opportunity that you may have. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By accepting this option, you acknowledge and agree that the right to continue vesting in the option pursuant to the schedule set forth in Section 1 is earned only by continuing as an employee, director or consultant at the will of the Company or an Affiliate (not through the act of being hired, being granted this option or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;). You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Option Agreement, including but not limited to, the termination of the right to continue vesting in the option. You further acknowledge and agree that this Option Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Option Agreement, for any period, or at all, and shall not interfere in any way with your right or the Company&#8217;s or an Affiliate&#8217;s right to terminate your Continuous Service at any time, with or without cause and with or without notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with the exercise of your option (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Withholding Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your option by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">payable to you by the Company or an Affiliate; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the exercise of your option with a Fair Market Value (measured as of the date of exercise) equal to the amount of such Withholding Taxes; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your option as a liability for financial accounting purposes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to this Section 11 shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock unless such obligations are satisfied. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;TAX CONSEQUENCES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#8220;fair market value&#8221; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notices provided for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control.  In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;MISCELLANEOUS. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your option shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns. Your rights and obligations under your option may only be assigned with the prior written consent of the Company. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Option Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Option Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;EFFECT ON OTHER EMPLOYEE BENEFIT PLANS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The value of the option subject to this Option Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the Employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Option Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">20.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Option Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Option Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Option Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent. Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Option Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of your option which is then subject to restrictions as provided herein. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>4
<FILENAME>exel20171231exhibit1022.htm
<DESCRIPTION>EXHIBIT 10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s69D6D0ECCCD05FA0B10A64FCB7092F39"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.22</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><a name="s5019FFD748B258EB8C3E1FE233516B03"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2017 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">OPTION AGREEMENT (NON-EMPLOYEE DIRECTORS) <br>(NONSTATUTORY STOCK OPTION)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to your Notice of Grant of Stock Option (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Option Agreement (Non-Employee Directors) and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has granted you an option under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Your option is granted to you effective as of the Date of Grant set forth in the Grant Notice. This Option Agreement (Non-Employee Directors) shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Grant Notice to which it is attached. Capitalized terms not explicitly defined in this Option Agreement (Non-Employee Directors) shall have the same meanings given to them in the Plan. In the event of any conflict between the terms in this Option Agreement (Non-Employee Directors) and the Plan, the terms of the Plan shall control. The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The details of your option are as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;NUMBER OF SHARES AND EXERCISE PRICE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for Capitalization Adjustments. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;EXERCISE PRIOR TO VESTING (&#8220;EARLY EXERCISE&#8221;).</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of your option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a partial exercise of your option shall be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any shares of Common Stock so purchased from installments that have not vested as of the date of exercise shall be subject to the purchase option in favor of the Company as described in the Company&#8217;s form of Early Exercise Stock Purchase Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">you shall enter into the Company&#8217;s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;METHOD OF PAYMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or by any of the following methods</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;unless prohibited by your Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by such delivery in cash or other permitted form of payment. Notwithstanding the foregoing, you may not exercise your option by tender to the Company </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;WHOLE SHARES.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;You may exercise your option only for whole shares of Common Stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option must also comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;TERM</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You may not exercise your option before the commencement or after the expiration of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">three (3) years after the termination of your Continuous Service for any reason (including your Disability or death), provided that if during any part of such three- (3-) year period your option is not exercisable solely because of the condition set forth in the preceding paragraph relating to &#8220;Securities Law Compliance,&#8221; your option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three (3) years after the termination of your Continuous Service; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Expiration Date indicated in your Grant Notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;EXERCISE. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You may exercise your option during its term by delivering a notice (in a form designated by the Company) or taking such other action as the Company may require together with delivering the exercise price to the Secretary of the Company, or to such other person as the Company may designate (such as any broker designated by the Company to effect option exercises) during regular business hours, together with such additional documents as the Company may then require. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;TRANSFERABILITY.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Your option is not transferable, except (i) by will or by the laws of descent and distribution, and (ii) to such further extent as permitted by the Rule as to Use of Form S-8 specified in the General Instructions of the Form S-8 Registration Statement under the Securities Act. Your option is exercisable during your life only by you or a transferee satisfying the above-stated conditions. The right of a transferee to exercise the transferred portion of your option after termination of your Continuous Service shall terminate in accordance with your right to exercise your option as specified in your option. In the event that your Continuous Service terminates due to your death, your transferee will be treated as a person who acquired the right to exercise the transferred portion of your option by bequest or inheritance. In addition to the foregoing, the Company may require, as a condition of the transfer of your option to a trust or by gift, that your transferee enter into an option transfer agreement provided by, or acceptable to, the Company. The terms of your option shall be binding upon your transferees, executors, administrators, heirs, successors, and assigns. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to exercise your option.   In the absence of such a designation, your executor or administrator of your estate shall be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;OPTION NOT A SERVICE CONTRACT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your option is not an employment or service contract, and nothing in your option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option shall obligate the Company or an Affiliate, their respective stockholders, Boards of Directors, Officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;TAX CONSEQUENCES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#8220;fair market value&#8221; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Any notices provided for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;MISCELLANEOUS. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your option shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns. Your rights and obligations under your option may only be assigned with the prior written consent of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Option Agreement (Non-Employee Directors) shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Option Agreement  (Non-Employee Directors) shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Option Agreement (Non-Employee Directors) or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Option Agreement (Non-Employee Directors) or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (Non-Employee Directors) (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Option Agreement (Non-Employee Directors) will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Option Agreement (Non-Employee Directors) may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Option Agreement (Non-Employee Directors) may be amended solely by the Board by a writing which specifically states that it is amending this Option Agreement (Non-Employee Directors), so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent. Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Option Agreement (Non-Employee Directors) in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of your option which is then subject to restrictions as provided herein. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>5
<FILENAME>exel20171231exhibit1023.htm
<DESCRIPTION>EXHIBIT 10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCAC46ED38509529A9F053AB8B80521B8"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.23</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><a name="sBD9F3737481D5892955C40DC85A425A7"></a></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC. <br>2017 EQUITY INCENTIVE PLAN </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;<br>RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to the Restricted Stock Unit Grant Notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Restricted Stock Unit Agreement and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has awarded you a Restricted Stock Unit Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award.  This Restricted Stock Unit Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Restricted Stock Unit Grant Notice to which it is attached.  Capitalized terms not explicitly defined in this Restricted Stock Unit Agreement shall have the same meanings given to them in the Plan.  In the event of any conflict between the terms in this Restricted Stock Unit Agreement and the Plan, the terms of the Plan shall control.  The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GRANT OF THE AWARD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Award represents the right to be issued on a future date the number of shares of the Company&#8217;s Common Stock as indicated in the Grant Notice.  As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Account</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) the number of shares of Common Stock subject to the Award.  Except as otherwise provided herein, you will not be required to make any payment to the Company or an Affiliate (other than past and future services to the Company or an Affiliate) with respect to your receipt of the Award, the vesting of the shares or the delivery of the underlying Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.  Upon such termination of your Continuous Service, the shares credited to the Account that were not vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;NUMBER OF SHARES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other shares covered by your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3.  The Board shall, in its discretion, determine an equivalent benefit for any fractional shares or fractional shares that might be created by the adjustments referred to in this Section 3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not be issued any shares under your Award unless the shares of Common Stock subject to your Award are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Your Award also must comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;TRANSFERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in this Section 5, your Award is not transferable, except by will or by the laws of descent and distribution.  In addition to any other limitation on transfer created by applicable securities laws, you agree not to assign, hypothecate, donate, encumber or otherwise dispose of any interest in any of the shares of Common Stock subject to the Award until the shares are issued to you in accordance with Section 6 of this Restricted Stock Unit Agreement.  After the shares have been issued to you, you are free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein and applicable securities laws.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Certain Trusts.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, you may transfer your Award to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the Award is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your Award pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.  You are encouraged to discuss the proposed terms of any division of this Award with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death pursuant to this Restricted Stock Unit Agreement.  In the absence of such a designation, your executor or administrator of your estate shall be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;DATE OF ISSUANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will deliver to you a number of shares of the Company&#8217;s Common Stock equal to the number of vested shares subject to your Award, including any additional shares received pursuant to Section 3 above that relate to those vested shares on the applicable vesting date(s).  However, if a scheduled delivery date falls on a date that is not a business day, such delivery date shall instead fall on the next following business day.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, in the event that (i) you are subject to the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time (collectively the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), you are subject to a lock-up agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with one or more underwriters or placement agents in connection with an offering or other placement of securities by the Company, or you are otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the public market and any shares covered by your Award are scheduled to be delivered on a day (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Original Distribution Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that (A) does not occur during an open &#8220;window period&#8221; applicable to you or a day on which you are permitted to sell shares of the Company&#8217;s common stock covered by your Award pursuant to a written plan that meets the requirements of Rule 10b5-1 under the Exchange Act, as determined by the Company in accordance with the Policy, (B) occurs within a period during which transactions in Company securities by you are prohibited under the terms of a Lock-Up Agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or (C) does not occur on a date when you are otherwise permitted to sell shares of the Company&#8217;s common stock on the open market, and (ii) the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original Distribution Date and shall instead be delivered, as applicable, on (X) the first business day of the next occurring open &#8220;window period&#8221; applicable to you pursuant to the Policy (regardless of whether you are still providing Continuous Service at such time), (Y) the first business day immediately following the end of the Lock-Up Period, or (Z) the next business day on which you are not otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the open market, but in no event later than the fifteenth (15th) day of the third calendar month of the calendar year following the calendar year in which the Original Distribution Date occurs.  The form of such delivery (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;DIVIDENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;RESTRICTIVE LEGENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;AWARD NOT A SERVICE CONTRACT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice.  Nothing in this Restricted Stock Unit Agreement (including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 herein or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Restricted Stock Unit Agreement or the Plan shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Restricted Stock Unit Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Restricted Stock Unit Agreement or Plan; or (iv)&#160;deprive the Company or an Affiliate of the right to terminate you at will and without regard to any future vesting opportunity that you may have.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award pursuant to the schedule set forth in Section 2 is earned only by continuing as an employee, director or consultant at the will of the Company or an Affiliate (not through the act of being hired, being granted this Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;).  You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Restricted Stock Unit Agreement, including but not limited to, the termination of the right to continue vesting in the Award.  You further acknowledge and agree that this Restricted Stock Unit Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Restricted Stock Unit Agreement, for any period, or at all, and shall not interfere in any way with your right or the Company&#8217;s or an Affiliate&#8217;s right to terminate your Continuous Service at any time, with or without cause and with or without notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">On or before the time you receive a distribution of the shares subject to your Award, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with your Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Withholding Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company or an Affiliate; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair Market Value (measured as of the date shares of Common Stock are issued to you pursuant to Section 6) equal to the amount of such Withholding Taxes; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your Award as a liability for financial accounting purposes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any shares of Common Stock subject to your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event the Company&#8217;s or an Affiliate&#8217;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Company&#8217;s or Affiliate&#8217;s withholding obligation was greater than the amount withheld by the Company or Affiliate, you agree to indemnify and hold the Company and Affiliate harmless from any failure by the Company or Affiliate to withhold the proper amount.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;UNSECURED OBLIGATION</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue shares pursuant to this Restricted Stock Unit Agreement.  You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Restricted Stock Unit Agreement until such shares are issued to you pursuant to Section 6 of this Restricted Stock Unit Agreement.  Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company.  Nothing contained in this Restricted Stock Unit Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or an Affiliate or any other person.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.  In addition, you acknowledge receipt of the Policy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.  Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to request your consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;MISCELLANEOUS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns.  Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Restricted Stock Unit Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Restricted Stock Unit Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.  In addition, your Award (and any compensation paid or shares issued under your Award) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Restricted Stock Unit Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Restricted Stock Unit Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Restricted Stock Unit Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;EFFECT ON OTHER EMPLOYEE BENEFIT PLANS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The value of the Award subject to this Restricted Stock Unit Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the Employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Restricted Stock Unit Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Restricted Stock Unit Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company.  Notwithstanding the foregoing, this Restricted Stock Unit Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Restricted Stock Unit Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent.  Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Restricted Stock Unit Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>6
<FILENAME>exel20171231exhibit1024.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7F44C62D6B775FB89562FB346C06AEB2"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.24</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><a name="s36DE046F940550ECA9D0050258A3E860"></a></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2017 EQUITY INCENTIVE PLAN </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;<br>RESTRICTED STOCK UNIT AGREEMENT (NON-EMPLOYEE DIRECTORS)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to the Restricted Stock Unit Grant Notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Restricted Stock Unit Agreement (Non-Employee Directors) and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has awarded you a Restricted Stock Unit Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award.  This Restricted Stock Unit Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Restricted Stock Unit Grant Notice to which it is attached.  Capitalized terms not explicitly defined in this Restricted Stock Unit Agreement shall have the same meanings given to them in the Plan.  In the event of any conflict between the terms in this Restricted Stock Unit Agreement and the Plan, the terms of the Plan shall control.  The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GRANT OF THE AWARD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Award represents the right to be issued on a future date the number of shares of the Company&#8217;s Common Stock as indicated in the Grant Notice.  As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Account</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) the number of shares of Common Stock subject to the Award.  Except as otherwise provided herein, you will not be required to make any payment to the Company (other than past and future services to the Company) with respect to your receipt of the Award, the vesting of the shares or the delivery of the underlying Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.  Upon such termination of your Continuous Service, the shares credited to the Account that were not vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;NUMBER OF SHARES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other shares covered by your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3.  The Board shall, in its discretion, determine an equivalent benefit for any fractional shares or fractional shares that might be created by the adjustments referred to in this Section 3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not be issued any shares under your Award unless the shares of Common Stock subject to your Award are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Your Award also must comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;TRANSFERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in this Section 5, your Award is not transferable, except by will or by the laws of descent and distribution.  In addition to any other limitation on transfer created by applicable securities laws, you agree not to assign, hypothecate, donate, encumber or otherwise dispose of any interest in any of the shares of Common Stock subject to the Award until the shares are issued to you in accordance with Section 6 of this Restricted Stock Unit Agreement.  After the shares have been issued to you, you are free to assign, hypothecate, donate, encumber or otherwise </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein and applicable securities laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Certain Trusts.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, you may transfer your Award to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the Award is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your Award pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.  You are encouraged to discuss the proposed terms of any division of this Award with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death pursuant to this Restricted Stock Unit Agreement.  In the absence of such a designation, your executor or administrator of your estate shall be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;DATE OF ISSUANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will deliver to you a number of shares of the Company&#8217;s Common Stock equal to the number of vested shares subject to your Award, including any additional shares received pursuant to Section 3 above that relate to those vested shares on the applicable vesting date(s).  However, if a scheduled delivery date falls on a date that is not a business day, such delivery date shall instead fall on the next following business day.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, in the event that (i) Withholding Taxes apply to the distribution of the shares subject to your Award, (ii) you are subject to the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time (collectively the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), you are subject to a lock-up agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with one or more underwriters or placement agents in connection with an offering or other placement of securities by the Company, or you are otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the public market and any shares covered by your Award are scheduled to be delivered on a day (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Original Distribution Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that (A) does not occur during an open &#8220;window period&#8221; applicable to you or a day on which you are permitted to sell shares of the Company&#8217;s common stock covered by your Award pursuant to a written plan that meets the requirements of Rule 10b5-1 under the Exchange Act, as determined by the Company in accordance with the Policy, (B) occurs within a period during which transactions in Company securities by you are prohibited under the terms of a Lock-Up Agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or (C) does not occur on a date when you are otherwise permitted to sell shares of the Company&#8217;s common stock on the open market, and (iii) the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original Distribution Date and shall instead be delivered, as applicable, on (X) the first business day of the next occurring open &#8220;window period&#8221; applicable to you pursuant to the Policy (regardless of whether you are still providing Continuous Service at such time), (Y) the first business day immediately following the end of the Lock-Up Period, or (Z) the next business day on which you are not otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the open market, but in no event later than the fifteenth (15th) day of the third calendar month of the calendar year following the calendar year in which the Original Distribution Date occurs.  The form of such delivery (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;DIVIDENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;RESTRICTIVE LEGENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;AWARD NOT A SERVICE CONTRACT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice.  Nothing in this Restricted Stock Unit Agreement (including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 herein or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Restricted Stock Unit Agreement or the Plan shall: (i) confer upon you any right to continue in the service of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of service or affiliation; (iii) confer any right or benefit under this Restricted Stock Unit Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Restricted Stock Unit Agreement or Plan; or (iv)&#160;deprive the Company of the right to terminate you at will and without regard to any future vesting opportunity that you may have.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award pursuant to the schedule set forth in Section 2 is earned only by continuing as an employee, director or consultant at the will of the Company (not through the act of being hired, being granted this Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;).  You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Restricted Stock Unit Agreement, including but not limited to, the termination of the right to continue vesting in the Award.  You further acknowledge and agree that this Restricted Stock Unit Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee, director or consultant for the term of this Restricted Stock Unit Agreement, for any period, or at all.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">On or before the time you receive a distribution of the shares subject to your Award, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with your Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Withholding Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair Market Value (measured as of the date shares of Common Stock are issued to you pursuant to Section 6) equal to the amount of such Withholding Taxes; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your Award as a liability for financial accounting purposes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any shares of Common Stock subject to your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event the Company&#8217;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Company&#8217;s withholding obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;UNSECURED OBLIGATION</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue shares pursuant to this Restricted Stock Unit Agreement.  You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Restricted Stock Unit Agreement until such shares are issued to you pursuant to Section 6 of this </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted Stock Unit Agreement.  Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company.  Nothing contained in this Restricted Stock Unit Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.  In addition, you acknowledge receipt of the Policy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.  Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to request your consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;MISCELLANEOUS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns.  Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Restricted Stock Unit Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Restricted Stock Unit Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.  In addition, your Award (and any compensation paid or shares issued under your Award) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Restricted Stock Unit Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Restricted Stock Unit Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Restricted Stock Unit Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;EFFECT ON OTHER EMPLOYEE BENEFIT PLANS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event that you become an Employee, the value of the Award subject to this Restricted Stock Unit Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Restricted Stock Unit Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Restricted Stock Unit Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company.  Notwithstanding the foregoing, this Restricted Stock Unit Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Restricted Stock Unit Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent.  Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Restricted Stock Unit Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>7
<FILENAME>exel20171231exhibit1025.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1DE2E422155A5DEB8106B519E1E67E8C"></a></div><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.25</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NON-EMPLOYEE DIRECTOR EQUITY COMPENSATION POLICY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  FEBRUARY 23, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE BOARD OF DIRECTORS:  SEPTEMBER 7, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 15, 2018</font></div><div style="line-height:120%;text-align:left;text-indent:220px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each member of the board of directors (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) of Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) who is not an Employee (as defined in the Exelixis, Inc. 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2017 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)) (each, a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be eligible to receive equity compensation as set forth in this Exelixis, Inc. Non-Employee Director Equity Compensation Policy (this &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  The Initial Option Grants, Initial RSU Grants, Annual Option Grants and Annual RSU Grants (each as defined below) described in this Policy will be granted automatically and without further action of the Board to each Non-Employee Director who is eligible to receive such equity compensation, unless such Non-Employee Director declines the receipt of such equity compensation by written notice to the Company; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that notwithstanding the foregoing or anything in this Policy to the contrary, any equity grants scheduled to be granted on a certain date pursuant to this Policy will not be granted automatically if (i) the number of shares available for issuance under the 2017 Plan is insufficient to make all such grants on such date or (ii) making any such grants would exceed any applicable limits in the 2017 Plan.  This Policy will become effective on the date of the annual meeting of the Company&#8217;s stockholders held in 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), provided that the 2017 Plan is approved by the Company&#8217;s stockholders at such annual meeting, and will remain in effect until it is revised or rescinded by further action of the Board.  Upon this Policy becoming effective on the Effective Date, (i) this Policy will replace and supersede in its entirety the Exelixis, Inc. Non-Employee Director Equity Compensation Policy adopted by the Board on February 28, 2014, as amended (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which provided for equity grants under the Exelixis, Inc. 2014 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and (ii) the Prior Policy will be rescinded and no longer in effect as of the Effective Date, provided that any equity grants made pursuant to the Prior Policy will remain subject to the terms of the Prior Policy, except as otherwise provided in Sections (e)(ii) and (f)(ii) below.  Capitalized terms not explicitly defined in this Policy but defined in the 2017 Plan will have the same definitions as in the 2017 Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The equity grants described in this Policy will be granted under the 2017 Plan and will be subject to the terms and conditions of (i) the 2017 Plan, (ii) the forms of grant notices and agreements approved by the Board for the grant of equity to Non-Employee Directors and (iii) this Policy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initial Grants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each person who is elected or appointed for the first time to be a Non-Employee Director automatically will be granted, upon the date of his or her initial election or appointment to be a Non-Employee Director, equity grants with a combined total dollar value of $680,000, which will be divided between approximately 50% in the form of a nonstatutory stock option (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Initial Option Grant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and approximately 50% in the form of a restricted stock unit award (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Initial RSU Grant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), based on the valuation methodology established by the Board.  The number of shares of Common Stock subject to each Initial Option Grant and Initial RSU Grant will be based on such methodology and the average of the daily closing sales prices of the Common Stock for all of the trading days during the 30 calendar day period ending on (and including) the last calendar day immediately prior to the grant date of such Initial Option Grant and Initial RSU Grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Annual Grants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;On the day following each annual meeting of the Company&#8217;s stockholders, each person who is then a Non-Employee Director automatically will be granted equity grants with a combined total dollar value of $340,000, which will be divided between approximately 50% in the form of a nonstatutory stock option (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Annual Option Grant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and approximately 50% in the form of a restricted stock unit award (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Annual RSU Grant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), based on the valuation methodology established by the Board; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Non-Employee Director may instead elect to receive 100% of such equity grants in the form of a nonstatutory stock option (in which case, the term &#8220;Annual Option Grant&#8221; will refer to such nonstatutory stock option).  Any such election must be made by a Non-Employee Director by the date required by the Company and will remain in effect until revoked by such Non-Employee </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Director, provided that any such revocation is made by the date required by the Company.  The number of shares of Common Stock subject to each Annual Option Grant and Annual RSU Grant, if any, will be based on such methodology and the average of the daily closing sales prices of the Common Stock for all of the trading days during the 30 calendar day period ending on (and including) the last calendar day immediately prior to the grant date of such Annual Option Grant and Annual RSU Grant, if any.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Terms of Options.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exercise Price</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The exercise price of each Initial Option Grant and Annual Option Grant will be equal to 100% of the Fair Market Value of the Common Stock subject to such option on the date such option is granted.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exercisability and Vesting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to Sections (e)(i) and (f)(i) below, each Initial Option Grant and Annual Option Grant will be fully exercisable upon grant and will vest as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(A) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Each Initial Option Grant will provide for vesting of 1/4th of the shares subject to such option on the first anniversary of the date of grant and 1/48th of the shares subject to such option each month thereafter, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(B)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Each Annual Option Grant will provide for vesting of 1/12th of the shares subject to such option each month after the date of grant, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Terms of RSUs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Vesting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to Sections (e)(i) and (f)(i) below, each Initial RSU Grant and Annual RSU Grant will vest as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(A) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Each Initial RSU Grant will provide for vesting of 1/4th of the shares subject to such award on each of the first four anniversaries of the date of grant, subject to the Non-Employee Director&#8217;s Continuous Service through such dates.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(B)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Each Annual RSU Grant will provide for vesting of 100% of the shares subject to such award on the first anniversary of the date of grant, subject to the Non-Employee Director&#8217;s Continuous Service through such date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Delivery of Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The shares subject to each Initial RSU Grant and Annual RSU Grant will be delivered on the applicable vesting date or as soon as administratively practicable thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Awards Granted under the 2017 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 9(c) of the 2017 Plan will apply to each Initial Option Grant, Initial RSU Grant, Annual Option Grant, Annual RSU Grant and any other equity award granted to a Non-Employee Director under the 2017 Plan (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Equity Grant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Awards Granted under the 2014 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary in the Prior Policy, Section 9(c) of the 2014 Plan will apply to each equity award granted to a Non-Employee Director pursuant to the Prior Policy.  For clarity, this Section (e)(ii) will supersede Section (e) of the Prior Policy in its entirety.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change in Control.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Awards Granted under the 2017 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event of a Change in Control, the vesting (and exercisability, if applicable) of each Initial Option Grant, Initial RSU Grant, Annual Option Grant, Annual RSU Grant and any Other Equity Grant will be accelerated in full to a date prior to the effective time of such Change in Control </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(contingent upon the effectiveness of such Change in Control) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of such Change in Control).  For clarity, this Section (f)(i) will supersede Section 9(d)(i) of the 2017 Plan in its entirety. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Awards Granted under the 2014 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary in the Prior Policy, in the event of a Change in Control, the vesting (and exercisability, if applicable) of each equity award granted to a Non-Employee Director pursuant to the Prior Policy will be accelerated in full to a date prior to the effective time of such Change in Control (contingent upon the effectiveness of such Change in Control) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of such Change in Control).  For clarity, this Section (f)(ii) will supersede Section 9(d)(i) of the 2014 Plan and Section (f) of the Prior Policy in their entirety.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>8
<FILENAME>exel20171231exhibit1035.htm
<DESCRIPTION>EXHIBIT 10.35
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFFEF231BF1430B851715B51AA784EF11"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.35</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2018 Cash Compensation for Non-Employee Directors </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.23076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:47%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$50,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">12</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Audit Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$15,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">13</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Compensation Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$8,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$12,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">13</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Nominating&#160;&amp; Corporate Governance Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td rowspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Research&#160;&amp; Development Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional Chair Retainer Fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">14</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:4px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:4px;"><div style="padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  1</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meetings for which minutes are generated count toward the meeting threshold to determine when Meeting Fees are to be paid.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  2</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of eight meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  3</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of seven meetings.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">  4</sup>&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Meeting Fee paid for all meetings in excess of four meetings.</font></div></td></tr></table><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>9
<FILENAME>exel20171231exhibit1039.htm
<DESCRIPTION>EXHIBIT 10.39
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3E48CE051023920E1A4D91F6F96A7E7D"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.39</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIRST AMENDMENT TO LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">THIS FIRST AMENDMENT TO LEASE AGREEMENT (this &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">First Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) effective as of October&#160;16, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">First Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), is made and entered into by and between ASCENTRIS 105, LLC, a Colorado limited liability company, formerly known as Amstar-105, LLC, a Colorado limited liability company (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and EXELIXIS, INC., a Delaware corporation (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A.&#160;&#160;&#160;&#160;Landlord and Tenant are parties to (i)&#160;that certain Lease Agreement dated May&#160;2, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Lease</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) for premises consisting of approximately 110,783 square feet of Rentable Area (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Original Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) in the multiple building project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California (as further defined in the Lease, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Project</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and (ii)&#160;that certain Agreement for Conditional Option to Amend Lease dated as of May&#160;2, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional 1801 Space Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), pursuant to which Tenant has the right to add Suite&#160;125 consisting of approximately 16,343 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional 1801 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) on the first floor of the 1801 Building (as defined in the Lease) to the Premises, by amending the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B.&#160;&#160;&#160;&#160;Tenant has exercised its option to add the Additional 1801 Space to the Premises, and therefore Landlord and Tenant intend that this First Amendment shall function, in part, as the Expansion Amendment contemplated by the Additional 1801 Space Option Agreement, amending the Lease to expand the Original Premises to include the Additional 1801 Space.  In addition, Landlord and Tenant have agreed to expand the Original Premises to include the premises known as Suite&#160;115 consisting of 2,703 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A&#8209;2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional 1751 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) on the first floor of the 1751 Building (as defined in the Lease).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">C.&#160;&#160;&#160;&#160;Landlord and Tenant hereby amend the Lease to: (i)&#160;expand the Premises under the Lease to include the Additional 1751 Space and the Additional 1801 Space; (ii)&#160;modify the Rentable Area of the 1801 Building and convert the 1801 Building from a Multi User Building to a Single User Building; (iii)&#160;modify the Rentable Area of the Project; (iv)&#160;modify the Base Rent; (v)&#160;modify the 1751 Building Share, the 1801 Building Share and all of the Project Shares; (vi)&#160;modify the Work Letter provisions; and (vii)&#160;make certain other modifications to the Lease as more particularly set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">NOW THEREFORE, in consideration of the mutual agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties do hereby agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Defined Terms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All capitalized terms used but not defined in this First Amendment will have the meanings set forth for such terms in the Lease.  All terms that are defined in this First Amendment and used in any provisions that are added to the Lease pursuant to this First Amendment will have the meanings in the Lease set forth for such terms in this First Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Demise of the Additional 1751 Space and Additional 1801 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms, covenants, conditions and provisions of the Lease, as amended by this First Amendment, Landlord leases to Tenant and Tenant leases from Landlord the Additional 1751 Space and Additional 1801 Space for the Term.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, Section&#160;1.1(d)(i) of the Lease is amended by the addition of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;As of the First Amendment Effective Date, the Premises will also include the Additional 1751 Space (Suite 115 located on the first floor of the 1751 Building and identified on Exhibit&#160;A-2 to the First Amendment to Lease Agreement).  Upon the Temporary Space becoming part of the Premises on the Commencement Date, the Additional 1751 Space and the Temporary Space will be referred to as the &#8220;1751 Space&#8221; consisting of approximately 14,668 square feet of Rentable Area, which shall not be subject to re&#8209;measurement except as set forth in Section 2.6 below;&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1801 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, Section&#160;1.1(d)(ii) of the Lease is deleted and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">1801 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Premises known as Suites 100, 150, 175, 200 and 210 located on the first and second floors of the 1801 Building and identified on Exhibit A attached hereto (the &#8220;Initial 1801 Space&#8221;).  Effective as of the &#8220;Additional 1801 Space Start Date&#8221; (as further defined below), the Premises will also include (i) the Additional 1801 Space (Suite 125 located on the first floor of the 1801 Building and identified on Exhibit A-2 attached to the First Amendment to Lease Agreement) and (ii) certain common area spaces containing approximately 732 square feet of Rentable Area (the &#8220;1801 Common Area Space&#8221;).  Upon the Additional 1801 Space and the 1801 Common Area Space becoming part of the Premises, the Initial 1801 Space, the Additional 1801 Space and the 1801 Common Area Space will be referred to as the &#8220;1801 Space.&#8221;  The 1801 Space will constitute the entire Building and contain approximately 58,417 square feet of Rentable Area, which shall not be subject to re-measurement except as set forth in Section 2.6 below; and&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Delivery of the Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Additional 1801 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord will deliver the Additional 1801 Space and the 1801 Common Area Space in the condition required by Section&#160;5(a) of the Additional 1801 Space Option Agreement and Section&#160;2.2 of the Lease, and with the satellite currently located on the 1801 Building, and all wires and cables associated therewith, removed and the affected areas restored to repair any damage in connection with such removal (the &#8220;Delivery Condition&#8221; and the date the Additional 1801 Space is delivered in the Delivery Condition is referred to as the &#8220;Additional 1801 Space Start Date&#8221;).  Landlord shall use commercially reasonable efforts to deliver the Additional 1801 Space, in the Delivery Condition, on February 18, 2018.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Additional 1751 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall Deliver the Additional 1751 Space on the First Amendment Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rentable Area of the Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The first sentence of the last paragraph of Section&#160;1.1(d) of the Lease is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The Premises contains a total of: (i)&#160;effective as of the First Amendment Effective Date, 101,521 square feet of Rentable Area (plus 11,965 square feet of Rentable Area making up the Temporary Premises), (ii)&#160;effective as of the Commencement Date, 113,486 square feet of Rentable Area, and (iii)&#160;effective as of the Additional 1801 Start Date, 130,561 square feet of Rentable Area.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Effective as of the First Amendment Effective Date, the Rentable Area table set forth in Exhibit&#160;A of the Lease is hereby replaced with the Rentable Area table attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of this First Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibits</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, Exhibit&#160;A to the Lease, entitled &#8220;Plan Delineating the Premises and Tenant Maintained Outdoor Areas&#8221; is hereby replaced by the updated Exhibit&#160;A-3 attached hereto, showing the total Premises leased as of the First Amendment Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Building; Project</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Building</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, Section&#160;1.1(e)(i) of the Lease is hereby amended (i) to delete the words &#8220;Temporary Space&#8221; and replace them with the words &#8220;1751 Space&#8221;, and (ii) to delete the phrase &#8220;74,170 square feet of Rentable Area&#8221; and replace it with the phrase &#8220;74,390 square feet of Rentable Area&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1801 Building</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Additional 1801 Space Start Date, (i) Section&#160;1.1(e)(ii) of the Lease is hereby amended to delete the phrase &#8220;57,685 square feet of Rentable Area and is a Multi User Building&#8221; and replace it with the phrase &#8220;58,417 square feet of Rentable Area and is a Single User Building&#8221;, and (ii) all terms and conditions of the Lease pertaining to Single User Buildings will apply to the 1801 Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Project</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section&#160;1.1(f) of the Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Effective as of the First Amendment Effective Date, the Rentable Area of the Project is amended to 384,799 square feet.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;From and after the Additional 1801 Space Start Date, the Rentable Area of the Project is further amended to 385,531 square feet.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, Section&#160;1.1(h) of the Lease is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(h)&#160;&#160;&#160;&#160;&#8220;Term&#8221; means the duration of this Lease, which will be 120&#160;months, beginning on February&#160;1, 2018 (the &#8220;Commencement Date&#8221;) and ending on January&#160;31, 2028 (the &#8220;Expiration Date&#8221;), unless terminated earlier or extended further as provided in this Lease.  Notwithstanding the foregoing, the Lease shall be in full force and effect with respect to each portion of the Premises on the date that Landlord Delivers such portion of the Premises to Tenant.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Base Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, Section&#160;1.1(i) of the Lease is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(i)&#160;&#160;&#160;&#160;&#8220;Base Rent&#8221; means the Rent payable according to Section&#160;3.1, which will be in an amount per month or portion thereof commencing on the Commencement Date and throughout the Term as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:54px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.45299145299145%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:37%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Period</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Monthly Rental Rate / SF of Rentable Area</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Base Rent Payable Per Month</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2018 &#8211;Day before Additional 1801 Space Start Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$187,251.90*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional 1801 Space Start Date &#8211; January&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$215,425.65*</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2019 &#8211; January&#160;31, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$221,953.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2020 &#8211; January&#160;31, 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$228,481.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2021 &#8211; January&#160;31, 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$235,009.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2022 &#8211; January&#160;31, 2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$242,843.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2023 &#8211; January&#160;31, 2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$249,371.51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2024 &#8211; January&#160;31, 2025</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$1.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$257,205.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2025 &#8211; January&#160;31, 2026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$265,038.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2026 &#8211; January&#160;31, 2027</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$272,872.49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;1, 2027 &#8211; January&#160;31, 2028</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$2.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$280,706.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">* </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Rent Abatement.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Base Rent will be partially abated in the amount of $88,251.90 per month (the &#8220;Initial Rent Abatement&#8221;) for the period beginning on the Commencement Date and ending on January 31, 2019 (the &#8220;Initial Rent Abatement Period&#8221;).  In addition, Base Rent will be further abated in the amount of $28,173.75 per month (the &#8220;Additional 1801 Space Rent Abatement&#8221;) beginning on the Additional 1801 Space Start Date and ending on the earlier of (A) four months after the Additional 1801 Space Start Date, and (B) Tenant&#8217;s occupancy of the Additional 1801 Space for the conduct of business (such date, the &#8220;Additional 1801 Space Completion Date&#8221; and such period the &#8220;Additional 1801 Rent Abatement Period&#8221;).  However, if Landlord terminates this Lease as a result of a &#8220;Default&#8221; (as defined in Section 20.1) at any time during the Term, in addition to all other remedies available to Landlord, the unamortized portion of the Initial Rent Abatement will automatically become immediately due and payable.  At any time on or before the Initial Rent Abatement Period, upon notice to Tenant, Landlord shall have the right to purchase any Initial Rent Abatement relating to the remaining Initial Rent Abatement Period by paying to Tenant an amount equal to the &#8220;Initial Rent Abatement Purchase Price&#8221; (as defined below).  As used herein, &#8220;Initial Rent Abatement Purchase Price&#8221; shall mean the aggregate amount of the Initial Rent Abatement remaining during the Initial Rent Abatement Period, as of the date of payment of the Initial Rent Abatement Purchase Price by Landlord.  Upon Landlord&#8217;s payment of the Initial Rent Abatement Purchase Price to Tenant, Tenant shall be required to pay Rent in accordance with the provisions of Sections 1.1(i) and 3.1 and there shall be no further Initial Rent Abatement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">** </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Proration for Partial Months</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If the Additional 1801 Space Abatement Period ends on a date that is not the last day of the month, then on the first day of the first full calendar month after the expiration of the Additional 1801 Space Rent Abatement Period (the &#8220;First Full Month&#8221;), Tenant shall pay Rent for the First Full Month together with prorated Rent based on the days in the prior calendar month following the expiration of the Additional 1801 Space Rent Abatement Period.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Building Shares; Project Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. The Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Building Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Commencement Date, upon which the Temporary Space becomes part of the Premises (and, together with the Additional 1751 Space, is thereafter referred to as the 1751 Space), Section 1.1(j)(i) of the Lease is hereby amended so that the 1751 Building Share is 19.72%.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1801 Building Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Additional 1801 Space Start Date, Section&#160;1.1(j)(ii) of the Lease is hereby amended so that the 1801 Building Share is 100%.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section&#160;1.1(k)(i) of the Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Effective as of the First Amendment Effective Date, the 1751 Project Share is hereby amended to 0.70%, subject to adjustment pursuant to Section&#160;2.6 of the Lease; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Effective as of the Commencement Date, the 1751 Project Share is further amended to 3.81%, subject to adjustment pursuant to Section&#160;2.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;From and after the Additional 1801 Space Start Date, the 1751 Project Share is further amended to 3.80%, subject to adjustment pursuant to Section&#160;2.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1801 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 1.1(k)(ii) of the Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Effective as of the First Amendment Effective Date, the 1801 Project Share is hereby amended to 10.74%, subject to adjustment pursuant to Section&#160;2.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;From and after the Additional 1801 Space Start Date, the 1801 Project Share is further amended to 15.15%, subject to adjustment pursuant to Section&#160;2.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1851 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 1.1(k)(iii) of the Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Effective as of the First Amendment Effective Date, the 1851 Project Share is hereby amended to 14.94%, subject to adjustment pursuant to Section&#160;2.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;From and after the Additional 1801 Space Start Date, the 1851 Project Share is further amended to 14.91%, subject to adjustment pursuant to Section&#160;2.6 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Letter of Credit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Within 10&#160;business days of the First Amendment Effective Date, Tenant will deliver to Landlord either a new Letter of Credit or an amendment to the existing Letter of Credit that increases the L/C Amount to $1,000,000.00.  Subject to Section&#160;1.1(r) of the Lease, the L/C Amount shall decrease by 10% every 12&#160;months after the issue date of the new Letter of Credit (or amendment, as applicable), provided that the L/C Amount will not be decreased to an amount less than the last month&#8217;s Base Rent under the Lease, as amended by this First Amendment.  Except as provided herein, Sections&#160;1.1(r) and 13.9 of the Lease will remain in full force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Work Letter Provisions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant acknowledge and agree that Tenant will construct Leasehold Improvements in the Additional 1751 Space and the Additional 1801 Space in accordance with the Work Letter attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Lease.  Effective as of the First Amendment Effective Date, the Work Letter is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Commencement Dates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Paragraph 1(a) of the Work Letter is hereby amended so that the Commencement Date has the meaning set forth in Section&#160;1.1(h) of the Lease, as amended herein.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Start Dates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The chart of estimated Start Dates in Paragraph&#160;1(b) of the Work Letter is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-left:102px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.84615384615384%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:39%;"></td><td style="width:61%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Premises</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Start Date</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1751 Space</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Temporary Space &#8211; Suite 225</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional 1751 Space &#8211; Suite 115</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">First Amendment Effective Date</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1801 Space</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Additional 1801 Space &#8211; Suite 125</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Estimated to be on or before February 18, 2018</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 200</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 210</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 150</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 175</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;15, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 100</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;31, 2017</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #00000a;background-color:#bfbfbf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1851 Space</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 200</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 210</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 1000</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 125</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;2, 2017</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite 150</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">May 2, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Maximum Allowance Amount</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Paragraph 1(j) of the Work Letter is hereby amended so that the Maximum Allowance Amount of &#8220;$5,539,150.00&#8221; is replaced with &#8220;$6,528,050.00.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Occupancy Estoppel Certificate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the First Amendment Effective Date, the form of Occupancy Estoppel Certificate attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Lease is hereby amended to include the Start Date and the move-in date for the Additional 1751 Space and the Start Date, move-in date and the Additional 1801 Space Completion Date for the Additional 1801 Space.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;Brokers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant represent and warrant that no broker or agent negotiated or was instrumental in negotiating or consummating this First Amendment except Cushman Wakefield and Kidder Matthews (the &#8220;Brokers&#8221;).  Neither party knows of any other real estate broker or agent who is or might be entitled to a commission or compensation in connection with this First Amendment.  Landlord will pay all fees, commissions or other compensation payable to the Brokers pursuant to a separate agreement.  Tenant and Landlord will indemnify and hold each other harmless from all damages paid or incurred by the other resulting from any claims asserted against either party by brokers or agents claiming through the other party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;Whole Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This First Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements.  Except as amended herein, or in a future writing signed by both parties, there shall be no other changes or modifications to the Lease between the parties and the Lease and the terms and provision contained therein shall remain in full force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;Successors and Assigns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This First Amendment shall be binding upon the parties hereto, their heirs, successors and assigns.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;Ratification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as amended hereby and by this First Amendment, the Lease has not been amended, and the parties ratify and confirm the Lease, as amended hereby and by the First Amendment, as being in full force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;Counterparts; Execution by Telecopy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This First Amendment may be executed in counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one agreement.  Executed copies hereof may be delivered by telecopier or other electronic means, and upon receipt will be deemed originals and binding upon the parties hereto, regardless of whether originals are delivered thereafter.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signatures appear on next page]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the parties hereto have executed this First Amendment to be effective as of the First Amendment Effective Date.</font></div><div style="line-height:120%;padding-left:126px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80.76923076923077%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:32%;"></td><td style="width:68%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LANDLORD:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:32px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ASCENTRIS 105, LLC, <br>a Colorado limited liability company</font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/Gabe L. Fink</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br>Name: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Gabe L. Fink</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br>Title:    </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Manager</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">TENANT:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:32px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC., <br>a Delaware corporation</font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/Michael M. Morrissey, Ph.D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br>Name:   </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Michael M. Morrissey, Ph.D</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;<br>Title:      </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President &amp; CEO</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-bottom:32px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s8331C19151A12D1BD62E91F6F999C087"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT A-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FLOOR PLAN OF THE ADDITIONAL 1801 SPACE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamendto_image1.gif" alt="exhibit10firstamendto_image1.gif" style="height:454px;width:590px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-1-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sF8925A5253B2078825F691F6F9B8BFD5"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT A-2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FLOOR PLAN OF THE ADDITIONAL 1751 SPACE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamend_image2.jpg" alt="exhibit10firstamend_image2.jpg" style="font-family:Calibri,sans-serif;font-weight:bold;height:535px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-2-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s659F8CD53F0620DE75EA91F6F9F7D903"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WATERFRONT AT HARBOR BAY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT A-3 <br>PLAN DELINEATING THE PREMISES AND TENANT MAINTAINED OUTDOOR AREAS AS OF THE FIRST AMENDMENT EFFECTIVE DATE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamend_image3.jpg" alt="exhibit10firstamend_image3.jpg" style="font-family:Calibri,sans-serif;font-weight:bold;height:450px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-3-1</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamend_image2.jpg" alt="exhibit10firstamend_image2.jpg" style="font-family:Calibri,sans-serif;font-weight:bold;height:535px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-3-2</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamendto_image4.gif" alt="exhibit10firstamendto_image4.gif" style="height:412px;width:544px;"><img src="exhibit10firstamendto_image5.gif" alt="exhibit10firstamendto_image5.gif" style="height:400px;width:538px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-3-3</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamendto_image6.gif" alt="exhibit10firstamendto_image6.gif" style="height:434px;width:574px;"><img src="exhibit10firstamendto_image7.gif" alt="exhibit10firstamendto_image7.gif" style="height:402px;width:536px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-3-4</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit10firstamendto_image8.gif" alt="exhibit10firstamendto_image8.gif" style="height:504px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-3-5</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TENANT MAINTAINED OUTDOOR AREAS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="exhibit10firstamendto_image9.gif" alt="exhibit10firstamendto_image9.gif" style="height:398px;width:622px;"></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">A-3-6</font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>10
<FILENAME>exel20171231exhibit1046.htm
<DESCRIPTION>EXHIBIT 10.46
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAE71E2383C097FE552F7B51B914AA1A4"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.46</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">THIRD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is entered into as of October 26, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Pharma SAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Licensee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#2e2e2e;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1, dated effective December 20, 2016, and Amendment No. 2 dated effective September 14, 2017 (together, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parties desire to enter into this Third Amendment to update certain definitions and manufacturing responsibilities under the License Agreement, all on the terms and conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;DEFINITIONS  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise defined in this Third Amendment, all capitalized terms have the meaning as defined in the License Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2&#160;&#160;&#160;&#160;&#8220;Cost of Goods&#8221; Definition.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The fourth sentence of Section 1.19 of the License Agreement is hereby amended and restated to read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Direct labor costs shall include the cost of: [ * ].&#8221;</font></div><div style="line-height:120%;text-align:left;text-indent:500px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;MANUFACTURE AND SUPPLY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Manufacture and Supply</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The third and fourth sentences of Section 7.1 of the License Agreement is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;It is anticipated that Exelixis will supply commercial Product to Licensee in final, labeled packaged form.  Exelixis shall be responsible for packaging and labeling for all countries in the Licensee Territory.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Third Amendment Effective Date, shall remain in full force and effect.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The License Agreement as modified by this Third Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;Severability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If, for any reason, any part of this Third Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Third Amendment.  All remaining portions shall </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">remain in full force and effect as if the original Third Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;Counterparts; Electronic or Facsimile Signatures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Third Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Third Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;{SIGNATURE PAGE FOLLOWS}</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties hereto have caused this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to be executed and entered into by their duly authorized representatives as of the Third Amendment Effective Date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  /s/ Michael M. Morrissey</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Michael M. Morrissey, Ph.D.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  President and CEO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  /s/ Christophe Jean</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Christophe Jean</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  EVP Corporate Strategy &amp; Business Development</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>11
<FILENAME>exel20171231exhibit1048.htm
<DESCRIPTION>EXHIBIT 10.48
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1CBD24FB2B89097A0B79B51C2E048469"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.48</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIRST AMENDMENT TO SUPPLY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FIRST</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT TO THE SUPPLY AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is entered into as of October 26, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a Delaware company having an address at 210 East Grand Avenue, South San Francisco, CA 94080, USA (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Pharma SAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Licensee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#2e2e2e;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1 dated effective December 20, 2016, Amendment No. 2 dated effective September 14, 2017, and Amendment No. 3 dated effective October 26, 2017 (together, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), pursuant to which the Parties have been collaborating on the development and commercialization of cabozantinib; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Licensee are parties to that certain Supply Agreement dated February 29, 2016, as amended by that certain Side Letter between the Parties dated August 26, 2016 (together, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Supply Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), pursuant to which Exelixis has been manufacturing and supplying cabozantinib to Licensee for development and commercial use under the License Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parties desire to enter into this Amendment to amend the Supply Agreement to reflect the expansion of Licensee&#8217;s territory under the License Agreement,remove reference to the concept of a transition plan transferring manufacturing obligations to Licensee, and make certain other changes, all on the terms and conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;DEFINITIONS  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The fourth sentence of Section 1.7 of the Supply Agreement (&#8220;Cost of Goods&#8221; or &#8220;COG&#8221;) is hereby amended and restated to read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Direct labor costs shall include the cost of: [ * ]&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 1.11 of the Supply Agreement is hereby amended and restated to read in full as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis Territory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the U.S. and Japan.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 1.23 of the Supply Agreement is hereby amended and restated to read in full as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;1.23</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Manufacture</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all activities related to the manufacturing of the Compound and Products, in final, labeled, packaged form for commercial use, including in-process and finished product testing, release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing.  &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Manufacturing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; has a correlative meaning.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 1.25 of the Supply Agreement (&#8220;Product&#8221;) is hereby amended and restated to read as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.25</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Product</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any pharmaceutical product containing the Compound as an active ingredient, in any form, presentations, dosage, or formulation.  For the avoidance of doubt, the manufacturing and supply of product </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">bearing the trade name Cometriq&#174; shall be covered under a separate agreement entered into between the Parties on November 21, 2016.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.5&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 1.30 of the License Agreement is hereby amended and restated to read in full as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.30&#160;&#160;&#160;&#160;&#8220;Regulatory Authority</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of pharmaceutical products in a given jurisdiction, including the FDA, the EMA, and Health Canada or other foreign equivalent.  For countries where governmental approval is required for pricing or reimbursement for a pharmaceutical product to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority shall also include any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.6&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.7&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Health Canada</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the federal department of the government of Canada having the authority to regulate the sale of medicinal or pharmaceutical products, or any successor agency thereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.8&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RoW Countries</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or Rest of the World Countries, means all of the other countries of the world except [ * ].  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.9&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise defined in this Amendment, all capitalized terms have the meaning as defined in the Supply Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;PRODUCT SUPPLY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.3(c) of the Supply Agreement is hereby amended and restated to read in full as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;2.3(c)  Delivery and Shipping Terms. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Purchase Orders submitted for quantities of Product that are in accordance with Section 2.3(a) and/or Section 2.3(b) will be binding on both Parties after acceptance in writing by Exelixis; provided, however, that should Exelixis neither reject a Purchase Order nor provide written confirmation of acceptance within [ * ] of receipt, Exelixis shall be deemed to have accepted the Purchase Order effectively.  The Purchase Order will specify a single delivery date for such order to be delivered in such Calendar Quarter, but will in no event be a date sooner than [ * ].  By way of example, a Purchase Order submitted on [ * ] would specify the quantity of Product ordered for delivery in the [ * ] Calendar Quarter of [ * ], with a delivery date no sooner than [ * ].  Licensee shall place Purchase Orders of desired quantity of Products labeled for commercial use in Canada for delivery by Exelixis in Canada, [ * ].  With respect to Products labelled for commercial use in countries of the Licensee Territory other than Canada, a separate Purchase Order shall be placed and Exelixis shall deliver all Products [ * ] once the Finished Products are released by Exelixis or through its contract manufacturer as described in Section 2.4(d) below.  Exelixis shall be responsible for obtaining all licenses or other authorizations for the exportation of such shipments and shall supply Licensee with the documentation required for filing or claiming credit or deduction for any applicable taxes and/or duties.  Licensee shall be responsible for obtaining all freight, handling, insurance, and shipping expenses for shipments upon and after unloading at the [ * ], and shall be the importer of record and responsible for all duties and taxes for such importation in the Licensee Territory, and shall be responsible for obtaining all distribution licenses for the Products.&#8221;   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.4(e) of the Supply Agreement is hereby deleted in its entirety.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.8 of the Supply Agreement is hereby deleted in its entirety and replaced in full to read as follows</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;2.8 Backup Supplier</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.&#160; Exelixis shall select a Third Party secondary manufacturer (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Backup Manufacturer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to Manufacture the Product for supply to Licensee.&#160; Exelixis shall engage the Backup Manufacturer, and complete, on or before the [ * ], to the reasonable satisfaction of Licensee, the transferring of the Manufacturing process to such Backup Manufacturer, qualification of the Backup Manufacturer, equipment and all validation of Manufacturing process in accordance with applicable law and regulations.&#160; At Ipsen&#8217;s request, Exelixis shall also assist Ipsen in its </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">applications for Regulatory Approval of the Backup Supplier by the relevant Regulatory Authorities of the Major Market Countries, to the extent commercially reasonable, and in accordance with Ipsen&#8217;s timelines.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.4.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;The following is hereby added to the Supply Agreement as Section 2.12:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;2.12 Canada-Labeled Product Reporting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  On a [ * ] basis, Licensee shall provide to Exelixis a report, in a form to be mutually agreed by the Parties, which specifies in reasonable detail the distribution and/or sale of Product labeled for Canada by Licensee, its Affiliates, its permitted Sublicensees, and/or any Third Party distributors in the previous [ * ].&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;FINANCIALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 3.1 of the Supply Agreement is hereby amended and restated to read in full as follows: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The transfer price (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Transfer Price</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) for Finished Product supplied by Exelixis to Licensee will be equal to [ * ], which shall be calculated for each configuration of the Product.  The Transfer Price in effect at the time the first Purchase Order is placed as part of the binding commitment under Section 2.2(b) shall apply as the Transfer Price for the Calendar Year.  The Transfer Price shall thereafter be calculated and adjusted annually in the manner set forth in paragraph (b) below. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;[ * ] Reconciliation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  On or prior to [ * ] of a Calendar Year, Exelixis and Licensee shall review the Transfer Price paid by Licensee for the Finished Product supplied during the preceding Calendar Year and determine if the [ * ] is either lesser or greater than the Transfer Price paid by Licensee during such preceding Calendar Year (the &#8220;[ * ]</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;Reconciliation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  If the Transfer Price paid by Licensee during the preceding Calendar Year is less than the [ * ] owed to Exelixis, Licensee shall pay the difference for such amounts.  If the Transfer Price paid by Licensee for the Product is greater than the [ * ] owed to Exelixis, Exelixis shall credit the amount of such payment due by Licensee to Exelixis until such time that the reconciling payment has been fully credited to Licensee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Adjustments to Transfer Price</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  On or prior to [ * ] of a Calendar Year at the time of the [ * ] Reconciliation, Exelixis and Licensee shall review the most recent Order Forecast provided by Licensee, and based on quantities planned for purchase and expected annual price increases by Exelixis&#8217; Third Party manufacturers, and other related price factors, Exelixis and Licensee shall agree upon a new annual Transfer Price for the Calendar Year.  The Parties agree that if by [ * ] of an applicable Calendar Year the Parties cannot agree on a new annual Transfer Price, the prior Calendar Year&#8217;s Transfer Price will apply, and any additional payments owed will be remediated through the next annual reconciliation in accordance with Section 3.1(b) above.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Section 3.3 of the Supply Agreement is hereby amended to add the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;FTEs dedicated to other Manufacture-related work and billed to Licensee under this Section 3.3, such FTEs shall be billed [ * ].  With respect to any Manufacture-related work that is specifically related to support Licensee&#8217;s: (i) [ * ] in RoW Countries of the Licensee Territory and (ii) [ * ] in RoW Countries of the Licensee Territory, the Parties agree that Exelixis&#8217; direct labor costs of personnel to be engaged in such activities shall be capped [ * ].  If Exelixis, acting reasonably, considers that Manufacture-related work mentioned in the preceding sentence would require additional FTEs, Exelixis shall notify Licensee and the Parties shall agree in good faith as to the reasonable out-of-pocket costs in excess of [ * ] incurred during the conduct of such Manufacture-related work for the purpose of this Section 3.3.&#8221; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;EXHIBIT B &#8211; QUALITY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 12.4 of the Quality Agreement set forth in Exhibit B is hereby amended and restated to read in full as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.4</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;Ipsen and EXELIXIS Quality Assurance shall review this Quality Technical Agreement in 2018 and make necessary amendments.  After 2018, EXELIXIS and Ipsen shall review this Quality Technical Agreement [ * ] and make any necessary revisions.  This review and any resulting revisions shall be documented in the Change History Log (Appendix I).&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly modified herein, all terms and conditions set forth in the Supply Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Supply Agreement as modified by this Amendment, and together with the License Agreement, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.3&#160;&#160;&#160;&#160;Severability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.4&#160;&#160;&#160;&#160;Counterparts; Electronic or Facsimile Signatures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;{SIGNATURE PAGE FOLLOWS}</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties hereto have caused this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.84126984126983%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  /s/ Michael M. Morrissey</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Michael M. Morrissey, Ph.D.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  President and CEO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  /s/ Christophe Jean</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Christophe Jean</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  EVP Corporate Strategy &amp; Business Development</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>12
<FILENAME>exel20171231exhibit121.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7D88277A93C539318865B6B5FBB7B3B2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 12.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">STATEMENT RE COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Our earnings were insufficient to cover fixed charges for the periods presented except for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. The following table sets forth our ratio of earnings to fixed charges for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;and our deficiency of earnings to cover fixed charges for the other periods presented.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Fixed charges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,060</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Interest portion of rental expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">755</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,271</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,714</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings available for fixed charges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,297</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(238,192</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Fixed charges per above</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,781</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">42,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,714</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total earnings available for fixed charges</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">167,848</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36,441</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(120,309</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(219,049</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(198,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ratio of earnings to fixed charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deficiency of earnings available to cover fixed charges</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(261,297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(238,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>13
<FILENAME>exel20171231exhibit211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9877923a3b814d05b8dbadc47c8c7f79"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARIES OF EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:548px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:277px;"></td><td style="width:270px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Name of Subsidiary</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">State or Other Jurisdiction of Incorporation or Organization</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Global Services, Inc.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis International (Bermuda) Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Patent Company, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis Plant Sciences, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis U.S., LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>14
<FILENAME>exel20171231exhibit231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s22e06775561747f0b6c36a0bbf4db68e"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-218236, 333-214766, 333-212866, 333-209824, 333-203758, 333-196761, 333-176674, 333-165389, 333-159280, 333-157825, 333-149834, 333-147063, 333-133237, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026 and 333-35862) of Exelixis, Inc. and the Registration Statement&#160; (Form S-3 No. 333-205397) and related Prospectus of Exelixis, Inc. of our reports dated February&#160;26, 2018, with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 29, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Redwood City, California</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>15
<FILENAME>exel20171231exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4286E7664C5B43AAF7D9B6B64D391E43"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-K of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>16
<FILENAME>exel20171231exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7A3896F2CE1D457F2F5FB6B64DE51DA3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-K of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February&#160;26, 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>17
<FILENAME>exel20171231exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s91FFB868B1319D4D2B6CB6B64E91A227"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Annual Report on Form 10-K for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">December&#160;29, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">26th</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">February 2018</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>18
<FILENAME>exel-20171229.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:dbcc174a62dc4eeda0bcd61dd8211ce7,x:651bd69633be4627b0c647e0ab32cf32-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:exel="http://www.exelixis.com/20171229" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="exel-20171229.xsd" xlink:type="simple" />
	<xbrli:context id="D2017Q4FYYTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4FYQ4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_EquipmentAndFurnitureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:EquipmentAndFurnitureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2008Q4October_us-gaap_MajorCustomersAxis_exel_GlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-10-01</xbrli:startDate>
			<xbrli:endDate>2008-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:ProductsDerivedfromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksandPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:OtherDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:OtherDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:OtherDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:RebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:RebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksandPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksandPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:RebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:RebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:RebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksandPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:OtherDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksandPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:OtherDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:SecondMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Sep30-Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-30</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:GlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sep01-Sep30_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Sep30-Dec29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-30</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Jan032015-Dec292017_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SanofiAventisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:InitialMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierThreeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29_exel_MilestoneObjectiveAxis_exel_HCCAcceptanceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:HCCAcceptanceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29_exel_MilestoneObjectiveAxis_exel_HCCFilingMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:MilestoneObjectiveAxis">exel:HCCFilingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Nov01-30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-01</xbrli:startDate>
			<xbrli:endDate>2015-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SanofiAventisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:RoyaltytierAxis">exel:FinalTierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithMerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:ProfitSharingTiersAxis">exel:ProfitSharingTierOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_exel_ContractRevenueMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">exel:ContractRevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithBMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SanofiAventisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:SanofiAventisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_dei_LegalEntityAxis_exel_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">exel:BristolMyersSquibbMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug31_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="invest:InvestmentAxis">exel:AkarnaTherapeuticsLtd.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:CapitalLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OperatingLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May02-May02_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-02</xbrli:startDate>
			<xbrli:endDate>2017-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct16_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OptionalAmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-28</xbrli:startDate>
			<xbrli:endDate>2017-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Nov_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Jul31_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-01</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-29</xbrli:startDate>
			<xbrli:endDate>2017-03-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun27_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SiliconValleyBankLoanAndSecurityAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun27_exel_InterestPaymentTypeAxis_exel_PaymentinKindInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:InterestPaymentTypeAxis">exel:PaymentinKindInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun27_exel_InterestPaymentTypeAxis_exel_CouponInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:InterestPaymentTypeAxis">exel:CouponInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul01-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Mar18_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Jan_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul01-31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Sep11-Sep11_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-11</xbrli:startDate>
			<xbrli:endDate>2017-09-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3WarrentExercise_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar18_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-18</xbrli:startDate>
			<xbrli:endDate>2015-03-18</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PlanNameAxis_exel_ChangeinControlandSeveranceBenefitPlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:ChangeinControlandSeveranceBenefitPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_PlanNameAxis_exel_ChangeinControlandSeveranceBenefitPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:ChangeinControlandSeveranceBenefitPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q4Q4FY_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2010Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-01-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">exel:WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:SecuredConvertibleNotesDueJune2018Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorSubordinatedNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OptionalAmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OperatingLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-02</xbrli:startDate>
			<xbrli:endDate>2017-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToBuildingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OptionalAmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-02</xbrli:startDate>
			<xbrli:endDate>2017-05-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_BuildingShellsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OperatingLeaseandOtherFinancingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:BuildingShellsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseMember_us-gaap_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OperatingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OptionalAmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec29_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseMember_us-gaap_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OperatingLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:SouthSanFranciscoCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">exel:OptionalAmendmentAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToBuildingLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exel:StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_exel_RestofWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:RestofWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_exel_RestofWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:RestofWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_exel_RestofWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">exel:RestofWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueGoodsNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4FY2015_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-03</xbrli:startDate>
			<xbrli:endDate>2016-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jan022016-Sept302016_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct01-Dec30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Sep30-Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-30</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct01-Dec30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul01-Sep29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2FYQ2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-02</xbrli:startDate>
			<xbrli:endDate>2016-07-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul02-Sep30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-02</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Dec31-Mar31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-31</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1FYQ1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-02</xbrli:startDate>
			<xbrli:endDate>2016-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="cad">
		<xbrli:measure>iso4217:CAD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="property">
		<xbrli:measure>exel:property</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="debt_instrument">
		<xbrli:measure>exel:debt_instrument</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="option">
		<xbrli:measure>exel:option</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="D2017Q4FYYTD" id="Fact-937BAC7C6A4C7B4E62CEB6B5E4A5160F">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="D2017Q4FYYTD" id="Fact-304AC4C93B280C8A5DC8B6B5E4A5BAA4">--12-29</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="D2017Q4FYYTD" id="Fact-5EB2D106CCEE543B90E5B6B5E4A52F98">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="D2017Q4FYYTD" id="Fact-D3816279C66A3BF6AC25B6B5E4A548E1">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="D2017Q4FYYTD" id="Fact-2CA54A7D7FCB9A8BD5E7B6B5E4A567EF">2017-12-29</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="D2017Q4FYYTD" id="Fact-031D1F92BF537752E878B6B5E4A5965F">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="D2017Q4FYYTD" id="Fact-44F704840AFEF4C01165B6B5E4A58549">0000939767</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1Feb12" decimals="0" id="Fact-2403FED33BE956373FB6B6B5EFEF3E7E" unitRef="shares">296307278</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="D2017Q4FYYTD" id="Fact-3D0A5A23D4EE401C186FB6B5E4A54C01">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="D2017Q4FYYTD" id="Fact-6D991D0F60D6131F5333B6B5E4A528B4">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="0" id="Fact-FF304CD60320E2C1F42BB6B5E4A5A17B" unitRef="usd">7116352282</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="D2017Q4FYYTD" id="Fact-52CD06835A863BBF5305B6B5E4A56A79">EXELIXIS, INC.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="D2017Q4FYYTD" id="Fact-38A23B2F9A621BBC8441B6B5E4A52ADC">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="D2017Q4FYYTD" id="Fact-E85B37A5B00E354152D9B6B5E4A5BD45">Yes</dei:EntityWellKnownSeasonedIssuer>
	<dei:TradingSymbol contextRef="D2017Q4FYYTD" id="Fact-84D60F40401A901741FBB6B5E4A5F882">exel</dei:TradingSymbol>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="FI2016Q3" decimals="-5" id="Fact-38525E08D1A50B071CE3B6B5E90CDCF7" unitRef="usd">18700000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-89D62A09C20BE7B35424B6B5E513DD91" unitRef="usd">14131000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedClinicalLiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-EB07E5D5841C5FB3EC53B6B5E533E5B6" unitRef="usd">19849000</exel:AccruedClinicalLiabilitiesCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-DC2D63857479F9BAA8BCB6B5F00E8AA3" unitRef="usd">2046000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:AccruedCollaborationLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8F2C1BE9CD782396ACE9B6B5F00E9659" unitRef="usd">8974000</exel:AccruedCollaborationLiabilityCurrent>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-999FA8F1D3C0EC85E101AF2B541006BC" unitRef="usd">358000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-F926FCCF76886B818D0FAF2B53D0E3A6" unitRef="usd">39000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-5D8B80EE802C94C0FFC2AF2B53CF81B2" unitRef="usd">-2000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-3C1F34FD1B76DB6B6F1DAF2B53D45D29" unitRef="usd">313000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-38F26ECC5A1FB93B4498AF2B53D2562D" unitRef="usd">8000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-32A960D370BBE1A60546AF2B542727F8" unitRef="usd">1441000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-4445C1910A29366429F5AF2B53D7DA53" unitRef="usd">817000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-AA0575C8C82468307AE3AF2B5460FB1C" unitRef="usd">0</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-552156EDE294BC764224AF2B5400EBED" unitRef="usd">624000</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-FAF0D373EF33FD055247AF2B543E0A6B" unitRef="usd">0</exel:AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment>
	<exel:CIPdeemedacquiredinBuildtoSuitLease contextRef="D2015Q4FY2015" decimals="-3" id="Fact-85C8D5B12BA56C1B19848A8462EAA6D4" unitRef="usd">0</exel:CIPdeemedacquiredinBuildtoSuitLease>
	<exel:CIPdeemedacquiredinBuildtoSuitLease contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B38F856EA17FCC03F983B6B5F06D3382" unitRef="usd">0</exel:CIPdeemedacquiredinBuildtoSuitLease>
	<exel:CIPdeemedacquiredinBuildtoSuitLease contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-AEBA9F72F6F5FFB10CD2B6B5F07D11A1" unitRef="usd">14530000</exel:CIPdeemedacquiredinBuildtoSuitLease>
	<exel:CapitalandOperatingLeasesNumberofOptionstoTerminate contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="INF" id="Fact-8132716E0A6242FCCCC0B6B5F38D0132" unitRef="option">1</exel:CapitalandOperatingLeasesNumberofOptionstoTerminate>
	<exel:CapitalandOperatingLeasesNumberofRenewalOptions contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="INF" id="Fact-92FC2875F36574A88CDFB6B5F38DB03A" unitRef="option">2</exel:CapitalandOperatingLeasesNumberofRenewalOptions>
	<exel:CapitalandOperatingLeasesNumberofRenewalOptions contextRef="D2017Q4FYYTD_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseMember_us-gaap_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember" decimals="INF" id="Fact-2A360CD48E3B2D307706B4582FB07351" unitRef="option">2</exel:CapitalandOperatingLeasesNumberofRenewalOptions>
	<exel:CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="-4" id="Fact-1AF160E0E053BECBB6C4B6B5F38DA6E5" unitRef="sqft">170000</exel:CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty>
	<exel:ClassofWarrantorRightPeriod contextRef="D2014Q1Jan_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" id="Fact-C234F4B44919BBBD969CB6B5EB153F27">P2Y</exel:ClassofWarrantorRightPeriod>
	<exel:ClassofWarrantorRightPeriod contextRef="D2015Q1Mar18_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" id="Fact-942853197409AEDA4BFCB6B5EB155576">P2Y</exel:ClassofWarrantorRightPeriod>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="D2017Q4FYYTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-5D8D803A1A3B5D739A218C003693D779">P2Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" id="Fact-0714F35AEE1F1B28E399AF5C3E39FBB7">P10Y</exel:CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-118CD14F40C603CFA6A7B6B5F0DB9976" unitRef="usd">0</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-55F673299DDE956F5199B6B5F0DB603C" unitRef="usd">4417000</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementDevelopmentCostReimbursements contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-2683ADFC308D0121BA77B6B5F0BCBFF8" unitRef="usd">4320000</exel:CollaborativeArrangementDevelopmentCostReimbursements>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2015Q4FY2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-16E2B20AA42BF56946A18BDB9ACB7F6F" unitRef="usd">-16600000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-150B40A97DB0579239238BDB9AC8DB35" unitRef="usd">8771000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementIncomeLossfromAgreement contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-1F7CEAC8498B5A54BE5F8BDB9AC58D41" unitRef="usd">-2140000</exel:CollaborativeArrangementIncomeLossfromAgreement>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-33A85D80454F35899A71AF6ACE7B5D8B" unitRef="usd">240000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="INF" id="Fact-8D955B858535BF8DE5D8B6B5E8FC1A01" unitRef="usd">130000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="INF" id="Fact-420162856A50279DB003B6B5E90C678C" unitRef="usd">231000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-47B822975695E20C8A48B6B5ED2A06C2" unitRef="usd">95000000</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember" decimals="INF" id="Fact-BBE7D7234466259AFF6EB6B5E8FC471B" unitRef="usd">745000000.0</exel:CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
	<exel:CollaborativeArrangementShareinCostsPercentage contextRef="D2017Q4FYYTD_dei_LegalEntityAxis_exel_BristolMyersSquibbMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" decimals="4" id="Fact-AB05379644E1277FAA9400A5D2C55599" unitRef="number">0.6667</exel:CollaborativeArrangementShareinCostsPercentage>
	<exel:CollaborativeArrangementShareinCostsPercentage contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" decimals="4" id="Fact-04B3705570C17FECB67800A5D9C85B16" unitRef="number">0.3333</exel:CollaborativeArrangementShareinCostsPercentage>
	<exel:CollateralProvidedForPurchasingCardProgram contextRef="I2016Q4Dec30" decimals="-5" id="Fact-240129490FFBDF913A63BFC65D9636E4" unitRef="usd">3000000</exel:CollateralProvidedForPurchasingCardProgram>
	<exel:CollateralProvidedForPurchasingCardProgram contextRef="I2017Q4Dec29" decimals="-5" id="Fact-D1E2F5BE23A9D119632BB6B5ECEBC626" unitRef="usd">3000000</exel:CollateralProvidedForPurchasingCardProgram>
	<exel:CostMethodInvestmentOwnershipPercentage contextRef="I2016Q3Aug31_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="2" id="Fact-AECD0B527955AAF8DFD3B6B5EA39ECA5" unitRef="number">0.09</exel:CostMethodInvestmentOwnershipPercentage>
	<exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection contextRef="I2017Q2Jun27_exel_InterestPaymentTypeAxis_exel_CouponInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-B9FCA48601F2C638F86DB6B5EAC7744B" unitRef="number">0.075</exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection>
	<exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection contextRef="I2017Q2Jun27_exel_InterestPaymentTypeAxis_exel_PaymentinKindInterestMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-82A308A6C57E95C92B9AB6B5EAC7DBE5" unitRef="number">0.075</exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection>
	<exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection contextRef="I2017Q2Jun27_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-E05F0D7681662BFBC9E6B6B5EAC7A027" unitRef="number">0.15</exel:DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection>
	<exel:DebtInstrumentNumberofInstruments contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-7EDC1EB6CC79C4FB5038B4452D704E78" unitRef="debt_instrument">2</exel:DebtInstrumentNumberofInstruments>
	<exel:DebtInstrumentPrepaymentPenalty contextRef="I2017Q2Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-10FB420B11A51B2C2C86B6B5F1E46C06" unitRef="usd">5800000</exel:DebtInstrumentPrepaymentPenalty>
	<exel:DebtInstrumentRedemptionofConvertibleDebtAmount contextRef="I2016Q4Nov_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-68A886643DF6845577D4B6B5EAC706E5" unitRef="usd">600000</exel:DebtInstrumentRedemptionofConvertibleDebtAmount>
	<exel:DebtInstrumentsUnamortizedClosingFeesAndExpenses contextRef="I2016Q4Dec30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-6E7F9714001907991A20B6B5EAC79866" unitRef="usd">400000</exel:DebtInstrumentsUnamortizedClosingFeesAndExpenses>
	<exel:DeferredRevenueRecognitionPeriod contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-68F28FC0A01257A0DEBAB6B5F11A3966">P4Y</exel:DeferredRevenueRecognitionPeriod>
	<exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified contextRef="I2016Q4Dec30" decimals="-3" id="Fact-A2E9D3425121EC4149F4B6B5ECBC6CA8" unitRef="usd">14780000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
	<exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E529578BB7E4FA9F6B3BB6B5ECBCB588" unitRef="usd">8966000</exel:DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified>
	<exel:DefinedContributionPlanNumberofSharesAvailableforGrant contextRef="I2017Q4Dec29" decimals="INF" id="Fact-C164D722A0FC6FC6AF3DB6B5EC2E40E1" unitRef="shares">231090</exel:DefinedContributionPlanNumberofSharesAvailableforGrant>
	<exel:DiscountsandAllowances contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-8E31CC47DDDD3EF7D35A8B0C442C591D" unitRef="usd">1299000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-804AD5A42394D76DB2DF8B0C401A1F13" unitRef="usd">119000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-0C57F1D4CB00247A5BE48B0C40039B6C" unitRef="usd">251000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-C00EDD7F54056136D4E28B0C3F0C8930" unitRef="usd">891000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2015Q4Q4FY_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-F529F2FC0F1A711C09A28B0C3E0601AA" unitRef="usd">38000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2016Q4Dec30" decimals="-3" id="Fact-A2ABEE250E2625E95B458B0C3D2E0FF2" unitRef="usd">5574000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-9ACF2B877CDBCA2FF55C8B0C41B5E202" unitRef="usd">1802000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-00621C949F1341F40B578B0C3EAFF46B" unitRef="usd">794000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-FA46CB6DC05002218C708B0C405488C2" unitRef="usd">2627000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2016Q4Dec30_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-C359F6167D0933D824E98B0C4036E69D" unitRef="usd">351000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2017Q4Dec29" decimals="-3" id="Fact-26A01C23F1B0CD85018D8B0C3C9BFC51" unitRef="usd">9493000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-2BF063B6FE56246290168B0C3CB08526" unitRef="usd">1928000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-CFEFD775DBC039AC8FC68B0C3CC3B35A" unitRef="usd">1795000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-5A8A580CA0ADE2F3BD1C8B0C3CEDB5A3" unitRef="usd">5770000</exel:DiscountsandAllowances>
	<exel:DiscountsandAllowances contextRef="I2017Q4Dec29_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-A217E43B5E80F5EB0B6A8B0C3D83BA1C" unitRef="usd">0</exel:DiscountsandAllowances>
	<exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount contextRef="D2015Q4FY2015" decimals="-3" id="Fact-D6963B57B92928057672B6B5EC9DE9F5" unitRef="usd">0</exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount>
	<exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B629B568CE0E135DD1FAB6B5EC9DD5D7" unitRef="usd">4726000</exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount>
	<exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-EA7B7E8D7BF6FA7691FDB6B5EC8D94A3" unitRef="usd">0</exel:EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2016Q1Feb29_exel_MilestoneObjectiveAxis_exel_HCCAcceptanceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-919B2D515FA5E2D3357AB6B5E8FCC939" unitRef="usd">40000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2016Q1Feb29_exel_MilestoneObjectiveAxis_exel_HCCFilingMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-B68D655954B2D1743572B6B5E8FCB5B9" unitRef="usd">10000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement contextRef="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-9862FB030FE3D968736BB6B5E8FC3FE8" unitRef="usd">209000000</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
	<exel:ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-3" id="Fact-FD5A09129A69C0524BA2B02B843FC1B9" unitRef="usd">7338000</exel:ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue>
	<exel:ExtinguishmentofDebtIncludingPaidinKindInterest contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-2D884078C5B7C08F3031B6B5F1E4ECB7" unitRef="usd">123800000</exel:ExtinguishmentofDebtIncludingPaidinKindInterest>
	<exel:ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-3" id="Fact-24B6DE43F81DD7503F59B029E4F9DF7A" unitRef="usd">83000</exel:ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-1D3B2B8288B4996B93BC8A7E50DF8E4A" unitRef="usd">-23474000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-CA4D22D1D1F30FE0755A8A7E50DC1BE1" unitRef="usd">-3940000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseAccruedClinicalLiabilities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CD210ED9A33BB4F91D728A7E50E342B3" unitRef="usd">5718000</exel:IncreaseDecreaseAccruedClinicalLiabilities>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2015Q4FY2015" decimals="-3" id="Fact-9699D598BEC52C294E2E8A7E9312C283" unitRef="usd">10206000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-74DF2A84F609D36875D68A7E9319F856" unitRef="usd">-10938000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:IncreaseDecreaseinAccruedCollaborationLiability contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1EF5E7F0CAA7721183418A7E9331D4A4" unitRef="usd">6928000</exel:IncreaseDecreaseinAccruedCollaborationLiability>
	<exel:InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-F872985C2A9869EFDD49B0217096C493" unitRef="usd">3600000</exel:InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness>
	<exel:InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-3" id="Fact-676906DF83B36D39C041B0252B9B1020" unitRef="usd">3572000</exel:InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness>
	<exel:LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue contextRef="I2017Q4Dec29_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="-5" id="Fact-66FAFE32191674A92B9BB4497DFA3F1A" unitRef="usd">28500000</exel:LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue>
	<exel:LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" id="Fact-EB55CD6D0391578FD5E4B6B5F38D3851">P5Y</exel:LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm>
	<exel:LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" id="Fact-A22639474287603B3791B6B5F38D4DE6">P10Y</exel:LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract>
	<exel:LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract contextRef="D2017Q2May02-May02_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" id="Fact-AAC3F4C5ABF9E83BB2C5B6B5F38DFBFC">P6M</exel:LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract>
	<exel:LossonExtinguishmentofDebtTransactionCosts contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-3" id="Fact-C9307801C6F2E1B962E1B02C7E6A86A1" unitRef="usd">514000</exel:LossonExtinguishmentofDebtTransactionCosts>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="I2016Q1Feb29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-7BEECE6A9FB739D54449B6B5E90CA8CD" unitRef="usd">546000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-668618C44CEBBA8936D7B6B5ED2AEE31" unitRef="usd">83000000</exel:MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
	<exel:MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-8494DC0C122E46E7A3FFAF6B473814F1" unitRef="usd">150000000</exel:MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement>
	<exel:MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="INF" id="Fact-61DF301F415E562C233FB6B5E8FC16D1" unitRef="usd">375000000</exel:MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement>
	<exel:MaximumPotentialMilestonePayments contextRef="I2017Q4Dec29" decimals="-8" id="Fact-FCF01087F461A7609BD2B6B5E90C4F02" unitRef="usd">1900000000</exel:MaximumPotentialMilestonePayments>
	<exel:NumberofProductsinCommercialMarket contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-A67F1216D5017AE2F9C1B6B5E7F14586" unitRef="product">3</exel:NumberofProductsinCommercialMarket>
	<exel:NumberofProductsinCommercialMarket contextRef="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_ProductsDerivedfromCabozantinibMember" decimals="INF" id="Fact-45A93F80B3A91A54F2C9B6B5E7F115A7" unitRef="product">2</exel:NumberofProductsinCommercialMarket>
	<exel:PaymentOfReimbursementsFromCollaborationArrangement contextRef="D2017Q4Sep30-Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-2A8352365854393E8C8EB6B5F11ADDA1" unitRef="usd">3900000</exel:PaymentOfReimbursementsFromCollaborationArrangement>
	<exel:PaymentandCreditsIssued contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4700EE72DF06890C92CEAF2BEA1462AD" unitRef="usd">11849000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-36DE1CF9D3A1CA617214AF2BE33D8B35" unitRef="usd">6549000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-AD81CCCE0AACA479C690AF2BE4AD9A65" unitRef="usd">2206000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-C94168A25E2207B4D925AF2BE724D5E0" unitRef="usd">3056000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-F17321316B943D8A86ECAF2BE895AC66" unitRef="usd">38000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-84B409602B9B298117E8AF2C0D0D7667" unitRef="usd">49641000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-32A169D6286DF39AB948AF2C05398856" unitRef="usd">32367000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-329FEC593FC35B720423AF2C0732BAB0" unitRef="usd">6300000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-FC60B08A41CB0B406E0EAF2C09251807" unitRef="usd">10623000</exel:PaymentandCreditsIssued>
	<exel:PaymentandCreditsIssued contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-CCAD0916349D57F7F8D8AF2C0B1888EB" unitRef="usd">351000</exel:PaymentandCreditsIssued>
	<exel:PaymentsforConversionofConvertibleDebt contextRef="D2015Q4FY2015" decimals="-3" id="Fact-B1637E5A861DC2AAE86A8A8CE992E631" unitRef="usd">0</exel:PaymentsforConversionofConvertibleDebt>
	<exel:PaymentsforConversionofConvertibleDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-6681F70240FF65C0FEED8A8CE99936A6" unitRef="usd">7135000</exel:PaymentsforConversionofConvertibleDebt>
	<exel:PaymentsforConversionofConvertibleDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6CD827222D47754117648A8CE99BE940" unitRef="usd">0</exel:PaymentsforConversionofConvertibleDebt>
	<exel:PaymentsforInducementsofDebtConversion contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-D0D5AE38D3E61E7B5322B02157911133" unitRef="usd">2400000</exel:PaymentsforInducementsofDebtConversion>
	<exel:PaymentsforInducementsofDebtConversion contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-3" id="Fact-D6097BE5EA0FB60C80BAB024E92DDC7F" unitRef="usd">2394000</exel:PaymentsforInducementsofDebtConversion>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2008Q4October_us-gaap_MajorCustomersAxis_exel_GlaxoSmithKlineMember" decimals="INF" id="Fact-73994C430B7FAAD30ADEB6B5E7F1EB68" unitRef="number">0.03</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-625A5D769D997A62CF97B6B5E8FC0112" unitRef="number">0.26</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-C3BB08D2703A0F1DC56FB6B5ED2A1F14" unitRef="number">0.3</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-8065F4891FC0DBF76259B6B5E90CA99A" unitRef="number">0.22</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-29E721A2049D205648B4B6B5ED2A3962" unitRef="number">0.2</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-19984E4D71BD141054D4B6B5ED2A3B99" unitRef="number">0.24</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-EF86ACDD467741994360B6B5ED2AD1C4" unitRef="number">0.15</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-BFCC2108D2A579F0628DB6B5E8FC0757" unitRef="number">0.12</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentOfRoyaltyOnNetSale contextRef="D2017Q4Sep30-Dec29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-C6EE5E2B5FC68772BB00B6B5E90CDACE" unitRef="number">0.02</exel:PercentOfRoyaltyOnNetSale>
	<exel:PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment contextRef="I2017Q4Dec29" decimals="2" id="Fact-D04CEAC93D8632984AACB6B5E8FCC48D" unitRef="number">0.09</exel:PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment>
	<exel:PercentageofMaximumPotentialMilestonePaymentsCommercial contextRef="I2017Q4Dec29" decimals="2" id="Fact-DBFFB3829EE26589E67BB6B5E90C34C8" unitRef="number">0.42</exel:PercentageofMaximumPotentialMilestonePaymentsCommercial>
	<exel:PercentageofMaximumPotentialMilestonePaymentsRegulatory contextRef="I2017Q4Dec29" decimals="2" id="Fact-A28933900738EF535B46B6B5E8FC776D" unitRef="number">0.49</exel:PercentageofMaximumPotentialMilestonePaymentsRegulatory>
	<exel:PeriodOfSpecificSalesVolumeThreshold contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" id="Fact-D2487F44FCF1D0449085D2CE167E1B7F">P6Y</exel:PeriodOfSpecificSalesVolumeThreshold>
	<exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce contextRef="D2015Q4Nov01-30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="2" id="Fact-7644689E52908C45FD61B6B5E8FC5B48" unitRef="number">0.25</exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce>
	<exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce contextRef="D2017Q4FYYTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-8C14DCE5E672B00F3447B6B5E7F1F2C4" unitRef="number">0.25</exel:ProfitSharingAgreementOptionalPercentOfTotalSalesForce>
	<exel:ProfitSharingAgreementPercentOfProfits contextRef="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierOneMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-12227513EE156EDC8BD0B6B5E90C5255" unitRef="number">0.5</exel:ProfitSharingAgreementPercentOfProfits>
	<exel:ProfitSharingAgreementPercentOfProfits contextRef="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="INF" id="Fact-042DC6D199D8B202E866B6B5E8EC8A1C" unitRef="number">0.3</exel:ProfitSharingAgreementPercentOfProfits>
	<exel:ProfitSharingAgreementProfitThreshold contextRef="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierThreeMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-86CBF0BE90C426B53241B6B5E8FC9ED0" unitRef="usd">400000000</exel:ProfitSharingAgreementProfitThreshold>
	<exel:ProfitSharingAgreementProfitThreshold contextRef="D2017Q4FYYTD_exel_ProfitSharingTiersAxis_exel_ProfitSharingTierTwoMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-845B3A1709F90C4F07A5B6B5E8FCA6BF" unitRef="usd">200000000</exel:ProfitSharingAgreementProfitThreshold>
	<exel:RecoveryOfExpensesExpensesInCurrentFiscalYear contextRef="D2016Q3Jan022016-Sept302016_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-75789EDD8FD689364C5C7C3CFA8C58DB" unitRef="usd">9800000</exel:RecoveryOfExpensesExpensesInCurrentFiscalYear>
	<exel:RecoveryofExpensesExpensesPriortoCurrentFiscalYear contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_exel_ContractRevenueMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-FB080D4C7C1275E2FCD98C085741E4BC" unitRef="usd">-4500000</exel:RecoveryofExpensesExpensesPriortoCurrentFiscalYear>
	<exel:RecoveryofExpensesExpensesPriortoCurrentFiscalYear contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-17D999F2F58179918DA9B6B5E90CE7A2" unitRef="usd">13300000</exel:RecoveryofExpensesExpensesPriortoCurrentFiscalYear>
	<exel:RecoveryofExpensesExpensesPriortoCurrentFiscalYear contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-5699F7DE996F44CD970D8C0869EE9A38" unitRef="usd">8800000</exel:RecoveryofExpensesExpensesPriortoCurrentFiscalYear>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2017Q4FYYTD_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-5B72D242B67CA35CFA9EB6B5ED2A310E" unitRef="number">1</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2017Q4FYYTD_us-gaap_StatementGeographicalAxis_exel_GlobalMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-0DBFF8FAD1EB27B8AC64B6B5ED2A7A79" unitRef="number">0.2</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-4DBC8E2676FCECC4C6B0AF58A5156EC4" unitRef="number">0.35</exel:ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent>
	<exel:RoyaltyTier contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_FinalTierMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-40AE63B0A957D26771ACB6B5E8FC3BFC" unitRef="usd">150000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="INF" id="Fact-9075DD8EF9DF02693274B6B5ED2ABFD3" unitRef="usd">300000000.0</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2017Q4FYYTD_exel_RoyaltytierAxis_exel_SecondMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-2DA80755B9251FFE0860B6B5E90C085D" unitRef="usd">100000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2017Q4Sep30-Dec29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-5A5C85D67D2DDB79981CB6B5E90C6314" unitRef="usd">50000000</exel:RoyaltyTier>
	<exel:RoyaltyTier contextRef="D2017Q4Sep30-Dec29_exel_RoyaltytierAxis_exel_InitialMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-3CB8A4263352B582C332BACC9A2AA05D" unitRef="cad">30000000.0</exel:RoyaltyTier>
	<exel:SalesRevenueDiscountExpectedtobeEarnedPercent contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-5D0C93D4EB38362FBDE9B6B5E7F128C7" unitRef="number">1</exel:SalesRevenueDiscountExpectedtobeEarnedPercent>
	<exel:SalesRevenuePercentDiscountForPromptPayment contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-C07ABEF46BB5145B8D28B6B5E7F1C75D" unitRef="number">0.02</exel:SalesRevenuePercentDiscountForPromptPayment>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-F7742618C23050C51140B6B5EC6E49EA" unitRef="usd">114395000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-8509D00460D7B05EB7DDB6B5EC6E698D" unitRef="shares">708541</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-42008D062DA2E51879ADB6B5EC6E450C" unitRef="usdPerShare">7.97</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-B48EEB58FFE8EF11028AB6B5EC2EF474" unitRef="usd">18900000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-B82FF341B1BB585C5AB8B6B5EC2E8B17" unitRef="usd">13400000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue>
	<exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-EF9FDF5940120F5412DCB6B5EC2ED1D0" unitRef="usd">13100000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue>
	<exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-D4EBCC77BCB5002B5230B3B1444BCBB0">P6M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod>
	<exel:SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension contextRef="D2017Q4FYYTD_us-gaap_PlanNameAxis_exel_ChangeinControlandSeveranceBenefitPlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-7E795610D30E771392E8B6B5EC2EBBEF">P1Y</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension>
	<exel:SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl contextRef="D2017Q4FYYTD_us-gaap_PlanNameAxis_exel_ChangeinControlandSeveranceBenefitPlanMember" id="Fact-B83E30147384752FDCB9B6B5EC1E5EBB">P1M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl>
	<exel:SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl contextRef="D2017Q4FYYTD_us-gaap_PlanNameAxis_exel_ChangeinControlandSeveranceBenefitPlanMember" id="Fact-CD4F9393D987DC974C35B6B5EC2ECF3A">P13M</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl>
	<exel:SharesWithheldforConversionofWarrants contextRef="D2017Q3Sep11-Sep11_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-93A1D87AB3B5A9F431ECB6B5F1F4F4B8" unitRef="shares">122549</exel:SharesWithheldforConversionofWarrants>
	<exel:TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-5DDA74A5A1BA6D176CF3B4229498E914" unitRef="usd">184800000</exel:TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross>
	<exel:TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-8544613D782E33D8C877B9D60C574506" unitRef="usd">-184800000</exel:TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance>
	<exel:TenantLeaseImprovementsAllowance contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_CapitalLeaseandOtherFinancingLeaseMember" decimals="-5" id="Fact-62E64B0926B02E41362CB6B5F1A68D26" unitRef="usd">7700000</exel:TenantLeaseImprovementsAllowance>
	<exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions contextRef="D2015Q4FY2015" decimals="-3" id="Fact-E726CC554D09C3751E61B6B5EC8D4916" unitRef="usd">21696000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
	<exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-05C2E4AE645384F6AEDEB6B5EC8D8057" unitRef="usd">-29110000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
	<exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-4EAE3A5A2C54D5D45BCDB6B5EC8DF1B4" unitRef="usd">247000</exel:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions>
	<exel:UpfrontAndMilestonePayments contextRef="D2017Q1Feb_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-94346C9F80AA6A621F2AB6B5F11A0AAC" unitRef="usd">50000000</exel:UpfrontAndMilestonePayments>
	<exel:UpfrontAndMilestonePayments contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-DCE8C9595E33DF63E8438BD9A5E1E825" unitRef="usd">210000000</exel:UpfrontAndMilestonePayments>
	<us-gaap:AccountsPayableCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-7D94846AA7705196E011B6B5E542C33E" unitRef="usd">6565000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5583ADAA1AE2911FDB2DB6B5E513116D" unitRef="usd">9575000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-1FA28603F227D8632B75B6B5E533285F" unitRef="usd">20334000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccruedEmployeeBenefitsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6CDBD95D0BCF51E26DC3B6B5E533C9C1" unitRef="usd">21073000</us-gaap:AccruedEmployeeBenefitsCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I2016Q4Dec30" decimals="-3" id="Fact-07415B60E3F569FFA153B6B5EA680FB8" unitRef="usd">24882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I2017Q4Dec29" decimals="-3" id="Fact-D008DBBF9303FE0F4C89B6B5EA688396" unitRef="usd">22800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2016Q4Dec30" decimals="-3" id="Fact-487B0DE473882216DA08B6B5E53366EA" unitRef="usd">-416000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6DC5F7E35AF8FFC68959B6B5E533D452" unitRef="usd">-347000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="I2016Q4Dec30" decimals="-3" id="Fact-5FB6FD017C289A260217B6B5E533BA69" unitRef="usd">2072591000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8BC5018A55B5B4D3DAB5B6B5E533040B" unitRef="usd">2114184000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-72F8CEFD63126A2BAEE7B6B5EAC7C7AD" unitRef="usd">342700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2015Q4FY2015" decimals="-3" id="Fact-9F9C001E63A4E226F269B6B5E6A95025" unitRef="usd">21977000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6FAC7D42DBB2765D50ADB6B5E6A91548" unitRef="usd">21977000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8993584B5784968AEF0AB6B5E6B98A51" unitRef="usd">22912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3B977BE4B0702A892691B6B5E6B9DCDA" unitRef="usd">22912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7B04B6D57477C0669CD47C07563D5ACC" unitRef="usd">23938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0C304E453D9BD2AF4F6A7C074F459C9F" unitRef="usd">23938000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="D2015Q4FY2015" decimals="-3" id="Fact-C85E89D48A71E7758D5D7C155C0B39EA" unitRef="usd">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F0AE30EE07B53E997B0E7C155C12724F" unitRef="usd">1470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-9FA4393F3DBEF93137ACB38D9F49BEF2" unitRef="usd">21977000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="-5" id="Fact-018FDE53B3AF7303B3F3B3ABB3A112E5" unitRef="usd">13200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-8F2959D380C71CAA4924B6B5EC2E81BC" unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4FY2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-A345BAFFCB38D8F4C0A4B38D9D5978DD" unitRef="usd">11691000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4FY2015_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5EB49A1D9D25AF387C64B38D9E53FBF1" unitRef="usd">10286000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0CA1A1CA0C97B6452159B38D7C4209F0" unitRef="usd">22912000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="-5" id="Fact-C9F4E68A609259EE3F78B3ABA54E740D" unitRef="usd">4100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-1613227300D6B8A1101DB6B5EC2E1370" unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-AF6D82C3EAFADE12137EB6B5EBFF56CD" unitRef="usd">9366000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-2C1DFC8703B437DC71AAB6B5EBFF4157" unitRef="usd">13546000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-2580D8609C2B4C5BA9A4B38D7B308097" unitRef="usd">23938000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-98CD90CD59D6BFF45FE4B6B5EC2EF98A" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-7F54FDC99A28B7F89F72B6B5EC1E84BF" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-ED01336B5746D27A5C19B6B5EBFF32F6" unitRef="usd">7569000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2017Q4FYYTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-491336A9EFA981E82284B6B5EBFF1BD5" unitRef="usd">16369000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2015Q4FY2015" decimals="-3" id="Fact-AA0ABB932F56706121D68A7CC948F8C6" unitRef="usd">17041000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8C53E316D058559541A48A7CC945DA4F" unitRef="usd">8432000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-09C941E38D0FF33B32448A7CC94C8023" unitRef="usd">182000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2015Q4FY2015" decimals="-3" id="Fact-DB8EBB60DDE6D3C7EB91B3CAF04B3A07" unitRef="shares">117478000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-3" id="Fact-FE86247746DEE9135622B3CAE6671DBF" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-A870CC2CDB5033FB74BCB3CAEBF1B690" unitRef="shares">54118000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-DC2C78C90E3F7AC83A59B3CAE0370723" unitRef="shares">33890000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2015Q4FY2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-9FDC66C523B1B2890A83B3CADBFA4F24" unitRef="shares">28470000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-6CDCE33EC466CF699545B6B5ECCC9B7B" unitRef="shares">62458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-3" id="Fact-2C87E62CE9A0E4935BB6B3CAE41F1896" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-73D79F8A17ACDA9ADBF8B6B5F31F93A5" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-1E46B253D0ACB7A0AE7AB6B5F31FC37C" unitRef="shares">33890000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-47BF944A3D1532DD6AE0B3CADA083D47" unitRef="shares">27568000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F3E20F8F3236BA32BD7CB3CAED3D4FEE" unitRef="shares">1645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-3" id="Fact-913C2DE7ED2E07A38B40B6B5ECCC6B57" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" decimals="-3" id="Fact-75B5B8DA3F6468A7A01CB6B5F31F5498" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member" decimals="-3" id="Fact-5A8E0A3E33EA635F8478B6B5F31F6839" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2017Q4FYYTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" decimals="-3" id="Fact-F5F0C41A50228322A505B3CAD813B0D4" unitRef="shares">1645000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="0" id="Fact-48C80D5B78CCF9706E6AB6B5F1A64E0B" unitRef="sqft">110783</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="0" id="Fact-30ECDBE75F57423406D3B6B5F38D3561" unitRef="sqft">16343</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q4Dec29_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseMember_us-gaap_StatementGeographicalAxis_exel_SouthSanFranciscoCaliforniaMember" decimals="0" id="Fact-6D19BB43D046B9CD9A19B45940A8F1E6" unitRef="sqft">116063</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q4Oct16_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="0" id="Fact-23BBE45B30BF6CA5CEE3B6B5F1A6ACAB" unitRef="sqft">19778</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="I2016Q4Dec30" decimals="-3" id="Fact-72AB813D336A7E0F14FAB6B5E53375F3" unitRef="usd">595739000</us-gaap:Assets>
	<us-gaap:Assets contextRef="I2017Q4Dec29" decimals="-3" id="Fact-24DC00DE62F208D8B3DDB6B5E533E746" unitRef="usd">655294000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-406A621C517DCEF29683B6B5E53395CE" unitRef="usd">469001000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C5F22D90D17763B1C3F0B6B5E5331FE1" unitRef="usd">484874000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30" decimals="-3" id="Fact-884666CAC20D0F855C70B401D8551046" unitRef="usd">459966000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-8429F0587327E6842F9EB401D4705FA5" unitRef="usd">71457000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-4AAF72D8F70A66015324B401C542F6F0" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-EC10F1ADD2CF9915148DB6B5EB536674" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-FEA84239FBB7764C1E86B6B5EB530FBE" unitRef="usd">71457000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-83E0CDA3F0519C9E69BCB6B5EB442B46" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-8ACC8B2299ED49852D93B401D662776F" unitRef="usd">388509000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-42476D1BBCB7472D36C8B6B5EB539923" unitRef="usd">165375000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-1B2EDE93165657B7FCF8B401CBC55F35" unitRef="usd">152407000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-9B17BBF43C096C0E4322B6B5EB44622C" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-87D59D09716210864500B401D0D8F2FA" unitRef="usd">70727000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-0A1AF0388CE9B960258BB401C90995A9" unitRef="usd">165375000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-ED558760042B83851E65B401CE0D42BF" unitRef="usd">152407000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-AC56B6AA2141FB2D57B1B401C3F502E5" unitRef="usd">71457000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-FEF823648705E67DBDD3B401D3217709" unitRef="usd">70727000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E27280DFD9E4CF85F165B4016829039A" unitRef="usd">440410000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-81E94BFEAEC3F235EB47B40164422183" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-900A1C2F8FE2AAAAC2BEB6B5EB635CF5" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-F34CF1300CAE74C73BB3B6B5EB63F229" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-E59DD44EDB705EEAFE28B6B5EB63CD0E" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-0CC66ED86C7E829C92F0B4015F4045C4" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-2B38555430C7FD4FA4C8B40166358776" unitRef="usd">394932000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-CD3EB58794E46F406CC3B6B5EB63CE4B" unitRef="usd">199647000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-76444DDD73DD2D6F85E3B6B5EB63BAF5" unitRef="usd">179022000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-E91DC2DBB807B717656FB6B5EB63DF25" unitRef="usd">0</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-5298F048F8E9A4B87FECB6B5EB63C178" unitRef="usd">16263000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-CD61C99168CED9180EA5B40159BA0147" unitRef="usd">199647000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-5CEEACD1B718FDA6EFECB4015DF018F1" unitRef="usd">179022000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-F79C33396BC7D58BFF44B401557950B8" unitRef="usd">45478000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AssetsFairValueDisclosureRecurring contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-871084D7BF07A2961796B40162F40EFC" unitRef="usd">16263000</us-gaap:AssetsFairValueDisclosureRecurring>
	<us-gaap:AvailableForSaleSecurities contextRef="I2016Q4Dec30" decimals="-3" id="Fact-222701CA75B841CD7EE5B6B5E9EB9DBA" unitRef="usd">459966000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-650CAA1BCFED4A59C62DB6B5E9EBB57F" unitRef="usd">165375000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-3C6DEAB93AFE132890E0B6B5E9EB324C" unitRef="usd">152407000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-8A0D77444A9CBDF16A1AB6B5E9EB0D7A" unitRef="usd">71457000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-C2FD0D78C3D21FCA8939B6B5E9EBD68B" unitRef="usd">70727000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-80D6C8E5C9888DCEA2DCB6B5EA2AA725" unitRef="usd">440410000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-432A8F2685DA637AC579B6B5EA2A3390" unitRef="usd">199647000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E4262DEA3AB48DF3199EB6B5EA2A624D" unitRef="usd">179022000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-1FA8996BEFEAC24D25FFB6B5EA2AB533" unitRef="usd">45478000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-0185EE8945F0FE1E4CDBB6B5EA2AA18A" unitRef="usd">16263000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2016Q4Dec30" decimals="-3" id="Fact-F2A139BFC3E9B6367AAAB6B5E9EB694A" unitRef="usd">14000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-AC86575E673A074E1AB2B6B5E9EBE0B4" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-0EA499AA80B919208241B6B5E9EBAAEF" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-74E63915F5C170908644B6B5E9EBEE10" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-F14E137153DBA481A611B6B5E9EB991D" unitRef="usd">11000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A6F3F03EE05C3DB1CCD9B6B5EA2A29BF" unitRef="usd">18000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E560603CB44FED0ED6DDB6B5EA2ADB0B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-A718AC6DAAB31D95D2E7B6B5EA2A80D5" unitRef="usd">18000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-1F90AC4C58F6D2E22A37B6B5EA2AE7C8" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-0D5EA6EC00DAF826166AB6B5EA2AB17A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2016Q4Dec30" decimals="-3" id="Fact-D110C00E5C50EF5ED3AEB6B5E9EBB323" unitRef="usd">322000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-BA9B3540B59985EA9687B6B5E9EBE106" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-3BBED2B86BA41A86E94DB6B5E9EB0435" unitRef="usd">308000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-72A37AD15BE2DBAFA268B6B5E9EB42B3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-2EC14651737B6897A353B6B5E9EB1572" unitRef="usd">14000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29" decimals="-3" id="Fact-039D493758EB07093357B6B5EA2ADED9" unitRef="usd">364000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-95E931731712438A14C8B6B5EA2AA507" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-F5DE79954F44107645AAB6B5EA2A9062" unitRef="usd">332000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-3A41A24BF0FA8C496D08B6B5EA2A8A0A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-6E0815478744B6861BE6B6B5EA2AED15" unitRef="usd">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2016Q4Dec30" decimals="-3" id="Fact-E042E643162913881C91B6B5E9EBC20F" unitRef="usd">460274000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-AD0617D726EAA01D4324B6B5E9EB4BD6" unitRef="usd">165375000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-FAF5282F00C5EDC1FFCDB6B5E9EB9AB1" unitRef="usd">152712000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-20A5EFE961405241AF26B6B5E9EB4018" unitRef="usd">71457000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-B810E2D732DFE1B09144B6B5E9EBC9DE" unitRef="usd">70730000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2017Q4Dec29" decimals="-3" id="Fact-328F010E7103DDD42051B6B5EA2A9EEF" unitRef="usd">440756000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-8AD4CDB1D77487E104C8B6B5EA2AED81" unitRef="usd">199647000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-89F7A35B71CAD77A6E2FB6B5EA2A8845" unitRef="usd">179336000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-14D4944B1F47CA6F42EDB6B5EA2A3C8F" unitRef="usd">45478000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-A7123D0B6B93D0FC9CD3B6B5EA2ACCAF" unitRef="usd">16295000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2FC22AC88B35C1E6F7B000E4387B1F72" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-31DAA811E01FBE5CE1C500E428F90801" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-628623D54DC66A1828E300E3B50D1C1C" unitRef="usd">3000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-933747912EE027B95A7000E3CA199A34" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-4F9D4513C29EC1D6DD9B00DEE624746D" unitRef="usd">45000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-89C69F3772F4BE95EEE400DEE610EDA6" unitRef="usd">36000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses contextRef="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-2C3D3E6CC0B4D2C5AF2D00DEE642E63F" unitRef="usd">9000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A30ED3D96866879680D300E43CB3F3C5" unitRef="usd">322000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-D2DD27F6D81A2149AD4900E42FE5E1E0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-C7DA67165D8A1A62EAF100E3BCDB998B" unitRef="usd">308000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-0F645C6682003FB4944700E3D0CCB6DF" unitRef="usd">14000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-9D25E753AAEF19C071CD00DF0E4B29E0" unitRef="usd">364000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-5BC84C3F8E9F5937217700DF0E780EC9" unitRef="usd">332000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses contextRef="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-07781B9CC6F252CEF8BB00DF0E5893B1" unitRef="usd">32000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-8346DB5008672BB913D000E43A901DB6" unitRef="usd">172215000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-E28851038044EA5AB37D00E42C6D70B3" unitRef="usd">998000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E573E7F0134C4467306900E3B8F136AA" unitRef="usd">143560000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-BE9B6C51B6253B7173D200E3CD643A5C" unitRef="usd">27657000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F046906FFF4C010D13BD00E02006627B" unitRef="usd">177055000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-9B1E4FCDDD7A1160363700E020324A07" unitRef="usd">160793000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-B9F71D788FB27648A8DC00E02014FA12" unitRef="usd">16262000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-6EC4D3CA693E7FED026300E43490DB41" unitRef="usd">319000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-8858FDBC01E138BBD23900E422B29837" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-96B342432634F32DD4E500E3AE5EB0C9" unitRef="usd">305000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2016Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-3C1CB7985D02069FE46B00E3C35098F2" unitRef="usd">14000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B25CB3CE95D6F382902100DD1AF131B3" unitRef="usd">319000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-8BF5605DBF098982602000DD1827C4CB" unitRef="usd">296000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses contextRef="D2017Q4FYYTD_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-716B9506726E2B9D6E1500DD19820BAE" unitRef="usd">23000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-1431C676106F16A6AC8400E432779F5E" unitRef="usd">169214000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-63E5ED18F319035C661B00E41F900F6B" unitRef="usd">998000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-D0A45F1A6A00F9EE0F9300E3AB4558EA" unitRef="usd">140559000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-EA271AF943AF2BB4639500E3BFB471F6" unitRef="usd">27657000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2E003E07BB4CCD9BDE1000DCF84AA45C" unitRef="usd">154357000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-E5A7CAA91F0AEE0F121B00DCF846DD8C" unitRef="usd">140746000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-E416F14BB3144AB4ED3B00DCF84F81EA" unitRef="usd">13611000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-B485E3C2A6E51CE361B700E436A46259" unitRef="usd">3001000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-4A4A2077892CAD70066000E425976FE3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-69026CE696F86F2C608D00E3B209E1B0" unitRef="usd">3001000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2016Q4Dec30_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-9DB9345B31FDD751480900E3C6AA0EFB" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E23C7389B0EA2C88F14E00DFF90E64C6" unitRef="usd">22698000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-1D2B2C5CC327E9EB733000DFF90AEE3A" unitRef="usd">20047000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue contextRef="I2017Q4Dec29_us-gaap_InvestmentTypeAxis_us-gaap_USTreasuryAndGovernmentMember" decimals="-3" id="Fact-DB329B034CABB82E1C1100DFF9078C70" unitRef="usd">2651000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-C392205FB00032833F0800FC7C0F537B" unitRef="usd">55601000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-DDA3F8B713389BBC927700FC7C0D260D" unitRef="usd">63255000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-BDA3C73E3789436366B000FC3143CC82" unitRef="usd">404365000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-95370A64EB95CD78B4BF00FC31298BD6" unitRef="usd">377155000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2016Q4Dec30" decimals="-3" id="Fact-D224C7BAAF30997AD01600FC9BE5D0ED" unitRef="usd">459966000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C34A38FD6B4547341A9800FC9BE25D3C" unitRef="usd">440410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="D2015Q4FY2015" decimals="-3" id="Fact-4B502C01938B98D359F3DF621AD2C9A0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9D154666C1DC760CD78CB6B5F187098B" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F81BED78FB7FD83C6AABB6B5F1779C6A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
	<us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 contextRef="I2016Q4Dec30" decimals="0" id="Fact-618D9AF420D590F3120E00F572C145A3" unitRef="investment">86</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
	<us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 contextRef="I2017Q4Dec29" decimals="0" id="Fact-8A8E0BDCF9A03168DFC9B6B5EA39B919" unitRef="investment">134</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C3463B8770F9BD4F8C8DB6B5F3AC92DE" unitRef="usd">21493000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8F06F0A1CC8A4E0C1D06B6B5F3AC4CF1" unitRef="usd">800000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F4E9E719D3897BB9E51AB6B5F3AC4161" unitRef="usd">2282000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-56FE07293808F14BF55BB6B5F3AC2673" unitRef="usd">2213000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8B2868850F1546DE571AB6B5F3ACFB8D" unitRef="usd">2129000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F39CB22E154D08E09739B6B5F3ACFFC2" unitRef="usd">1905000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8E230CFC7B28DDE98187B6B5F3ACEFC8" unitRef="usd">12164000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2015Q4FYQ4" decimals="-3" id="Fact-219FE58904D75247E28C8A832CDEEA68" unitRef="usd">80395000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-E56E8BA424145B87D4168A832CECCF8A" unitRef="usd">141634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-D575BC2098D958875459B6B5E542AB3F" unitRef="usd">151686000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9C9E83FB776C4BE36A33B6B5E5422C7D" unitRef="usd">183164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="D2015Q4FY2015" decimals="-3" id="Fact-8B7177E6A93425CC6FED8A83115B2579" unitRef="usd">61239000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BD92102A0FFC787E11238A831150A868" unitRef="usd">10052000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-60D316BC5407843C3A0B8A8311565528" unitRef="usd">31478000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-E43F99211A2011C29CB4B6B5EB152B58" unitRef="usdPerShare">9.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q1Mar18_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-0ECBF2863D18A803CF0AB6B5EB15975C" unitRef="usdPerShare">3.445</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2014Q1Jan31_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-6174FD79486513BF33A1B6B5EB1521E9" unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2017Q3WarrentExercise_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="INF" id="Fact-6D96475B46AEF686DE75BEF89B8D172E" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="I2016Q4Dec30" id="Fact-0853E24FC5A0A6999039B6B5E5423548" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="I2017Q4Dec29" id="Fact-F7F28B8D1C39F42973DCB6B5E5134FE4" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2016Q4Dec30" decimals="INF" id="Fact-ACBFF53D06E0F84EC91AB6B5E552F5A3" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q4Dec29" decimals="INF" id="Fact-EC6AF84BEF1EAE3BEB81B6B5E55279EB" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2016Q4Dec30" decimals="INF" id="Fact-4090C99C893A48FEEEC7B6B5E552076C" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2017Q4Dec29" decimals="INF" id="Fact-BC6544AD5831DD885D11B6B5E552A677" unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="I2016Q4Dec30" decimals="INF" id="Fact-366632F150F4DA79E4C8B6B5E55219C3" unitRef="shares">289923798</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="I2017Q4Dec29" decimals="INF" id="Fact-555D2BC5761E85364198B6B5E5528B4C" unitRef="shares">296209426</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-524178A336B7F900C49DB6B5E6A9F7E3" unitRef="shares">195895769</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2EBE8DD84F17DE957726B6B5E6B96EA7" unitRef="shares">227960943</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2016Q4Dec30" decimals="INF" id="Fact-B5FE9308000C90574BFDB6B5E55234FD" unitRef="shares">289923798</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1B43385ADC1E15BD239CB6B5E6B9BEDD" unitRef="shares">289923798</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29" decimals="INF" id="Fact-31C90117B043C9B3379DB6B5E552E1AB" unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F3154B5AE748E5A8B98A7C16F5A549C6" unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-2EF4C5CD2A7C9188A994B6B5E5133122" unitRef="usd">290000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9D4C91654A902DA423FFB6B5E54263C5" unitRef="usd">296000</us-gaap:CommonStockValue>
	<us-gaap:CompensatingBalanceAmount contextRef="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember" decimals="-5" id="Fact-E6325F9790E8782F4355B6B5EA39E9F4" unitRef="usd">81600000</us-gaap:CompensatingBalanceAmount>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2015Q4FY2015" decimals="-3" id="Fact-6370FF84AFF343C2B5B6B6B5E5CFC000" unitRef="usd">-161855000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9FE4E91BACDCB028ED4DB6B5E5BF0611" unitRef="usd">-70406000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-FADAFF2BEB1115289A6FB6B5E5BF041C" unitRef="usd">154296000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-6B90A2F1CEB4D3CB5EF57C3FB46A4C1E" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-10625ABF44CC7B6612AB7C3FB8CF1A9D" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-1B04E7E4C48B36DCCAA27C3FB0CCC331" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-4A678E62D528B800B828B6B5ED1A2F88" unitRef="number">0.83</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-E811FDDB05AACC8B63D4B6B5ED1AB8AC" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-AA1C49634EE9EF0A847CB6B5F4680B1C" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-3E96C5F9BCF58B742B77B6B5F46807A6" unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-7CD63466E456DBF403C7B6B5F4688A86" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-94C6899D60AC31AAF53DB6B5ED1AE6CF" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-7E4A5915AF7FCBD6EC2CB6B5ED1A414B" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" decimals="2" id="Fact-03109081977F0D566EB7B6B5F458C3F5" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" decimals="2" id="Fact-713F04DEB2E91C3BFB47B6B5F4681020" unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_CaremarkL.L.C.Member" decimals="2" id="Fact-8BB28A8C3FDF54F95824B6B5F4689AAE" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" decimals="2" id="Fact-A3522B6B1C3A3B4AD518B6B5ED1A5BBC" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_exel_IpsenMember" decimals="2" id="Fact-7F33A006289CDB9F973FB6B5ED1A7D06" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ContractsRevenue contextRef="D2015Q4FY2015" decimals="-3" id="Fact-7EE679912AEE3DBF2732AF01FA2EEBA6" unitRef="usd">3014000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="INF" id="Fact-08E52D757FA745F0D5F4C8C6F48AF07D" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-B62B514B98AEA87CEE62D294A5E803BF" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2FAE7ED63857AD15C9EEB6B5E5904285" unitRef="usd">56079000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-AB6F6F094587F384A0C1B6B5F0DB8F45" unitRef="usd">33252000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-3EA8359C302E45156124D28EEDBFCB48" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6D0CD73A3DD706EB9D11B6B5E5A03992" unitRef="usd">103469000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-1A9EF516DF8BA2ED9265B6B5F0DBD86A" unitRef="usd">69792000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-D4627422BC64C8307624B6B5F0BCCA7C" unitRef="usd">14779000</us-gaap:ContractsRevenue>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="D2015Q4FY2015" decimals="-3" id="Fact-980569967F63EC1BEA127C2814B75803" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3DCA268BC7099BA26DA5B6B5E755EE8B" unitRef="usd">286925000</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConversionOfStockAmountIssued1 contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-514D807F8D6C89CA110AB6B5E755F059" unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
	<us-gaap:ConvertibleDebtCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-2941DBECD6A463CD290DB6B5E5330E69" unitRef="usd">109122000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E6672D783B51FC13706DB6B5E533C7E5" unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:CostMethodInvestmentsRealizedGainLoss contextRef="D2015Q4FY2015_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="-3" id="Fact-BDE152C05BD36A7D169BAFBA147149C9" unitRef="usd">0</us-gaap:CostMethodInvestmentsRealizedGainLoss>
	<us-gaap:CostMethodInvestmentsRealizedGainLoss contextRef="D2016Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="-5" id="Fact-E024D66D61412CCE802CB6B5EA39EADD" unitRef="usd">2500000</us-gaap:CostMethodInvestmentsRealizedGainLoss>
	<us-gaap:CostMethodInvestmentsRealizedGainLoss contextRef="D2017Q4FYYTD_invest_InvestmentAxis_exel_AkarnaTherapeuticsLtd.Member" decimals="-5" id="Fact-D1F07323910BC1938FD300F634F87D96" unitRef="usd">3000000</us-gaap:CostMethodInvestmentsRealizedGainLoss>
	<us-gaap:CostOfGoodsSold contextRef="D2015Q4FY2015" decimals="-3" id="Fact-FB40ECA1828B0F3F19EAAF01FF8531F9" unitRef="usd">3895000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B5677D5A6DA2E9DEF82DB6B5E59057B4" unitRef="usd">6552000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-5C66DAD449C36C7B5DE2B6B5F0DB0864" unitRef="usd">1555000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-022E33E19FE9FBD50E50B6B5E5A06FE6" unitRef="usd">15066000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-C79217D4E8B873AD99D4B6B5E85E745A" unitRef="usd">6390000</us-gaap:CostOfGoodsSold>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2016Q4Dec30" decimals="-3" id="Fact-D4DFEDB6884E7AA6BE97AF1EBAE160B4" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2016Q4Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-CB6C833BF57AADCB8E9A8BC43A2F3BD3" unitRef="usd">-300000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FD3A2AC39AAB2D2CF6CCBA782FDE9369" unitRef="usd">252000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-77F18A41EECBF90EF1057C1266A9D2A0" unitRef="usd">-252000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-5C2CF2ECA078539C6A05B6B5F08C14BB" unitRef="usd">300000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-717BDFEC14C9648B9EC8B6B5EC9DAAB7" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-63C3F16EF8FD8315A851B6B5EC9DCCD3" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-5D968016251F6B0CE039B6B5EC9D481E" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-907903F3E438A5846FC8B6B5EC9D05B1" unitRef="usd">55000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-32E01363AB58000B0DF0B6B5EC9D00CD" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6270FA3CD71C9E79A683B6B5EC9DF633" unitRef="usd">4350000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-72B1AFE93E5521302420B6B5EC9D43C9" unitRef="usd">55000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B8A96BEA2D87BD67FFF4B6B5EC9D8516" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-2F8AAC71D08BC51979C7B6B5EC9D35F0" unitRef="usd">4350000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-4EE00A804DD28B5B5C657BFBEA25C278" unitRef="usd">3420000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:CustomerRefundLiabilityCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-06DC0FE4FF42E18C9FF67BFBEA2725CB" unitRef="usd">7565000</us-gaap:CustomerRefundLiabilityCurrent>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-6BA7420C207B5A90826AB6B5EB151BEE" unitRef="usd">286900000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="INF" id="Fact-CA9CF39EB03EE98871FFB6B5EAC77023" unitRef="shares">54009279</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2015Q4Q4FY_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="4" id="Fact-0CCE0B868D472DF6BAD2B6B5E7F1B061" unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="3" id="Fact-F37542419B6B7B5A9DF7B129CE285A52" unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-9791B340038D38079F63B6B5EC9D8710" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9863EA173A5B7D70ADCFB6B5EC9DF4CE" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-AFDE10F76B6D5997B252B6B5EC9DAEFD" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-F55E634E8A16AEA7D6BAB6B5EC9D2C9E" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-E197850E23A5E985455AB6B5EC9D0CEC" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-3711EF17A2CDFD62B2F4B6B5EC9D96B6" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredRevenue contextRef="FI2017Q1_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-E75F7F8FAAF414740B42B6B5F11A0BD3" unitRef="usd">-9000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-94DDF54D2B96D98D3846B6B5E513432F" unitRef="usd">19665000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-891AB8D5A6DCF1975F7EB6B5E5137366" unitRef="usd">31984000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-9FF3D3C49C8D6E508FD9B6B5E8FC433C" unitRef="usd">19000000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-8529F7EEE4F1E7808C99B6B5F129345B" unitRef="usd">11300000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-672A1553DE6F97816430B6B5E542D203" unitRef="usd">237094000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-BE6107388710932ACAD9B6B5E51374D4" unitRef="usd">238520000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-716A4983F0BF257648AAB6B5E8FC8AFE" unitRef="usd">210200000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="I2017Q4Dec29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-5" id="Fact-ECC37E15182C94E248F0B6B5F11A0DD1" unitRef="usd">28300000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-86100B698D1645A91577B6B5EC9DB017" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A6D11DE2EDA57A2B442FB6B5EC9D59AC" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-9C3B74291CDCE016EC1DB6B5EC9D1730" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="I2016Q4Dec30" decimals="-3" id="Fact-F32BE178BFB82F3CA12FB3BE4AE875DD" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="I2017Q4Dec29" decimals="-3" id="Fact-2479D27D6A6612EAB9DEB3BE4AE22921" unitRef="usd">53543000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="I2016Q4Dec30" decimals="-3" id="Fact-91DFF6311ABC855215E5B6B5ECCC8B5E" unitRef="usd">629314000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-95295858D52D14DB6BF9B6B5ECBC847E" unitRef="usd">418958000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="I2016Q4Dec30" decimals="-3" id="Fact-25E200586FF5D160B22AB6B5ECBCEABC" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6E6D2D6A1BCEB8C96B97B6B5ECBC1E59" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="I2016Q4Dec30" decimals="-3" id="Fact-6FA55D8392A1BB2D6FDFB6B5ECCC7D36" unitRef="usd">252000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="I2016Q4Dec30" decimals="-3" id="Fact-BD0448766F1434AC8560B6B5ECCC29B6" unitRef="usd">471327000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8E0254E3D708E7FDF4F6B6B5ECBC1180" unitRef="usd">244205000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="I2016Q4Dec30" decimals="-3" id="Fact-5711DB593B1402A99A7AB6B5ECCC1437" unitRef="usd">106000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C9822A99655E777B9B64B6B5ECBC9C79" unitRef="usd">1088000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="I2016Q4Dec30" decimals="-3" id="Fact-EE9CC2F90F896F540B93B6B5ECCC74BA" unitRef="usd">70617000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C05788ECCE6BAB1F0583B6B5ECBC4E1F" unitRef="usd">39472000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="I2016Q4Dec30" decimals="-3" id="Fact-5708FD57C8A82A32C750B6B5ECBC2DC6" unitRef="usd">64367000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F5EE42845B0D22C62705B6B5ECCC25B0" unitRef="usd">66770000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="I2016Q4Dec30" decimals="-3" id="Fact-35669DDDFF96B7F3A4F7B6B5ECCC9000" unitRef="usd">8117000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5766EDD1C22D0B0C44ECB6B5ECBC45C0" unitRef="usd">4914000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="I2016Q4Dec30" decimals="-3" id="Fact-6017EF0EB3FE2FED2A88B6B5ECBCCFF2" unitRef="usd">629062000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="I2017Q4Dec29" decimals="-3" id="Fact-0D80E3E3FEF57172424EB6B5ECCCE923" unitRef="usd">418958000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="I2016Q4Dec30" decimals="-3" id="Fact-11C3FE803C365F34B25EB6B5ECCCF1FB" unitRef="usd">252000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6F240F2414CFCC4AB483B6B5ECBCAA91" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesOther contextRef="I2016Q4Dec30" decimals="-3" id="Fact-B63E1E7A5026E0CCF711B6B5ECBC9C27" unitRef="usd">252000</us-gaap:DeferredTaxLiabilitiesOther>
	<us-gaap:DeferredTaxLiabilitiesOther contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B1C60687E899A2CC2FB2B6B5ECBC6AE7" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="D2015Q4FY2015" decimals="-5" id="Fact-1D6309C6E4443AEAD973B6B5EC2E0D23" unitRef="usd">400000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-7E340463D44E4B601776B6B5EC2E4745" unitRef="usd">1100000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-6A566A9612E1FC681204B6B5EC2E0FD7" unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-C96CCCF3BD77C87970EBB6B5EC2E380A" unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-883261CC0674AD6F20C7B6B5EC2EA8CF" unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
	<us-gaap:Depreciation contextRef="D2015Q4FY2015" decimals="-5" id="Fact-5E9215E00D5FC4F6CD9800B57A9280F3" unitRef="usd">1400000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-0850FC5958B71633704BB6B5EA680ECE" unitRef="usd">1000000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-A529C8AFB67075A08C46B6B5EA683E04" unitRef="usd">1200000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2015Q4FY2015" decimals="-3" id="Fact-04D261A1274CCDF307138A7C83F776D9" unitRef="usd">1406000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-216CFAB4F22DEAFB63478A7C83E607B9" unitRef="usd">1002000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-962068C4B3A83CACC5D08A7C83EE6151" unitRef="usd">1187000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="D2015Q4FY2015" decimals="2" id="Fact-F15215472C7593410C92AF0210B74597" unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2016Q1FYQ1" decimals="2" id="Fact-DED0E81CC6B613D5A93CB6B5ED69ABE8" unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2016Q2FYQ2" decimals="2" id="Fact-A96E835C721FEAF79ACFB6B5ED690205" unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2016Q3Jul02-Sep30" decimals="2" id="Fact-F13F4D08FCA1E5F3EE8AB6B5ED69C8F3" unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2016Q4FYYTD" decimals="2" id="Fact-1AC4D5D3474675408C0EB6B5E5AF3302" unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2016Q4Oct01-Dec30" decimals="2" id="Fact-69E30C2CA76B2CE2AC68B6B5ED6994B6" unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q1Dec31-Mar31" decimals="2" id="Fact-6FD7B19D8738A3496F5D7C2FBCC921E9" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q3Jul01-Sep29" decimals="2" id="Fact-8CB69BC6A0BC0E2C00257C2F91882E8B" unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q4FYYTD" decimals="2" id="Fact-15020F31C057E9936B87B6B5E5A06F42" unitRef="usdPerShare">0.52</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="D2017Q4Sep30-Dec29" decimals="2" id="Fact-3031349B70A2C4B9E08FB6B5ED695827" unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-5F5EAC30255A7E2C41D97C2FA7659D41" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="D2015Q4FY2015" decimals="2" id="Fact-90AD74622C5FF6CDCB16AF003B3D50D9" unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2016Q1FYQ1" decimals="2" id="Fact-B1E02578551B1BE57EC97C2FE5CD7C62" unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2016Q2FYQ2" decimals="2" id="Fact-95AF5C3E85D1D3E4E8DD7C2FE487C4B9" unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2016Q3Jul02-Sep30" decimals="2" id="Fact-703190B1D33ECD1BD8FB7C2FE35ADC29" unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2016Q4FYYTD" decimals="2" id="Fact-F7A7AF346D4C711CC61CAF003B2E83AA" unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2016Q4Oct01-Dec30" decimals="2" id="Fact-D44512FEAB823304D330B6B5F03E9E78" unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q1Dec31-Mar31" decimals="2" id="Fact-E5CB9F6D827116DCABE67C2FBD7C85E3" unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q3Jul01-Sep29" decimals="2" id="Fact-8C54FE43F2E052EC490F7C2F926CE804" unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q4FYYTD" decimals="2" id="Fact-A79FFA154E9F80FFDBAFAF003B21DA46" unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="D2017Q4Sep30-Dec29" decimals="2" id="Fact-ADB421B6DF1D8CE56D39B6B5F03E2800" unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-0711CE23B391FD1EFC017C2FA8170207" unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-E4B57FDE520B627DDBCFB6B5EC2E7CF5" unitRef="usd">39700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-E955C08EA257B69837D5B6B5EC1E8F96" unitRef="usd">61200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-A2574972AF806AB0B1C2B6B5EC2E492E">P2Y6M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-A99366D3E6EFE23D6A3DB6B5EC2E247E">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:ExtinguishmentOfDebtAmount contextRef="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-31583A7DE1D8A1632621B6B5F1E47A09" unitRef="usd">80000000</us-gaap:ExtinguishmentOfDebtAmount>
	<us-gaap:ExtinguishmentOfDebtAmount contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-453ED21D1A5FE49D0F55B6B5F1E44B46" unitRef="usd">113900000</us-gaap:ExtinguishmentOfDebtAmount>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="D2015Q4FY2015" decimals="-3" id="Fact-9995ADA65BEE204005488A7D3D09B1DD" unitRef="usd">548000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4AB0EB449A85E693652A8A7D3D266F30" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-2BF38A16611959BE134F8A7D3D11A052" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="3" id="Fact-7E0B3EF6B82B1AFA3E33B6B5EB34FB34" unitRef="number">0.095</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="3" id="Fact-28E4D19D52D28071BEE0B427B184A31E" unitRef="number">0.095</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="D2015Q4FY2015" decimals="-5" id="Fact-D899C575F15A19DE1CE1B6B5ED0A1640" unitRef="usd">100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-84950D6ECC4B64236E80B6B5ED0AE5D9" unitRef="usd">-200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-C18211C6969EE85FEF80B6B5ED0A7C20" unitRef="usd">-200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2015Q4FY2015" decimals="-3" id="Fact-844C3BCD2ECEA2B47CA38A7D20E36102" unitRef="usd">112000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1AE875A150235E564CB48A7D20E0EA55" unitRef="usd">2494000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainLossOnSaleOfOtherInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-68FF3449BC5EA4BF622C8A7D20DD4F4F" unitRef="usd">2980000</us-gaap:GainLossOnSaleOfOtherInvestments>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2015Q4FY2015" decimals="-3" id="Fact-65BC2145C38EC798D9678A7CB2D0368F" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-61F78C438EE24C3FD66AB6B5EB15A694" unitRef="usd">-13900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3AE35C403464FBB317F78A7CB2CE9730" unitRef="usd">-13901000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2016Q4FYYTD_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-3" id="Fact-912F1735033B08F2DF46B024387C46A5" unitRef="usd">-13901000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-5D72D167F64BB92329EEB6B5F1E456CE" unitRef="usd">-6200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B0155D7D198433396F198A7CB2D43F8E" unitRef="usd">-6239000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="I2016Q4Dec30" decimals="-3" id="Fact-60691A4F0574F0A49575B6B5E5332EA2" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5C9137AD124B00828F95B6B5E533911B" unitRef="usd">63684000</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairmentLoss contextRef="D2015Q4FY2015" decimals="INF" id="Fact-51FDC43E31AA99D652BEB6B5E83F1EEF" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="D2016Q4FYYTD" decimals="INF" id="Fact-9044556CBF00DA3B0EFAB6B5E83FB12B" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-91FD1662EEF2B85298A9B6B5E7F11AE1" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GrossProfit contextRef="D2016Q1FYQ1" decimals="-3" id="Fact-4907D1782C4E8F30190EB6B5ED69AD50" unitRef="usd">8414000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2016Q2FYQ2" decimals="-3" id="Fact-E3CCB4B45F96875DD9C7B6B5ED6906EA" unitRef="usd">30058000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2016Q3Jul02-Sep30" decimals="-3" id="Fact-D85DE41FFC50B8FB2520B6B5ED692239" unitRef="usd">40287000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2016Q4Oct01-Dec30" decimals="-3" id="Fact-190BA153CC7261C7183B7C2F14924991" unitRef="usd">50064000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-F51A9F8D2C53D64A9B117C2FBAC445FD" unitRef="usd">65674000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2017Q3Jul01-Sep29" decimals="-3" id="Fact-68050CBAB4C8FC2ADAEB7C2F8F431E6D" unitRef="usd">91758000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="D2017Q4Sep30-Dec29" decimals="-3" id="Fact-CE917D5BD7842B6BFB06B6B5ED693CDD" unitRef="usd">91520000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q2QTD" decimals="-3" id="Fact-12C716E3D49A7211BE267C2FA567D0D3" unitRef="usd">84990000</us-gaap:GrossProfit>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="D2015Q4FY2015" decimals="-3" id="Fact-C16C924A9CC6C641A2FCB6B5ECBCC8D7" unitRef="usd">-150846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8F638BAC0D67D9B390FAB6B5ECBC17E0" unitRef="usd">-70222000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C6F1C5EF8B3D8A8396ADB6B5ECBC1A58" unitRef="usd">158577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="D2015Q4FY2015" decimals="-3" id="Fact-CC4D01977516CE25561AB6B5ECBC734F" unitRef="usd">-10843000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A632B60A33DD93EFECBAB6B5ECBC8575" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7C7D890553CF1AAFD7A1B6B5ECBC52C5" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2015Q4FY2015" decimals="-3" id="Fact-1F42B149EB36758891218C1034ACC858" unitRef="usd">-161689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-EC643CE794BA899D10EEB6B5E5A06CC7" unitRef="usd">-70222000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-6762D96D61CEFF4E099CB6B5E5901DAF" unitRef="usd">158577000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2015Q4FY2015" decimals="-3" id="Fact-5141780F31D7ECEB6812AF020F37D7C7" unitRef="usd">55000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BB837178B7202D227F17B6B5E59078DA" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-80C2709A238D22481CFBB6B5E5AF4C76" unitRef="usd">4350000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="D2015Q4FY2015" decimals="-3" id="Fact-FF69A3989A6002ECD740B6B5EC8DA5D1" unitRef="usd">51421000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BC3BDB6125AC2199EF29B6B5EC9DB2F6" unitRef="usd">6377000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-73C1DCFB5A99E7A80C6AB6B5EC9D7515" unitRef="usd">-34266000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="D2015Q4FY2015" decimals="-3" id="Fact-BE0365760148CA7495FDB6B5EC9D97F2" unitRef="usd">-54974000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2525E18E07F55E05E069B6B5EC9D165B" unitRef="usd">-23876000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8DF478D1225969B39E4CB6B5EC9D1CD0" unitRef="usd">53916000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-F47D08E6BFEA194950DCB6B5EC9DD963" unitRef="usd">3308000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-D5DD4035565E31708941B6B5EC9DA4AC" unitRef="usd">2680000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A475E46016A979FD6BD6B6B5EC8DD9DA" unitRef="usd">1367000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="D2015Q4FY2015" decimals="-3" id="Fact-9A3CCBABFD334BC858F6B6B5EC9DFDBA" unitRef="usd">195000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7B5FC5380D0C2E8854FCB6B5EC9DF007" unitRef="usd">3155000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1EE0E30BB07549FAE95DB6B5EC8DF5E2" unitRef="usd">-20548000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="D2015Q4FY2015" decimals="-3" id="Fact-BF7CC1EE721C37C2636CB6B5EC9D3195" unitRef="usd">50000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-20F5CB92AE2F3AB80A29B6B5EC9D86F5" unitRef="usd">418000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-DA29224268B77BE45A54B6B5EC9DD142" unitRef="usd">-4401000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="D2015Q4FY2015" decimals="-3" id="Fact-B5BBD7D3E8703050F3B2B6B5EC8D9114" unitRef="usd">55000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1ACF613D7B2AE95A7DD1B6B5EC8DEF7B" unitRef="usd">6520000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-782E4CE61EC752342487B6B5EC9D2164" unitRef="usd">8282000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxesPaid contextRef="D2015Q4FY2015" decimals="-3" id="Fact-57533B4D9C7D7428D8F9B6B5E7557AC9" unitRef="usd">192000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4CEB9852953AB37D633FB6B5E7557F97" unitRef="usd">190000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C4F71056D4B53A72154AB6B5E75513ED" unitRef="usd">538000</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="D2015Q4FY2015" decimals="-3" id="Fact-63370E74F588A99BAF198A7D68DE434D" unitRef="usd">540000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3408863500DFEEC99D058A7D68C2CEC4" unitRef="usd">35318000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-93AD3EDAA71CA94A90608A7D68CB7F6C" unitRef="usd">40839000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2015Q4FY2015" decimals="-3" id="Fact-70988D7F1FC847F65CE38A7DD9614DC2" unitRef="usd">-12000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3E02035FF5C44541B5568A7DD9631137" unitRef="usd">164000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1B8AF703E5C7828354488A7DD987B1A1" unitRef="usd">3010000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2015Q4FY2015" decimals="-3" id="Fact-D7974E33FBB57B89CCDB8A7EABEBA7F3" unitRef="usd">-2582000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-E7A6481EBBCC2C898E4FB6B5F06D009C" unitRef="usd">256759000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-81EE3E38392531D56446B6B5F07DA292" unitRef="usd">13745000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-A207955BAC94DA25017C8A7E02BF0736" unitRef="usd">279000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B3346E8DEF1DA0DF67DA8A7E02CF2F0E" unitRef="usd">16705000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CB1F5C2E7DE34C8D085E8A7E02CCBB9B" unitRef="usd">739000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2015Q4FY2015" decimals="-3" id="Fact-BAE0B6ADF646C7338F028A7D87E9301B" unitRef="usd">235000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-CF75BB0143248A547A658A7D87E47EF8" unitRef="usd">722000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-027B43F6ED7B580907F38A7D87E6E97B" unitRef="usd">3319000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2015Q4FY2015" decimals="-3" id="Fact-BAE747F482DDFCF07F8D8A7DBF236955" unitRef="usd">-1340000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-EA29B9619B8310BB876C8A7DBF0857EE" unitRef="usd">-1077000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-941A63E700786EFBEA558A7DBF0F76A0" unitRef="usd">-430000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-3E578D008391BB2B16B88A7EC9133D11" unitRef="usd">-10502000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-CCC4B3433C3A7CCA93958A7EC9008E05" unitRef="usd">5090000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-DAB5209BF31B0755DCF18A7EC8F96994" unitRef="usd">9910000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2015Q4FY2015" decimals="-3" id="Fact-3AB68261429F0E6C0BB58A7DA4109813" unitRef="usd">325000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-E53075015B424F012B848A7DA4053084" unitRef="usd">1610000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C42E0A1264A5C0323B3C8A7DA408FFF3" unitRef="usd">3268000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="D2015Q4FY2015" decimals="-3" id="Fact-96ACF9B9AE14F7B4B8938A8FEBCA0C5E" unitRef="usd">-19789000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
	<us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3223858E2E85E116D9788A8FEBCF884F" unitRef="usd">-7150000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
	<us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-70826C6A570582584B7E8A8FEBCDD253" unitRef="usd">-14650000</us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments>
	<us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-68F84DEFC765305EB5B3B6B5EAC77E9F" unitRef="usd">6000000</us-gaap:InducedConversionOfConvertibleDebtExpense>
	<us-gaap:InterestExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-500EC51E2A152BDFDAFDAF020AF98839" unitRef="usd">40680000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-606377B819730F9346D7B6B5E5A00C7F" unitRef="usd">33060000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F364D2D00A55A1F888E2AF01B850C336" unitRef="usd">8679000</us-gaap:InterestExpense>
	<us-gaap:InterestIncomeOther contextRef="D2015Q4FY2015" decimals="-3" id="Fact-BAC57833A95AC0F85B98AEFF6330B7DC" unitRef="usd">793000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1D58944EA3090ECEC187B6B5E5A07529" unitRef="usd">2578000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C3A3921346FCBB7E4781B6B5E5A0855E" unitRef="usd">4883000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestPaid contextRef="D2015Q4FY2015" decimals="-3" id="Fact-1426D16E81D2AAEFBD9AB6B5E755E72E" unitRef="usd">19822000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-74BE94C595E466B3D249B6B5E7554EA6" unitRef="usd">21044000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="D2017Q1Mar29_us-gaap_DebtInstrumentAxis_exel_SiliconValleyBankLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-5" id="Fact-A47AE200992ED716AB2CB6B5F1E4FB14" unitRef="usd">100000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-D393094A97A9C75140BFB6B5F1E4B636" unitRef="usd">4200000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CB6155AD1AE2599C2582B6B5E755A499" unitRef="usd">20460000</us-gaap:InterestPaid>
	<us-gaap:InventoryFinishedGoods contextRef="I2016Q4Dec30" decimals="-3" id="Fact-E5C1D572B67CEC69C2F1B6B5EA59E92E" unitRef="usd">738000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods contextRef="I2017Q4Dec29" decimals="-3" id="Fact-3A67BBF0D90B758A71A8B6B5EA599BE1" unitRef="usd">2854000</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross contextRef="I2016Q4Dec30" decimals="-3" id="Fact-E10DD02D2020FBA6A3B20103C6D530C5" unitRef="usd">3944000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2016Q4Dec30_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" decimals="-3" id="Fact-CD9CC41054FD785682DE0103E32AFBF0" unitRef="usd">606000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2016Q4Dec30_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-839973BF667927BD024D0103DF400190" unitRef="usd">3338000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6E4384C63D2708A0B64D0103C49BA4C4" unitRef="usd">7349000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" decimals="-3" id="Fact-7D40EFBCD314F02B23E70103E09668DE" unitRef="usd">692000</us-gaap:InventoryGross>
	<us-gaap:InventoryGross contextRef="I2017Q4Dec29_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" decimals="-3" id="Fact-FD2C7695FFEA6458D3690103DD1190F6" unitRef="usd">6657000</us-gaap:InventoryGross>
	<us-gaap:InventoryNet contextRef="I2016Q4Dec30" decimals="-3" id="Fact-406BDC24D56184969B70B6B5E5426038" unitRef="usd">3338000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-EB7B5F1D4A16C22EBBACB6B5E513A9A8" unitRef="usd">6657000</us-gaap:InventoryNet>
	<us-gaap:InventoryRawMaterials contextRef="I2016Q4Dec30" decimals="-3" id="Fact-4DE68EC5A2850A3A8D5BB6B5EA598460" unitRef="usd">863000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials contextRef="I2017Q4Dec29" decimals="-3" id="Fact-66B62323506047D09D5AB6B5EA595797" unitRef="usd">498000</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess contextRef="I2016Q4Dec30" decimals="-3" id="Fact-EB70D5169F4B92C8BAB3B6B5EA59AFBC" unitRef="usd">2343000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B0F286C0371AFCD6F51DB6B5EA59B64A" unitRef="usd">3997000</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWriteDown contextRef="D2015Q4FY2015" decimals="-5" id="Fact-E0111BCA73B251541DCC010A8428C7C6" unitRef="usd">1200000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-64D3731DB0E9E5770143010A841AF76E" unitRef="usd">500000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-83F38AC2DD0CA8BECA41B6B5EA59DE58" unitRef="usd">1200000</us-gaap:InventoryWriteDown>
	<us-gaap:LeaseAndRentalExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-E44DD984E3F561A18D7CB6B5ECEB88D7" unitRef="usd">13942000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-56C009773E4521910861B6B5ECEB90BA" unitRef="usd">9676000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-11F4AA27524651A5D531B6B5ECEBC4B4" unitRef="usd">6160000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="I2017Q4Dec29" decimals="INF" id="Fact-F4B333908BD48D90AFAEB4431637D79C" unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:Liabilities contextRef="I2016Q4Dec30" decimals="-3" id="Fact-C502ABBC27642A2F9455B6B5E513A10B" unitRef="usd">506421000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="I2017Q4Dec29" decimals="-3" id="Fact-537B4B484D735FA8FCB9B6B5E5136B63" unitRef="usd">370333000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2016Q4Dec30" decimals="-3" id="Fact-1E59A7DF17EB4BCF4CCCB6B5E513BB2C" unitRef="usd">595739000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="I2017Q4Dec29" decimals="-3" id="Fact-AD6CB4FAD9D507C38698B6B5E533BF19" unitRef="usd">655294000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-EB9701A1C0EC1F56B05DB6B5E533F861" unitRef="usd">268786000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9651DF6426D7D4CC5496B6B5E54216AC" unitRef="usd">115170000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" decimals="INF" id="Fact-5B1E393604737DF24418B9ADF4333DC9" unitRef="usd">500000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2016Q4Dec30_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" decimals="INF" id="Fact-C830DD5691F33583C475B9AE424E38FC" unitRef="usd">600000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2017Q4Dec29_us-gaap_CreditFacilityAxis_us-gaap_StandbyLettersOfCreditMember" decimals="INF" id="Fact-F83899F6A1493CA496F3B6B5F38D134D" unitRef="usd">1000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" decimals="INF" id="Fact-E3F520F66A1AA1230AC8B6B5ECEB1127" unitRef="usd">500000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2017Q4Dec29_us-gaap_DebtInstrumentAxis_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" decimals="INF" id="Fact-F893EA0F1E4C20BF7AADB6B5ECEB565F" unitRef="usd">600000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="I2016Q3Jul31_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-1B9AF5E35C4848105D82B01C96BA7A4E" unitRef="usd">287500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2016Q4Dec30" decimals="-3" id="Fact-ED0B8AFF2625C9729A96B6B5EAF6C0E8" unitRef="usd">189122000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2016Q4Dec30_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-D19156A3A0A7D286F9CEB6B5EAF6C630" unitRef="usd">109122000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2016Q4Dec30_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-0F9702BAAD5DC1A1A97AB6B5EAF6195E" unitRef="usd">80000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A78A46820CA76671468BB6B5EAF677EC" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2017Q4Dec29_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-C49CD926C43F2DB7D5A4B6B5EAF60FA9" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="I2017Q4Dec29_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-9050FDB1CA8D0756EFC6B6B5EAC778FF" unitRef="usd">0</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtFairValue contextRef="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-82B0BD953AA40AAE5EC8B6B5EB2402E2" unitRef="usd">109122000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermDebtFairValue contextRef="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-C47CE066A0EAE66D3CC3B6B5EB2453ED" unitRef="usd">80000000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermDebtFairValue contextRef="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-4D86100B59A5A6163A21B6B5EB2433D4" unitRef="usd">121220000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermDebtFairValue contextRef="I2016Q4Dec30_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-2A9D47FD23EA2B6D63A3B6B5EB24C66C" unitRef="usd">79784000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermInvestments contextRef="I2016Q4Dec30" decimals="-3" id="Fact-47E4D6A2C7F389FCB027B6B5E513487D" unitRef="usd">55601000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="I2017Q4Dec29" decimals="-3" id="Fact-29AA3C5764E44D3E29CBB6B5E513F19D" unitRef="usd">64255000</us-gaap:LongTermInvestments>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="I2017Q4Dec29_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="-5" id="Fact-47C27F9528EBBEA52092B457760EB149" unitRef="usd">1200000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualProvision contextRef="D2017Q4FYYTD_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="-5" id="Fact-75EA581F71BA6D0841CEB6B5F38D55CC" unitRef="usd">1400000</us-gaap:LossContingencyAccrualProvision>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OptionalAmendmentAgreementMember_us-gaap_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" decimals="-5" id="Fact-C0DB9C7E6BE4A781F56CB6B5F38DE666" unitRef="usd">1500000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-FB244FDEA1962D547F458A82F555B317" unitRef="usd">152213000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2015Q4FY2015_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-2172F4915DF49996FF388BCA53A6B2BE" unitRef="usd">-500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-24968A373D7E454153C48A82F562324F" unitRef="usd">15696000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2016Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-710C741EFCAB8A5587418BCA53BAC71E" unitRef="usd">-4100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1286661085BFB7826AEE8A82F56C8B22" unitRef="usd">-169928000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-D56FE1EBCBF26AA4EC308A81B5350CAA" unitRef="usd">50077000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B9573B5667D7EEF632728A81B52D979D" unitRef="usd">-216048000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-9A61ADAEFBDB00475A2F8A81B521F23A" unitRef="usd">35795000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-1986700E449066EF6A3E8A802A51BECF" unitRef="usd">-141051000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2015Q4FY2015_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-B57DFFBB0AB44A1980328BC76E6BC84D" unitRef="usd">500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0C36EE5BDC9696B213B88A802A678A7B" unitRef="usd">210404000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2016Q4FYYTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201609Member" decimals="-5" id="Fact-E92A4CEC41149C12C239B6B5F08C5E72" unitRef="usd">4100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-EA1F7822C3557F16A5D08A802A5F4FEF" unitRef="usd">165611000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="D2015Q4FY2015" decimals="-3" id="Fact-22CD11540E30E5F958D4AF021009D5A9" unitRef="usd">-161744000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E6505789DFECBFA06185B6B5E6B92AC0" unitRef="usd">-161744000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q1FYQ1" decimals="-3" id="Fact-DBA506FDA7047E0AB5E1B6B5ED699253" unitRef="usd">-59223000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q2FYQ2" decimals="-3" id="Fact-3DBD2A1BBB7749CAD979B6B5ED69F778" unitRef="usd">-34838000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q3Jul02-Sep30" decimals="-3" id="Fact-FF674BBFC14D2047E677B6B5ED694500" unitRef="usd">-11284000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-93B01D59427F214676038A7C5ACCAA0A" unitRef="usd">-70222000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DCA9CE9C2124A34865BEB6B5E6B99FC8" unitRef="usd">-70222000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2016Q4Oct01-Dec30" decimals="-3" id="Fact-F9C871B690BF4DE48BE2B6B5ED695F43" unitRef="usd">35123000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-A64874D160B234614D747C2FBC11C8AE" unitRef="usd">16700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q3Jul01-Sep29" decimals="-3" id="Fact-8C048CDE9F8DB30BC0197C2F90B44130" unitRef="usd">81382000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-92B2052107B33DDD35CD8A7C5AD198DC" unitRef="usd">154227000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-52A1B2232EC008888FA47BFF4FAEB158" unitRef="usd">154227000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="D2017Q4Sep30-Dec29" decimals="-3" id="Fact-69C17C2BAE50C5DF207FB6B5ED697376" unitRef="usd">38489000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-CE5E7D1E2630E50774547C2FA6BD416C" unitRef="usd">17656000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2015Q4FY2015" decimals="-3" id="Fact-120DCBEFF876CFB5DE71B3C945DDAE5D" unitRef="usd">-161744000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4A508A4B8EEDF1BB5202B3C9443CB563" unitRef="usd">-70222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-C8959A818804BBD36C7AB3C9427A6B1E" unitRef="usd">153860000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2015Q4FY2015" decimals="-3" id="Fact-93C1504A70C42F456B53B3C94E529F86" unitRef="usd">-161744000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7EC4F1A605E883FF8420B3C94CB36941" unitRef="usd">-70222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-E67AA27A8B2517A9C601B3C94AF1353E" unitRef="usd">153882000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-B3817664796FF2B4C8D2AF020CB5696B" unitRef="usd">-40268000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-67864DA73C6C7A46F5EFAEFF7B187EE8" unitRef="usd">-42098000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-62F0F50473B21B5D7628B6B5E5A01EA3" unitRef="usd">-7333000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayableCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-7FC448A1B1599670AA96B6B5E5335E2C" unitRef="usd">80000000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-55504AD442F8898D86CFB6B5E513AB46" unitRef="usd">0</us-gaap:NotesPayableCurrent>
	<us-gaap:NumberOfOperatingSegments contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-9478E63D73797A64470CB46E4681BDA9" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:NumberOfRealEstateProperties contextRef="I2017Q2May02_us-gaap_LeaseArrangementTypeAxis_exel_OperatingLeaseandOtherFinancingLeaseMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_BuildingShellsMember" decimals="INF" id="Fact-C8280D510FC1159EEE2EB6B5F38D4AC0" unitRef="property">2</us-gaap:NumberOfRealEstateProperties>
	<us-gaap:NumberOfReportableSegments contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-7CE40DF243A58A18AABB8BB050040340" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="D2015Q4FY2015" decimals="-3" id="Fact-491EA3A6A9C79EC9E4D1AEFF22DB2809" unitRef="usd">158593000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-219699EEF1572B2D1CF0B6B5E5AFAC28" unitRef="usd">219578000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7224F4F472C67BFA3B3CB6B5E5903FDB" unitRef="usd">286567000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="D2015Q4FY2015" decimals="-3" id="Fact-A8C9582BB434F9E17D8BAEFF42049DE7" unitRef="usd">-121421000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2016Q1FYQ1" decimals="-3" id="Fact-90FCD6ACD5A87C21D854B6B5ED690875" unitRef="usd">-49135000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2016Q2FYQ2" decimals="-3" id="Fact-4DA037DC7831750B6D6BB6B5ED69F449" unitRef="usd">-25136000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2016Q3Jul02-Sep30" decimals="-3" id="Fact-167F8384EFC72F2073F6B6B5ED69E0C6" unitRef="usd">7264000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-720FD4B1078B560D66CEAEFF42007F44" unitRef="usd">-28124000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2016Q4Oct01-Dec30" decimals="-3" id="Fact-90F47AC8356782C34172B6B5ED698078" unitRef="usd">38883000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-392996B9A43F76E8667B7C2FBB51494B" unitRef="usd">20186000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q3Jul01-Sep29" decimals="-3" id="Fact-D8118BD34CC026673E7A7C2F8FF42854" unitRef="usd">81180000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-FE75E10E1D94B4798F17B6B5E5A0568F" unitRef="usd">165910000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="D2017Q4Sep30-Dec29" decimals="-3" id="Fact-0C1018BB07BC091E0B46B6B5ED691332" unitRef="usd">37431000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-154C6119066F3EFF99987C2FA60BF2BC" unitRef="usd">27113000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-DD8F63AF2C6DA4D1A73BB6B5ECEBCC03" unitRef="usd">9340000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-CA0584BD183B344B6BFAB6B5ECDB72BE" unitRef="usd">2864000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-0F11E9FC432014FB0235B6B5F3AC22A1" unitRef="usd">704000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-58B17398FABF8F8FE1E1B6B5F3AC4A12" unitRef="usd">694000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C21C1AEB78D0B3759B74B6B5F3AC9C37" unitRef="usd">684000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="I2017Q4Dec29" decimals="-3" id="Fact-C57199BCD1B28F653DE9B6B5ECDBC84C" unitRef="usd">664000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A65F50D8A63465494FBBB6B5F3AC114B" unitRef="usd">3730000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="D2015Q4FY2015" decimals="-3" id="Fact-7058815C1A5A68AC67ADB439E15971BF" unitRef="usd">8737000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-FBC34A3AB0D7C3137B94B439E0748B5F" unitRef="usd">6123000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-D0FD2AB6E147F4C1D057B439DFC551C8" unitRef="usd">4935000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="D2015Q4FY2015" decimals="-3" id="Fact-4CD7E1EB3D37BDBD0408B6B5ECEB050C" unitRef="usd">5205000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-CF9DB4688CCB42A07CECB6B5ECEB3444" unitRef="usd">3553000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-FF64FF6309AB933EDAE3B6B5ECEB3D1F" unitRef="usd">1225000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
	<us-gaap:OperatingLossCarryforwards contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-6" id="Fact-0B5B472FD88E233AD736B6B5ECACF7CE" unitRef="usd">1105000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-6" id="Fact-6180A2FAFBE67FCA5983B6B5ECAC63EF" unitRef="usd">424000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-49429F2850AEA9922F8CB6B5E51371B6" unitRef="usd">13503000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-5F1D9519938C7CA7A013B6B5E533A39C" unitRef="usd">16150000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-113983DB615DB1E0D6CDB6B5E51368F2" unitRef="usd">1232000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-23AF771C6E93EF926C82B6B5E5428573" unitRef="usd">12092000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2015Q4FY2015" decimals="-3" id="Fact-909C5D4FFD3004F50D15B6B5E5CF606F" unitRef="usd">-111000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-50A859C6335DBD9A396FB6B5E5BF1CCD" unitRef="usd">-184000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-BC98CDBED18549A40A00B6B5E5CFEF87" unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2015Q4FY2015" decimals="INF" id="Fact-0057C8BB18029176DABBE75E82B614A1" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2016Q4FYYTD" decimals="INF" id="Fact-52A232182232F2CE7C55B6B5E5DE266B" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-582FA59707934DE64056B6B5E5CF437C" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2015Q4FY2015" decimals="INF" id="Fact-0E1145C7EC6FA1B9BFD0E75E84EAA9FB" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2016Q4FYYTD" decimals="INF" id="Fact-F6FB00866763A1CB457CB6B5E5DE2178" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeLossTax contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-3F4B635E623139A772E5B6B5E5CFB886" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="D2015Q4FY2015" decimals="-3" id="Fact-75EADC409B9F82B9EA5DB6B5E6B9884F" unitRef="usd">-111000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9C552AAF0E0D5DE1762EB6B5E6B9D61A" unitRef="usd">-111000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-DB26E604CF717BC6C2CBB6B5E6A99AAE" unitRef="usd">-184000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-010080F83EE70A2EFB29B6B5E6A96A6A" unitRef="usd">-184000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-16FEA6DCCC8A6427CD5E7BFF59D249B3" unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-38BF74036AD3883D3ACB7BFF547ECF9C" unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q1_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-5" id="Fact-06AB3B81F4A0B4841C8EB6B5E90C0406" unitRef="usd">9000000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-E086C6BFB9A558003566B6B5E533908A" unitRef="usd">541000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-202FBDFC1FB137F0D66BB6B5E533E4F6" unitRef="usd">16643000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-59C78199AC310B3F394F8A7D52D21585" unitRef="usd">-1861000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-4E921F3AACE18EBB53E48A7D52CF3434" unitRef="usd">-1598000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-927986B9CBF21D44FEC18A7D52D52011" unitRef="usd">-1589000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-90C1EF3362231D90B22EAF020C0D8B3E" unitRef="usd">-381000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BFB99E8B4C7C6686DA8EB6B5E5A03903" unitRef="usd">-11616000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-0CFE3236E00911F4D3AAAF01B8F8055C" unitRef="usd">-3537000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="D2015Q4FY2015" decimals="INF" id="Fact-B07288E2A3C777CF30F1B6B5EA493156" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="D2016Q4FYYTD" decimals="INF" id="Fact-094D4BA7B410228E8A52B6B5EA59F879" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-D3ADBF8F64CA8376E76AAFB7696B7AE8" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaidInKindInterest contextRef="D2015Q4FY2015" decimals="-3" id="Fact-78A439602F77B0673B178A7CEF0C5132" unitRef="usd">3817000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B2923D1BA7D68F1FA21BB6B5F07DD7C1" unitRef="usd">8008000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="D2017Q2Jun28-Jun28_us-gaap_DebtInstrumentAxis_exel_SecuredConvertibleNotesDueJune2018Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-49DDB9BD213F1929DF79B6B5F1E405A1" unitRef="usd">13900000</us-gaap:PaidInKindInterest>
	<us-gaap:PaidInKindInterest contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-5E1313732227933DF1F0B6B5F06DC1D0" unitRef="usd">-11825000</us-gaap:PaidInKindInterest>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2015Q4FY2015" decimals="-3" id="Fact-1916C249385CEC2654868A8DFE912DC9" unitRef="usd">534000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-CA0E9CD01C9D23D38033B6B5F06D8F39" unitRef="usd">4108000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-63C199BACD97E71B3682B6B5F07D01DE" unitRef="usd">6563000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2015Q4FY2015" decimals="-3" id="Fact-6B077CD31DB80CC2DE978A81691071E8" unitRef="usd">143992000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0BD51634158F72B219F58A8169095673" unitRef="usd">369187000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A6D3EEE7F3673E52432B8A8168FC6DDF" unitRef="usd">319090000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2015Q4FY2015" decimals="-3" id="Fact-868DC7E430221CD3C4CF8A807993F21C" unitRef="usd">447000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-AF33A5D2105A37C1E3F08A807996D1C7" unitRef="usd">1703000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1BC452DA06404B4128F48A8079958414" unitRef="usd">21143000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="D2015Q4FY2015" decimals="-3" id="Fact-42EF7E41E45135F367A08A812879311B" unitRef="usd">5650000</us-gaap:PaymentsToAcquireRestrictedInvestments>
	<us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8017141EBEFFC6916FA88A8128600F2B" unitRef="usd">8650000</us-gaap:PaymentsToAcquireRestrictedInvestments>
	<us-gaap:PaymentsToAcquireRestrictedInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-7B2B2F11691CB31BC68E8A812848CB12" unitRef="usd">15650000</us-gaap:PaymentsToAcquireRestrictedInvestments>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2016Q4Dec30" decimals="INF" id="Fact-98EE098C1A339E880A2BB6B5E5526F95" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2017Q4Dec29" decimals="INF" id="Fact-4AFE5AA8D4345C8D9468B6B5E5527E3C" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2016Q4Dec30" decimals="INF" id="Fact-6D2BB98B8C9FAF9C5F48B6B5E5521F9F" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2017Q4Dec29" decimals="INF" id="Fact-CD898E339417D30E413AB6B5E552ED8D" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="I2016Q4Dec30" decimals="INF" id="Fact-3A6ED86EF254E916ACC3B6B5E552FCC9" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="I2017Q4Dec29" decimals="INF" id="Fact-5DE47D4999D719281F6AB6B5E5525A70" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockValue contextRef="I2016Q4Dec30" decimals="-3" id="Fact-EADEFA182C1D6C04D6D2B6B5E533B39C" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-6AB64819051AE1B8012EB6B5E54202D2" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-48450ADAB3E52F577838B6B5E5332EF7" unitRef="usd">5416000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-F0D6C8428FC15AD359B9B6B5E513C148" unitRef="usd">8750000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-5" id="Fact-1C7E93E0CF5F6CBFAFB2010D85C92DF4" unitRef="usd">11100000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2015Q3Jul01-31" decimals="-5" id="Fact-BDC0DCE8C1AA42D30171B6B5EB15DDC4" unitRef="usd">145600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2015Q4FY2015" decimals="-3" id="Fact-7215F42A79414100F02F8A81E0F64ABF" unitRef="usd">145649000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-FAC4E5C6991DA5B5FE5E8A81E0FA2E15" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-5636376FD254FD9249948A81E0FEDF93" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-E683BC4C1E3A3237C8738A80D38B891B" unitRef="usd">178936000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-638889E58010E49BAC678A80D37D07AF" unitRef="usd">151485000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8ADF082967089E16F4348A80D36F7A67" unitRef="usd">336590000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2015Q4FY2015" decimals="-3" id="Fact-BB2B93E96D47EEA0F0B28A8B88C16E2C" unitRef="usd">95000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0540FEA78F02F443F02A8A8B88B5BB60" unitRef="usd">2494000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-E2ED5610C07BD1C2D0988A8B88A7A9CE" unitRef="usd">2980000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="D2015Q4FY2015" decimals="-3" id="Fact-B7B18175263CF6BD9CB18A80F42344BB" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1C0241B8205B24E25CCA8A80F41FD8DA" unitRef="usd">2266000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-F82615EF4F9B510F366A8A80F425A877" unitRef="usd">37294000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="D2015Q4FY2015" decimals="-3" id="Fact-554D340D55A320248CA78A809C95FA9E" unitRef="usd">1346000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-8CC1D93051E422F5230F8A809C8EF03F" unitRef="usd">97000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-101B317271B81AD925AD8A809CA21E55" unitRef="usd">164000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2015Q4FY2015" decimals="-3" id="Fact-577180D2F503FCD02F268A8D2F654739" unitRef="usd">10911000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-67FB60B91D688350D373B3936585BA8D" unitRef="usd">10900000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0F28507FD981E5894EBE8A8D2F5D783E" unitRef="usd">25327000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-08E68911EC117CB4A907B393564260F3" unitRef="usd">25300000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-D0251613E2DB53FFEBAE8A8D2F6DC8DD" unitRef="usd">17555000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-9EABF4F532EA2A5E0353BA9E4B8853B8" unitRef="usd">17600000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockPlans contextRef="D2015Q4FY2015" decimals="-3" id="Fact-E91B7F1DD6FEA38EEBF18A8DA551F250" unitRef="usd">568000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-6AA5321B7E49A2700CB8B39093F6B683" unitRef="usd">600000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-17A6D0B7F634A763B33D8A8DA56604B4" unitRef="usd">2187000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-E63C52F35FD50A24477DB39085722691" unitRef="usd">2200000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-07CBE9508A51F746726B8A8DA55E05B0" unitRef="usd">4868000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="-5" id="Fact-92A371124E344BC59D7EBA98F5503A88" unitRef="usd">4900000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="D2017Q2May02-May02_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-5" id="Fact-5E2A50A90786EBC2674AB6B5F1A6B72E" unitRef="usd">14500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-5" id="Fact-4C1BDC41DB75B5938FA0B6B5F1A666FE" unitRef="usd">6600000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2016Q4Dec30" decimals="-3" id="Fact-62663FB753705528454000B749574164" unitRef="usd">26953000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-27D7FD56B1F2517A1290B6B5EA68218D" unitRef="usd">13738000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-1CDA0C96BF9325C5ABDDB6B5EA68E717" unitRef="usd">4310000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-1CF20FB68B9EA8EEEB3CB6B5EA68FD56" unitRef="usd">19000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-B64FE5BA4A587233F695B6B5EA6870C7" unitRef="usd">2240000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2016Q4Dec30_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-68892B06C49FC45B9C95B6B5EA68E500" unitRef="usd">6646000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29" decimals="-3" id="Fact-E4DE630F8D8D7687FE5700B7478D36E4" unitRef="usd">48543000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" decimals="-3" id="Fact-A55FA1D2085589A32A80B6B5EA6828F5" unitRef="usd">14146000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" decimals="-3" id="Fact-FCADB9194D436211836EB6B5EA68CE04" unitRef="usd">5959000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-BEB70CD110365AA34370B6B5EA686721" unitRef="usd">22114000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-BED6835AB1C25502F41EB6B5EA787B93" unitRef="usd">1609000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="I2017Q4Dec29_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-350238182C454AD5B206B6B5EA6886C8" unitRef="usd">4715000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2016Q4Dec30" decimals="-3" id="Fact-211EB100DF431A633DDCB6B5E513CD39" unitRef="usd">2071000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="I2017Q4Dec29" decimals="-3" id="Fact-923607B27C0118EF5DD6B6B5E533CB23" unitRef="usd">25743000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" id="Fact-BF2FF275078ED2A568A9B6B5E800FEC3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_EquipmentAndFurnitureMember" id="Fact-6C6E20FA5104E9A997678AB9534CF564">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" id="Fact-9F90E908E17A8BAD4EF1B6B5E8007CB3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" id="Fact-B0689DB4B1CF5918292A8AB93D576F6D">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-05F10DC94EA6070F8DAE8ABCADD6070A">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="D2017Q4FYYTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-10A4331B26BB4334E726B6B5E84EDE7E">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-335856BC3A1DF6EBD1B2AF2A258BB1A9" unitRef="usd">16482000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-5932E0F6ED0962ECA442AF2A257C9A3F" unitRef="usd">8271000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-F109497AE46A546967CDAF2A2580DACD" unitRef="usd">2747000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-18F77E47689C89D9BC63AF2A25745DEF" unitRef="usd">5105000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2016Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-E9FF3E222680B2E77CABAF2A258608DD" unitRef="usd">359000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-035E65CC720DF93076D9AF2A256FBAF3" unitRef="usd">55001000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksandPromptPaymentMember" decimals="-3" id="Fact-B8E634ECCC0726573457AF2A2594E7AB" unitRef="usd">33310000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_OtherDiscountsMember" decimals="-3" id="Fact-475B2563771D153B68B2AF2A2578A8C2" unitRef="usd">7301000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_RebatesMember" decimals="-3" id="Fact-DC4D029760CF65A202AAAF2A25767B48" unitRef="usd">14390000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="D2017Q4FYYTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-3" id="Fact-1BEF5B3BA923306C03EBAF2A2572FEE2" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ReceivablesNetCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-6F4E8A3419828256DC27B6B5E5135160" unitRef="usd">40444000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-75CA5F0E18801D57E0FDB6B5E513A4ED" unitRef="usd">81192000</us-gaap:ReceivablesNetCurrent>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-8685D3B006FC9A60986AB6B5F0DB80A4" unitRef="usd">13284000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-844381BF756C72CB6566B6B5E85E7EE7" unitRef="usd">18531000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecognitionOfDeferredRevenue contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-77C86278D3FD0FFBABC7B6B5F0BC214C" unitRef="usd">10377000</us-gaap:RecognitionOfDeferredRevenue>
	<us-gaap:RecoveryOfDirectCosts contextRef="D2016Q4Oct01-Dec30_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-5" id="Fact-052B6F940CFFE360BB86B6B5ED592596" unitRef="usd">23100000</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2015Q4FY2015" decimals="-3" id="Fact-606012ADE9E2E23113818A821DA9C01D" unitRef="usd">4381000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-BC51D89AD3CF253AC5D28A821DA713CF" unitRef="usd">575000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1E71F5ED68636230588B8A821DA4AD5B" unitRef="usd">185788000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-5532ED7096A16F61E10DAEFED594883B" unitRef="usd">96351000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-C66C76464072400F0212AEFED5896D43" unitRef="usd">95967000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-8E0292DCA356E0B838E1AEFED59181C9" unitRef="usd">112171000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-E06DCAB977279AA7AD690076F6BD1D05" unitRef="usd">0</us-gaap:RestrictedCashAndInvestmentsCurrent>
	<us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-A3CC00008E027C73BC920076F6AF3A33" unitRef="usd">504000</us-gaap:RestrictedCashAndInvestmentsCurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="I2016Q4Dec30" decimals="-3" id="Fact-96987176448BF004CFF1B6B5E533B900" unitRef="usd">4150000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="I2017Q4Dec29" decimals="-3" id="Fact-8C0551DD21665FA57FD9B6B5E533B77D" unitRef="usd">4646000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
	<us-gaap:RestructuringCharges contextRef="D2015Q4FY2015" decimals="-3" id="Fact-E4E95918C7E64ADF3CCAAEFF046EDEE7" unitRef="usd">1042000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-17F95FC18AA07BBA31DFB6B5E5A05ABD" unitRef="usd">914000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-0B197D67686CD7AF24F0AEFF046BB754" unitRef="usd">-32000</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2016Q4Dec30" decimals="-3" id="Fact-50E74C64ED1297B00BFBB6B5E5131C3A" unitRef="usd">-1983147000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2017Q4Dec29" decimals="-3" id="Fact-D3A84C72311766C0E272B6B5E5330B7C" unitRef="usd">-1829172000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_StatementScenarioAxis_us-gaap_ProFormaMember" decimals="-6" id="Fact-BDB2C3BB802DCC92752A8BCE6184E3EC" unitRef="usd">-260000000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="INF" id="Fact-0E480E6A3AE444E9454300A29FD9947A" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="INF" id="Fact-4D28C7153C51C669C029AF95B4C37D5A" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="-5" id="Fact-2F49286D3B30DDAC798CAF5EEAEF154C" unitRef="usd">3000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember" decimals="INF" id="Fact-2E5CA19E1AD156D19847AF7103BF0323" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q3Sep01-Sep30_us-gaap_ProductOrServiceAxis_exel_CabometyxMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" decimals="-5" id="Fact-F739EAA083CCB396E11FB6B5F11A6E4C" unitRef="usd">60000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-937FB0C2F9723530869FB4A28E475CB8" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="-5" id="Fact-3E81400A805E9DF62C0FAF5E155611FC" unitRef="usd">15000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-9497B33D66F0C89FC593B6B5F0DB2C2F" unitRef="usd">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="-5" id="Fact-2035B293FFD76C346BE4B6B5E8FCE05E" unitRef="usd">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember" decimals="INF" id="Fact-3AF755CD0DCDA12B24DDAF71120AF0DE" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithBMSMember" decimals="-5" id="Fact-4FC6828F1CD2F92A1178B6B5F12995D6" unitRef="usd">12500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithDaiichiSankyoMember" decimals="INF" id="Fact-1F6B263987BF2407B8FBB6B5E8FC315D" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-891664838B001D714370B6B5E85E27D8" unitRef="usd">45000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithMerckMember" decimals="INF" id="Fact-7422E9626A65E3CF3AFEB6B5E8FCF233" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="D2017Q4Jan032015-Dec292017_us-gaap_TypeOfArrangementAxis_exel_SanofiAventisMember" decimals="INF" id="Fact-E0B05B0ADC9F679BC4FFB6B5E90C0A2E" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:Revenues contextRef="D2015Q4FY2015" decimals="-3" id="Fact-42E2D7671764843F8211AF01FC184F66" unitRef="usd">37172000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-935ABF545CDF1CDF9E4DB6B5ED2A6C81" unitRef="usd">33869000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_exel_RestofWorldMember" decimals="-3" id="Fact-9E6B4140D1C420D755B8B6B5ED2A57CD" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2015Q4FY2015_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-B51E9B59EC0ADECAA3CFB6B5ED2A1F0F" unitRef="usd">3303000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q1FYQ1" decimals="-3" id="Fact-7644E5BF2B75EA9F8D30B6B5ED6905CF" unitRef="usd">15427000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q2FYQ2" decimals="-3" id="Fact-17DA74491E629E82D3D7B6B5ED6914A5" unitRef="usd">36252000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q3Jul02-Sep30" decimals="-3" id="Fact-061BF0B028DE493ACF60B6B5ED69EAC3" unitRef="usd">62194000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-AC90DAF3E189CF896435B6B5E5901FCD" unitRef="usd">191454000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-336A790DE32A9F908568B6B5ED2AF9E0" unitRef="usd">140709000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_exel_RestofWorldMember" decimals="-3" id="Fact-DC20E2DCB7AA867422CFB6B5ED2A3B3D" unitRef="usd">15000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-6FF5610ACD9A873FA62CB6B5ED2A2F4B" unitRef="usd">35745000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2016Q4Oct01-Dec30" decimals="-3" id="Fact-ADF9D350B9B6B68AFB4AB6B5ED69E687" unitRef="usd">77581000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q1Dec31-Mar31" decimals="-3" id="Fact-3E20DA2E14E0095E1C0B7C2FBA52F72B" unitRef="usd">80887000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q3Jul01-Sep29" decimals="-3" id="Fact-782B4CDFB67B1AD264B37C2F8E7AF345" unitRef="usd">152510000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-87B065D855F3EFB9CBFBAF01AB97B738" unitRef="usd">452477000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-3" id="Fact-B2DE47950BF062211A10B6B5ED2AF528" unitRef="usd">367906000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_exel_RestofWorldMember" decimals="-3" id="Fact-205DAACEE6BE7E2629F5B6B5ED2AE8F8" unitRef="usd">14779000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q4FYYTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueGoodsNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_us-gaap_StatementGeographicalAxis_us-gaap_EuropeMember" decimals="-3" id="Fact-1ECBC237D4CD70FC87C9B6B5ED2AA3D9" unitRef="usd">69792000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="D2017Q4Sep30-Dec29" decimals="-3" id="Fact-A5829F5F65E872410350B6B5ED694727" unitRef="usd">120072000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-3" id="Fact-011124D4E95193CE9DA07C2FA4B8AB2D" unitRef="usd">99008000</us-gaap:Revenues>
	<us-gaap:RoyaltyExpense contextRef="D2015Q4FY2015_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-2C11EA05B6491455D1A2B6B5E90CE3B9" unitRef="usd">1029000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-320722532F46686798F5B6B5E8FC3A34" unitRef="usd">4334000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-0953D01E8EE78334DBDAB6B5F0DB270B" unitRef="usd">264000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" decimals="-3" id="Fact-A2B27192F738EFE57473B6B5E8FC38AA" unitRef="usd">12413000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-2823A89EA2E3D758DF25B6B5E85E9F79" unitRef="usd">1987000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyRevenue contextRef="D2015Q4FY2015_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-ABF89EC3F1D391569554B6B5E86F89F8" unitRef="usd">14000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="D2016Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-22A7F94056E94300F255B6B5E86FC87E" unitRef="usd">2827000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-F6523912FE7E375C0720B6B5F0DB9A47" unitRef="usd">175000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" decimals="-3" id="Fact-E9B11717551FF33134D6B6B5E86F4F79" unitRef="usd">6398000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-46B3CCE57E5C95252AACB6B5E85E5BC2" unitRef="usd">3831000</us-gaap:RoyaltyRevenue>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2015Q4FY2015" decimals="-3" id="Fact-78D86892E27C270D91A4AF01F887A6E9" unitRef="usd">34158000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2015Q4FY2015_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-324207ACA67C7F4ED825B46A36725CF9" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2015Q4FY2015_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-463ECC843DAC668C9427B46A376C618C" unitRef="usd">34158000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-44AD6FB0EAC21D3F2430B6B5E5A09CA3" unitRef="usd">135375000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2016Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-B4B82EE48BF772AB00FBB46A0FDCC635" unitRef="usd">93481000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2016Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-E3E605B179651BAD06DFB46A10E1ECF9" unitRef="usd">41894000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2016Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-8E9368904982B005BF60B6B5F0DBCBD1" unitRef="usd">1612000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-647612A14F4479675606B6B5E5A0E898" unitRef="usd">349008000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CabometyxMember" decimals="-3" id="Fact-CDCF0EAC5A0601B5F14BB469F7778612" unitRef="usd">324000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2017Q4FYYTD_us-gaap_ProductOrServiceAxis_exel_CometriqMember" decimals="-3" id="Fact-F82E852173B54C157A6AB469F86E8D74" unitRef="usd">25008000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" decimals="-3" id="Fact-2253EE6398F9A6E11280B6B5E85E9426" unitRef="usd">6390000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="D2017Q4FYYTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" decimals="-3" id="Fact-00970EEC8F64EFA302148C027E28FBAA" unitRef="usd">82000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2015Q4FY2015" decimals="-3" id="Fact-95CAE335954D78A41BE5AEFEED9E3659" unitRef="usd">57305000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-2F0CE2776A9929254AB8AEFEEDA19E3C" unitRef="usd">116145000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-CF7972353D7BB4557D32AEFEED9F2B6A" unitRef="usd">159362000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="D2015Q4FY2015" decimals="-3" id="Fact-1B147F5A624F05F949B18A7C98CEE2A9" unitRef="usd">21977000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-A6097BA6B166022793AC8A7C98BEB097" unitRef="usd">22912000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-1AB6DDC3795ED8E905D38A7C98BAA138" unitRef="usd">23938000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-85F61FE841D2ECE6607CB6B5EC1E197E">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-4A1F54315057C0B4DB2BB6B5EC2EBBEC">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2010Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-31548E1EE51D305A70CBB6B5EC2E14CF">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-EB7422C7F4EFE8869046B3AF8F3773AF" unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-261C78DC79EDA2D1225AB3AF8F293C52" unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-F86D086FCE4A116D8589B6B5EC6EE472" unitRef="shares">136077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-7415D35263966D55FB14B6B5EC6EC157" unitRef="usdPerShare">11.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-1AF6ECA61E36AF3F54F1B6B5EC6E3B8C" unitRef="shares">2137817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-CB644DCB33B7812A8EBCB6B5EC6EEC9E" unitRef="usdPerShare">24.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-66321E0AE4CEEE5560DDB6B5EC6EB295" unitRef="shares">2469791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-B73F4C4C6C63C6E742AAB6B5EC6E45B4" unitRef="shares">3762990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-0CD71B932004E099A2F0B6B5EC6E81D2" unitRef="usdPerShare">8.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-91C6A31F72698EB79F92B6B5EC6EB6A5" unitRef="usdPerShare">17.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-239DE5169898724D5D39B6B5F2139525">P1Y11M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-B2E95E252F5247D61C4FAEE04C7655FE" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-C81F13F63479C6C8A166B6B5EC5EFEB4" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-1BF18D87FE88EB2CB98DAEE04B058416" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-42B975FC601DCF45A177B6B5EC5EBFE0" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-18B26F59AED1BF535827AEE0498627B9" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-0F93DB16660EBBF3B7E7B6B5EC5E6B0F" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-5D16966E3DD9AF2D8145AEE048BD6181" unitRef="number">0.0015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-C09C9441D7A4979CCB20B6B5EC5E6013" unitRef="number">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-5E9B4FE47F83686C7745B6B5EC4F40CD" unitRef="number">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-D5B44187DF7DE473FB84B6B5EC5E5C87" unitRef="number">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="4" id="Fact-E9C6226E1379182860E2AEE04694A679" unitRef="number">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-3CF8022AC774A0A42DB0B6B5EC5E8108" unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-17CF1CB0A83C5F0F29E3AEE04FBC63CB" unitRef="number">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-5D4F76E35A8F18B6A6AEB6B5EC5E0D18" unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-76B22F28BE47E3907546B6B5EC4FAB36" unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-674D8A9A00D566ACAE5EB6B5EC5E4A66" unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-742ECE815C316A1A32E4AEE04D4B17FB" unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-E70E29E9475691E11942B6B5EC5E7C24" unitRef="number">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate contextRef="I2017Q4Dec29" decimals="INF" id="Fact-6A1B0134501C0B8C70BDB6B5EC2E9217" unitRef="number">0.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2017Q4Dec29" decimals="INF" id="Fact-11CC6BEDEB3EF983B78DB6B5EC2E541A" unitRef="shares">20328545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-073F766D3858A5DF5681B6B5EC2EA430" unitRef="shares">5052500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="I2017Q4Dec29" decimals="INF" id="Fact-0413A2FF2E70B99C8ABBB6B5EC6EA41E" unitRef="shares">16158740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="I2017Q4Dec29" decimals="2" id="Fact-92CC66511909962010BDB6B5EC6E0BC0" unitRef="usdPerShare">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-5A1DF8B5032556B26EAAB393BA81DE9B" unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-BC8ADD67AD1747352CA2B6B5EC2EA296" unitRef="usd">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-0F541B8C596D58DAE6F0B6B5EC2ED7C6" unitRef="usd">85200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-719A0BFDA38312566989B6B5EC6E9E38" unitRef="shares">258333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-F5A82700A84FEA4A4993B6B5EC6ED081" unitRef="shares">229793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-39BE20B8DC95297AB2C6B6B5EC6E92C3" unitRef="shares">2166110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-F7AC2255085A8EF176A6B6B5EB6384F1" unitRef="usdPerShare">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-275DA07FCDED148AD018B6B5EB63853A" unitRef="usdPerShare">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-597E3DCA65C227F7CFCBB6B5EB630B04" unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-CC440D11237062C6A861B6B5EB63011D" unitRef="usdPerShare">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-28C4AD471A1B92629DD1B6B5EB631807" unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-FE30124FAF7D10882B79B6B5EB63A49E" unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="I2017Q4Dec29" decimals="-3" id="Fact-11996C82E9E79166A49FB6B5EC6EF36A" unitRef="usd">523448000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2016Q4Dec30" decimals="INF" id="Fact-1956124BDE4996E99032B6B5EC6EC898" unitRef="shares">24999665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2017Q4Dec29" decimals="INF" id="Fact-A3495A92BC59C2C90246B6B5EC6EE6A2" unitRef="shares">22208446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-00FA644B260A33E7CEEFB3AADA620B64" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2016Q4Dec30" decimals="2" id="Fact-3F1C79CDEAA227A55D4EB6B5EC6E030B" unitRef="usdPerShare">4.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2017Q4Dec29" decimals="2" id="Fact-4AE0946593B1D7E41667B6B5EC6EB62B" unitRef="usdPerShare">6.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="I2015Q4Q4FY_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-415E34D599F0A5CD71D2B6B5EC2E80C6" unitRef="usdPerShare">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="I2016Q4Dec30_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-DC5942966E086293E8D6B6B5EC2EA788" unitRef="usdPerShare">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased contextRef="I2017Q4Dec29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="2" id="Fact-0C2CFC1D7A1989C4EC13B6B5EC2EB9AA" unitRef="usdPerShare">11.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-1AB32E96DBA3B1F1125BB6B5EC2E8193" unitRef="shares">324315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-37D6DCBA87955231DFDDB6B5EC2E2B73" unitRef="shares">559936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" decimals="INF" id="Fact-537C1B97EBF7D2375703B6B5EC2E4DEF" unitRef="shares">434523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="D2017Q4FYYTD" decimals="2" id="Fact-A3141D689CAD6A52B8EDB6B5EC6E4DA7" unitRef="usdPerShare">3.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="D2017Q4FYYTD" decimals="2" id="Fact-E23B72E970BEB43770F0B6B5EC6E110B" unitRef="usdPerShare">9.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="D2017Q4FYYTD" decimals="2" id="Fact-77357BC6FFD9BD35998EB6B5EC6EBA9C" unitRef="usdPerShare">8.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2017Q4FYYTD" decimals="2" id="Fact-D1EF83E7448F281B77FCB6B5EC6E7307" unitRef="usdPerShare">23.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2015Q3Jul31" decimals="INF" id="Fact-CC274457BD60E1EC1BF1B6B5EB152B44" unitRef="usdPerShare">5.40</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-237919437A8C24CB84ABB6B5EC2E81C8">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-F186B381A565F036E8E5AEE053363EE0">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-2F0563C69A1E3656C3E2B6B5EC5EF85E">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-0D78B03208EBB6ED0D20B6B5EC4F94C9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B56076350D3408CFC4D5B6B5EC5EA98E">P4Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" id="Fact-44CFA60957FDADA7EA19AEE0508C9915">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q4FYYTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-4BE29111253172849DB5B6B5EC5E3D7C">P4Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="I2017Q4Dec29" decimals="-3" id="Fact-B91651C4444A5CDD060FB6B5EC6EE7CE" unitRef="usd">418304000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="D2017Q4FYYTD" id="Fact-56A52432BDEABB69CA9AB6B5EC6E156C">P3Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2017Q4FYYTD" id="Fact-EB7FBD196645428A0552B6B5EC6EE051">P4Y0M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2015Q4FY2015_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-EAF985D421D916542870B3A98842BBD2" unitRef="shares">6982613</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2016Q4FYYTD_us-gaap_AwardTypeAxis_exel_PerformanceStockOptionsMember" decimals="INF" id="Fact-5AF164BFFD5666552566B3A9884EEC6D" unitRef="shares">5870303</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:ShortTermInvestments contextRef="I2016Q4Dec30" decimals="-3" id="Fact-10B7C52B01245FBEBBCAB6B5E542AC11" unitRef="usd">268117000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="I2017Q4Dec29" decimals="-3" id="Fact-9EAE233FE5D3EF5DA3D6B6B5E5429AAA" unitRef="usd">204607000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A1A6FE55C287DDA662DAB6B5E6B957AB" unitRef="shares">54009279</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q3Jul01-31" decimals="INF" id="Fact-AA37E4E2D73E3193245FB6B5EB15BAEF" unitRef="shares">28750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q3Jul01-31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-B563952BAC68EB195157B6B5EB15739B" unitRef="shares">3750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E96486A7E5E22D9F0F76B6B5E6B967DE" unitRef="shares">28750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="D2017Q3Sep11-Sep11_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="0" id="Fact-F6274D04CBEED0E5C1CDB6B5F1F425D2" unitRef="shares">877451</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-19C81A2975DAE1AA79EC7C2074F8B47E" unitRef="shares">877451</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F9D6D3DB5B15C7453DE0B6B5E6B90ABE" unitRef="shares">3315174</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-ACA1FF369A3FC907D252B6B5E6B91EE1" unitRef="shares">7953576</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FB7F26F2BFEBD598BC447BFFBB6E4E98" unitRef="shares">5408177</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2017Q4FYYTD" decimals="INF" id="Fact-B58113860166A9350425B6B5EC6E7C67" unitRef="shares">4469203</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4Aug01-Nov30_us-gaap_DebtInstrumentAxis_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorSubordinatedNotesMember" decimals="-5" id="Fact-9410CEC7EA094279BED4B6B5EAC73F39" unitRef="usd">592700000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-1F0062E0F9AD198393B0B6B5E6B963EA" unitRef="usd">253080000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9EED218C2E32E5ED722EB6B5E6B9B4C7" unitRef="usd">253026000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7B8AF854BEC3C08F77EDB6B5E6B9FCAF" unitRef="usd">54000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2015Q4FY2015" decimals="-3" id="Fact-A03D3B10E6A5BE7684F4B6B5E6A9D965" unitRef="usd">145649000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4AA2A9191B4D82F1F294B6B5E6A972ED" unitRef="usd">145620000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5A5F80DD4516D1B24068B6B5E6B98987" unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-03B669689B80775937A5AF1E8A347F14" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-91073256E4C654C98F227C0179416396" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-27DFC9A0045C8E917EF47C03A9AC197C" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2015Q4FY2015" decimals="-3" id="Fact-AD0B7B3451FD3FD0BEB5B6B5E6B9C2C5" unitRef="usd">11277000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8482B7635FB43135595CB6B5E6B9EDC9" unitRef="usd">11274000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2015Q4FY2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-66CD01769770EDBC126CB6B5E6A97F03" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-6DC8026F5534220CD5EBB6B5E6B964E0" unitRef="usd">24538000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-FD8B2FFA58CF11744E91B6B5E6B94C40" unitRef="usd">24530000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2016Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3D21D2843AC90F96FABDB6B5E6B9B547" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-3F9966DF0139F47611967BFFC8C5425D" unitRef="usd">17409000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-175B2DFA72E71A17A03B7BFFC0D3F079" unitRef="usd">17404000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="D2017Q4FYYTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-0BD00DD4F889A60CA9D47BFFBE0779F7" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4FYQ4" decimals="-3" id="Fact-A0BC5AA9C4506C7382FFB6B5E6B92F09" unitRef="usd">-159324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-0CEB5B8ED37870E4C15BB6B5E6B939A0" unitRef="usd">-121000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-685E099FE84FD62E20FFB6B5E6B97AF0" unitRef="usd">1591782000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B0464E03DE80A0B30DB4B6B5E6B93490" unitRef="usd">196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4FYQ4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E9F0EEE507C40F11AF05B6B5E6B98315" unitRef="usd">-1751181000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-F7C2B739621793F41ADAB6B5E6B974CA" unitRef="usd">-140806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-57F0C014C78488933014B6B5E6B985E1" unitRef="usd">-232000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2041F3C1EDD1611DFA17B6B5E6B96DC7" unitRef="usd">1772123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-48E35D0E9532BF8177E6B6B5E6B90692" unitRef="usd">228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2015Q4Q4FY_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-EB39B04C1A5E13951BBBB6B5E6B92489" unitRef="usd">-1912925000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30" decimals="-3" id="Fact-D8155CE7D6151D13336AB6B5E5334440" unitRef="usd">89318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-BFC9CAFDC5F4E15241FCB6B5E6B941BE" unitRef="usd">-416000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7BE5DD163EB45A9A5A19B6B5E6B9F68A" unitRef="usd">2072591000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-1FCBF4FD8B65E91F0555B6B5E6B9D1F9" unitRef="usd">290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2016Q4Dec30_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AECF99F221ED814D540AB6B5E6A964E4" unitRef="usd">-1983147000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29" decimals="-3" id="Fact-18E332A9FD9F99A2060BB6B5E5138314" unitRef="usd">284961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-53639EE68E32CEF3641A7C16FD7CFD98" unitRef="usd">-347000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-528FD20967D659F4D2217C16FA950778" unitRef="usd">2114184000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EFED7F615044CE7F49FA7C16F846855B" unitRef="usd">296000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AD0E601003414AC6F5DA7C170060113C" unitRef="usd">-1829172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-6" id="Fact-F16C7A18A0E6D07635CAB6B5ECACF4CA" unitRef="usd">83000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="I2017Q4Dec29_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-6" id="Fact-F2D4136E8749C3C6D9F8B6B5ECAC2DD6" unitRef="usd">28000000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2015Q4FY2015" decimals="-3" id="Fact-F67483640BA35C240B4CB3C941809864" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-B49774AE62EAC50E3248B6B5F2D1C186" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-38F0755789E689BD4AB2B6B5F2E1D441" unitRef="usd">367000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2015Q4FY2015" decimals="-3" id="Fact-D8B15EF2B9E9C19C9133B3C949F77C14" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-819362A910980210C25DB6B5F2D16AF0" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-84CEA60DE7D3BE00BE71B6B5F2D10855" unitRef="usd">-22000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2015Q4FYQ4" decimals="-3" id="Fact-4510FE7E4F60FB27BBF6B6B5EC8D06AA" unitRef="usd">58215000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2015Q4Q4FY" decimals="-3" id="Fact-A87AE0EDA5150B5CF4FAB6B5EC8D5699" unitRef="usd">88638000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2016Q4Dec30" decimals="-3" id="Fact-BE5F785689A2A2F52958B6B5EC8D4B82" unitRef="usd">61809000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="I2017Q4Dec29" decimals="-3" id="Fact-17130A505C7984893227B6B5EC8DC90C" unitRef="usd">79342000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="D2015Q4FY2015" decimals="-3" id="Fact-C52A87DA17E5810FB31CB6B5EC8D3C8F" unitRef="usd">8727000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-7F06E3246A822CFAB489B6B5EC8D53E0" unitRef="usd">2304000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-B6FC18053707AC494A60B6B5EC8D3F53" unitRef="usd">17378000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="D2015Q4FY2015" decimals="-3" id="Fact-A706CC6EB1B1502F24F4B6B5EC8D0EA8" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-3C37D62493CDE472B24BB6B5EC8D849B" unitRef="usd">23000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-5895C847F41F71B87214B6B5EC8D7E5B" unitRef="usd">92000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="D2015Q4FY2015" decimals="-5" id="Fact-10EE5536B76167F94A12B6B5ECAC765E" unitRef="usd">7900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="D2016Q4FYYTD" decimals="-5" id="Fact-9D55B41C31A1931DD128B6B5ECACCAE1" unitRef="usd">92700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="D2017Q4FYYTD" decimals="-5" id="Fact-E15D9157EF656794BA1FB3BF3B065A67" unitRef="usd">-210100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="I2015Q1Mar18_us-gaap_ClassOfWarrantOrRightAxis_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" decimals="-5" id="Fact-80C8AE0BC7E3F89BC6F5B6B5EB153200" unitRef="usd">1500000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2015Q4FY2015" decimals="-3" id="Fact-E5CD74B4DB45C714A1A0B3C95D2BFEA6" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-9A6F5A85721869C6F806B6B5ECDBEA22" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-A6601A2DFB3D90A7F784B6B5ECDBBC62" unitRef="shares">18415000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2015Q4FY2015" decimals="-3" id="Fact-DFD490D8443452B1F79BAF00FC04C138" unitRef="shares">209227000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-FAD7291ED0B667F52C4AAF00FC0C3AEA" unitRef="shares">250531000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-9CDE2CC1ABE6336737BCAF00FC0AA64D" unitRef="shares">312003000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2015Q4FY2015" decimals="-3" id="Fact-08418C9375F4AA264045AF00965F4580" unitRef="shares">209227000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2016Q4FYYTD" decimals="-3" id="Fact-0500F8E921F43537443EAF00965A5885" unitRef="shares">250531000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="D2017Q4FYYTD" decimals="-3" id="Fact-4C6A024C7446AC00ECFAAF00965CBC36" unitRef="shares">293588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<exel:EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-84A69ACF983328125899B6B5E7F1AA70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7 to 15 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</exel:EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
	<invest:InvestmentTextBlock contextRef="D2017Q4FYYTD" id="Fact-79321B333AF7108D01FFB6B5EA39A356">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INVESTMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Investments Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash equivalents and investments by security type were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;460,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investments available-for-sale were nominal or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value and gross unrealized losses of investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;160,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;143,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;169,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;172,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross unrealized losses on commercial paper were less than &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;$1&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; thousand.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;134&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;86&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;377,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;404,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash is excluded from the table above. The classification of certain restricted investments was dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. As a result, certain investments with contractual maturities within one year were classified as long-term restricted cash and investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we were required to maintain compensating balances of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$81.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in connection with our term loan payable to Silicon Valley Bank, which was included in short-term investments on the accompanying Consolidated Balance Sheet; as a result of our repayment of the term loan, the compensating balance requirement was terminated in March 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Cost Method Equity Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we recognized gains of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, related to the August 2016 sale of our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; interest in Akarna Therapeutics, Ltd. (&amp;#8220;Akarna&amp;#8221;) to Allergan Holdco UK Limited (&amp;#8220;Allergan&amp;#8221;). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. The gain on sale was included in Other expenses, net on the accompanying Consolidated Statements of Operations. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. The gain on sale of other cost method equity investments was nominal during the year ended December&amp;#160;31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</invest:InvestmentTextBlock>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-5DE776C4A6727DE7471E00F4B9D67492">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value and gross unrealized losses of investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,746&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;160,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,611&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,698&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;177,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br clear="none"/&gt;Unrealized&lt;br clear="none"/&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;143,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;169,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;172,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross unrealized losses on commercial paper were less than &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;$1&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; thousand.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-026509C8A706D748C6BAB6B5E7F198E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&amp;#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&amp;#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-4558E61746D47BB8CFD7B6B5E7F1419E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-7A257B3F993C7ECC71B5B6B5E8FCCBFA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COLLABORATION AGREEMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&amp;#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&amp;#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&amp;#8217;s ongoing development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The collaboration agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Ipsen for all development and commercial activities, research and development services, and participation on the joint steering, development and commercialization committees (as defined in the collaboration agreement). We determined that these deliverables do not have stand-alone value and accordingly, combined these deliverables into a single unit of accounting and allocated the entire arrangement consideration to that combined unit of accounting. As a result, the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;aggregate &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; has been recognized ratably over the term of the collaboration agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the European Union (&amp;#8220;EU&amp;#8221;). At the time we entered into the collaboration agreement, we determined that the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; milestone we achieved in September 2016 upon the approval of cabozantinib by the European Commission in previously treated advanced RCC was not substantive due to the relatively low degree of uncertainty and relatively low amount of effort required on our part to achieve the milestone as of the date of the collaboration agreement; the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was deferred and has been recognized ratably over the remainder of the term of the Ipsen collaboration agreement. We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018, which will materially impact the timing of recognition of revenue for our collaboration &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;agreement&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; with Ipsen. For information on our adoption of ASU 2014-09, see &amp;#8220;Note 1. Organization and Summary of Significant Accounting Policies&amp;#8221; in the &amp;#8220;Notes to Consolidated Financial Statements&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; contained in Part II, Item 8 of this Annual Report on Form 10-K&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the time we entered into the collaboration agreement we determined that the remaining development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We have achieved additional milestones of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$209.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, including milestone payments of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; upon &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;European Medicines Agency (&amp;#8220;EMA&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;filing and the approval of cabozantinib &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as a treatment for patients with previously treated advanced hepatocellular carcinoma (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;HCC&amp;#8221;) and additional milestone payments for other future indications and/or jurisdictions. The collaboration agreement also provides that we will be eligible to receive contingent payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$546.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; associated with the achievement of specified levels of Ipsen sales to end users. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Excluding Ipsen sales in Canada, we &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;received a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty on the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which was achieved in the fourth quarter of 2017, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and are entitled to receive a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;12%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty on the next &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;following this &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, we are then entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on annual net sales. These tiers will reset each calendar year. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In Canada, we are entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;on the first CAD&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of annual net sales and a tiered royalty thereafter, up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;26%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on annual net sales; these tiers will also reset each calendar year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with Bristol-Myers Squibb Company (&amp;#8220;BMS&amp;#8221;); CheckMate 040, the phase 1/2 study evaluating the combination of cabozantinib with nivolumab in patients with both previously treated and previously untreated advanced HCC being conducted in collaboration with BMS (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with Roche. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;s a result of a change in operational responsibilities for certain clinical programs, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;in March &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017, we reclassified &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of deferred revenue to Accrued collaboration liabilities and accordingly adjusted our amortization of the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;aggregate &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we had paid &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; toward the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$9.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of reimbursements due to Ipsen for these clinical programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen in February 2016,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which, pursuant to its amended terms, effective October 2017, we will supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan, indefinitely. The product will be supplied&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;at our cost, as defined in the agreement, which excludes the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty we are required to pay GSK on Ipsen&amp;#8217;s net sales of any product incorporating cabozantinib.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;U.S. Food and Drug Administration (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;FDA&amp;#8221;) or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen terminated only for a particular region, then for the terminated region. Following termination by us for Ipsen&amp;#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Milestones achieved&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of upfront payments and deferred milestone&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product supply agreement revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cost of supplied product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,555&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty payable to GSK on net sales by Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues under the collaboration agreement with Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; such revenues for the year ended December 31, 2015. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, short-term and long-term deferred revenue relating to the collaboration agreement was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$19.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&amp;#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; upfront nonrefundable payment from Takeda. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The collaboration agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Takeda for all development and commercial activities, research and development services, and participation on the joint executive, development and commercialization committees (as defined in the collaboration agreement). We determined that these deliverables, other than the commercial supply and joint commercialization committee participation, are non-contingent in nature. The commercial supply deliverable was deemed contingent, primarily due to the fact that there is uncertainty around approval in Japan, which is dependent on successful clinical trial results from a study in Japanese patients. We also determined that the non-contingent deliverables do not have stand-alone value, because each one of them has value only if we meet our obligation as a whole to provide Takeda with research and development services, including clinical supply of cabozantinib under the collaboration agreement. Accordingly, we combined the non-contingent deliverables into a single unit of accounting and allocated the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; upfront fee to that combined unit of accounting. We also determined that the level of effort required of us to meet our obligations under the collaboration agreement is not expected to vary significantly over the development period of the collaboration agreement. As a result, the upfront payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, received in the first quarter of 2017, has been recognized ratably over the development period of the collaboration agreement of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018, which will materially impact the timing of recognition of revenue for our collaboration &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;agreement&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; with Takeda. For information on our adoption of ASU 2014-09, see &amp;#8220;Note 1. Organization and Summary of Significant Accounting Policies&amp;#8221; in the &amp;#8220;Notes to Consolidated Financial Statements&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; contained in Part II, Item 8 of this Annual Report on Form 10-K&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are eligible to receive development, regulatory and first-sale milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$95.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestones payments for potential future indications. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We determined that the development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$83.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; associated with potential sales milestones. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; on the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, and after the initial &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of net sales, we are then entitled to receive a tiered royalty of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;on annual net sales. These tiers will reset each calendar year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Takeda is responsible for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the costs associated with the global cabozantinib development plan&amp;#8217;s current and future trials, provided Takeda opts into such trials, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the manufacture and supply of cabozantinib to Takeda, as well as a quality agreement setting forth, in detail, the quality assurance arrangements and procedures for our manufacture of cabozantinib. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&amp;#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; years of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&amp;#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&amp;#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of upfront payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product supply agreement revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues under the collaboration agreement with Takeda&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; such revenues for the year ended December 31, 2016 or 2015. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, short-term and long-term deferred revenue relating to the collaboration agreement was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$11.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$28.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cobimetinib Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Genentech Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we were responsible for developing cobimetinib through the determination of the maximum-tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, which Genentech could exercise after receipt of certain phase 1 data from us. In March&amp;#160;2008, Genentech exercised its option to co-develop cobimetinib, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On&amp;#160;November&amp;#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&amp;#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allowed us to provide up to 25% of the total sales force for approved cobimentinib indications in the U.S. Between November 2015 and December 2017, we fielded &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a recent commercial review, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&amp;#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of profits and losses from the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of U.S. actual sales, decreasing to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of profits and losses from U.S. actual sales in excess of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;These tiers will reset each calendar year. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (the &amp;#8220;Genentech Collaboration P&amp;amp;L&amp;#8221;) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&amp;#160;either party based on uncured material breach by the other party.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales of COTELLIC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2016 Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&amp;#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay certain disputed costs that had been accrued by us; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the year ended December 31, 2016, we offset Selling, general and administrative expenses with a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; recovery of disputed losses that we had recognized and recorded prior to 2016 and also recognized a loss under the collaboration agreement of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for 2016 activities, resulting in a net cost recovery of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$8.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have established collaborations with other leading pharmaceutical and biotechnology companies, including BMS, Daiichi Sankyo Company Limited (&amp;#8220;Daiichi Sankyo&amp;#8221;), Roche, Merck (known as MSD outside of the U.S. and Canada) and Sanofi, for various compounds and programs in our portfolio. Pursuant to these collaborations, we have fully out-licensed compounds or programs to a partner for further development and commercialization.&amp;#160;Under each of our collaborations, we are entitled to receive milestones and royalties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;With respect to our partnered compounds, other than cabozantinib and cobimetinib, we are eligible to receive potential contingent payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.9 billion&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the aggregate on a non-risk adjusted basis, of which &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are related to clinical development milestones, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;49%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are related to regulatory milestones and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;42%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are related to commercial milestones, all to be achieved by the various licensees, which may not be paid, if at all, until certain conditions are met.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Daiichi Sankyo&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the mineralocorticoid receptor (&amp;#8220;MR&amp;#8221;), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including CS-3150/esaxerenone (a specific rotational isomer of XL550). Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below. In September 2017, Daiichi Sankyo reported positive top-line results from the phase 3 pivotal trial of CS-3150/esaxerenone and communicated its intention to submit a Japanese regulatory application for CS-3150/esaxerenone for an essential hypertension indication in the first quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are eligible to receive additional development, regulatory and commercialization milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. In addition, we are entitled to receive royalties on any sales of certain products commercialized under the collaboration. Daiichi Sankyo may terminate the agreement upon ninety days&amp;#8217; written notice in which case Daiichi Sankyo&amp;#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognized contract revenues of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for milestone payments during the year ended December 31, 2016 under our collaboration agreement with Daiichi Sankyo. We did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any such revenue during the years ended December 31, 2017 or 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;The Roche Group Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2017, we established a clinical trial collaboration with The Roche Group (&amp;#8220;Roche&amp;#8221;) for the purpose of evaluating the safety and tolerability of cabozantinib in combination with Roche&amp;#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Each party is responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the clinical supply agreement entered into by the parties in February 2017. Based on the dose-escalation results, the trial has the potential to enroll up to four expansion cohorts, including a cohort of patients with previously untreated advanced clear cell RCC and three cohorts of urothelial carcinoma, namely platinum eligible first-line patients, first or second-line platinum ineligible patients and patients previously treated with platinum-containing chemotherapy. The trial was initiated in June 2017 and is open for enrollment. We are the sponsor of the trial, and Roche is responsible for supplying atezolizumab to us. Ipsen has opted to participate in the study and will have access to the results to support potential future development in its territories.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Merck&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December&amp;#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta (&amp;#8220;PI3K-d&amp;#8221;) program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-d program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are eligible to receive additional payments associated with the successful achievement of potential development and regulatory milestones for multiple indications of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$231.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We will also be eligible to receive payments for combined sales performance milestones of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and royalties on net-sales of products emerging from the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Merck may at any time, upon specified prior notice to us, terminate the license. In addition, either party may terminate the agreement for the other party&amp;#8217;s uncured material breach. In the event of termination by Merck at will or by us for Merck&amp;#8217;s uncured material breach, the license granted to Merck would terminate. In the event of a termination by us for Merck&amp;#8217;s uncured material breach, we would receive a royalty-free license from Merck to develop and commercialize certain joint products. In the event of termination by Merck for our uncured material breach, Merck would retain the licenses from us, and we would receive reduced royalties from Merck on commercial sales of products. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognized contract revenues of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for milestone payments during the years ended December 31, 2016 and 2015, respectively, under our collaboration agreement with Merck. We did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any such revenue during the year ended December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Bristol-Myers Squibb&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Previously Untreated Advanced RCC, Bladder Cancer and Previously Treated HCC Combination Studies&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of evaluating the combination of cabozantinib and nivolumab with or without ipilimumab in various tumor types, including, in RCC, HCC and bladder cancer. To date, CheckMate 9ER, a phase 3 pivotal trial in previously untreated, advanced or metastatic RCC, and CheckMate 040, a phase 1/2 trial in both previously treated and previously untreated advanced HCC evaluating these combinations has been initiated. Pursuant to the terms of the collaboration agreement, each party will grant to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement), non-transferable, royalty-free license to use the other party&amp;#8217;s compounds in the conduct of each clinical trial. The parties&amp;#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&amp;#8217;s operation. Each trial will be conducted under a combination Investigational New Drug Application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the supply agreement entered into between the parties in April 2017, and costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two-thirds&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the costs and we will bear &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one-third&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the costs for such study treatment arms. Unless earlier terminated, the BMS collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. Ipsen has opted in to participate in both trials (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab) and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at its choosing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;"&gt;ROR Collaboration&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Under the terms of the collaboration agreement, we were responsible for activities related to the discovery, optimization and characterization of the ROR antagonists during the collaborative research period which began on October&amp;#160;8, 2010 and ended on&amp;#160;July 8, 2013. Since the end of the collaborative research period, BMS has and will continue to have sole responsibility for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are eligible for additional development and regulatory milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$240.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the aggregate and commercialization milestones of up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The collaboration agreement was amended and restated in April 2011 in connection with an assignment of patents to a wholly-owned subsidiary. BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&amp;#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&amp;#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognized contract revenues of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for milestone payments during the year ended December 31, 2017 under our collaboration agreement with BMS. We did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any such revenue during the years ended December 31, 2016 or 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Sanofi&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2009, we entered into a global license agreement with Sanofi for SAR245408 (XL147) and SAR245409 (XL765), leading inhibitors of phosphoinositide-3 kinase (&amp;#8220;PI3K&amp;#8221;), and a broad collaboration for the discovery of inhibitors of PI3K for the treatment of cancer. The license agreement and collaboration agreement became effective on July&amp;#160;7, 2009. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Under the license agreement, Sanofi received a worldwide exclusive license to SAR245408 (XL147) and SAR245409 (XL765), which entered into a series of phase 1, phase 1b/2 or phase 2 clinical trials, and has sole responsibility, including funding, for all subsequent clinical, regulatory, commercial and manufacturing activities. We were notified by Sanofi that the initial clinical trials involving XL147 or XL765 have been terminated or are in the process of concluding, and that Sanofi is still considering whether to initiate any further trials. We are eligible to receive contingent payments associated with development, regulatory and commercial milestones under the license agreement of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$745.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the aggregate, as well as royalties on sales of any products commercialized under the license. Sanofi may, upon certain prior notice to us, terminate the license as to products containing SAR245408 (XL147) and SAR245409 (XL765). In the event of such termination election, Sanofi&amp;#8217;s license relating to such product would terminate and revert to us, and we would receive, subject to certain terms, conditions and potential payment obligations, licenses from Sanofi to research, develop and commercialize such products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any revenue under our collaboration agreement with Sanofi during the three years ended December 31, 2017, 2016 and 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;GlaxoSmithKline&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2002, we established a collaboration with GSK to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under the terms of the product development and commercialization agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. As a result, we retained the rights to develop, commercialize, and license cabozantinib, subject to payment to GSK of a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty on net sales of any product incorporating cabozantinib. The product development and commercialization agreement was terminated during 2014, although GSK will continue to be entitled to a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty on net sales by us or our collaboration partners of any product incorporating cabozantinib, including COMETRIQ and CABOMETYX. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalties accruing to GSK are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-A026183C7DD12B09111BB6B5ECEB4FBA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COMMITMENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On May 2, 2017, we entered into a Lease with Ascentris for an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;110,783&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of space in office and research facilities located at the Premises in Alameda, California. We also have the right to make certain tenant improvements to the space leased on the Premises. The Lease has an initial term of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; with a target commencement date of February 1, 2018, and, subject to a partial twelve-month rent abatement period, rent payments will begin upon the target commencement date. We have &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;five&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year options to extend the Lease and a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-time option to terminate the Lease without cause on the last day of the 8&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year of the initial term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;170,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of space, as that additional space becomes available over the remainder of the initial term at 1601, 1701, 1751, and 1801 Harbor Bay Parkway, Alameda, California at a market rate determined according to the Lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We are deemed, for accounting purposes only, to be the owner of portions of the Premises, including &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; building shells, even though we are not the legal owner. See &amp;#8220;Note 5. Property and Equipment - Build-to-Suit Lease&amp;#8221; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for a further description of the accounting for that portion of the Premises.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On May 2, 2017, we also entered into an Agreement for Conditional Option to Amend Lease (the &amp;#8220;Optional Amendment Agreement&amp;#8221;) with Ascentris. Under the terms of the Optional Amendment Agreement, a current tenant (the &amp;#8220;Tenant&amp;#8221;) occupying approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;16,343&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of the facility located at 1801 Harbor Bay Parkway was given the option to relocate to another building on the premises or terminate their current lease early, requiring them to relocate within &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; from the termination date. Under the terms of the Optional Amendment Agreement, we would reimburse Ascentris for the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs incurred to induce the Tenant to relocate. In August 2017, the Tenant communicated to Ascentris that they were terminating their lease early. During &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recorded a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; expense for our anticipated reimbursement of costs to Ascentris for the Tenant&amp;#8217;s relocation of which &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; remains payable as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. On October 16, 2017, we executed an amendment to the Lease for an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;19,778&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of space located on the Premises, which includes the space vacated by the Tenant, with terms consistent with the original Lease. Including the amendment, we are obligated to make lease payments totaling $&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;28.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; over the Lease term. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We also lease &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; buildings in South San Francisco, California with a total area of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;116,063&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet, the lease for which expires in July 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the aggregate future minimum lease payments under our leases were as follows (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Operating leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other financing obligations&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Year ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;704&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other financing obligations includes payments related to our build-to-suit lease.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Rent expense and sublease income were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,676&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;less: Sublease income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Letters of Credit and Restricted Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We obtained a standby letter of credit related to our South San Francisco lease with a credit limit of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at both &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We obtained two standby letters of credit related to a workers compensation insurance policy with a combined credit limit of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at both &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We obtained &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; standby letters of credit related to the Lease with Ascentris for a combined credit limit of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. All of the letters of credit are fully collateralized by certificates of deposit. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;none&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of our letters of credit have been drawn upon. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As part of a purchasing card program we initiated during 2007, we were required to provide collateral in the form of certificates of deposit. The collateral requirement at both &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The certificate of deposit used to collateralize the standby letter of credit related to our South San Francisco lease was included in short-term restricted cash and investments. The certificates of deposit used to collateralize all other letters of credit and the purchase card program were included in long-term restricted cash and investments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-9CA610B8F9EF6BEAC90CB6B5E7F16B37">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:CostOfSalesPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-6D39D80C218B72291711B6B5E7F13B50">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost of Goods Sold&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cost of goods sold is related to our product revenues and consists primarily of a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty on sales of any product incorporating cabozantinib payable to GlaxoSmithKline (&amp;#8220;GSK&amp;#8221;), indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. A portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ and CABOMETYX and therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. See &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; for additional information on the royalty payable to GSK on sales of any product incorporating cabozantinib.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-1CE95DF397379CBBB266B6B5EAC71D5D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The amortized carrying amount of our debt was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;109,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;189,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance of unamortized fees and costs was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which was recorded as a reduction of the carrying amount of the Convertible notes on the accompanying Consolidated Balance Sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Secured Convertible Notes due 2018 (&amp;#8220;Deerfield Notes&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. The repayment amount totaled &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$123.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which comprised &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$113.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in principal, including &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of interest paid in kind paid through the repayment date, a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; prepayment penalty associated with the early repayment of the notes and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in accrued and unpaid interest. As a result of the early repayment, there was a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; loss on the extinguishment of the debt which comprised the prepayment penalty and the unamortized fees and costs on the date of the repayment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Prior to our early repayment of the Deerfield Notes, the outstanding principal amount of the notes bore interest at the rate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per annum to be paid in cash, quarterly in arrears, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per annum to be paid in kind, quarterly in arrears, for a total interest rate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per annum.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;4.25% Convertible Senior Subordinated Notes due 2019 (&amp;#8220;2019 Notes&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Between August and November 2016, all &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$287.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; aggregate principal amount outstanding under the 2019 Notes was either converted into &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;54,009,279&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of common stock or redeemed for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in cash. In addition, certain holders received inducements of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which included an aggregate cash payment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in accrued interest payments which would have been payable if the notes had not been exchanged. Under the terms of the indenture for the 2019 Notes, certain holders who exchanged their notes on August 9, 2016 would have been required to repay the interest payment they received as holders of record on August 1. The exchange transactions were structured such that the holders were not required to repay this interest. We have included those payments as an additional inducement and as financing activities on the accompanying Consolidated Statement of Cash Flows. A summary of loss on extinguishment of debt for the conversion and redemption of the 2019 Notes was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash inducements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Waiver of requirement to repay interest, described above&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Unamortized discount on redeemed notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Third-party costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Loss on extinguishment of debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The stock issuance on the conversion of the notes resulted in an increase to common stock and additional paid-in capital of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$592.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. A portion of the settlement consideration transferred to the holders of the notes was allocated to the reacquisition of the conversion option embedded in the notes, which resulted in a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$342.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; reduction of additional paid-in capital. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Prior to the extinguishment of the 2019 Notes, the outstanding principal amount of the notes bore interest at a rate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;4.25%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;per annum, payable semi-annually in arrears on February&amp;#160;15 and August&amp;#160;15 of each year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On March 29, 2017, we repaid all amounts outstanding under our term loan payable to Silicon Valley Bank. The repayment included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$80.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in principal plus &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in accrued and unpaid interest. There was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; gain or loss on the extinguishment of debt as a result of the repayment of the term loan. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Prior to our early repayment of the term loan payable, the outstanding principal amount of the loan bore interest at the rate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;per annum, which was due and payable monthly. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we were required to maintain compensating balances of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$81.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in connection with our term loan payable to Silicon Valley Bank, which was included in short-term investments on the accompanying Consolidated Balance Sheet; as a result of our repayment of the term loan, the compensating balance requirement was terminated in March 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D2017Q4FYYTD" id="Fact-429F284141A1AAE4455BB6B5EC2E71D1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;STOCK-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The allocation of stock-based compensation for our equity incentive plans and our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;Employee Stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;) was as&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have several equity incentive plans under which we have granted stock options and RSUs to employees, directors and consultants. At &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;20,328,545&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under our equity incentive plans. The Board of Directors or a designated Committee of the Board is responsible for administration of our equity incentive plans and determines the term, exercise price and vesting terms of each grant. Stock options have a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year vesting term, an exercise price equal to the fair market value on the date of grant, and a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;seven&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year life from the date of grant. Stock options issued prior to May 2011 have a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year life from the date of grant. RSUs granted to our employees generally vest annually over a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a Change in Control and Severance Benefit Plan for executives and certain non-executives. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&amp;#8217;s employment is terminated without cause during a period commencing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one month&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; before and ending &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;thirteen months&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all of such participant&amp;#8217;s stock options accelerated with the exercise period being extended to no more than &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one year&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;of the closing price at the beginning of the offering period or&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;of the closing price at the end of each&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;month purchase period. Compensation expense related to our ESPP was&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;for the years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively. As of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, we had&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;5,052,500&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares available for issuance under our ESPP. Pursuant to the ESPP, we issued&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;434,523&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;559,936&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares, and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;324,315&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares of common stock at an average price per share of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$11.20&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$3.91&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$1.75&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;during the years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;Cash received&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;from purchases under the ESPP in the years ended December 31, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We use the Black-Scholes Merton option pricing model to value our stock options. The weighted average grant-date fair value of our stock option grants and ESPP purchases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We considered implied volatility as well as our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Stock option activity for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24,999,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,166,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,469,203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(229,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(258,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,208,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.05 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;523,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,158,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.46 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$39.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to stock options will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2.57 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and the exercise prices, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The total intrinsic value of options exercised was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$85.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. Cash received from option exercises during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$17.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$25.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. The total estimated fair value of employee options vested and recorded as expense during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$18.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In April 2016, March 2016 and July 2015, the Compensation Committee of the Board of Directors of Exelixis convened to determine we had met certain performance objectives for performance-based stock options granted to employees in 2013, 2014 and 2015. As a result of these determinations, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5,870,303&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;6,982,613&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; performance-based stock options vested during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. During &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;the years ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;we recognized&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;and&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;$13.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;in stock-based compensation for those&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based stock option grants&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;. We did&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;t have any&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based stock options outstanding during the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and therefore, did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;stock-based compensation for&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance-based stock &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;options during the year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of RSUs was determined based on the value of the underlying common stock on the date of grant. The expenses relating to RSUs are recognized over their vesting period. A summary of all RSU activity were as follows (dollars in thousands, except per share amounts):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awards outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,469,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,137,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(708,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(136,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awards outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,762,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.95 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;114,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$61.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to employee RSUs will be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3.20 years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;401(k) Retirement Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We sponsor the Exelixis, Inc. 401(k) Plan (the &amp;#8220;401(k) Plan&amp;#8221;) whereby eligible employees may elect to contribute up to the lesser of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. We make matching contributions in the form of our common stock of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the first &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of each participant&amp;#8217;s contributions into the 401(k) Plan. We recorded compensation expense related to the stock match of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;As of&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;231,090&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;shares were available for issuance under the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;401(k) Plan&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="D2017Q4FYYTD" id="Fact-3A1A9D459A1BD78EDCC5B6B5ECCC1086">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NET INCOME (LOSS) PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;293,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;209,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;209,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The 2014 Warrants were participating securities and the warrant holders did not have a contractual obligation to share in our losses. See &amp;#8220;Note 7. Common Stock and Warrants&amp;#8221; for a description of the 2014 Warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Potentially dilutive shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;28,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deerfield Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2014 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;62,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;117,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Deerfield Notes were repaid in June 2017. The 2014 Warrants were exercised in September 2017. The 2019 Notes were converted or redeemed between August and November 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="D2017Q4FYYTD" id="Fact-8CC4A49F4EC045E09C81B6B5EB344815">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;394,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;388,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="D2017Q4FYYTD" id="Fact-19A664C22E4AD8AA91D9B6B5EB3455C6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;FAIR VALUE MEASUREMENTS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;394,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;388,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and there were no transfers of financial assets or liabilities classified as Level 3 during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The estimated fair value of our financial instruments that are carried at amortized cost was as follows (in thousands)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;109,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;121,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying amounts of cash, trade and other receivables, accounts payable, accrued collaboration liability, accrued compensation and benefits, accrued clinical trial liabilities, rebates fees due customers, and other liabilities approximate their fair values and are excluded from the tables above. We had no additional financial instruments carried at amortized cost as of December 31, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The following methods and assumptions were used to estimate the fair value of each class of financial instrument: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We estimated the fair value of our debt instruments using the net present value of estimated future cash flows through maturity. For the Deerfield Notes, we used a discount rate of &lt;/font&gt;&lt;font style="font-family:Calibri;font-size:10pt;color:#000000;"&gt;9.5%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which we estimated as our current borrowing rate for similar debt as of December&amp;#160;31, 2016, which is a Level 3 input.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For the term loan payable, we used an interest rate that is consistent with money-market rates that would have been earned on our non-interest-bearing compensating balances as our discount rate, which is a Level 2 input.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Financial Assets, Liabilities and Equity Measured on a Nonrecurring Basis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In connection with the conversions of our 2019 Notes during 2016, we were required to determine the fair value of the settlement consideration received by the holders and the fair value of the liability component of the 2019 Notes, as of the various settlement dates of the conversions. The following methods and assumptions were used to estimate the fair value of those financial instruments:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The settlement consideration comprises, in part, shares of our Common Stock. The fair value of our Common Stock was determined based on the closing market price of our Common Stock on the various settlement dates of the conversions, which are level 1 inputs;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying value of the remaining settlement consideration, which includes cash and the forgiveness of the repayment of certain prior interest payments, approximates fair value; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We estimated the fair value of the liability component of the 2019 Notes using the net present value of estimated future cash flows through maturity. We used a discount rate of &lt;/font&gt;&lt;font style="font-family:Calibri;font-size:10pt;color:#000000;"&gt;9.5%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which we estimated as our current borrowing rate for straight debt as of September 30, 2016, which is a Level 3 input.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="D2017Q4FYYTD" id="Fact-D1F7547B5C5D3ED88E8EB6B5EB34C9D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The estimated fair value of our financial instruments that are carried at amortized cost was as follows (in thousands)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;109,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;121,220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="D2017Q4FYYTD" id="Fact-141E44B288473220B51BB6B5E7F123A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 1 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 2 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 3 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-6EFDF8CB7AA29B584007B6B5E7F1CA1A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Remeasurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other expenses, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="D2017Q4FYYTD" id="Fact-D930EAD3C1A7B80D62E8B6B5E7F1A40B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&amp;#8217;s goodwill exceeds its implied fair value. We continue to operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-B482B32910BEF44367EBB6B5E7F190EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-1BAED1E313F53CBED781B6B5ECAC1117">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INCOME TAXES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes was based on the following income (loss) before income taxes (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;158,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(150,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income (loss) before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;158,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes for the year ended December&amp;#160;31, 2017 primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset any federal taxable income. The Provision for income taxes for the year ended December 31, 2016 related to state minimum and franchise taxes and were nominal. The Provision for income taxes for the year ended December 31, 2015 relates to state minimum and franchise tax expenses as well as true ups related to prior year tax returns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reconciliation of income taxes at the statutory federal income tax rate to our Provision for income taxes included on the accompanying Consolidated Statements of Operations was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. federal income tax provision (benefit) at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(34,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;51,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt extinguishment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(20,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carry-forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net operating loss carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;471,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Book over tax depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tax credit and charitable contribution carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;66,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of deferred stock compensation &amp;#8211; non-qualified&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accruals and reserves not currently deductible&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;629,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(629,062&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Unrealized gains on derivatives and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law. The Tax Cuts and Jobs Act contains significant changes to corporate taxation, including among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. As a result of the signing of the Tax Cuts and Jobs Act, we recorded a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$184.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; reduction of our deferred tax assets along with a corresponding reduction of our valuation allowance. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2017, or are expected to be recorded in future periods.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Additionally, further guidance may be forthcoming from the FASB and the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Securities and Exchange Commission&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASC Topic 740 (&amp;#8220;ASC 740&amp;#8221;) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely (as defined in ASC 740) to be realized and, accordingly, has provided a valuation allowance. The valuation allowance decreased by &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$210.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during 2017 and increased by &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$92.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$7.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during 2016 and 2015, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At December&amp;#160;31, 2017, we had federal net operating loss carry-forwards of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1,105 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which expire in the years &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2024&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2036&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and federal business tax credits of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$83 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which expire in the years &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2020&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2037&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We also had state net operating loss carry-forwards of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$424 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which expire in the years &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2028&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2036&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and California research and development tax credits of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$28 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which have no expiration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carry-forwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carry-forwards before utilization. We completed a Section 382 study through December 31, 2017, and concluded that an ownership change, as defined under Section 382, had not occurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASC 740 clarifies the accounting for uncertainty in income taxes by prescribing the recognition threshold a tax position is required to meet before being recognized in the financial statements. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The following table summarizes the activity related to our unrecognized tax benefits (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to prior year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(29,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to current year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We do not anticipate that the amount of unrecognized tax benefits existing as of December&amp;#160;31, 2017 will significantly decrease over the next 12 months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2016 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-2F0176D4D57EBFB9752D8B071B358353">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income tax provision is computed under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;together with assessing carry-forwards &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;an unrecognized tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-4A93725BDC3BC52DCDF7B6B5EA59DA29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;INVENTORY&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other long-term assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and therefore was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and 2015, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory expected to be used or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Consolidated Balance Sheets. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the non-current portion of inventory consisted of finished goods. As of December 31, 2016, the non-current portion of inventory consisted of raw materials and a portion of the active pharmaceutical ingredient that was included in work in process inventories.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-32E0D8558A90D3A5A232B6B5E7F1FECD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory related costs are recognized as Cost of goods sold on the accompanying Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets on the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. Only once regulatory approval is obtained, would we begin capitalization of these inventory related costs. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-39F641FD30ECD7DAA9C7B6B5EA39D16A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;377,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;404,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;63,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,601&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="D2017Q4FYYTD" id="Fact-F5536722BE2D35CF9A47B6B5E7F17833">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net on the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments on the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-94545C245549474E510FB6B5E7F175BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2014-09&amp;#8221;).&amp;#160;In August 2015, the FASB issued ASU No. 2015-14, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which delayed the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, which is when we will adopt the standard. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of net product revenues. ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration agreements with Ipsen Pharma SAS (&amp;#8220;Ipsen&amp;#8221;) and Takeda Pharmaceutical Company Ltd. (&amp;#8220;Takeda&amp;#8221;). We will record a net adjustment of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$260 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accumulated deficit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(a concept known as &amp;#8220;lost revenue&amp;#8221;) for amounts associated with these collaboration agreements upon recording our transition adjustment in the first quarter of 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration agreements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Leases (Topic 842),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-02&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require both types of leases to be recognized on the balance sheet. The ASU also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 is effective for us for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. We are in the process of assessing the impact of ASU No. 2016-02 on our Consolidated Financial Statements and are considering early adoption of this standard in the first half of 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU No.&amp;#160;2016-15,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-15&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-15 addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing and contingent consideration payments made after a business combination. ASU 2016-15 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-15 to have a material impact on our Consolidated Statements of Cash Flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2016, the FASB issued ASU No.&amp;#160;2016-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-18&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-18 to have a material impact on our Consolidated Statements of Cash Flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&amp;#160;2017-04,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&amp;#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2017-04&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU No.&amp;#160;2017-09,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2017-09&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-09 streamlines the application of modification accounting by stating that when making a change to the terms or conditions of a share-based payment award, a company should apply modification accounting to the award, unless each of the following conditions is met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, and 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2017-09 to have a material impact on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="D2017Q4FYYTD" id="Fact-1F9ADFD596566B725103B6B5E7F156FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (&amp;#8220;Exelixis,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;our&amp;#8221; or &amp;#8220;us&amp;#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products discovered at&amp;#160;Exelixis&amp;#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX&amp;#174;&amp;#160;(cabozantinib) tablets approved for advanced renal cell carcinoma (&amp;#8220;RCC&amp;#8221;) and COMETRIQ&amp;#174;&amp;#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&amp;#174; (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc. (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&amp;#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&amp;#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&amp;#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain prior period amounts on the accompanying Consolidated Financial Statements have been reclassified to conform to current period presentation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net on the accompanying Consolidated Statements of Operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments on the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were insignificant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 1 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 2 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 3 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair values are determined utilizing &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory related costs are recognized as Cost of goods sold on the accompanying Consolidated Statements of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets on the accompanying Consolidated Balance Sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. Only once regulatory approval is obtained, would we begin capitalization of these inventory related costs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7 to 15 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&amp;#8217;s goodwill exceeds its implied fair value. We continue to operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We did &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any impairment charges in any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018. For information on our adoption of ASU 2014-09, see &amp;#8220;- Recent Accounting Pronouncements,&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; below&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and title has transferred or services have been performed; the price is fixed or determinable; and collectability of the resulting receivable is reasonably assured. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize net product revenues upon delivery of the product and when there are no remaining customer acceptance requirements which is frequently referred to as the &amp;#8220;sell-in&amp;#8221; revenue recognition model. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&amp;#160;trade allowances, such as discounts for prompt payment; (b)&amp;#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations generally purchase the product at a discounted price. The specialty pharmacy or distributor, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The specialty pharmacies and distributors in the U.S. receive a discount of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect the specialty pharmacies and distributors will earn &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; pay fees to our customers for account management, data management and other administrative services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty pharmacies and distributors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to our customers, plus an accrual balance for known prior quarter&amp;#8217;s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also includes the Medicare Part&amp;#160;D Coverage Gap&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the U.S., the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&amp;#160;D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&amp;#160;D coverage gap are based in part on historical utilization rates, specialty pharmacy and distributor customer and payer data and third-party market research data. We also estimate when eligible patients who are prescribed our product enter and exit the insurance coverage gap. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarters&amp;#8217; shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and discounts for prompt payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other customer credits/fees and co-pay assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Rebates and fees due to customers on the accompanying Consolidated Balance Sheets. Balances as of December 31, 2016 have been reclassified to reflect that presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Collaboration Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration agreements under which we may obtain upfront license fees, milestone, royalty, development cost reimbursements, and/or product supply payments. These arrangements have multiple elements, and our deliverables may include intellectual property rights, distribution rights, delivery of manufactured product, commercial and development activities and participation on joint steering, commercial and development committees. In order to account for these arrangements, we identify the deliverables and evaluate whether the delivered elements have value to our collaboration partner on a stand-alone basis and represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver future goods or services, a right or license to use an asset, or another performance obligation. If we determine that multiple deliverables exist, the consideration is allocated to one or more units of accounting based upon the best estimate of the selling price of each deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement will be combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue then will be determined for those combined deliverables as a single unit of accounting. For a combined unit of accounting, non-refundable upfront fees are recognized in a manner consistent with the final deliverable, which has generally been ratably over the period of our continued involvement. Amounts received in advance of performance are recorded as deferred revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record royalty revenues based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Historically, adjustments have not been material when compared to actual amounts paid by licensees. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases in revenue are generally considered to be changes in estimates and will be reflected in the period they become known. If we are unable to reasonably estimate royalty revenue, we record royalty revenues when they are received. We consider sales-based contingent payments to be royalty revenue which is generally recognized at the date the contingency is achieved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our product supply revenues are recognized upon delivery of the product. See &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; for a description of our product supply agreements with our collaboration partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For certain milestone payments under collaboration agreements, we have made a policy election to recognize revenue using the milestone method. A milestone is an event: (i)&amp;#160;that can be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii)&amp;#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&amp;#160;that would result in additional payments being due to us. The determination that a milestone is substantive requires estimation and judgment and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is: (i)&amp;#160;commensurate with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from our performance to achieve the milestone, (ii)&amp;#160;relates solely to past performance and (iii)&amp;#160;reasonable relative to all deliverables and payment terms in the arrangement. In making the determination as to whether a milestone is substantive or not, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. A substantive milestone is recognized as revenue in its entirety in the period in which the milestone is achieved. A non-substantive milestone is recognized as revenues over the estimated period of our continued involvement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are also entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are entitled to low double-digit royalties on ex-U.S. net sales. See &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; for additional information about our collaboration agreement with Genentech. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. As of December 31, 2017, we have not recognized a profit for any year to date period from the commercialization of cobimetinib in the U.S. Until we have recognized a profit under the agreement, losses are recognized as Selling, general and administrative expenses on the accompanying Consolidated Statements of Operations. In connection with our agreement to co-promote with Genentech, we were responsible for providing up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the sales force necessary to assist with the promotion of cobimetinib. Genentech reimburses us for these costs which we include as a reduction of our Selling, general and administrative costs when the obligations are incurred or we become entitled to the cost recovery.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Patient Assistance Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We provide CABOMETYX and COMETRIQ at no cost to eligible patients who have no insurance and meet certain financial and clinical criteria through our patient assistance programs. We record the cost of the product as a selling, general and administrative expense at the time the product is shipped to the specialty pharmacy for patient assistance use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost of Goods Sold&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cost of goods sold is related to our product revenues and consists primarily of a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty on sales of any product incorporating cabozantinib payable to GlaxoSmithKline (&amp;#8220;GSK&amp;#8221;), indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. A portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ and CABOMETYX and therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. See &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; for additional information on the royalty payable to GSK on sales of any product incorporating cabozantinib.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Foreign Currency Translation and Remeasurement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other expenses, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The expense for stock-based compensation is based on the grant date fair value of the award; the grant date fair value of Restricted Stock Units (&amp;#8220;RSUs&amp;#8221;) is estimated as the value of the underlying shares of our common stock and the grant date fair value of stock-options is estimated using the Black-Scholes Merton option pricing model. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on a straight-line basis over the requisite service period. Compensation expense relating to awards subject to performance conditions is recognized if it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2016-09,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-09&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences and classification on the statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, with a cumulative adjustment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to accumulated deficit and additional paid-in capital as of January 1, 2017. No prior periods were restated as a result of this change in accounting principle. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on the accompanying Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in operating cash flows of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; along with a corresponding decrease in financing cash flows on the accompanying Consolidated Statement of Cash Flows for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our income tax provision is computed under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;together with assessing carry-forwards &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;an unrecognized tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued ASU No. 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2014-09&amp;#8221;).&amp;#160;In August 2015, the FASB issued ASU No. 2015-14, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which delayed the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, which is when we will adopt the standard. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of net product revenues. ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration agreements with Ipsen Pharma SAS (&amp;#8220;Ipsen&amp;#8221;) and Takeda Pharmaceutical Company Ltd. (&amp;#8220;Takeda&amp;#8221;). We will record a net adjustment of approximately &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$260 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accumulated deficit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(a concept known as &amp;#8220;lost revenue&amp;#8221;) for amounts associated with these collaboration agreements upon recording our transition adjustment in the first quarter of 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration agreements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU No.&amp;#160;2016-02,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Leases (Topic 842),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-02&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require both types of leases to be recognized on the balance sheet. The ASU also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 is effective for us for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. We are in the process of assessing the impact of ASU No. 2016-02 on our Consolidated Financial Statements and are considering early adoption of this standard in the first half of 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In August 2016, the FASB issued ASU No.&amp;#160;2016-15,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-15&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-15 addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing and contingent consideration payments made after a business combination. ASU 2016-15 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-15 to have a material impact on our Consolidated Statements of Cash Flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2016, the FASB issued ASU No.&amp;#160;2016-18,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-18&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-18 to have a material impact on our Consolidated Statements of Cash Flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&amp;#160;2017-04,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&amp;#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2017-04&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, the FASB issued ASU No.&amp;#160;2017-09,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2017-09&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-09 streamlines the application of modification accounting by stating that when making a change to the terms or conditions of a share-based payment award, a company should apply modification accounting to the award, unless each of the following conditions is met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, and 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2017-09 to have a material impact on our Consolidated Financial Statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="D2017Q4FYYTD" id="Fact-C34DD31E79114361BBAF8B01FA2C5A09">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain prior period amounts on the accompanying Consolidated Financial Statements have been reclassified to conform to current period presentation. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-B0D8E7407BDCFEFE583EB6B5EA68BD36">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(24,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Depreciation expense was &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Build-to-Suit Lease &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On May 2, 2017, we entered into a Lease Agreement (the &amp;#8220;Lease&amp;#8221;) with Ascentris 105, LLC (&amp;#8220;Ascentris&amp;#8221;), to lease &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;110,783&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of space in office and research facilities located at 1751, 1801, and 1851 Harbor Bay Parkway, Alameda, California (the &amp;#8220;Premises&amp;#8221;). On October 16, 2017, we executed an amendment to the Lease for &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;19,778&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of additional space located at the Premises with terms consistent with the original Lease. See &amp;#8220;Note 12. Commitments&amp;#8221; for a description of the Lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In connection with the Lease, we received a tenant improvement allowance of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$7.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; from Ascentris, for the costs associated with the design, development and construction of tenant improvements for the Premises. We are obligated to fund all costs incurred in excess of the tenant improvement allowance and to certain indemnification obligations related to the construction activities. We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises including the building shells did not qualify as &amp;#8220;normal tenant improvements&amp;#8221; under Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 840, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Accordingly, for accounting purposes, we are the deemed owner of such portions of the Premises during the construction period. As such, we will capitalize the construction costs as a build-to-suit property within property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. The capitalized construction costs will also include the estimated tenant improvements incurred by Ascentris. Accordingly, we capitalized &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of costs related to the Lease in construction in progress as of May 2, 2017, with a corresponding build-to-suit lease obligation in Other long-term liabilities. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have capitalized an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$6.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of construction in progress for tenant improvements related to the Premises. As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have also prepaid an additional &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for future constructions costs which is included in Other long-term assets on the accompanying Consolidated Balance Sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Once the construction is complete, we will consider the requirements for sale-leaseback accounting treatment, including evaluating whether all risks of ownership have been transferred back to Ascentris, as evidenced by a lack of continuing involvement in the leased property. If the arrangement does not qualify for sale-leaseback accounting treatment, the building assets will remain on the accompanying Consolidated Balance Sheets at their historical cost.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-0AB2A19EDD0F2030AB89B6B5E7F1401A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:200px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Estimated Useful Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;7 to 15 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="D2017Q4FYYTD" id="Fact-9A7C8CAA3B4E2B4F1A51B6B5EA687D42">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,715&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,646&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,609&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;48,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;26,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(22,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(24,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="D2017Q4FYYTD" id="Fact-3B21C420B51169EB9DBBB6B5ED59E5AC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;120,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;84,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;77,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;62,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;36,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;30,058&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income (loss) from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(25,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,135&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;35,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(59,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross profit is computed as Net product revenues less Cost of goods sold. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2016 Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&amp;#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$18.7 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of disputed costs that had been accrued by us as of September 30, 2016; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the quarter ended December 31, 2016, we offset Selling, general and administrative expenses for a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$23.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; recovery of net losses which had been recorded from 2013 through September 30, 2016, which included &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$9.8 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of losses that we had recognized and recorded during the three quarters ended September 30, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="D2017Q4FYYTD" id="Fact-D97505F4251046DC5B62B6B5E7F1E5D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-99563BD67344E716560BB46735485C12">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues earned by geographic region were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;367,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;35,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Rest of the world&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
	<us-gaap:RevenueRecognitionAllowances contextRef="D2017Q4FYYTD" id="Fact-A8F97022B99B8AC8E3568AC34E11B6DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and discounts for prompt payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other customer credits/fees and co-pay assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionAllowances>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="D2017Q4FYYTD" id="Fact-648DA73CB0E166AFFFC7B6B5E7F12086">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018. For information on our adoption of ASU 2014-09, see &amp;#8220;- Recent Accounting Pronouncements,&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; below&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and title has transferred or services have been performed; the price is fixed or determinable; and collectability of the resulting receivable is reasonably assured. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Net Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recognize net product revenues upon delivery of the product and when there are no remaining customer acceptance requirements which is frequently referred to as the &amp;#8220;sell-in&amp;#8221; revenue recognition model. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&amp;#160;trade allowances, such as discounts for prompt payment; (b)&amp;#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Chargebacks: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations generally purchase the product at a discounted price. The specialty pharmacy or distributor, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Discounts for Prompt Payment: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The specialty pharmacies and distributors in the U.S. receive a discount of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for prompt payment. We expect the specialty pharmacies and distributors will earn &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Customer Credits: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; pay fees to our customers for account management, data management and other administrative services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Co-payment Assistance: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty pharmacies and distributors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Rebates: &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&amp;#8217;s shipments to our customers, plus an accrual balance for known prior quarter&amp;#8217;s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Allowances for rebates also includes the Medicare Part&amp;#160;D Coverage Gap&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the U.S., the&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Medicare Part&amp;#160;D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part&amp;#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&amp;#160;D coverage gap are based in part on historical utilization rates, specialty pharmacy and distributor customer and payer data and third-party market research data. We also estimate when eligible patients who are prescribed our product enter and exit the insurance coverage gap. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarters&amp;#8217; shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Chargebacks and discounts for prompt payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other customer credits/fees and co-pay assistance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rebates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;251&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,056&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,802&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,627&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(351&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,641&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;5,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Rebates and fees due to customers on the accompanying Consolidated Balance Sheets. Balances as of December 31, 2016 have been reclassified to reflect that presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Collaboration Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration agreements under which we may obtain upfront license fees, milestone, royalty, development cost reimbursements, and/or product supply payments. These arrangements have multiple elements, and our deliverables may include intellectual property rights, distribution rights, delivery of manufactured product, commercial and development activities and participation on joint steering, commercial and development committees. In order to account for these arrangements, we identify the deliverables and evaluate whether the delivered elements have value to our collaboration partner on a stand-alone basis and represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver future goods or services, a right or license to use an asset, or another performance obligation. If we determine that multiple deliverables exist, the consideration is allocated to one or more units of accounting based upon the best estimate of the selling price of each deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement will be combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue then will be determined for those combined deliverables as a single unit of accounting. For a combined unit of accounting, non-refundable upfront fees are recognized in a manner consistent with the final deliverable, which has generally been ratably over the period of our continued involvement. Amounts received in advance of performance are recorded as deferred revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We record royalty revenues based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Historically, adjustments have not been material when compared to actual amounts paid by licensees. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases in revenue are generally considered to be changes in estimates and will be reflected in the period they become known. If we are unable to reasonably estimate royalty revenue, we record royalty revenues when they are received. We consider sales-based contingent payments to be royalty revenue which is generally recognized at the date the contingency is achieved. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our product supply revenues are recognized upon delivery of the product. See &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; for a description of our product supply agreements with our collaboration partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For certain milestone payments under collaboration agreements, we have made a policy election to recognize revenue using the milestone method. A milestone is an event: (i)&amp;#160;that can be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii)&amp;#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&amp;#160;that would result in additional payments being due to us. The determination that a milestone is substantive requires estimation and judgment and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is: (i)&amp;#160;commensurate with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from our performance to achieve the milestone, (ii)&amp;#160;relates solely to past performance and (iii)&amp;#160;reasonable relative to all deliverables and payment terms in the arrangement. In making the determination as to whether a milestone is substantive or not, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. A substantive milestone is recognized as revenue in its entirety in the period in which the milestone is achieved. A non-substantive milestone is recognized as revenues over the estimated period of our continued involvement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are also entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are entitled to low double-digit royalties on ex-U.S. net sales. See &amp;#8220;Note 2. Collaboration Agreements&amp;#8221; for additional information about our collaboration agreement with Genentech. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. As of December 31, 2017, we have not recognized a profit for any year to date period from the commercialization of cobimetinib in the U.S. Until we have recognized a profit under the agreement, losses are recognized as Selling, general and administrative expenses on the accompanying Consolidated Statements of Operations. In connection with our agreement to co-promote with Genentech, we were responsible for providing up to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the sales force necessary to assist with the promotion of cobimetinib. Genentech reimburses us for these costs which we include as a reduction of our Selling, general and administrative costs when the obligations are incurred or we become entitled to the cost recovery.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Patient Assistance Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We provide CABOMETYX and COMETRIQ at no cost to eligible patients who have no insurance and meet certain financial and clinical criteria through our patient assistance programs. We record the cost of the product as a selling, general and administrative expense at the time the product is shipped to the specialty pharmacy for patient assistance use.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="D2017Q4FYYTD" id="Fact-42BD5C1771706F7AC935B6B5ECCC106D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Potentially dilutive shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive were as follows (in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;28,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deerfield Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2014 Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2019 Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;54,118&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;62,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;117,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-FAADEA3343978254165BD278EA6F56F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,413&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Milestones achieved&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of upfront payments and deferred milestone&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,831&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product supply agreement revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cost of supplied product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(6,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,555&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty payable to GSK on net sales by Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues under the collaboration agreement with Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales of COTELLIC&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(2,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(16,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of upfront payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Development cost reimbursements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product supply agreement revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues under the collaboration agreement with Takeda&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-B83A048BFB03DDA0C540B6B5ECAC0AED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total current tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-9695E3886D914A64AC56B6B5EAC7B810">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The amortized carrying amount of our debt was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;109,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Term loan payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;189,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-25902AF6E78BD4AC31D3B6B5ECACEF26">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our deferred tax assets and liabilities were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net operating loss carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;244,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;471,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Book over tax depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;39,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tax credit and charitable contribution carry-forwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;66,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;64,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53,543&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Amortization of deferred stock compensation &amp;#8211; non-qualified&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accruals and reserves not currently deductible&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,914&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;629,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(418,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(629,062&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Unrealized gains on derivatives and other liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net deferred taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-A7D9757657F82AD70C1AB6B5ECCC6D89">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;154,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,860&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Adjustment to net income allocated to participating securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income allocable to common stock for diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;153,882&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;293,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;209,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Outstanding stock options, unvested RSUs and ESPP contributions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;312,003&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;250,531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;209,227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-D003DC036B0A69E4F31DB6B5ECAC9F92">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The reconciliation of income taxes at the statutory federal income tax rate to our Provision for income taxes included on the accompanying Consolidated Statements of Operations was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. federal income tax provision (benefit) at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;53,916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23,876&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(54,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(34,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;51,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;State tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt extinguishment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,726&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Non-deductible interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(20,548&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D2017Q4FYYTD" id="Fact-370A9C6918213E679145B6B5EC1E8DE3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The allocation of stock-based compensation for our equity incentive plans and our &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;Employee Stock Purchase Plan (the &amp;#8220;ESPP&amp;#8221;) was as&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,546&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;10,286&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="D2017Q4FYYTD" id="Fact-547506B785BE715E91D2B4662F419B1C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues by product were as follows (dollars in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;324,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;41,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;349,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
	<us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock contextRef="D2017Q4FYYTD" id="Fact-71EE110531FB72CCA5B0B6B5EAC737A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A summary of loss on extinguishment of debt for the conversion and redemption of the 2019 Notes was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash inducements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Waiver of requirement to repay interest, described above&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,572&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Unamortized discount on redeemed notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Third-party costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Loss on extinguishment of debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-A721A2548ABC0974600CB6B5ECEB4E75">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the aggregate future minimum lease payments under our leases were as follows (in thousands):&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:72%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Operating leases&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other financing obligations&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Year ending December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;664&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;704&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;12,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,340&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other financing obligations includes payments related to our build-to-suit lease.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-AF62FF134C4AA4406050B6B5ECAC8679">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes was based on the following income (loss) before income taxes (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;158,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(150,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(10,843&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income (loss) before income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;158,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(70,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(161,689&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-0CBDC967AFA8C5878761B6B5EA59C18E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other long-term assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;692&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;606&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,349&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,944&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-18B20FED1E2240C89987B6B5EC2E2BE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A summary of all RSU activity were as follows (dollars in thousands, except per share amounts):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awards outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,469,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,137,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(708,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(136,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awards outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,762,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.95 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;114,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-AC6383D6FEEE1FF0A361B6B5ED592DF4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;120,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;99,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;80,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;91,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;84,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;37,431&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,180&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;27,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;20,186&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;81,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.06&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;77,581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;62,194&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;36,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross profit &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;50,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;40,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;30,058&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Income (loss) from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;38,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(25,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(49,135&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;35,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(11,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(34,838&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(59,223&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(0.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Gross profit is computed as Net product revenues less Cost of goods sold. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRentExpenseTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-42106B700427AFFFF646B46143E4ED37">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Rent expense and sublease income were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9,676&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;13,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;less: Sublease income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(1,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(3,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(5,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net rental expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6,123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,737&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRentExpenseTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-F9F12A5FF339AE8DA8A7B6B5EC2E5487">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Stock option activity for the &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;year ended&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;24,999,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,166,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;23.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(4,469,203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(229,793&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(258,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;22,208,446&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.05 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;523,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,158,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3.46 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;418,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-47830ABD8029104E740AB6B5EC2E1D0E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-156795169FB7559F0C8CB6B5EC2E6708">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.4 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;0.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6 months&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-CF145E30FE62AA663B33B6B5ECAC47BC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The following table summarizes the activity related to our unrecognized tax benefits (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;58,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to prior year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;247&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(29,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;21,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Change relating to current year provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;8,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Reductions based on the lapse of the applicable statutes of limitations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;79,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;61,809&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;88,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="D2017Q4FYYTD" id="Fact-5444FBDFEC0AFC85F69FB6B5ED0A1242">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-F1D38032560F4DE15751B4647B74A998">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;SEGMENT INFORMATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment which focuses on &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Enterprise-wide disclosures about product sales, revenues from major customers, revenues and long-lived assets by geographic area are presented below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues by product were as follows (dollars in thousands):&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;324,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;93,481&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;25,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;41,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;349,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;135,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;34,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues earned by geographic region were as follows (dollars in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;367,906&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;140,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;33,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;69,792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;35,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Rest of the world&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to regions based on ship-to location and Collaboration revenues are attributed to regions based on the location of the collaboration partner.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; loss, a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; loss and a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; gain relating to foreign exchange fluctuations for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-5D9BC97AFBA4EAEA0503B6B5EC2EA71A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The weighted average grant-date fair value of our stock option grants and ESPP purchases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;4.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;1.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="D2017Q4FYYTD" id="Fact-C83CD615C1AEA611BD26B6B5E7F1CA20">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The expense for stock-based compensation is based on the grant date fair value of the award; the grant date fair value of Restricted Stock Units (&amp;#8220;RSUs&amp;#8221;) is estimated as the value of the underlying shares of our common stock and the grant date fair value of stock-options is estimated using the Black-Scholes Merton option pricing model. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on a straight-line basis over the requisite service period. Compensation expense relating to awards subject to performance conditions is recognized if it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we adopted Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2016-09,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASU 2016-09&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences and classification on the statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, with a cumulative adjustment of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to accumulated deficit and additional paid-in capital as of January 1, 2017. No prior periods were restated as a result of this change in accounting principle. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on the accompanying Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in operating cash flows of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; along with a corresponding decrease in financing cash flows on the accompanying Consolidated Statement of Cash Flows for the years ended &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D2017Q4FYYTD" id="Fact-1087AC99BF7A0393BF33B6B5EB15DA30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;COMMON STOCK AND WARRANTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Conversion of Debt into Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Between August and November 2016, we issued &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;54,009,279&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of our common stock pursuant to the conversion of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$286.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of aggregate principal amount of the 2019 Notes. The conversions resulted in a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$253.1 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; increase to shareholder&amp;#8217;s equity and a &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$13.9 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; loss on extinguishment of debt. See &amp;#8220;Note 6. Debt&amp;#8221; for more information on the conversion of the 2019 Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Sale of Shares of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In July 2015, we completed a registered underwritten public offering of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;28,750,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of our common stock, including &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;3,750,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares issued under the underwriters&amp;#8217; 30-day option to buy shares, at a price of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$5.40&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per share pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission, which was filed and automatically became effective on July 1, 2015. We received &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$145.6 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in net proceeds from the offering after deducting the underwriting discount and other expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2014 Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In connection with an amendment to the note purchase agreement for the Secured Convertible Notes due 2015, (the &amp;#8220;Original Deerfield Notes&amp;#8221;), in January 2014 we issued &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;-year warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of our common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$9.70&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per share (the &amp;#8220;2014 Warrants&amp;#8221;). Subsequent to our March 2015 notification of our election to extend the maturity date of the Deerfield Notes, the exercise price of the 2014 Warrants was reset to &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$3.445&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per share, the term was extended by &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to January 22, 2018, and the 2014 Warrants were transferred to Additional paid-in capital as of that date at their then estimated fair value of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as their terms had become fixed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On September 11, 2017, we issued an aggregate of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;877,451&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares of common stock pursuant to the cashless exercises of the 2014 Warrants issued to an accredited investor transferee. The number of shares issued upon exercise was net of &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;122,549&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares withheld to effect the cashless exercise of the 2014 Warrants in accordance with their terms. As of December 31, 2017, there are &lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; remaining warrants outstanding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="D2017Q4FYYTD" id="Fact-C35E272B39C2C27F375B8B05265FE932">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were insignificant. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="D2017Q4FYYTD" id="Fact-C7CB98F217F9BB8BDA3DB6B5EA39F014">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;45,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;199,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,336&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;179,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;16,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;440,410&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;71,457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;165,375&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;152,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;70,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;460,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;(322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;459,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="D2017Q4FYYTD" id="Fact-5F702F55C06D460E0C2CB6B5E7F168E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-50A859C6335DBD9A396FB6B5E5BF1CCD" xlink:label="Fact-50A859C6335DBD9A396FB6B5E5BF1CCD_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-909C5D4FFD3004F50D15B6B5E5CF606F" xlink:label="Fact-909C5D4FFD3004F50D15B6B5E5CF606F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BC98CDBED18549A40A00B6B5E5CFEF87" xlink:label="Fact-BC98CDBED18549A40A00B6B5E5CFEF87_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-50A859C6335DBD9A396FB6B5E5BF1CCD_lbl" xlink:to="Footnote-FAE331AEF8A47DD61660B6B5E5CFEB8E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-909C5D4FFD3004F50D15B6B5E5CF606F_lbl" xlink:to="Footnote-FAE331AEF8A47DD61660B6B5E5CFEB8E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BC98CDBED18549A40A00B6B5E5CFEF87_lbl" xlink:to="Footnote-FAE331AEF8A47DD61660B6B5E5CFEB8E_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-FAE331AEF8A47DD61660B6B5E5CFEB8E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income (loss) during the periods presented.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>exel-20171229.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20171229" xmlns:exel="http://www.exelixis.com/20171229" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20171229_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20171229_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20171229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20171229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2102100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenueTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails">
        <link:definition>2402405 - Disclosure - Collaboration Agreements (Collaboration Revenue - Takeda) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails">
        <link:definition>2402407 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesGskDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails">
        <link:definition>2402409 - Disclosure - Collaboration Agreements (Collaboration Revenues - GSK) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails">
        <link:definition>2402403 - Disclosure - Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsGenentechCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails">
        <link:definition>2402406 - Disclosure - Collaboration Agreements (Genentech Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails">
        <link:definition>2402402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails">
        <link:definition>2402408 - Disclosure - Collaboration Agreements (Other Collaborations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2302301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails">
        <link:definition>2402404 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.exelixis.com/role/Commitments">
        <link:definition>2114100 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails">
        <link:definition>2414404 - Disclosure - Commitments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails">
        <link:definition>2414402 - Disclosure - Commitments (Schedule of Aggregate Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails">
        <link:definition>2414403 - Disclosure - Commitments (Schedule of Rent Expense and Sublease Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsTables" roleURI="http://www.exelixis.com/role/CommitmentsTables">
        <link:definition>2314301 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockAndWarrants" roleURI="http://www.exelixis.com/role/CommonStockAndWarrants">
        <link:definition>2109100 - Disclosure - Common Stock and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockAndWarrantsNarrativeDetails" roleURI="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails">
        <link:definition>2409401 - Disclosure - Common Stock and Warrants (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical">
        <link:definition>1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.exelixis.com/role/Debt">
        <link:definition>2108100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt2019NotesDetails" roleURI="http://www.exelixis.com/role/Debt2019NotesDetails">
        <link:definition>2408404 - Disclosure - Debt (2019 Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfDebtDetails" roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails">
        <link:definition>2408402 - Disclosure - Debt (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuredConvertibleNotesDetails" roleURI="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails">
        <link:definition>2408403 - Disclosure - Debt (Secured Convertible Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryOfLossOnExtinguishmentOfDebtDetails" roleURI="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails">
        <link:definition>2408405 - Disclosure - Debt (Summary of Loss on Extinguishment of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.exelixis.com/role/DebtTables">
        <link:definition>2308301 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTermLoanPayableDetails" roleURI="http://www.exelixis.com/role/DebtTermLoanPayableDetails">
        <link:definition>2408406 - Disclosure - Debt (Term Loan Payable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2113100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2413404 - Disclosure - Fair Value Measurements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails">
        <link:definition>2413403 - Disclosure - Fair Value Measurements (Schedule of Estimated Fair Value of Outstanding Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails">
        <link:definition>2413402 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2313301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2111100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>2411403 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2411406 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails">
        <link:definition>2411402 - Disclosure - Income Taxes (Schedule of Consolidated Net Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails">
        <link:definition>2411405 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails">
        <link:definition>2411404 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>2411407 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.exelixis.com/role/IncomeTaxesTables">
        <link:definition>2311301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2106100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryDetails" roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails">
        <link:definition>2406402 - Disclosure - Inventory (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleOfInventoryDetailsCalc2" roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2">
        <link:definition>2406402 - Disclosure - Inventory (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2306301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.exelixis.com/role/Investments">
        <link:definition>2105100 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsGrossUnrealizedLossesDetails" roleURI="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails">
        <link:definition>2405404 - Disclosure - Investments (Gross Unrealized Losses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/InvestmentsNarrativeDetails">
        <link:definition>2405402 - Disclosure - Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails">
        <link:definition>2405405 - Disclosure - Investments (Summary by Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails">
        <link:definition>2405403 - Disclosure - Investments (Summary by Security Type) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.exelixis.com/role/InvestmentsTables">
        <link:definition>2305301 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare">
        <link:definition>2112100 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>2412402 - Disclosure - Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails">
        <link:definition>2412403 - Disclosure - Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareTables" roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails">
        <link:definition>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies (Allowance Reserve) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails">
        <link:definition>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2107100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2407403 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2307301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2119100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedNarrativeDetails" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails">
        <link:definition>2419403 - Disclosure - Quarterly Financial Data (Unaudited) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails">
        <link:definition>2419402 - Disclosure - Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2319301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.exelixis.com/role/SegmentInformation">
        <link:definition>2118100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationConcentrationRiskByCustomerDetails" roleURI="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails">
        <link:definition>2418404 - Disclosure - Segment Information (Concentration Risk by Customer) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuesFromGeographicRegionsDetails" roleURI="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails">
        <link:definition>2418405 - Disclosure - Segment Information (Revenues from Geographic Regions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleOfRevenuesByCustomerDetails" roleURI="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails">
        <link:definition>2418403 - Disclosure - Segment Information (Schedule of Revenues by Customer) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentInformationNarrativeDetails" roleURI="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails">
        <link:definition>2418402 - Disclosure - Segment Information Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.exelixis.com/role/SegmentInformationTables">
        <link:definition>2318301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2110100 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2410402 - Disclosure - Stock-based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2410403 - Disclosure - Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails">
        <link:definition>2410405 - Disclosure - Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAllRsuActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails">
        <link:definition>2410407 - Disclosure - Stock-based Compensation (Summary of All RSU Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfAllStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails">
        <link:definition>2410406 - Disclosure - Stock-based Compensation (Summary of All Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2310301 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails">
        <link:definition>2410404 - Disclosure - Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AkarnaTherapeuticsLtd.Member" name="AkarnaTherapeuticsLtd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AlamedaCaliforniaMember" name="AlamedaCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment" name="AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_BuildingShellsMember" name="BuildingShellsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CIPdeemedacquiredinBuildtoSuitLease" name="CIPdeemedacquiredinBuildtoSuitLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CapitalLeaseandOtherFinancingLeaseMember" name="CapitalLeaseandOtherFinancingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalandOperatingLeasesNumberofOptionstoTerminate" name="CapitalandOperatingLeasesNumberofOptionstoTerminate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalandOperatingLeasesNumberofRenewalOptions" name="CapitalandOperatingLeasesNumberofRenewalOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty" name="CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CaremarkL.L.C.Member" name="CaremarkL.L.C.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinControlandSeveranceBenefitPlanMember" name="ChangeinControlandSeveranceBenefitPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChargebacksandPromptPaymentMember" name="ChargebacksandPromptPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ClassofWarrantorRightPeriod" name="ClassofWarrantorRightPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" name="CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementDevelopmentCostReimbursements" name="CollaborativeArrangementDevelopmentCostReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossfromAgreement" name="CollaborativeArrangementIncomeLossfromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementShareinCostsPercentage" name="CollaborativeArrangementShareinCostsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithBMSMember" name="CollaborativeArrangementwithBMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithDaiichiSankyoMember" name="CollaborativeArrangementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" name="CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithMerckMember" name="CollaborativeArrangementwithMerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" name="CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollateralProvidedForPurchasingCardProgram" name="CollateralProvidedForPurchasingCardProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ContractRevenueMember" name="ContractRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" name="ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CostMethodInvestmentOwnershipPercentage" name="CostMethodInvestmentOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CotellicMember" name="CotellicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CouponInterestMember" name="CouponInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" name="DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtInstrumentNumberofInstruments" name="DebtInstrumentNumberofInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DebtInstrumentPrepaymentPenalty" name="DebtInstrumentPrepaymentPenalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtInstrumentRedemptionofConvertibleDebtAmount" name="DebtInstrumentRedemptionofConvertibleDebtAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" name="DebtInstrumentsUnamortizedClosingFeesAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DeferredRevenueRecognitionPeriod" name="DeferredRevenueRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" name="DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_DefinedContributionPlanNumberofSharesAvailableforGrant" name="DefinedContributionPlanNumberofSharesAvailableforGrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_DiplomatSpecialtyPharmacyMember" name="DiplomatSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_DiscountsandAllowances" name="DiscountsandAllowances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" name="EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_EquipmentAndFurnitureMember" name="EquipmentAndFurnitureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue" name="ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ExtinguishmentofDebtIncludingPaidinKindInterest" name="ExtinguishmentofDebtIncludingPaidinKindInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts" name="ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinalTierMember" name="FinalTierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlobalMember" name="GlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_HCCAcceptanceMember" name="HCCAcceptanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_HCCFilingMember" name="HCCFilingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseAccruedClinicalLiabilities" name="IncreaseDecreaseAccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseinAccruedCollaborationLiability" name="IncreaseDecreaseinAccruedCollaborationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InducedConversionofConvertibleDebtExpenseAbstract" name="InducedConversionofConvertibleDebtExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" name="InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InitialMember" name="InitialMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InterestPaymentTypeAxis" name="InterestPaymentTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_InterestPaymentTypeDomain" name="InterestPaymentTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue" name="LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm" name="LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract" name="LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LossonExtinguishmentofDebtTransactionCosts" name="LossonExtinguishmentofDebtTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" name="MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_MaximumPotentialMilestonePayments" name="MaximumPotentialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveAxis" name="MilestoneObjectiveAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_MilestoneObjectiveDomain" name="MilestoneObjectiveDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseMember" name="OperatingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseandOtherFinancingLeaseMember" name="OperatingLeaseandOtherFinancingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OptionalAmendmentAgreementMember" name="OptionalAmendmentAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherDiscountsMember" name="OtherDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PaymentOfReimbursementsFromCollaborationArrangement" name="PaymentOfReimbursementsFromCollaborationArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_PaymentandCreditsIssued" name="PaymentandCreditsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PaymentinKindInterestMember" name="PaymentinKindInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PaymentsforConversionofConvertibleDebt" name="PaymentsforConversionofConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_PaymentsforInducementsofDebtConversion" name="PaymentsforInducementsofDebtConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_PercentOfRoyaltyOnNetSale" name="PercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment" name="PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_PercentageofMaximumPotentialMilestonePaymentsCommercial" name="PercentageofMaximumPotentialMilestonePaymentsCommercial" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory" name="PercentageofMaximumPotentialMilestonePaymentsRegulatory" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_PerformanceStockOptionsMember" name="PerformanceStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_PeriodOfSpecificSalesVolumeThreshold" name="PeriodOfSpecificSalesVolumeThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedfromCabozantinibMember" name="ProductsDerivedfromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" name="ProfitSharingAgreementOptionalPercentOfTotalSalesForce" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementPercentOfProfits" name="ProfitSharingAgreementPercentOfProfits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ProfitSharingAgreementProfitThreshold" name="ProfitSharingAgreementProfitThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierOneMember" name="ProfitSharingTierOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierThreeMember" name="ProfitSharingTierThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTierTwoMember" name="ProfitSharingTierTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersAxis" name="ProfitSharingTiersAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProfitSharingTiersDomain" name="ProfitSharingTiersDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RebatesMember" name="RebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RecoveryOfExpensesExpensesInCurrentFiscalYear" name="RecoveryOfExpensesExpensesInCurrentFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear" name="RecoveryofExpensesExpensesPriortoCurrentFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" name="ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ReserveRollforwardRollForward" name="ReserveRollforwardRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RestofWorldMember" name="RestofWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RoyaltyTier" name="RoyaltyTier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierAxis" name="RoyaltytierAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_RoyaltytierDomain" name="RoyaltytierDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenueDiscountExpectedtobeEarnedPercent" name="SalesRevenueDiscountExpectedtobeEarnedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SalesRevenuePercentDiscountForPromptPayment" name="SalesRevenuePercentDiscountForPromptPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SanofiAventisMember" name="SanofiAventisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SecondMember" name="SecondMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SecuredConvertibleNotesDueJune2018Member" name="SecuredConvertibleNotesDueJune2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension" name="SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl" name="SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl" name="SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharesWithheldforConversionofWarrants" name="SharesWithheldforConversionofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SiliconValleyBankLoanAndSecurityAgreementMember" name="SiliconValleyBankLoanAndSecurityAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SouthSanFranciscoCaliforniaMember" name="SouthSanFranciscoCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" name="StandbyLetterOfCreditRelatedToBuildingLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" name="StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross" name="TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance" name="TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_TenantLeaseImprovementsAllowance" name="TenantLeaseImprovementsAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_UpfrontAndMilestonePayments" name="UpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" name="WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>exel-20171229_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20171229.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20171229.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20171229.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20171229.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:href="exel-20171229.xsd#CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:href="exel-20171229.xsd#CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20171229.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommonStockAndWarrants" xlink:href="exel-20171229.xsd#CommonStockAndWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails" xlink:href="exel-20171229.xsd#CommonStockAndWarrantsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20171229.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20171229.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt" xlink:href="exel-20171229.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt2019NotesDetails" xlink:href="exel-20171229.xsd#Debt2019NotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:href="exel-20171229.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails" xlink:href="exel-20171229.xsd#DebtSecuredConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:href="exel-20171229.xsd#DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTables" xlink:href="exel-20171229.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTermLoanPayableDetails" xlink:href="exel-20171229.xsd#DebtTermLoanPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20171229.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20171229.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20171229.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20171229.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20171229.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20171229.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20171229.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20171229.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20171229.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2" xlink:href="exel-20171229.xsd#InventoryScheduleOfInventoryDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20171229.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Investments" xlink:href="exel-20171229.xsd#Investments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20171229.xsd#InvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsNarrativeDetails" xlink:href="exel-20171229.xsd#InvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20171229.xsd#InvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20171229.xsd#InvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsTables" xlink:href="exel-20171229.xsd#InvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20171229.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20171229.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20171229.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20171229.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20171229.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20171229.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20171229.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20171229.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformation" xlink:href="exel-20171229.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails" xlink:href="exel-20171229.xsd#SegmentInformationConcentrationRiskByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:href="exel-20171229.xsd#SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:href="exel-20171229.xsd#SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails" xlink:href="exel-20171229.xsd#SegmentInformationSegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationTables" xlink:href="exel-20171229.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20171229.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20171229.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1f6ea3e9-2a9b-9570-265e-fe7de665524c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1f6ea3e9-2a9b-9570-265e-fe7de665524c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_dffd4b04-634b-3a6d-2c65-52b2bf4bbf15" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_RoyaltyRevenue_dffd4b04-634b-3a6d-2c65-52b2bf4bbf15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_05ca609c-5d87-898f-3376-5194cad9e4be" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_RoyaltyExpense_05ca609c-5d87-898f-3376-5194cad9e4be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_46413cd3-e44c-f902-d508-3a3681b9931f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_46413cd3-e44c-f902-d508-3a3681b9931f" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_646e659b-002b-7d7e-2f86-a4d7b1d06716" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_646e659b-002b-7d7e-2f86-a4d7b1d06716" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_38694d24-9bde-3c85-0262-b82030d7e61a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_38694d24-9bde-3c85-0262-b82030d7e61a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_729f77b8-2a9e-0142-52d3-9a6513fc6787" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_729f77b8-2a9e-0142-52d3-9a6513fc6787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_585c4efd-47a1-e7a2-64da-ace6ee154ecd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_585c4efd-47a1-e7a2-64da-ace6ee154ecd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_64c5f922-1f5f-cc1d-b281-f412a1fd922a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_64c5f922-1f5f-cc1d-b281-f412a1fd922a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_01dc36ce-445b-7f61-af51-1e46c58f3dee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_01dc36ce-445b-7f61-af51-1e46c58f3dee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_246b6201-33fc-c9d3-a60d-777ab787073b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_d42a3dad-23e9-d83e-cd05-0b20e0cdbc1f" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_246b6201-33fc-c9d3-a60d-777ab787073b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_043a006e-1044-5f7d-39af-f81e77758ab8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_us-gaap_LeaseAndRentalExpense_043a006e-1044-5f7d-39af-f81e77758ab8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_ef7b47fc-0378-cd73-c39b-e8af2d207ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_76028802-8840-5ab3-8fa9-9ae9f121d32c" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_ef7b47fc-0378-cd73-c39b-e8af2d207ec6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommonStockAndWarrants" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c7f7eb62-cfa0-f151-36ae-c1d591e39819" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c7f7eb62-cfa0-f151-36ae-c1d591e39819" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_3d7a448c-a43d-5ed6-40e5-a4d7b1565e4b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_3d7a448c-a43d-5ed6-40e5-a4d7b1565e4b" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_4262322a-2489-b411-eb38-a4d7b1a2b4b6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_4262322a-2489-b411-eb38-a4d7b1a2b4b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_734add4d-1361-7540-71cd-3913f8eb4085" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_734add4d-1361-7540-71cd-3913f8eb4085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_398178db-2a20-f509-e672-630b4bfd2e21" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_398178db-2a20-f509-e672-630b4bfd2e21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_189ed464-8269-5603-b7eb-5de9e1c3102b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_NotesPayableCurrent_189ed464-8269-5603-b7eb-5de9e1c3102b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_4261eb63-a0fe-7be1-e8a2-dcf5644ff056" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ReceivablesNetCurrent_4261eb63-a0fe-7be1-e8a2-dcf5644ff056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_742238c6-99b5-ec8f-811f-240c929f1974" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_742238c6-99b5-ec8f-811f-240c929f1974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3ec21982-5910-da92-94e7-46475f11e9f6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_3ec21982-5910-da92-94e7-46475f11e9f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_f3731d81-24aa-7428-8853-34b405ade4d0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockPlans_f3731d81-24aa-7428-8853-34b405ade4d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2b72fe5f-3c0e-d5e0-8e5c-ad01818e58e5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforConversionofConvertibleDebt" xlink:label="loc_exel_PaymentsforConversionofConvertibleDebt_9fbfe540-c889-d130-b241-ded3d6c872c7" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_exel_PaymentsforConversionofConvertibleDebt_9fbfe540-c889-d130-b241-ded3d6c872c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7ed6106-862d-edb5-3fd1-677e7651af64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7ed6106-862d-edb5-3fd1-677e7651af64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e6d6486e-82d1-24a8-4687-2a4e31bd898e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_e6d6486e-82d1-24a8-4687-2a4e31bd898e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_01ed7929-89fd-a15c-4c09-fffeb6bfce57" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_01ed7929-89fd-a15c-4c09-fffeb6bfce57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_e9aa6015-2f50-2aa5-4e39-ecac19d263b5" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_e9aa6015-2f50-2aa5-4e39-ecac19d263b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_d3d89aab-5be8-f6a4-66e9-41f55e0839cd" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_d3d89aab-5be8-f6a4-66e9-41f55e0839cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b49c7a2f-2986-824d-e7cb-bc082ac0e888" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b49c7a2f-2986-824d-e7cb-bc082ac0e888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_15394837-f38b-15ac-34b9-3c880d46492b" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_15394837-f38b-15ac-34b9-3c880d46492b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3db65903-3171-d63c-a688-532ba00b8108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e9a2cdf1-6f49-806b-7b55-b9320bcfa87f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e9a2cdf1-6f49-806b-7b55-b9320bcfa87f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_a475da0e-33d6-3035-9745-df51106bd7f7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_PaidInKindInterest_a475da0e-33d6-3035-9745-df51106bd7f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_df77eda3-f4a4-736d-7f34-64539d78db5d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_df77eda3-f4a4-736d-7f34-64539d78db5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_20f1ed35-6a0e-5b11-130c-ae721712c4a7" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_20f1ed35-6a0e-5b11-130c-ae721712c4a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c014c8e-ef65-6055-d342-3e048173d471" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c014c8e-ef65-6055-d342-3e048173d471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1db3941a-7187-c2ca-9a11-6155b0a4bd72" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1db3941a-7187-c2ca-9a11-6155b0a4bd72" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_bb173832-ab89-e3c6-b629-a4d7b19177ae" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_bb173832-ab89-e3c6-b629-a4d7b19177ae" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_c46af164-63f2-fbd2-b7ff-a4d7b168f873" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_c46af164-63f2-fbd2-b7ff-a4d7b168f873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7e3bb724-19f9-7fc7-d3fb-60f34a11e15a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_ContractsRevenue_f8bb9f35-75cb-5b04-38c9-16f74c5c5ce5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_b1917564-9f69-b82f-0545-2b32cc97d9dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestIncomeOther_b1917564-9f69-b82f-0545-2b32cc97d9dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Debt2019NotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DebtTermLoanPayableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_36ba223a-0466-98b6-2d31-f243492419f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d2250640-c0ab-3b70-41b7-136d9a4aad78" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_10028fc1-eee3-03f5-6f20-ff5d85e3c0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15bb8413-7c16-05ff-0f24-330007bd87a4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_15bb8413-7c16-05ff-0f24-330007bd87a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40691c72-4a6d-af64-c37e-f5abe38c6165" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_40691c72-4a6d-af64-c37e-f5abe38c6165" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_684e73bc-c774-15b7-cfc4-307e06892c2e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_684e73bc-c774-15b7-cfc4-307e06892c2e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_77aad584-eda7-6ab9-9bf4-262b9a6dd394" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_77aad584-eda7-6ab9-9bf4-262b9a6dd394" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c63966d8-8cd7-cadc-7cf6-f799677021d3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c63966d8-8cd7-cadc-7cf6-f799677021d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_573a84d7-ea77-e5cc-0a22-8ce37b1812cb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_573a84d7-ea77-e5cc-0a22-8ce37b1812cb" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_ddde94c3-5804-d670-1159-ded3d6f3a239" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_ddde94c3-5804-d670-1159-ded3d6f3a239" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_40c7d4a7-f1a1-0c55-497e-f9a3bb09604c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_644ceb1c-07ef-6a89-f014-9d7b5dfbc918" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_40c7d4a7-f1a1-0c55-497e-f9a3bb09604c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_553df36e-9753-8848-960f-086f1d52da7b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_553df36e-9753-8848-960f-086f1d52da7b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b1d9c48-50e9-fd05-543d-8637e0170a2a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_0b1d9c48-50e9-fd05-543d-8637e0170a2a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_871dac3c-b185-7cb7-edb4-30b0698d7c06" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_871dac3c-b185-7cb7-edb4-30b0698d7c06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_bd6cbacd-ff8a-9263-dfac-ded3d763b16b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_bd6cbacd-ff8a-9263-dfac-ded3d763b16b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_79bdd473-22d2-ef01-683b-1be9d9655f97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:to="loc_us-gaap_InventoryRawMaterials_79bdd473-22d2-ef01-683b-1be9d9655f97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1f11a0f3-903b-2881-9953-5b32589e626c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:to="loc_us-gaap_InventoryWorkInProcess_1f11a0f3-903b-2881-9953-5b32589e626c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_608e386b-8c6f-7cfc-fabb-123ca6d40239" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a1ccb7c0-548d-1a3f-2ef9-3c3b8989be64" xlink:to="loc_us-gaap_InventoryFinishedGoods_608e386b-8c6f-7cfc-fabb-123ca6d40239" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetailsCalc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Investments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>exel-20171229_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20171229.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20171229.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20171229.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20171229.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:href="exel-20171229.xsd#CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:href="exel-20171229.xsd#CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20171229.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommonStockAndWarrants" xlink:href="exel-20171229.xsd#CommonStockAndWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails" xlink:href="exel-20171229.xsd#CommonStockAndWarrantsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20171229.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20171229.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt" xlink:href="exel-20171229.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt2019NotesDetails" xlink:href="exel-20171229.xsd#Debt2019NotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:href="exel-20171229.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails" xlink:href="exel-20171229.xsd#DebtSecuredConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:href="exel-20171229.xsd#DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTables" xlink:href="exel-20171229.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTermLoanPayableDetails" xlink:href="exel-20171229.xsd#DebtTermLoanPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20171229.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20171229.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20171229.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20171229.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20171229.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20171229.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20171229.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20171229.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20171229.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20171229.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Investments" xlink:href="exel-20171229.xsd#Investments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20171229.xsd#InvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsNarrativeDetails" xlink:href="exel-20171229.xsd#InvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20171229.xsd#InvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20171229.xsd#InvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsTables" xlink:href="exel-20171229.xsd#InvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20171229.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20171229.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20171229.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20171229.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20171229.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20171229.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20171229.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20171229.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformation" xlink:href="exel-20171229.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails" xlink:href="exel-20171229.xsd#SegmentInformationConcentrationRiskByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:href="exel-20171229.xsd#SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:href="exel-20171229.xsd#SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails" xlink:href="exel-20171229.xsd#SegmentInformationSegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationTables" xlink:href="exel-20171229.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20171229.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20171229.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:to="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_2B1E2732636492CD500ED293EBA352C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_2B1E2732636492CD500ED293EBA352C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_97C56B20E63C8C583153D293EBA87DE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_97C56B20E63C8C583153D293EBA87DE8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_4BFEAB5AFF06FE3A11BED293EBA90C1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_4BFEAB5AFF06FE3A11BED293EBA90C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9372C9D286F85DEEFDDAD293EBA949EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9372C9D286F85DEEFDDAD293EBA949EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_81F7A46561510D0B7EA1D293EBA95322" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_ContractsRevenue_81F7A46561510D0B7EA1D293EBA95322" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_6AB109D1B9E841B4F48CB3772F6157D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_6AB109D1B9E841B4F48CB3772F6157D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D" xlink:to="loc_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_71348BF222E09373E0C6B3772F61B528" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_71348BF222E09373E0C6B3772F61B528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:to="loc_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9863864CD2663C50837EB3772F58F63D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9863864CD2663C50837EB3772F58F63D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9863864CD2663C50837EB3772F58F63D" xlink:to="loc_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_CA1657E703C59260DDB0C8C75259939D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_CA1657E703C59260DDB0C8C75259939D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:to="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:to="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8A290445AE5DAD033970D03D8A305F1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:to="loc_us-gaap_MinimumMember_8A290445AE5DAD033970D03D8A305F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_0EEBC04B647DA0862F6FD03D8A30F26D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:to="loc_us-gaap_MaximumMember_0EEBC04B647DA0862F6FD03D8A30F26D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:to="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:to="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="loc_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="loc_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="loc_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_92703EE8BD4F3715D06DD03D8A31C738" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_92703EE8BD4F3715D06DD03D8A31C738" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ContractRevenueMember" xlink:label="loc_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:to="loc_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear" xlink:label="loc_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:to="loc_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:to="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:to="loc_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:to="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:to="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_HCCFilingMember" xlink:label="loc_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:to="loc_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_HCCAcceptanceMember" xlink:label="loc_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:to="loc_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:to="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:to="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_75676C9EFF057C67AF6DD07DD0CBC0E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:to="loc_exel_InitialMember_75676C9EFF057C67AF6DD07DD0CBC0E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:to="loc_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_80161EEE76AB73DEB397D07DD0CB44C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:to="loc_exel_FinalTierMember_80161EEE76AB73DEB397D07DD0CB44C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:to="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:to="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0BD631C7B359FE987DAED07DD0CCDA97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:to="loc_us-gaap_MinimumMember_0BD631C7B359FE987DAED07DD0CCDA97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C324F999511FA06C303CD07DD0CCA1C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:to="loc_us-gaap_MaximumMember_C324F999511FA06C303CD07DD0CCA1C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:to="loc_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_6C56010828D4EFCEDA30D07DD0CCD6FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_UpfrontAndMilestonePayments_6C56010828D4EFCEDA30D07DD0CCD6FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C9B38D46741EA280984D07DD0CC6B38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C9B38D46741EA280984D07DD0CC6B38" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_A9616272908D8B28A000D07DD0CCE520" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_A9616272908D8B28A000D07DD0CCE520" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_C2627D21138681C94DE9D07DD0CCAD58" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_RoyaltyTier_C2627D21138681C94DE9D07DD0CCAD58" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_DF845611E212F0664277D07DD0CC1EBE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_DF845611E212F0664277D07DD0CC1EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentOfReimbursementsFromCollaborationArrangement" xlink:label="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_DCB7DF2C60DD9AF11CA2D07DD0CCE916" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_DCB7DF2C60DD9AF11CA2D07DD0CCE916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F96984A17AA7347A461BD07DD0CDBD9A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F96984A17AA7347A461BD07DD0CDBD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_39E1E57D36EF7A32402CD07DD0CD50EB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_39E1E57D36EF7A32402CD07DD0CD50EB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:to="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:to="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_BristolMyersSquibbMember" xlink:label="loc_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:to="loc_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" xlink:label="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SanofiAventisMember" xlink:label="loc_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_C3656ACBC22FABBD2AA1B4A50A20DF4E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_GlaxoSmithKlineMember_C3656ACBC22FABBD2AA1B4A50A20DF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_C4657A888BD1E3AE793FB4A50A20DB82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683" xlink:to="loc_exel_GlaxoSmithKlineMember_C4657A888BD1E3AE793FB4A50A20DB82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:to="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:to="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_39D88AA21E77DDE624D3B4A50A208114" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C" xlink:to="loc_us-gaap_MaximumMember_39D88AA21E77DDE624D3B4A50A208114" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumPotentialMilestonePayments" xlink:label="loc_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsCommercial" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_1CF61146E271B1C4F356B4A50A20C194" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_1CF61146E271B1C4F356B4A50A20C194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_BF2DCC6516AC74F7AAF2B4A50A20A96B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_BF2DCC6516AC74F7AAF2B4A50A20A96B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementShareinCostsPercentage" xlink:label="loc_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_626A559C468DA3C61902B4A50A20CC2F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_626A559C468DA3C61902B4A50A20CC2F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_CE4AE2238E13C530C671B4A50A20AB2F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_us-gaap_RoyaltyExpense_CE4AE2238E13C530C671B4A50A20AB2F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:to="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:to="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:to="loc_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:to="loc_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:to="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:to="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:to="loc_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:to="loc_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:to="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:to="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:to="loc_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:to="loc_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DeferredRevenueRecognitionPeriod" xlink:label="loc_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:to="loc_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SouthSanFranciscoCaliforniaMember" xlink:label="loc_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:to="loc_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:to="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:to="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_BuildingShellsMember" xlink:label="loc_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B" xlink:to="loc_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_656855C985ACB42C3973BFC661F91093" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_656855C985ACB42C3973BFC661F91093" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OptionalAmendmentAgreementMember" xlink:label="loc_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="loc_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseMember" xlink:label="loc_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="loc_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesNumberofOptionstoTerminate" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty" xlink:label="loc_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfRealEstateProperties" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentNumberofInstruments" xlink:label="loc_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollateralProvidedForPurchasingCardProgram" xlink:label="loc_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:to="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommonStockAndWarrants" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_34E216F8AAF95FFB6EB8BEF9A6776A0C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_34E216F8AAF95FFB6EB8BEF9A6776A0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ClassofWarrantorRightPeriod" xlink:label="loc_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4AFFD23B3C23CCBE8172BEF9A67796C1" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4AFFD23B3C23CCBE8172BEF9A67796C1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharesWithheldforConversionofWarrants" xlink:label="loc_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:to="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:to="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:to="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F89551319C8B8B14178EBBBF59B0D45F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_NetIncomeLoss_F89551319C8B8B14178EBBBF59B0D45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Debt2019NotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_3D34607FF675998ACE76D293EAD29444" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_3D34607FF675998ACE76D293EAD29444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:to="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_2898097C5EE8A9E1548ED293EAD2428C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_2898097C5EE8A9E1548ED293EAD2428C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3E79C562FCB0E4DFD609D293EAD38716" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3E79C562FCB0E4DFD609D293EAD38716" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentRedemptionofConvertibleDebtAmount" xlink:label="loc_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforInducementsofDebtConversion" xlink:label="loc_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42570075BC384F575F61D293EAD3D213" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42570075BC384F575F61D293EAD3D213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12657FAF7CF86EF29FABD293EAD33E9C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12657FAF7CF86EF29FABD293EAD33E9C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:to="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_6165D547D6C78E77C6EDB3772F38759D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:to="loc_us-gaap_ConvertibleDebtMember_6165D547D6C78E77C6EDB3772F38759D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:to="loc_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:to="loc_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" xlink:label="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:to="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeAxis" xlink:label="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:to="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:to="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CouponInterestMember" xlink:label="loc_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:to="loc_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentinKindInterestMember" xlink:label="loc_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:to="loc_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:to="loc_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtIncludingPaidinKindInterest" xlink:label="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentPrepaymentPenalty" xlink:label="loc_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" xlink:label="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_80CF41D4929C52E0B033D293EAC3FED7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_80CF41D4929C52E0B033D293EAC3FED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:to="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_96EF0BAB415A5E08FC85D293EAC9BAC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_96EF0BAB415A5E08FC85D293EAC9BAC8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforInducementsofDebtConversion" xlink:label="loc_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue" xlink:label="loc_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts" xlink:label="loc_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LossonExtinguishmentofDebtTransactionCosts" xlink:label="loc_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D2CF1F65F0C56C72A73DD293EAC9F75E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D2CF1F65F0C56C72A73DD293EAC9F75E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DebtTermLoanPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtLineItems" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_14FBC7385182387BDB12B8D7474EF11D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1" xlink:to="loc_us-gaap_SecuredDebtMember_14FBC7385182387BDB12B8D7474EF11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:to="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseAbstract" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:to="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_E43310B23537B455A685B8D7474E4A9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_E43310B23537B455A685B8D7474E4A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E262CB4015B21A5CFFF9B8D7474ECFC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_InterestPaid_E262CB4015B21A5CFFF9B8D7474ECFC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_661C57E96C3412D8EE28B3772EE51984" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_661C57E96C3412D8EE28B3772EE51984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_0A975CE63CF6FA679DF2B42D3594AE33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_0A975CE63CF6FA679DF2B42D3594AE33" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_6D69C9F700F4E43B1B76B3772EE52352" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_6D69C9F700F4E43B1B76B3772EE52352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ECB7CAF89F19ED68F36FD041C3F45385" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ECB7CAF89F19ED68F36FD041C3F45385" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_62653D5D1E4449056DC9D0591079FBCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:to="loc_us-gaap_ConvertibleDebtMember_62653D5D1E4449056DC9D0591079FBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_878BA31DA0F0434C022DD041C3F4FEF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:to="loc_us-gaap_SecuredDebtMember_878BA31DA0F0434C022DD041C3F4FEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ECB7CAF89F19ED68F36FD041C3F45385" xlink:to="loc_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:to="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_0CCA9AEB37A9504557E6BF55EDADCEE4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_CommercialPaperMember_0CCA9AEB37A9504557E6BF55EDADCEE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_532C8D45A35F544A0C08BF55EDAD7846" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_532C8D45A35F544A0C08BF55EDAD7846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_FDA922D6333A8608681DBF55F05B3CD8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_FDA922D6333A8608681DBF55F05B3CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:to="loc_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross" xlink:label="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance" xlink:label="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:to="loc_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:to="loc_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Investments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:to="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="loc_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:to="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:to="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:to="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:to="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AkarnaTherapeuticsLtd.Member" xlink:label="loc_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:to="loc_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedGainLoss" xlink:label="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CostMethodInvestmentOwnershipPercentage" xlink:label="loc_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:to="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3D455E40FE0DDCF3F798BF470FF6E87C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3D455E40FE0DDCF3F798BF470FF6E87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_BADB91694A4F28B4D0C1BF470FF6CC91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_CommercialPaperMember_BADB91694A4F28B4D0C1BF470FF6CC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_83169D4A9389C699D8AEBF470FF64743" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_83169D4A9389C699D8AEBF470FF64743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_C0D8ED4E8E0DCCACBE55BF471257143D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_C0D8ED4E8E0DCCACBE55BF471257143D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:to="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_7685A9729D6D6B00D1B4B9A1119AE85E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_7685A9729D6D6B00D1B4B9A1119AE85E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="loc_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_9CACB18AAA9EE5EA0E56B9A1119ADE46" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_9CACB18AAA9EE5EA0E56B9A1119ADE46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ChargebacksandPromptPaymentMember" xlink:label="loc_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OtherDiscountsMember" xlink:label="loc_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RebatesMember" xlink:label="loc_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ReserveRollforwardRollForward" xlink:label="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:to="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DiscountsandAllowances" xlink:label="loc_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment" xlink:label="loc_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentandCreditsIssued" xlink:label="loc_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D3BA47C75B653D772F7D2589C8313E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D3BA47C75B653D772F7D2589C8313E9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_1E52BC69887903FD2A5FD2589C8241AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_exel_LaboratoryEquipmentMember_1E52BC69887903FD2A5FD2589C8241AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EquipmentAndFurnitureMember" xlink:label="loc_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_8FE06D0F5E806C8D2EDAD2589C8270A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_8FE06D0F5E806C8D2EDAD2589C8270A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3F57B8FC80059C114C63D2589C834842" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3F57B8FC80059C114C63D2589C834842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:to="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:to="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:to="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C16E38422A8FE6436394D2589C83B25C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:to="loc_us-gaap_MinimumMember_C16E38422A8FE6436394D2589C83B25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_AE9EA9E2FA21F94B1E28D2589C83E700" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:to="loc_us-gaap_MaximumMember_AE9EA9E2FA21F94B1E28D2589C83E700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D3BA47C75B653D772F7D2589C8313E9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20171229.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:type="locator" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:to="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:to="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5A3503BC88EDDD37F508D2589C8BAB84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:to="loc_us-gaap_RetainedEarningsMember_5A3503BC88EDDD37F508D2589C8BAB84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_20B310136574C620FC2ED2589C8B3255" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_20B310136574C620FC2ED2589C8B3255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C" xlink:to="loc_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_84BB25C9E7D6BB1272A4D2589C8B722D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_84BB25C9E7D6BB1272A4D2589C8B722D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_FA957328C28E5B99B60DD2589C8CA6DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F" xlink:to="loc_exel_GlaxoSmithKlineMember_FA957328C28E5B99B60DD2589C8CA6DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:to="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:to="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5638B887BF798490F76CD2589C8C66A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3" xlink:to="loc_us-gaap_MaximumMember_5638B887BF798490F76CD2589C8C66A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_123B5AC68C955A3B385FD2589C8C8D4A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_123B5AC68C955A3B385FD2589C8C8D4A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_0A41BEE74609A6E5628ED2589C8C48CF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_0A41BEE74609A6E5628ED2589C8C48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:to="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:to="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_AE66A3989DA5F6353B2BD2B16B16D963" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B" xlink:to="loc_exel_AlamedaCaliforniaMember_AE66A3989DA5F6353B2BD2B16B16D963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_36B882ED411906CC4E66D293EB0658BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_36B882ED411906CC4E66D293EB0658BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OptionalAmendmentAgreementMember" xlink:label="loc_exel_OptionalAmendmentAgreementMember_F71491754AFB1B2F241CD293EB0600D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:to="loc_exel_OptionalAmendmentAgreementMember_F71491754AFB1B2F241CD293EB0600D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:to="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_58392EB38F1E0CDE12ABD293EB06A66F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D" xlink:to="loc_us-gaap_ConstructionInProgressMember_58392EB38F1E0CDE12ABD293EB06A66F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_4B174F6C6ADCFF52A472D293EB064715" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_4B174F6C6ADCFF52A472D293EB064715" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RecoveryOfExpensesExpensesInCurrentFiscalYear" xlink:label="loc_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:to="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_3E6918708C202FB1407DB472B7C8B708" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_3E6918708C202FB1407DB472B7C8B708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:to="loc_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:to="loc_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RestofWorldMember" xlink:label="loc_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:to="loc_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:to="loc_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:to="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_F6A782CB367713E60129BBC3EB8622B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:to="loc_exel_CabometyxMember_F6A782CB367713E60129BBC3EB8622B1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:to="loc_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_280D10718295C71B651FBBBF584AAA18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_280D10718295C71B651FBBBF584AAA18" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BD50F2E9543A0E6A2185BA99817FBBA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BD50F2E9543A0E6A2185BA99817FBBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4FEB3DA7051ED05473FDBA99817F85A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4FEB3DA7051ED05473FDBA99817F85A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B348BB9BD4E31539B348BA99817F2218" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_us-gaap_EmployeeStockMember_B348BB9BD4E31539B348BA99817F2218" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PerformanceStockOptionsMember" xlink:label="loc_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:to="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:to="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ChangeinControlandSeveranceBenefitPlanMember" xlink:label="loc_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:to="loc_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:to="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:to="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_53ED1A429D81D4929746BA998180EAFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791" xlink:to="loc_us-gaap_MaximumMember_53ED1A429D81D4929746BA998180EAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_20321310D31A72A29A7FBA998181B316" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ProceedsFromStockPlans_20321310D31A72A29A7FBA998181B316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DefinedContributionPlanNumberofSharesAvailableforGrant" xlink:label="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:to="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40444EA3CEE40A248B0EB3772F193B58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40444EA3CEE40A248B0EB3772F193B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_CD5BB35CA9A943D39594B3772F193F18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:to="loc_us-gaap_EmployeeStockMember_CD5BB35CA9A943D39594B3772F193F18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:to="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:to="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:to="loc_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>exel-20171229_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:to="lab_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:to="lab_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss position, fair value, less than 12 months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses, less than 12 months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss position, fair value,12 months or greater</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses, 12 months or greater</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss position, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:to="lab_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:to="lab_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:to="lab_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:to="lab_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:type="arc" />
    <link:label id="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832_terseLabel_en-US" xlink:label="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832_label_en-US" xlink:label="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832_documentation_en-US" xlink:label="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:to="lab_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:type="arc" />
    <link:label id="lab_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F_terseLabel_en-US" xlink:label="lab_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan [Member]</link:label>
    <link:label id="lab_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F_label_en-US" xlink:label="lab_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:to="lab_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0_label_en-US" xlink:label="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:label id="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0_documentation_en-US" xlink:label="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:to="lab_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF_terseLabel_en-US" xlink:label="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF_label_en-US" xlink:label="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">royalty tier [Domain]</link:label>
    <link:label id="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF_documentation_en-US" xlink:label="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for royalty tier [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:to="lab_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:type="arc" />
    <link:label id="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C_terseLabel_en-US" xlink:label="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C_label_en-US" xlink:label="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:label id="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C_documentation_en-US" xlink:label="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:to="lab_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:type="arc" />
    <link:label id="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4_terseLabel_en-US" xlink:label="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4_label_en-US" xlink:label="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Final Tier [Member]</link:label>
    <link:label id="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4_documentation_en-US" xlink:label="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Final Tier[Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:to="lab_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8_label_en-US" xlink:label="lab_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:to="lab_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830_label_en-US" xlink:label="lab_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:to="lab_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B_label_en-US" xlink:label="lab_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:to="lab_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897_label_en-US" xlink:label="lab_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:to="lab_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:to="lab_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:type="arc" />
    <link:label id="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4_terseLabel_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4_label_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4_documentation_en-US" xlink:label="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:to="lab_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:type="arc" />
    <link:label id="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17_terseLabel_en-US" xlink:label="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, recognition period</link:label>
    <link:label id="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17_label_en-US" xlink:label="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Recognition Period</link:label>
    <link:label id="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17_documentation_en-US" xlink:label="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Recognition Period</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DeferredRevenueRecognitionPeriod" xlink:label="loc_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:to="lab_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:to="lab_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643_terseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643_label_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643_documentation_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:type="arc" />
    <link:label id="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB_terseLabel_en-US" xlink:label="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB_label_en-US" xlink:label="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:label id="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB_documentation_en-US" xlink:label="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Tier</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:to="lab_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement performed for others, reimbursement for costs incurred, percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:to="lab_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration period to achieve specified levels of commercial performance</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:to="lab_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB_label_en-US" xlink:label="lab_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:to="lab_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:to="lab_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:type="arc" />
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585_terseLabel_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for specific commercial performance</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585_label_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:label id="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585_documentation_en-US" xlink:label="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Specific Sales Volume, Threshold</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:to="lab_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:to="lab_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:to="lab_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid in kind</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:to="lab_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on other equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in warrant fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81_label_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Accrued Clinical Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) accrued clinical liabilities</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:to="lab_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B_label_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:to="lab_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash and Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:type="arc" />
    <link:label id="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B_negatedTerseLabel_en-US" xlink:label="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on conversion of convertible notes</link:label>
    <link:label id="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B_label_en-US" xlink:label="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Conversion of Convertible Debt</link:label>
    <link:label id="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B_documentation_en-US" xlink:label="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Conversion of Convertible Debt</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforConversionofConvertibleDebt" xlink:label="loc_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:to="lab_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:to="lab_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2_label_en-US" xlink:label="lab_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:to="lab_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:to="lab_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activity:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:type="arc" />
    <link:label id="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C_terseLabel_en-US" xlink:label="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress deemed to have been acquired under build-to-suit lease</link:label>
    <link:label id="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C_label_en-US" xlink:label="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIP deemed acquired in Build-to-Suit Lease</link:label>
    <link:label id="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C_documentation_en-US" xlink:label="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CIP deemed acquired in Build-to-Suit Lease</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CIPdeemedacquiredinBuildtoSuitLease" xlink:label="loc_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:to="lab_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569" xlink:to="lab_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:to="lab_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Product Revenue by Product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedules of Revenue Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Earned from Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at ending of the year (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2017 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at ending of the year (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2017 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options outstanding at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross rental expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:to="lab_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less: Sublease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net rental expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:type="arc" />
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15_label_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15_documentation_en-US" xlink:label="lab_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="lab_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30_terseLabel_en-US" xlink:label="lab_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30_label_en-US" xlink:label="lab_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:to="lab_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E_label_en-US" xlink:label="lab_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:to="lab_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:to="lab_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:to="lab_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:to="lab_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717_label_en-US" xlink:label="lab_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:to="lab_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B_label_en-US" xlink:label="lab_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:to="lab_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:to="lab_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421_label_en-US" xlink:label="lab_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:to="lab_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:to="lab_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20_label_en-US" xlink:label="lab_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:to="lab_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:to="lab_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:to="lab_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:to="lab_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction-in-progress [Member]</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:to="lab_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658_label_en-US" xlink:label="lab_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:to="lab_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="lab_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:to="lab_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:to="lab_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:to="lab_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards Update No. 2016-09</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of shares of common stock, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of shares of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in settlement of convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on warrant exercise (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on warrant exercise</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants transferred from other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="lab_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:type="arc" />
    <link:label id="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE_terseLabel_en-US" xlink:label="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Axis]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE_label_en-US" xlink:label="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Axis]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE_documentation_en-US" xlink:label="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeAxis" xlink:label="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:to="lab_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:type="arc" />
    <link:label id="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C_terseLabel_en-US" xlink:label="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Domain]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C_label_en-US" xlink:label="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payment Type [Domain]</link:label>
    <link:label id="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C_documentation_en-US" xlink:label="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Interest Payment Type [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:to="lab_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:type="arc" />
    <link:label id="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099_terseLabel_en-US" xlink:label="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coupon interest [Member]</link:label>
    <link:label id="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099_label_en-US" xlink:label="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coupon Interest [Member]</link:label>
    <link:label id="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099_documentation_en-US" xlink:label="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coupon Interest [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CouponInterestMember" xlink:label="loc_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:to="lab_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:type="arc" />
    <link:label id="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300_terseLabel_en-US" xlink:label="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment-in-kind interest [Member]</link:label>
    <link:label id="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300_label_en-US" xlink:label="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment-in-Kind Interest [Member]</link:label>
    <link:label id="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300_documentation_en-US" xlink:label="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment-in-Kind Interest [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentinKindInterestMember" xlink:label="loc_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:to="lab_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes [Member]</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:to="lab_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:to="lab_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:type="arc" />
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F_terseLabel_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes due June 2018 [Member]</link:label>
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F_label_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F_documentation_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Convertible Notes Due June 2018 [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:to="lab_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="lab_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:type="arc" />
    <link:label id="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83_terseLabel_en-US" xlink:label="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of principal</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83_label_en-US" xlink:label="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Including Paid in Kind Interest</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83_documentation_en-US" xlink:label="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Including Paid in Kind Interest</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtIncludingPaidinKindInterest" xlink:label="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:to="lab_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of debt amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895_verboseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest paid in kind</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:to="lab_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment penalty</link:label>
    <link:label id="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E_label_en-US" xlink:label="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty</link:label>
    <link:label id="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E_documentation_en-US" xlink:label="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Penalty</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentPrepaymentPenalty" xlink:label="loc_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:to="lab_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued and unpaid interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:to="lab_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest after extension option election</link:label>
    <link:label id="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1_label_en-US" xlink:label="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election</link:label>
    <link:label id="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1_documentation_en-US" xlink:label="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" xlink:label="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:to="lab_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term loans payable [Member]</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:to="lab_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:to="lab_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance of unamortized closing fees and expenses</link:label>
    <link:label id="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6_label_en-US" xlink:label="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instruments, Unamortized Closing Fees And Expenses</link:label>
    <link:label id="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6_documentation_en-US" xlink:label="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instruments, unamortized closing fees and expenses.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" xlink:label="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:to="lab_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:to="lab_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Member]</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:to="lab_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:to="lab_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="lab_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:to="lab_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:to="lab_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:to="lab_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3_label_en-US" xlink:label="lab_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:to="lab_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:to="lab_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:type="arc" />
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery of net losses</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:to="lab_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:type="arc" />
    <link:label id="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE_terseLabel_en-US" xlink:label="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery of net losses, recognized in current fiscal year</link:label>
    <link:label id="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE_label_en-US" xlink:label="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery Of Expenses, Expenses In Current Fiscal Year</link:label>
    <link:label id="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE_documentation_en-US" xlink:label="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recovery Of Expenses, Expenses In Current Fiscal Year</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RecoveryOfExpensesExpensesInCurrentFiscalYear" xlink:label="loc_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:to="lab_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capital Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capital Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:to="lab_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease and other financing lease [Member]</link:label>
    <link:label id="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87_label_en-US" xlink:label="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease and Other Financing Lease [Member]</link:label>
    <link:label id="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87_documentation_en-US" xlink:label="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease and Other Financing Lease [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:to="lab_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145_label_en-US" xlink:label="lab_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:to="lab_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Future minimum lease payments, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing obligations</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659_totalLabel_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Future minimum lease payments, capital leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659_label_en-US" xlink:label="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:to="lab_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior subordinated notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134_label_en-US" xlink:label="lab_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Subordinated Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:to="lab_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:type="arc" />
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99_verboseLabel_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2019 Notes [Member]</link:label>
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99_label_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Subordinated Notes due August 15, 2019, 4.25% [Member]</link:label>
    <link:label id="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99_documentation_en-US" xlink:label="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Subordinated Notes due 2019, 4.25% [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:to="lab_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-allotment option [Member]</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:to="lab_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:type="arc" />
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6_terseLabel_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Warrants [Member]</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6_label_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:label id="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6_documentation_en-US" xlink:label="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:to="lab_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued pursuant to conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount of debt converted</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase to shareholder's equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering of common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668_label_en-US" xlink:label="lab_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:to="lab_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from public offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:type="arc" />
    <link:label id="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140_terseLabel_en-US" xlink:label="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant period</link:label>
    <link:label id="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140_label_en-US" xlink:label="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period</link:label>
    <link:label id="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140_documentation_en-US" xlink:label="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Period</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ClassofWarrantorRightPeriod" xlink:label="loc_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:to="lab_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:type="arc" />
    <link:label id="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90_terseLabel_en-US" xlink:label="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares withheld for exercise of warrants (in shares)</link:label>
    <link:label id="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90_label_en-US" xlink:label="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Withheld for Conversion of Warrants</link:label>
    <link:label id="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90_documentation_en-US" xlink:label="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Withheld for Conversion of Warrants</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SharesWithheldforConversionofWarrants" xlink:label="loc_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:to="lab_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic concentration risk [Member]</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:to="lab_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:type="arc" />
    <link:label id="lab_country_US_A903BCB790F491BADFE6BBBF58066DFA_terseLabel_en-US" xlink:label="lab_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. [Member]</link:label>
    <link:label id="lab_country_US_A903BCB790F491BADFE6BBBF58066DFA_label_en-US" xlink:label="lab_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:to="lab_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:label id="lab_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90_label_en-US" xlink:label="lab_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:to="lab_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:type="arc" />
    <link:label id="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131_terseLabel_en-US" xlink:label="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world [Member]</link:label>
    <link:label id="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131_label_en-US" xlink:label="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of World [Member]</link:label>
    <link:label id="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131_documentation_en-US" xlink:label="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest of World [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RestofWorldMember" xlink:label="loc_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:to="lab_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9_label_en-US" xlink:label="lab_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:to="lab_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:type="arc" />
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED_terseLabel_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change relating to prior year provision</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED_label_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:label id="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED_documentation_en-US" xlink:label="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:to="lab_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change relating to current year provision</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions based on the lapse of the applicable statutes of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:to="lab_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign exchange</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:type="arc" />
    <link:label id="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F_terseLabel_en-US" xlink:label="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash inducements</link:label>
    <link:label id="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F_label_en-US" xlink:label="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Inducements of Debt Conversion</link:label>
    <link:label id="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F_documentation_en-US" xlink:label="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Inducements of Debt Conversion</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforInducementsofDebtConversion" xlink:label="loc_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:to="lab_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:type="arc" />
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D_verboseLabel_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Waiver of requirement to repay interest, described above</link:label>
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D_label_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Induced Conversion of Convertible Debt Expense, Interest Repayment Forgiveness</link:label>
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D_documentation_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Induced Conversion of Convertible Debt Expense, Interest Repayment Forgiveness</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:to="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:type="arc" />
    <link:label id="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15_terseLabel_en-US" xlink:label="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15_label_en-US" xlink:label="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Difference Between Settlement Consideration and Net Carrying Value</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15_documentation_en-US" xlink:label="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Difference Between Settlement Consideration and Net Carrying Value</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue" xlink:label="loc_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:to="lab_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:type="arc" />
    <link:label id="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A_terseLabel_en-US" xlink:label="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount on redeemed notes</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A_label_en-US" xlink:label="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Write-off of Unamortized Debt Discounts</link:label>
    <link:label id="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A_documentation_en-US" xlink:label="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Write-off of Unamortized Debt Discounts</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts" xlink:label="loc_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:to="lab_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:type="arc" />
    <link:label id="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17_terseLabel_en-US" xlink:label="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third-party costs</link:label>
    <link:label id="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17_label_en-US" xlink:label="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on Extinguishment of Debt, Transaction Costs</link:label>
    <link:label id="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17_documentation_en-US" xlink:label="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss on Extinguishment of Debt, Transaction Costs</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_LossonExtinguishmentofDebtTransactionCosts" xlink:label="loc_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:to="lab_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:type="arc" />
    <link:label id="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803_verboseLabel_en-US" xlink:label="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803_label_en-US" xlink:label="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</link:label>
    <link:label id="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803_documentation_en-US" xlink:label="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:to="lab_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve Balances for Discounts and Allowances</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Allowances [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionAllowances" xlink:label="loc_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:to="lab_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:to="lab_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C_terseLabel_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement adjustment [Member]</link:label>
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C_label_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:to="lab_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement with Ipsen, approval of product by EC in Second-Line RCC [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen, Approval of Product by EC in Second-Line RCC [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:to="lab_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:to="lab_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:to="lab_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724_label_en-US" xlink:label="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724_documentation_en-US" xlink:label="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:to="lab_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196_label_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Axis]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:to="lab_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:type="arc" />
    <link:label id="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33_terseLabel_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33_label_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MilestoneObjective [Domain]</link:label>
    <link:label id="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33_documentation_en-US" xlink:label="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for MilestoneObjective [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:to="lab_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:type="arc" />
    <link:label id="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C_terseLabel_en-US" xlink:label="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HCC Filing [Member]</link:label>
    <link:label id="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C_label_en-US" xlink:label="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HCC Filing [Member]</link:label>
    <link:label id="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C_documentation_en-US" xlink:label="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HCC Filing [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_HCCFilingMember" xlink:label="loc_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:to="lab_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:type="arc" />
    <link:label id="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C_terseLabel_en-US" xlink:label="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HCC Acceptance [Member]</link:label>
    <link:label id="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C_label_en-US" xlink:label="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HCC Acceptance [Member]</link:label>
    <link:label id="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C_documentation_en-US" xlink:label="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HCC Acceptance [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_HCCAcceptanceMember" xlink:label="loc_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:to="lab_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:type="arc" />
    <link:label id="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F_terseLabel_en-US" xlink:label="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:label id="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F_label_en-US" xlink:label="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:label id="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F_documentation_en-US" xlink:label="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:to="lab_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:to="lab_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:to="lab_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized, milestones</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:type="arc" />
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Upfront payment reclassified</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:to="lab_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:type="arc" />
    <link:label id="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D_terseLabel_en-US" xlink:label="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of reimbursements from collaboration arrangement</link:label>
    <link:label id="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D_label_en-US" xlink:label="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Reimbursements From Collaboration Arrangement</link:label>
    <link:label id="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D_documentation_en-US" xlink:label="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Reimbursements From Collaboration Arrangement</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentOfReimbursementsFromCollaborationArrangement" xlink:label="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:to="lab_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:to="lab_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:to="lab_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:to="lab_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:type="arc" />
    <link:label id="lab_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E_verboseLabel_en-US" xlink:label="lab_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deerfield Notes [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:to="lab_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions [Member]</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:to="lab_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt [Member]</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total potentially dilutive shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388" xlink:to="lab_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock for basic net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustment to net income allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income allocable to common stock for diluted net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:to="lab_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:to="lab_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Consolidated Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:type="arc" />
    <link:label id="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6_terseLabel_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6_label_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6_documentation_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:to="lab_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:type="arc" />
    <link:label id="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA_terseLabel_en-US" xlink:label="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA_label_en-US" xlink:label="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:label id="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA_documentation_en-US" xlink:label="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">South San Francisco, California [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SouthSanFranciscoCaliforniaMember" xlink:label="loc_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:to="lab_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:to="lab_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:to="lab_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby letters of credit [Member]</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:type="arc" />
    <link:label id="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885_terseLabel_en-US" xlink:label="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building shells [Member]</link:label>
    <link:label id="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885_label_en-US" xlink:label="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Shells [Member]</link:label>
    <link:label id="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885_documentation_en-US" xlink:label="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Building Shells [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_BuildingShellsMember" xlink:label="loc_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:to="lab_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:type="arc" />
    <link:label id="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8_terseLabel_en-US" xlink:label="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optional amendment agreement [Member]</link:label>
    <link:label id="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8_label_en-US" xlink:label="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optional Amendment Agreement [Member]</link:label>
    <link:label id="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8_documentation_en-US" xlink:label="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Optional Amendment Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OptionalAmendmentAgreementMember" xlink:label="loc_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:to="lab_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasing Arrangement [Member]</link:label>
    <link:label id="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810_label_en-US" xlink:label="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease [Member]</link:label>
    <link:label id="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810_documentation_en-US" xlink:label="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseMember" xlink:label="loc_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:to="lab_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:type="arc" />
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8_terseLabel_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building lease [Member]</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8_label_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Building Lease [Member]</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8_documentation_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Building Lease [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:to="lab_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:type="arc" />
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F_terseLabel_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workers Compensation Insurance Policy [Member]</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F_label_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Workers Compensation Insurance Policy [Member]</link:label>
    <link:label id="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F_documentation_en-US" xlink:label="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standby Letter Of Credit Related To Workers Compensation Insurance Policy [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:to="lab_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of leased property (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:type="arc" />
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC_terseLabel_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of lease contract</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC_label_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital and Operating Leases, Term of Contract</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC_documentation_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital and Operating Leases, Term of Contract</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:to="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:type="arc" />
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5_terseLabel_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5_label_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Number of Renewal Options</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5_documentation_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Number of Renewal Options</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:to="lab_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:type="arc" />
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49_terseLabel_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal option term</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49_label_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital and Operating Leases, Renewal Term</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49_documentation_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital and Operating Leases, Renewal Term</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:to="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:type="arc" />
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF_terseLabel_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to terminate</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF_label_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Number of Options to Terminate</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF_documentation_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Number of Options to Terminate</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesNumberofOptionstoTerminate" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:to="lab_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:type="arc" />
    <link:label id="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B_terseLabel_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option for additional area of lease (sq ft)</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B_label_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Option, Additional Area of Real Estate Property</link:label>
    <link:label id="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B_documentation_en-US" xlink:label="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital and Operating Leases, Option, Additional Area of Real Estate Property</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty" xlink:label="loc_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:to="lab_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of properties</link:label>
    <link:label id="lab_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD_label_en-US" xlink:label="lab_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Real Estate Properties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfRealEstateProperties" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:to="lab_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement cost for contract termination</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual for contract termination</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:to="lab_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent payable</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:type="arc" />
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA_terseLabel_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital and operating leases, Minimum lease payments due</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA_label_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital and Operating Leases, Minimum Lease Payments Due</link:label>
    <link:label id="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA_documentation_en-US" xlink:label="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Capital and Operating Leases, Minimum Lease Payments Due</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:to="lab_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Line of credit borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of letters of credit entered into (in debt instruments)</link:label>
    <link:label id="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4_label_en-US" xlink:label="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Instruments</link:label>
    <link:label id="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4_documentation_en-US" xlink:label="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Instruments</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentNumberofInstruments" xlink:label="loc_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:to="lab_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:type="arc" />
    <link:label id="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152_terseLabel_en-US" xlink:label="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral provided for purchasing card program</link:label>
    <link:label id="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152_label_en-US" xlink:label="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral Provided For Purchasing Card Program</link:label>
    <link:label id="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152_documentation_en-US" xlink:label="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collateral Provided For Purchasing Card Program</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollateralProvidedForPurchasingCardProgram" xlink:label="loc_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:to="lab_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value inputs, discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706_label_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:to="lab_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05_label_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tiers [Domain]</link:label>
    <link:label id="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05_documentation_en-US" xlink:label="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Profit Sharing Tiers [Axis]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="lab_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861_label_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier One [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:to="lab_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7_label_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Two [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:to="lab_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906_label_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:label id="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906_documentation_en-US" xlink:label="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Tier Three [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:to="lab_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:type="arc" />
    <link:label id="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102_terseLabel_en-US" xlink:label="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract revenue [Member]</link:label>
    <link:label id="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102_label_en-US" xlink:label="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Revenue [Member]</link:label>
    <link:label id="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102_documentation_en-US" xlink:label="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Revenue [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ContractRevenueMember" xlink:label="loc_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:to="lab_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9_verboseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of share of the Company in promotions</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Optional Percent of Total Sales Force</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Optional Percent of Total Sales Force</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:to="lab_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Percent of Profits</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:to="lab_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:type="arc" />
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396_terseLabel_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396_label_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:label id="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396_documentation_en-US" xlink:label="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Sharing Agreement, Profit Threshold</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:to="lab_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:type="arc" />
    <link:label id="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC_terseLabel_en-US" xlink:label="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recovery (loss) of expenses, expenses prior to current fiscal year</link:label>
    <link:label id="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC_label_en-US" xlink:label="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Expenses, Expenses Prior to Current Fiscal Year</link:label>
    <link:label id="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC_documentation_en-US" xlink:label="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recovery of Expenses, Expenses Prior to Current Fiscal Year</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear" xlink:label="loc_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:to="lab_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments to net loss resulting from realized gains or losses on sale of securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61_terseLabel_en-US" xlink:label="lab_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61_label_en-US" xlink:label="lab_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:to="lab_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:type="arc" />
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA_verboseLabel_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Term Loan and Line of Credit [Member]</link:label>
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA_label_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Loan And Security Agreement [Member]</link:label>
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA_documentation_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:to="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109_terseLabel_en-US" xlink:label="lab_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109_label_en-US" xlink:label="lab_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:to="lab_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398_terseLabel_en-US" xlink:label="lab_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398_label_en-US" xlink:label="lab_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:to="lab_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:type="arc" />
    <link:label id="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6_terseLabel_en-US" xlink:label="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Akarna Therapeutics, Ltd. [Member]</link:label>
    <link:label id="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6_label_en-US" xlink:label="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Akarna Therapeutics, Ltd. [Member]</link:label>
    <link:label id="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6_documentation_en-US" xlink:label="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Akarna Therapeutics, Ltd. [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AkarnaTherapeuticsLtd.Member" xlink:label="loc_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:to="lab_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C_terseLabel_en-US" xlink:label="lab_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C_label_en-US" xlink:label="lab_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="lab_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collateral balance</link:label>
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419_label_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensating Balance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:to="lab_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A_terseLabel_en-US" xlink:label="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on sale of cost method investment</link:label>
    <link:label id="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A_label_en-US" xlink:label="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost-method Investments, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedGainLoss" xlink:label="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:to="lab_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:type="arc" />
    <link:label id="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE_terseLabel_en-US" xlink:label="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost method investment ownership percentage</link:label>
    <link:label id="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE_label_en-US" xlink:label="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE_documentation_en-US" xlink:label="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CostMethodInvestmentOwnershipPercentage" xlink:label="loc_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:to="lab_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:type="arc" />
    <link:label id="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4_terseLabel_en-US" xlink:label="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4_label_en-US" xlink:label="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks and Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4_documentation_en-US" xlink:label="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks and Prompt Payment [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ChargebacksandPromptPaymentMember" xlink:label="loc_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:to="lab_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:type="arc" />
    <link:label id="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A_terseLabel_en-US" xlink:label="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Discounts [Member]</link:label>
    <link:label id="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A_label_en-US" xlink:label="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Discounts [Member]</link:label>
    <link:label id="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A_documentation_en-US" xlink:label="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Discounts [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OtherDiscountsMember" xlink:label="loc_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:to="lab_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:type="arc" />
    <link:label id="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9_terseLabel_en-US" xlink:label="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates [Member]</link:label>
    <link:label id="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9_label_en-US" xlink:label="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates [Member]</link:label>
    <link:label id="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9_documentation_en-US" xlink:label="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_RebatesMember" xlink:label="loc_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:to="lab_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns [Member]</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:type="arc" />
    <link:label id="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA_terseLabel_en-US" xlink:label="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve Rollforward [Roll Forward]</link:label>
    <link:label id="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA_label_en-US" xlink:label="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve Rollforward [Roll Forward]</link:label>
    <link:label id="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA_documentation_en-US" xlink:label="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve Rollforward [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ReserveRollforwardRollForward" xlink:label="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="lab_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:type="arc" />
    <link:label id="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C_periodStartLabel_en-US" xlink:label="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C_label_en-US" xlink:label="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C_documentation_en-US" xlink:label="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DiscountsandAllowances" xlink:label="loc_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:to="lab_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for Doubtful Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656_negatedTerseLabel_en-US" xlink:label="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656_label_en-US" xlink:label="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Prior Period Adjustment</link:label>
    <link:label id="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656_documentation_en-US" xlink:label="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Prior Period Adjustment</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment" xlink:label="loc_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:to="lab_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:type="arc" />
    <link:label id="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619_negatedLabel_en-US" xlink:label="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment and Credits Issued</link:label>
    <link:label id="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619_label_en-US" xlink:label="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment and Credits Issued</link:label>
    <link:label id="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619_documentation_en-US" xlink:label="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment and Credits Issued on Discounts and Allowances</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentandCreditsIssued" xlink:label="loc_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:to="lab_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:type="arc" />
    <link:label id="lab_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF_periodEndLabel_en-US" xlink:label="lab_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DiscountsandAllowances" xlink:label="loc_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF" xlink:to="lab_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:to="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:type="arc" />
    <link:label id="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224_terseLabel_en-US" xlink:label="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Loan And Security Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:to="lab_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtLineItems" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:to="lab_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:type="arc" />
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C_terseLabel_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan payable</link:label>
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C_label_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Induced Conversion of Convertible Debt Expense [Abstract]</link:label>
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C_documentation_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Induced Conversion of Convertible Debt Expense [Abstract]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseAbstract" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="lab_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F_terseLabel_en-US" xlink:label="lab_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensating balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:to="lab_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0_label_en-US" xlink:label="lab_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:to="lab_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:type="arc" />
    <link:label id="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863_terseLabel_en-US" xlink:label="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</link:label>
    <link:label id="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863_label_en-US" xlink:label="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:label id="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863_documentation_en-US" xlink:label="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equipment And Furniture [Member].</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_EquipmentAndFurnitureMember" xlink:label="loc_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:to="lab_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash Equivalents and Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Gross Unrealized Losses on Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:type="arc" />
    <link:label id="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F_terseLabel_en-US" xlink:label="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COTELLIC [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F_label_en-US" xlink:label="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F_documentation_en-US" xlink:label="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:to="lab_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues on ex-U.S. sales of COTELLIC</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:to="lab_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:to="lab_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:to="lab_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount of debt converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:to="lab_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:type="arc" />
    <link:label id="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0_terseLabel_en-US" xlink:label="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of convertible debt</link:label>
    <link:label id="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0_label_en-US" xlink:label="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption of Convertible Debt, Amount</link:label>
    <link:label id="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0_documentation_en-US" xlink:label="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption of Convertible Debt, Amount</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentRedemptionofConvertibleDebtAmount" xlink:label="loc_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:to="lab_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240_terseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducements in conversion</link:label>
    <link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240_label_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:to="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:type="arc" />
    <link:label id="lab_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792_verboseLabel_en-US" xlink:label="lab_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash inducements</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforInducementsofDebtConversion" xlink:label="loc_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:to="lab_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:type="arc" />
    <link:label id="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2_terseLabel_en-US" xlink:label="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of interest required upon a conversion under the terms of the indenture that were not repaid under the terms of the exchange agreements</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:to="lab_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of additional paid-in capital resulting from conversion</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount [Member]</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:to="lab_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D" xlink:to="lab_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C_label_en-US" xlink:label="lab_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:to="lab_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:to="lab_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:to="lab_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:to="lab_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D_label_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D_documentation_en-US" xlink:label="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:to="lab_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7_terseLabel_en-US" xlink:label="lab_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:label id="lab_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7_label_en-US" xlink:label="lab_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:to="lab_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:to="lab_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:to="lab_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge on goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2_terseLabel_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent discount for prompt payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2_label_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:label id="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2_documentation_en-US" xlink:label="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Percent Discount for Prompt Payment</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:to="lab_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:type="arc" />
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4_terseLabel_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount expected to be earned</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4_label_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:label id="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4_documentation_en-US" xlink:label="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue, Discount Expected to be Earned, Percent</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:to="lab_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D_negatedLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards Update No. 2016-09</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carry-forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book over tax depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit and charitable contribution carry-forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:type="arc" />
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E_terseLabel_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred stock compensation &#8211; non-qualified</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E_label_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified</link:label>
    <link:label id="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E_documentation_en-US" xlink:label="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets amortization of deferred stock compensation - non-qualified.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:to="lab_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains on derivatives and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:to="lab_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of All RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:to="lab_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C_terseLabel_en-US" xlink:label="lab_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C_label_en-US" xlink:label="lab_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTextBlock" xlink:label="loc_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:to="lab_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="lab_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="lab_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:to="lab_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:to="lab_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A_label_en-US" xlink:label="lab_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:to="lab_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:to="lab_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:to="lab_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D_label_en-US" xlink:label="lab_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:to="lab_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22_label_en-US" xlink:label="lab_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:to="lab_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:to="lab_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:to="lab_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:to="lab_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A_label_en-US" xlink:label="lab_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:to="lab_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:to="lab_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="lab_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:to="lab_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:to="lab_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:to="lab_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Extinguishment of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:to="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E_negatedTerseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term, Awards outstanding at December 31, 2017</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Awards outstanding at December 31, 2017</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestones achieved</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484_terseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of upfront payments and deferred milestone</link:label>
    <link:label id="lab_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484_label_en-US" xlink:label="lab_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition of Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:to="lab_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:to="lab_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development cost reimbursements</link:label>
    <link:label id="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272_label_en-US" xlink:label="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Development Cost Reimbursements</link:label>
    <link:label id="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Development Revenue</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:to="lab_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Product supply agreement revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of supplied product</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:to="lab_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable to GSK on net sales by Ipsen</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:to="lab_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6_totalLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues under the Ipsen Collaboration Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:to="lab_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468_label_en-US" xlink:label="lab_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:to="lab_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:type="arc" />
    <link:label id="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C_terseLabel_en-US" xlink:label="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, reduction in deferred tax asset</link:label>
    <link:label id="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C_label_en-US" xlink:label="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C_documentation_en-US" xlink:label="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross" xlink:label="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:to="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:type="arc" />
    <link:label id="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF_negatedTerseLabel_en-US" xlink:label="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, change in valuation allowance</link:label>
    <link:label id="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF_label_en-US" xlink:label="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF_documentation_en-US" xlink:label="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance" xlink:label="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:to="lab_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:to="lab_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:to="lab_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:to="lab_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="lab_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:to="lab_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52" xlink:to="lab_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:to="lab_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A" xlink:to="lab_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring (recovery) charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:to="lab_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:to="lab_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B" xlink:to="lab_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:to="lab_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522_label_en-US" xlink:label="lab_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:to="lab_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70" xlink:to="lab_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income (loss) per share, diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC_label_en-US" xlink:label="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC_documentation_en-US" xlink:label="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:to="lab_exel_CometriqMember_C57807E7FE5117F152E3BBC3EB86FAAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock and Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Aggregate Future Minimum Lease Payments Under Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Rent Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:to="lab_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal income tax provision (benefit) at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:type="arc" />
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36_terseLabel_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt extinguishment</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36_label_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36_documentation_en-US" xlink:label="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:to="lab_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121_terseLabel_en-US" xlink:label="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Options [Member]</link:label>
    <link:label id="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121_label_en-US" xlink:label="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Options [Member]</link:label>
    <link:label id="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121_documentation_en-US" xlink:label="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Based Stock Options [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PerformanceStockOptionsMember" xlink:label="loc_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:to="lab_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:to="lab_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:to="lab_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8_terseLabel_en-US" xlink:label="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Control and Severance Benefit Plan [Member]</link:label>
    <link:label id="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8_label_en-US" xlink:label="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Control and Severance Benefit Plan [Member]</link:label>
    <link:label id="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8_documentation_en-US" xlink:label="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Control and Severance Benefit Plan [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ChangeinControlandSeveranceBenefitPlanMember" xlink:label="loc_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:to="lab_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life of stock options granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination period prior to change in control</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Prior to Change in Control</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Prior to Change in Control</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination period subsequent to change in control</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Subsequent to Change in Control</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Subsequent to Change in Control</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension of exercise period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period Extension</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period Extension</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate from market value on purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate from market value on offering date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from option exercises and purchases under the ESPP</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300_verboseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of employee options vested and expensed</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expensed, Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, vested and expensed, fair value.</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options in vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan, employee contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contributions for first 3% of participant contributions (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of participant contributions into the 401(k) Retirement Plan (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses relating to stock match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:type="arc" />
    <link:label id="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E_terseLabel_en-US" xlink:label="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance under 401(k) Retirement Plan (in shares)</link:label>
    <link:label id="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E_label_en-US" xlink:label="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Number of Shares Available for Grant</link:label>
    <link:label id="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E_documentation_en-US" xlink:label="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DefinedContributionPlanNumberofSharesAvailableforGrant" xlink:label="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:to="lab_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:to="lab_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="lab_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:type="arc" />
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9_terseLabel_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9_label_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9_documentation_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:to="lab_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:type="arc" />
    <link:label id="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777_terseLabel_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777_label_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777_documentation_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:to="lab_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF_label_en-US" xlink:label="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF_documentation_en-US" xlink:label="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:to="lab_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:to="lab_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer concentration risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:type="arc" />
    <link:label id="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9_terseLabel_en-US" xlink:label="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital lease and other financing lease [Member]</link:label>
    <link:label id="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9_label_en-US" xlink:label="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease and Other Financing Lease [Member]</link:label>
    <link:label id="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9_documentation_en-US" xlink:label="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Lease and Other Financing Lease [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:to="lab_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E_label_en-US" xlink:label="lab_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:to="lab_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvements allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in process costs capitalized</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid construction costs</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289_label_en-US" xlink:label="lab_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:to="lab_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D_label_en-US" xlink:label="lab_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:to="lab_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:type="arc" />
    <link:label id="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49_terseLabel_en-US" xlink:label="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49_label_en-US" xlink:label="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49_documentation_en-US" xlink:label="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member].</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_BristolMyersSquibbMember" xlink:label="loc_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:to="lab_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" xlink:label="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:to="lab_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:to="lab_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Merck [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:to="lab_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with BMS [Member]</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:to="lab_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:type="arc" />
    <link:label id="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0_terseLabel_en-US" xlink:label="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0_label_en-US" xlink:label="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sanofi Aventis [Member]</link:label>
    <link:label id="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0_documentation_en-US" xlink:label="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sanofi - Aventis [Member].</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_SanofiAventisMember" xlink:label="loc_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:to="lab_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:type="arc" />
    <link:label id="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6_terseLabel_en-US" xlink:label="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6_label_en-US" xlink:label="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:label id="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6_documentation_en-US" xlink:label="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Potential Milestone Payments</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumPotentialMilestonePayments" xlink:label="loc_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:to="lab_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:type="arc" />
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD_terseLabel_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of maximum potential milestone payments - clinical development</link:label>
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD_label_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Maximum Potential Milestone Payments - Clinical Development</link:label>
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD_documentation_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Maximum Potential Milestone Payments - Clinical Development</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:to="lab_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:type="arc" />
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74_terseLabel_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of maximum potential milestone payments - regulatory</link:label>
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74_label_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Maximum Potential Milestone Payments - Regulatory</link:label>
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74_documentation_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Maximum Potential Milestone Payments - Regulatory</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:to="lab_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:type="arc" />
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB_terseLabel_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of maximum potential milestone payments - commercial</link:label>
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB_label_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Maximum Potential Milestone Payments - Commercial</link:label>
    <link:label id="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB_documentation_en-US" xlink:label="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Maximum Potential Milestone Payments - Commercial</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsCommercial" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:to="lab_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of costs</link:label>
    <link:label id="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2_label_en-US" xlink:label="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Share in Costs, Percentage</link:label>
    <link:label id="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Share in Costs, Percentage</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementShareinCostsPercentage" xlink:label="loc_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:to="lab_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:type="arc" />
    <link:label id="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922_terseLabel_en-US" xlink:label="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for royalties on sales under collaborations agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922_label_en-US" xlink:label="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922_documentation_en-US" xlink:label="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:to="lab_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:type="arc" />
    <link:label id="lab_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB_verboseLabel_en-US" xlink:label="lab_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sales</link:label>
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:to="lab_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>exel-20171229_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20171229.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsOtherCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20171229.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:href="exel-20171229.xsd#CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Commitments" xlink:href="exel-20171229.xsd#Commitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:href="exel-20171229.xsd#CommitmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:href="exel-20171229.xsd#CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:href="exel-20171229.xsd#CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsTables" xlink:href="exel-20171229.xsd#CommitmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommonStockAndWarrants" xlink:href="exel-20171229.xsd#CommonStockAndWarrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails" xlink:href="exel-20171229.xsd#CommonStockAndWarrantsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:href="exel-20171229.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20171229.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="exel-20171229.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt" xlink:href="exel-20171229.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Debt2019NotesDetails" xlink:href="exel-20171229.xsd#Debt2019NotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:href="exel-20171229.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails" xlink:href="exel-20171229.xsd#DebtSecuredConvertibleNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:href="exel-20171229.xsd#DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTables" xlink:href="exel-20171229.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DebtTermLoanPayableDetails" xlink:href="exel-20171229.xsd#DebtTermLoanPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:href="exel-20171229.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20171229.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:href="exel-20171229.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20171229.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20171229.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="exel-20171229.xsd#IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:href="exel-20171229.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="exel-20171229.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesTables" xlink:href="exel-20171229.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20171229.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:href="exel-20171229.xsd#InventoryScheduleOfInventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20171229.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Investments" xlink:href="exel-20171229.xsd#Investments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails" xlink:href="exel-20171229.xsd#InvestmentsGrossUnrealizedLossesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsNarrativeDetails" xlink:href="exel-20171229.xsd#InvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails" xlink:href="exel-20171229.xsd#InvestmentsSummaryByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails" xlink:href="exel-20171229.xsd#InvestmentsSummaryBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InvestmentsTables" xlink:href="exel-20171229.xsd#InvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:href="exel-20171229.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20171229.xsd#NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:href="exel-20171229.xsd#NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:href="exel-20171229.xsd#NetIncomeLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="exel-20171229.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20171229.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20171229.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="exel-20171229.xsd#PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20171229.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="exel-20171229.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformation" xlink:href="exel-20171229.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails" xlink:href="exel-20171229.xsd#SegmentInformationConcentrationRiskByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:href="exel-20171229.xsd#SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:href="exel-20171229.xsd#SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails" xlink:href="exel-20171229.xsd#SegmentInformationSegmentInformationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SegmentInformationTables" xlink:href="exel-20171229.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20171229.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20171229.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:href="exel-20171229.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83B9F4250C1B385EFE43B6B5E1DB581E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83B9F4250C1B385EFE43B6B5E1DB581E" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_42089DDC12F734566814B6B5E1DB77B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8B2C40DDAA7235CFA1FDD293EBA3209E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8B2C40DDAA7235CFA1FDD293EBA3209E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:to="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_31260141AF0A247DA3A2D293EBA31FC0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_2B1E2732636492CD500ED293EBA352C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3D31D1DFF4ED115A27F9D293EBA319E0" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_2B1E2732636492CD500ED293EBA352C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8A91C2B4E4C076E37BE0D293EBA3D508" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_97C56B20E63C8C583153D293EBA87DE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_97C56B20E63C8C583153D293EBA87DE8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_4BFEAB5AFF06FE3A11BED293EBA90C1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_4BFEAB5AFF06FE3A11BED293EBA90C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_9372C9D286F85DEEFDDAD293EBA949EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_9372C9D286F85DEEFDDAD293EBA949EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_81F7A46561510D0B7EA1D293EBA95322" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_D8C60A2C73644BB78BA8D293EBA31C0E" xlink:to="loc_us-gaap_ContractsRevenue_81F7A46561510D0B7EA1D293EBA95322" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE155E0F6D08C55CBFF7B3772F61DB76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE155E0F6D08C55CBFF7B3772F61DB76" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_726E1699B8A4136F9D18B3772F610586" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_6AB109D1B9E841B4F48CB3772F6157D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9226B708C622F569CF4FB3772F6140E2" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_6AB109D1B9E841B4F48CB3772F6157D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_66880478940C24F7161AB3772F612F28" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A6333AEB2C72390F235CB3772F619B9D" xlink:to="loc_exel_CotellicMember_002CCFC9164920D9E8A9B3772F61215F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_85C0E2E5536D02ED48ADB3772F619297" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_71348BF222E09373E0C6B3772F61B528" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_DC40200B8944D5AC89CAB3772F615A8D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_71348BF222E09373E0C6B3772F61B528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02FB5C964530F039974CB3772F61BDD1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:to="loc_us-gaap_RoyaltyRevenue_705DB769EE2F80ED2325B3772F6103E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementIncomeLossfromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4827878B741834A0A744B3772F61E3D3" xlink:to="loc_exel_CollaborativeArrangementIncomeLossfromAgreement_019C1399581B9976D133B3772F619398" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0A81E8EC3B30F2280FDB3772F58D54C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C0A81E8EC3B30F2280FDB3772F58D54C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2FA715BC9EDB7EC3B805B3772F587EFF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_062070B8C8EB557E1C48B3772F584CF8" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FF89C7F03A22A2F4293B3772F5889C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9863864CD2663C50837EB3772F58F63D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8C58B5CBA95CD70E4AA0B3772F586E63" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9863864CD2663C50837EB3772F58F63D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9863864CD2663C50837EB3772F58F63D" xlink:to="loc_us-gaap_RoyaltyExpense_14153F918BC5FB009F90B3772F58C4D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CF1656C15EA069051390C8C75259EC1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CF1656C15EA069051390C8C75259EC1C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_AB4445254CBEFF7A2246C8C752590446" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_CA1657E703C59260DDB0C8C75259939D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DBD7F895EBBE9C7DE246C8C7525915AD" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_CA1657E703C59260DDB0C8C75259939D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E77F241A8DF47D2070D7C8C752590D73" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_7EF875C2C5998A385BEDC8C75259104C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecognitionOfDeferredRevenue" xlink:label="loc_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RecognitionOfDeferredRevenue_66D6999988B49A3CC4CAC8C752599484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RoyaltyRevenue_D453EE384B5173149665C8C75259C231" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementDevelopmentCostReimbursements" xlink:label="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_exel_CollaborativeArrangementDevelopmentCostReimbursements_3179C158664498D9329BC8C7525E4272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_13ECE786D979F3C062A8C8C7525EB3EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_CostOfGoodsSold_9BC3C25EC33699DC22C2C8C7525E5304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_RoyaltyExpense_1200E4D8377E14002763C8C7525F3D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94C803D9D77415CABBA0C8C75259AC4E" xlink:to="loc_us-gaap_ContractsRevenue_AD2E38E6599CC1127BCBC8C7525F53D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_938A1C31F81C78665D5ED03D8A30045F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_938A1C31F81C78665D5ED03D8A30045F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_182C4355D4329CF302FBD03D8A30F405" xlink:to="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8A290445AE5DAD033970D03D8A305F1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:to="loc_us-gaap_MinimumMember_8A290445AE5DAD033970D03D8A305F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_0EEBC04B647DA0862F6FD03D8A30F26D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_030807EB5F92640C7CB7D03D8A30F4C4" xlink:to="loc_us-gaap_MaximumMember_0EEBC04B647DA0862F6FD03D8A30F26D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F58EC0A90FBF5897D747D03D8A315730" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BAF5AE726031CDCF21ABD03D8A3134F1" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_F4A2633324BC03BB26B8D03D8A312546" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersAxis" xlink:label="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTiersDomain" xlink:label="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersAxis_1338388F107F22644F6DD03D8A315706" xlink:to="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierOneMember" xlink:label="loc_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="loc_exel_ProfitSharingTierOneMember_07DBA3A21059C91F6DDBD03D8A31D861" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierTwoMember" xlink:label="loc_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="loc_exel_ProfitSharingTierTwoMember_43449A325164315E6164D03D8A3120D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingTierThreeMember" xlink:label="loc_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ProfitSharingTiersDomain_B5D683F09B260FA38940D03D8A31AE05" xlink:to="loc_exel_ProfitSharingTierThreeMember_F44443C61A7F9726B395D03D8A311906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_81B58E3FCA9EDE76A9F8D03D8A313126" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_92703EE8BD4F3715D06DD03D8A31C738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_92703EE8BD4F3715D06DD03D8A31C738" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ContractRevenueMember" xlink:label="loc_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_08A8649F566007D30AD7D03D8A31067D" xlink:to="loc_exel_ContractRevenueMember_DF04A1F028F64FADEF15D03D8A31B102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4765B412F136E979808DD03D8A307054" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_EE46D28656257B1792DCD03D8A31EBE9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementPercentOfProfits" xlink:label="loc_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_ProfitSharingAgreementPercentOfProfits_2288E6A58EE882D5E017D03D8A314CAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementProfitThreshold" xlink:label="loc_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_ProfitSharingAgreementProfitThreshold_4287B0D1A9837238A95BD03D8A31B396" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear" xlink:label="loc_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_39507A8AD8DC541172BFD03D8A31C7D5" xlink:to="loc_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear_0BEBBC1ACEDD4F175041D03D8A3137BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F9A27E3BC28FBC981EDCD07DD0CAE89C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F9A27E3BC28FBC981EDCD07DD0CAE89C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_9CA942107561C53CD2CCD07DD0CA2A10" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_BBAA50A64BEF5DEC153CD07DD0CA2430" xlink:to="loc_us-gaap_RestatementAdjustmentMember_AAEE73B1AA86DD6E51FDD07DD0CB838C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B8B5368FF94D367190BFD07DD0CB148F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_EA5B95952770B305241DD07DD0CB00EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D8BAD8AA0A0162D9BBA8D07DD0CB208B" xlink:to="loc_exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember_2323A22CF53190D50DB9D07DD0CBA8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_836E290C3A77C95F2D63D07DD0CB5F16" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8CB9E5114949F08CFF8ED07DD0CBA2AB" xlink:to="loc_exel_CabometyxMember_A5DE70B4C1F1EDA761F2D07DD0CBE724" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveAxis" xlink:label="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MilestoneObjectiveDomain" xlink:label="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveAxis_B541E33D9519BA38FAC1D07DD0CB8196" xlink:to="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_HCCFilingMember" xlink:label="loc_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:to="loc_exel_HCCFilingMember_954F9F7401CB6741104CD07DD0CBDE5C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_HCCAcceptanceMember" xlink:label="loc_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_MilestoneObjectiveDomain_E72FE2C60FBF1CD36254D07DD0CB3A33" xlink:to="loc_exel_HCCAcceptanceMember_47ED019F3757A83DF1AED07DD0CB282C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierAxis_EDE948A839456FD0C099D07DD0CB0D3A" xlink:to="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_75676C9EFF057C67AF6DD07DD0CBC0E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:to="loc_exel_InitialMember_75676C9EFF057C67AF6DD07DD0CBC0E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecondMember" xlink:label="loc_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:to="loc_exel_SecondMember_F773BD6874A0B44FCD29D07DD0CBA70F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_80161EEE76AB73DEB397D07DD0CB44C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_F55F6F2BE1A0DBD6BB07D07DD0CBE5F7" xlink:to="loc_exel_FinalTierMember_80161EEE76AB73DEB397D07DD0CB44C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_470B467F8827F7E8EEE0D07DD0CC43EC" xlink:to="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0BD631C7B359FE987DAED07DD0CCDA97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:to="loc_us-gaap_MinimumMember_0BD631C7B359FE987DAED07DD0CCDA97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C324F999511FA06C303CD07DD0CCA1C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_E678314DD1065E6D434BD07DD0CC8999" xlink:to="loc_us-gaap_MaximumMember_C324F999511FA06C303CD07DD0CCA1C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_0FA00E71ED5F7C5AE7CBD07DD0CC4DBB" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_09D6C73F62517CF493F4D07DD0CC45BC" xlink:to="loc_exel_GlaxoSmithKlineMember_BFAE5C0C04ADC629DFA5D07DD0CCA508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B91CDFC02133B4A0B784D07DD0CA1C7E" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_6C56010828D4EFCEDA30D07DD0CCD6FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_UpfrontAndMilestonePayments_6C56010828D4EFCEDA30D07DD0CCD6FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_10C8AC8704AC6D720929D07DD0CC06CB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_36AAA326CD027A5E9557D07DD0CCA05E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C9B38D46741EA280984D07DD0CC6B38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_1C9B38D46741EA280984D07DD0CC6B38" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_A9616272908D8B28A000D07DD0CCE520" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_A9616272908D8B28A000D07DD0CCE520" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_C2627D21138681C94DE9D07DD0CCAD58" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_RoyaltyTier_C2627D21138681C94DE9D07DD0CCAD58" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_DF845611E212F0664277D07DD0CC1EBE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_DF845611E212F0664277D07DD0CC1EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_DeferredRevenue_53CA1E57CB256AF90C8FD07DD0CCD0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_82C30BF3106E88E8B5C1D07DD0CC2774" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentOfReimbursementsFromCollaborationArrangement" xlink:label="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_PaymentOfReimbursementsFromCollaborationArrangement_D2C287097192EFDA3E4FD07DD0CCE19D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_DCB7DF2C60DD9AF11CA2D07DD0CCE916" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_DCB7DF2C60DD9AF11CA2D07DD0CCE916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F96984A17AA7347A461BD07DD0CDBD9A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F96984A17AA7347A461BD07DD0CDBD9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_39E1E57D36EF7A32402CD07DD0CD50EB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2A3963459B3A7B0C36F9D07DD0CC102B" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_39E1E57D36EF7A32402CD07DD0CD50EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC8B839446B3C99C470BB4A50A205A9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC8B839446B3C99C470BB4A50A205A9B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2CE5D32AE800E966E18CB4A50A203289" xlink:to="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_BristolMyersSquibbMember" xlink:label="loc_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_8FCAEA6DCCA13F20E317B4A50A20536D" xlink:to="loc_exel_BristolMyersSquibbMember_ED3FD2205170CAD2AA6AB4A50A208B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_DA83E9E475938AD8638EB4A50A207F3F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember" xlink:label="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember_C64AC0EB4DD386B4DDFBB4A50A20E046" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithDaiichiSankyoMember_6F3C92A9A1B540B0E80FB4A50A20CF2C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithMerckMember" xlink:label="loc_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithMerckMember_433C035D890F4335654FB4A50A2092EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithBMSMember" xlink:label="loc_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_CollaborativeArrangementwithBMSMember_40A7C81F603C0DEECED6B4A50A20F182" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SanofiAventisMember" xlink:label="loc_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_SanofiAventisMember_E6BB3B9FD08A741E7A89B4A50A20A1B0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_C3656ACBC22FABBD2AA1B4A50A20DF4E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_590CC62E3B9A471F1FCCB4A50A203645" xlink:to="loc_exel_GlaxoSmithKlineMember_C3656ACBC22FABBD2AA1B4A50A20DF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_2A2D1A343BA0C3943957B4A50A20EFCB" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_9AA34627613CA0E5E5A5B4A50A20C683" xlink:to="loc_exel_GlaxoSmithKlineMember_C3656ACBC22FABBD2AA1B4A50A20DF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_862884873FAE0F6C7F57B4A50A200487" xlink:to="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_39D88AA21E77DDE624D3B4A50A208114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_21167DA5972D983E0B05B4A50A20963C" xlink:to="loc_us-gaap_MaximumMember_39D88AA21E77DDE624D3B4A50A208114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_644747FC4D00979EDCE4B4A50A201E8B" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumPotentialMilestonePayments" xlink:label="loc_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_MaximumPotentialMilestonePayments_EDF14781BAA2FFFD26F5B4A50A2094D6" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment_D54A1A434CE209D1FDB4B4A50A20AECD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory_3BB3D10B12F1A762ED47B4A50A20AB74" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentageofMaximumPotentialMilestonePaymentsCommercial" xlink:label="loc_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial_3A7DCBA5AA9AFE9E993CB4A50A2003EB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_1CF61146E271B1C4F356B4A50A20C194" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_1CF61146E271B1C4F356B4A50A20C194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_BF2DCC6516AC74F7AAF2B4A50A20A96B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_BF2DCC6516AC74F7AAF2B4A50A20A96B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementShareinCostsPercentage" xlink:label="loc_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_CollaborativeArrangementShareinCostsPercentage_C4A2353824F9FD2D984EB4A50A20E5D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement_81471CF2A15CB50D15E7B4A50A203922" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_626A559C468DA3C61902B4A50A20CC2F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_626A559C468DA3C61902B4A50A20CC2F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_3982FE18413B351BB6E3B4A50A20C5DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_CE4AE2238E13C530C671B4A50A20AB2F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ABEE9083051C2B23F59EB4A50A20AD4E" xlink:to="loc_us-gaap_RoyaltyExpense_CE4AE2238E13C530C671B4A50A20AB2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51D0F31FDC8A1F75F29DD2589C758745" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51D0F31FDC8A1F75F29DD2589C758745" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_211F4ABB471BE9DEDBDCD2589C75D02F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833F1B5A90BB477A0014D293EBB832D4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_99FE70992A725E31E6E5D293EBB8E280" xlink:to="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlobalMember" xlink:label="loc_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:to="loc_exel_GlobalMember_E1C7BA3EB4A4124A3DE6D293EBB8E832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_623D135AF23528A60691D293EBB80B43" xlink:to="loc_country_JP_18F12D5F8E5AF69985D2D293EBB93A8F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierAxis" xlink:label="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltytierDomain" xlink:label="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierAxis_27ACD63A39DAC5C56E9FD293EBB9B8D0" xlink:to="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InitialMember" xlink:label="loc_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:to="loc_exel_InitialMember_26DEC08553F21CA82F05D293EBB9A72C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_FinalTierMember" xlink:label="loc_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_RoyaltytierDomain_4346DAEC11317F4F1C05D293EBB910AF" xlink:to="loc_exel_FinalTierMember_D2E21F675335AD48302DD293EBB978A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_19A8E0379D68740E97F6D293EBB93DE8" xlink:to="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:to="loc_us-gaap_MinimumMember_C79087E699167B6DF858D293EBB99E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D8194B84A938D3E9406AD293EBB95830" xlink:to="loc_us-gaap_MaximumMember_485D311A88CD4B8BEE81D293EBB9D897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C88D2134CA72EEE9E547D293EBB97375" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_171ACCB1DCBBCCD49692D293EBB920F7" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_CF02BED360B577B7AFBAD293EBB940CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A8F9C750E14B813A4C32D293EBB863E6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_UpfrontAndMilestonePayments" xlink:label="loc_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_UpfrontAndMilestonePayments_9036259E9A729EDAEFDAD293EBBB00C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DeferredRevenueRecognitionPeriod" xlink:label="loc_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_DeferredRevenueRecognitionPeriod_8BC7B7E5A0147F32E008D293EBBB1E17" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_DCC0E0EB98892C8BDAF4D293EBBC5C3B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FD0FD4D077B933615A63D293EBBDAFD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_B9A5FC064745AFB7ED5DD293EBBD0643" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RoyaltyTier" xlink:label="loc_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_RoyaltyTier_60A95004A8575CFC56CED293EBBDD8DB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent" xlink:label="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent_17D9A67F58E48E842F49D293EBBD09AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod" xlink:label="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod_3A2A2B0ADFD96C0DCA8FD293EBBD0CAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_ContractsRevenue_84DBE8CDFDFBEBB2EE11D294A5C8E6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_DeferredRevenueCurrent_7EE54ED0B5E90C189DF3D293EBBDBB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_425D2317972153D35227D293EBBD28C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PeriodOfSpecificSalesVolumeThreshold" xlink:label="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2FEDD019EB6D7D36535FD293EBBA12B9" xlink:to="loc_exel_PeriodOfSpecificSalesVolumeThreshold_AF9642ADDFE0A0EA72FFD2CE15773585" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E025B4B22785953D43E5B6B5E17D0507" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E025B4B22785953D43E5B6B5E17D0507" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9FB02D95FB07F85D7CB3B6B5E17D7E34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33258DCB47B5D05E234EBFC661F9B92C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33258DCB47B5D05E234EBFC661F9B92C" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_2722803257FC27849B5BBFC661F9DC41" xlink:to="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:to="loc_exel_AlamedaCaliforniaMember_910858EE320DFCAC44B9BFC661F93BD6" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SouthSanFranciscoCaliforniaMember" xlink:label="loc_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_6A574D84C9689AB6A318BFC661F9E59A" xlink:to="loc_exel_SouthSanFranciscoCaliforniaMember_4F3F49942DB3D02E454EBFC661F98EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_191F93DC22FE1FEF1720BFC661F980CC" xlink:to="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StandbyLettersOfCreditMember" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_FC67156CB9892BEBC392BFC661F98F41" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_4510FE71C4596132DF85BFC661F97D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47748D1EC62B323EBA87BFC661F9FCF1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_BuildingShellsMember" xlink:label="loc_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DAAB93D60EEFCD39BB46BFC661F9B66B" xlink:to="loc_exel_BuildingShellsMember_5F567A268A222F929AD8BFC661F9E885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_628E7CB40F6C4CDB4A9BBFC661F9EF0D" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_656855C985ACB42C3973BFC661F91093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_656855C985ACB42C3973BFC661F91093" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OptionalAmendmentAgreementMember" xlink:label="loc_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="loc_exel_OptionalAmendmentAgreementMember_3C40402FD9BC145530EFBFC661F960F8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseMember" xlink:label="loc_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_72E032CC1615530CD075BFC661F93A07" xlink:to="loc_exel_OperatingLeaseMember_A63E2BC1709E24235F5ABFC661F96810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F69C1386139562BAC6CCBFC661F97794" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember_A3196BB2E09B2021B1A5BFC661F97AC8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember" xlink:label="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_BEE4C772A31DEF464857BFC661F9DD79" xlink:to="loc_exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember_C5C149A3B375D4DDEBEABFC661F9E28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1997267E8342717BBF0EBFC661F92A4F" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_B4D6A8EA1281DC2471E4BFC661F93401" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract_0E725C89A6173AB5737DBFC661F96CAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesNumberofRenewalOptions" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CapitalandOperatingLeasesNumberofRenewalOptions_48547426761B9BDE1C2CBFC661F956C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm_1446C13BC2434B3D55BEBFC661F9BF49" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesNumberofOptionstoTerminate" xlink:label="loc_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate_E80F5BE2B6B439FABBFDBFC661F91FFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty" xlink:label="loc_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty_8E9F4D9555A88B5A75BABFC661F9B30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfRealEstateProperties" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_E51B7219690DDA632D72BFC661F98EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_BB39D899E42E5E0402BCBFC661F94DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_927D4800AEA3FA406C5CBFC661F91E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_580B5A1F7696F200CA62BFC661F94715" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue" xlink:label="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue_BC5B7056E4939F183061BFC661F90ECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_13DBBA0300967D4CA186BFC661F943D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentNumberofInstruments" xlink:label="loc_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_DebtInstrumentNumberofInstruments_B49CE04E74B875F8EAECBFC661F902A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_B773B8CAEE679BF5EF51BFC661F91EDA" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollateralProvidedForPurchasingCardProgram" xlink:label="loc_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_E99A040124FB65DA1894BFC661F92C24" xlink:to="loc_exel_CollateralProvidedForPurchasingCardProgram_02BAF55BE974F9552BC5BFC661F99152" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0954F066DC09E6DBB903BDF289AF9C28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0954F066DC09E6DBB903BDF289AF9C28" xlink:to="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_08EC42BD82EFEA1A51EABDF289AF15C0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87AAEE1B495EBA99E49ABDF289AF8E9E" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_4E075DB434CC5C09C9FBBDF289AF0A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasedAssetsLineItems" xlink:label="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalLeasedAsssetsTable_6C950587068F66D4E2F5BDF289AF9F93" xlink:to="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_887245488F8FDE60E13CBDF289B03C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_6C99B034884D73C0DF6FBDF289B040D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_864A9AEA8C546370A046BDF289B03A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD0CE4615D1BD8316331BDF289B047A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_454FD7F14AB8A7B2E26CBDF289B00663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_BC5309542EC9C4001075BDF289B029C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_C77B548AC6CA64CB66D1BDF289B04229" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_5B69712CE605BFB7E408BDF289B0CAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasedAssetsLineItems_B895DD1396EB58E97138BDF289B07145" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_4C5B5347C7A61DE3F4ABBDF289B1BDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_8A922384EC26AE8F0FB2BDF289B1EF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears_46001D1B9C178170C2F4BDF289B1A00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears_E2B4088422466D2BA72FBDF289B104AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears_D7DF68080BB946B8821FBDF289B10E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter_C9C8AE3E51072960454FBDF289B17089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract_77CABC385D94728F299BBDF289B0E370" xlink:to="loc_us-gaap_CapitalLeasesFutureMinimumPaymentsDue_AEA27BE020046C628F11BDF289B1A659" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:to="loc_us-gaap_LeaseAndRentalExpense_0CF9CF193770939A79C1BBBF5857081B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_928BEF6EFD36B4865BBBBBBF58573A06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BDEC980B62BC16670E03BBBF5857F4F1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_4E9FAFC3324CB076952FBBBF585794C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DFEB8F91D206DD8C05AB3772EE1E00A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DFEB8F91D206DD8C05AB3772EE1E00A" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_44B836735CEA5FE9B76BB3772EE1E87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRentExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DFEB8F91D206DD8C05AB3772EE1E00A" xlink:to="loc_us-gaap_ScheduleOfRentExpenseTableTextBlock_BD7843FE6EF53E05631CB46183582A0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommonStockAndWarrants" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_8A8D369F955A894B3F8AB9A111DDC029" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_8A8D369F955A894B3F8AB9A111DDC029" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_095963A24E7C48B62B19B9A4EAC316C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_3567EB2E5CD31B49DD01BEF9A667BF1B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_C4CBB9FFBA92E71408F0BEF9A667EFE9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_95AEF53AD80F1BFFFBFDBEF9A667CC6F" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_67D1856CB5E156C021E2BEF9A6677134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_BF82E73977D94F9F2887BEF9A6671DF6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_39E407C200E66C9266EEBEF9A667368E" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_9ED84D6B175C1AE88006BEF9A667AE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01EEF2315CEA6C50B249BEF9A667E152" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FF147D3008B00034575BEF9A66725C4" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7DEF12A1B87EBDEE3EB7BEF9A6677874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_CB0906BFF361CD81AB21BEF9A6679D2F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6BEAEEFEA53CDF4CCAABBEF9A6775D24" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_3AF09C4820E54633AFEFBEF9A677DFA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_086F4998E7E59F10163BBEF9A667D16E" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_652B1CBDA5C423A6E0E4BEF9A67734AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_BFA08552D7802938E7B4BEF9A677C25A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_A8F06158EAD0052E7F49BEF9A677856B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_34E216F8AAF95FFB6EB8BEF9A6776A0C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_34E216F8AAF95FFB6EB8BEF9A6776A0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CA6BC14B00E9A735FF93BEF9A677D67B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_SharePrice_A3B7E08E85AC6F303D95BEF9A677C668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2A51D160BC3E40695C7EBEF9A67752C3" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ClassofWarrantorRightPeriod" xlink:label="loc_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_exel_ClassofWarrantorRightPeriod_26C0B18B32165176619BBEF9A6774140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_19589DDA04706476F55DBEF9A677B359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_82EEDECF2E0839E72A4BBEF9A6774DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_0037C6507CA68F697E9ABEF9A6771908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4AFFD23B3C23CCBE8172BEF9A67796C1" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4AFFD23B3C23CCBE8172BEF9A67796C1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharesWithheldforConversionofWarrants" xlink:label="loc_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_BC83EBB0F1BAC72EF40FBEF9A677A351" xlink:to="loc_exel_SharesWithheldforConversionofWarrants_32BCDE057D4440E6DD57BEF9A677AD90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:to="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8E0A6219E6D8572AEE68B9A113AB3541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_ShortTermInvestments_BECB659BE84E0E4CF223B9A113AC8CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_A9E644EF27BF21B0E671B9C22DA38A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_ReceivablesNetCurrent_602D917733EF8DBCF760B9A113AC0C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_InventoryNet_254AC5E2A7F5C6E75670B9A113AC1E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5F583F07F0E1F2358F41B9A113AC8E20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E49E77936FB6852A02C3B9A113ABE07C" xlink:to="loc_us-gaap_AssetsCurrent_3D61D6176CC06151AD29B9A113AC5D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_LongTermInvestments_2C3E37CA7553DE0E07A2B9A113AC7081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_15E7344B871F9C08F37AB9A113ACBE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5D28F96C1E7EB132848BB9A113ACC92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_Goodwill_2B913F1F5ACC8E631830B9A113ACA25D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A83FC32E9E3381E7CBAEB9A113AC0EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_20F2A659852715548341B9A113ABA9C4" xlink:to="loc_us-gaap_Assets_00FAE6154937E67A526EB9A113AC6B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_AccountsPayableCurrent_AD0E9E7194F9F30C15C0B9A113AC4552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_334B7AFFC997E33195BAB9A113ACA405" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_526D563835F8390CB714B9A113AC9285" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_526D563835F8390CB714B9A113AC9285" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_78B6179916FB848E2904B9A113AC2EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_EBB79373A3B829F944F5B9A113AC6AB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_707B981B26CAE10F4745B9A113AC2545" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_DeferredRevenueCurrent_707B981B26CAE10F4745B9A113AC2545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_13A093F315AABAA3AAFCB9A113ACE7EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_NotesPayableCurrent_FD0FA52889988ACA184CB9A113AC52CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_333BAD2549E87F518F37B9A113ADA183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95172BCE6222D5BD75CCB9A113AC3919" xlink:to="loc_us-gaap_LiabilitiesCurrent_F3354E0769E446A5D083B9A113ADC700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_706E896E4EEC5180F46DB9A113AD2BDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_706E896E4EEC5180F46DB9A113AD2BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_285C25950D5BA3BB1688B9A113ADFB02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:to="loc_us-gaap_Liabilities_771CF8A2A0C0C43FC65FB9A113AD826A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_A23C93DFF502F6607119B9A113ACEB99" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7530A780F213F52783BAB9A113ADCB7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:to="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="loc_us-gaap_PreferredStockValue_5E12A4DFBC091783E7AAB9A113AD451A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="loc_us-gaap_CommonStockValue_1A8BE271BB1C791622B0B9A113AD6A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="loc_us-gaap_AdditionalPaidInCapital_A80594F925480837D61AB9A113AD6209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99F453E81614A25DEA98B9A113AD366C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4671EF9EB54AC530F1D6B9A113AD8E4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_76DCCE8125B1DA193A41B9A113ADEC4A" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5CCA9CAF4AFED9939352B9A113AD0CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A48E9AB44A0A313DE5B2B9A113AB4728" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_13CFCB1A142607E83E6EB9A113AD5FCC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A10E9D12F6DE476468DFC8DA301BE931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1F26CBBFFF3CBCD78BD8C8DA301B955E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_BFADA26DF71594893691C8DA301B6346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6F5FB350025017A367A5C8DA301BF3F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_091B4483DA91EDDC19C0C8DA302099C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_CommonStockSharesIssued_214DB3A146FDBA782804C8DA3021C8A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C446A283CCA12569948FC8DA3019004F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_73D854FDECF97FD6F4ECC8DA30215D96" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:to="loc_us-gaap_NetIncomeLoss_74DBF2AED57B3D4706B1D2589C9F52FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_B94694D7D13CD69F01B2D2589C9FDE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_ShareBasedCompensation_76CFA4C91C8A09E4C064D2589C9FD51D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_09DAC31000DDECBF66D0D2589C9FF51A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_D6EDBDDE4BE2A7F95913D2589C9F22D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_PaidInKindInterest_DE51EBEC6108B9489644D2589C9FFEF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_609EFBA8802974340E45D2589C9F18B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_DEB20E426F29B8649319D2589CA0B858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_F0B088F456C6AA76C3A2D2589CA0507B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A29FB3A5ED7CB4852298D2589C9FA293" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_4D0DF0DD4E966D11476DD2589CA056E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_67343645518F9E51F0ADD2589CA00A71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2E926BAE842A337EE71DD2589CA00787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1537AFB0EE054970BED4D2589CA0F4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D04743B1631A5A34DAACD2589CA05F83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_511611064DEC6656DE8CD2589CA0D2B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_IncreaseDecreaseAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_exel_IncreaseDecreaseAccruedClinicalLiabilities_0CA520A3F6D2B00ADC87D2589CA05F81" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_IncreaseDecreaseinAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_exel_IncreaseDecreaseinAccruedCollaborationLiability_EE8F4C6C914487365C15D2589CA0443B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_1493526BF6E04E09A361D2589CA019BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_E621D1B1CC008F0A5001D2589CA0B43D" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_959ECC6EC515482DC7A7D2589CA05E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_29591839D41EED931F00D2589C9FFD32" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C5F9AA09FC599D53E9B4D2589CA0F46F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3A2D97C5681A97C744FAD2589CA0015F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_EF2AC0C583BDBBEF0CDCD2589CA03889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_B83DE5C63DDB59B08D38D2589CA070BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F997C20A0FF152BA4C3FD2589CA0F605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_B77CF784A3337CA7E7D7D2589CA09B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_A28D8118181FE1FFFF19D2589CA07B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments_220E47EBB0CA607EAF1FD2589CA0C722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_837458F3C63604A5649FD2589CA15906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F6FB9D2C1D4F0D7AB229D2589CA08B65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1D0826557297F012EAA0D2589CA1E30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_BD336FD3949264D37F6ED2589CA1BA6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforConversionofConvertibleDebt" xlink:label="loc_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_exel_PaymentsforConversionofConvertibleDebt_B2146CA7811CABFE95D8D2589CA1315B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C0F3B1DF157CD3229F3BD2589CA17DA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_47CEDEBDBE0F35EC3B1BD2589CA132F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_us-gaap_ProceedsFromStockPlans_9EFBBF5D95DE04D082F3D2589CA13F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_D97D03D2C3E1126A59F1D2589CA13D9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3546306B2D85E046703AD2589CA13344" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DECFBA3572B5242B57A2D2589CA1B455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_90BD2959A5A2D43102D6D2589CA14286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_662687BD419F2F5D808BD2589CA18AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C6D0298809ED7E2E405CD2589CA1CD22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:to="loc_us-gaap_InterestPaid_293D9D6D50473F69AD20D2589CA189A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_78F061CD28F495F3DDFDD2589CA1FBE7" xlink:to="loc_us-gaap_IncomeTaxesPaid_9BD9EA8DEF2EE865694CD2589CA21E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_A90EF6111D63AD39DFFBD2589C9F431C" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CIPdeemedacquiredinBuildtoSuitLease" xlink:label="loc_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:to="loc_exel_CIPdeemedacquiredinBuildtoSuitLease_70230300D71122FBE4C5D2589CA22A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_017D21BCC05FC80F0A1FD2589CA29CCE" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_7956AD4B390FC19277E3D2589CA28F6D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AD0757FE2F90BB8C4EE2D2589CAE4CA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0E74ABD447ACB86B4231D2589CAEDAE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AD0757FE2F90BB8C4EE2D2589CAE4CA6" xlink:to="loc_us-gaap_NetIncomeLoss_0E74ABD447ACB86B4231D2589CAEDAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AD0757FE2F90BB8C4EE2D2589CAE4CA6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5DF501BC3B5AA1841A50D2589CAF2157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AD0757FE2F90BB8C4EE2D2589CAE4CA6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_394CDFF2888C83371031D2589CAF6CBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_05D2C64C92A3A0C192E9D07DD1023065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1390ED39876467FA0D89D07DD10260B0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_ED0F1CE168692BC8A702D07DD102C564" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_D14C29473F4BBDC7442DD2587B5AD9A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_A774C32B3CB55539AA54D2587B5BE7C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:to="loc_us-gaap_ContractsRevenue_A774C32B3CB55539AA54D2587B5BE7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_0EE7E07D5F61CAD0F3B8D2587B587DA6" xlink:to="loc_us-gaap_Revenues_DEA09CEC0968D660F5BCD2587B5BCF52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:to="loc_us-gaap_CostOfGoodsSold_40DCC6CA33E49DFDA865D2587B5B213A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2046A9785BA41315C607D2587B5B627A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E7D5F79CAB0E73F914E0D2587B5B0981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:to="loc_us-gaap_RestructuringCharges_55B3187E4AC5B7F7AF48D2587B5BA3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C48059397B90C0EA0FE6D2587B5BB602" xlink:to="loc_us-gaap_OperatingExpenses_6407897FBE79433F3C8FD2587B5B09BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_OperatingIncomeLoss_CE082806852F9AF9598DD2587B5B386B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:to="loc_us-gaap_InterestIncomeOther_AF87CAEC343A565A9F34D2587B5B3B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:to="loc_us-gaap_InterestExpense_950CE1C90EB6ED63BBCFD2587B5BB522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_EFD9C74CAD6C230FD59CD2587B5BF482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_29C4BB393459030508E7D2587B5BD127" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B4FF12364ED959189927D2587B5CFD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_6FD26C4E58A5A738CD87D2587B5C7B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_FA9B9459CB5E30069645D2587B5C5513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_NetIncomeLoss_A6EA5F09EBF6012F3F8ED2587B5C2B70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_6338B5563276FA84DF61D2587B5C6764" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_EarningsPerShareBasic_6338B5563276FA84DF61D2587B5C6764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3279E2948E6C66FBC48ED2587B5C7CF0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3279E2948E6C66FBC48ED2587B5C7CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7AA55C641542A8C29F9AD2587B5C50D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_B6D9E13E0D1D139EE15ED2587B561A69" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_DF176AAB90D2E1FE9A78D2587B5CFD4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E8E05E85262498323D25BBBF59AF089E" xlink:to="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3AA3B59E9D70B89125C9BBBF59B0B264" xlink:to="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_CommonStockMember_BC5898AD9FA6C680A8D5BBBF59B00C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2EE8016B17403EC1A83EBBBF59B009F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_32582D6F4867B4334E1FBBBF59B0F6F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7859E20278D94976C30ABBBF59B0E016" xlink:to="loc_us-gaap_RetainedEarningsMember_1F41CC7389E29EB3C22DBBBF59B07412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5649E6C069FB432A898CBBBF59B09658" xlink:to="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D0ED4763F8F06CD5A88FBBBF59B00B49" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_D750C8CAC5D34800E9E2BBBF59B0B923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_228FDD5B350E12CB64C3BBBF59B0C5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_26F69D091C906A3D9E5ABBBF59B05705" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F89551319C8B8B14178EBBBF59B0D45F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_NetIncomeLoss_F89551319C8B8B14178EBBBF59B0D45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41124B2C3365D5C7027BBBBF59B056F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_93A095DE1FB0E3B354F3BBBF59B0AA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3D70205BBE7EC14769CFBBBF59B13EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0B03A7A6E38B8CDCE253BBBF59B1967F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_009EF04AE4353007160BBBBF59B1D666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_FEB87E4D67ED70AA760EBBBF59B11F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_17FF5F289F03873A1761BBBF59B1477C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_925132257617A9A01378BBBF59B1829A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_070F956597A78C4BE0D7BBBF59B139F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_67D567F6C11E494DF46BBBBF59B151C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9C8065C700C5557EFDADBBBF59B1DFA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6826A99F66C382800A62BBBF59B19BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_23C1DBB3D8BF3FB62421BBBF59B0BCDE" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3CBF52E820323B7D0B3FBBBF59B11E16" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_34956D44E7A47F4702AEB6B5E3BB5569" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_68FB1DCF29BB04C1909CB6B5E3BB4C89" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Debt2019NotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F5F612BA6FA57283AA6FD293EAD2E8F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F5F612BA6FA57283AA6FD293EAD2E8F8" xlink:to="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4CBA2628AC6640D1903BD293EAD2373E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_3D34607FF675998ACE76D293EAD29444" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_CB9530509A89D03827A3D293EAD2C596" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_3D34607FF675998ACE76D293EAD29444" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:to="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_70745342F7CDBB3851FED293EAD2DD5A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_2898097C5EE8A9E1548ED293EAD2428C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F37FEB6F7E8E4A108F4BD293EAD2D744" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_2898097C5EE8A9E1548ED293EAD2428C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CF2DAD3808C85FA68C95D293EAD2CB04" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_LongTermDebt_D4363271B6B3FAE32C73D293EAD2B428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3E79C562FCB0E4DFD609D293EAD38716" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3E79C562FCB0E4DFD609D293EAD38716" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentRedemptionofConvertibleDebtAmount" xlink:label="loc_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_exel_DebtInstrumentRedemptionofConvertibleDebtAmount_80971C0A28649FBF272DD293EAD382E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_16C4FBC0642A29B1169FD293EAD3E240" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforInducementsofDebtConversion" xlink:label="loc_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_exel_PaymentsforInducementsofDebtConversion_084E80C23F9E205B7A2AD293EAD39792" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_350C899F9F3E90538907D293EAD3E7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42570075BC384F575F61D293EAD3D213" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_42570075BC384F575F61D293EAD3D213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_AA9A590B979D03EE5B93D293EAD3EFE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12657FAF7CF86EF29FABD293EAD33E9C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4316ADACD38847682BDED293EAD2973E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12657FAF7CF86EF29FABD293EAD33E9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E3FD56BD1C0405451574B3772F370A15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E3FD56BD1C0405451574B3772F370A15" xlink:to="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_BDCB3D18F3183C4874C1B3772F38D387" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_6165D547D6C78E77C6EDB3772F38759D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:to="loc_us-gaap_ConvertibleDebtMember_6165D547D6C78E77C6EDB3772F38759D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_721B2EA6C01B7B90E1F3B3772F381F53" xlink:to="loc_us-gaap_SecuredDebtMember_CEF949FAA314F68C1501B3772F38C557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0EBA289B733858755293B3772F374837" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:to="loc_us-gaap_LongTermDebt_B9C30FA174361BCFE7F5B3772F38F304" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses" xlink:label="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8CE5731D4A0DF03C7E67B3772F387252" xlink:to="loc_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses_71748C7BFB1E2D425EE8B3772F3860B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C1EE894B8361592B37F5BF9F198B5BC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C1EE894B8361592B37F5BF9F198B5BC7" xlink:to="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeAxis" xlink:label="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InterestPaymentTypeDomain" xlink:label="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InterestPaymentTypeAxis_FC6D0BA02D293540CE2CBF9F198B5CCE" xlink:to="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CouponInterestMember" xlink:label="loc_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:to="loc_exel_CouponInterestMember_7C4FEDC1DAD0E73A7948BF9F198B7099" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentinKindInterestMember" xlink:label="loc_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InterestPaymentTypeDomain_67BB73859121BDA60BB2BF9F198B201C" xlink:to="loc_exel_PaymentinKindInterestMember_4049B27576D48CD205C4BF9F198BB300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_10CAB4989E0D8E5C7783BF9F198BF174" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_584E03E2DB8EAC7C5AF1BF9F198B5F85" xlink:to="loc_us-gaap_ConvertibleDebtMember_C237996A9605085EF83DBF9F198B59CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070D5AF0327AC827E8ABF9F198B0C36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_97FDEDAEE1A541B0DD1EBF9F198BAB64" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_B3108BA929F38DF2D52FBF9F198B171F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_BA35B5B40B88FFD552E1BF9F198B2457" xlink:to="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtIncludingPaidinKindInterest" xlink:label="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_exel_ExtinguishmentofDebtIncludingPaidinKindInterest_C1F7A68C229A1337DD65BF9F198B8E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_28B730EB769CAF6FB6D6BF9F198BEFA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_PaidInKindInterest_B5700E14AFC1A1776728BF9F198C3895" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentPrepaymentPenalty" xlink:label="loc_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_exel_DebtInstrumentPrepaymentPenalty_888665DB6C2D79691E34BF9F198C076E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_InterestPaid_C7FE8B588E36AD553505BF9F198C5227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9279435A013892BFF699BF9F198C668B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection" xlink:label="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_60CA2538063675BFBD62BF9F198B8F5C" xlink:to="loc_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection_4BBE70A3EE13992B9B2ABF9F198C48C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F76A1E5C0FE4573376FCD293EAC3D8CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F76A1E5C0FE4573376FCD293EAC3D8CA" xlink:to="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7F89BBF1ED3CF54B9BC6D293EAC30F60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_80CF41D4929C52E0B033D293EAC3FED7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_038C7DF6437780A6D2B6D293EAC3A8C2" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_80CF41D4929C52E0B033D293EAC3FED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:to="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_051900CE774761B3EDB9D293EAC9C8E4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_96EF0BAB415A5E08FC85D293EAC9BAC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D45FEAD42F8438CFF389D293EAC99B70" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_96EF0BAB415A5E08FC85D293EAC9BAC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_29AD75781BDA884D693CD293EAC37CFF" xlink:to="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentsforInducementsofDebtConversion" xlink:label="loc_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_PaymentsforInducementsofDebtConversion_C5296D6D10474031553DD293EAC9D10F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness_7E7CA703A244C7E298F1D293EAC9316D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue" xlink:label="loc_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue_2A452A4D9089DC332E47D293EAC92D15" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts" xlink:label="loc_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts_CAD66FC3D0C6A2F3DFD6D293EAC98A5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LossonExtinguishmentofDebtTransactionCosts" xlink:label="loc_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_exel_LossonExtinguishmentofDebtTransactionCosts_F6B8A10B7C28E5F2D98CD293EAC92E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D2CF1F65F0C56C72A73DD293EAC9F75E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_52BD9E04A059E6C67561D293EAC99268" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_D2CF1F65F0C56C72A73DD293EAC9F75E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_83BEDFBD54FFDF0B6E00B006400C2E05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_83BEDFBD54FFDF0B6E00B006400C2E05" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_5C762153C0ACD1975873B006400C4C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_83BEDFBD54FFDF0B6E00B006400C2E05" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock_ED5DA2C56DD0A4CAF6DEB006400D2AB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DebtTermLoanPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_28FC23BBD8F8CB4ADE24B8D7474E7180" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_28FC23BBD8F8CB4ADE24B8D7474E7180" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8C7B9C1E9DBBF914B852B8D7474EE376" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_14FBC7385182387BDB12B8D7474EF11D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5F9FC0DB80280845942BB8D7474EB3A1" xlink:to="loc_us-gaap_SecuredDebtMember_14FBC7385182387BDB12B8D7474EF11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:to="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F08E2F089835FD3E7A24B8D7474E13A1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EFD3531F55F906E6A9CCB8D7474E7888" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_B530670FAC40429CBE86B8D7474E9224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtLineItems" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_FE2943D31B8D93856CB1B8D7474E464E" xlink:to="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_InducedConversionofConvertibleDebtExpenseAbstract" xlink:label="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_0F3AAF0B0CB639F8187FB8D7474EA431" xlink:to="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_E43310B23537B455A685B8D7474E4A9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_E43310B23537B455A685B8D7474E4A9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_E262CB4015B21A5CFFF9B8D7474ECFC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_InterestPaid_E262CB4015B21A5CFFF9B8D7474ECFC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_43AFF6B4345F998716BAB8D7474E88BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_InducedConversionofConvertibleDebtExpenseAbstract_6589C26D063538318D68B8D7474E773C" xlink:to="loc_us-gaap_CompensatingBalanceAmount_3B4DF96973463856D866B8D7474E4E2F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="exel-20171229.xsd#exel_DocumentAndEntityInformationAbstract" xlink:label="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_DocumentType_7987AA30B5A65D29CEB7BA12702ABE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_AmendmentFlag_9E02EAFCA3FB6DAFEC44BA12702DE72E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_DocumentPeriodEndDate_6BE7A0D7F46064242FDFBA12702DC14B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_DocumentFiscalYearFocus_4F90F8C807768CF1915CBA12702D90BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_DocumentFiscalPeriodFocus_FAF434EACEF65BF61CA2BA12702EFF7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_TradingSymbol_972AB41B8846E790A54FBA12702EA717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityRegistrantName_7718259106C8704CFF5ABA12702EE81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityCentralIndexKey_3E347807F85279524C38BA12702EEC8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityFilerCategory_E79DA827B3C5C73CE5EEBA12702E4421" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_CurrentFiscalYearEndDate_BFF29369E6E54D22EEE1BA12702E3902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_A927D993681D15E9D0F6BA12702E5570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6DEA30BFD337125B8188BA12702EF9A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityPublicFloat_DFFB592E04D85B87D472BA12702EBF20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityCurrentReportingStatus_10A346346AE3BCF9DD56BA12702E8D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_DocumentAndEntityInformationAbstract_9F16DC4BB9E22179463DBA1270254E15" xlink:to="loc_dei_EntityVoluntaryFilers_54EB3E5D4874155518B8BA12702ED85D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06AC9CE24939783DCCC4B6B5E0CF1AFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06AC9CE24939783DCCC4B6B5E0CF1AFA" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2792D22847372B85E3AFB6B5E0CF2E08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_106B151390707D972B5AB3772EE5571E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_106B151390707D972B5AB3772EE5571E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5C221147D3550961110AB3772EE58AF4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_D99AD3BA5EBDCC551F46B3772EE5A56B" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9030374A1ED842625E79B3772EE5F42A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6D8B768B6A1101A1B3FCB3772EE5B6EC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeniorSubordinatedNotesMember" xlink:label="loc_us-gaap_SeniorSubordinatedNotesMember_661C57E96C3412D8EE28B3772EE51984" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4B2EB9C3B1B2B9690F02B3772EE5A6AD" xlink:to="loc_us-gaap_SeniorSubordinatedNotesMember_661C57E96C3412D8EE28B3772EE51984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_CCDAB69C9856D95DD3E3B3772EE5DA95" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_0A975CE63CF6FA679DF2B42D3594AE33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_0A975CE63CF6FA679DF2B42D3594AE33" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_6D69C9F700F4E43B1B76B3772EE52352" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_19E07C7F8FE1B38DD2AEB3772EE5155F" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_6D69C9F700F4E43B1B76B3772EE52352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_B5C7A654C768D7FA5572B3772EE5F639" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_11BE1D15A4BB56ADB4D5B3772EE5634E" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_3A57EC09D77017D4C5A5B3772EE59EE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2E98D6FA5539BC0A9565D041C3F4B3CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2E98D6FA5539BC0A9565D041C3F4B3CF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6251ACA9EC6821E7549ED041C3F4B768" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_C156811C0EC2963EA212D041C3F4D4FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_45DF17F40638A0B6B77DD041C3F407F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3614A88E4BEC86BA29A0D041C3F42149" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9ED83C7D5772A7369BEED041C3F47AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5EC4FD07A7E45803F974D041C3F424FD" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_62653D5D1E4449056DC9D0591079FBCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:to="loc_us-gaap_ConvertibleDebtMember_62653D5D1E4449056DC9D0591079FBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_878BA31DA0F0434C022DD041C3F4FEF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_53EE32C578392BC301E5D041C3F4FE8E" xlink:to="loc_us-gaap_SecuredDebtMember_878BA31DA0F0434C022DD041C3F4FEF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ECB7CAF89F19ED68F36FD041C3F45385" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D389A6C321CD876BC27BD041C3F479B6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ECB7CAF89F19ED68F36FD041C3F45385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ECB7CAF89F19ED68F36FD041C3F45385" xlink:to="loc_us-gaap_LongTermDebtFairValue_D97C1D23C9A5DD40481AD041C3F4EB60" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_AA6AD81A4BE7309F8561BF55EDAD6BC4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6448654343501231AE09BF55EDAD6E14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_07572759B4C24B27107EBF55EDAD15DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5D24ADECD9DEA97EE564BF55EDAD70FF" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_03896F4B2E7759B50ED7BF55EDADDACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:to="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_EA96F0FDE7B90869317BBF55EDADD065" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_MoneyMarketFundsMember_97465509578F812457ECBF55EDADD60E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_0CCA9AEB37A9504557E6BF55EDADCEE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_CommercialPaperMember_0CCA9AEB37A9504557E6BF55EDADCEE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_532C8D45A35F544A0C08BF55EDAD7846" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_532C8D45A35F544A0C08BF55EDAD7846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_FDA922D6333A8608681DBF55F05B3CD8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_934A5ED3D0D7A7A6FD99BF55EDAD1EFA" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_FDA922D6333A8608681DBF55F05B3CD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_658AA57621C3B571202DBF55EDAD4603" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="loc_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1C5B7B517BAC984E58D3BF55EDAD1DD0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureRecurring_943EB962400327B82345BF55EDAD81BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7BADE45EBFFB78D5AA11B3772EF06524" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7BADE45EBFFB78D5AA11B3772EF06524" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_8C0AB4B8C8422AB3B648B3772EF00AD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7BADE45EBFFB78D5AA11B3772EF06524" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_F067D707F79A0376D66BB3772EF06E27" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FE943583F2C24BF74B67B6B5E1BCE22D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FE943583F2C24BF74B67B6B5E1BCE22D" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_B633913E8B132B83BC96B6B5E1BCFD51" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_00ECB6162A2CA3D3B66A0A33894E784D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2D9E03E1D6D1D46078C90A33894EF3EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_B50855B5299DBA4E78FF0A33894EC415" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_BEEF382355EBA06808360A33894E3961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_FC5FF0B17BB70DEE7EAF0A33894EACCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_98C9128478E0C7230BF20A33894E65A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ED407656D3797435DB300A33894EF916" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_B7EDA0208CD852C686610A33894F9DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B92B6EF6C262C37E982E0A33894EABD5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_C94D9A96FDA8CAB3315F0A33894F6EB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0FA15AFC4B145D51317EB9A111A6FA55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0FA15AFC4B145D51317EB9A111A6FA55" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_FEC283272522C5AAC686B9A111A7AAB4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_7880EA726C33ECA27507B9A111A7BC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_32ACC7169619CD1BDCF0B9A111A76B3B" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_BC535EC50F6D30584A45B9A111A796EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_B25885CE92A9EACA167FB9A111A7DC88" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D42EA4098D61BF9815F3B9A111A7A052" xlink:to="loc_us-gaap_ResearchMember_F6E448C0519B8D99DA4AB9A111A7A468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_904BD84A2D356BDAF4C3B9A111A65FD5" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross" xlink:label="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross_2826B20331E00A6C46A6B9A111A7E28C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance" xlink:label="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance_395CBA0E20C46667CAA2B9D60C0EC0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_F20C3B9E44FCE0B3F220B9A111A78B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_OperatingLossCarryforwards_243D513CAD8762CD2166B9A111A752DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_5B67C4EB4A8B013B1CB1B9A111A7B552" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1C7354E74449EC29926BB9CFC78ACB29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06495868E9C7ED7B7714D2589B1A1107" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06495868E9C7ED7B7714D2589B1A1107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_AE8F964DDF2381C72BDDD2589B1AAEF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06495868E9C7ED7B7714D2589B1A1107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_E91B1C48B243085D9096D2589B1A2340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_83E3DCA35EB29E527AD3D2589B1B75FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06495868E9C7ED7B7714D2589B1A1107" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_83E3DCA35EB29E527AD3D2589B1B75FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_D8D5C56D0F23581A167BBFADA6721CD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D8D5C56D0F23581A167BBFADA6721CD5" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_02D46F099E7302F91117BFADA674C512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E34060F60CBD9BC7E65ABFADA674BE01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4B107DDC855AED18A856BFADA674B5CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_B3CC3C27164D10F8DAB4BFADA6745CC9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified" xlink:label="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified_A069D361931CB81D91F8BFADA674711E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_553F417D359CAE8C2EEABFADA674D766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1C4780BA3972F012D5DCBFADA674739F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_94CE19DB26042C3251D0BFADA67442AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2127A1AEE78600B92EFCBFADA67461BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_7BE6702379641114C1DDBFADA674584C" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_4CA1755B4E4294929B24BFADA67472EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D8D5C56D0F23581A167BBFADA6721CD5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_E042A52DE3F17FCFA78CBFADA6751B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_D702489D42BE75333851BFADA675F1E7" xlink:to="loc_us-gaap_DeferredTaxLiabilities_C9BFF9770F2D956A19C0BFADA675ECD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_D8D5C56D0F23581A167BBFADA6721CD5" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_131A0DE085C223EEB891BFADA675B95E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F12EEB34A4844A513AA5D293EA202A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_E297D10C9D44B261046DD293EA205146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_256A7FB80D49C42D5FE7D293EA20DABE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount" xlink:label="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount_00D4B67BC88AB66EB6A9D293EA204D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_A9262073B3E741FD4156D293EA200DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84BF44BF5DF17F02DCA4D293EA2048BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_8B9EA31D979817439D28D293EA2079D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_58665AAA7DF149E3B495D293EA2037F5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BF4C988A52C70C5C3F75D293EA20BDFE" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_58665AAA7DF149E3B495D293EA2037F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_607C64A4D8F5ABE9B60E8C339875485F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_607C64A4D8F5ABE9B60E8C339875485F" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3823E99C27274E0B2CF88C339875C98F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions" xlink:label="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:to="loc_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions_8B2889D7E7AF68015E198C33987A20ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_070B5FA0A3DD44517B6F8C33987A7781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_F5A2AEB660482355EA6F8C33987B0B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_E6C16E10ED40763962888C33987558C1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_0B82C116A5DF49040BE28C33987BFFF3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_BDEA9B86E255AE3E2695B6B5E300E7CE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDEA9B86E255AE3E2695B6B5E300E7CE" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_07D01C88EDFCCC454266B6B5E300EDB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDEA9B86E255AE3E2695B6B5E300E7CE" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_C4EC644E6DF290A1E72FB6B5E3002FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDEA9B86E255AE3E2695B6B5E300E7CE" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_979443BCF1400912D4CFB6B5E300FB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDEA9B86E255AE3E2695B6B5E300E7CE" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26A3D885B01386414167B6B5E300866B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BDEA9B86E255AE3E2695B6B5E300E7CE" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_F7D640C8ECE185C38CACB6B5E300221F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3E0044D340302A943044B6B5E31040E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3E0044D340302A943044B6B5E31040E1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_56D9C6E566F067AF5245B6B5E3102785" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_B9DBF4B25837828385B3B3772F4564B0" xlink:to="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B01603316801B2F61BD5B3772F4568A1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:to="loc_us-gaap_InventoriesMember_17129BD7A9694ADBA096B3772F453FDF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F1E4FC0FE1149E746FB9B3772F45E30D" xlink:to="loc_exel_OtherLongtermAssetsMember_5CB1B034C2B0159DCAA7B3772F45C11F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_F916DDBED1593F4347F9B3772F458C5B" xlink:to="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryRawMaterials_F6FA5F650AFD5048D0DBB3772F45CF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryWorkInProcess_CA170CDEE8A8B0F9B2ABB3772F468DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryFinishedGoods_7F3EF15059C03C6E5759B3772F46A407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryGross_B8783E05D75EDA762DAAB3772F46CEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_6366A0E8085418D3D0CCB3772F45D4D3" xlink:to="loc_us-gaap_InventoryWriteDown_E2DBF23BC539776E28C9B3772F46CACC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_195C0BD032CC3791FAB4B6B5E17DA1FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_195C0BD032CC3791FAB4B6B5E17DA1FE" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_C49E29075139C899A0BCB6B5E17DD863" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Investments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A282B9A8CBE86D9C7FB5B9A11291CBAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTextBlock" xlink:label="loc_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A282B9A8CBE86D9C7FB5B9A11291CBAA" xlink:to="loc_invest_InvestmentTextBlock_9BCD490D9DF73AFED085B9D8C6FFC76C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5184D631C012F6FBCA93BF485E9E773F" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:to="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1F3D61E32FF90ADC623CBF485E9E5B6D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_769A0083B9575EAB1169BF485E9EE493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_964988A5D4294137E3BEBF4860A14194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EF6616FB3802A4876401BF485E9ECCBB" xlink:to="loc_us-gaap_CommercialPaperMember_12CC1D37D7D796E18078BF485E9EF111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EA59C0F0E0626E6EA871BF485E9E26AE" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_79075CD516197444565DBF485E9E4CBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses_F78B594778E04042F3CABF485E9E3256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_5B6B97EFDCF4BE05FBA9BF485E9E8C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses_B8C0EFFF6C60F7203316BF485E9EB8BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A7D81F5F3989F41206D5BF485E9E866A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_69DF74DCC7F9BDE3A90FBF485E9EF4AB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses_3386F249D00786C6C626BF485E9EC894" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C9D3F01F86CF49C4224BF4B38301B69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3C9D3F01F86CF49C4224BF4B38301B69" xlink:to="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:to="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3C06DD776A9E4D72ED06BF4B3830656A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SiliconValleyBankLoanAndSecurityAgreementMember" xlink:label="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C24CF69BDFD9D65CC28EBF4B3840DB34" xlink:to="loc_exel_SiliconValleyBankLoanAndSecurityAgreementMember_2343B6B7C97EEE06D2C2BF4B384078AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentAxis" xlink:label="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:to="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentDomain" xlink:label="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentAxis_C7B95FB621E1586004B0BF4B3840D109" xlink:to="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AkarnaTherapeuticsLtd.Member" xlink:label="loc_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentDomain_E5E471F50E550A167CD5BF4B38402398" xlink:to="loc_exel_AkarnaTherapeuticsLtd.Member_8A0D7100C2F2AF10B227BF4B38409CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_6EAA39C020BD1D3FE64CBF4B38309C61" xlink:to="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_DB45D04399BE04C052F1BF4B38402BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_A1E36457A2797B30A8EDBF4B3AC0D04B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_04CCDD36F643F077402ABF4B3840EA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensatingBalanceAmount" xlink:label="loc_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_CompensatingBalanceAmount_4309C33AFCDC71CEF847BF4B3840D419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostMethodInvestmentsRealizedGainLoss" xlink:label="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_us-gaap_CostMethodInvestmentsRealizedGainLoss_AEB08D93F4B1A7413220BF4B3840529A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CostMethodInvestmentOwnershipPercentage" xlink:label="loc_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_08105DF81674C9DC0E84BF4B3840EF7C" xlink:to="loc_exel_CostMethodInvestmentOwnershipPercentage_CED1ADA1C09467BC3F91BF4B38407EBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B42D85178C7FDA43A6C6BBBF58D652A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B42D85178C7FDA43A6C6BBBF58D652A2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ED71F805ACD42BDA91A0BBBF58D6CBB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B42D85178C7FDA43A6C6BBBF58D652A2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0D40772D72C296F1DD42BBBF58D669B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B42D85178C7FDA43A6C6BBBF58D652A2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1B4812E8FF4B78519E2FBBBF58D67C43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8F005C35D473D69CE1C4BF470FE75DF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8F005C35D473D69CE1C4BF470FE75DF8" xlink:to="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:to="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_1D58109D51F757BF5973BF470FF6CD43" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3D455E40FE0DDCF3F798BF470FF6E87C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3D455E40FE0DDCF3F798BF470FF6E87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_BADB91694A4F28B4D0C1BF470FF6CC91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_CommercialPaperMember_BADB91694A4F28B4D0C1BF470FF6CC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_83169D4A9389C699D8AEBF470FF64743" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_83169D4A9389C699D8AEBF470FF64743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_C0D8ED4E8E0DCCACBE55BF471257143D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_476E004AEC5679AD0D38BF470FF63F6F" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_C0D8ED4E8E0DCCACBE55BF471257143D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_76691777BA9B5771DCFEBF470FF6E28C" xlink:to="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2534E05A44760C541632BF470FF6312B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F1B6727BB10F6A20660BBF470FF66E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48965908422CEE2DB80BBF470FF6BDCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_BE732E2EF61EC5ACD7A7BF470FF6C8D3" xlink:to="loc_us-gaap_AvailableForSaleSecurities_EAA22090692BCB88E904BF470FF6F806" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71185B90EDEB91B25958B9A1128AA105" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71185B90EDEB91B25958B9A1128AA105" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_FCA387C47986915668A1B9A1128AD63F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71185B90EDEB91B25958B9A1128AA105" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_B392FF29EFE1C0154E46B9A1128AF663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71185B90EDEB91B25958B9A1128AA105" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_B885DFD7203E5DEA38C6B9A1128A6C50" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30DA435AC5FAF4981FE4B9A111A2CA09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30DA435AC5FAF4981FE4B9A111A2CA09" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_DF4BF714A6214876BC1CB9A111A29488" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_32F1D1B56A462ADA98D8D2589AE08860" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_32F1D1B56A462ADA98D8D2589AE08860" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:to="loc_us-gaap_NetIncomeLoss_9D6FB27CDCD10BECC458D2589AE03388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_12E96A067C66D7CB0B98D2589AE134CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_FD1FB173FBCD49C32623D2589AE13D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_F512171ED8D23A145579D2589AE1F323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_BF44FAC7663297ED5649D2589AE0482C" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1692EBFAD7218EFD68F1D2589AE136C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_32F1D1B56A462ADA98D8D2589AE08860" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_D25BB0F23C905EECE3CCD2589AE10EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_345D20C77A52AB32D067D2589AE1DC5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0DA60DFDB7559F585212D2589AE14F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:to="loc_us-gaap_EarningsPerShareBasic_203E0DB956F4439EFDF7D2589AE12C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_92709425F96FEB98C562D2589AE10976" xlink:to="loc_us-gaap_EarningsPerShareDiluted_113D1A7B0F50E80242DDD2589AE16D7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_62A1882EC4BA6574E727B9A1119A42FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_62A1882EC4BA6574E727B9A1119A42FA" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:to="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8899BDB4AD821500D2FCB9A1119A08C8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SecuredConvertibleNotesDueJune2018Member" xlink:label="loc_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:to="loc_exel_SecuredConvertibleNotesDueJune2018Member_529B7AC4483EEB82D33AB9A1119AFC6E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member" xlink:label="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_7685A9729D6D6B00D1B4B9A1119AE85E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88A36B04E4735E887153B9A1119A7567" xlink:to="loc_exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member_7685A9729D6D6B00D1B4B9A1119AE85E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AEB19BDABCD9A523DE94B9A1119A461D" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="loc_us-gaap_StockCompensationPlanMember_2DCF2B97264DB6FF1465B9A1119AC859" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_B7723374CC285E4EA0C8B9A1119AA0D2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember" xlink:label="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_9CACB18AAA9EE5EA0E56B9A1119ADE46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_95157344F1C11EC8BCCBB9A1119A9F45" xlink:to="loc_exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember_9CACB18AAA9EE5EA0E56B9A1119ADE46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6158D2FDAA317407D2A3B9A1119A0D91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A5B6D1720BDD348C0874B9A1119A6592" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C3710F0ED020B7DA1313B9A1119A9279" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7FEDA4101F904A1065C1B9A111A1DBD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_983A552D6EB472866DF4B9A111A16D1A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22C9C54C887BA8713457B9A111A113F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0657A43F2EDCF52ADD7B6B5E1EB4411" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B0657A43F2EDCF52ADD7B6B5E1EB4411" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_EA8BD789BCD71C67B40CB6B5E1EBEDA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B018A0821C717F9EA092D07DD0D494DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B018A0821C717F9EA092D07DD0D494DF" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_362DF5E60D5F0E85CB3AD07DD0D4BCAD" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ChargebacksandPromptPaymentMember" xlink:label="loc_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_exel_ChargebacksandPromptPaymentMember_560B1A75A50D3025EBD4D07DD0D4F3B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OtherDiscountsMember" xlink:label="loc_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_exel_OtherDiscountsMember_72D4BE6835F44646343CD07DD0D42F7A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RebatesMember" xlink:label="loc_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_exel_RebatesMember_BD9924110294DAD93F8FD07DD0D58FF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2170757AFFAADFF0DB12D07DD0D4C1E1" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_81307B96FECA71289E22D07DD0D5E298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_CC111FDE3CA5F327C801D07DD0D46665" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ReserveRollforwardRollForward" xlink:label="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_6540E18CA14E584B0620D07DD0D5B144" xlink:to="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DiscountsandAllowances" xlink:label="loc_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_DiscountsandAllowances_D9500476A5032B04921CD07DD0D5045C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_299D8649947311309BA2D07DD0D5CBFB" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment" xlink:label="loc_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment_20D23FB986D7340B9874D07DD0D5B656" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PaymentandCreditsIssued" xlink:label="loc_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_PaymentandCreditsIssued_3A8DFD788C2CCB856496D07DD0D51619" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DiscountsandAllowances" xlink:label="loc_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ReserveRollforwardRollForward_FF5075A50319BE77EEE7D07DD0D50BAA" xlink:to="loc_exel_DiscountsandAllowances_34CC1437E6D2EBCF512AD07DD0D5D8AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50C14671D09460D2375AD2589C8239AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_50C14671D09460D2375AD2589C8239AF" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589FAE7410B173FB56D4D2589C82F4A2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_us-gaap_BuildingMember_FDE24E9737A096C3F8DDD2589C825EA0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_1E52BC69887903FD2A5FD2589C8241AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_exel_LaboratoryEquipmentMember_1E52BC69887903FD2A5FD2589C8241AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EquipmentAndFurnitureMember" xlink:label="loc_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_exel_EquipmentAndFurnitureMember_230982966AD4A75DD782D2589C82A863" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_8FE06D0F5E806C8D2EDAD2589C8270A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_8FE06D0F5E806C8D2EDAD2589C8270A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3F57B8FC80059C114C63D2589C834842" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8C734AFA04FB9D77F612D2589C82BC1E" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3F57B8FC80059C114C63D2589C834842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:to="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_B613680FDC19E19F6222D2589C83EAAC" xlink:to="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C16E38422A8FE6436394D2589C83B25C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:to="loc_us-gaap_MinimumMember_C16E38422A8FE6436394D2589C83B25C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_AE9EA9E2FA21F94B1E28D2589C83E700" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_31CE545966FBFE48AE4AD2589C83D230" xlink:to="loc_us-gaap_MaximumMember_AE9EA9E2FA21F94B1E28D2589C83E700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D3BA47C75B653D772F7D2589C8313E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9D5C46F307D56D520D0DD2589C8285E2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D3BA47C75B653D772F7D2589C8313E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D3BA47C75B653D772F7D2589C8313E9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20D67A3CC7548E9D01E2D2589C83073B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2611B1E9CE868E1746DED2589C8AE484" xlink:type="locator" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2611B1E9CE868E1746DED2589C8AE484" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_6C4F05DA066549C19792D2589C8A37AF" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2253C1112C6CAB1F1347D2589C8B10FE" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_506BC69C1BFE7A9B1AD3D2589C8B3ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D8DBF256F53B5A97C1A2D2589C8B7E30" xlink:to="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5A3503BC88EDDD37F508D2589C8BAB84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:to="loc_us-gaap_RetainedEarningsMember_5A3503BC88EDDD37F508D2589C8BAB84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_20B310136574C620FC2ED2589C8B3255" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A8BB6FC7273E367A72B1D2589C8B8FC0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_20B310136574C620FC2ED2589C8B3255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_80C9DB9093BA06797669D2589C8BED0F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_BCB6F54A85A268DF5C95D2589C8BE80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_63568C2700FD4C2E1542D2589C8B974E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201609Member_FED34D67D856ADD75553D2589C8B6272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_C9474A85ABB08A4701C8D2589C8B1BFF" xlink:to="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProductsDerivedfromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_76C14898AA876E4245D2D2589C8BE247" xlink:to="loc_exel_ProductsDerivedfromCabozantinibMember_5FAC5F9672FAA833D827D2589C8BBA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_EC8BCC006265883D7597D2589C8BD796" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:label="loc_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F8061751BDF152A9534DD2589C8B8D2C" xlink:to="loc_us-gaap_ProFormaMember_923458F73C7C973ACCA3D2589C8BF8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3EA9547309C00ACFEC79D2589C8B8B3A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_84BB25C9E7D6BB1272A4D2589C8B722D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DA2CA050C1C0CD9E320D2589C8BC95B" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_84BB25C9E7D6BB1272A4D2589C8B722D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_51EF5DB6AE6388A92FD2D2589C8BE2E5" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_FA957328C28E5B99B60DD2589C8CA6DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_CB858647DDD6F1CF35C1D2589C8B021F" xlink:to="loc_exel_GlaxoSmithKlineMember_FA957328C28E5B99B60DD2589C8CA6DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7115F919377E741B1965D2589C8C94DE" xlink:to="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5638B887BF798490F76CD2589C8C66A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_021AAB8F8C613A548FB9D2589C8C6FB3" xlink:to="loc_us-gaap_MaximumMember_5638B887BF798490F76CD2589C8C66A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_CE1C9152A015E51D45F5D2589C8A0DEC" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_NumberofProductsinCommercialMarket_3929618EF4F84C2C2124D2589C8CA7DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_NumberOfReportableSegments_45E2C03B10E85113678FD2589C8C8F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_DF6A7993E7BC942CFE70D2589C8C142F" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SalesRevenuePercentDiscountForPromptPayment" xlink:label="loc_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_SalesRevenuePercentDiscountForPromptPayment_11B09F98EDAB591473E1D2589C8CDAB2" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SalesRevenueDiscountExpectedtobeEarnedPercent" xlink:label="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_SalesRevenueDiscountExpectedtobeEarnedPercent_1A1F7A1B23F545F8651FD2589C8C47C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce" xlink:label="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_123B5AC68C955A3B385FD2589C8C8D4A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce_123B5AC68C955A3B385FD2589C8C8D4A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PercentOfRoyaltyOnNetSale" xlink:label="loc_exel_PercentOfRoyaltyOnNetSale_0A41BEE74609A6E5628ED2589C8C48CF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_exel_PercentOfRoyaltyOnNetSale_0A41BEE74609A6E5628ED2589C8C48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CFBD54AE4158D361F468D2589C8CE78D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39C8A40C6D13B70F058ED2589C8C07D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4E6AB39A7DA5C439C092D2589C8C3A43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_3353B23732AF2AC1D617D2589C8CDAF0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_AE02EDCEACFFF07D3F4BD2589C8C4E28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_33CA3326163E1708F30F8B013B978891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F6E2E1060E963787A5A28B013B979120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_UseOfEstimates_56DC4D71CC58B10134FC8B013B97CD4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_25D685F16664917CE3B78B013B986416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B0FE12F739097EC333FD8B013B98BD07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1740FCDE4468352C93DD8B013B98F301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9B04FAE6AC18276C8BBF8B05260EE7ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5C0C41BF8A35602F17728B013B98AD4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_9F0422C1E5D1B46EEFB88B013B98FC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2F7ADB99BEA59971C0A68B013B989EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_FEFCA2AF2E31912B83C68B013B984F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_A606E04369DA92694D188B013B98416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_45530777FA24A53109068B013B9856CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_176CC6645B9CE662DE848B013B98EEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_DD77331FDE763084CAB08B013B985D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_238DF60893D54445CA388B013B98273F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7FA50F47035AF2B1476D8B013B985F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_FEAA46E2A9B33674E6A68B071B007618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDB0C831048EFB87EBC18B013B96601C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_CA6AC0F5FE7F74A7A47B8B013B991CE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ECA3C9BD400EA642B248B95070F8885" xlink:type="locator" />
    <link:loc xlink:href="exel-20171229.xsd#exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ECA3C9BD400EA642B248B95070F8885" xlink:to="loc_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_6F396F8066E9F83947138B95070FF803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionAllowances" xlink:label="loc_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9ECA3C9BD400EA642B248B95070F8885" xlink:to="loc_us-gaap_RevenueRecognitionAllowances_607279FBC677AE49CF718B95070FD420" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7958A74E927593C89704B6B5E4287F07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7958A74E927593C89704B6B5E4287F07" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6083FD7059531E887C0CB6B5E4289485" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E522BE358A18ED662674D293EB05C5F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E522BE358A18ED662674D293EB05C5F2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_4B24FA71333986BAF653D2B16A6E4A17" xlink:to="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_AE66A3989DA5F6353B2BD2B16B16D963" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_7D1CC3AB3E806697FFC0D2B16A7E932B" xlink:to="loc_exel_AlamedaCaliforniaMember_AE66A3989DA5F6353B2BD2B16B16D963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_8CECC22271A31C90841BD293EB062FA0" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OperatingLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_36B882ED411906CC4E66D293EB0658BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:to="loc_exel_OperatingLeaseandOtherFinancingLeaseMember_36B882ED411906CC4E66D293EB0658BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_OptionalAmendmentAgreementMember" xlink:label="loc_exel_OptionalAmendmentAgreementMember_F71491754AFB1B2F241CD293EB0600D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:to="loc_exel_OptionalAmendmentAgreementMember_F71491754AFB1B2F241CD293EB0600D7" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CapitalLeaseandOtherFinancingLeaseMember" xlink:label="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_FB5D8653E77C58BCA116D293EB066CC1" xlink:to="loc_exel_CapitalLeaseandOtherFinancingLeaseMember_A503FEAD1B8D214E1FD7D293EB0665B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_61C4ACAAC55162B17A8ED293EB06DCD7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_58392EB38F1E0CDE12ABD293EB06A66F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6CA4B450714EB02C54C4D293EB06C54D" xlink:to="loc_us-gaap_ConstructionInProgressMember_58392EB38F1E0CDE12ABD293EB06A66F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E67799B80E0529627B14D293EB05C17A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_Depreciation_D0154CE4BC955FB1444FD293EB06335E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_4B174F6C6ADCFF52A472D293EB064715" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_4B174F6C6ADCFF52A472D293EB064715" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_A68DBF51EBA5340CCF4FD293EB067CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_8C4AD22A9E07E643CFBDD293EB06808A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CBA9FE9F00DCB0F455D7D293EB06FD5E" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_F1E280752AE0DC3DDDD7D293EB064E7F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95F3A0DCD7E3AB884F6BB0007747E197" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95F3A0DCD7E3AB884F6BB0007747E197" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3E23356BA860D949586AB00077472F3E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_646064F38A77AD6DF93BB00077470FC1" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_exel_LaboratoryEquipmentMember_C389DB1B35A3F6DDDD57B00077484CD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_F60A72658097FB8AA9E1B0007748ED5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_F03FEE78A01FBFBA9E8EB00077483DCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_D562A435A15B7EC762EBB00077472F63" xlink:to="loc_us-gaap_ConstructionInProgressMember_149BC407AB10D1B57961B00077483408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_702FB8DF43801E544C2DB00077477838" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_F2E4A6ACD59EA62D476DB000774865C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_B5C307E2F841C7259DF3B000774866EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_D6B1087391063351F555B0007748C4A9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3A3491BC71684A5508B0B0007748098D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D3D5CF8EA5D19BABAEC7B6B5E219E364" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_A87DF06E876F69557B81B6B5E2196165" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0CB26C92F88874AE792CB6B5E0DED569" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0CB26C92F88874AE792CB6B5E0DED569" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_C424F1A0E15E1280F003B6B5E0DE3F31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_06B0EFF4F26AA83290F9BDF289262498" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_06B0EFF4F26AA83290F9BDF289262498" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C0E68F42353A9BA9C4C4BDF28929EA42" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F5DC8C0E634CAB11AE6ABDF28929E17B" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_C3831DFC7B2D4A442948BDF289296800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_9F026C0816B48BC77809BDF289281A33" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_6954387F73E477866A00BDF2892AC519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_69E02E244971A041CFC2BDF2892A5327" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RecoveryOfExpensesExpensesInCurrentFiscalYear" xlink:label="loc_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_7EF43A891A0F7E4DD278BDF28929B22C" xlink:to="loc_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear_5F550EA01B09A57077A5BE0753728BCE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:to="loc_us-gaap_Revenues_60614EAF1CBEB54B5E2DD07DCFC9CC1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:to="loc_us-gaap_GrossProfit_C68FA3CA527229FB7ED8D07DCFC9F77C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:to="loc_us-gaap_OperatingIncomeLoss_83AD3657A32533FF2057D07DCFC9F4CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5F5469DAEA7C9907A2A3D07DCFC94B12" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:to="loc_us-gaap_NetIncomeLoss_5F5469DAEA7C9907A2A3D07DCFC94B12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_93AE60B519C91FBF03CDD07DCFC97A7D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:to="loc_us-gaap_EarningsPerShareBasic_93AE60B519C91FBF03CDD07DCFC97A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9BA15198C01BCB14D859D07DCFC9AFEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0F64B5041FFBD6D4964AD07DCFC9F03F" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9BA15198C01BCB14D859D07DCFC9AFEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6867134972E30B8DE05FB6B5E273CB8A" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_1EEFCAB263760D6B2CB9B6B5E273CCB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_D2929266B1D4F3DCBB8BB4643B6A5A42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_D2929266B1D4F3DCBB8BB4643B6A5A42" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3C56191952CA8FBCA498B4647B68BCEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_A14D02B77CE99F690E1DB472B5803EE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_A14D02B77CE99F690E1DB472B5803EE0" xlink:to="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_A7CD88229AF3E154878FB472B797F1C2" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_F35A3919B720704AC3BEB472B7B100F9" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_CaremarkL.L.C.Member_1B3EB8A9C666F7DA7B89B472B7D59777" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_IpsenMember_9E570114C7471BC1D576B472B7E402FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_AccredoHealthIncorporatedMember_7F6E0156EF121AFFF455B472B7F20C9D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E720288A0F849DCE6FCEB472B7985355" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_084CCFFBE418AB465DB7B472B8028C74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_A02F0B02E5A2DD752CADB472B7832804" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_3E6918708C202FB1407DB472B7C8B708" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1802E619D1E806BB1169B472B784D57A" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_3E6918708C202FB1407DB472B7C8B708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A4D64FFECC5B3DC4807FB472B76DC28F" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_871323F2CEFF6153F89BB472B76F1E87" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5CBD02014C607C988BDAB472B7BCE4DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90E86A3438F336B3281CB472B75391E0" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_D592F3DBDE67E6EC5F0DB472B7546DF5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0AB1470731C24187BCF3B472B761ACB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_05613792218F25A6C255BBBF580681E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_05613792218F25A6C255BBBF580681E8" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_3C458F5879DBFB732A5CBBBF5806BEB8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0EDABA458691946C074FBBBF580615D1" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_4B3D9DCD60ED155CFA4CBBBF580647C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9E609553D07B8EDE4B76BBBF58065F7A" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNetMember" xlink:label="loc_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BC01FF06DF599A4D8B3FBBBF5806392B" xlink:to="loc_us-gaap_SalesRevenueGoodsNetMember_41914A9A3D4639E676E3BBBF58066DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_045BAA8B96DECF9467CDBBBF58066A2C" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:to="loc_country_US_A903BCB790F491BADFE6BBBF58066DFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeMember" xlink:label="loc_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:to="loc_us-gaap_EuropeMember_C977C86059D77A3B21BDBBBF5806EA90" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_RestofWorldMember" xlink:label="loc_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0F7E63D3F9F6ED34C8E1BBBF58063DC1" xlink:to="loc_exel_RestofWorldMember_96377EB7D3153CAF59FBBBBF58067131" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_41E088DE9E3EF391DA99BBBF5806C70C" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_30BD85D2AD686C67B69ABBBF5807001D" xlink:to="loc_us-gaap_Revenues_D88D472A82E79D35D2C7BBC675F0C4A9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_3E0561E21991772C0668BBBF584AFAC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3E0561E21991772C0668BBBF584AFAC0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:to="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_94A813DDCD1F13A6F00EBBC3481E36BD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_F4AF9831483C7867C182BBBF584A9353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:to="loc_exel_CabometyxMember_F4AF9831483C7867C182BBBF584A9353" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_A920CCF262C977618C0BBBBF584A0526" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_AEEBB4285C9CF92D058CBBC3EB7DBD14" xlink:to="loc_exel_CometriqMember_A920CCF262C977618C0BBBBF584A0526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_DBDCF131E6DAFDAA963ABBBF584AA0CD" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_280D10718295C71B651FBBBF584AAA18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_71E8A55A0A80436E83FCBBBF584A0470" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_280D10718295C71B651FBBBF584AAA18" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_39132FDAEA3F2DD95117B9A11173B45F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_39132FDAEA3F2DD95117B9A11173B45F" xlink:to="loc_us-gaap_NumberOfOperatingSegments_29E350E129DB35777401B9A11174A5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_39132FDAEA3F2DD95117B9A11173B45F" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7C8C598BA67F701B47F6B9A111743655" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2E6C0A5E645207DF2A06BBC266895017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38AF6503CC02D0FE7075BBBF584D85C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_33EF9359F0233BF62E10BBBF584D5E63" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0203A3EA5F8223D3A18ABBBF584D01DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_859E78D5B6EC6D211CDA7C2929E8DA3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_859E78D5B6EC6D211CDA7C2929E8DA3F" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FA821F5D332CB56D95807C2929E9FDCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89A48BC7EFA7179A7FF8BA99817F2BE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_89A48BC7EFA7179A7FF8BA99817F2BE5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A5DA35591B2B98BEB6C3BA99817F0635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_BD50F2E9543A0E6A2185BA99817FBBA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_BD50F2E9543A0E6A2185BA99817FBBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4FEB3DA7051ED05473FDBA99817F85A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4FEB3DA7051ED05473FDBA99817F85A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B348BB9BD4E31539B348BA99817F2218" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_us-gaap_EmployeeStockMember_B348BB9BD4E31539B348BA99817F2218" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_PerformanceStockOptionsMember" xlink:label="loc_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15CBF8604FEF41017247BA99817F16C4" xlink:to="loc_exel_PerformanceStockOptionsMember_1F967063EF668AF3D624BA99817F4121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9F5CD7F7FC63FBD31DA6BA99817F18D9" xlink:to="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ChangeinControlandSeveranceBenefitPlanMember" xlink:label="loc_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0E07B94A94D40C7D1710BA998180549E" xlink:to="loc_exel_ChangeinControlandSeveranceBenefitPlanMember_2D8B40D340F6967E7034BA99818089C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_A3D76C450DFFE08C3DFDBA9981806E29" xlink:to="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_53ED1A429D81D4929746BA998180EAFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F4E838FBEC4F5B5F338EBA998180B791" xlink:to="loc_us-gaap_MaximumMember_53ED1A429D81D4929746BA998180EAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46CB183AC0EC65FAB326BA99817F2EBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_E11A557B30175B452BBBBA998180EEF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5BAB87EC3065E84FF70FBA998180550A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1587C63A986D8AA434C8BA998180234C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl_5EC1DDE9A5C6E907F95EBA998180402D" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl_1170B195D3D0EADF920CBA998180169C" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension_D954B376374F0AD6D7C2BA998180DE6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2017D3057FC6070825ACBA998180F10E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_B11190E1E0AE78E4CB75BA9981806BB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod_CAD0391D9115D52BE6EFBA998180F1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_071B40668A103D0D922FBA998180CEF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_A104B7F9C391FD8F7729BA998181CE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_682229D2F148791FBB7DBA998181F72D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_20321310D31A72A29A7FBA998181B316" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ProceedsFromStockPlans_20321310D31A72A29A7FBA998181B316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_CC488B2D5BBC8766A89ABA998181A47F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_32A1DF88E290E8B89BD7BA998181AFFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D89EC58F5CA5C0F610DCBA99818139E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E2D90B717F9D05399C31BA998181F960" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue_A68AE4C45BEDB2812325BA9981814300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_E8AD412BE08F8342CDA9BA9981817108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_814E80A6A05CD67014D4BA99818113A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_FA6FEAFE1B162049B67CBA9981815BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3EF57D48089A0BCEB7DEBA9981818E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_289ED585B5F726051A14BA998181DE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_807E2011156D9253EFFDBA998181BB1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_DefinedContributionPlanNumberofSharesAvailableforGrant" xlink:label="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B3FA9FDCF6CC51A690FFBA998180C61C" xlink:to="loc_exel_DefinedContributionPlanNumberofSharesAvailableforGrant_CB3F3878E77B97503972BA998181F57E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96247B068BAA0B3C099DB8D74735AC91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96247B068BAA0B3C099DB8D74735AC91" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C5E1081E49E268654BD9B8D74735FB6D" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C35BDF06B36F1A1D7DEBB8D747351A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E4AECB6728A205BFDF93B8D747355298" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E25F0B8043C0D70B8443B8D74735AA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1C0082B1F22B1290D05CB8D74735C465" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_19DDE81CFC7113D88600B8D74735E229" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_BFC14F35C132DB3F2EF1B8D7473563B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4C6B26DDA1E2CCC13DA3B3772F1900D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4C6B26DDA1E2CCC13DA3B3772F1900D6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:to="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C70EEF57C69FD54A2192B3772F19C3A4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40444EA3CEE40A248B0EB3772F193B58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40444EA3CEE40A248B0EB3772F193B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_CD5BB35CA9A943D39594B3772F193F18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0E4C8D812FB1A156C448B3772F196F47" xlink:to="loc_us-gaap_EmployeeStockMember_CD5BB35CA9A943D39594B3772F193F18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_75DCBD1713256BF81181B3772F19EC28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E3B78724C71465B07FDFB3772F19A796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_A997C0375F965B9964D0B3772F191ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_DA9D6888CD58ADFAFFB1B3772F1948E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_763234FBB91E500D0538B3772F190781" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_B932A664BDCD21BB80C0B3772F1950AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F86495DD97D7974801E1B3772F0FF100" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F86495DD97D7974801E1B3772F0FF100" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:to="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D6F6DBA7AACFA996A46CB3772F0FA8AD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3A7BBE35B3687F84B82B3772F0F8B43" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B80A54DA8ECB3DCBA463B3772F0F84DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32995678373BAF8A48E5B3772F0F8994" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B0A03936BCA6BDE6EA0AB3772F0F082B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5947E06714151A19A13B3772F0FDBB8" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased_1627A0B39235465579A0B3772F0FFA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40CF1FCEBE3B5D9CD59CB3772F0F1498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3140A82919D447A229DBB3772F0FCE50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A0F55A255A5D5F93C418B3772F0FBD65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B292C228BBF415B28FDEB3772F0FDE83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FEB8BD5E0FF2F88514EB3772F0F2678" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue_29175FA7E0AA0E21C097B3772F0F4B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_EC8038994209759109D7B3772F0F5222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_EF5DA8D6E0055E5E0B2EB3772F0FEF3D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4DC141AC3C6C1BAC4B53B3772F10AB0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_A0CA0152C80D8756E699B3772F103AD4" xlink:type="arc" />
    <link:loc xlink:href="exel-20171229.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D143308ADA4BB15D4DA0B3772F0F33B0" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_15C306862DCCCA14C48CB3772F10160C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FDD1BB0E297C834B0C5DB3772F1669DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6E1B63D5965E11A5F46FB3772F16230B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_325EAD96F6F0CA323A0FB3772F163A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_831802CD664B965276DBB3772F16BB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5F8E904A95CEE2404435B3772F16CC97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E05DB3F6F532AE3647EEB3772F16522D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_633A8AADC874DCDCE919B3772F166FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_31C0DDE49A527C78C0A4B3772F1608CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0F6BC18E1EA81304842BB3772F165A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30EBB91F0DAE22884841B3772F168086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9A84166176517757D224B3772F16B646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_45DBF0E29B056D2F6503B3772F165C95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_6A6630278231588133EAB3772F16DB64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_018903A60C59790C0A80B3772F16BF7B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_428490263A2C0ED8E0BEB3772F164B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_DF67B98C45C7A8AFFBEDB3772F1710E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_A92FF91EBE80FE9C676AB3772F172CED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_A2D0F04B6B14CF91BDE5B3772F17A8AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15D7A3E4560B965EDD90B3772F17AD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D9A070704A68294AAE8EB3772F167EE0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_CFECD0E20377EA959B8EB3772F17BDE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EA4E45A1138774250DACB3772F264137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_4B3B0630C1354996EBA4B3772F26F433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9689971B6DD2EE6E6806B3772F262ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_DF34EF2DD23703BE2DD2B3772F26B5FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6047B4D60A3A6BDEDC64B3772F268FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7979AFB56A82BE24DACB3772F2603FC" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_8DABD1601AE9B9F67A0AB3772F264CB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_537B6B8766AA6A90CDC2B3772F1B1D15" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:to="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_81B80E0E112E5CA2C95AB3772F1B4458" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C197108CA8BB6B37EB77B3772F1BD372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13131C4DE2E73466BC50B3772F1BA222" xlink:to="loc_us-gaap_EmployeeStockMember_B6EEC5137D1832B9AFE7B3772F1BD31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C99D0BBAAA21AE216670B3772F1B5748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_284049A768EAEF9AA527B3772F1B06E2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D6DE02A60D19C22CD430B3772F1B0344" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cabo01a.gif
<TEXT>
begin 644 cabo01a.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M@;M$;S>#I6AI+O$XG4AYGFO6F)-)H:@8;2A6?G_HI1=Z5P^4)(&:'FHJ<Y.
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MSLW<S>3<".;,RN:,S+[\S7L<QXUP"(Q@SX9PL%T@<Q,U420<R[W@"W*D#.X
M$\4+PS@7#<L0"II@!$8 !$5@ 3]@ 4;P P]=!$#PT!?MT!S=T0X-!Q]M!" -
M!R1=TD80!R5]!R2MTG: TG"@TG%@!YM@!W 0"C$="B\="G80"CH="G<0"J#
MTT(="J= U$9=U*>0U$J=U-&PU*?0U$\=U=$PU4U-U5/]U%5MU5I]U0BM$RW<
MU8VA# P-!S_P P]0UO\_  1HK=9E#01IX-9P_=9%H 9   =U7=<A;=(EO==\
MW=<DK0E_#0> #0>;H EVH EW8-B&#0J;  >,_=A!K0D,/=E!'=3+$-1B'0K*
M4-2;'0K1X-F@_=D*?0K+(-JA?=H*#=:J/23+L QV#005D -MG=:T3=MJ3=9J
M\ -DG09&P-MID-MJ0-9PD 9P$-S$'=Q^+=B!_=<TK0EQ  IP(-."+=,R#=U
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MYHM49UKI6._:=U*?+,6IL9E,#-R^R<S=K[)-I.,2Y6.U:[:LT$-/$(X?<GC
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ML9*INJO[",-*N.AD&E%-BY2K*5.[(U*UOT:L,(Y@4TV24X.8/RK3TO/3'HQ
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M%%2=CJ"H;V-<BB;1<D:$\'#_+\R[#/#RY<*#C+ CJF,:&#4Y)"#4Q%U3V27
M<BD>^A5+8$/['I9HB":!K A)>YDE)+,I)0 !L"1W((D1!_/+*:*'=E.ZHO'T
MEKP]XNDGW9D*]""CO[UT1)E2P=Y2H"B]!MT2(S44R/!0B!UL'N2=["&HT$#$
MQSXZLX;,)%:MDF.5A\9F4VD(5D2BMD:^K4B4VM3FVG*7+(IY:4N7N:@)*X+,
M*SUS@JUQX+0DTD&!K@N,&_D:AO2(P,MLRIK3O$M(@#.4CW2*D()SWMU"@D3
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M11-M=I<IG=VJEY)3S/+(B3GE!!5-B6-2F=27TP!KTHL+GG6M!U6]*0_+(L5
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M)]%MPR85;R"O,M8^S-8PBB)I+0*GX,K>_@,\YT()A59PK3?K]&T53>+LK,^
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MU+A)3KB*5O0A>FK)QG:8)=J"B)41J^+=^BS9;O?3O!EP]\%H%@:';P!&WJ9
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M=V2H1K+Y('R"$71)B@Y;+?:7J)4SJIQ,&PYLZ$NIG#.GG&5./6G)PG]I9!C
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MFO.+P.[1O[DS-3(@!KH;$N)+(7'HOPM5NJ1W(M:%AR/S%O29P!]<'<-P5V.
M!FE@$5DKKE-*(B^3!MN:!FKHP0:AKRM"#YHP"5H1%I,P#"@,PCT,(!(<)>SK
MPT,L+FVKPETBP$2LQ/$"Q$PBQ"1+#,7&4KQ9\KQ1;,77TL1+XHU7S,7.LK^L
E<KA=+,:^DL5%\L078XS&F3+%6#+#:>S&IG(+8<DJLYHG 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cometriq.jpg
<TEXT>
begin 644 cometriq.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!217AI9@  34T *@    @ ! ,"  (
M   ,    /E$0  $    ! 0   %$1  0    !   .Q%$2  0    !   .Q
M  !)0T,@4')O9FEL90#_X@>X24-#7U!23T9)3$4  0$   >H87!P; (@  !M
M;G1R4D="(%A96B 'V0 " !D "P :  MA8W-P05!03     !A<'!L
M                ]M8  0    #3+6%P<&P
M                                      MD97-C   !"    &]D<V-M
M   !>   !6QC<')T   &Y    #AW='!T   ''    !1R6%E:   ',    !1G
M6%E:   '1    !1B6%E:   '6    !1R5%)#   ';     YC:&%D   '?
M "QB5%)#   ';     YG5%)#   ';     YD97-C         !1'96YE<FEC
M(%)'0B!0<F]F:6QE               41V5N97)I8R!21T(@4')O9FEL90
M
M    ;6QU8P         >    #'-K4TL    H   !>&AR2%(    H   !H&-A
M15,    D   !R'!T0E(    F   !['5K54$    J   "$F9R1E4    H   "
M/'IH5%<    6   "9&ET250    H   ">FYB3D\    F   "HFMO2U(    6
M   "R&-S0UH    B   "WFAE24P    >   # &1E1$4    L   #'FAU2%4
M   H   #2G-V4T4    F   "HGIH0TX    6   #<FIA2E     :   #B')O
M4D\    D   #HF5L1U(    B   #QG!T4$\    F   #Z&YL3DP    H   $
M#F5S15,    F   #Z'1H5$@    D   $-G1R5%(    B   $6F9I1DD    H
M   $?'!L4$P    L   $I')U4E4    B   $T&%R14<    F   $\F5N55,
M   F   %&&1A1$L    N   %/@!6 6$ 90!O &( 90!C &X _0 @ %( 1P!"
M "  < !R &\ 9@!I &P 1P!E &X 90!R &D!#0!K &D ( !2 $< 0@ @ '
M<@!O &8 :0!L %  90!R &8 :0!L "  4@!' $( ( !G &4 ;@#H '( :0!C
M %  90!R &8 :0!L "  4@!' $( ( !' &4 ;@#I '( :0!C &\$%P0P!#,$
M, 0[!$P$/00X!#D ( 0_!$ $/@1$!# $.00[ "  4@!' $( 4 !R &\ 9@!I
M &P ( !G .D ;@#I '( :0!Q '4 90 @ %( 5@!"D!IU*  @ %( 1P!" """
M<E]I8\^/\ !0 '( ;P!F &D ; !O "  4@!' $( ( !G &4 ;@!E '( :0!C
M &\ 1P!E &X 90!R &D <P!K "  4@!' $( +0!P '( ;P!F &D ;,=\O!@
M( !2 $< 0@ @U02X7-,,QWP 3P!B &4 8P!N /T ( !2 $< 0@ @ '  <@!O
M &8 :0!L!>0%Z 75!>0%V07< "  4@!' $( ( 7;!=P%W 79 $$ ; !L &<
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M &D 8P!O $$ ; !G &4 ;0!E &4 ;@ @ %( 1P!" "T < !R &\ 9@!I &4
M; Y"#AL.(PY$#A\.)0Y, "  4@!' $( ( X7#C$.2 XG#D0.&P!' &4 ;@!E
M &P ( !2 $< 0@ @ %  <@!O &8 :0!L &D 60!L &4 :0!N &4 ;@ @ %(
M1P!" "T < !R &\ 9@!I &D ; !I %4 ;@!I '< 90!R ', 80!L &X >0 @
M '  <@!O &8 :0!L "  4@!' $($'@0Q!$D$. 0Y " $/P1 !#X$1 0X!#L$
M3  @ %( 1P!"!D4&1 9! " &*@8Y!C$&2@9! "  4@!' $( ( 8G!D0&.08G
M!D4 1P!E &X 90!R &D 8P @ %( 1P!" "  4 !R &\ 9@!I &P 90!' &4
M;@!E '( 90!L "  4@!' $( +0!B &4 <P!K '( :0!V &4 ; !S &5T97AT
M     $-O<'ER:6=H=" R,# W($%P<&QE($EN8RXL(&%L;"!R:6=H=',@<F5S
M97)V960N %A96B        #S4@ !     1;/6%E:(        '1-   ][@
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M;'0#%:=K,Z?$;Q5>0IYAM=.@3;ZOAF KJTT_3M,66YMK"V@94)9H855B!SU
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296\EPOW96B4N/QQFK5% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cotellic.jpg
<TEXT>
begin 644 cotellic.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X@>X24-#7U!23T9)3$4  0$   >H87!P
M; (@  !M;G1R4D="(%A96B 'V0 " !D "P :  MA8W-P05!03     !A<'!L
M                        ]M8  0    #3+6%P<&P
M                                              MD97-C   !"
M &]D<V-M   !>   !6QC<')T   &Y    #AW='!T   ''    !1R6%E:   '
M,    !1G6%E:   '1    !1B6%E:   '6    !1R5%)#   ';     YC:&%D
M   '?    "QB5%)#   ';     YG5%)#   ';     YD97-C         !1'
M96YE<FEC(%)'0B!0<F]F:6QE               41V5N97)I8R!21T(@4')O
M9FEL90
M            ;6QU8P         >    #'-K4TL    H   !>&AR2%(    H
M   !H&-A15,    D   !R'!T0E(    F   !['5K54$    J   "$F9R1E4
M   H   "/'IH5%<    6   "9&ET250    H   ">FYB3D\    F   "HFMO
M2U(    6   "R&-S0UH    B   "WFAE24P    >   # &1E1$4    L   #
M'FAU2%4    H   #2G-V4T4    F   "HGIH0TX    6   #<FIA2E     :
M   #B')O4D\    D   #HF5L1U(    B   #QG!T4$\    F   #Z&YL3DP
M   H   $#F5S15,    F   #Z'1H5$@    D   $-G1R5%(    B   $6F9I
M1DD    H   $?'!L4$P    L   $I')U4E4    B   $T&%R14<    F   $
M\F5N55,    F   %&&1A1$L    N   %/@!6 6$ 90!O &( 90!C &X _0 @
M %( 1P!" "  < !R &\ 9@!I &P 1P!E &X 90!R &D!#0!K &D ( !2 $<
M0@ @ '  <@!O &8 :0!L %  90!R &8 :0!L "  4@!' $( ( !G &4 ;@#H
M '( :0!C %  90!R &8 :0!L "  4@!' $( ( !' &4 ;@#I '( :0!C &\$
M%P0P!#,$, 0[!$P$/00X!#D ( 0_!$ $/@1$!# $.00[ "  4@!' $( 4 !R
M &\ 9@!I &P ( !G .D ;@#I '( :0!Q '4 90 @ %( 5@!"D!IU*  @ %(
M1P!" """<E]I8\^/\ !0 '( ;P!F &D ; !O "  4@!' $( ( !G &4 ;@!E
M '( :0!C &\ 1P!E &X 90!R &D <P!K "  4@!' $( +0!P '( ;P!F &D
M;,=\O!@ ( !2 $< 0@ @U02X7-,,QWP 3P!B &4 8P!N /T ( !2 $< 0@ @
M '  <@!O &8 :0!L!>0%Z 75!>0%V07< "  4@!' $( ( 7;!=P%W 79 $$
M; !L &< 90!M &4 :0!N &4 <P @ %( 1P!" "T 4 !R &\ 9@!I &P P0!L
M '0 80!L .$ ;@!O ', ( !2 $< 0@ @ '  <@!O &8 :0!L9FZ0&@ @ %(
M1P!" "!CSX_P98=.]DX @BP ( !2 $< 0@ @,-<P[3#5,*$PI##K %  <@!O
M &8 :0!L "  4@!' $( ( !G &4 ;@!E '( :0!C Y,#M0.] [D#N@/, " #
MP /! [\#Q@.O [L ( !2 $< 0@!0 &4 <@!F &D ;  @ %( 1P!" "  9P!E
M &X Z0!R &D 8P!O $$ ; !G &4 ;0!E &4 ;@ @ %( 1P!" "T < !R &\
M9@!I &4 ; Y"#AL.(PY$#A\.)0Y, "  4@!' $( ( X7#C$.2 XG#D0.&P!'
M &4 ;@!E &P ( !2 $< 0@ @ %  <@!O &8 :0!L &D 60!L &4 :0!N &4
M;@ @ %( 1P!" "T < !R &\ 9@!I &D ; !I %4 ;@!I '< 90!R ', 80!L
M &X >0 @ '  <@!O &8 :0!L "  4@!' $($'@0Q!$D$. 0Y " $/P1 !#X$
M1 0X!#L$3  @ %( 1P!"!D4&1 9! " &*@8Y!C$&2@9! "  4@!' $( ( 8G
M!D0&.08G!D4 1P!E &X 90!R &D 8P @ %( 1P!" "  4 !R &\ 9@!I &P
M90!' &4 ;@!E '( 90!L "  4@!' $( +0!B &4 <P!K '( :0!V &4 ; !S
M &5T97AT     $-O<'ER:6=H=" R,# W($%P<&QE($EN8RXL(&%L;"!R:6=H
M=',@<F5S97)V960N %A96B        #S4@ !     1;/6%E:(        '1-
M   ][@   ]!865H@        6G4  *QS   7-%A96B         H&@  %9\
M +@V8W5R=@         ! <T  '-F,S(       $,0@  !=[___,F   'D@
M_9'___NB___]HP   ]P  ,!L_^$ =D5X:68  $U- "H    (  0!&@ %
M 0   #X!&P %     0   $8!*  #     0 "  "':0 $     0   $X
M    8     $   !@     0 "H ( !     $   #IH , !     $   !3
M    _]L 0P " @(" @$" @(" @(" P,&! ,# P,'!04$!@@'" @(!P@("0H-
M"PD)# H(" L/"PP-#@X.#@D+$!$/#A$-#@X._]L 0P$" @(# P,&! 0&#@D(
M"0X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.#@X.
M#@X.#@X._\  $0@ 4P#I P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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MO1M2\7:_=-LMK:RA9]Y[X Y8#J3P .20*_03X+_L!>)?%2V?B3]HC6Y;#3G
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M[/W%H_/WM#]-,CUHR/4?G7YK_M/_ !\^*OP[_:IO/#OA'Q1_9.BIIEO,MO\
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MW.[=G.>];2Y?91YE<^5RVGF<^)<R6!Q4:+YM>9)WU>UUT_4],^#GQ1MOB_\
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M+KLI(-Q<R;D@7/W(U'RHH[*H %>H?MB:A<-_P46^+5E;JR*OB!E=@,ER88,
M8]<]!R:]:_9X_P""?OQ%^*E[9>(?B2NH_#7X?.!( RJNKZ@IY AC8$6ZD?\
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M7>@^(K!#';ZE;1J^Z,G/ER(>&7/(Z$<\\U\MG]@"X+D_\+*M_J=$'_Q=??\
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M_0BOZ \"OBWXB_L?>&=1^,FF_$/X;FU\)ZPNL07VK:0J;;&_*RJ[RH!_J92
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C656V[E#8.1D=Z=110 4=:** $QQBEHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>exellogo2017a.jpg
<TEXT>
begin 644 exellogo2017a.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^%(8VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,3,W(#<Y
M+C$U.3<V."P@,C Q-B\P."\Q,2TQ,SHR-#HT,B @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@
M>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O
M:6UG+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^#0H)
M"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^=%\P-C(Q,3<\+W)D9CIL:3X-"@D)"0D\+W)D
M9CI!;'0^#0H)"0D\+V1C.G1I=&QE/@T*"0D)/'AM<#I-971A9&%T841A=&4^
M,C Q-RTP-RTQ-%0R,3HT,SHT-"TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X-
M"@D)"3QX;7 Z36]D:69Y1&%T93XR,#$W+3 W+3$U5# T.C0S.C0W6CPO>&UP
M.DUO9&EF>41A=&4^#0H)"0D\>&UP.D-R96%T941A=&4^,C Q-RTP-RTQ-%0R
M,3HT,SHT-"TP-SHP,#PO>&UP.D-R96%T941A=&4^#0H)"0D\>&UP.D-R96%T
M;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(P,3<@*$UA8VEN=&]S:"D\
M+WAM<#I#<F5A=&]R5&]O;#X-"@D)"3QX;7 Z5&AU;6)N86EL<SX-"@D)"0D\
M<F1F.D%L=#X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D\>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^
M#0H)"0D)"0D\>&UP1TEM9SIH96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H=#X-
M"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X-
M"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%
M<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"
M3$%!04%!14$-"D%117-!04%!05%!0B\K24U716Q$43$Y455K.4=357A&04%%
M0D%!04U317AP8FTX0T5!04%B5S4P8VQ*2%%I0EE75F]G0C@T04%G04H-"D%!
M64%-44%!65=.>F-%,512;%%!04%!05-55D1)2$Y34C!)04%!04%!04%!04%!
M04%!04%!4&)704%%04%!04$P>3%)54-!9T%!04$-"D%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M4EDS0GED04%!059!04%!07H-"EI'5GI9=T%!05E104%!0G-D,U)W9$%!04%F
M04%!04%566UT=V1!04%!9U%!04%!56-L:%I79T%!06AG04%!055:,6A:5V=!
M04%I=T$-"D%!0559;&A:5V=!04%K04%!04%56D<Q=5I!04%!;%%!04%"=UI'
M,6M:04%!07-104%!0TED;E9L6D%!04$P=T%!04-'9&UL;&1W04$-"D$Y44%!
M04%K8DA6=&%104%!+V=!04%!56)75FAC=T%!0D%W04%!06MD1U9J84%!04)$
M04%!04%-8VQ24U%W04%"1'=!04%G35HQ4E,-"E%W04%"1'=!04%G35EL4E-1
M=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U8VUL;F%(46=+1TUP241%-4]4
M9V=31U8S8D=6,&1#,5$-"EE73G)96$IK245.=F)80FAB;FM!04=2;&,R34%!
M04%!04%!045N3E-2,$EG4U561$YJ135.:EET36DT>$%!04%!04%!04%!04%!
M05,-"F,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04$-"D%!04%!04%!
M04%!04%&:%I7:4%!04%!04%!1'I544%"04%!04%28DU71FQA24%!04%!04%!
M04%!04%!04%!04%!04)95U9O9T%!04$-"D%!04%B-DE!041J,4%!041K1FA:
M5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L84E!04%!04%!04-39T%!05!H
M04%!=',Y:UI83FH-"D%!04%!04%!04):2E)536=A2%(P8T1O=DPS9#-D>35P
M6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-9V%(4C!C1&]V3#-D,V1Y-7 -
M"EI73759,F=!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!6D=6>EEW04$-"D%!04%!04%U4U56
M1$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H
M63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!04%U4U561$E$67A/5%DR3%1)
M=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#
M04%!04%!04$-"D%!04%!04%!04%!04%!04%!04%!04=2;&,R34%!04%!04%!
M04Q&2FQ:;59Y6E<U:EI30E=A5U8S85<U;DE%3G9B;5)P9$=L=F)I0G -"F)I
M0DI254TR351K,DYI,'E,:D5!04%!04%!04%!04%!04-X4UI76FQC;59U63)5
M9U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7-&<-"E-55D1.:D4U3FI9=$UI
M-'A!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!0C)A5U8S04%!
M04%!051P4#1!1D8X=4%"1% -"D9!040W8W=!0D)-3$%!3F-N9T%!04%&65=6
M;V=!04%!04%"34-664%504%!049C9C4R,6Q96$U!04%!04%!04%!44%!04%!
M04%!04$-"D%!04%!04%!04%!04%!2U!!04%!06Y.<%IY04%!04%!43%*54E'
M3C%C;EE!04%!04%!045!04%!04%504-G05!!0E%!1U%!94%#34$-"DM!071!
M1$E!3G=!-T%%04%244)+044X059!0EI!1C1!67=";T%',$%C9T(S04AW06=1
M0T=!27-!:T%#5D%*;T%N=T-K04MK07)G0WD-"D%,8T%V041"04U907EW1%%!
M3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"1%%%5$%2:T)(=T5L05-S0DUG
M131!5#1"4E%&34%624(-"E=11F=!5V-"8F=&,4%8=T)G=T=,05I)0FUG1VA!
M86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"*V=)1$%G=T-&04ED06E90TQW
M230-"D%K14-3=TI506PP0UIW2GA!;F]#:$%+3T%P9T-O9TMS07)90W=13$Q!
M=%5#-$%,<D%V541!04U,07A91$E1371!>F=$47=.4$$Q;T0-"EIG3GE!,S1$
M:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%11T)"345)05%T0D1S15-!4E9"
M1TU%8U%2*T))=T5M9U-O0DQ917A!5%0-"D)/144X050K0E$P1DA!57)"5&]&
M4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8;$)F64="9UE70FEC1TYW6DE"
M;&M'86=:-T)O=T<-"FY1879"<T%',%%B:D)V54A"=V-:0GES2%!19%!",D5(
M9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G>4-%64E79VAU0TE)26QG:7$-
M"D-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8:TIJ=VUK0V)O2GIW;FQ#9G-+
M15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R>D-W<TP-"DEG<S5#,45,85%U
M04,U9TQS079)0RM%3"M1=U-$0V]-47=X8T1(54UJ9WEN1$U!33)1>GI$43!.
M2F<Q0416;TYD03)/1&%K3G=W,V4-"D1F9T]%=S1U1&MK3UI!-2]$<'-/=&<W
M4T1U-%!#43AL1#!%4%AG.39$-5E0<W<O4$0K=U%#4D%M145-45E20BM%2G-1
M=5)$6$5055(-"D5X17A%53A28E)'345A;U)Y4DAO16=C4TIH2D9%;5%3:$)+
M:D5S35,T>$U$17E-5%%X3FI%-$U4<$)01D4K555":%%N1D5K56%H4TP-"D9+
M,%5Z:%1W1E))5DY"5E=&6&=6;7A7.49E05=!>%EM1FMK5V)"85!&<DE7,6AB
M-D9X,%A14F1L1C1K6')H9E-&+V-91WAH04='55D-"FEH:79'3E59*VAK9T=5
M55IA>&U21V)C6C-2;T5':6]A55)P,T=P-&%X4G)S1WA18D]X=&I'-&]B<VAV
M84A!26-+:'A32$AS8V]X>DT-"DA0561(:#%(2%A!9&U2,T1(97=E1F@U04AM
M;V5L0C8K2'5K9D5X."M(,FMF;$(K+T@K;V=&4T)"24=W9VU#1$5)4$%H2$-&
M24E856@-"F]32$])9G-I2GE*5DEO26ER>4QD27=O:D]#3FU)-5%J=VE0=TI"
M.&M44U(X2DMS:S)I54I*5&=L84-76$IC8VPY>5EN2FQC;6AY83,-"DIU9VY'
M0V1*2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'2U1G<&%Y;61+9$%Q06EO,4MM
M9W%M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,-"F)I>6E,3F-T1$,Q0DQ8671Q
M>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](3"\T=TY40G--2U%W,GI%4TU5
M;WAG:D<V369)>4MJ2FH-"DUP<WDQ1$U.33!9>F9Z3S1-+T4P2WI2;$Y*-# R
M1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K3C)!,VY$9EA/0E$T541I34]-
M9S4-"D)4;$-/6#@U=D1N-4]J639D1'%Y3W4X-TQ4=')/-F\W-D1W;E!'53AP
M1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH4#)%+V]J+VD-"E%#3D%:14-M
M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP1&954$%204Y%4C!32U)--49%
M:U964EIP1C-K66E2;61'<3!B=U)Z5D@-"F4P9D%3059)4S!I4E-.9$I(56QJ
M4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P36-K>39444I.4VLR5%1D>$]*
M535U5')D4$%%.4H-"E0U3E S5D%N54A&474Q14=55D)2;3%(;55J1E-F1DQ(
M57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*5T0Q6F-6<6Q7.3%D158U2E@-
M"C1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L<C%7,%9B;%9V;%A$5F-H;'I7
M6%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%69U8R0W$-"EE0>&A4,D=I6696
M:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!75U-:961M4%=A4UIU:&Y05V54
M6BML;U R:5=A3WAP43)M86%F1G$-"E-'<69A=F1R5#)U;F$O.7-6,GEV8E%H
M=%E',C5B:$IU83(W16)X-79E1R]28T-T=VAN1&=C5'!X;%A(=V-K='EP;DU"
M8S$Q>G5(454-"F1(0C!Z2%5O9%E6,31862MD<'0R*TAD5V0W3C1%6&AU94UX
M-4MN;4IE960V4FYQ;&5W4C=9,W9#9D-&.&=8>FAF548Y;U@T0F9M2BL-"G=N
M.&IF-%(O-5E"2&=+:4)#;T9R9V,R0TU)2U-G=E-$5C1/-FA",D5G251J:%5E
M1G$T64]H;DM',31C-V@U*TE"26AP:4TV2DTT;5H-"FEF-DM:27)+:7I#3&QO
M=CAJ1T]->6\P>&I::4XO-#5M:G,V4$YO*V5K06%18G!$5VM4*U)Q2DE2:VYQ
M4S0U3DYK-V%524I32VQ04U8-"E@U6$IL:E-7;C5C2VPS5U@T2FA-;4QI6DI*
M;5%M9GEA84IR5FTP2V)R-7=C;DEM8SDU,6MN9$ME44HV=6YX,F9I-2\V;T=M
M9S)+1D@-"F]B86E*<4M7;W=A:F1Q4&UP1F%K>#95-'!A;6U'<6%,<'8R;F)Q
M9F=Q1DMO>$MK,W%A;7%(2W%0<7=+<F1A=G!R1GES,$LQ17)B:74-"DQA-FAR
M>&%V:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ<G)1;'1*>3%%-U=+=&=',F5B
M8G=T,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4-"G4V93A)8GEB=E)7.6HW-$MV
M;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$5TU057A&2$5Z<U9,>&-J1U)S
M8D1X,$A(=CAG.7E,>DH-"D]S;35Y:FI+=#AS,GDW8DU.8WDQ>E183G1C-#)Z
M<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14>'122C%-=E94=%A2,6Q85S).
M9&,-"C$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW1C-)<F1%3C)7,VAZ96]T.' S
M-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K+T]7135G,VT-"FQU8V8U-FYO
M375I.#958G P3W!B-G58<F-/=C<W26)T164R8S=I:G5T3SE!-SAZ=U=01&PX
M6$QX+R]+33AX;GIP+U$P.4U,,5506&4-"CEM,S(K+V5+*T)N-'%0:S0K8V8V
M5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O+R\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44$-"D)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&8-
M"DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8-"DAX.&9(>#AF2'@X
M9DAX.&9(>#AF+SA!04519T%D045!07=%4D%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!448-"D%W24=!44%(0T%K2T-W14%!9TE$05%%
M0D%114%!04%!04%!04%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34(-"D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%4-"EI(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]013%/5#!:6%=&;&%7
M,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95@-"G W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1544-"D)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%,-"DYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<# K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<-"C%U8C)2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM$;$I75VPU:5IM<'5C
M;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$-"D%!=T1!44%#15%-4D%$.$$Y
M531Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M;#D-"GHU:#!#,75H85A/<%<P1C!D=E)K;5)8<65L5DIQ2S563%!J:6%-9T0W
M,TIX-DQ.3U!&1T5J2'9!2UE!9VEO,T(V2$Q81V1I<5A7=74-"C)L,W)&>G!L
M<T=L97E65&1Z0VYP;S<O6FER,V5L4V9$-3542$U*5$U2,#4O<6-R2G!*47A2
M>5,R12M1-FYZ.7E9-6,T<G-69&ER<U8-"F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%895I,=39S
M+TPR<%AD<B]V5$(-"F)3>5%K8C!:54I"<#=D8W Q16I(2$EJ;4%82S!/3TTX
M.$EY*VMY05!Z9DU5:VIY3S!K:D8U2$I:,UDQ2DHS2DI/8U548C8T04%+2$H-
M"C=R*U1T+V989FQ)<F1->G)A,T1W5S=T=6940TEW6&9S<%EG9F0R>G%/>5IY
M;&DS-D=N>G(R;7=W:'%B:B]&1WHW-TM*+TU,>G%D1'0-"D5S3E O938U9F9"
M8E)Q3U)J1$AJ-FA(:EA:0C-0>7EE=C%N:$1H:CEC=516,DPR6"M9;'AZ,G=W
M-2MF;"MT3F9*,VPT849O8TYO-34-"C-K:$TY.4U457902G4U2E!7;E0V378P
M;41W;T%D95HY-V@Y<#8S.'AM36@Y23)I3S9)-4HS;5,V.3)+=7A6,DMU>%8R
M2W5X5C)+<TH-"B].=GIB<69L<GDQ2%!P:D-/.74U,6=367%'.4YE3$]Z04U#
M2R]$5&-946=V1G8X06QA+S5H9CA!5C5K+S5&=R\X,%EA4F)V*U9R+VT-"D8O
M,65:4#A!:UA$+T%-,%DP='-O+TQ0>G@U.3%Z>FI:5V1Z9GDS5FE/8C-I8TEW
M;VI61V]72W%+9D94=FE1:TUS+TYU9GHQ;SA3-C,-"F]7<%-P<&]!4SET5E-.
M=E-B;W-G2E5N:3-1*T(K97=#;$EF>7DO3B]56CE56%-F33%Y2F\W;VAB4SE:
M55%P251S:FQ1;S1T,E!9*S,-"E))548W5&=3.$TO368X-$Y53W1'>#AS,VYO
M5V1M4VMT,&=2+U=K-DYX3$)H=UAO0T]V6'!42D%)=&U(-510-3(Q3WIB5R]-
M1V]Y>3(-"FMW-#)&;WEX<GE(95IU2W%A9&PK+W=!34)5354O3E@X>2].5VTK
M8EHY2C!Q-TYL8E=34FAU0TEZ4U!*1W-P66PQ8F](<%%9449,1'8-"BM6<B]!
M2FAF.5AM5"]K6$0O=T$P63!I,V8X<E@O34PO04MV36XO275(+VUJ1VQT-T(K
M5&UT95IT6C!/-W8Y8FYE-%9P*T9N3$EQ<%8-"E98-"M014Q58W1Q*T]!<$1'
M9GIE+TU8>E!P2&U.3DHP:34K<'=1=W!*239O:D\W>59/-6-.44%D:&E!<%HW
M*U=7<F%H<3-K:E1D43$-"D=9,T8U4#8O<7I-04,S0S1K4F1L04=Y<4)I56AL
M1T)71R]M>#5R,4QY,3571C-P<%9,>35U171O-6U!8C K4T\U64LQ45133VTK
M14D-"DQ%=GE:.#9E6CEE,3(K='17=C-U-%ER6#%),%I55VIE;V]R.$MR,D]*
M54DO.#!.5C@V84)Q160U<"MO>4IP5C,X2V]%:DEI;%5B<%4-"G%44F@X42MN
M3D@R;&QZ67!C55IE:W999&=A9E-A;4)H3T$X4U!V,TAF>BM#<BM74#5H,V5R
M,T5M:F$S2W-T,#9L<E-C<7%M44%F2$<-"G=5045G8FIB<%A*9&TV.#5$=U0U
M.4=(8C-9<V-%4FQW:6\Y4C-D>%(Y-RM44&Q7-79M=55K=4QA2C(U3F)236Y!
M5C-)6&MR1E(W6EH-"E!S:D5:6'502GAS6'12<5EW-%-)>5!E8G8W,#,Q<E9D
M1#AJ*U=L5T-.55-)1T]X=$%F:6MK3RLU-CED,F(K3UI'8DQ$5%ET=F=(0S -
M"G5N>F1O86IC,V4X:C-$.&-G=V8X<V1*=F9-4&U+-3@R87543#9,;C!#=S)A
M8VHY:V9Y>$PP2&)B=WI79&TT<%IC:'EZ-F9F*W@V1'0-"C=543 R0T]M>&)7
M3B]W0W(O=T%E4#95-B]/5'IL<EAL>E,W1DY*:T5%.3E)-G9C1E%Z2W-953!5
M34-T5S5D8S9%4$5&1"]K<#5P,2\-"E@W6%9N,64X83=A,V5%46QL4F5)65!Y
M*WE&-C!X2VAK;FXO>C%:955D2U<T:U0Q-S(T2E-Y=&$P-4UO*TIM4%I6<4LT
M9TIE139N*V$-"G9N,U4W:FM.4VMT9W@O9'=79T53:7998V9J8B]!1U)/1VU.
M<4YL*UHS;C)Y;35P<D4W:TAD2C942V99:5%.:E,R.64O3$@X,')J>E0-"D\K
M;3,Y;#9D+T1'6E1C=T%M0FQ"02M)16MO,B]I469B05%K1DMR>E@O37AV:'%0
M-E%K=#1V5&UK:TIQ3&5+84Y*;5<P-$(K2EE.0T4-"DEA3W)F1E)G,T59<3E9
M:5IM:5)M6&EZ2T-Y*T))-EE%<G-695=F.$%/468O04-J3VYF.$%-8B]Z2V9#
M149I+S5$439F3'$K<4,Y4T8-"C%&=6Y!5$)32S@K,TQ#5D0R:C9L-5HO-5HW
M3"]!24-,*VU24VER2TQ466=Y,E-1;T1U-G=H4CE*-#1Q<E1W43-%16M%-DQ,
M1$MP4U<-"DYH5E=6:%%G9SEI359F32\U;651<"]+=7-K=V=V<$8R4S%L2V0K
M4&-X368U;#=E22MN2D%S4VU&>"MC3W1Z95-6,$4X=C!I9C-%=7 -"F-V:6$R
M06]"-"MO9G-L=D0S3TY*=$0O;%HK6#AN;6I69G).-&A':3)403-,9%!69G%)
M5E!V*S!2,$AZ1TI+02MK;S0T-#0Q:FI52D<-"F=#;VEI9T%'=T%!-UI&:RM:
M+WII+W=$2FHV=B]!3D<O+U5,1FMG>$PR4#A!3'$P,$(O2D=J=%!$871-8F-C
M,FM737-453EA:75!<%H-"D@Y4SAS+SA!3%!:9CA"1B]406Q-62]4.4YF4W V
M9%!G-# T,#EQ67$K9&9Z>"\U5#)8+VU(:"]58VM%1C9Z*U1V+VMU3DDO-D]0
M.$$-"G%+;'=&47I006PU;B]W035!9CA!2T<R9B]B4FDO=T-413)%24Q%=BMC
M9E K56TQ2"]M0R\U;7!H2V@W4C5G,$\P,7I33&I48F]F=34-"C%O<C!Q56-B
M<38K-$]9*V9#37-$13E83#!7<FQP.&]Y4C5J-V9*.#185G1Q96=A,CA,:W=A
M:' X=V\V.6U1,59L<C%",DDY<S0K55H-"EEP,7EL179Q94]E4%4T8D<X2F@W
M-6]V;FI3<C-Y;4YF=5I&9VIH5VPV;E5P2W5X441V>4I(2#5J3W%W-C)%<UAI
M2&%U9G9F3CE6,E0-"FMX-FYW26EY9G X>#,O<F5-835R3W(K9&9-,%-O<#54
M=4E,0S%R.$UA13DO*TI/,SA--7I.;6YQ8W9V,D%E.#!M;'AA1%1M*V=U4C<-
M"B]W061!.3@P2%)R6%)D271T3G1H*S=T,$-L=6AD:G5Z;C-:=#@V<D)H1T]!
M:4]J-79R3E9,4&QL:VQZ:V9W2&PS+T]22"LX96@O.$$-"D=3-"\T:DAL=V-5
M=2]W0V-D+SA!95!84"M-;'8O=T%2:WA+:$IV.$%N24U82"M*=$],5BMR1WE(
M<"M(4#%8-2]H>'=H4W4O2C-Z=C4-"E P0S!U3%165BMQ6#@X=DID44M&=S!:
M54)9>7EH;5AI450P<'9I46]E<E-W*U)F3CEU56(V;'%Y.6%O>5!)=BMY52MO
M;C1:1DM-.'8-"BM6=$$X=E<X:T=J,F%7:V-P-5-K1FY::4]N2C-,36%D=#A6
M5D@X=6%&2F9F6#-S65=U*U%K37!58G5V4GE/:%ED;7!81E5X>%8R2W8-"DQ0
M.$%N25 O04I2;E1V.$%M3B\U;%!H0T,X5S!B>3ER5W13>5)A5EIY6&MK2VAP
M1FI!2E9384%M=5-1;3,O2W,O4&XO049:3&XW:"\-"EA"83 Y62]*5'E8<FUG
M439J96%T06)6-WHP:V=G66=V>&HU17-W0DY+;'1H9TM1.4]W2EE&*V,R=&%&
M6F55<')(54EX8UA6.3A.:$(-"E=J3$EV*S=Q.6A(6#9E;F,T46=V;D1*2694
M2#53-C%O5V]E54Q7,S!U3F)A4WA54EAL<E=R3$MD>DE4,T5H<3%F;S=:17!$
M3DU#6'H-"DXK8U@O:W@Y6"\V3B]W1'%&:7E166Q+-TAY1C5X=C=32SAS.4IN
M;G1:,3524W%">%IF16(T,G%*:B],1'HY239O3D9N0EDP0F)I;RL-"FML9T)J
M83 K:V9+*VQZ-E8U8S S5%HR5G W4S)J:&Q:3C$U2V]"<%AT6$ES;F<S-30O
M.$%+97DO.'<X4#9J:V=G=E=F>60O.&QX<$@-"B]2>"\Q1E,T0V]:;F=3.'HO
M=T-C9U X06Q$8E O=&]X9CAM2G-)45=*9CA!3U!N+T%#:S)O+SA!348O>DY4
M0U9$,VY)<&5(+T%*>E@-"C)M6$AM84M',E%F5S=714IE>D0Y<&HX4TEF9$90
M6#-P,GIM93$U>$]7:'I!,V91=EIF1FMJ<'E:2#!Y4'!(,VXT+VIM>'!F3"]M
M0F8-"DMS;7)H6%A2,VY25U-P05IL0E9:4W94:4,S2&PT;DU0=TUN:&-F.$%"
M9C1,=%1R34(Q27AF-5AH+T$O5%-C9FQ0<65M,DAM,DPV-F<-"C582TY"8E1N
M<$A+-490.$%G=G,O5&U2,EAK:DA,-G5U=V-(,FDP*U1*<&IW9G=M>4\X9G,U
M=F9C-G X,F50.$$O3U)(*SAE:"]W1$<-"E,T+S1J2&A#0S<O;DAF.$$S:C%Z
M+VI*8B]W1$5:35-O6B\U,3AK-E@U<S!X8D\X2FEM:$IE,75K04QX<U)1-TAQ
M<"]A6'9G=$QX3%<-"G9Y5#@W864W1S%H:C%+059):W0S06%N=DA*=V%V<W1C
M;&%+661E861R3VHS4W)E5S%X65A+;7%E;VIX4%5D,4I!4#!J0V@V,RM4+S4-
M"FUA<&9A:VYL,U=P:F1'6E=.:F1U87EC:U5S63-B.7%Q9VM%-R]/=5))4T,Y
M:W=*9&ER<U9E5V8X-4(O.&]Z<#,O36(O04UY;G=H0ED-"DXK5"]!2G4P3'DQ
M<5=O5#9V33!-9'A#:5)&56%3<D(V;C=)3T5Q2'%F+TLV=GDY+S5B<% K4D4S
M+TY/0VQT1V%0*V%F:WI73E-G,#(-"G=U,VMU-VML66M-36EG:TM73S=+0C!'
M3DIT4%!-1W9A9F]/:S-'<5@W.$QE0F$P2#)N62]:4D(S6FHP=TLK661D,6Y7
M=D]0;54S3&\-"C Q-61U27)3,51C271A2D=N>7(Q*UIY5$8V>&-F:V9:1'E3
M=&Y%5E!M4E Y24XS5VEV2U)V0E4O-W(R;T0T-SEY349P<#56-58X>38-"G0U
M3SAX0S921U8T5TU.+UI05F5A03!E3F@R645B2'-C2T@P+V\R<U='<S9:8C9L
M65-E<F$S2SAK8G5/>%9H,EI4<U)K5U0U>B]/3"\-"D%-;5!Q+SA!,&(O.5%S
M5U-$17924$I(-7)E4W1+.' V6G Q-V502&17,$E36D)$2W=$5DHV:%-$9TE4
M865F.$%+-G9Y.2\U8G!0.$$-"FM23B]Z5&I3,GE$>7HU=3!,>DQ"3E!P17I4
M4C(W0DI3>4Y(4FE+:C=11T),=WHX.&8K53EL+S5H-&8Q2$I"0EID*UA(-6XK
M5'1%.&T-"F%D<&5O,V)X6&QV-C-Q;W--:F=C-35(6#1L56HW3$1!471S;"]W
M0U8Q9FPW+W=!=#!N+TEI8B]M;D=L=$M0>C5N:FXX:F%D4$5A>'D-"C,X3&]E
M;%9A,VU)>$-L:3,O3U!N+TM486HO>D)F.'I5=VQ1.6DX,F5965!,*VA83W!3
M56%20G=T-'HK,TLR>4PO12LQ8WAD5FY'3$<-"EI(.$9Z*WIT1614;6IJ2$QR
M-41R*T\Y-'0U23AP6'9M+UA*8G$Y6FI9<$E:9%%U5'-89&IY.4Y4+TTS9G=(
M,%IZ96HP<W123S5F5#$-"DPS=F$S855.1FA%66985E)(9#4O1#=8=3AU;5=%
M=6UT<')W3#E284PP1$%"4E)(5&IX04A48D]P3T]*:G<Q-F54-3%(4$U:4$5"
M.60-"C-F;2MC9DYF;#(V.'4V-U!P.'!*5D1Z='!U;D]*:CA$9E!S9F9/4#%7
M;D]'6FEF9RMP9&YA,D]Q=VE9*TDW:C$O2&,Y<B],9GIC4$T-"D]H2THS<G%6
M;E-+-TAD='9G:R\R44<O=EA/:S=0,5AI=S,K;V,O,79!.75D;2]L<S-P+W4U
M8FHY22M(,TU,+S5Y22\S:C!0+T%)>5@-"D@O15DX,D%D25AF.#0W+S=X-C4O
M>&MT+RM)>5EL46YV-6AF;35B958Y4EA3-U,P1CEF2W%V8SAN-$I'1S-69&=3
M5TLW*S(S6$5"8E<-"C9$*V58;$,O:%5A:UI.2W5F,FMK5G!9-B]W0U1*1W!0
M+T)+36%7,'0O37(X>E!),F]E5C=R5&)346%P9#-+.%E&5TYW<U16,FQ,=7$-
M"C!+.75/+S!99TM3.#DO2T14<FDY."]A8UEG949R>G5*,U@Y;$519U8Y:7I+
M=C T4V=0<&Y)<VY9<3=&5TDO;58U2G5V3C)L5W1L8E@-"DM7<E<X+W)&-4%7
M0DA";'!T+W)9459E9&8Y0S@V>B\Q9')B+T%*1G9H=$9/+W=#:&5D6B\V=3%T
M+W=!:3-X=&%:2C5$+TIK*UAT8VD-"C%I+W8Q=7!B64XY6&AI47%V2FQ+.&U:
M:G9113=5=T5R4TXO36(X=F9-;FTV.6E#86Y$8F%88D%'0S%+=5-:0U!I:V5M
M>&)S4$%F330-"F=Q,RM84#555R]L83=M,4,Y;E,Y,45J:&)/<6Q6:5%J-&E+
M+W1.,'(T9E!%;&%E9S1%=E!0>D$O2TMZ.'I8=S%/>75266%G=T,S1E4-"C52
M>3!&07I524EA;3%D.7-)2TM6=GDT.&@K62]+33 X12MP43-E;#-!-4YB2W)H
M:VQ(4C!R='5.;3AF;WA*5DIV3R\U3C9N-6DX,%@-"G5S=S9J1$)&9&5L>&ED
M2$Q$,#15:DY33G1Y;&-15G!)=BMH961:+S9U,70O>4QF1&$P-R]!2T8U,6XO
M<3<R+R]!0TQF1S%P-EHK6"\-"D%*2'0O2T=K4U=A6$)U<FDT:SE7-&Y+.$%4
M44M&5F%T44%$>"]P9TI3>&8X=U!Y:C%(>E U:69664PK1S-J84M/4# U15ET
M5D)3=%(-"FE#:6U.+SA!479/<R]W1%8R='8K4F(T8E=K4EDO=T1/4$XS.6%J
M3CEQ.&8Q545'4EE9,C5S3S1"66=#=FIV.$%,0F$P>C<X>%!*33,-"FUJ>3EA
M-E1:>G@R;C%A-%-:5V-&;#12>'9(>$90.69%1DM$+T%#,R]!0WEJ.&]08S-5
M,3,Y8W9R;%)(>5)3:4I'1'E)04I*2DQ$<FD-"E-I;4TK9%HW-WIR-7EI.'4V
M5S%B3%1Y4E!.,5)8-E-Y3E0K5#=#*R]Z>FYT6DM7<'I$2$AL2#A%=F,Y;%%H
M;TY+8RM4-C4X:#$X:#@-"F5:+UDY43!04F)$4F1-:# V>%1H0D-/<"LP-T@W
M5'-E-5DU=3A/1T]/26I(:TAK3EAQ<#4X:'E43S4O1DDO3%A'67HU-#AJ,F9M
M;3 -"FE2<&9Q,35B:VU#-4,X.6HY<$=&5G%P*V4R65=T,%%Z9V1#3W)T=7EE
M,7!A3U).8U5:8W@K;&IV;$0X<W1F.$%,;71X86A&<6-,>&8-"EEU;T%R:C%)
M;39J-6IQ4&9-4%-D;EI-37A)4TAM-U1T3'0W1'%S2F=94W9O9'1I;5@U;2M1
M3'IZ:$)P.&1T9'@R<',R:UIJ27).>3D-"E%+0E1J+W$U=6=8;$-I=GDW.&=W
M*U0Y3W5)4')2=3=Q-V18;FPT.$9!445+<7)6=6Q4=EA%;$M*.#,K45!,=FUQ
M141526I(9'AI:TX-"C=#47-Q:G=*24E:9EIH.'%9,G)Y+U50*V-E=&%342]O
M-U9B86%/=G<O5T9K:$Y09F=*<TYO<%I9+W=$3U!F;4(U44PO049/,&AI<G4-
M"C!!:VUA;GED65(K3TYR5#%8>6(U1S!4>7!:3D)P-FPU-7%'-74U2T=346IO
M3G5I:G-O>4YP6D1I<G-69&ER<U9D:7)S5F1I<G-69&D-"G)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U931'IP<F1Z<'5K*VQP-FU85CE18C9R<#!3+V%-
M:FID+VMI+T95-V5/66US>D=%2VH-"CEC=&<W3'-V4WAY-6)N=&EH-G!(>3=V
M:GE7*U-V2T9T-6(P<U$Q170O4%(W,C4V;#,X051V>%AT.2]F2%(V55E9,2]%
M95I4,G(R;$P-"E9:3#512#!J.&17435L=7-D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U8-"F1I
M<G-69&ER<U9D:7%K,7!B4&-P8W9%:EA%4VQ9-5-!5U97*S!&2C96-S!Y2FE,
M=G%Z1U-1:5EG*VLY1EA*34A9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T98+R\R43T]/"]X;7!'26UG.FEM86=E/@T*"0D)"0D\+W)D9CIL
M:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\+WAM<#I4:'5M8FYA:6QS/@T*"0D)
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-3!A,C8X,BTU.60V+30R,&0M
M8C=F."TX93$X,&5F-60T8V,\+WAM<$U-.DEN<W1A;F-E240^#0H)"0D\>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F(U,&$R-C@R+34Y9#8M-#(P9"UB-V8X
M+3AE,3@P968U9#1C8SPO>&UP34TZ1&]C=6UE;G1)1#X-"@D)"3QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U
M.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@T*"0D)/'AM
M<$U-.E)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@T*"0D)"3QS=%)E9CII;G-T86YC94E$/G5U:60Z8F1C,S)B
M,S<M-&$X82TQ-30Q+6$P-V8M.#)F9C$W9F,W-#$W/"]S=%)E9CII;G-T86YC
M94E$/@T*"0D)"3QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3%F-S8Y9F(M
M838P."TT.#4Y+6%B-S<M.3(U960Q-CEC9CED/"]S=%)E9CID;V-U;65N=$E$
M/@T*"0D)"3QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR
M-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@T*"0D)"3QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@T*"0D)/"]X;7!-33I$97)I=F5D1G)O
M;3X-"@D)"3QX;7!-33I(:7-T;W)Y/@T*"0D)"3QR9&8Z4V5Q/@T*"0D)"0D\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z9C1B.3AA,3<M,F8W,"TT-38W+6(U8S M968U
M,C0Q-F8R969D/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H
M96X^,C Q-RTP-2TR.%0R,CHS-3HP,BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)
M"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-#
M(#(P,3<@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)
M"0D\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)
M"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F(U,&$R-C@R+34Y9#8M
M-#(P9"UB-V8X+3AE,3@P968U9#1C8SPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)
M"0D)"3QS=$5V=#IW:&5N/C(P,3<M,#<M,314,C$Z-#,Z-#0M,#<Z,# \+W-T
M179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B!#0R R,#$W("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)/"]R9&8Z4V5Q/@T*"0D)/"]X;7!-
M33I(:7-T;W)Y/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R
M:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)"3QP9&8Z4')O
M9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX-
M"@D)/"]R9&8Z1&5S8W)I<'1I;VX^#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE
M=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_>'!A
M8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M
M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \&_
MX*'?LGK^U?\  .ZL;&-#XGT(M?Z,Y.-\@7#P$^DBC'8;@A/ K\8M0T^?2;Z>
MUNH9;>ZMI&BFBD4J\3J<,K \@@@@@]"*_H6KX1_X*@_\$X9OB'+??$GP'9^9
MKB)YNM:5"OS:B!UN(@.LP'WD'WP,CY\A_P 1\6.!*F/A_;& C>I%6G%;RBMF
MN[CVZK;:S_ISP"\4Z655/]7LVGRT:CO3D]H3>\6^D9/5/92O?23:_-&BG$;3
M@C:5ZBFU_,)_;@4444 %%%% !1110 5U'P8^$.M?'CXF:/X4T"W-QJ6L3B).
M#LA7J\KGLB*"Q/H#UXK)\)>$M4\>>)+/1]%L+K5-4U"016UK;1F269CV 'MD
M^P!/:OUX_P""=W["%I^R+X&;4M76WN_'6N0A=0N$(=;&+.X6T3>@(!<C[S =
M0JU]QP+P9B,_QJA9JC%ISEY?RK^\^G9:]#\Q\4?$C"<)Y8ZEU+$S35.'=_S2
M7\L>O=^ZM7=>R? KX.Z7\ ?A)H?A#1U_T'1+80B0C#7$A):25A_>=RS'W:NN
MHHK^SL/AZ="E&C15HQ222V22LE\D?YNXO%5L57GB<1)RG-N4F]VV[MOS;U"B
MBBMCG"BBB@ HHJ&\O(=,LYKBXFBM[>W1I)99'"I$@&2S$\  #))XQ2;MJQI-
MNR,7XG_$W1?@YX"U3Q-XBO8]/T?2(3//*_7T"J/XF8D*JCEF( ZU^+/[8/[5
MNM?M<?%NY\0:ENM=-M\P:3IP;*6%OG@>[MP7;N>F%"@>E?\ !2?]NV;]J?Q]
M_8>@W$B> ]!F/V0 %?[3G&0;EQUVX)"*>BDG@L0/E^OY2\4./GFU?^SL%+_9
MX/5K[<EU_P *^SWW[6_O/P.\*5D&%6<9G#_:ZJT3_P"74'T\IR^UV7N_S7**
M**_(3^A K[$_X(_?LJGXN_&23QUJMNSZ!X)D5[;>OR7.H$;HP/7RAB0]PQB[
M&OD[P;X0U#Q_XMTW0])MVN]3UBYCL[6%>LDCL%4>W)'/05^Y/[,/P#T_]FCX
M(Z'X/T_RY#IT.Z[N%7!O+EOFEE/?EB<9Y"A1V%?JWA/PK_:>:?7*ZO2H6;[.
M7V5\OB?HD]S\'\?.//[#R/\ L["RM7Q5XJV\8?;EY7ORKU;7PGH%%%%?UL?Y
M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
M#4K1Z3!RGVZ3D->2*>=S<A ?NIQ@%GS48W9,I6/(OVJ/VEO$'[6GQHU3QEXB
ME_?7C>7:6JMF+3K92?+@3V4$Y.!N8LQY8UYW\WM1\WM1\WM708A\WM1\WM1\
MWM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK]%?\ @B]_P3M_
MX3'5+7XP>-+'_B4Z?+GPU8SIQ>3*>;Q@?^6:'B/^\X+<!%W> _\ !,O]@J\_
M;3^, EU*.:W\!^&Y$FUFZ&5^TGJEI&>N]\'<1]Q,G@E ?W#T/1+/PSHMIING
MVL-E86$*6]M;PH$C@C0!510.     /2LJDNAI&/5ENBBBL30**** "BBB@ H
MHHH *_-__@XA_P"1,^%O_7YJ/_H%O7Z05^;_ /P<0_\ (F?"W_K\U'_T"WJH
M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?S\_\% _^3W/BK_V,U]_Z-:O(/F]
MJ]?_ ."@?_)[GQ5_[&:^_P#1K5Y!\WM75'8YP^;VH^;VH^;VH^;VI@'S>U'S
M>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S
M>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1
M\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U>R_L?_ +"WCS]L[Q>E
MGX;L&M=%@D"ZAKEVC+96*\9&[_EI)@\1KR<@G:N6"O8#H_\ @F9^QS<_M??M
M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
M=E'_ !#I_P#58O\ RU/_ +LK],J*.>0<J/S-_P"(=/\ ZK%_Y:G_ -V4?\0Z
M?_58O_+4_P#NROTRHHYY!RH_,W_B'3_ZK%_Y:G_W978?#?\ X-]/ >AW"2>*
M?&WB;Q#LP?*L;>+38WZ<-GS6QUZ,#[^OZ!44<[#E1P/P(_9<^'_[,VBO8^!_
M"^F:"DRA9IXD,EU<@?\ /29R9''?#,0.V*[ZBBI*"BBB@ HHHH **** "BBB
M@ HHHH X7]J#_DVGXB?]BSJ7_I++7\ZGS>U?T5_M0?\ )M/Q$_[%G4O_ $EE
MK^=3YO:MJ1G4#YO:CYO:CYO:CYO:M3,/F]J/F]J/F]J/F]J #YO:CYO:CYO:
MCYO:@#TW]BG_ )/(^$O_ &.6C_\ I=#7]#%?SS_L4_\ )Y'PE_['+1__ $NA
MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
MQ)^'>K?"3Q]JWAO7+9K35M%N6M;F/G&Y>C*>ZL,,I[J0>]8=?I?_ ,%D?V0?
M^$Q\*Q?%+0;7=JFAQ"WUR.-.;BT'W)SCJT1.">?D8<@1U^:%?Q+QEPS5R/,Y
MX*>L=X/O%[?-;/S3Z'^FGASQK0XHR2EF5.RG\-2*^S-;KT>DH^376X4445\J
M?=!1110 4444 %?=G_!&_P#; _X0_P 5R?"W7KK;IFMR&?0Y)&XM[L\O!ST6
M4#*C^^",$R5\)U8TO5+G0]3M[VSGFM;RSE6>":)BKPR*0RLI'(((!![$5[W#
M.?U\FS&GCZ'V7JOYHO=/U6W9V?0^5XUX3PO$F3ULIQ6TU[LNL9KX9+T>_=76
MS/Z%**\4_8-_:KM_VL_@-8ZS(\2>(M-Q8ZU N!LN% _> =DD&&'8'<O.TU[7
M7]PY;F%#'86&,PSO":33\G^JV:Z,_P P\XRG%97CJN78V/+4IR<9+S7;NGNG
MU5F%%%%=IYH4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X+%?\HX_B
M-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[
M4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_ &&;/_T>
ME(#^CZBBBN4Z HHHH **** "L3XC_$/1_A+X$U;Q)X@OHM.T71;9[J[N).D:
M*.PZECP HY)( R2!6W7Y'?\ !:3]OG_A</CA_A7X5O=WA?PW<;M8N(7^74[Y
M"1Y>1UCA.1Z-)DX.Q#51C=BE*R/FC]MK]K?6/VS/CMJ'BO4?-M=-3_1='T]F
MRNGVBDE$XX+MDLY[LQ[!0/(OF]J/F]J/F]JZ%H8!\WM1\WM1\WM1\WM3 /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#7\#_ ! UWX9^(8=6\.ZSJFA:I;_Z
MN[L+I[>9/8,A!P?3O7V/\ ?^"[/Q2^&R0V?C'3])\?:?'@&64?8;_'_76-2A
M_P"!1$GUKXA^;VH^;VI<J>XTVC]H_@W_ ,%N_@I\2HXH=:N]8\$WS\,FJ6;2
MVY;_ &98=XQ[N$Z=J^F/AS\<_!?Q>MUD\*^+/#GB)6&[&G:C%<,H]U5B5/L0
M"*_G$^;VI8)WMIHY(W:.2-@RLIPRD<@@^M9^S1?M&?TR45_/'X*_;*^+/P["
M+HOQ(\;6,,?W8!K$[0#H?]6S%.WI_6O2_#O_  5Z_:&\.A57X@37D2]4N]*L
MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _GY_X*!_\GN?%7_L9K[_ -&M7D'S>U>O_P#!0/\ Y/<^*O\ V,U]_P"C
M6KR#YO:NJ.QSA\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:C
MYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;V
MH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;V
MH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK]4?^#>OX93:7\,O
MB%XNFC98]9U&VTNW9AC(MHWD<K[$W"C/3*>QK\P?!7@S5/B+XPTS0=%LYM0U
M;6+E+.SMHA\TTKL%4#L.3U/ ')Q7]!7[)7[/MG^RW^SQX8\$69CD;1[4?;)U
M'_'U=.2\TGK@R,V,]%"CL*RJ2TL7#<](HHHK$U"BBB@ JEXC\16/A#0+W5=4
MN[?3]-TV![FZN9W"16\2 LSL3P  "2?:KM?E'_P6>_X*'?\ "QM=NOA'X-OM
MV@Z3/CQ#>0O\NH7*-_Q[ CK'$P!;^](/1 6J,;NPF['@O_!2?]NZ^_;6^,;/
M927%MX(\/N\&B6;97S1G#74B_P#/23 X/W5PO7<3\X?-[4?-[4?-[5T15C /
MF]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?57_!
M+3_@G]/^V/\ %7^UM=MYH_A[X9F5]2?E?[3F&&6S1ASR,%R.53C(+*:\@_9*
M_9;\0?M??&G3?!^@+Y7GGSK^^9-T6FVJD>9,XXSC.%7(W,57(SD?O9\"_@EX
M>_9U^%FD>#_"]F+/2-'A$:9P9)W/+RR-_%([99CZGC P!G4E;1%QC<ZBPL(-
M*L8;6UAAM[6WC6*&&) D<2*,*JJ. H   ' %3445@:A1110 4444 %%%% !1
M110 4444 %%%% 'PK_P6*_X)X?\ "^O"$GQ*\(6._P 9^'[?&HVL"9?6K1!U
M 'WIHAG;W9,KR50#\A/F]J_IEK\C?^"R'_!.\?!;Q7-\4?!MCY?A'7KC_B;V
M<*?)I%VY_P!8H'W896/3HKDC@,BC6G+HS.<>I\&?-[4?-[4?-[4?-[5L9A\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U;/P]^(.L?"GQQI?B3P_?3:;K
M6C7"W5I<Q'YHG7]"#R"#D$$@Y!(K&^;VH^;VI ?OO^P7^VAH_P"VO\$K?7K7
MR;/Q!I^VUUW35;FRN,?>4'GRI,%D//&5R65L>W5_/G^QC^UKKG[&WQNL/%>C
M[KBS;%MJNGE]J:C:D@O&?1AC<C?PL!U&0?WG^$'Q;T'X[?#;1_%GAF^34-%U
MJW%Q;RCAE[,CC^%U8%64\AE([5SRC8VC*YTM%%%24%%%% !7YO\ _!Q#_P B
M9\+?^OS4?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\
MWM1\WM728A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\W
MM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U 'N__!,GX;3?%#]NSX;V<,32
M)INK)K$S#.(TM,W&2?\ >C4#U+ =Z_>ZOSQ_X(/?LCW'@GP7JWQ8UJU:&\\3
M1?V=HBR+AA9*X:6;'I)(J!>AQ$3R'%?H=7/4=V;1V"BBBH*"BBB@ HHHH X7
M]J#_ )-I^(G_ &+.I?\ I++7\ZGS>U?T5_M0?\FT_$3_ +%G4O\ TEEK^=3Y
MO:MJ1G4#YO:CYO:CYO:CYO:M3,/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@
M ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;V
MH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH /F]J/F]J/F]JZ_X!_!/6OVB_C!H/@S0(3)J6NW0@5MI9;=.LDSX_@1 S'V
M4T@/UD_X(3?#27P9^Q;-K-Q'MD\6Z[<WT+$8+01JENO_ (_#*?QK[2KGOA1\
M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?FS_P6B_:J.N>);+X5Z1<'[+I)2_UMD;B2X*YA@/J$5MY'(W.G=:^_
M/C3XWU'X=_"O7-9T?1K_ ,0ZM96K&RTZS@::6ZG/RQKM7G;N(+'LH8]J_+#P
M=_P3-^.7[1/CB\UCQ!I/_"/MK%R]Y>ZEKDZQL[R-N<^4NZ4L<G V@9XR.WY/
MXIXW,:N$CDV54ISG6^)Q3:4%T;V7,][O9.^Y^^>!.6Y/0Q\^),]Q%.G3P^D%
M.23E4:W46[OE6UD_>::U3/GOX8?#+6OC'X]TOPUX=L9-0UC5YA!!"OKW9CT5
M% +,QX502>E?M+^QY^RGH_[(_P (K7P_I^RZU*XVW&KZAMPU]<8Y/J$7[J+V
M'J2Q.-^QS^P?X1_8\T-FT\'6/$UXFR]UJYB"S.O!,<2Y/E1Y .T$DD#<3@8]
MQH\-_#S^Q(/&XZSQ$E;35079/JWU:TZ+2[9XS>+W^LU199E;<<'!WN]'4DMF
MUNHK[*>M_>:O91****_6#\#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>exhibit10firstamend_image2.jpg
<TEXT>
begin 644 exhibit10firstamend_image2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (7 G # 2(  A$! Q$!_\0
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MSG_GB_;_ &369X4Q_P (GI? _P!2.WN:;Q$K72)66P4^5N^G^1U8^,>K\_\
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M?S-5]@R?\5>C_-&Q1114FI@ZQ_R-'AW_ *Z2_P#H-;U8.L?\C1X=_P"NDO\
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M:THK%H[M;A[R>8JA15DQ@9[\=ZFR74U4IOI;[CG-0EN5\>:);SSB50&=<)M
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MQ!_X#C_&HKGQD39W /AG7U!B<$FW&!\IY/-=;N;^\?SJ&\).GW0+'F"0=?\
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M(RAI.5^K_1$M%%%2:F/XI /ANY5@"I:,$'T+"O8SHFG:C'I5Q+'Y5KI2AX9
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M:OQ'S_\ M-=?"_\ V]_^T:\ KW_]IKKX7_[>_P#VC7@%(S"BBB@ HHHH *]
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M%,HSD#KGI7TH  ,#H*A[G+4^(\ _::Z^%_\ M[_]HUX!7O\ ^TUU\+_]O?\
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MO9Y#_P *@U/_ *"]M_W[:H-1^%^KV.FW%R-5BF\I"WE ,-V.W6O9:1E#*58
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MM=1+<YJOQ'S_ /M-=?"__;W_ .T:\ KW_P#::Z^%_P#M[_\ :-> 4C(****
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M07VJ6]SIMU @</+"R+D<9(J/2=1@LM'LK67=YD,*HV!QD4_[.Q7+;V;(_M?
M^TO[5;=S=HK._MJT_P!O\J4:S9GJ7'_ :C^SL7_S[?W&JS? /_E['[R?4/\
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M6[NU*PJ?W%OCECV)'KZ#M7EOB6Y6W^)&@3W=Q'#&)[KS \@"QG QD^IKE?\
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MI-3E?#O_ "._C'_KO!_Z!755ROAW_D=_&/\ UW@_] KJJ$*.P4444#"BBB@
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MNNV!*?O!P,=J^KT_U:_05#W.6HWS'@/[377PO_V]_P#M&O *]_\ VFNOA?\
M[>__ &C7@%(@**** "BBB@ KT#X)_P#)7M"_[>/_ $1)7G]>@?!/_DKVA?\
M;Q_Z(DH ^N;O_CSG_P"N;?RKR/X7:?8ZCJ>JQWEK%/L4%1(N<?,:]=N>;68'
M^X?Y5Y7\).-;UD#^X/\ T(UWX9M8>K;R_,\_%)/$TD_/\CT3_A&=#_Z!5I_W
MZ%,?PIH$@ ?2+0XZ?NQ6Q17)[6I_,SL]E3_E7W&)_P (?X=_Z ]I_P!\4?\
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M&^&(5\^?PYIPDE^2*W6!<X]_?U]*P/$OC&[T*Z:RT_3HB]E;?NQ.3LB^7(
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MKXXU;4+I[2T\(W)NHU$CQ37"H0IZ'_ZU3*.MT=U&K%047N=K17+_ -O>+/\
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MQ8Z-_P!?$G_H%:W@ O)X.M+>U^0G<9YL?=YZ#W_E7HQ_W/\ [>_0\V7^^O\
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MN,$],<<"J6@:'\4D-U):W.EO'<0!&D<*5().1]1SG\J[FY^(&F:?ILQ2WO\
MS!<-$PCCWSS$9RR@=N#ST%8]]XVM;'1H;O08;J>WNX_M#:<8R?+YYWL/]6">
MQZ]J-/Z_K[D&O]?U][*"> /&TVD^0?$VE>3;NC17!M2" O8'^Z/UK'MO!TM]
MXZNX?&3Q:I=2VB7"RQ@QK@':O [UZ_IES>7NF1WNM6<=E&I'E6L;[]_H3[^@
MKD;V>XE^*]TLZ(@&EH44?>4%CPQIHJGK-(V%4*BJ.B@*/H.*6BBH/2"BBB@
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MQ'KI\SQS$K*-QS:@8B Y.[I^%<5K.N^./#^I2FV\3PZG%*HS-;",?,>1U/(
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M[AA]S_Z_H*\8LSX_U;3WNXKJR;3Y9D9P2%<LK!=N.WX5[-&OF0_9H6\N!/\
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M<!E'F#J?3M75>*QX@\A3I4R0@[HKDS*,8)RJC'IWKD;S2/%4EK=K<:A:M#*
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M"1C'M'56[Y-=GHU[>7NA"ZUH6T<MJSHT%OG8SKTX//3H*X#3_)C^*UJ6@6*
M(W[G&23MXZ=_:O0K[3IS,U_%-]GOK@%%MPF]6XP"1_>'=A7/6235C>BVT[GG
MECXY\;ZWI4VO6-GH\L-O<M;)#)OWY!P6 _$5.WBOX@P7S.;+P_)(P)^65RRH
M/PX!JW=> -4\/>'+?3_"OB&:QU$2275Y(%W>:",G [<CCUKS7P[K7Q!UKQ%;
MZ</$FL68NI"CSS61PC < \<?TKG;M_7]?\$Z4KG<ZMXR\>^'K6R-S8Z.]WJC
M%$CAWF17VY&X]!@=JQ]'?XH/#=01:G81VEI$9'<',87DD9QDGM7>V_A+4+K2
M=)&H:M]LU+19WN%OB-B3.<@JW<C!P6I]SXFL=:D_L,[].>-AYUM*NS?&HRS*
M>C+TQCK3).1N_'7C.VL-'%[;:%;+?2A$ADWJH7;E78_W?\FI='U?5M4^(E['
MK4-BEY:V"(6LW+(RDY'/M5GQ))#JNB:*J-#(T1:%#Y@$<3.N!EO[PZXZ<<U@
M^#(9+7XAZU9NMN?LUI%%YENP992!]_([GN*:+I_&CT>BBBH/1"BBB@ HHHH
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M%'N5\W#EB,E1GGZFO/M2B\57WA^?3HO"%G!++;_9_,,RL1\^[=TZ]JK+I/B
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M''-+69Z(4444 %%%% !1110 44#KSTK-L9M5DU*Y2[MU2T4'RF"XSSQSWXH
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MHNU*/H;E%<3I?Q-T:XL%DU+[3;71)W1I:2$ =N<5<_X6-X8_Y^KS_P  I/\
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MJBX8GT MY*X&N^^"BAOBYH:L 5(N 0>_^CR4 ?3=BVGZF_\ :6I7=M*SL3!
M\JE(DSQQG!8]2:YW0@@TO]V$">?*1L Q]\],5T[>!?"Q9F.AV>223\G>O&O
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MQ^9Y#]Y1W 7I@]:Z8O"MN+F5=VCD_NX,<J>QQZ?[/:OJX04(J,>G]?>9>O\
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MZ^00<$8I*Y+PKX ^(.B:6]H^M:8 9=^9T>9C[9["MX^%_'A! UO10>Q^R/\
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M[S_A,?#/_0?T_P#[^T?\)CX9_P"@_I__ ']K@_\ A16E_P#0<N_^_*_XT?\
M"BM+_P"@Y=_]^5_QJ=2KS['>?\)CX9_Z#^G_ /?VC_A,?#/_ $']/_[^UY7I
M'PCL-2UO7K!]6N473+A(4<1*2X9<Y/I6Q_PHK2_^@Y=_]^5_QHNP4IOH=Y_P
MF/AG_H/Z?_W]KEK?Q5H$7Q/U&[?6+,6LNF1(LV_Y2P;E<^M9G_"BM+_Z#EW_
M -^5_P :Q;?X2V$WC2^T-M5N1%;VD=PLHC7<Q8X((HU$W/L>I_\ ":^%O^@_
M8_\ ?RLK6_'/A@"UB?6(9K1Y";@6Y+$@#A3[$]:YO_A16E_]!N[_ ._*T?\
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M_:+/&/\ 7VN<^GG"O:ZB6YS5?B/G_P#::Z^%_P#M[_\ :-> 5[_^TUU\+_\
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MW/YG9+;&T>_-49_B!!:V\EQ/X>UV.&-=SNUN %'J:+AS(Z^FRJ'@E1EW*T;
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MV$=O$RNZB4=,^AZU]&U#W.:J[R/G_P#::Z^%_P#M[_\ :-> 5[_^TUU\+_\
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M5&6 )QD]:YGP_P")=0U?7]4TV[TAK.&SSY4YW8F^;'?CWXKI:4L2,$D@=.:
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M_P"!G_UJ/^$2^(?_ $$#_P"!G_UJ]?HH_M"I_*ON#^SJ?\S^\\@_X1+XA_\
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M3TH_K]17.OHKGO"/BVV\7V-Q=VUK/ D4IC'FCAQV8'OG]*Z&@84444 %%%%
M!7!_&.Y2U^&FHO(&P7B'R]?OC_"N\KSCXY_\DLU#_KK%_P"A4 ,T'6;7Q!HE
MOJ=FLBP2@JHE&&^7@UI5Q_PM_P"2<Z9_O2?^A5V%:([8NZN%%%% PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "H+X$Z;> #)-O)_Z":GI&R48#J5(&?I0!S?P]!7X?:*"""(#D$8_B
M-=+6)ILESHVFVEIJ4"+'&/+^TPON0$DXW#J.O6MOH:$);!1110,\Z^(NLVNG
MZQIEE,)?-N)+>1"G3"R\YKWP'(!'>OF7XP?\CIX;_P!U?_1@KZ93_5K]!4/<
MY:C]X\!_::Z^%_\ M[_]HUX!7O\ ^TUU\+_]O?\ [1KP"D9A1110 4444 ?:
M_P -[*WT_P"&WAR&UC\N-M/AF(W$Y>11(YY]69C^/'%=17/^!/\ DGGAK_L%
M6O\ Z*6N@H 1ON-]*\9^'NL:=H_B35Y=1NX[9)%*HTAQD[S7L]<-=?"O0KF[
MEG$MU'YC%BJOP">N*[<+5I1A.%3:5MCBQ5*K*<)TM7&^YL_\)SX8_P"@U:_]
M]&C_ (3GPQ_T&K7_ +Z-8'_"I-#_ .?F[_[Z'^%'_"I-#_Y^;O\ [Z'^%5R8
M+^9D\^-_E7WF_P#\)SX8_P"@U:_]]&C_ (3GPQ_T&K7_ +Z-8'_"I-#_ .?F
M[_[Z'^%'_"I-#_Y^;O\ [Z'^%')@OYF'/C?Y5]YO_P#"<^&/^@U:_P#?1KSC
M3;NWOOC']JM95E@DG)1UZ,-E=1_PJ30_^?F[_P"^A_A6EH7P\TC0=334('GE
MFC!">8W SWQ6D*F%I1ER-MM6,IT\56E'G223N=+=V%G?JJWEI!<JIRHFC#@'
MVS45MH^F64WG6NG6D$H&-\4"JV/J!5VBO,/4(+VSM]0LY;.[C$MO,NV1"2-P
M].*RY_".@7-P\\^F0R2O;BU9FR<Q#HO7H*VZ* .9;X>^$WB$3:';%02>K<DG
M)R<\\C-/M_ 7A:TLKNS@T6W2VO-OVB,;L2X.1GGFNCHH YY? WAE;7[,NCVX
MA\U9M@S]\# /7MVIEOX \*6@86^B6T>XL3MS_$,'OW'%=)10!G-H6F-H8T4V
MB?V:(_*%N"0NSTZYQ1::#I=C;VD%M91QQ6886ZC)$888.,^U:-% &&_@[P])
MI#:2VEPG3VD\UH,G:6SG/7U[=*EOO#&C:G!:PWEBDL=J-L +,"@QC&0<UKT4
M <?I_P .-#MKK4+B]@BOWNYS,OFQ!1"#CY5 [# YZULVWA;0[*XMY[;3((I;
M=76)E!!4,<L/<$^M:]%'2P%/3=*L=(@>"PMU@B=RY12<9/7 /3\*N444 %%%
M% !1110 5PGQ@@CN/AKJ*2+N&Z(@9QSO%=W7$_%HX^'&HGT:+_T8M %#2=+L
M]%TN"PL(3#;1C<J%LX)Y//UJ[2+_ *M#_LC^5+6AW!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !14,-W:W#LD%U!,ZC)6.4,1]0#3Y9H8
M(_,GFCBC!QND8*/S- #Z*JC4].) &HV9)Z 7"_XU:H **** "BBB@ HHHH *
M*** "HYV=+:9XEWR+&S(O]Y@.!^=24A.U6;GY03Q[4 >1S_$/QE):S0W'A0@
M,C+)^X; %=;8^(O$[:=:D>#;B4&%<2?:T&X8ZXK9BO[O7]/0VT,UI9W"_--,
MWSE,X(51TSZFM955$5$4*J@!1Z 4B$GW.7_X2'Q1_P!"1<?^!B4A\1>*!_S(
M]R?I>)7544RK/N>2>+&O=:UO39M6\*W%DT4T"+,]PK!%,HSD#KGI7TF!@8':
MO%/&Q N+;/>>T _[_"O:ZA[G-55I'S_^TUU\+_\ ;W_[1KP"O?\ ]IKKX7_[
M>_\ VC7@%(S"BBB@ HHHH ^W_ ?_ "3SPU_V"K7_ -%+705E^&M-FT;PKI&E
MW#1M/964-O(T9)4LB!21D XR/05J4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/Q9_Y)SJ/^]%_
MZ,6NVKS[XUW#VWPPU!TQDR1 Y_WQ0!87[B?[H_E2UA>#-9N/$7A.RU2XA2.6
M7<I6,';\IP*WL'T-:'<G=7$HI<'T-&#Z&@!**7:W]T_E1M;T/Y4 )12X/H:,
M'T- "44N#Z&C:W]T_E0 E%+M/H?RHP?0T )12X/H:-I]#^5 "44NUO[I_*DP
M1U% !1110 5#=_\ 'A=?]<'_ /034X!/0$U#>*?[/NOE/^HD[?[)H X+PCIU
MG9W/A">TM(X9KK3;@SO&N#*1TW>M=7J-O::W>0Z=/!'=6MN_G7*N-R;L?*I]
M^]9GAC2+._\ "7AZYG63S;>T*QM'(5P&)W#CUKIH+>&UA$,$2QQCHJC]?K03
M%:''>,?#&@VG@_4KBVT:RAGC12DB1X93N'(-=G%_J(O^N:_^@BL#QT ? VK
M_P#/)?\ T(5T$2M]GAPI_P!6O;_9% TM1:*7:W]T_E1@^AH&)12X/H:,'T-
M"44NUO[I_*C:?0_E0 E%+@^AHP?0T )4-Y(T5A=2I]Y()&7/J%-3X/H?RJO?
MJW]F7G!_X]Y.W^R: ,;P-<R7G@;1[B8@R/!EL#'\1KH*YKX> _\ "O=$X/\
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M]K<K.Q;(X*L$ &,\Y[#CG@ ]THKQ_P#X:.\(?] W7/\ OQ%_\=H_X:.\(?\
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M7CCRK=8H][>8W ..^.OX5\ZR?M$^*Y5VR:3H#KD'#6\I&1T_Y:T__AH[Q?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O?_P!F7_F:/^W3_P!K444 ?0%%%% !1110 444
<4 %?('QM_P"2O:[_ -N__HB.BB@#S^BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>exhibit10firstamend_image3.jpg
<TEXT>
begin 644 exhibit10firstamend_image3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0 ^8# 2(  A$! Q$!_\0
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M444 %%%% !1110!SOCR-9? NL1."4>W*L <9!P"*O>&E">&-+09PMK&!DDG
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M_H*V7_?]?\:Y*RU?3E^*&H737UL+=[$(LID&TL/+X!Z9H [^BLW_ (2'1O\
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M.<LL4>Q<XQT&!71T4 <__P (1X:_Z!%O^O\ C2_\(3X;QC^R(,>F6_QK?HH
MY_\ X0CPU_T"+?\ 7_&C_A"/#7_0(M_U_P :Z"B@#G_^$(\-?] BW_7_ !H_
MX0CPU_T"+?\ 7_&N@HH RM.\-:-I%T;JPT^*"=D,9=<YVD@D?F!^57+_ $^T
MU2S:TOH$GMV()1^A(((/X$ U9HH @M+2WL+2*TM8EB@B7:B+T45/110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MA>-+ZZTSP1KE_93&&ZMK*66*0 ':RJ2#@\=JCTG0H9K6QOM1NKK4;CRTE4W3
M@JC$ Y" !0??&12>/(Q-X$UJ%B0LELR-@X.#P?T-7_#F?^$:TP,S.1:QC<QR
M3\HZF@#3HHHH **** ,_7?\ D7M2_P"O67_T UR/AC_D*:?_ +]S_P"BX*Z[
M7CCP[J9_Z=)?_0#7G7@FZU1_B VE7QL_*MM.%^A@5LDS"-=I)/;;Z4 >JT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?.6IG=JUXWK.Y_\>->R67_ !X6_P#UR7^0KQK4
M?^0I=_\ 79__ $(U[+9?\>%O_P!<E_D*]*MLCSJ6[)Z***P-PHHHH *QO#O^
MJO?^OD_R%;-8WAW_ %5[_P!?)_D* -FBBB@ HHHH X>&.:6/]Q9/*R7&\S*#
MR!CY*W_[8OO^@-<?G_\ 6H\-_P#'A-_UW;^0K9H QO[8OO\ H#7'Y_\ UJ/[
M8OO^@-<?G_\ 6K9HH PO[?N?.\G^RY?-QG9N.<>O2I/[8OO^@-<?G_\ 6H'_
M "-C?]<*V: ,;^V+[_H#7'Y__6H_MB^_Z UQ^?\ ]:MFB@#AVBE@AB6>R>-S
M<!O/8$9&/NUW%8WB/_CUMO\ KX7^1K9H **** "BBB@ HHHH **** "BBB@#
MPQ_]8WU->Q/XAU&_FCTR6SGT".;$8N[O:6D]HBI*ACV+'/H#7CK_ .L;ZFO;
MI_%GA*]L6M+K4[26&1-CHV2"/RJ\6OA)PKW.@L[2"PLX;2V0)#"H1%'8"IZY
M[PGJ\-[HI4WJW MIGMUG9N954_*W/4E<9/KFM]75QE&##U!S7"=@ZBBB@ HH
MHH **** "BBB@ HHHH **** "BBHYYHK:"2>9PD4:EW9NB@<DT 245REY/K6
MHZ)>:FEV^EVRV[RV\,<:F9@%)#.6!"YZ[0,CN:\"NM7U^=+:Y@NM/:2XA269
MKV\6)F=E!) +KP2>U 'U1D45\G?VKXF(_P"/KP]GT_M5/_CM>M?!V6[EFOVO
M9(GF,*;O(F\R/[S=""0?SH ]7HHHH **** "BBB@ HK.U;4SIT420PFXO+A_
M+MX <;VQDDGLH ))]*X7XAG6M/T"WDN-8=VNYS!-!!&(X@AC<D#^/J!R6_*@
M#TNBLSPY_P BUIO)/^C)R3D]!6G0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &!XW_ .1*U7_KA_45<\._\BWIO_7LG\A5
M/QMSX+U4?],>_P!17/:1X[BM='L[<Z+J<GE0JF](P5; QD'/2@#T"BN,_P"%
MA1?] '5O^_(_QH_X6%%_T =6_P"_(_QH [.BN,_X6%%_T =6_P"_(_QH_P"%
MA1?] '5O^_(_QH Z+7_^1<U3_KTE_P#0#7GWA$ ?%V\('7PY:9_\=K3U?Q[%
M/HM_#_8FJ)YEM(NYH@ ,J>3STK ^'^HC4OBK?S+;S0[- MH]LHP3@KR/:@#U
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#YQU'_D*7?_ %V?_P!"->RV7_'A;_\ 7)?Y
M"O&M1_Y"=W_UV?\ ]"->S6O_ !YP?]<U_E7I5MD>=2W9-1116!N%%%% !6-X
M=_U5[_U\G^0K9K&\._ZJ]_Z^3_Z"* -FBBB@ HHHH Q?#.\6%P' #+=2+P<]
M#C^E;58]E:ZAID<RA8;F-YGEPA*M\S9QSQ6G;W$=U")(R<9P01@J1U!'8T 2
MT444 8P_Y&QO^N%;-8P_Y&QO^N%;- !1145S<1VL/F29QG 51DL3T '<T 9?
MB-7:UM1&%)-U&OS''4X_K6S61=VVHZBL *P6\:3I*0Q+M\ISCCBM>@ HHHH
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M_P"R:BU6]\:ZKILMDNB-9^:5!GM[K$B ,"=I!') (Z]ZZ2P_Y'#6O^O>U_\
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M'[N"@#OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK[T ;U%%% !1110 4444 %8'C?\ Y$K5O^N!_F*WZP/&_P#R)6K?]<#_ #%
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M_E7B=S_Q]3?[Y_G7MD'_ ![Q_P"Z/Y5Z5?9'G4=V24445@;A1110 5C>'O\
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MPY_R+6F_]>R?RK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#GO'<\UKX \07%M-)#/%83/')$Q5D8(2"".0:DT#1-/MK
M*SO5@,EVUNA-Q/(TLARHS\S$D9]JC\=HDO@;5XY%#(UN0P/<9'%7/#2+'X8T
MM$&%6UC"CT 44 :M%%% !1110!GZ[_R+VI?]>DO_ * :\_\ "H_XO%?\YSX>
MM/PY6O0-=_Y%[4O^O27_ - ->?\ A4C_ (7%?\]/#UIG\Q0!ZA1110 4444
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M "BBB@ HHHH **** "BBB@ K"\)$'0059"/M$_*6_DC_ %C?P_U[]:W:QO#
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MR!G\X':-IR:7PT -7L0IW 276#Z_NX* .]HHHH **** "BBB@ HHHH ****
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M^VVG_/U#_P!_!7C^LL&UW4&4@J;F0@@]?F-0BPO&+!;2<E3A@(SP>O/YTO\
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MA#_D4=+_ .N"T 9'_"N;'_H*ZK_X$4R7X;:?+"\3ZIJI5U*M_I'8C'I7:T4
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M]KZ;_P!!"T_[_+_C7*7MQ#<^(KAX)HY4^V:>-T;!AU?TH [>BBB@ K \;_\
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M_"@8!X_89X(_$5-8W\=_'(Z1RQF.0Q,LBX(8=: +5%%% !1110!1O5#7MBK
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M*Z_;6\1G\EH)3(I,2R*<HR$%6X/#'\0*V** *]A:+8:=;6:,SK;Q+$&;J0H
MR?RJQ110 4444 %%%% '-?$,@?#GQ&<XQITY!SCG8<?K5[PW8V%KH5B]C;6\
M2R6T9W0H!N^4<Y'6JWCE0W@G5E8 @P<@C(/(JYX< 7PUIBJ %%M&  , ?**
M-2BBB@ HHHH S]=_Y%[4O^O67_T UR/AC_D*:?\ []S_ .BX*Z[7?^1>U+_K
MUE_] ->;>";>6V^*EY9/J%Y=0Q:/#=(D[C:DDFP,0  .0!VH ]9HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H1H UJKWW_(/N?^N3?R-6*KWW_(/N?^N3?R- &1??\ (+O?^O6'^9K7L?\
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MLS_A'-._NR_]_31_PCFG?W9?^_IK W-/S8_^>B?]]"CS8_\ GHG_ 'T*S/\
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MN#F[T]VLI_=HSM!_%=K?\"J"SSJOCJ]NSS;Z3"+.+T\Z3#R$>X7RQ^)HB/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#QO\
M\B5JO_7#^HJYX=_Y%O3?^O9/Y"J7C@@>"M6). (.I^HJ[X<(/AK32#D&V3^0
MH TZ*** "BBB@#/UW_D7M2_Z])?_ $ UP'A7_DL-]_V+MI_,5W^N_P#(O:E_
MUZR_^@&O./!4TEQ\4KJ_-E=P6T^CPVL<D\>T-)'L+@?0$4 >KT444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5%<_P#'K-_N'^52U%<_\>LW^X?Y4(#YQ@_X^(_]X?SKW&O#K<$W
M,0'4N/YU[C7I5^AYU'J%%%%8&X4444 %8WAW_57O_7R?_016S61H$(A34%#.
MW^FR?>.<=.* ->BBB@ HHHH P/%-K>7$%A)96QN)+>[28H&"Y SW-1_VUK__
M $+3_P#@4E='10!SG]M:_P!O#3_^!24?VUK_ /T+3_\ @4E='10!SG]M:_\
M]"T__@4E UK7\<^&G_\  I*Z.B@#G/[:U_\ Z%I__ I*DBU?6G)\W0'B '!\
M]6S^5;]% '-WTFI:BL,3:9)&$E#D[@?Z^]=)110 R;_42?[I_E69X<_Y Z?[
M[_\ H1K#\>W]W9"P%K<RPB3S-^QL;L;<9_,UQ<6MZI!'Y<5_<(@.=JR$"M8T
MG)7,Y55%V/9J*\<_X2'6/^@E=?\ ?PT?\)#K'_02NO\ OX:?L'W)]LCU36_^
M0/<?0?S%3:?_ ,@ZV_ZY+_*O(Y-<U6:,QR:A<,AZJ9#@TJZ]JR($34;E548
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M<K&KS7#RA4;=@''?UK+M/$^C6MK'"LDWRCYCY+<GN>G<ULZ?J-MJ=N9[5RR
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M_P#O\O\ C1_PD&C?]!2S_P"_R_XU1_X0?PS_ - >W_7_ !H_X0?PS_T![?\
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M?PKTS7?^1>U+_KTE_P#0#7 >%?\ DL-]_P!B[:?S% 'I]%%% !1110 4444
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MXJ:%M'^SE&>[GD5+)4.'\_JK ]MN-Q/H#4/A#=#I\]I>$'6(92=0?_GK*?\
MEH/]AAC;Z 8[5+H\4FIWC:]=(R[U*6,3CF*$_P 1'9GX)]!@>M/UJTG@FBUJ
MPC+W=LNV6)>MQ#U9/]X=5]^.YKSSO#Q7_P BY<?[\7_HQ:-"_P"/_7O^PA_[
M1BJ'Q!=07WA%[JVD$D,ODNC#N#(M3:%_Q_Z]_P!A#_VC%0 :[_Q_:#_V$?\
MVC+6-\2H?$TOAV&3PQ=-;SP3^;<E)5C9H0C9 +*1G.WM6YKUK>S_ -GSV,,<
M\EI=B9HY)/+W+L=>#@\_,*S]8OM=.AZ@'T2!5-M)DB^!P-I_V* /%7T/X@W=
M]#ON;MIS<C8S:G%Q)+ >?]5WCR#5:+0O'+Z;:1I-=?9HH+.6%/[3CPB"3;!C
M]U_"WY>]>CQW>L#4;=ETJ+>+NV*XNL\BT?'\/IS^E5O#MSJ%SX>@?4;);61;
M'3UC"R;O,071PY'\)/\ =[4 <'+X>\=)I]U:/+=?9C'>>='_ &G'AE\S]_\
M\LN['/O5N/0?B)#J$ICN;M;B6[(=AJD7S2K;]3^Z_P">7&:]'O?]3J/_ %QU
M/_T<M7_^8T?^PI+_ .D5 'C::5XULK$7)N[R""*TM%5UOXW*QDLT V^6,@-D
MXR,9ZU]&:']K.@:<=0)-Y]FC\\D@Y?:-W3CKFO,]4_Y%.7_KQTK^35ZM:_\
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M?6+^IK=K"\&?\B?IG_7+^IK=H ***S=9MM4NH;==*OX[*1+A'F9X?,WQ#[R
M=B?6@#2HHHH *\SOT5OC+;,R@E3'@D=/W35Z97FUW#/+\9(3#"TBQA'E(!_=
MKY9&X\8QD@=>] 'I-%%% 'GGQD /@R#(Z7J$?]\/78^'O^1<T[_KW3^5<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUZUZ#7&>-_\ D+^&/^P@G_H:4 +]O\??] ?3?^_W_P!E1]O\??\ 0'TW_O\
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MCJ$=BI'<' JOI.L^+8M(LX[;P]!- L2B.0S;2ZXX..V14WQ5=4\,6I9@H-X
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MF%%%%8&P5SF@Y_X2;Q#D_P#+6/\ ]!-='7.:%_R,WB'_ *ZQ?^@F@#HZ***
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MN$1ENH9?-B4L!@/P"G7&2,>]=%0 5C>*_P#D5=2_ZX&MFL;Q7_R*NI?]<#0
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MGL?3'YU2T&:X@TH6\=G*TQDD(+KM0 L2"3Z8]*VK2V-M$0S[Y78O(^,;F/\
M3L/I0!G2#Q& NQM-/S#.%?./Q-'_ !4'K:?]\G_&MFB@#&_XJ#UM/^^3_C1_
MQ4'K:?\ ?)_QK9HH YB;6M3L-3M+6Z6%O.EC0[%[,2,YSZBN@O)FM[&XF3&Z
M.-F7/3('%<QXB1V\1V+)&\GER0R,$7)"AFR<5NL)M294>%X;0$,PDX:3'08[
M#Z]: ,Q#XO9%;_B5#(S@[Z=_Q5__ %"O_'ZZ*B@#G?\ BK_^H5_X_1_Q5_\
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M2@G:,\X%:Z_$9[_4?L6A>'+[4V$9D9A-%$ H('\3>IKM]B_W1^5* !T 'TH
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M\TBZYY']E$DR75J8]OE]P!NQ[#FNA\*?\A'3?]ZY_P#1<% 'H%%%% !1110
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M:1O]<W5Q@TQO"^GOC+7/$0B'[YN@_K0!M45B_P#",V'F[LSXW;_]>V<_G_\
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M/*#_ *YK_*IJAM/^/*#_ *YK_*IJ "BBB@ HHHH QG_Y&U/^O8?S:MFL9_\
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MOB*\D>H>'7B=TD%W\K)%YC [X^B]_I6F6UH2;/[8NL^:(L_V4,9QG.<_=]Z
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M\A#3O]^Z_P#1<- 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9VO?\ (NZG_P!>DO\ Z :T
M:CGACN;>2"9=T4JE'7U!&"*:=G<35U8^;XI7@F26-MLB,&4^A'(K7_X2S7?^
M@@__ 'PO^%>K'X>^&"Q/]G$9/03R?_%4+\/?#"L#_9Q..QGD_P#BJ[GBJ;W1
MQ+#5%LSRG_A+-=_Z"#_]\+_A1_PEFN_]!!_^^%_PKUO_ (03PS_T"D_[^/\
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M $#/_)B7_P"*I_6*7;\@^KU>YY7_ ,)EK_\ S_\ _D&/_P")H_X3+7_^?_\
M\@Q__$UZI_PK_P +_P#0,_\ )B7_ .*H_P"%?^%_^@9_Y,2__%4?6*7;\@^K
MU>YY7_PF6O\ _/\ _P#D&/\ ^)J.X\5:U=0-#->[HVZCRD&?R%>L?\*^\+_]
M S_R8E_^*IO_  KWPQ_T#V_[_P G_P 51]8I=OR#ZO5[GEB>+]=C146^PJC
M'DIT_P"^:7_A,M?_ .?_ /\ (,?_ ,37J?\ PKWPQ_T#F_[_ ,G_ ,52_P#"
MO_"__0,_\F)?_BJ/K%+M^0?5ZO<\O_X3;7?^?E/^_2_X4?\ ";:[_P _*?\
M?I?\*]/;X>^&&7 TXK[B>3^K5'_PKKPU_P ^<G_?]_\ &CZQ2[!["KW/-/\
MA-M=_P"?E/\ OTO^%'_";:[_ ,_*?]^E_P *]+_X5UX:_P"?.3_O^_\ C0?A
MSX:/_+I*/^V[?XT?6*/8/85>YY:?%6K&]%WYZ><%V9\M>GTQ[U/_ ,)MKO\
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M;[5%;1ECMBDC5Y"%^[]]^O&:]6KSAWN5^)NNK;1WLC-;*I^R-&&3Y(>?GXH
MU/\ A84?_0!U;_OR/\:/^%A1_P#0!U;_ +\C_&K9NM4+EOL&N >8K[?,M\8
MQMZ]#U/>F";50H'V37CA77/F6V3NZ'ZCM^N: *__  L*/_H ZM_WY'^-'_"P
MH_\ H ZM_P!^1_C5HW&J'/\ H.NC.S_EI;\;>O?^+O\ IBD%QJ@8'[%KIPSM
MCS+;G=T'7H.WZYH K?\ "PH_^@#JW_?D?XT?\+"C_P"@#JW_ 'Y'^-6#/JIC
M*_8]>!,:IN\RVSD'.[KU/0]J=]IU3S-_V#7,>89-OF6^,8QMZ]._K[T 5?\
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M_NO_ .@FO2_B+_R)=U_OQ_\ H8KRSPO?6VG:]#<W<GEPJK MM)Z@CH*[\/\
MPF<-?^*CURBL+_A,M _Y_P#_ ,@R?_$T?\)EH'_/_P#^09/_ (FIY)=BN:/<
MW:*PO^$RT#_G_P#_ "#)_P#$T?\ "9:!_P __P#Y!D_^)HY)=@YH]S=HK"_X
M3+0/^?\ _P#(,G_Q-'_"9:!_S_\ _D&3_P")HY)=@YH]S=HK"_X3+0/^?_\
M\@R?_$T?\)EH'_/_ /\ D&3_ .)HY)=@YH]S=HK"_P"$RT#_ )__ /R#)_\
M$T?\)EH'_/\ _P#D&3_XFCDEV#FCW-VO*/%W_(>G_P!XUW7_  F6@?\ /_\
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M<]*8-/T78,S:%NVOG&J2XW?P?Q=/7]*WO^$$\-?] M/^_C__ !5'_"">&O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ/_P ?&E_[\_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH H:YI46NZ%?:3/(\<5Y \#O'C< PP<9K+2#7-!LXREPNK
M6D"!7A,0CGV@8RI'RL?8@9]:TM=U,Z-H=YJ(A$QMX]XC+[ Q],]OK7G ^+NH
M$<Z+9@]Q]NSC\0M 'J5K=0WMI%=6T@DAE0.CCN#4U>9^&?B!8V>FS)>VLZ,]
MS)+'';*)$C5CG:#D=R>U;7_"R]%_Y]M0_P"_ _\ BJ .RHKC?^%EZ+_S[:A_
MWX'_ ,51_P ++T7_ )]M0_[\#_XJ@#I=8_Y E_\ ]>TG_H)KS[P5H^GV6OV=
M[;6XCN95GA>3>Q+(J0E5Y/0$G%:6I?$;1I]+NXEM[\,\#J"80!DJ?]JF^%T:
M/5-/1QAE>Z!_[XAH [ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!B[:?S% 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%MWHEC8Z9;Z7]OAD>0M=PB;9"<YP^(CSDX^4GH:Z'_A,[S_H'P_^3/\ \8H
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M !1110 4444 %)M&[=@;O7%+10 4444 %%%% !1110 4444 %%%% !535?\
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M]>C5YS\;5#_#X*PRK7]L"/4;Z -O1/$&C1W&L%]5LUWW[,N9E&1L3D<UK_\
M"2Z'_P!!BQ_[_K_C6!HWA+09Y]6$NF0L([YD3)/RKL0XZ^YK5_X0KPY_T"8/
MU_QH M?\)+H?_08L?^_Z_P"-'_"2Z'_T&+'_ +_K_C57_A"O#G_0)@_7_&C_
M (0KPY_T"8/U_P : +7_  DNA_\ 08L?^_Z_XT?\)+H?_08L?^_Z_P"-5?\
MA"O#G_0)@_7_ !H_X0KPY_T"8/U_QH Q_!,T5QXC\4S0R+)$]RA5T.0PS)R#
M7;5Q'@:"*T\0>)[:!-D,5PB1H#PHS)P*[>@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JFJ_\@>]_Z]Y/_035NJFJ_P#('O?^O>3_ -!- &%\
M/O\ D4+?_KI+_P"AFNHKB_ VK:=:>%H8+F^MX95EDW))(%8?.>QKHCX@T95+
M-JMD !DDSKQ^M &E6=?ZW9Z?.MLYEFNG&Y;>WC,DA'K@=![G IE_K^G6>D7%
M^MY;2)%"TJ[95(? R,<]Z-"TW^S[ --\]]<8ENYCU>0CG\!T [ 4 <#H?B^P
M/CB_O4M[V1=0Q##$D.9-R;MV5SQC8U>C:=JMGJD;M:2[C&VV2-E*O&?1E/(/
MUKQ'P6P_X3[2ES\POKOCZ>=G^8KUKQ&D>G>5X@C(CEM&5;ANGF0%@&5O7&=P
M]"/<T =!15*;6-,MX_,GU&TC3(&YYE R> .M1_V_H_\ T%+/_O\ K_C0!S_C
M'_D8O"O_ %^G^E=C7 ^+=7TV;7_#+QW]LZQWA+E900HXY/I76_V_H_\ T%+/
M_O\ K_C0!HTC,J(SNP55&22< "J":[I$DRPIJEDTK D()UR0.IQGWK-U*2WU
MS6;31EFCEM%C:ZNT1P?,4$!$./X2Q)([[<=S0!D>,/%NFR>&+R&)+J6.[1H(
MKE8#Y+.5) #'&1\IY&13O"7C+2G\/V\;BZBBM6-I)<R0$0B1#@C?T'/<XJM\
M6]L?A:QZ*HOD ]/]7( *B^#RK)X1U-74,CZO=Y##A@6'Z4 >B AE#*001D$=
MZ6N=TF:WT;5+[1)+B..WB5+FT21P"L;E@4&>RLIQZ @5I/KND1RM$^J60D4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^/C2_P#?G_\ 1$E=%7 ?%W4+O1O"D&JV-PL%Q!=H@9XPZ[9 8VR#[,30!K>
M_P#D"2_]=(__ $1%74UP'A#Q!HFD65[9W6O6TQCNML<A 3>@C10<#Z5T7_"9
M^&_^@S:?]]T ;M%87_"9^&_^@S:?]]T?\)GX;_Z#-I_WW0!NUCW6LS/?26&E
M6?VRXBQYTCOLBA)&0&;!);H=H!]\56G\;>'DMY'BU:UDD5250/\ >..!7(:)
M\2=+TS28+:33-2:?&^=P(OGE;EV^_P!R30!V'A[1]1T_4M9OM1FM7DU&=)52
MV5@(]L:IC+=?N@UT%8/AGQ99>*8;A[2"ZA: @.MP@4\YP002"/E-;U !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!QGA#_D;/%?_ %\)_P"A2UV=
M>::KX(\52:_?WNDZI96\%S)OQYDB.>2?FP"#C)Q56W\,^+(M<LK'4]?(BN5D
M;=:7#LZ!!G)#*!C)4?C0!ZK17&?\(+>?]#5JO_?0H_X06\_Z&K5?^^A0!V=%
M<9_P@MY_T-6J_P#?0H_X06\_Z&K5?^^A0!TVL?\ ($O_ /KVD_\ 037&>%/^
M0AIW^_=?^BX:=JO@N\@T>^F/B?4Y!';R-L8C#84\'VK)\&M>Q_$J;2I[X3VM
MKI:7L:B%4(>8(&''8!1B@#U2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOQ]_R
M).H?]L__ $8M<'X$LK6\_M#[3;0S[?+V^;&&QG=G&:[SQ]_R).H?]L__ $8M
M<5\//^8E_P!LO_9Z]3#MK"2MW_R.*M_&7I_F=3_8NE?] RS_ ._"_P"%']BZ
M5_T#+/\ [\+_ (5>HK#GEW*LBC_8NE?] RS_ ._"_P"%']BZ5_T#+/\ [\+_
M (5>HHYY=PLBC_8NE?\ 0,L_^_"_X4?V+I7_ $#+/_OPO^%7J*.>7<+(H_V+
MI7_0,L_^_"_X5YY:(D?C^".-51%U10JJ,  2]!7J->86_P#R4.+_ +"H_P#1
MM=>%DVI7[&55)-'N-%%>0'QWXOS_ ,C7\*O_  8S?_%5XYZ!Z_17F_A;Q9XD
MU/Q':6=_X@^']W:R;]\.DWLDERV$8C8I.#@@$^P->D4 %%1SPK<6\D#EPDB%
M&,<C(P!&.&4@J?<$$=J\6\'6^M^);_XE>'8O$^JVGV;4(H;*Y>ZEG>U19I>%
M+/NY5 I^;GOF@#VVBOG(Z=X[OK_Q;:^#]9\1ZA;65U'IB?VA?D2 @[I9$D+J
MH97B"X )V3<@9HDU.<?#CQ5>)J'CBQ\0:5]D\R+5=6E/V?S9<#9MV;MR<G>G
M&1CU(!]&T5Y5XGE\27_P6\-_V'K'V?5[R&Q#227H@FNBT0)1)&(_>,V&^\"0
MK<G.#P&G_$V?P?K5_J-X?$<MTV(?^$:U>ZE(ME<[Q(LSY+8"J,-&K8E'+8)(
M!]*45X2?VBY1IWV[_A%(/*\[R2O]LIYF[&<^7Y>_;C^+&W/&<UNZ=\:I]<EU
M*ZT;PA=76BZ6JRWMV][%%+%$5+,WE'AB KX ;G Z9H ]9HK@/AW\2+OQU++Y
MWA:^TRU\HRV]XS-)!-AMK*'**-P/89SANF.>_H **** "BBB@ HHHH ****
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MF=XT1UV[VWL/O+QP#M&>@KU:B@#SR#X*^ FMXC<>&TCF* R)'J%PZJV.0&+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M02/F]ZGL?".K6NGVUO+%:S211+&TG]J7"[R  3C9QGKB@#J/^$FT+_H,6/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7-1;9:0$$@<@;B!UY( '<T =[17B=W-\:]"TYM=N;C3;V*)?-GL$C4L$')X
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M$;JV4!HC^ '.,G!'('!K0^)/C7Q38>,_#^B>%+RU0:I &0S1JRLS,0#D@X&
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M^[>U 'I=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>exhibit10firstamendto_image1.gif
<TEXT>
begin 644 exhibit10firstamendto_image1.gif
M1TE&.#EAZP)  O<   0$! P.$ H1%Q<7%PX9(AD>)!LA*!8F-2 ?'R<G)R(O
M.RPN,"TR.# O+S<W-QHN0!PQ0R0V1B0^52L^4#L^029!6CM!1S-'63-)72A&
M8"I)9"Q-:RY0;B]2<35.9#%.:#=09S12;#Y39SQ5;#)3<C%7>398=3)8>D='
M1T-+4T%/7$Q.44U25U=75TM99T-;<5-;9%!>:UI=8$AC>UIB:%5E=&AH:&9N
M=VMN<6-Q?F]P<&ER>G=W=QYJL"E?D#=>@"QAD#=@AC=BB3ADBSUHCCILF3YP
MFR5JJBULIBIMJR)ML2AOLBUPKB9PLRQSM2UUN"]XN35NHC9PI3-RK#QQH3ET
MJCUXK#!VMC%WN#)XMC1YN#AWL#MZM#I]ND%GBD-IBTUJA4IMC4)NET%QG%%J
M@5AQAUAYE$EXH41]LDE_L%)]I%!^J&1XBF-\DG1^B'Y_@#Z NTR KT2 MD.#
MO4J!LDB&ODJ(OUF#J5:(M5N0OVB E7V!A'J%CGB+G&*$HV.*K6F&H&R*I6F-
MKF>.L&Z1KFN1LW&.J'20J7&5M7&7N':8MG29N7J:MGR=NG^@O$>&P$F&P$R)
MP$R-R$Z3T5*-PEF.P%J2Q5>8U&"6QF&6R&*8QV29R6B6P&R:PVJ=RV&>UG&<
MPWF?PVZ@S&BCV'.BS7VAPGBFSGNHT7VQWGZQX(>'AXR0DY".C9>7EX*4IH*7
MJ(69K(Z7H(*;L8">N9>?II">JIV?H8&AO8VCMHJDNY.AK9F@I9RDK)6HN:"?
MGJ:FIZ.LM:"NN:NNL*>QNJZQM+&PK[:VMHJHPX.MTX^PSXJRUI*MQ9FNP):P
MQY2QR9ZSQIJSRI>ZVHBVX9*]XZ"TQZ"VR:*YS:^XP:R^S::\T;:\P;N]P)[
MW9O"Y:3!W+O#R;;(V+_0WZK'X;/,Y+O2Y\G)R<+*T<#.V\+1WL[0T\K4W=?7
MU\?9ZL;<\='=Z,[@[LS@\M/A[=GF\>'>V^'>W.#@W^?GY^/L]>OR^/'N[/+P
M[?/T]/'V^O7X^_CW]O[^_BP     ZP)  D<(_P#_"1Q(L*#!@P@3*ES(L*'#
MAQ C2ISXKQR/=03WH6A%L:/'CR!#BAQ)LJ3)DRA3JES)LJ5+D>L< !A <P"
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M>( CY- O.R(/N1*#0*(AZW%%F'0DU/_3+/EQ#XBP)7U0,K;3$.O  ]>@AVJ
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MJ?3*G&A1KY%J7!3Q?FXU$6GWJ0X1,SV! H_Z$#V$H4VT'"0#)\N! CRP#^L
M <MU![4"@=PV!RL25#UE(SAB<5=P(IWW<N$!!RNB5#?8CB5E'UJP(VK#-OKA
M;:NX(DPH$*+@9R?_>7I+Z2 0H@209(@9.R/]@&MR(R(,Z 12)0X52U/+DK'M
M$6(VTEBRY 0?2UO=$QX8BTL"<K*0T+$JR[*FTC[/"+,O:20=TFH[Y2'98A[Q
M:@3SBJ]N:[#W^K8,IJ\3H1%\P1EZ<;=^ 3L#45R< 3I)>BF T1=+2AA1X#/>
M<(,:2"#CLBW>D"U*  <5U'HFDI7C@@PBN"JQJ'5*<",/LC;CX+/L RW6(BM%
MVXZ%LR1+JR[1P'_60BQ1RQ],&'E- "[$^"I-$ V*FX2,JRZ.2WV3JS/B8+G=
MD[FPPBZ<>R/:J".X,B[*0+JK(BN<>R3C@#X1"0[U)Z]RN[T/\9;*R;T&_R&I
M#\&O3&0,QU$.+\H0XG:XW=-/XW)C0J(N'E6T38 %Y)"ZN;NZ@+2QZB(U%D<O
MX!)Y.U. XT(*0Z@N88-(ZA(O+5LBXJ!/D'L*4].X+:@NHH*SWP'![8NQOLM_
MXS*_NF*_U>LSRJ"_N,2__!&$_UN[["# 2TG ZN*+ ".[^*# _-$%\1"R#DP.
MV3L&Q0F^0(P0^Y 4#O!-!%8. Q!_HN%-F#H2VA1#!=$**#/$ $L1'P,10URP
MA'*) E$Q;2L0ZU !]W8&M8)PVD@T0,(L3\5O/Z(,1-=D]!() M)/36"*C65]
M4H4,AO.(RH9B=:QC@S>3(F>5)3>!W"8T(((@O?\JM4RB>5]9E?3"<V=\5?A0
M!\TH(FQ,(V_\-4T ;'3,PCJ7+7F\QR.R>A,"!W^,(X%\(N#3!-#C#G>P)3O
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M#YLPLP.A#$E9RB3E+@)%*@="$,@@E3E"4OK44%G)+EK&V9TW85=PZ'60Z*3
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M7H2Q!1EG#.V?7];YY<56V%JG'!X J/$Q(8<DLD@CCT3RKG4<&*B%Q9*$,DK
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MQI'=V:7=VK7=V\7==^&!O>(<_RKA ;]MB\N-BWUP76,HA^-%WN15WN4]7F/
MF-%AWNB-7M# W')H7>G%7N5=E\Z]BZD%7=&%$M)=7-0EW_(-OO'UO7U(([?Z
M&'M8A_>%7_@=J,V%BS9RL<HI!P!(2[>H6Y$5C* %WKXHAPIZH,3M)XXUWP16
M8-B)JP4.UGWH$6-P@!:$DG5H 0<H(?!UX TV7WM0!1X 81Y0A1'^8%4HA_A%
MX116X12VWGE)C!=.#-"8EQ->X1JVX7)X856 X1A^%QJVX1]&8=?=81B686,
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M.]GA/"V!$L"!%,Z3$J(A/,^3%,"!._' "&9P.LF2!ZQ3/_WS/Y6E.CO"&ZC
M'=KA$A 40>%!'D8A02]!'/A!&1)T$J:A'[K!096''!QT%.2!01V4'%KG$O\L
M@0KR,R,&@@=05'$RXB;^H16ZKC]:P 94 07V8Q]4X1=; 04LJ1QFJ#&/(B@2
M8G&&D@=LP!.UQ1-;  5L("ETD4C=YQ\2(AIG-%A^ 5ILU!DC4A.O%",&("XM
MP@90 !O_@4<A(D9APAXZL4C-Q1A^D0?V8RA5 47[TR3Z8TX!]$[QM%GLU!ON
MX$7$(4%GA!T2=!JXJD$OX73Z01H0E$,MXD(1-$DT%$&[(5!&01)(]"8[,1^7
MI4[MSQ[L 13WX5-1(E0]M50]-2E"U5A,M519+%1/<5U6U51[DE1C-5A"U1:5
MT1I3L<-HU51#XE:=4E2#52-ZE557M%;Y(U>#%5G_N256JU%8+^)4-\)3K3%6
M.2)5-<)9"8=:EW5:H@5;A?);Q;55H55 \Y31.!7?AJ5#QK0X40 3 6  G)$$
M'0 ;0^0?0T0I+X)#_@,LY55:'#,621 RC<($,Q(3*:TI+:(H!D!,I]4QXQ4L
M : BP1  G#$CRJ$@QM$BXJ<$)4U^LM4QH85?"59A-8)?9]$K)^(A.Y8_';-+
M.;9DXU5#6F'2)'9$]F%=EU0C.M88X%%F]35:(=9?_X/>;B)>)U-C+>025]9A
M-V)@(7, =K9%VX5-XU5"H)9@Z>UC(Y82';9B7=2B2- &6J$@=JAF+=9J818C
MT)9=S_5MX39NY79ND_-&_Q>'1O_A%V:H!7RVPUXS0EJ!1(:E!<Z4;/\A(M9!
M6U @9^&R!7[!6QT (5K@1-$46C"D'(S!!A*7;%FL9FNB2K'1#%LT%I/T+1\W
M*1RW/TAD'ZNQ',*44VOV8NEV=FFW=FWW=G$W=W5W=WFW]%R36%% 0GIW>(D7
M<-[R77\Q21LB23TQ-9WW>:&W3+?R%[>R>ATB>K$W>F<T>;F7>]_U(;(W?"D3
M3*?7>K>2;,77<3FB*L?7?-WW?>$W?N47!5: #=B@#/J &:KA&9Z!&OCW?P$X
M@ 78?Y^A&GK!?A$X@1.X#_JW@07X?PGX@2&8&F!!@2W8?F$A@B-X@"6X?PF8
M&O_ZX((M&!?VUX$E>(,#F("K@1E"6(1=V(*KLGME.$FK-RMM^"KG-X=U& 42
MLG@GZF@ID0?B5(B-P5F-^(B1V%DS-B>2N(F=^(FAN%0EC0>B.%CB1PQEES1C
MDR=DMHN]^(L=0#9?DP\TS"GNX RH((W3V/RB0(VIX S^H(W=^ _<F JBX(SK
M> WN0([7>(_KF([=^([16(WO> WJF(W_N(ZCX \&.8T%^9#]>([YV(X!F9#Q
MV(T168WA>)*IH)(=^9+56(\G.9/5V)/3N(S'X!@N@C#%I96II1P^41];(7%=
M65SZ QO7529]&*(JBG [:P <8)+0)25>TD#F Y9M=!W_RN$7AC(C?98']H$V
ME[F9+7,=(,*22M,CXN%$^E3E?J\#D\_XUNCX:N_VQ!DCO,)_S/F;56YZ&..
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M5RKLK7#_QM9LQQ[CS8 ,7_I,+( JRJH"GP1MR>%^SYILY*OB1P9%RMX[,;3
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MX"41X0YW4!EMH K:@ _W()IZ11+^0 N5802,Q@X&)B9EPR/] (;R=0\# 5T
M]& !&0TN8B#D &B*"0?EX9@6<BJ2"1^4^6KXX'<&T4GZU02Q(HSPP2GB0" >
M8CQ#$A$$]B7.")W_ "+P%9OVD2;G49OLP ^BL"&X^9H[R'?X,!# ^9C#.9DY
M<YS)61#CXX%VN9?Y>2]ZJ9]&8?\,-C"*57$+E7$+]V /!VH/\1 /"'J@"LJ@
M"1H/,S97;44L^( 8_4":V%,(E=$'@<(# <HH4Q$/6;$5I'D/,\8/&3H2$WJB
M9@%C$\JB%7JA*@HL7S&C*XJC(M&B@D&CE#42.]H5+YJC(7$/,DH8/4J7'ZB)
M_<FDG\&?37HPZ_"?2D$3 PI%W1,/C 8^R@-@77 /CV<BJE90WUDY#3%=^Y$0
M>^8$[+!-%C,.5) ='1H2C2*"II%E(#&B/KDFN20/6@!@6Y>'0\) 23<AS%8Y
MIR /WU4YXW1Y0^*E8/HE8MI29,H^^( YCIJF"\&F>V8YZEDYFW /9\I"=\=G
M\7!Z)9/_7DT@"GWZIW4&8(.JIN)@9MV3J/HQ:8U:7%^JIN009^E#J0UQJ<65
MJ0:QJ?H1#?>YI%"JK%5Q9;9W;<O:0UTF$U8Z!LO0*W,E'F81<&4S$MZ@5^P@
M;L,U$LQS#QNJ$7(Z$JI@, 23>ZA"HO;@#3/V6L""53$RKB,A#MCZ;OBPK6RE
M--\:KOW:K8A!#N(F#WS%K9HBKW.%6X3AK_Z:KZBRKP^+KP"KHP+[$4F*G]#*
ML7R9$S;PK!V[$B+Y$M0J!:'BAVSB%?*@J1]!$(WF.Q(BA&(JAV3**V.X-70T
M))]2KAQJ$K:G"J8S$NQ0&6>P)I#03;7Y,4HX)$G#17H'A06!_[+0E88L2ZPN
M6U Q6Q#>0K-S8;-!HS8PJ[.5LRQB.@=C0::9XH-#@C. Y'G?4Q!;F#-*VU8E
MTIP?\;01%+6/-#A4N[(+03\O:T=4UT9E UUR& \MB[-BBPDR*RP:ZY<B*[DQ
M06TL%[*3>Q(DZQ+46@CO @? U168L'UK9(!* X$0HD8<@RV/XX#XA#,]>ZXC
MX3IU.CL!2K0S> ?1H 52-! >\AB>@)8'-%CYP;MS +J'L0G1MT99H%8,4E<0
M$D:J:U7(T+H,4DDDDC\H@@EGP2)P\&\D,T?CP;MUX+NT!+Q/13*#93W%>[QE
M%9;*P+QN]+Q=$$8),;K4V[SWI+$L@/^Y_>L2K]=R_@L3FML2U'H&9V$U2K N
ME<F.;2-Y04,0<' 6;@8MTAF0[60?C80/:D,\;84(/ALHPQ2B39,5A4 07A@M
M,R-6Y "+=7@%0E@ID7,6"*+ PS<SS,.R>A@T,=0%$YP>%3PSV\.RWQ0TO]G!
M6@LM,@*9D90QWK/!".07FA="MBA6[-#"7_/"F@1(6A!"-+S -PR(.MP//.S#
M3;!4%AQ50]Q( O0^7GL&E<&_ BS')P' ESO'($' +$&M53 NP=D#VY.;^;A)
M81,_?>H$6/ ._#<S23,?$8DA@_,V8/$.;)(I]_#!&G$([-H2K< &,E@$@\ %
M]C$N!>F.S)/_FQJ3%^SP=4JYF&N*O.X(R!$I'R=#R/)3$'W<,=LCF06B%@P,
M-UEZ/0FUR/6C(3W /.(PC('5-/5)*H*6,:,L4,;,+L-8OJH<A87\LGT\B[$L
MR"P\-84<MK@<Q-$2D0;239'<3JW%0%GUQAI! _YPQ_$L$K^0 .TJSRR1QRM!
MK3K)S_WLS__<SQ$P',,1 4E5"/LT6/)$5LJ 6 I4=_*C5L7&5J< -,/7EB(4
MT9!022S2ODJ#E5GW5-FST9ZP5=$P3MFWSG6838)A"0O=T"?ST!B-%I3 5LA0
MT=T$0I15NO@ "77%T90B#A=-(J1B6AEA!,)PSTE-ST*;U"J1SRRQ_P_K(-53
MO0ZSJQ+VD"@\P ,HH-4MH HVX!0MT-6JP -. =:J<!.JT *ML _[T H[81/&
MT-9?G2@@.A($P]5R_1&MP ,%#45KPL5E8R&\8L6M>0\ETD]==;@?DVB\PL+J
M83+RL"9>PP]NVS^=0VN9(IWJ<2I6NS:2\;((-!>>Y@29LB7J$2O?R33W\)ME
M.A>Q%MC<5<.J;-B(?5**79^,_1^.K2)M\UU*( I!8]E[Y&NEK33"Z<#JL3)=
M9Q#4@P[M; 3)VM23N]33[=326A7&\*%,@0(#8,\NX6$)8-<DL0_E8'OK\"\@
MH<G&4,_KP -D;0_K< !)-0CW(&[PIE?WL/]Q636T0XL8LTD8]_UN6848\C!7
M_"#@0RNA>H4/]^W@Q!(/^;W?#N[?.CI7L#D2 \X.!7[@"=XTT"W=UMVQU2WB
MF8O=,;$."8 "=>H2U.;=154H,_$+ U!SN$$<O.'78T %>_HLER;!K6T0P<*I
MXB"IN42F_1.V!L$QG#H.;;HV1YXF7A(Y*')I[(!1XL6;^@$DC.8$/1S:MTRH
MR9BR0]+C"^'EER8/A%LY1,ZII)"X$/'$"['D^L%8>Z8R4+ZV%4'E^F'E=JX,
M'AC=)2[')"[H)/'4*8$PMT.YW?W==?(+-N#5Y<#7*V@,+>  SDHPQN#715 (
M]DTL[)#?XM8/ Z[_X06^<0B>X15.67/5X*F.*C,6#ZSNX2%!#I\>ZJY.ZZK.
M1QN'X;*BZRPCZ[A>U*@5XH4.I81N['-ZXB^1Z#/AXHU>$N5@ _;<U4R-$JW@
M " KNX0"$L;@ %J= $>U#A!P6CN>VX*M'H0-:)P2JNKQ*;A]V3;CRH\=B+ZM
M:5QEV5O'>9DMGZB=W'D3-'9@$+@R1?5QB,>M'A/SYN(%VD-B"6,A,VSR,;*M
M[H8=MECW#XU;$!*,[K<\R)#=5K^M*H%G$,3-[Y7)V?_.3K4T\.QLU,6>[/WI
M83 _W8>.$HG^H#FO\P@:U8R.$NZ=KHG"UNJZ#N5@]$=?U0;S9=#^#]1F_PQ]
MZ1&JP.U-WP(/D%2- "%SE! NW1;C$--].EAU)D49<M-*D],@\0[Q6X=S,/:D
M( J4X@U"K?9? P>5)#2S+#R3AM)/53Y:;PD*Q]!MD39\3WV20=.)]7ZE=/;I
MK%:"UO:)0TAR/R[#'N@Q+[+[D$S,P>+&;O,GT>R_]-6-TI=]^0M:MDM%@ AJ
MTP3CPB+N&%7>,(PPTC1?!PG8[/%!L\W"(\MJX<TGW39J<_#2-\S1X\@V_#(L
MH\ZD4FPJ7#_"*,V0##6IO/'-?#^K7S_1''ZPC\K+W 1U$#]QY,JX#\NZ+\A6
M+$[@S&?*/R!+3/P/J4#H;._K/.QCL >6+[*5"_\ VF[_G6\2I:CHO@00ZWBL
M^U?0X$&$!;T5&5.D41TG3N095*9$"3F#Y"PJ,WC/21-+_0KVB^1$RSV#IRRR
M,RC.8C2#\CYN,LAOCI,N^ R24M*$I4*+W@S&:Z)$E$%\79S,T5EP4Q.)!J-9
M%&>0G<53';4XB<3/H"6H$PM6O)AQ8\<K($7^ZT?)),J"*I7\_#?N9<R/F6K>
MS+FS)UV72F 6C.=$B2>D<);J='>'X1@6"25/IES9\F7,F35OYMS9\V?0H3NO
M<P  0 M[HE6OOKS.1@O8L67'ME';]FW<MV?OYKV[M"K1^U"8'M!*E:IRK)4;
ML]%JG\%?/'@X-]@*P"__R^ 8%KDU3LO@@O+JD/):D!^I.F(+1KM"]Q\Y)T)C
MSCFU]A^^393@CM7B?IR3JH;J IF#\+'$DJ8*0J:+> X2QXEQ#F)'"XXZHF23
M!/LY90[U_O'&"8RLN@*\?^2QPY/R_CDOO8/8<P\^^<*CSSY\/-&OQ?X.^B]
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M*2(5JNUU;UO@BXCX&&@^!E(B*>OKPCW<IZ[XA2H:XWC,&/IV.!2F4(7Z(ES
M5H@X+JEP901370(&<+)]Y%#_ASOD80]]^$,@!E&(.RQ>0X[!#Z!9K6SWD5J)
M$I+$>RP1'TU,8A5[=A^NL:6*3TS(/;+(#RIR\6M?#"-"H"C%,A[$B@C!1Q;[
ML46]S<N$+Z1C'>THFE\DH'!W%$WBI%2.VDA'D+G)S7 @)R77E:,5#4/.:QS
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M1C 4(VB$;$D;O6[H^%,_#WY -@KN^O#@^KL_#,P4#40(_S,C#V3N 2S  TQ
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MPYKQR3_>9509@5*VH#B+BY\ U+B#X#A)9QI*%[E+]Q"3DY"4FW26R[FBT3R
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MO4<F+-0IA)@X&91Z!@I[KM-[RD]\;M1\)LH<Q..D;$(DX(DRN&,R85D7L!E
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M:Y'A]T6!'P#=P;&0%,D!NKTP&B[P][=OS,6]^KKM#D.4XKSO]V4_$CUX#[L
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M6@EKS;!E([;=!+=NWB3]YI!P_Q#7A'':)>=$=\WU(%YTTYUWG1+9$78%=_]
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MM(1I,6NXE%3XCT*'4>8$K*Y=H6^[D*RWKR==<-8_AH:_<3AA6)]IG)<VH9\
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M!4L@^+!35] JA&,OUF$9"!0LWL?HM8):\R.BSE(98CXP9,X<M@$'7DX0@PF
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MTY^*LX<#  " %MCQGWB\'[SR-YP[+,0;?D)0//_.1*%^S*$)%FI4F[SRJ,4
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M 6>[@(QE7X_J/.=];SG>\82$#,#&'01>' 0/  #H\42A*81;)$#Q$$3N1.!
ME,,?*83*+2!9>(" $1@W)58RB4(_B,*2W4.#H8N1W8B!V4&289B5;1@2V8NX
M?)B4 1,_@!$2R0N6+9"6[0B+P4$R*4.,)1.-G1@22<P.?486Z!AM<), (9CL
ME> )/AB:2-B!+9"%!1D$X0,,+E"'T8D&U2 #\8,FE!@_[* 7J1BB=%E+?!G]
MO6' V1_ X1_"V45,7 59\,##U1%0#& !_TH<BPQ$AIS%3]A#@:2(L?2%WB5
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MM&C!+PKJ%6#.)AAJQB1'N'3,Q\P!H]:3JT*J<TQJN73!$+E'R_#+=8CI?;@
MFA9K&JDIB9Y=7DQ-C#Y%G,8$R<5=W+4"G>Z$A/R1,60KGZF1UFS:IC5/B>[I
M&$@!D7C"-M4)[+5E+>&(."A*$R )D 3*H#S)H8"&NS(*D&!)%?):8DW*H2@,
MF014\:EEN>T(.Q01CKS)O\H)D-@)D.0)D?#)O\+KCO0(I+2F,"&*NYY"H_QE
MEFQ)OQJL"N&(,HS#I?\0J[&F+.V,:#Z:'8/$%]; E,S.+$Q]U$85")OQU]_A
MUX;TX=[5%]1D$LW2K- .+>)5ZZP,GM(N+=,N3]&R%-0TK=*"06!8 RDXP78
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M:T7&%&&4SI@J'L;^A14[EFS9?ZH _#*[EFU;MV_AQI4[EVY=NW?QYM4;MM4
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M@FU(!?/PBW(P8N@\2&C^3=<H@2-0\,5.*S\Z[N_6 _]Q3FL3^.$>ZH"#[L%
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MV-/T&(WV.&I"VTD ,S'/Z(_?D8S:D9P$^0^4^!-YE)"JR9 2(9U[#8OV=8Z
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M_6#@5]GB5:^R5:UI?>M<[>I%NB9DK6>%ZUVATE:^%K2I;YAJ80U[6&^MPP$
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MI> 8CI YCN2XC>6(0J3 DN$XA2E 0>*+JA5L01@L0S-\%,0@)(S[EG[8D#,
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M8Y)99ICW@):FFFNRV29HF[D9IYLM#I!=:1$.(*-L*%PY %?EL,9#G:_I]A"
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%* ," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>exhibit10firstamendto_image4.gif
<TEXT>
begin 644 exhibit10firstamendto_image4.gif
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M(0 ":-<.('N [M_!@_\/3[Z\>._GLX_OSGX[ %&8J<NG_N\<@>R>\^O_?)\
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M,*I,+-0Y!(".X?@ 9GJF:(HR 7"C,Y$/O* +<,H+"L HLE*/*U!W"B"7P)4
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MT&A7N;A:699OX 3W2J\\5J]>Y3__!1)J@CK=X0.\T+F>^[F@&[JB.[JDV[G
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M.=JD7=JFC:*<Z1%@TF^JN<P>91G\< Z]_ #E.([RNHZUEP+Q0Z'VBJ;=U\G
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MZ<3+.SX0[=%NH])>[:C&QAD2ZDH[Z@*;#-'P[> >[N(^[N0.[LD@"QH$&^P
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MS[BBH@C!B*A(D&B QN*%Q5@(9PR 7R@*95J(7[0HAT"/120)]"  == %.2.
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M[: )Y:@H!Q]8T8L0G#<AI-PVG3,X[-_V[6\0 R\ @^\&[S 0[_$.@^">BM>
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M"&"AQT0T)I$5<'$_LQ2+2[[XWX+X8*$/.)=#<W@N %SL$R29T#\Z0@"3K+,
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M=-\_G$>!L4=H\()^,%N$I4 GR/]?_E%$D^G.^=V<"MJ$6MC1.3R +W'>WIA
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M0I*]P9*)T0_TI$_L5HCHPEA()$;HI$U,TS;>)59Y#@0*([EYAHG<'DX,099
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M!2!BD4KP=H5058&F=76@8 U,0#L?J13R'WX854@=)1-X[TD@-9T22#*QQ!4
M6?^1_XZE%PU2B3H??H7(S!T;*/@?4N"%3AUO&_W'S07GT\_([X9-"-Y[>MU7
M.U)PE?#09 W25X%\H(,5 $\-+<]/A2&-66;@UG'Y.8'*L?D^@!V$\#O\#B+5
M5(5072EBA%H%H.+Z5OKDH'6<<V\@7?0U\(=9!>H8@!1@3M Y'[ NZ$%ZQ_79
MOA7.+4@=G0_<]1]F.2SH''T3*'$A;0%P\2 =9WS;N140NM.'?W14ML:JG?X'
MV1U7W>Z3B;\CX!.%Y\T[;!.<DY(A@5$,0-U%S7,[:^Q$_V5$NPUVK@&6$?K%
M3='_X47? +13LM.#DF[)00T)8%V@FC/?E1\Q5QJ\0^?B=?_2Y[2=M)GYZ'SN
M>N;IJ:_>^NNQSU[[[;FW['&6 4A<O09E]QTAD.]YDH!?^$G!>+\+("@?'U;
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M.=,W(4L^.B$*=1!! 0WP00%6 (Q?E*#_$^7XA ET<0X3_  8^]$%,$A1@'(
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M&@SW(E2 =S7"=C?B=C'"=>\7>*404:^"/P@@7:/B>,.V-- 13;5'%(RGWX9
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M&G1A>5G=:*&^6( %=)5Q$7DF+.0JOT-4&V)1)JJ8/4-!,*4#@\Q"E*1X4P<
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MD,)H_)B@ '$%_'".0-_91,0*_)C'3X;Y\+,"$:,5]IA)[IVHU"\KK*,5=O\
M)111-O'320I#D,*:=2CNB!544IG&8Y!"#DEDD4'"9Q9:^RTI%P OK$7+ 7@)
M\:1=0@ @I5JA "#$.[0X^<Z677Y9)9-FZO478/^=)\H#+#JE@$!<=6)@ )DM
M=<\G#W0R6@JBC,92)RO<@Q(_":%4C@FD\%("98495MAG1DYZSP.B8.4BC-O)
MV%0# 20 Z*2BKN2C>:.>BFJJJJZ:TA[^"3;?F;*N%9):J759 9=J?43+.RH
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M&LPT*7'V&-18BPG)/K>8B[FSB[VH.Y&P3H)!#OY5#KQ0'N+X%4+3B2;P":(
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M)A"]:(M'0D.B<51*HW2IS=O@=%1*NRU*&^'<#5Z/B26YU>Q"ZYIP_2MH)?"
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M2 !/7Q4+,=*)(TJP5.TQT1_W'=\!;?OUC?OWK?OS#56];_MJ(AAA:[)&\7)
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M+LK+BT.DV]2Y&Z)), #[/O6+J$E>=4ZC!!#;5,0 E!"N4SG"J M4-[LZIY<
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M_.50JN=Z+M ]VJ-]Y8/FU45\TF=]VN=]XF=^ZN=^\F=_^N=_ FB "NB $BB
M\D.HV$H H%B 6LBNG!0AQ8E42NB$-J6A3"9@_<"\4.B&3BA]1<5#_M.%4F9Z
M8"0;J,&)JL$;:,([L&B+NNB+PFB,RNB,TFB-MN@WN  +#(*-\FB/^NB/ BF0
M@D,/L$ @M$.0TB@UH($8=&<A?B=A?,*F!)&6 (,/H$@X41:*J /,$,&FY /_
M0!K_OW3"O_#"$%RISQ!<E9: "&4%G?P3!Z+6_;0<5SR6"9@-+_R57@R:B.;*
M#S1571C:AV9(18[H>V!D4JPHDBKJHLHHCNHHHT)JI$HJC0YID1[II+IHDQ+B
MDPY&E/(+?OV/E?X#EOZ# /W#E@Z.EX*IV.QIH9GIJ*+I[ZB7U+5IG61<H6I%
MG=YIGN9%JU)%L/TI700J8(V4AO02KI(H!*B!$C!K$Z@HID)KCSKJCD9KM5HK
MCU8J(%QJM&IJ$7"J8'CJE(;JE0*+J:+J/W0IVZRJF)+IJ_Y4/IC \8@4-=DJ
MLF:%KD(%GNJ67/@JE/EI7PPKCD"0Q=DK(&9D(69FHE[K_\*RZ+0R[,,^;+9N
M*[1VZ[<&1KB":I62:Y:>*I>JJJJ$::L6$A2FP*I%RKQNA9O>:L%6!;X^19<0
M091BX,S2;,W:[,W:["<, =T=E@FH'\X";=#B+#$IGO>X&T'R*<N"!T9>9L)"
M[,(Z[--*+;1^0P^T@+9:ZU+T!3\DESITPIIF2P&,G0*4 #0V .8E0*4%0*TU
M0 #X60$D@)\%W0.P&*(=9-DF0-MJ")NBK%:HK-*V[*[8*7,TB@)D(."*AQ\T
M[;-.;;1^0PL\:N-*+J-^0Q2X -96J];RQ9ZJ Q&0K2C\@)3ZP+QH[*B6JY9Z
M+-N8 ,BRJG05FJ(U@):T4-_6ZO^;(FZ'.:A\^L;M).WM<H?B(BSC3JZD.FH@
M#._Q FGE7N[$8FK%O@%@G -:1:4.B2Z5BBJIFFOJ?BGKLNN4)0 T 0RMQDV]
M^FY6Y2YS\,,LV:I "J240&#Y,@?P$J+3(B^D%F_]XF^-?D,7S #F<JMW/F]A
M8*SU;FRIHFZJJBOW#MITA=I4T.[XVBYCZ%*=[2N]F$  /&AV ,.GP*]U (*)
MHJCPYF^0XJ@+&.\(H["+[F__,N^D.N]?1(B$J(@/C.XOE$ GJ!71G4,*#,&$
M%( NE ,I%$#TKH /])9'J16?_ ++/4!PR? 33T@GT$W*DN]B2-.QUL4)<0B2
MB0NF8-K_:QA)[51%VQ L7]1;!6_)!6?P=6"-^W7P<_@!HJ8P"<^ "<_Q'.^O
M#?@OQ0)P7U1<K/"C>(YGVL1(098CC'QQK7Y;8P##M_7N6*3OVG)QS[F(&+=&
M\:PQ5'QI&>\%D!0 &L.1&NLN<]C6&UN''RQKLXKP'=OH-\S #)PP*^=O'N]Q
M\_9Q7P #*<#4+H=2+/DR-O$R'@VRGB3R^ HE(SORUD)>!6U));^O9V"R/N4#
MD""-7G@R*.,N!H]R<C23&YNR<\@O9JZR+,^H*]M +),S\M)R"TOJ"YL&/]2)
M.7%MT?!"M8TJM1#<,TL%G=@7,A/J7FCQ TPROA66:P01WD#@_S0' !;7Q35[
MQ3V<KW6H@R!A\S<G1SC3;SK3Z#?80 Z@LT9/[@K7<I!60P]TP4FCM%*L0.+Y
MX67 \RR*K+NB*;A\!3^OK&(T\C_O!>&4P$ _U@KH<V>0"5"/\0,LM%\X=%=
MM")MLW#88 .<B45C!T:/,TBK<$=_M%5/K4BS\X]&@QC J.9.F0*(0D4OQDO+
M\YBZZIGR"TU[A4TS,CQ"9IDP,QQIT%SC]6/BVE1,<U[?XB<_=$\RR2/3!KPH
M5)A(]790M<)J]8MRM$<W=DA;[D@#Z5>']2U72 J KV; <W=U;YFR-4TEV%7
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M?=F3?0G420.8_=JS?=N[_=N3O0G(_=S3/=S;_=M3NP( Y=X[HWDN^=!+QQG
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MX G?\$(@R+&FL KK<-="*"\.2.]FD/^&34><CQ\"41 'D1 +T1 )D2N\(O6
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M_%/NOV YVODBXE/?8%;?8!I@FPWQ)M!=B'._<7DB!2C.SID/H),;(/X))
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MC'\PC.'3_#<UPPC0)P=9WD5&QD"!\*(!0S#-]58"C(+$S"'W0-<O&G*. B3
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M1>@F1YB$E/<[VL X3E@1G6$"9[@JZ_(?.,(+J/@8R*00]8**J>@#!7 ]]U
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M*= RXAL4\AHCT3;#\WF> , Y<S@OT_0)HE#$/FL"8M@ GF'$HK "&L@HGO$
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M(E(V],OE#7'D&NXCL'40M[WD2\YX6.WD5;'5P',))WX-%%$.*E(<6@[D1:<
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M?X=J (!0D'9DIPLS"PEUX F4D)VFD;WSWC)UX!MWX2TK]P@L#Y/IY?(8.0H
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MQP(+%2S$6(*(CQ6?\H&L6>1O$9\5=!88+ 2 D'=R:;T+!4#%.Q4 0KVK!J#
M3UJ7<U; ;#GQX6J*!^L$7*2FQWL/(@[DAQ>D*  -6,.M;=LEL ?G;K]] ""!
MP-I$,N[F/7(X@"'!09[K_V0"X^44TJ>G*/" ^O0& "S6W6C\._CPXL>3+V]^
M/)PCZH_0O)GVO=5H8,CU+"IK1M*E/:-Y80?_9S0N5/5?3]F(D4Q/77T5UE@]
MB2/&+03VM!9;;[AUWDIRU759 )T0E \P/Y2P3D=^ 2:890M1AI-<!;3XSD(
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MT^K,<#Z\K-  P@"(<BBW*)VC70':+HS<#Y^4T, G8G/_Q ^> 9@@-C]#^)H
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MC1)>-&&@KNX)K&4=Z"=[%]<?9F:O0]NZ1K\E!7]5V"<$1K"%,[SA#F<XP!J
MM:C)^R/2QO]Q =8MD7ND8#LFR$<G2I "=>@">\45DT4*<*3:I("!'1D. =0-
MGG8GX'45OSG.1<(+)JR'/6^@V;V5?!1]3Y;?')Y!KI'&#&868]%C/3%+JO8
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MXAM<@W&0PLIYQ"\$P(B4Q%%IA^+E9)CPY%U9W4_.8&]AG.41Q/9]W'<HI<,
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M(1>R;<CQ.RSK/ 0I']>>'X/'%=>P !LR)5<R3"!R#S?5%,/I&8LG#>,<*2C
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MBA"KL ?@D&SD,+) ;1''XMFB !)#H^\",/HH46T (-56$3HL<:J6JP< P08
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M 2A6]"%Q2$6$$@,0_WC[-@#&@266?C0QMFV*>RQ)24R!LB:PO$\56"PG$$
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MPVKW$ 41"E "Z:+U'@DP@5T&]%.4"?4<!-#5.H+S#XUVXA/[A4T*@-N)!"A
M4/VJ"5J&8-L'Q,A!L 6M@Q\,_^$(2YAPG\AI13)9$=7RIW0QX0<!2*''!:JC
M &I2!R$#P"!^^& %=A&)W\(R)Q-?Y@%"O60"<%,"VOX@ 0@K 60J'$,!A3>U
MZ8U)"5(0 ,W MT F*,MU K"N?Y / %\9W?(B5I$5T%% 7.2I3#I!@!AEE6%.
M<NZ$SXSF-*MYS42IL.FHJ",RJH47!'@ 1&$R%1,\H!P%R%%@&O #"P9H+2MN
M<7E2D)I[F" !I U,<TU@LCP7@)H5*8%0^5'(_(;9GG)\R#T>T$UD)4 =N87-
MD@^5@'7DMBJD$3 P_MLF>)5G!:\R 98;R#05OVLJFF.)#Q* 06 0 $H-8#&;
MCXWL9/\KF\UNCIN:-"Q'8$@U'VC]QW+4D0_':,8$!%" MPG XX,4NB(BP;94
MB4PFT@QA*31.28"K@A>M$*<34JVP033*%Y3-+;6@?DDG N!M!32$'P.*V+F'
M '!O)X!IYRA )Z92@E_@=W19/?<_Q+B.?)SC0!"IE (:T&W8 */7"'-X5@=#
MA*,0X+=(^>>R7P[SF,O\L;P80HQ\@)LE2:H<RTJ!SQVIDG/D[!QJ*L</&)0/
M'S"&%+H2Q0I\+L9S4%<S_!A"58C@2%[0NR)$R-F2?AX87KR4NES*!Q%(+MX?
MW,L'$3VB"7+4B1^83L6_N,="\O&)JAS]'[_P>8Y2$!51O#W"!2%-^KV(\!7'
M&%1C/@\I,$*JOEO/?/*4K[SE+P_8NF-^\YSOO.<_#_K0BW[TI"^]Z4^/^M2K
M?O6L;[WK15B.V,M^]K2OO>UOC_O<ZW[WO.^][W\/_. +?_C$+[[QCX_\Y"M_
M^<QOOO.?#_WH2W_ZU*^^]:^/_>QK?_O<[[[W=X_5\(M__.0OO_G/C_[TJW_]
M[&^_^]\/__C+?_[TK[_][X___.M___SOO___#X !*( #2( %:( 'B( )J( +
'R(#L%Q  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>exhibit10firstamendto_image5.gif
<TEXT>
begin 644 exhibit10firstamendto_image5.gif
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MENQRRU0 @@0A>"('$W 8LV)?R, !SB>93) $'!J,($<;(QPA1Q(B.!$'$2[
MX88(\BH1 A-RX.N&'%?"T88&<,!Q! CONF"$'$J( ' 1(R0L@A%Q)*SQQG#$
M4<2&:FW3!@5,0!KIBQ6\<FV)ZQ2QY+@KVY>.DK'.*@$(M_ZX#1$=*!&S.[_>
M5.S01!=MM$C'VO2S6G#)M1P[K[A@LCM*NE#!!)Q4D$Y:KR"1S'+3,C$'$5-S
M<L362[>5F 82^-R6-B'(6A<WZ:0#SBIQN$/-'"H;_P.'-.S\!LXV<:B<C!NZ
M_1;@$<:D0XT(=K_BA#O88#)7N<NX8XH>W( CAVUUAUYW973]]>&US(100:5I
M(^GR$3"W'MVT-1]&*\ZXNN#HST';=/3OP <O?$))UR2[6>C5*L$$%52@0?//
M*B^]"VTX8;WU[BF:5BL>5"!"!:%JCQ8H%1A1_?5.$"']\A0T_WP%%*RO/!SB
MF\4.*Q,P@;X3;7P@___+RX]BVM>\ CI/ P@T8 $'.($& O"!%1@-7; A@0IX
MX((8O& 'HO? #GI0>@T,80,'R$ 1.O"#'RP.ZD"PNN-)ZW6Q<V%SP,$$6,G-
M,+2R%:Y&L"O>U6AX0 RB$/^#53R:R/"(2 0:$NJ7Q)\90P[1:N*+/,"Z)DI)
M?;"SHI28, $CW+ P.<S9>EK!MJ\A$14XJ<,0U\C&-H:E'.71HAS3E@Y3, $3
MTIACS*2A+]W(\$4?J*(>&P,.GIUMD,<!AQ+F\T7"W$Z,YFD%#\UX1%6DT8V8
MS*0F43(69"'R9YEAAR@SLXY2FO*4J$RE*E?)RE..\I6PC*4HW:&,$'@@":U$
MY75<21=2AE*4N0RF,(=92G9H8V1*H 8IB<G,9JZ#'<KX *4^24@B@  ):*,F
M8139 20TLB_L<$4(0B1)"5!2AI:\B1HWR<YVNO,B1:2"-J]5#1[F39O2<(&,
MMA'_@KC,P0-,-(L;6!'0>4(G=2TT:%\*^0%L*I0OBF0D<M@!#FPL@Q7OXL0W
ME>.*#I@SB6A4YSM'2M*2(B2>#XU4-8@P ?^D%!S&: ._OH4)4\1P.?STIP?6
M40U0%*$(P,AF2D/TH@X(<JAL*61@A(I4M="PBQMM#A*0L1Q7E#&)I[BD2;?*
MU7:BM*DLJD:<7 I6=R2!6]:!SC9 T+VRRFB*1W6K60KY,KFFA88VM&N)LBK2
MKOKUKVO\JE[KL]+^V#4)&A !-Z*S5B)H8+ C0FA<(7LM=BAA B,(4(AH%E7*
M0H>O-EDG8$=+VJ,)UK/1J:<$[NG6)&AIL6H%P0@>B]KU_S"#A9.M;9/8P00\
MK2(RK%""'I#!U.-LHQ5.^)M8)>#%Y[S*!=:J+6AK(MK26O>Z.SJM;INC6M:6
M-0G>@^USUEK![5X'D+DU+XLL.P$1K,(-=N&&,9*@A#RZH@AZ %Q=\JD!;SJ'
MMQ(@0F?M.EV:5!>["$ZP=SJI-/5RUYZ'12MCMU4!!Q_T U2T<*0L&ZKWHH4;
MP("#$I!1T+6LPQ-'X,0SM"<-]36W.0 6\';3&5H%V_C&7V&P\32L'&:PKU:L
MFJ<V(,:$(C,A#OT,05K'NRWEM8LXT>5Q89C!M@FH3H)2)E$UGL'E+GOYRV .
MLYB_+ UE&"%4; /!30T3XP'+E?_&U,6QG.?<$AT;,<O'4:T&/""!(&NS&DQ(
M@J#IZP:V*I:Q_:PPGI,CV467%:^U8TZ;MQO2&M/YTI@>B78=S1?5,H$:S! O
M(MF!C628^M3)8(;+E(SH\G*Z,>A]-5(C>@0W%X;#*,RUKG?-ZUX#D ,X>42F
MATWLC6Q:UH[1%5G!>E96Q];5R$:+-$!ABE58^]JFJ#8F.J !@JXYVG.<$G$T
M*^D:REBWHPAVL=?-;HD<&]QJ*>RRFXK80\>6A8X&A9F08*>?_G1/&NB 'MK"
M#CY_ #;P_J2XD4#NIYG;UF5-]TV$W>Z*6_RD<4QX6\1:@7DCU;4C$'5S&DM;
M/&<"R.[_6(43ENR65B@!'.R@P 41KG$]+KSARIDTNM5]\9[W_-TU+TLUE'U8
M"MB;R8YU-":>Y6>S'*,(+ <%'!H9<Q%X@.9!U^+-__OP[4K<)A3WN=C9?8Z,
M9QTMW8UP"$3.G+5^0-%XQL0'*-!T^W4M-I]62\PK</"SRY%V$%^+-N"0B<(;
M'A/]E$ >=S[QL3N^V':6I]_1#F%MAM-M)2(OW+.\]#Z;Q1-M*'$LJE46=CQK
M!%B?_!%I'7B-DX+GCX\]G2.O^K-40P2^?F!^#MB!"W[@ R  00A"((+B%W\$
MR$^^\HU?_.$'__<:Y#;\*,#!7#N;R=#.\LFYU0:.>?_["5.?_P107WNZ*,-(
MP#!,$A .AUBX QR:4$]:CI"$.=C__OB?@QPT$64V@^/_ !B Z5!B<O5ZC2=[
M"(AC0%=^WR5AL04^N;=K^?%!T<,\\%,!'<!M&H!A&8AAON=\&01]&8A "61
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MG"XPN&D1C6]B!(32RORVRK[\RTF !(*&!*:\ROPV)L+</40PR\QL!.!S-1H
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M>N $3TQPL( $>JPW1;#$<I4.;E"7F,"SG  ,R<T7 O].X :^Z"J!X([&Q2#
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MMP=%O=WQL-'TH/+.I#$"F_ ]ZEP#T$W"K0-KUZ??H&5.'_ZP9^[5(]J.XO#
M!*:&DG2P(A;:<UQT\E41ZP#H)%<!WT#2P87E2<^"%\1@!O,V#O_Y4*$5$)O#
M!)" P,-8#&._^5[]L.:*"A!!*N6SG$FHT0I6K.(3<' !$Y 10Q5>I',?>!](
MJJ&D^?6P?K^K '$:PXPD0,A_%Z$2<EBR# J((!,5<4*U3/&)3X"B#2! %^Z
MT:F!+",.MB.( KOGFPE64(-OA&,<Y8@><W30CG?$8Q[UN$<^]M&/?]3C%9XQ
M2$*NB8Q&+,ZK6-0!\Z%$1C1"(R([P@1\5=*2:*( "#K0 0T449*W"PX%E*@_
M_CW1(E$T5P5,Z9%R4>"*O\&$1J(4/C^X<8ZWQ&4N=;G+O<%#/H/XY*]>=2!S
M-3)&,ZI1,#O##$L=3YGANQ_J)O.,6/7_#R11C.1'J"B""'8F(Q.8Y>W*8$M>
MEM.<YT1G.O72#/GPXIE9&J9B(,-#C^A* DK(YCL1 RIGZG-ST<R?8:@Y 4RL
MDB)P  $%!GB2#8W@.7K89#A+5TOQ,$^=%\5H1C5:SD?(!QK^;-(P)0"">:9$
M5YG+)TA1PHP/@*"?*E4:TYPV3005])H*66A*P,&,5B3!BM68C!XH4 &)DHZB
M@K'H1I6Z5*8V56^ A&I4^9@&JE*U#H+ *E8= 0FN0B(2O  K6']!#+*2%1IG
M/6LTNK'6M:HC):]@46Y"0,^.V!.?,/4)2S7P4KQZS!@5V$YCJ"D!FWX$F[S1
MAFU^$DL)%'5S_T<-2U*=.EG*5M:RE]V3/_*QV<W& QZ?_:PWO)$&^62C1]1
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MA\B5D(0QRA!!4LSWOF-,AIC7W.M?!SO#;AZ6@_N$YX"&+07:T#H'!MTP0Y<
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M!CU0@OI+P)_ /_WSOPWD0,L#0+ 00+,C0+3[ (>[P"Q90'=P/X& O\: !3E
M.N32-TPPM@?+P [$P1P,.V^0#QT0/X\@OP)T+=@B"I\QPB-$PB14PE9HA5=@
M@I$H E9@PBFDPBJTPBO$PBS4PBWDPB1\!4\0$4]@/)EPO#D00KRZ01U4P_\U
M##@>% \?',#R0[MF,C%.6#4W&$/=HH8F^H0\;#Q]BX,SA"DPD(]\8,-#1,1/
M<T/!@,,37"DZ?# [E  \?+ ]E( ^- S'<P,V,S%"% ]#3,10%,4:6\2P:$1'
M- DBY#V5DD1*?# ^]$.6T[<VX,0'\T3! ,51U,5=%#!V$@\:^,%)&L$KTZLP
MZB].4 Q79#!8[!%C\  -H(#+$(%II,9I)((:9(F, ('J^YA;#(M<Y,5P%,?@
M\D7!H(%8-(D@)$$3_ VHH( /\AA. "QE["]]P\2E(0):*0PY8!=N]!@M*,1Q
M%,B!K*QR#(L>",:+4$=B;*E5E EWA,=TD<<)H,?_]CJ"ST%'B^"&"7"!YY #
MR'A I?%&L !'@C3)DU2G8I /'DA(BUC(&!,TAV2)5X ,5OB8B:S(ZZ*&(QB:
MC*P.6&".!O$->1F!D$R:D:2"DD3)I61*7/(%^7B!EJR(ETPQEJ( ?@R!NLN$
M5V@[PGB%D;+)>)Q'GU0I:C ""@ %LB2>5XA&5R@.?@0!H^S&@&S*NCP+ $B+
M#Y2JO>1+/FJ' ,/+NWE*\8C*E&"&EV@<MX.M"9"#H;&(-C YG(!(CWB0Q%0F
M;)" "@BBBM &D6F#&]E)C.R15K@D)3'-TT1-)4&3U&1-T^R $)!+CT%*I;1+
MI@S,L^B@8=#-W>3-WO3-_]\$SN 4SN'\S0X"3+P93,$H3%1,&FHPA558!5,P
M2F:I0'T"!R=HNGJ" S< A1M)+B6(!;6<C&5(@I1"I-FLS?2\3;/(3>)TS_>$
MS_C43>-\CUD @-NT3P"8A7]   ?X!TH @!+X!W2XS[+(S[3(3W0@"W2@A/58
M3X7I*/'H ^:DT IUDI#CA)7!A%=(AF>H!FPD'?1,3[M\4+)H3_E$T1253_K,
M)0#U3_,H482)4,%@! LMB&,P@C90$1UU B9(M23X,AL54IG8!B*P0-*9MR>@
MRQ%MRA@]416%TB@M3ODXSKN9T;[$TBS5TBWETB[UTB\%TS 5TS$ETS+M(R8E
M4?^U:(="N (S==,K&(1U$+ 81=,ZM=,[!2X#N,\]Y=,^]=,_!=1 %=1!)=1"
M-=1#1=1$5=1%950^30 \A=1(E=1)I=1*M=1+Q=1,U=1-Y=1.]=1/!=50%=51
M)=52-=531=54=:I^8%7UV =]T(=]H(M6O2Q6[0>[L-4:ZX=]N%55]=5?W9-;
M2  #(-8 V-,3( M)V%-*Z%6RD(4]%=!_.($]U86SZ =+.-9<0 !B10!CO<]R
M@(L(V%,"L 19-0M)\-9S( M<V-,%> MZV-,$4-"TN <(2( $((%_V <4V-,(
MN >UV <2V--\_0=]<  _#8 &)8MR4( ]K86R0(#[% #_<4@+2Q" ^PP >H +
M".C7MT@ C-58MF  :%V+>CC8^[R$6\76^TR ?U4+$_!6!""+?9A6E$V+?JC9
M $ !N*"%8U4+@;W/!T +$UC6 ;A/ S#7LE#6^R0!EST+7=C322"+2R" HVW6
MLGC6H)W7B 6  $!6M:B'C[U/2UC0/56 <5 +HP4 F7V+?5!; WC8LT 'K@6
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M*=F&SF$"I4%YP5!Y]6;Y[UX?:7 !9ABVON][; "'LV\O;4"""=B)PT=\Q*>
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M(DJ!"E! 0#0B4(XDJE$*2" J#V0H3][IQGF2M*3)HX<10;I+ '9+@,K4A'^
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ML/C^*F#8@0HH01,>J9@+3*'^];.__9H0OH%<\ E-: T3;DY*Z4_OCE@P@17
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M*UQ,1(@ '+@!'!1!!X2 $F0BW(6B*(XB*;J!&^"="#@!K2A8!7B $[2!$4P
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MHUB4XSFF)9&E8Z.M8VZYHT8D0Q$ @Q+4DCO<(V_I(X,PD1.1QV5('N5EA"?
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ME;SJ*)Y%MJ$(.L#E8:767W'C@:OC_[?:LU_J%49 X8*B#23 !4Y.X AM&_3
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M7$ >\/O?EP0.)$CVXILW/.(5#_HB,]Z^-;6H^4!YXIA'UU0?*$((1#""V(M
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M@;XJ<;,?P GJVRO&T 8B0&8(1+I_I_\,?!DG<= 4;J '<0"[.B>[-T2[MJO
M98*[O^K #^RKP2I_RJ@!WBM=[(#!80@+$S "XBMHZ8 ,>L $]"(7KW $*00*
MV<.^[0(V$X $>N &P. &J>$.+4%F5[:_4Q>5$Y"Z1@+ 84NKYC>3"TS$--+
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MG9[.77XHL! '28#_2CVF#,]PWD*B#6+6F=4V L=0#5C["AV@UAH1!R>-M=4
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M$RM6I@T]# 89<?#9%:6!SWZ&MDM,J@!+-7#:$0!R D2H%/],P#&'5:@$'!*
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M/?]Y?59 [:63&C@R4>Z4L"/&'03&$193$F 0W>@(DD#2)TD5K>,RGQ0X[0=
M4!;@/_0#'?A :?FI[LE?D1I*Z !."0K0TD9?^ELB**HPB,A,X?\Y^;]!PF&D
MDXXA,![RXR>_XR6_?>+)%1F6]P#F/ZYYDRAC#IU9A2?8L8XY#.89<8".*1SC
M#A< #7 0 79@AV/H%7#PA-AB!L4PMTSX"TR0%:I;#)[!%;>0 &43H-([O4F#
M!:3R*MB3/;"#)MM3CW4X!E8 AM%["7!P@PE@ FL#!SU0@@S\F0IPMI0J";7
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M8SR6Q#S*F$[<8Q7FHUWP8RNN@S;8WQ'DG(.Q A$H 3!P V0PI% DPS;4#TM
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M:9MQ)'!E+' U3+PVJ@1XK+ 2:\GZK,FB[*4Z1*9:J<S1;*YJ+$W=;-)&!#O
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M$61(D2-)EL1H#@("A"L!G!AX8B6*?03[45H986 Y!2M/S/RW+\+*!__$03#
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MG)5(6&C#I"HZ""D#'(  A0X)JJH^"!XX$\TS'9AR-@@J*F>E 6:!"!WZ $!
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M^9]QH&?IJH$(OG![R:W_WO4M"5>:4Y;TFF\H79O(,V<@ GT%S@!@[W%_? $
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M-2M1/2TQ-LWQ(FDS#SW! R;  SR ")A "2A "9B@"#J@#9@@!$; "9+  Y#
M"8K@ YB "49 !)P "4*@"-J "$( 0D/ !2BT XZ "8Y  YR "43@0BF40IT
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M!U L0W5X:86K,,JQ36ATJH -[,^,)K>S]B2KATN'$90QJ6T #ZQB)0DUBI!
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M[A\8036D0?QG&/_XR$^^\I>_?&I40\V1;Y,$YCDE#8! D29DO>NW#T[8P]G
M6A5?$H*/^Z3 '/%L[[WO7\(.)NAS%2Z0@QR,D6NHL*,:JVA#'-@7?9AH0_]Q
M$( !" =+-0'ZE47:QWT*Z$G>1V:T)7[DQVTB@'Y9QQV9M7XNT7[OQR?_V' 9
MFO ,[!43ZQ +<= &L8 NTO R6&=_ZD$$JD<[";B ,EA%#7AD#YAFME=^A=1M
MO <1F;9X<K>!"+$.QD!:ZR43U6!#G&!:!I&"]H47[2<!+MA',3B#5@A"-0AC
M-PAIG*>#/9%/O-:#C82!,"%W'B "J\ G#4$-IB!7V(<0L9 $\Q=3*5@!;P2%
M+?B"KU.%5]B'\Y.%&+:%]S9XW#8!^S9S/T2&['<[:*B&)9$.RB '18 W!;$-
MF' $IE -(=B$,7>'H96'5-AJ?CB*Q@.(!":(+%=V7D@4E-:#5*.(&3AWC<@X
MJ[ 225!D,(%?&N")+"B%>F@Z?$B*PI@YIMA>_Z@X=FNVBNW1BHN':;"($G)'
M=VEX)ZPP IG &,MP!$K #)MX$+K(BT\1A5,(1L$XC.;(-N>@:/QVC+2W9O6'
M=LR8>,#VC)4T=R,PC26Q#M(@!RX0"R3!#7I !*Q@=PU1A\K5B^.H18<@BN?8
MD$(S3H4U<^QH.OB&3_&8?O-(CR01C2Z CPBA#:Z !' 0*RX!"T8P!\F022EX
M$[]82: (1D[U;@XYDT,#D6PWD:!3D;KF2SVH,AIY5'/7D6JX#LB@!TG "D[6
M$-4P!TR0B4VH@BUY5"^I13%)DU:Y-A]%2B+7716P(#]H+=R@9@(Q 3C"())F
MD;Z4#N"PENEP;HO&2/^KD Y)Z7O1>(]QL ZFT :8@!AWD0ZO  =R@ S/8!,B
MP JP8 S=^'M3F455>96.&30VF772<"0+\G9YLP['X JPL)F<:0PN4 &=EV^2
MPR KZ&M3(Q#(\9,(47H> !(54 1,@ 2RB01'4)NV>9NXF9NU.9NRF01)  *1
MX0%$, ).YY8R(8Y1>3B-^9C,63&1B8@;4IF?PPP5T '6:9T>,#!GN9.^) &[
M@00D:6W,H &I5@&@H)H'P0XV02RBUI[NB4O 0I;39YR*Z8M]M)S-F9_0\IPB
M)PT58'T"89F!LP[,  S&<*#&\ Q&D(S<UB 5$&+A:9JNLB$=<)[H22GIH![_
M.=(!]%F&BQE#^*F?(KHL_+F.$P@\$F"94U80*^H.+?JB, 2C!A&C-,JB+VJC
M..JB-ZJC,VJC,+0,N#0!O':&RE@OE+8.2)JD(F>!GE -U="A%WH>/Q$4V-"B
MX?BA)A2B([JEC%*B[#92_WD3RZ -GB 'R< -F: 'QP .F( )R! P<8 ,VO )
M<7"FF@! Z8 )  1H<7 ,VP *?<H-G# 'QI .F3 'K9 .IA 'P, -BVH,W/ )
M<@ ,ZW"GK+ .JR 'L, -K,"H 2,')P@*'X.I<F *U  *;< *T@ *'A"!D\:3
MS9A645HI4]I_<8>E):2E7+JKA^*E],84J92BG[,,_P[2(R!P>PUZB$LJJ[,Z
M*;6:G*B!JPRDJ[Q:K0""#NKXI4PAGP)ZF=60?-MP!*!9I#4#/,K*;^K7K';"
M*]#*$,C91P\#;=8ZKP%2C-LU4M/GDX=3#;')F[7GCFUFKKSW7NKJK/5UD%=J
MGV"$"@Q)KPZ[%O8J6_B*(]VJ->E@(DK !!JK!!GK*MOY<@+;C!\PA@5[*T0%
MCDD1A;8Z0*2 'X_PL#"['Q%K62,U:K"@:6.$(H88FO@4LO*HKR6[*R?;KJLY
M=Q\WEF1):CVB 1IPG4ZB3@*E3M?)M+QV:CB2:AW' 2X;LUPK9MGZJR1U:P";
M6SZ+D:\8M$*+.\NE'B)P#/_2P'QP&[=R.[=T6[=VFWS4P =;V[5\"[%?FW),
M$7YI-K8]"ZORR%!H"R<SL[8*JT6CL+=]&[EF,;.&A9.?HY,O=Y$5F)&)BR#8
ML* 2P(0(2;1S\[AU\;*2F[IC0;EG9;F'@[GP:+B+EJ2TFZ3\\P$=4+&=*Z4G
M@@0$F; )F46F6Q6HJ[K&ZQ6L>U6R)[8?&[OGVE[I, >/<21FT@%5ZP$69 JF
M$*&[>RV]^[LI*ZT#-+Q44;S'>[Y9D;P[M;S:QJ"31@'/NUUYBKO6J ?V>[^8
M<$@A, )%, +&T+V\&Q+@*V7BJS_D.Q7FB[[HJ[XAE7FS1Y&JR&UI8FGKH ="
MJ@?_E;14'_"_ !P>X/"]C!N\,73 5)# "GR\#%Q.@:=MA#AI$"%;VO ,Q#?#
MQ$<-S(!W&H#!1T4V&]S!'@S">-BXP@NY)WR^*5Q**K=Y/*MK*R%;F- @%. !
M5S*RHM951Z7!'.S#Z '$GRC$(TS$16R\1TQ(]79K.<AM(T"!.Y4)WMD4<R!_
M< S'<]"F=%S'F  'D='#6KS% AS"I*LU)&S"82RY8^Q'9:QMKFJ1,2=;;-P4
M3L"]* $*3D"6>KS': <2H>O'?13(@VS$?PMVM?; .9G(NK9[EM7(KZ -2Q,3
M2K *ZT !'5#)EBQ#7#RZFPS&G1RYA=Q'APR!R#IIGW?*_P%:$$C "HGI#JK,
M6.Q  >F4Q;.<%!_<QT$LPB;$R;FLNKL,1BLL?D3J>6H<4HTLH)[0!MT("[#"
MHA00 A[@S,^\-;4,O']L-=9\S83\R8 W.*)\N5WHS8P\S :Q#"Z0.WKZ8,LL
M NO<SK0LS5U,S24TS_3<M]FL10Y\:^/*;:9L6.'L)T= B07!#6ZP"JM9=@>-
MT$@1S;ZKR6#DT _=M1&=1>PK?A.PQ)F[R):%"1RBN^F@!U;L#LO@!.SLHND\
MTB3]5N\<OEY<S;B\TC#;TC'TTH/;O(5WK-]<3IC0 1.@NR[Z"AX""TSPALNL
MSC\]U#%AT@-\JT?=T$FMU [+U/\FY+J! [M1K6].[ $4@-4%H0S9AAI1+-1B
M/1/<<"(,;=:!/;YIK=;SRM8EY-9Y ]>YUQU._ %U31+;, > F65ZK0&RW-=C
MK6[)N0Y5-F7K8(^0S$!Z>[J&W;6^"KAA:V/I@ W/ - 2  +D"C8@X 'QZT>8
M -E830U'L#,5O"+N*FJ9K=EWPMD\0:PU(KHQU+*F?=HQF]I@%[BOPP[+, ='
MP D'2$#=<=M]E-N1C1#&0 2& PIP\#7L$!D@$-;$?1+LNC_;P WP'=_PO0U0
MVCW,3;S.';-924X2*=V?$UY(P-%LXF9.;-7=R@Z9L'+'H 1,,Z.1$0+JO=XT
M\5GQO%/_]UV^^0VS^QV16^G?FM;*@D+@-=V5 JI8-RO92>"/+!H9(A#A$CX^
M0PMZ%X[ &?ZPT UX'DXWZW $Y&4G(FY83RRL[O ,+O"&"!$')>.BD>&_+PX3
M&1IB%1Y2,U["->ZP-XYY.3XWK2 '7J6Y:SS,IN $[T@2KI $X'#>=.?B69<,
M1;"_ F=P%Q?G<GYP!3=PQC0"$T@!I3ES4R[(5;ZE5QY[66XU)X79U&<F>G"I
MR=K/!-,&H%#?!5$-(D -2Z[F,Z<,(3 !X+(PX" '&_*@J):TH@;JH( O?K8-
M:K;G(M?G?SZO@?Y]VWHCFS+KM#[KIG;KN)[KNFZUM4X![_GK_P(1 K/-.%X.
MSF/YOY^=[,J^#J#+Y&2H#, IX"^1!-/C#G#@C^# "2#=$#.VZZ6VY*/-;JS>
MZM7ZZF2F#4GPM BU[NS>[M1K)#+MO(R>"<8P'/9^[_8>"UW9XHJ(Z10@[2Z1
M!!Q\[>X #IJP[0P1!Z]PS$GQ##42 N&N/^-.[KMJ[DT.'HQM?L5>3HT,\.Q'
M-A"NB,F@;QY_$@)?$ 1O\ B/$,R !&.N'>>$<"PU,)F<TH5-\<R)V!?/$!F_
M@[ZT#$ ?]$(_]$1?]$9_]$B?]$J_]$PO],S@&!+ "MJ #51?]59_]5;_K:[R
M 27/=B-? 5U?$B=O[=A^\)8A!PS_'?\J&^5(DP@WC_..J?,[?Q ]_X7 &9^_
MGO=ZC[6_,FKP^Y]->YU)<NC4]R136[6RSO='"RP=H.(8F QI[/@Q,?8I;_8E
M 0Q&$/'A\:XVW]QP/Z)R/_<%4?>LV %&,!V<@?K+P0DODR)!]@%&T 9,$ )$
MT 9ML(M.X 0=< 1.H 0B, *]3QJYKP%&,/P5I@0H^@%Q=4-8<@2RK[$:ZP1M
MX/LAX/S2/P+P";]/NSU6(B78RVOP62,;-]R@!_D:(/DP0?EEO_(-D0XE:.2;
M7\#YH]*?WYRQ)@_XG__ZO__\W__^__\ (4_@0((%#1Y$F% A0G<-'3Z$&%'B
M1(H5+5[$F#'_8A()(<!I!.F.73)@F/2<1(D2$PA0ZS!BH@#'B39WVI)\DC"A
M@QMD[M;I>=50Q+.&2*2Y P>*E4]-2]T525:4Z#I.$B2T<8?,B1M.2B:(,,;.
M(34D<#*UD= AZ*<.$]QH@IM)[ERZ=37)D>#!DR9.??MZPN2A@@8*':Q^,!92
M\6+&C1T[3N:B0ZS%21*[@T,9G*95&->]8N)$V>.,[)A(($*3]&K6CT=1@1W[
MT3_:M6W?QIU;]V[>O7W_!AY<^'#BQ8T?1YY<^7+FS9WK[A=;.L2%U:U?QYY=
MN\+6W;VWYNCQ.\@DQS)BDC Z24QVW')J*-)F3AP01N;HT>!$CIP*_TSDP!%A
MA/E$(.(^#Y280PX-_(M#A DJ<.,9#^+0)IEDM,E$ _/<V::"([9AYAAP/)$
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M(D"":%5!Y-$()S ")."Z#W !.*B)OY6W.% &$/$$#W"%#K">6. &:F %KI(
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MLH.>*$R@IC&CDPD2BD@T]M2=O*Q:MW+MFM46@$I:EUCP:E9> [%GM1[(:@$
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M> 9KJZ'3)E&C&M7 AC$F  (8?V<=_VZ0G336D8XQD[G,9DX'.SZ!G8R (S]
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M$AR!,BXC,S*CR$P%KQC!&))=:(!#:,4!)Z2$KC$',R!!*#U#$DA&'5X$]56
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M9L66!S5\DE%>Q2?4!%N.+=F.K5L2"\)6+#:$ -HEA\/>JL3&K=SJ!L5N+9X
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M0-J,<,#*R $$'I!@'.20! T,;UK)\^ '01A"KA".4?9SE#8\H0G>@ H4&O@
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M9EH5E#4G1H0=N9/(QB)J18BP@Q5ZD @XA->WQ"Z7N<W-RF(;"]O\F!2E;IQ
M""09JJ(4H4TRK0T[7F$IU+8)%N" @R= L0KUKI>][77O>^$;7_6V[1/L:&V;
MD"#=+25#!!7 I)%HBT3;?O)*1%DC@KB18 5O(P324'""P=&*WK$B'0_FQC9
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M)AV16,PA>\>%PY E@ 01(*'X$0&')SXQ'&SXOO?:(* +)O"!BH##",/F1C7
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M8SK@FD1F*@5T0 FT0*>R/_NSLB1@!%K!O4S! ]R&O5CAB-H$#AJ4O4RA#8Z
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M80I(\B[7#33 "3#W"'K'"/BW<MV@"-;W<MO@ XKW>!TX]Y*719@78.,B#34
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M\ZXZ0&6!X;]]V\-EG2*PH<YM_20L2<\U9]=E'"..Z!7LM:F%=M'= ?_AE$"
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MWWT$=:_[!SI  :(7W1T^M@D3/F!VB(+@ \^2VT!+J@%3) ,9I"^]Z4F_C"1
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M0[!A%D_<+6MM\$ULN$>5=5!#AC.D80UM*,-J4 ,)9ZO " J7O_TI4(A#S \
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M$DP9*62*1M&41E6J4_W,)XX BX>^5*9;Y6H37R(YG(95K,/0:5-F0:B54 (
M#E")4/_ATQ+\ QUK7<E9 7A6HJJD!$M=2E,?TPOHV(&J@R5L84=##4\880[
MY*96N_K8F-*4"F.E[$?+VA*?0BJO-+$K2Q!0*+;^HP0 B.M< 8 .E73V)49]
M*Z$<\%D S$(EIAUJ6@N5U\P"M25^=<PCH,,'PP97N,/=2CJTH0Q3S,$)(M#
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M0GD $B"!ZP0  K $E?C$6WB U*1.FKB%SP0  2"!7#C%<T !UK0$5T1*0BD
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MKRP ER!0[BQ02>C(<6#--+5*EM57$^R'<="%<,@%(C5/EY706T '7"B!KT0
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M>P#[F<2%69C1&EZ)?=AK<KV$H3<4 T#<:J='(R;W'=?:'M]3\DYS<A=O0E$
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M/Y<88)\^!6Q[[BRR<*NM ";T@YJV R 0SC^U]$N  "7L\Y&_$)BWSR0!#!
M S7]T]=ZY!!P#BX4<RL  PJVI$\$)%BD@ E%'F0) Q9!<$*1YPSP#VL #&P
M+O8H@/, !<AKT#@(4+)</1 $X-4)$MXS0-#70AVUU%-3776S]Q@PF$$H0&P0
M5+29A1PE =0)0 &ZG).60?0L ( "L.T3@7!> S#+12<48%=6"?1S2P&A'82
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0RV(VLYK=+&<[Z]G]! 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>exhibit10firstamendto_image6.gif
<TEXT>
begin 644 exhibit10firstamendto_image6.gif
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MAQ C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)<N"! [Y2JEP9@L !#3!CRIQ)<V8
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MX0&I6S2QAQ=19+%'%%&D[ '+=->]A3 VMYLSU7SW_ZUPOD+[G:;1+B+M].'
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MJ4W0Q+ZD>]XHKV1#K^9KQ8P#*'Z5KFG"KQO\5%Z<)9WB2MQ0/G',G7.L(I9
ME3R'QV>C0]*6RK02#YVL+)1BN(;$1ZSB!3(9#S(+2-%:?6W'?.?UNTC7,DU
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MR"=SZ4*T<3[FW54(P% I^&Q\@]*4:][E\F8J\A;HO_],#FQ><Q"(S_&4*-/
M#H/2?87@,6439&0MDU),R5]EX1#>)>%082#^F#OI)*9^ZJB>ZJH^([O7/>^'
M?NVW/2KN, ILE%CBHC6I>[C'LNTJ)C_W.##C,9R.)7GE66<F.@-.V<-L95D
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MRAHOFT:?7OUZ]NW=OX<?7_Y(U*EGBQB?/W^*V4RN6AW( P$']* 9A]IASBH
M"?1*HJVB($RA>*;98JXH]D!,0'0.8LZN+!Y;K*\!!PHPKX<0)'!$!0%<*S']
M$"I&"27 >['&%\O+Z+SY=N2Q1Q]_!#)((8=,B9W4X)B-!AN7E(Q"#_803IYV
M]O# B[T V\J#!BLJQH,M$&JG&"C3\((/O 1<KHDGMU!,LG/PJ@ZP0CR ;AHO
MMN"EB2Q<K+'+)T%D,M#):$EM#G;_B$0T44479;111Q_UQ\C4;A&T4L#*F T'
M+9OQHLHKL]JJJT\;FN:_%4]%E<0T4V2U50^:X ZBOJ*(,ZLYBPG3"UK5W,Y&
M/VFT--BL"$WM4$B/139999=EMEF3YCDR26&GC4@3J:9Z@40U!2PDGG:^!3=<
M<?WT0 D26Q15HG2R@'"A=H!YKIBT"-S0+0&CX,7,[:!KB$I<(WJ3Q!2;$"8=
M@P]&.&$G6Y5QK39?]),/0*FE.")BB3+668TWYKACCS_V+)]"U6B-$V,J1CDA
M8F8CP<"$PGK598:H+,2+0LI:*$LZ%7IWL(;>B@*AZ?@HAAEA"CE3.0[O'428
M:<YIA@]>_]B!$:Z)VQ'&9X7.K%6A=.2%"V<P^:AR8L3.Y!-B 27NKAVRMX@P
MY<4NUBACD._&.V^]][Y;9*+:F*T(N5.>YCZ9I308G:^CT$W-+*9)1_%TFN$%
MN2CX8":=;^-!!S$O)D8(F-^""ZY"TTTG?4^VEB98&-==YV60/0HY:P]>7G_]
M]K@7FF9;&9M -7@U"6[&SCW0F>9I@]O)$*ZT]?L5],C<]G+WP9NB.R.[^>:^
M>^^_!U^^U  _2O#K*2[U7B7NY&6:9MZ'_WWW$>.70NNE/,N@=+C:4C*!T%R:
M![( FUGQRVU=BP<?@)&0<DF-=@^$H._,9:[35=""%ZP0NX*WP?^K" A8L)E2
ME>YWOJ2THE#S"%\*5;A"%K9P)X6: R](B+)IK& V@H@'+[8PC;VD8Q!>*$L[
M.E6,>,CC'!@J!CO:D0YVG&,06]"+$1'3OZ:T@QQ'*QC9 &BO5YUC&H7@13'2
M4410^>4@T]F"&)EX#CYD84OM")L\F@'%;TT'/(A1@C#(Z"L/2@\R(?3""&<X
M$56<T(6'1&0B%7E(4Q!%#;/IP2"%-8TKN  %]\'D461P.AED,I.!2$@E/(G)
M359H#S@8Y7UPP$D1D,"5)5B!"5;PA3.< 1"!"(0S$G(.9Y#C'+_\5%HP6$$@
M+N0^!\(08@YWD'B D2%O0PP?&#*(0HS_2A[3@$L%!^''Q>1F"VR3I%(*F1H4
M+M*<YT1G.IW52(VX00V5:(TNPSE/>M8S'05J!S.@U(Q/L:,8=#$0V0KCI6OR
MX3F?L@M=<-47L=5S<"8DISHE.E&*5K1'V?O!;$#9G7ITU*,?!6E(13I2DI;4
MI"=%:4I'ZM#H'#,Z*H5I3&4Z4YJN=#P0)4HY+;I3GO;4IYK!J$;#4U.B%M6H
M165I;%P:FZ,VU:E/%6E^V$F4?/S4JE?%:E9;@B.,A",_3>T" ,0*@ YT=!=B
MK4<YQ+J+>D!#K.6HQP, \(".AK6L;BUK2#LP5Y'R-:T>'8!8\TK4I,+&&8<]
M+$>/NM>Q=L&L_VA5*P#8ZE8 P%6N=*V'7=M*5I'N%;-_W:Q8H1'6 734LT:5
M:J&JNH\0$$ 7^]!J;&4[VYW6)R,9/<I&7PI5WO:6L(6=S%)AXUOB%C>EJ4U-
M546"CP_X@K;/A6YT4VA;C+C3$:WA!G"UNUUZ&M>[WP4I<JDJ7?*6U[S=DU1&
M?# ;3G#7O>]=BG#A.U^G3%4CRCUO?O6[WV6E%R/K/4I[Z3M@ B-$O@5&,$04
M42A]\-?!#X8PD:"5FE;,L%/ \8 U.50( JZ%PZ_9BD,Z124E=*EK"&$C.4 \
M1=B0XW,_J](%8(#8!-<X(C",<(YUO&/W3#@C*IB-/.76J;EXX"#GJ/_<S<)S
M#FZ%!VM[(-I71GR5+D$G'5G#G(8CXQP/?#@Z88+RO][BA0/;V,P'P3&/U;QF
M-G/&;QE10YQ;P\U@$5G+X2%'<KQ<(Z0UH:'ZX?*>7S26VYS9T I)<YL5O6A&
MU^3-& 'R400Y+>1L@6HVRG,3!*V?/O\Y/X%FTA[*?.@$)[K1IT9UJDM"E$@;
M9=+"JO2E:Y3I3>=G3DKP]'BR),,EB7HVI#ZTJ54];&(WVKX960<)8[VD/'>9
M27/R\Y)V'6H9TQC89EY'H4Q1;&YWF\WV;;4(7EUG+]VY.TQV]I*@G6OQ3+O7
MH[XV?;.=FFU[V][W=O!4<9M*H_Q (_OFM[__;\OOHP@<(P!/I<'G8 05--SA
M#W^X$33"<(A7O.%JT(@:+&YQC,/9!Q\'><A#WG&,M.$')T=YRE/>AG;&V>4O
MA[D;- *'-M3<YC>_.1QFCO.:P\'G/_?YS($^=*+#T.A'1WK2E;YTIC?=Z4^'
M>M2;7F]\5]WJ5\=ZUK6^=:YWW>M?!WO8Q3YVLI?=[*D.P%C5OG:VM]WM;X=[
MW.4^=[K7W>YWQWO>]5YW IS=[W\'?"(!(!)]'%OJAT>\TQ6!7\$'WO&/A_S>
M!A\2&')7V(><?.0UOWG.(ROS'ZG\=B\/%%\ H.\>>8?:W^&17*C]]/XH_>M#
MH@&Q]OT#0/E\YY5%_WNQPK8C[SC VYT+D@_ 70/X"$D(Q'J E."# '1W+C[&
M>@#DPS[M<J<^2'QQ?;<?OR/*KWLN3K*/UL]= _[ Q_4#H(N4N./Y;P^ .T;"
MVKA_H/JLI[OW4Y)ZL0;@%R,9JP"XOX_ A^"K/=_["/J;N^'K"%V8.P$,"?*+
M._WSB%_@/N-;O>;CO?H;P 1\/P (@)"PP+$2/Y%PP/[[OY/@O_I#0)  /[&2
M/Q&DNPVX/W<8*P)(08_ APT$ .:S0;'2@ ST"!Z,P0J\/@(0PH[8!^[+/I#8
M0 )H08\HO;'*09G(O8X(/>T:O8_@P;@K091HO=<KOABDO=LCOB\,0Y'P!?_9
M*SWQ*\..H#WQ:[W;$ROG*C[9XS\&_(@KU#U(>8</1, 5;#LS_#ZYH\".D+[E
M:[X/?#OV0\3IJ[[M&ZL-^(!*K,0-X#X"*$)_&,&V(X -^,((#, D3 D)C#LH
M1$3U<\212$33.PGN^X4='*L0,(DI!(#S\X?R T%*M,0/V "UH\']LSL(1+T-
ME#]=9#Z/4, >[,5*-, Z](@3C#O_PS^Q6L61^(6Q"D).Y+YF]$7NVT:4D$5#
MC$+@&RODD\9D#(D";#M21(D5#  -V(!YW(!G[+V/D$;Q,T>Q&L!LK#UO_,6Q
M(L0?;+L-B$("Y#UJ-$ H;,4-@#T2#(EG9#^"#,?_D"B^M0L /;0)/LQ"X-I"
M%N+#/G24/QPKV&I%T_,%V'H''OP V'K!'G0'?-"%"R3%5E1'DW ^B,1)2.P(
M201!=\2'@ 0 0A1*F,0'?'"'HCQ$)1S%EC#%H3R)] O  Z#*JJS*&#Q)$/P
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MGIY!6 )M.^-[2^,Y0 4^K@CP<F3C>A$-+IM*<=R@X0V],!AV6)XW>14B.^%
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M0QHL:URD9T*< S"D@<#)X"$Q!(#%1<1RQL1::YZ82Z. [,AN+=?>3,E:1!M
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M%$?Q$N_+!JN%%%\Q%F>Q%F_Q%'/&#F_*#X>Q&(M*3KB!&D#"9G(#$7.Q$7<
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M1NRY/[S#':_6G4?T'4<TH^?Y!P" 056Z+S"ZC&W$FJ?Y2N"#H1\R0NV#'Q^
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M8B=U5MMMN>W6VV_!S0U:A:0%5MAK(S4VW'79;=?==^%%=MQ0?_'57&L5NHX
M!_?!_\???_^-5^"!"2[8X(.#G!>A<JD]M[(>$8Y8XHDIKMABBA0^B&&&JAVV
MH4.GO5CDD4DNV>1N,S8(JY-8;MEEEGT!P.."/B" @ /".EGGG7GNV6=*4R8.
M'Z)^+MKHHY%.NKJ@B]LG%PN5CEKJJ:FNFB.F;?LK%Q&M[MKKK\$.VQ^L:\-6
M[+/13CNY$#Y8T^VWX8[[3+#47HYLVLRN6^^]^9:-Z^%R^:!OX^Z>+>_!$4]<
M\87^OLB78/M]QY<#-/BQH< 7#ZYPV0[/W///^6[<HL<M+^B[^Q+"''3>-H^M
M\]5ACWTY??*IW?;;<<]=]]UY[[WW>^8)7OCAB2_>^..13__^> FBF:<==J"/
M7OKIJ<\D F2HGQX&3;*'W@\JN@]_G7'(+]_\\]%/7_WUV6\?'%S@CU_^^>FO
MW_[[\<^?EOWY[]___P$80 $.D("M,,4!$9A !2Z0@0A\ R),P8;]Q:]\ZX">
M\&SGD=>]AG;Y %[PGL>.\9'O??#CGP$/. <5KI"%+73A"UDH.QG6AA8PM.$-
M<9A#'>Z0ASWTX0^!&$0A#I&(133B$9&81"4ND8E-=.(3H1A%*4YQAE6,30VG
MF$4M_C .77S#%]\0!SF,D8QE-.,9T9C&,W:1C6T4XQG!^,5(S)&.=;3C'?&8
M1SO&D8]]Y",;)'$+0::"#718A2#_$9E(12Z2D8JDA238$$E)3I*2E8SD$3"9
M24UNDI.=].0G.6F&3YCA"'0PY2G-X A5JO(1C7#E*V$92UG.DI:0,(,9\' &
M7>H2#XPX@QG"8(9=ZO*6EC#F,8UY"64NDYG-=.8SG9F',P2"FM6T)B6PF<U
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M[P$ H!QFKP.ZX/?*03O2#QJT PEE#P &0/8Z  "@H1ZN, NAL /JH0ME;P
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MQ[9MW?9M#:QL7>ALT;9O_]16A=A6I"POPGBJ;_V6IXK!6P77^< 4H_R/JSQ
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M#+?<0+ZDM-U7VXGF#D^B)=FIIY^"&JJHHY):JI)\&53505"214!V)<%EE)H
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M[N(R;M@RG'[NJ]DR+-*J[3+J6Y#-[9PV;:OR =[F+4?D)-^>;9!1K>+Q017
M!RT0KM08[GL@+J<V;NS*[NR.[?_",4.C#MO&4NZL%<(6% ,O:%LA:)N8_9@7
M0)[FUJWQ%NOG=D3HHJR]':W?*IR6HNY[J.[JXDSK@L3K;BKM>N_W*B[#W6[M
M]1S:UMJSE16IQ=DYR*WQTBW..2WSZFV0/6^]16_I'N#IIB[V9N_A)B[X G
M\ZSX-FK]-ISYXJ'2'F\88AF_RB]'1)WH3JX2X"^NM<,@[,#^\J_-:*]$<.^C
MANTN , NT&P' $ 7].P#G##-0@, !.U0E$/-FG ,#\ #L/ *=P$ Q' ]#,
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M!F=P!O< !E.0Q0@PSPY0A_JIO2S_XUP&X;1P2M5:(@V0A0%W(OL";/[*;GY
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M/1:_\3W_JR%?];];LV*?R4O?]#.?/&@?"%G?]5T;S4*?[F__+&Q?^%DB<SU
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MJ@A,J2@HYU!4/':& J%W3?)%7LB+!>%J:6=Z_]WW)?03-)?%B0V1AN'T 2%
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M!V%%)8R;84%J(FK(EA*C*)5FF5U"X0X'<)*H09MP>9O<Q [7,9<8X3ZE]YO
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M61*Q.NZ*D^X:*ZV2J'14HO!CK!7!#@:6K+>QK).ZD$%7@?FFE;B:&<T +.0
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M+L0[7O*65[RP.,(1'&$+\X;#O>^%;WSE.]]QF,.^][UO%79P!OSVU[_K '"
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M%#[0MX[X.ZX9G,&;@\)#O JTP L\/'P(@5SP"P#0!< XKLM(C_50(=BR"G0
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MUI*C[WD8RFF"A\%!%S%*UCB')E "I?P-I6O*$5-,24K(L33-TT1-?,&'7-B
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M]!D]30<^6++4  96I8C-;((FY8V1.)%"#<^!I8B"C8N#5=BD5?_:. F!  "
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M\COG\">?##C(1AH0YGX#\YMP#B]0\YV-OZM8K>>.H"^A5?S@ V#H:TYD<]E
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M..*C199D/DJD"/]0I$FNI#EB),SD@T?&I$PV#TA>A4C>HTJ.8Q<  $^6PRY
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M]I07H"WYUHGYHB\%8Z+ZJ@"V<&P<R>_X"!+$#-IBY*\'[.][/%B$I00 1\8
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M+V__=XEO"XYP3_<W*0+,$+1<&[>V=/-L+TAMAS8BX?9(._=S]_9O4S=ZDQ(
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4/_WS/P$T0 5T0 FT0 U4*0," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>exhibit10firstamendto_image7.gif
<TEXT>
begin 644 exhibit10firstamendto_image7.gif
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MU'MBZ+#'+KO#O!!!.7[=V,'$$6[8TLW:?MMB'X_W'<%-R![+3#.&"IL3QX;
MKUSQD^8P2;(;]B%NH>./ZQ WX^YV P<%;@P#_KR6=SZO.=UDN*DYV-[KI9;F
M-_QYVK-/./KI_/?OOT"I<\WJ!@:UD>7O@ A,H(,R=(,?_.J!$(36$:A%P2/T
MQS\4N $&-2@E'?A'@S>X8 <QJ(,0]D=*'!2A"C=(0@^Z$$QPH* ,96C!*5%@
M"@2*7WZ&D3Q0A<L-N[L=?O_,X:11P8L)ZO/4-8B@LOUTPPW# A.NA*8?#^G0
M4_-KPA0-% \[V.%\GKJ? O47F_^9\8RD"V!KC$&P-KKQC7",HQS-00['_<"
M8\RC'A$8"P_:[EM$!%,3Q;:N;25LD%P<1HA2Q$A>V&*1C(RD)"=)243NQQR\
MX,4D<Q$+35+RDZ ,I2@G>0L4;9(;5\R/.5[$2$OJ!Y.[F"0O8@')4=K2E:K,
MI"P[:4M;3@.,>TS0_M!(S&*R9Q2QJ8:5"H?+8#KSF;([6Q-B5JI 'J&92<N0
M&\87.6AZ\YO@Q-<PC4G.<HH&$\GT(>*8X(:=A0B;X8RG/$WUGR2&BH@ZN";9
MUJ7_12E1<9X #:A %S1.<QKTH&U!)VR4V377%6B@$(WH@^(1BQ_$[5-$]($^
M%W:C3'J4%[L87S^[*=&2FM2;A2LH0E?*4IP@<Z'5=!T>3TK3FN+G!T+L4K,V
M>J\NSO0^_,0526U*U*+"3J4M3:I27?+2US"4=04TJE2A:8XA??2J1/JG3O,)
MSU'Y])(9TF()M3K5LIJ57$A=JEK72A).Q"8<,:4 $7YZUKJ.$4F<PB*L>#JO
MK[Y2FV[PP0W(:M?"&K9":66K8A>KD4K$1AQ6LJ +)SM981'VL)C%EYGL"2IK
M=E54?E4E8/USV<R:]K3Z22QC5\M:B#@6-I#EDI>F\%G4_]HV76?#WSWW6EM0
MA7:(@/7G;8<[7-6V]KC(-<AK7Q-;J/;GH<2-+J@B!DC>+JR+NR+'?;A1PUDA
M;*C2#6]=C9O<\AYW$H\M53QD*M[V6NELVQJ0?.?++?K:][X#DA)?W=5%6FH7
MN.3[;FG=2^"2DM>\"%XL>F&K7E[TAZX%GJHY:O@?#T*80L*P QUFR.$/@:U"
M7O*BB$=,XA*+&)@&RH6)5RSB)AC.54>XL$2OX8,.UO@'G(UH-YB PA^$<,#!
M[".87$SD(C=A=QONL)*73,' ]N? "8[R4A?,W&\Y^(X1SK*6M\SE>\4">V@M
MHY3'C-SENF8'Y$,QEX3Q'QEW^?_-<(YSE[45M%3>"\IDSK,YS=P:))C0AH .
MM* '#6@/$MIM![H&H)N@YF%@D-"0CK2D)VT'.^<G0Y/.M*8WS>E.>_K3H ZU
MJ"$-9 5=@\*C3K6J5\WJ5FOZ!\)0D#E</>C$-<@<-VH;')I@"VX5;6QTOM;#
M\*SG8A.3SZQI[H.(]#7&=0/71U S@KX,Q@GKP$RRJM)^/-1;!M67#B-[E6Z=
MV 3H^<=#%,"F,,IW(!W\EU2YB(.T+S2S;M\:83ZP0Q,8=",[N %NTJ[COSOY
MV6[\X,/7R%&7;N&&)GX)O!%ZHJWL+6<$X?0^ES,''<CZQ-(ZSA9NB 5=4=:-
M6]CALV7_HH/('$T!A1EH"F[>Q;41UO"RW8((=1ZVF(W-\Z0B&PW*=A"S$2TS
M:,\[0O.+VK=^L"UP[X<7C,Z/%\_'BW/#(5>Q$ ;!'N3N;\7[Z @*EP_B9FF,
M(NP(^DY0ZYA A%AP WX-B@>N[?"#*?!"S0;_\-,OAR >-O/AI4Z0Q.- \8H;
MZ.+RR/C&'21W7 _C%B(/^<CI0+E745.5B'>5R'E80@_> (3]Z>JK+EASL@6[
M[.DB=L]7;[J?![U!O. 6T7EV:K _:'Z@6[J G&Z@8<#-#D3/3]7]> 0B_,KX
M1#!^C6F=ZL /\4LX=E?U].N&*5C_^M8WLO:WSWWL>Q_[N\J@_]X5!/+H,^CA
M+<>J^M<?B^43WO 0FEFG.^_Y/Q-:!TT8.<7VXR2H&ZA]*.(?+L<A4T ^A5<J
M=*9M#J-ZK-> 5N-Z:B-[MF<AN#=NH,)TO()'(88@PL!W\C!\L8!Z^*$D.58J
M7]<ET%>"&*4M:/,PZW(#XZ<?W- $N !,_J8X4Z* $2)_$P=_#S(-L!('[]8@
MYH)'A1-\]%)N^($DL:8?3F(WRY,? ,AR R@AUP K<'" +K@SI3(,#.B 8+@O
M5.8:K\<@L==L@ 1]%O@IW_8L$X@?=E!#(9@MDW5!E'6'>)B'>JB'(;2'?FAH
M]21]=K2&Y%)(>J=Q*A=Q-2)U.4@A//_X?@MB#Y(XB918B99XB9B8B9JXB9S8
MB9Z(B58R#18DA!!2A&'W W278TQX'U?(61,F+U.(05]$A&Y$,D&HA>XR#'07
M"[@X(5ZX<V$8C/XSAJU1AH9E#CQV!$-85TJC@ECD.$1 B("$:7>4"[APC=B8
MC=JXC=RH8LM' 3H8?S4$B0KRB9E(#0   !,PB4M #<"0C@1@#^D( , @C^E(
M#1,PC_0HB?-8CY1(#928CO68  "P!/P( -0 "P 0C_:0CP9ICI<8BA9D!\NX
M(*;H/.2H=G9 6_)P"[QS<K?V99N'0?(V1VX4)7)E0%=( 5E8-KA 6B+8A5\H
MC#29&A"(6LC_""85:5;-N!]'<'GM55'^$8X/\HBU!9%(F91*N91(R24S:"MO
M*#770 =420=YM2"YHU\'='H.\XNP49-@63HW>5J!1 0[658]J1\_66!]%$)$
MZ2#RIP,@&8E,69=V>9=-:24K28H1I2)@LI7<(FP-XY6O$9:&^8#IA9/-8I:'
MA7M)M)92LSBJ5$-5"#NQ8$)OV2!Q.9<^V"![>9;RY)=1*#LWEW.#.9.'F9IQ
M,9:FA4^,>8SGTH3Y 9D/(YE#!"L48 OY@VG@Z(B2Q9F=N2"G9BN@&4^B"9A!
M8Y+*N9S,:1^$Z1JJ&9V3PIJ9140 4IQ&E46RB1^TZ3"V"52P<@-N_Q8VO)F9
M#+*9O0AGP\F7$*4B#K25,-F5J"F=](D6U(E9UOF:A34_3+"=Q0.4#?.=(8.;
M,1@ZO.E\^\&#*1.<GGD$-\"> Z4BOP*?ILDPS]D:]9FAIT&,R69;&:6?=H5[
M_BD/W6D__W:B_P8TE6F@PE4AW5" &<F@"+*>V E.[CF:L7.9R>DPN3"?&OJC
M-,&A0.>ABUFC1.68/IE3A)0E7X,YF7<@(E=$+KHDO*B1NAF</A('58H@YJ ]
MT*0B^71 +PF.,0EO/@JD:/H20FJ,^]D$-P"B=54RG%6B8S,_XBDV\9!PN8<A
MMR"E5T*E@_1$[R.C^9&E6PI4='=WQJF5S__4I?OF=6>:II*J$O?9F'MEI#9U
M#7"0"\_FDP!Z6-P0C=/6IPCZ?X"J+K12IEQFJ,V4"_OE3,>9/Z5)(BRV*DQ&
M+55)E;4J8E7I;Y$ZJ<!:$I5ZC,F(J365EL0%-))&6A:RDIFF R,J9[['!$Q0
M([7J!N8'JXP*4(B3GOOQJ\$:KB QK/M9K(VY6;?F)/31#4K"282WKE-W27'@
M._11,A!V:M.PKH5C3\'V,$)6JDZ$,#%*J/OQF3IF0CBJ0"QX!)O7J5,#C.(:
ML3715*[Q5*UIKK#99K($3%772'1@+>P3AT*2(GW*6:I"!)"T)+AD#L)P!'#@
M20<SBTYD2PX&)JS_U$LX.TI$X(P?."NW2+ )<@T\!J$!U0TZ@',)FT#<LZ(/
M^Y42^[0T0;&M8;'5B;'[&9LVU0W_\:@+0R3P5'5+TH- FV@.2K0 U0T(&TRY
M4&/C^2G@"K5P.Q%2RQI4BY]6&Z)?TI\#Y6]**CN.QPLFAR,MYZU=5E69!'EQ
MP 3 &4Y:"R9)2RI5UX=]*S/*2FAWZBYO&[>:ZQ"%D$RJ*E4YJ8R-B;7SE"7X
M!3D3) _Q\+GWH;4^QK,6\J(4L*#AU7AMQ+H7XB4%BCEO]+EHNZWI H*OHQ]8
MPK3ZD0O;TK9C,C.9N[G.FQ *]1HED&Z%Y63&]T!$@'_9VC5?]F\O%I)Q_U!C
MT5922[0MMWJ^Z/LAV2M?'C0%#]*X_X$?>N,]MMN<!),[J$@KG I4]OM&Y/"_
MY$ P]2O (?-X_V9!=Y2S"KS #/Q)5Z5(,%,A9T@!DVM:\6!R,SI7]\%Y *L?
MU\!!$13"T.(#L&MJS7L1ZS 4SYNA<XL&=6M60H5(W?"J'UAWN AU/&,@.3-$
M'V(?6!*C$P8F4>E,'9-FZ=)%E=N^[SLE/?1$;H ?!Z."#(<MF@J[UV +2Y*9
M[=-.NP!V@A.( U7%$@PT)8Q9W= KM[-$;A-[WG,APO*X,N,DN)L@PJ OL] 4
M_Y .DY$.6/$/M4 +FP'(_\ .BO$/%Y 5KC 4^?\P"TJA#[,@%?_0"I#L"I!\
MQTOA"A70QRLLG2W\PF7E!C@GPS2,JBWX?-_;(#ML#B1R/H5#11.F44,<3*<F
M@ G2!,(PQW!S1;CY:$KL((W[ SZ .__6.#67"U%7L'#@C+E !.5S='.'BMCY
MQ=L+4&),(1-<QN+%QAVL'_[QQ.ERH:PA$*\ &?] "WU,"ZX@$+,P&;0P"S^A
M#D4A$!*0%9IA%:\@%?E@& )1 7A< 57!"E[Q#[/@"OW "JRPR9R<3H85PU(X
MRKT78PF*?]VVP_&@BVUST1A]T1ZI7[&\1T6<0:?;'_-5:/>E0?0U)136RPWR
MR\'<NL.\'QU(.:L"1BK_X@/AQWR9AC0"5<T3<LV&QPL^T,86TLVYJ"\7D,[]
MT H8$!GS',GU[ H8,!2T( $_T0\!(!#Y\ !*L0X6 !E<'= ($- 0$- 6H!BN
M<,CEC  (K9IJQ!H#5%??)<JN=,;6\Z=W!$:I[#@,*]1 U:=7>4DM]U=N\*EY
M]-$,F]%M$W(_\"' US;*>@,AA]BQP#N(36% H](, K]-_-()9YX\_&'#,'88
MTA_;W"5T$"\0Q=,1V!_8+)4.>@MSS###5]KX0=3?;-1;T0]GS=1$P0H_ =5#
M40M4+1 "@-5:_0]<#1GL8 %@+=;D7-:1<<@%#0 'O=:&V=9H\-9G]5U#2 [X
M_T=V_1O>M=@Q@Y4?>FT'?/UTA&>[1# ^QFN+PY*^\CW?]/TA!2@E#0?  ?R_
M=+3?^SW#4W(BZSH?.3+@W_4?(^2^OHS3*-0MZW/:.AU0JATA;*P#K>TPZU)Z
M"#3;%R(E7/LMX(P&7.$7^: 45@')[$#B)JX/D)S'@5$5_< .5<T.*JP.-?X3
MR*W")3X0_9 /&*#)UBV,V*W=8TLJVZ(#9HQ!/C!N<+,?Z <F%Z3@MY<E'D3;
MA)HE&D[A3&?A>C0_<&"LM%/E%V+;Y!+B G'40*'4O.W4OQW5Y3S<5FW<6]W5
MR,W< A'6 C'6 @'=_[#; JW6D8P )A[D8=@( 5/D[O]BJ]M4(YW4T?/4#<L'
M:P>R-TYN0_Z!V;?&I.F-Z/R6S!:"WER>0,.9PPI4=:(]U!V4"ZINC;<@4J6T
MZJI^+KB9OOI& ;@=&4O]#W;1V^)<S\(]$%?]#_KP &.QW$W!#A= SGC^#Q!
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MD2,AV,E/AG*4[:?@KC#8(C8,3S><X@8)_6"L+=E-$XJLD0E:1 ZDH=6HOFS
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M\"MF;"-RM,!T_*ND,XA=4$>_@@(X(@%XE,=WM,=[Q,=,@XC[4D4G;*)8!,B
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M"P3H70"  '8(7EJ8W, -@ BH6\65A>MUV0?0W<B-W@"0!=&=V=XEW^T]BW6
M7@ 8@%HH"]5-#P-07K'HAPJ(6;;0!\PM759(W+,P7 #06K,XWMXM@+0EW,X%
M  '8W+*@A;/]!P46@%DH"_Q-#U>06]<< +,(8)DEBWYP6=8MBU?0X-G-BY--
MV3I9V?QIV0%^#J[MVKD(X @0BUJ W0&0@ BXW?0X@/]UA=X%7[,@W?2H7[0
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MY9R>>"CY$D7&_R6(CK4+C"5L-P$ 2( ]E@   M@#&    # :_6AJV(,  )A
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MV 7B&N5<I]#%H>SAC$P$!00?52Q@) 9COTPB2%2BU%SBT[W6'5X$<(14#/G
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M/[@"!NC#C$J J_9# (A$/CP ._S#.EA +?"J!=""2"" L/X#!!2K!?3HJUX
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MJ9\ZJJ>ZJJ\ZJ[>ZJ[^Z1Z"">%3Z0^08,!"Y/5##HVF7H<4YJMG80XS !FS
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MTX(6 %5$S6(6='46YB(?TE0 7D$M*B!- 2!8S:(?1O, !O4L-C7[3%4M],$
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M(8+#DV+)%&73HED/@"VX-?L&(%7=HA_"MU/18GY_%%"!-RWR@5:]]5>%."U
MN$Y?(7%;& -@6!\&=X?3(8*'E7+50AUN-G[70H=+4P#*&';=4XEQV'.GV"R2
MMU9!MR[R86S%-8:U3X.'F%,[E%-]>!U@%4;7P5*)%RT*-OOHV#O-]U1+&"WZ
MH8!?ERW"MP B>(L1Q&,W$Y0!>)1)N91-^90#HP">UBQ<@9.7M  P]56SN"V8
MN$R]DV9G00!$5(V_\W8MX(;_01WL]EIYV"S0%$8-8)7_SS0 4)86 H 6UL$
MKI85 B!/#P TL121438?$*!.Z<([ V"5F1B-SR(?#D   D!6T30 >O55:9-4
M,_DL9#9P^V$ PO2:F9DN#H"<,4!6TR$ "J"(47F@";J@Z4L=*F"/MT4?6 &,
M#?JA(3JB)7JB*;JB'845$$ ?:,&A]>$!>C4 SF)+_^%$4985&%0"4E@" A<#
M&%0=5CF:8[9.:X$5+,  Z-BB<3JG=7JA6F%+:8$5B/2"N90V53@"R#,?, !.
M]?5)+2"%+>!L62&%U2&3UZ%8@W=KQ;05+@ !;GJGO?JKP;I]:*$5]&$=:*%&
M)[A7K]85T/IE611E90%19<%A_VD!4?/A2?.!0==!1->A%F:!%>XXK 5[L D;
M9UCA -AA%B[@J!] 5@/@1_L! 6 T'RH 2_L! UA7 IY4 D3T IZT%JQ:C<UB
M1VMT%C"@IKNZL%5[M5D[4ES!8L>:2/5!4,U"H(\UJ#' 0"?X22^@L\^V%78Y
M7N6411.T%EP! R!@AEM[N9F[,""!?Z$[NJ5[NJF[NJW[NK$[N[5[N[F[N[W[
MN\$[O,5[O,D;9IJ;[IZ[O-5[O=F[O=W[O>$[ON5[ONF[ONV;NL\;O<50-SCF
M3_[$=$R'O6S!&0G\7(Q+R8[B&OC%C@PB#D:*C6X@*S3J.7(!WV2#QN*@-IZD
M('0K*__ 1A[(8=2$X0@,0H+L9_AHPET< L7AA*I>I,.FY:(JZG9Z!<&!1L8K
M2N1LG/ X-K]5+KTM9 PIPQ9JI\"-O**NPP=V'"@4/ X87![ AJ=N@%UNX#MB
MJ,*?0SE^)\/E@1?H@,-C(5H^W!RF0%5DK,3IX,01"WEPPY1<O E@7%IP'!:O
MXP>67,ZE;P^!1L>!K\=]'.6.8;]U@V 8YL@-W6OJ_,Y]HLF?/ YPX1J0@\JM
MW"!R 0ZR',,UW [ O,%S@\S-G,3E85_D(1X^/"&82YQ8:<7='$KB'%3FO'YH
MW,XKZM7KA\]?S\__?.+$)<@%1+A^P WT_-"%73<2O3$8G5W_'#PK(%S"Z:29
M0)RYMES#R:?#H3PW0KPV1KS$NZA%>.C49R<EUNE=5OW%9SW/9[S838G6(\?6
M.0_7<SWB?/!"G@%4)''8[=TQT#W->J7)J*S?_=W?E<S;>X*52H/%U8O5R[T1
MSR76%7U3S$KASX7=-\_=W_WAXMU"YMWA 80#[[WC?R+)&YZD=H$7,NP6A $D
MB!!+ (X->8&N  YW(@N.'FO/A&$\B% D &[/6G[&>,$6N$,8N";@<@%9!)XG
MW 6@#+[7$3[=S=V4:'S39KSI32G70O[L*+[B@^WB%2/C R4> "00/3[L9\*X
MAA[SM(K!J5UHE%U5UBLK-*;$68P<_^* NC8\U!WHPZ_=B[IF.7RBZ%-\3C(B
MZ?'#Q<L\X96-S@>BZB=I-@X?BJB^SS$$ZWM.ZQ.#ZU?EZ\4^\VT.I3A08W**
M7^0A%R@(?'"$TO;,8>HH#G0@ERK(#DB?7WY@SU;'R2,BEV(?]MU ESAH/*#*
M]7W_]Z,$U<](W*'(Q:$N<CJE\2/GZ16_BA@_V*?E\6\]\B5?Y2A?+"Q_KE("
M[#6_^T^)".YH&$(B1G@![1U([>6!>=J^RT%=U.6>[J?][JU]U(AG2[)IV1YB
M=(!D7W!^6KH!#@""@ILC.NS$LN/&3C=Y#!LZ? @QHL2&Y.Q0:#)LHL:-$^/=
M<A,G5BPB/__<7&PB\)8=.'$R<GSYTIS%*5,HQ%$)TB7,G1-S43C"BZ?0H41A
MHCF*].B_I4R;.GT*-:K4J52K6KV*-:O6K5R[>OT*-JS8L63+;EV5%.FSHCS-
M^?QQBZW<N73KVKV+-Z_>B<-R[>(%.##@74=R;>2E4%XL6^;DN0DJ[\A"<S\8
M#CO"\* \<W&"(EXHDF$<P^;<7)-WS4WC6W'FWJ( &_:4'[CB/>3<>B_#;G$$
M,CER^N$U(CIU5[Q8?*^YPK8==G/3I'<3-SH,/^3&Q+KNS1;=4-?>D!O0[0U]
MCB>/WFA:I6;;NW\//[[\^?3KV[\O%>WZM>C=_HR;7H "#DA@@7K_Q1);@@HN
MR&"##CX(88022JC#$3_\H$,3M#7WD$>YZ<6;0$T )Q%EP>UUW!')Y?7#B0\]
M%]U/WTWD!GAYR731C!(=(0QYYD%F(('KL8=?D48>B6222B[)I%;ZI<4?>?[!
M%6255EZ)98 (_N3B=N:@)%F6M\5R@PZQ^:#B1.9,^* .;OIPX0\^N.DF;'8T
M)A$O;.ZI()UT^@!GG'$"ZF>=$L:!)T3FO$;!#3]P.=$U?#+H9Z!R^@E;$UTZ
M-ZF"9;XY*)VP_0"DF+H-B4:3JJ[*:JNNOLKJDTF]P&:A;]Z*Z8)N FAJK[[^
M"FPL;A*QJ7)@+N2K.5O*28&-P#X+;;32__Z**JS67HMMMMINVY2L:M65$"_#
MC$ONN,(,@^RTZJ[+;E%;,C%-@%_^E*ZI.";H;+OZ[LMOOQ%5RVW  @],<,%A
M63)D-7;%@JB_#C_<[Y9'Q)O>ES>$F2R"T\&6+\0>?PQR@0 ;3'+))I^L+28)
MYY5+$[%P&'+,,@^(H ZE2ME$A?6*J6R.',\,=-!"%S4RRD8?C732\ZF\GL+D
MQ4..+;#%,G355K^$X \KZO:ESK_VO'&S5X]-=M!%*XUVVFJO/17"35?LDPZX
ME$WWU5N6>40LQ=[U)9H[9PFV26+737CA['83R]EL+\YXXR8SG9;34EIDD^&6
M7]T-$;? 3%??&/\;&(\=O#84^,^7GXXZEL,0H;CCKK\.^ZN9K-Q?W*.GCCO(
MK/'=A-]5AG[[9AH+WG'NQA]?%R]'M!Y[\\X_;]\HM$MI._+6/WN+F14>P7WW
MW>OPX5SQY/QY@< K.KR9Q5_/?OL;,0]]_/+/_Y7T;]=.@0[!N\\_S;#I("A!
M$2H[N2B@ 0^(P 0>\!9$\%J0SC>F'*FO?Q2LX$/@1[\,:G"#3K%?Y.!& 2I9
M<(2J.P+GV-*U\A$(@@[IV13<X(,;K(^$-$0=!CF(PQP^SX-)D9R7S+._&@IQ
M+\/XP=_D,B\5#HB%I$.0=^8TPR%*L6PWU*$5K[BX2@Q)'" 4X12_*!3_<W2C
M&]/@A2VXEXM$W>A8OQ,=^@1"'1F"<8Z$JR(6[XA'HVEQ/4@@@A__Z,< "G*0
MA!Q4_H)(QT0V)&M;,Q:]VAB\GGEG@HJLY-#LF,=,:E)@>TP+%^DBNA-:<I0:
M8:2 DGC$ #&1(9*DSN!("<N/87*3M*SEJSJ9E$_2I1MIBJ4O(5*SFWF)C0]T
M8P2]8[I?*G-?L[2E,Y^9)%PB19=V651.E@G+8)Z2F* SR!B_V8UK=(=XV"SG
MNIH)S72J<S[2/ HUMU,]<TXQ:\+D&C?-9P<-X:D;.<L?,E\ISX#Z"IWK+*A!
MQ]).-+Q3.7&;FT"%2,]M/K*8.1L-+N+@LD;]_S.*#^UH@ AZT)"*-"N1V&+%
M&$4UCY*P9D1H@DM?"M.8RG2F-'4I$\RD1 &%CF$N:F4R50I4(0UII$0MJE@F
M85+TQ".>0:5@1#G2C<H@\9XK-$@<*,9*)Y*SJ5Q-#TB-"M:B(G4]"]5+//2D
MOZY^;#DA--,A\5*S1K[H!Z+<2=<8]*E<+8@<,$&)KOQT UVY 0XZ*MPU8OBH
M4<G5:MU@0@@#FS^.]BM[MJILI0J)V5#9JDP4^&I8/WO0L7HR0&A%I%K;-:\$
M>3&1V8N#'>)P ]-:[1INC8W6#,?+!4F67]Q C'=^"USOM'0[TS@";#P+VN2F
M4[2Y)&T(97O:Z$IWNO]/4YZ D*O<[-:2N=-TKN:H"][PBO<NL2#1@+"KW?3F
M,:%EU8N>OCO>^,IWOI1S@S"Z88ZZ?G2HZNWO2!,J! K<B3S#>.Y\#XS@Z6:O
M6?H]+W_]"^&")A0)!<&O.2Z,X0QK>,,<UG!I.]S@S6AX(^3HL(4[C.(4J[C#
M+XG'BB]\XA?'6,7DF/&+;SS&&XM1QSOFL8]_#.0@8[AS0BZRD8^L8QNG6,D=
MKC&27QR3)Z]X+D,&EN!BH<8JH3?"7*9?0G61"\&(><R!B84/!!+FOU#@%L+R
MRR[>#.<X_R4P">%K1"AS@]YDJ#H34=XMQIR+U\9AT(0NM*%AF[]''7K1BZ;_
M@ULQ2H%4+K)&O(@S+V08F%S$XL]D!G0LPMQI,<>A,(.1LZGG+)A<"*ZE, 7@
M2X]@AU#GXA:<#G6F[9 +X^J .J.ND.AL(9)@"WO8Q"ZVL3?-&H(<P23@.[:S
MG6T+P0&4*,^A@.8Z?>IL:WO;V;:UM[\-;C%K&M3?SH4MR.UM-@>&V[O(Q:,X
MVRC(W@"R.@@L$0"#D+TUY#5PB%'^_FVABSR[V+T)B9GL -58@(07>.*%#A0N
M$$E;:<&Y"/%^U]/EC#N3O411'@6PW! ==$,\6>:('0:L*()D+0XZV(5$5"UQ
MGCSJ!W2X!3>(9=<F%-!,#(NT1G@1AV+IP,[HR47#_WRD&KR4A@(^R*=$KH&+
ME8RFY##IQBU8@FMN1"2J+_N(UN<RC1K)@W*[E4BUXQ!SC[:((1C9#!V<90XZ
MV&(CKXGVIB&"&)["A!RNW?0P#CZ105-='KMXN$G<D'8#W>)1%<_2EC4.>=AQ
M?"@>!SE#C$ARHJ3FZ*Q4>0A9[G*'W*()#,?+S&O.2CBDE"]MEX?#/]Z;5'Y$
MTD,/D-$'7Q>$)#Z,)FEZ$X02C][&PJ5I7)1+8W%?H7"]B6@?RG-&1_:YG'WW
M EV[/-H>]XZ1PPVKATC=N1\\7M#A- ;!_69:)@_$W:*( HZ(2LQ?^%C (>+
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ML-(LR2G=+]>,RU4<)(G#S2,MU%:1MO_L ^/,Q81<T-'"&<P\Q3]%_VTF ;I
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MV%M!;KT1MK#A08BL8ZL1W"!5RS3B7.B:5YWB0G.,=Z'E6]ZE76XY-]ZVS4F
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M.%'WA+"QH9%WKF-E@"]ZHR^3?= .2FB9)#\K5%=1J5QBJXL%(A &F>D%V-P
M6WA1 S3%QI@/WH@4*8!-(0CY8J=PSR:, 1R1O0"1MI^+VB",Q"W2$(!-=&^O
MMY \.2%QUO#YBLB>,8I-GO^.N'GNHS]\Q%>3I%>.I9^8IO>II^\-VDGTI5 M
MAI<'75]-P!"0!B$"!R&0C&>*C>]X.)$#C YYJ"!Y)TF>JG#2@="6IC2>:]B?
M:9,';H"2V"#6T[,%.C@4<R 'JY!'';#UUUP$$6L"OF^,Y.<,$^=OCI8#5*2
MK<Z #?]P@!P8?.,H?!Y/?.[O_NM8_*%H?(EY_):*3>-I@EL ?GM?_V[@A=BL
M>%?%^.W<>.PWCD. S0\ &3O0IH%5]64/'H X(G"@P!\Z*% XTDT>PX8.'T)T
M>"L6A5CRKMUHDNM(PF$,K[E)&(O.C5OR>.FP0\=<Q)8NY>G8D&%FAEXO;^+,
MJ1-G$YHS=P*5YS-#T*(,R2'4P<LH0W.Y*.@PR73G,#1HAJ+YIW4KUZY>OX(-
M*W8LV;)FSZ)-JW8MV[9NW\*-*W<NW;IV[^+-JW6?U;Y6S>S9T^@98<+.5B%.
MC!@5X\:,1W6*+#ER)4J6+U.:A&;+%A0S4?BE,G0T3=!]19/_'FW:ZA4.KEUW
M\"!;M@D4**CX[:)B]VX75'X/19V:-,+BPT<CC,42J#DZ':?*NX4P%_2=R>2$
M6+ @!"]>;JXQ'/8CSO*7YJ1';6KG!@4W"^5Q,ZBP.L-;=F()=',+/*_G%T-:
MU$TN=#0QWBTKT0?3 A_(T6 V"4(X54\^1?C0$Q\LX(0<%;IDSA0)O6>44U#A
MPF%$5:'!VVY9Z=6BBR_"&*.,,])8HXTWXD@C/W[QV*.//P(9I(]DE.$7&9PA
M><5O2\:PVQ9^76';";/-]IIK,?BEPG$^J9#EEJ7Y](*)U9D3!P5->#0510G9
M<4N(8\IC#A$Z_$#!#3?HD*>>/QS1_P03! %:4'$4^&#0G@8E-1]]]@G("S<,
MQ=/?$6F"5%$W<>AP@QM-5(0@?3IPU$030GPYTP:#,E!J!J<2D2:<\C2A70B+
M+ *G=!1(]2I#W0QSD [@Z1HABCWF6*RQQR*;K+++,MNLL:- &RVTBBGFC#37
M8GMM..5PVVTYY\P3KKCAWK./N>>:ZRQ<TH3FDQ3!%E7FF:Y6Z!01P$+82YCF
M#//=J^9PJFAU$U44IQM,Q!)PFMR$]$,LFX)W2TJ>5G<0$0SI6ZJ8#66L:@9O
MCLDI!3_H.A2'PQR1"SGP!HLB5NK"'+/,,]-<L\TWXYSS5NR>YB[+0'43$@74
MZ7I+'/F&*?]/O_B:: Y' D,W$:ANT/G#,)(N#&!#YG0#7B[D)9CGQ6/RTD0\
M0PT*59Z%_M"VVV[[H&?:<QM'X9@F)]A-$TO]#*_+/K&HL^"#$UZXX8<CGOB+
M//.X2M] D6-'0M- 1\XT=O 9Z$ ZN)%@-CZ)<!$<3'/HM ]03V7?+3\0X08O
M"_7'1-84Q'%P' M)K%)YT.E Q-@FEDW.4"";."%-<.)='3=-V)&+\\]#G\LU
MQ#\>U-\T!:ZX]MMSW[WWWX,_(^-H")?!N]6WQ.LNL=3Y ]],W4JW_'CJ6;_]
M]]^)T ?[AR"'.=Z1KEY, %&""!8@'6CD:;.+A1WZ)#V*Z"YL%/C_'8>$,:GA
M!6L*R>/0A3"T /F!,(0B1,@/J*>3$>F@1"VSBHJZ%+X7PC"&,IPA#0LWOO*=
M#WWF2-C[.'0K%<++:72:QC5RX:\$#2,.<'"3K>Q@)H0<82E88PC#DA*W0]VO
M?B,3AE$$1 <WQ,*$0+%@=U;7'C%": K9F56MQG2K7 4+8+U#XTV<@B<@OHH7
M/ZHA'_OHQS\",I!P*8>7:+*AZI&CA,&26'I8-I1AW.*(3#F/>Q*T"Q!F,4^#
MFA050W*[7#0A@/":AAN(9A0R#N51NII"^TIFMSA:C([F>8H/\+@3(E[#'/'@
MQO3BT;5N^/(:PR#']6:2/4$B,YG*7"8S_Q-'R+YHR9#H&YGF"O(#-^!"EB]Y
MX\]$X)-=X$*21;D&'"@7(7.@LQO"@-A-=J&P3I[).W#0YIB^1L^'H-(GJGR5
M!E_)H0W^ZR"H8\Y3B #'$XHR(MW@E55>ULR'0C2B$IVHC9[)HRR,,*,:W2A[
M$(*FJ"'$EJ\:@4]LD*DLTB]3-T#C,&[ MBO:;Z O@>#NE/:#W9FC@1.D5$A
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M+7+FI)Z>**4-;=5:;7[]R,U67;$Z;==Z[=>"+7!I&PC""]!>[=FB;5CU!1F
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M'M]Q'?>-.=@"0IRIKN@1WAY=&QOR(:^%(%@%'+LMTO+Q3>3Q!   ,.CP$DR
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M#V& @0=JS7(Z2]W("CD#"-@I="6&AK*P(EQ'\,%!=A];K?PY< #2DNL@X'S
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M27T=45A7@ =TQ0(#R)11],:7UT" *_]85PY=1" -7?\FFK5S40$6<H 'K&,
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M%%"5-"SD1QX60]6.@C'@H:OD!H[;39[@.56V4BZ#%*XE)7S<QIG I%[J/-;
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M__FRS&TAAQMT1%XT5TC-Z66M@]^[J5S$E\Z7GJZ=58;GF.IYG'SV<N5(8HO
MYJ(NW9C"HAN=VM"@=X7,;7/ 6$)')HJJTG+&=*XS+=GRIA'&C03U.676D#"3
M:Q>YP$6RE;UL7-Q"T8"J2PN;< MF5QL7N6#TJG$R3XNL1SSA@_77VD,!7DQ:
M4[>>LJ[535M-=XW3$_PU'XE(R<T*65_$IB.YXN &0*MD%V[0C*GIT@TZ- $.
MM^AW2IZ6;6W;A!=,^ $'.SAQBG?P!SXXM.V6YH-8 ^S-HT(WU=8]<MFV6W$&
M]G5^XT+OW@(L'NA[(KFL@Y-8W,(DI]YW+,AKCEQ,H?_A=)E&L_QC$]" >ZV2
MGE?(64=RIL_5Y+1[MZ=IBCX=Q.$65[>%+78R=(V]'+ Z%7-$:G[S@>><O-TX
MPC5^?F2AGST.&=?XT9MFBS8)G%Q*QU[3]2[5IX,/Y>*\+5#+I .&BPK?8=_4
MR^-@D[';G2WE ?AINT$$M:^=+4&/@\X]E/FDVE-FUSC)+6)1<#<$.$9XO^'>
M58_0OC_PMH"WZC0B;H?*^ZOV&N-=S.DE##>*W>:.7POD-8^0>,!!6Y9G>^;A
M"29ZQYUOE#/'->R0]DJA'HRKQSXW6\]I\L5[C=>(0_/K?3.OYSM?YN#%$>SP
MWL;C//('$<:(O(]\@F!^^ ;_&081;%'K!7M^<>BGOCZQONPCP%;:OK][F?FK
M(O 3OY:[MUE#/,9)/V;)A6N@ SH@ N!3B_(X@K?CA5C(")TS-_H+BJ"C@UB8
MB\3X"&X8P1CSO\?I!K([/4LKP!K,(2S3K;!10"%B0(EPP/.#.4)CG%T(P6'(
MBX!SOUC DUS8#($@P;H8MXY:$W[C/_TQ)MOI!B:XO0W9!1JTP2],(!S<,QTL
MK!Z,B!_4%+AX$S>)DP[AN1_ !81HO[)[/X, D^-[0K6P/X2Y!H+B!@BZPIOQ
MMN\@AUM8O!B),#!4Q!OD->/"G3(,/Q^TMTTI.(&R1($Z H;H$%X@ GB:P[80
M/GBJ_X@JS$..V,.("+1)I)Q U!CTZ:B(@\58K)$F&,1:M$7PB+-T6\1=[!XQ
M_+1[V<'E8A,W,$+Q0,,>BPS&^[TDE+S>*T6<.$5)<@-2?!Q6M!BUN8\UU$:2
M4!/X\4;X:1,Q\4)>),?"\46:RI!@?*$/T0$1@Y:'**\3O(E/?#RSLXDL5,5G
MK+^V\Q FI,:\L<: (8=I&(9I,$B#]"7UPXR*B(6"/,B'A,B(E$@\&<=RM$BL
M.4=ANA1\";ST:;2BF\=EI,/[VQ=>: )]O(EHE(B\B,!J?$&TZ89AD,F9I,EA
M<(/U^X^*O,B=1)Q&1*V-5,<5BAPT<X,IN+JC1,JC;(+IT__ M.! @$O*J+2#
M'RB\)P0_.^ ZB>B??QR;@'R>H(,[N]!)GB3+D,E(O4K'RU(,\?.0+8R(/:F7
MJFPBN=R07(B%N\3+O,1+;&G*H)BG(]#+P+S+6Z!+Y.,%0:NXQ.R@)F!+M,&8
MYZN@\A#"NAC+LK3,=_')R0)*M?3(G "3BG!+@M@%%ZF)FYB3)KA)KFRB.)@"
M&=2HO@2*;E"T5$')MIBG;<1--[F!W>3-WMS-W 3.EURP)@C+NZC,RT3.1CE+
M[4K+#%.,7>B&Z)3.Z:1.,.$%<K! 8IQ.7)BV/8F%.- 3ZIS.WR.'\L .\93.
M:XBF:<#.)H!.] Q/U901&H&V@9O_S<*L33L,#9-8D?[TS_\$T  5T!7)!34I
MJ?V)AUM@@JS,25Q+S@=EE^4,I<UTSKVXA6N0R(CT"">;N#49/=:B.)IPR(>4
M"1"U./3 4(@LT*6B.!^X@?> 2.DC"=BD%/JDT9R0357+3[8@)B'JAG#L.)SI
M!E[(!=&+@P[$MA@Y3@AE4MG)S,MJSH[$()RPEYSJAEC A;M$B%MHPTR* Q.B
M""'<RH-(M.9#'7JAGQO%B1RES1U-BQ[UH1\5SM,)L^^@E"5MTCQ%D%&0D&K
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MR?.Q9Q)0G#!W@[1J;AK"T.G!W I7I\!OD<>SD5WT@9A\((8==LF'7?JQCK^
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M;P#Z'S[5F,,P '(3(#52F]01<<DNO!W;(4>O&X<.N#7_][__[PI W!(XD.!
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MN[FG7.CP68<F>/9IFB: )D)HP6FOW?;;UR*\*\-)[STPX!J7!UI@  #&'FH
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M"E1TZ5,C_.QG(X6E0[[DXFY_B44NII%4VCQA+%!@#6G_#BD><U1LD1ZIZ:H
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M;$B2%)A6V(A6 (")_ =9")@'^ <+  !90$B!6<B'2,F5A(B(/$F'L(!_2$D
MB,F >4B':,F X4F'$,B;=,F(T$@R+,(CC$*^T(=\H(56N(!66 =]D$J(@,HG
M3$**T =:@( #,  )D 7_=N!*BNB'JKS*5JB%?%!+B$#"BO#*KOS*K0P)O%Q"
MA[#+CN@'=I@%5K@ 5X!+N0Q+=I %#+B 5U"'O S+O=2'C_#*P_P'RJS+(\3,
MO3S,R*S,N0S,P72%=(C+BHA,R?0(K_S*C/#+B+A,S7Q,C$A-)\R(J%Q+TYP(
MUI0(L,S-A^#-AZ!+B?!-AP#.TLS,D_!(A #)8J0+G(P(H:1$FRR @/%)AVA.
MBAC)@)E)FJ3.A#S)EGS)[(1) $#*?[A(AY!.B'#**^P'@:%.RW2%DI1(=6A-
MZ8Q/ '@ FWR("! 8S]1-"+#/\"1([ 30@.%*=:C/^ P [8R(?)   JV TWP(
M_UH8 ($9@ A]B'4(@( ) )[4A_\DT ?(!X] T ?]!W5  (&I!8U@!P<%T%:H
M3'4P  )]!;7$  (5& FXT(OHAQ8%@ J@B!Y%@,-4!^61 (I T1L%@ N02OA,
MTE>8"';83Q=5RXN\T0-8!XX RAN=3XIHTH!Q!8F@!0T-F OH4H$) %K(B'P8
M4P)-4]Q4G@.@B I(4@! @ B-48%9T(>8!>4I '7HAPO T8A@!R0%  /(SW^@
M!8$Q -WLT0'@4H@HU #048=8AT)=TN/DQW;T1V]D3I5<RH>\2/=\B =82>N,
M"%G04^GTR83DSJ!TB(2\R)E<59TTR(E03RG4!W90!_\^%9@(<(A\^%"5E(!7
M: 4(H-" D0"I7 >!/ !G?=8#P( HS(=U4(<#4)[^A(A90%9#?041S0<,0- !
MB$)VP,X!0 !T3==T/0!E'4YN#8 '>(6MG(4($ "!P<_>E-%%C0!7F 57@  2
MS5$)Y=: P5*(R- -[5!A+0!U/0 2%0 1W0@$-0!U;=@'F,D335&,T(<!-0!^
M%<QC51X,&-2&/( *>(59P( 'L%>!>=*'L-$-E0"9E=D(*%7E<=G8G-/I!%*!
M$5*)R >2),^'*%0$F%F9A0 $X-8#6$@O#0"*7==KK5"((-0S-4N4984'(%CR
MK%(!@ "CK=FH#9A90,D*K5C_ARW2B:@%-@T8-XT(!$6 UH190X74BUC319U9
ML&53@8V( 04 ")@(G06  8B KWT ?06   !3$PW;!>V'5V#3 C#8?P#:@#$
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MJ[+:6S^TS$(+GOJP\XH%%LR23WV"ZI,.!A7_N++.KB>M ^MIT_6C#@0&%%#
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M"CW!4C$7S>M! %6!9J:SI((=+&$+:UB2GO0@2VSB$Z-2*&K)8FXSJ06EVC6
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(WC*7Y1(0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>exhibit10firstamendto_image8.gif
<TEXT>
begin 644 exhibit10firstamendto_image8.gif
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M=FI  D4  %<V:EH6QZ9[9Z9[ K2)DBX:;$P0E@ Y;T6@R.1LSNZ)O@T*HW6
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M-',63'.6D%RM3V$#"\B0"WL +9@PB-%)GIR0;2F2'*""FGPMC 0; "C(* "
M&!A(*P  %"A((VC*@61*IQS(-[@ %("#'W  ,[@#K92 .:C(LC3+LYQ(+"B
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M"I8858%2@VS2E,7%)^%2002((F&9*8V?=*S2;[@?$)F@/8$>J&",STA<T/B
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M%C-*%YO,Q%)*TN#<XRJO#>-P% ! #+ Q *# #;>Q!,S!'+MQ#F-! 2P  .C
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MES<1"_<-"[<5O#$B4W-[5_,-OW<;^S$T _=\@[)A8W>O:K=Y][=_^[=UZ[>
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M_&-X_:3_N6>8.-O#>FZX;0'$5,_WN5Q]^2D!Q\J'AME?&6"FN*<3N5L8QQ%
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M,27_3H\5'Y'6MJP38S'F.M'V(E$/=2X7>7 7L88;P7 +TPL8$Z49@6O(8+$
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M0$A;@D@KYZIX,D25-$N=]!)KYQ;'L]J@DQ?!D3/',45-!$^7[!BY]%R\5-+
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MJ> !R* .OCW<I[T.U& "R+W-DT#=P;T.A&#5U1T 4'W<ZR )VET(VOW&J0
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M?/_=$0K6KCC6T@QHH2P?ULR2VCVOY%W@J3QT GQ$C%3 "BN]_,JVU$M, >O
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M(MM/D^!VSFD3;DM$^K[JZ:?6B+*5(->>->BLGRH#8JG+^I0(0Z$V,JX@WMQ
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J2R1-4B55"B-M4B=]4BB-4BF=4BJM4BN]4BS-4BW=4B[M4B_]4N@*"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>exhibit10firstamendto_image9.gif
<TEXT>
begin 644 exhibit10firstamendto_image9.gif
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MRUK64I:SQ!NM\B[KC<TRULQHP(6/6-=5$2M"7B+PM!;DA3*BN4R\DF24""!
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M[&$6+I 6+Y@' @(G&Q&<#.5&H#B<%B@3K]D2/N&QTPTO&C*6"\"18RF"^5O
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MQ>8# U:L.C )Z8U0^T<E2VW45>?<@*X=@YHNU[4CP4)2%16!!(D5!0  "%"
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M<MI3+8XCV\4$_1CA-.UP,<9,XO!1;@.QRWI# PT.C'\H*F7M*G<[;K17;F'
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M_U0))!;$]8U1P*"!&UG7 RF=(>J7!*D=I.@%1\31RVB($OB4F+0$TGC=1;3
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M(1A"HBSK;[J"%YW$7.J"79::*S"D@FR)*W@!7=J(XL'43%W.!D948GP@!D:
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MRC91PWOM,SE?H>;Q%!*C6&7Z:7,_0?@%S/I<87<H-;-<-\G38!'V.\J =XX
M0'(4P6-,@9Z&],H./2"CR_=TYL&X1KQL&>TUG@:0#]!>(24JP4G"S*BX"BCV
MC)'(!@C,:E8=6O1@;9G$7*>4_2*"N'?( )N$>(RL_8?'T<P 2QPM34W84+=*
MJ[?NB<.E<^%N.VJDX&3]9IH6 0(\AI=\TY?!%]T)!AO)R),SN3F;<]0R;G[Y
M_V)V'80,*(&/H$$RRD#(_00H5P#6L800E(+IGWXI3 (&Q #JGSXYY%X)*(M
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M 0X1K58+V88$LL"76ND"#0ZBP';_,#(%)#BK95+<38E X+G/80-<^D$" !#
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ML,#JG)$'#50()%^@S &!W&5VR4K<;#$+@OYYV0+@\0!W#%CPD0AQP\ @8$Q
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MM$2\?&X'H@X'6A8"<* "_S#@+&Q"6<EOT"J*0?UF"^*2AR*@OK[(%!@A==Y
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MUB.*G*6$."D@*3X=&"0\)) *%J.J_]U/<8[AA&V:VOF;(S" )=+"(UQ*RQ#
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M;=.%Q LQB=NVW=/E!>K-;1F-WD,CP022DP5)JLSX1J4N)@E!9"%)+1K+9<6
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M02=&, $%?-2:UF1!+G&S"4TNPJ8V >,-7AB=9T 0HA*"@ ,:V&%!O(" #E(
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MM)S-J4]Q%6N=[I2TN$1DJA9H2V$+@]8PF8,#)D2&7 0EJ*I,70& ,F#5+L9
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M7-5"\ <R+&ORP@,'6[#<<0-"\$WE@5#[$C+W,QX<G*]"4+?#E<$>'&AI:8)
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MV6);"1/;[>;].Z;J#<[_ LJU:P A 82%Y-J[@V#(]^.\>7S5[V;/OO<R8KJ
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MD)D(:8*K:MBQU+@M8+B_AQ 6PG(0/&DE)J1+%PJ<>VE \HD0Q1 ]P$@Q(JJ
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M+<14@M@BIPX!G!QY/YAA/[04B!S! KL@#=)(4?):"DV@J0N8BD.,  B,SL)
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MW,;MD[LAG\RC6AT.*0/BACR3ET23,:L)V/5BF0C6F0"!ML2F=%*(:NV./&I
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M+#C$<LRIE $,8-C$& >)B+@R]JT;$.$"7 ')R"YP@X+@8$I^VPS=IM".(C"
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M4# I#N LB1SZBP'I!$W@  2XW7#D0-RAUYRP20]TEW?)#!=JX4,4D=/,#+8
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MCU 2#X()N)MOLP MO%"B[@J(2(<(ICJ)/I-0DN\"'70 ,+L0:TNPO)0$L@"
M"&0H8KGL)&  @ (@*@"!J1!0R:2!"N")( T$"L$#GPK"R:>JJAJHI:0._Y+
MIX9DD&%*@2(2JB 08%KH(9:ZS#*T@2+X<3X,&"@S1BU3?'%''0EB  0CL(2(
M( ]NRA*GFL94:2&6"A34):*0JU,)(UIR,J=""2J"B2F8,()2(R:E%(0BIC!(
M3#_-C$G+@U@B<B":0-CT*8+$/%52)ER-%-97F1"+5EF5D-75*71EHCN"3)+2
M5U!+]12AFF@*=LDI"WP)(F$1.O8A/J45E4B7A#UVVFP/RNK%A/"4R4UGI?56
M6Z1@.FK*((W2$MUA#9J1H8)H_/0X!SD*KK(NJ+M@B2,Z\@N']\H+KHHJ[KK!
MA]%\4+):8PTJ2B9K8?*T72X+-"JII+:$Z5>.)_\" .208S+.PZE\G"I'E&/\
M;((>>3P@HA]30BD"6FV^^69=WC)&&66688<=9<[SZX8<&,L+Z<$&R^LR'7!8
M(K6GH18JQI0^X\XC#&)[;K/5,/NONG\M@@\')B( @#*FESZ:Z1YB5$@^[!:(
M"+RF,*B[J?\\XPSO "L0;;7._L8 @KR1Z^BBNX*C[+SI?"#B,;QN$*F\)#R:
MC;G)9ONLA?#J*P]LL"_O",$B:(0   26 SL\L$'/[:++K;N@))$ %R^EJC/L
M:'(<?- L;_DDRGWE"V+$;,38X;L09 00."#DE$V6GN.2-S2IJZRR7RM/4H4L
M("=NE4W(R!NWQ';*KN3_9/))4$$(P8GX11!AACW7XHF#XWR8S[0D,$AB"<3Q
M#((\0L E'% R5XF(R81RIS[MQ"5/6DNC6I*J9V5K8E-JT@3+U<$L;0E4$=E)
MIP1E&J?HA%P@4,+#R(5"]+$J5[J2X:YL%JD9Z@I+0.+2M%I8E(=%I$59@2"<
M/%C$:;6+3\<2E[8TT*EA9<EBX+J@KS@RN1O<QTWARLI#,)"1F.BP(#)0R;$D
M.*6)E9%9$C"2]YJE*@R8K  YBI:([J.UC@C'=Y9Q#,)\ ($;!(<W",.!$"#W
M&.#8(#$;T>%07 *":$U1+1F!B%".Q8"N9(QJ *@>'#EILAZ!+(XYNM#RSI8C
M_^?AQSXHF@ &EE"Z ])H-1.Y3\UPY@I;NH(1N,SE+7'62R\$1RQMZ9G/?B87
M1@!,,4=36@\DTA'BQ 9L6KM:UV3IH*B1!P(ML"+R''0#(DR.:$7+2QPQE\W1
M<&=Y"RC<U:"CF=#Q;3NJD8CID+.1"K2(/IB#C;TX,Y[5O&XV!^S(%JP3-?C,
MYR,7F5 _T=FBS4@(;%P#SW%*<#B.Z+,B78,=V"SBSHI^Q#JK"0^$Q),<U?C.
M.A.-48QPX#2:!3&>IJ,G@H"XHJM=IJ;N!, !, #*Z/VT>2 K)5!#&;V8Q=$D
M^0F8*[I ,Y- X  ;$@@30)(E+$7%7'V2UD\P H*IK/\)#:@J2%9FY9$D)*$U
MK.R">K90F0-^QCE%6$(2BF YU;3 !Q<H*I#,I*V<_"1+>O) %)+$1/M1J8P^
MN<E5*G:4AI#06V4\3E( P!7PA6^L0>R.[R:#(0)]*U0OBA:==,6%&\KP9F+M
MUK<&U47TT<M#(HS/1J!&HH> $(X_*E:Y',G;#K(Q74OT%5*4& $Q-00#7F!A
M&[48@;SF *4C*9- D*.E66+DC0K\RB.OER4=)41\UDKC6A9H(W,=QP*6C.->
M+W2]DT M,G9I*W40QH,=(&PV ,/!1(55I@QU!T,%ZJ)*@.6\.+ILO0@@JBBK
MACJ6=J$*R*&1U28L(-,(Z*+_]EE""XI[G*9T1J8RI>HKB^!+$Y_8"XQ0,2-2
M')S;L!C%-V-$6WBFC+>,8QE,5=K7.&*1S;W3.B785VY<@P.1)"ROOL/+79#6
M9+SL@)G3-(U"[\:YZX1NFISACH""F"#1W*UP%Y[R[&KC-<2=$W/;42A\SOD_
MD*+&7@\B$7&NMCK1X2#-F\&<.U>4H+!)QUZ86Y"0>T?H'O>Q,II)T3-78V0R
M7X 'KKG;=YK#YZ3FYV-/U=U0HU<>M.4(U"&#GN9PM\#U26"5)4!@YSABN2*
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M:H[O H[ (CY#\SQB"4Q *RR$,9O#!/(M(>\L/Z5FOYJ2SQ+TXB:"8[+H;UH
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M@!-DHKKU;/<->.=Q![I@$>0Q1?5.""!@WX)C!U@ .L8X[VK[@.9VQA@!09+
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M5B(;B/]F-*-)+29+10O,IR"P+&;9Q0*+2N!35(.RN>Q)*04H %TV @&(0:
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M:B2I+(M#7(@1)UD$?)D*X(NB982/N(6,BL1;W=HQTYGNHQW*<%IVTC*](K0
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M%Q>13[9W7974%XY5;"YSK;1<#:GX:P;K&I2PG&X'%;BIN5(6:XUV<O]8A@D
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MJF@1@MN\\3&?&8(>S?E):I0_F?G_,IEI.I#P@0BX@!LX,BI1&=P$B9$A4,C
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MYF&.9V*09WCV\IMCYR^_N>3HHA"8.BJ8E$N"L<3B'R,M032- ,PRDY"M#%<
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MID"0P,*2P#*9'.N8$8"EB[ILB'L^>!,0L\F[F[&-5+K"8E[ZPJ#<7-%52;'
M%L:B3O^Q2"5J37LG53#Q-*?!DYYC,4LWMN 6 "R 2DF@D@RH)%!YY:HAH&(;
M7%*"4%=ERB@<@%L(3*"OVP!&H:#ZR??@4@  < M@H:$D)8DA2@XT:X^*">0@
MC2 #9\D@D *I5F*V):QE .-PD?1/:H*U.2!]A@F"NR(&>H"#$E&)J"**'0YX
M<#O@Q*E.-^CA#GK@ R$0(7B_M)##=AF>?DT(0S',2&(0H$;&S 4E1C&1%RCH
MA=\MH47*,-P2@H($T>3("Y"IVT6*$#B@M'25,W1?A<XD/.UX;QG&( _W8+2%
M%M5H13<BH"ZVL 3"7L<D)K'22?+FO0NT8*FW4RIP>, ]"?[_SE\3,PP(O'",
M8PA3AA2*$$@TED+ 4LRUM>507SH##+M* &^Y611RD-@B_N&&B O!S1I_]DU3
MU<J+!U+H&EL%J\ E-[D7+2B2?L:V_&AF):D5S;<^*D<ZF@9=:/C(O00YR,0\
MM)#W>N@?_0@W#J"A<;J8P0R:,)_>XBLQ(&&0?T3SAC=, 0NE] *Z0%K'T^1T
M&\N80F^GH $CF$"S#.&OO8ZD$*%8 )87XIAU0("$CCPNA+-D4RPW@I%:6J=F
M_&*",<&# 2^,J\;+B"7'"G(FB4%H??,#T_H.4I(I9 D8*[ZL2P:B!)UU:&1.
MKJ42))=<*/H$  40JTH P!,RJDI)_^0,6E JL(5,.&464%&G.Z/&M'HV;9Y5
M0?,]:;$('LR*5M?EL+R.BYN4]"TH=^[FS?P\75?UV<\L.8F=@=(9PXF7P:<A
MABZ61;FW<4!:]D)I*?=8TE*:X F=T<6PWM".^R@HD'X,L()7TSC'30$O\HI7
M3RZ  =7YX (^V!,.4OD>SB('.7#J0J<B\$OA 5,[/)XM,<FD;'[EJ#$JN:)0
M$J.9#H53G*GU'G]5&VD0L*0 )O "%IZ@F&)P@QN,+C<63&"$=/P##1""H<&.
M[9TU)?NJ_GJBDZ3TV.&R:$<%K&L1='D\#!@) Q4V0J$M<($*M(""215M8B/.
M/<GR@".4PO^(9_!3%^O(((7M6_%K*SM8[FBUQ]IA4I:(=,)7JM0(7N "S+GP
M3^E^^:Y?9$B>H;V9S=PF7J&"[LZ##NLOYV8A*F%)&K-8W9_MV<HK88)'&YWJ
MTWBA"8@<I+0NIR 3-"%;SLHTYK[[AB$E3F!:1F-#%%.L10$)<OZ= K@@&; L
M 8RWGH'TMYXPA2QXP0@4R @P'#SU!8^&&HG#% B:X!)1UCQOBG$.%T/UXHTD
M+. ER3%XACUR-97)KT9 @HN%]^G_Q%)X%Y+85<5$,B=K7F(YLGQU)).8CH80
M 8KD#ZCO$:AYZ%X7$L!";Y<+M'T=Z%:C&CHWY8(!"BBD!4PIQU/_T,SFJ+@3
MGK&8IYO;2?U8S*)KL>#!3F:E0:&T9'![-KZS(X,SA#*70**ZE4$;VOY0H5_^
M.SD,2U0"K'8$2NK=^AP6($'S%$'6;5I\58YZ^9&]%%(TD<:  0FCM0.0>(YG
M;(/@+1C_M0,:"(0$#%ZW9)QGM,,Q<!L'7%A#R!H.1,=M? > %0LQ5 0)>0=F
M"$7(Z1B0%9NQ%0Q@T9!W- 0(0<Y%2)M*J%%O=4<ZM ,WW$>#7 ?<!8H3'L-'
M8  "> @7Z$10*$86$)@$4,#)= R]^1C)P,_*W6 ;)1&_#5<#\<_]6%N'$!1!
M709Y5% %<!8.+-:G@9"3F$>62"!>W);Q_[ <,/%8]FS>F:SAB6U(_ S$@JA$
M#F&&"1*%T<D%J!3?(VX8@="?ER'))*:-7! 4^Y'1%7&1KMA?0KQ1!+Q$X@Q+
M@B%.XXP+)1$+,+P!AE$.'T74VR3(@A02&YH I+4=:WA4U*6'9W24!:++X7P&
M,.94XJ#!76@&BRS#V+&'LM14!(+&/#!C8F#&ASQ8U1D!1/V1_WD@P.@"8R2$
M 4P&11E(7H1B\?&7R_F';$22FE2',/&+AA"$+I5>YQU;90T;Y0T9))F$_+R8
M@)B-L/4+U$620$I,:ZWAA]R/^?"?$P;*/4P!W&PA9WB&*#5$$SA!$TP;7/26
M%$7>AF&63[1 %__$0O3!V9IMWYDQ34N^6=-<Q51<!95HS9HM0MBX2JN0TZ5H
M"J%%F]&)BJ?<0 YP"JRD39)4QITEEP NA SHUF?\0VB$(TA%TF&<5)=8SK0D
M"+88("TJX!4AP2^B 1I (*-!HTZ!EWE)6D9$RPZR2-B!P!L$BA=(RRI.G>:D
M!GCI0D)LI-%%0$MUB>!<Q@SV2J;TUBR5(@-DR,%4A[TI3)G$T++MH,?H! :@
M 34X83O<0VC45V?.@S5Z9CQB 6MP6P%@P.,P@4X  $3H0C%PP63H CQP0S3<
M)C7$ADVH FL(S*]P%6Q=2.H]IOH,A.;-#TBX0G M%I#L2-OQCWFDDA?_;$'X
M^<3X_1RM7,9B&<J37-;&30S"I,D%*,%9SD<A;D?)2<@N.>9U"-/&O59784[D
M-2([QLJK*<2>W:=#L U1ALK\R0M0[*>H2,9"R%_D'=U/L$VPJ1%0".!#2.6P
M.)CCI-HES10P-($WDE1$J9NU>%TMOLW7#=*[O,%9?DC_#8OAW ,UH,$;+ ,#
M+F T,<_L@<!(G(QU1$N')*(>?1K".<1MTE1XH8L%Q@9H%&.$@@83G.)A=. ]
M;&#A&($&P!==6B6%CH87R-Y&AN(ZZIP$K$0J%40^^M(O2<<*1B9XL@G6M<^$
M;,$'%5=?^,YU),%HC1;V'$\)E$ 16,0*'B8H_][<1$6 2CG$8S@!&(!!" 0-
M%DU&"T0' [3 F#F%]%G?.BT-2VJ?I6Y?)F2-5E1"+-1"+/#/%@@4;@!4"95J
MV>2+0?;,1364S:V1SGG*1FE9DNC+2HB-!4S!,<Q#H-Q'VQW#L0P+,: !0J17
M+7[=I@&2 BZ('B4&\[D<>:EE"(+&'!4>D1H.NDSH,NB1$30!AF8$42# W^G=
M$^C"&^@",7A!B?[E@D $,7AF%B <JGF@K]*4:+1#CQXH#3Y2=62$2'3,$S@H
M?U'480C%FI#)QB@3,!7LALR2"@D9L858)\'C;C&?";!F4:1F-'4)$LP%>U!#
M-52#+F2!!'" RV6!+O_T A98AF#T31%@@9JL";I2PSP(#"T9I\%HGF46Y\'\
M2 ,YYP>%D&#(P,_E3NYLSQ(X7 45+5H5"4?<(,?5!1-L20CM!<>%"<0@(B'>
M$L?ES2CY9 0H08X\4%VT2M<>1<V5T175''-Y$U$T%%,VY?'QW/PU1M](5[W@
M38"MY;$<P[.B1M\ADK:$940)D@*6E$#H0B@Y!+?$AFA4J^$Y6)$J8VJ@JVH8
M&-L%3&<L ^^1ICW8PS(\!$L@0 (D0(2AZZ) F$-$*0B@032(1C%4A%\F1GTE
M#J-M0VY6:SL,J06&AJ0U!##\@Q%$P8?85?/HP@6*8[V"QF+T5H"F+69(FY;_
M,HE2%E1G=$FK8-8AJL_ \<O [D02!$D#&8,RK(<'Y4@27-#"50#P5%;F&HER
M,=UA2D #C!'RL>WP2< 6\$\,C-E63-]4K%GU72I5J)DZ.<4MA"H_+8#/ 0W9
ME!!JD8W>%$8)58E?R "M=!M9_0P";/ &]\P7W0]DQ"IGF$__T>MJ_*+B]!W8
M95JF=2A8BF5#4(!GY!0(ZH)GEFNDN9S>K@9<OLL3Y"SF,!*%45BU,.%9TC"0
M]$(LHD$O*+'FO$;K@E<DI9UIMD,69$%B[/"6Y,AIF"M?@@8Z6HH$R,"2H8W@
M2&*N2-NW@5MG_"7L[2 O6>TAGEC[#&=&Z%(+#=FO_S#:/(BF1;1(W_D$C2(!
M!2" ;1C<V83)P*"J9A1!30&#*O@'BP@%\JA;2*P/# T;+^%LD,V2S[;=%OC%
M0K0 ]92'DY"'[RQ!'CK)$BP6ZJR54O$+LZVF";V;8-%QFM1CUC[,7D@18/B$
M8%@ 1J $OB;/_1S=**4M)K[*J/B,2]S/JD &J:@?J@A:9+"*8#*(8DQ!NYQE
MCO3M:+3&JIG&+Z !1"D@CD[+LQ!2>UU.'*$KB:KP[.E"_Q$OJ*6H!'(Q3W5Q
MYH)4P(A&B49@,>JN!2*+@[&&X9$+D11++U1$ZWJ!(4_2J*DBNJ N725O[>;N
M[NZNX2P#9O3%%! I%[@<-?\TA((H!C%0::H=C@P\1@/@6=&Q2L[]Y-@P0;GV
M0C#T'4C<K0X3R1/E3?9 9A'\CI5(5G6DA(= R6-%CT%"UR@N'=T2(5$PD2%,
M125(1?]6PE5'A5?X;U5L3?^VTRPTA?>%Z@*$#0 @15+PS30SE* EE*GTA /K
M!9/0RV'\A6:5#6X(K?VYBA&82JP*&WN 1EZ>\%KNUK)VB)> !%S6RUQ*4BFE
MKFE>="^@)6^)9,XD=DKEK((P$FE4M'_I$7K!3:=Q*[MD 1J\:VHIXV<4=DJW
M S$(( A0@+T(+ =DP6E0@P &"VA0@7\AKVFD!V:&(A.DZX5LH2:MILZ=2J_(
MUL+_RO''P>>&A"%WW ]'F$U24^XRS$1%%$-.(T!J[8DJFPAR !!\^ #O^$ <
M!NAEY.A))(87] (2,,!W""3EU4S.A@F(48@O*B?Z?-'08<"L$!$1Y8X72,ET
M G(7S"GW!%/5]L?%_1@=BPD>0_?SV. NAYC]M(!P-%SO.&K16 GE]:A_RBVK
MR'3Q91>2/-?1+6C:K(V@?='+B42[4 '?X;!.M88OLL8$(LX&$BN.LK"]A("G
M?1 2X+@O7M*Y,.X'B5AJSR((8$%*9^NB*"(&S%6JD6NJ!1CN:C0V; ,V?+GC
M]IW>L2:J]?/B",NP7#8:Q :P$HD)3($)C#"7O':1VFYN_QH.1\^#D6G$C$6D
MRW%+;_F1$1@O<(]&>NR$!] &.SH$;MC?6P<<Y[48Y7T)$ZBR=3C)=4A7IFA/
MJKYOK4 U%T76F$G%C4C%5G-%6&?"55>"5D2%JVOUIK+ZIJ8ZJT--+61"(;2
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MZ")25[J X*,U_WI0^=K-7U[(O=:;/?D>]=(= -9G;V/RBUKLDP2__[RH A7
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M.I:!AG:T,SBO.HI:1KJ,SDYTB49X@V:B0:>@C06H/9G<+II 5\WP)E#$$(9
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M029H6>2P/KI"0W(MW; MVXCDKCY$#PVM"+ @4 [1?XY0,>TCU^Y3L9B@!;H
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M8^ /_C;&&+;@!HA2158$2T@+*?[K6?)4Q98C.-IAB;  HBP%T?)$:"!D0XQ
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MN?]-2I31+5UP"R7&8$0+D <!Q>%@7*O$0 N6L82G]!"&(,-CO/ZA"Q'IA G
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M91Q4Y1FA455*P!I;D%?&>CF),SOF$5;G5N?,4;D88AQ?89(%4 '6TP@9HC)
MLO&.4K($5S"0&9NM=Y%8NA4+* %H:H97?CA":H[.1!"T;NM4;.O=4T&Y#@P=
M4R?3Q'<-#! F3!218 3-,H0)E>F:8L)+.X@1)4YLI\L($A 2).A*"&R9+A <
M0( HPK'=,B3MC(#@N&S;LB<:-'"@.1($!2--FCPQTO,)_S"@P(H56U:LUYM>
MNM 8T:AQI D0)GJN1*#1H9<W3 L40 !B"@<,83&$E#FRII&6U(@MS=*V:4*X
M<#W&12C,KC!=>1$:F3+%2Q' &BV49%38BQ=E260 9MP8\%0FD3-J9,!  DD0
M%B(PB-!Y<V4)GV5$9@*Y9Q$CC*>NGNJX" @ORXPM+%R[L"YC+3#HKE AP@7=
M.' <;O?O9,N$Q)33A4N,.<+8"$/H;!+5X+*>SI?-K7A8%T2$%9&\>;.,HL1[
M]TZBR1C!YOOW2/P6_U=?8D)JS_4_Q\)1%[7\]D,H/^T0@BJC*3(:R:_#T'#P
MC2>6(6:*-Z9H9YN(MM%PPPPQQ/_P/(J6\2(C"N 32T&;,&AJ10R  7&B>_Y9
M1H(2!:*  @R@PL D7=[P @VAAA)2R+D0(FJ97A*D@$4,#DI(R&4 3,@X$)P4
MD*[EE",&(L]T<<4+&2S@0I=C_O+,/8(N&^FRJ6YRZK354&/-""7FA*RTTNR,
M3(D\>U*BSIY*0RU!$,9RSPM=O'#OS]08VT((2+O8@@=*MYB4TA8R!:Z%WB*
MX%/=+A"UA248<<453DI1=556(Q%BTTQY6&()'$2]H(@DDKB@@D\C"*N(SGCP
MP8<6?FM!5AYND%4X9I>@E(=:1?VT@@LP &")%D0%#(-=,2"MB+ *[:P"L7H#
M3C$,9.C_S *QPK+@W<XP\,P.5E?M8HDMZEM&B0B0 R8O@ ,.^%]@M(1+EP)<
M1(B) T>Z#J)MB$D3-@?;2>^>*S/6^,H"-^980.?^T25-"9AP":Z7(D,"B95*
M#"T"I\0][.7.-"J )826FZ(G"0[RXM__  PP+J5^_%<J([+0!1IHANS%P:54
M#'<D.1TF*366>UI3@BEZV="EH25,]#"RO6./F@]7$L@L!4T((80.O.AKBB>\
M,!DH8H 2>&^^ 3:FHI%X*L@("VRS+2]P7S.BPJT9*,#QK3CC#&:-/ MM*\H[
M(ZD(TOXL#= Y(W-M=, 64\68V<KVPC8O>-!45!\LQ=>5?]ZH_V^;O(KT^+F7
M]H+OO;&,@*@^79@ TN)V*ER21LQLNA$$([QP[D7FA-[]>J([WABYBM0L%"U=
MMNSNC>\N_(@C#5^$2!=LL/G(;N@OPD)I8HXLBJAHHCE20S3$DD!%C0"P*2:0
M@'DJTI$IW*@(\GD#48XT%)=H* N_HZ!-FD(!$_CG9QJB1O[TQY%H"(U0%*2
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M",S:@C'U]4YFZF<;WJ.@3&:B(+^4AQH6NP<R,^2<L%DOJF--".>FF1"Y05-
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M%J>  X!/ 2 L"][5'R,A@^"LKPC<+.:;82R7N:PX*!Q-\;\*E*5%?Z10 8Q
M$222*([T\DH)<DJ\(_*1^+J"8 $SE>$X#@PF^)J:Y?/"5#BP%)P=!K4@V((Q
M9)2?D;QM"FC@B0F>((&Z52E@=I&0<OXE##0(XR$0\<XR['%YO1AG(O.(47T
MBD^JE4[I@"F45\IGP!BIYSB]Q#Q9VVG1XA?_SHY73EZPX,(":/C$KK!U?7Y#
M4WPR@6QY<<46>H.!+C ,LA$J1L 6'F@P9NF"5K@!&R""2R,""(Q ">R!_PC4
M.[U"+R5P#?5BC Q4N93S0,;(B\-((X Y#$0S#-<QL&>1%< P+.,H"6*+P;B
M*AE4L8+1#[:2   HB"GR,2KJCNB@0;D0MXV9$(+[":^0MBGP#S>;J Z9MVU
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MX@-@M:FQ>!FI@-_X*Z4(  IO$T$?)N(\03F^ -S"W<12$SJ^>(W!.*Z="5%
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M3F#L:<I#1%&&C]B",YD<F'$7S2#&Z%@(9_8/'B""15 P8L: )/C@NV6"5P1
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M$LF2$@&S$ 5\/%A"4F1U2X%MT9%9XDRI,@0,+V)'-;\KPA(*EJ%QS$X76XC
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MF(D$T%%-&6"FK @&I(JVF$JDL5RUA!SKI%FR_([JM(9:R$]@X8;N'-9@#5;
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MP*RTYF8JLFL^R[!PV<LA"^GZ=F(-5B+;"FR;2@\D!5#Y0']RC/"0&CN,Q/]
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MVW=3\;3$5KKMJ'ON2H$^'9$A?#4:L3('GYKU*Y^2]$&P_TAQZ.H")KRJH*?
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M*RVDBW!A*R9*N(\7J,$$$ 0T2]33A3H?TA-)W@"+-\C!R1*%* -=L;_\)0*
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M$+.UJGZUA $6T!;'!W0 5OD0+@#@ '0S7'MS3F).<135JT*R2)?.!IW "9I
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M5E 8$39>6!I8C8%10Y4%TT4\XP3T5C0YYR%&E)U]7!$M("<0VS)HU$(%'&*
MG&JKN69$F7?7599C,C3Y84%!?TC1!2VY)*%QF3%X75::*HF3X50+9;:3774D
MLD.Z,H2J@#"]+"%--R5%^H"AUX24Z*(?J'D$#1IXA.?TR41YJ^8:5T*M/7(4
MU41A^3YR1W9+V=-&&CT=<T\7)#=0:"1Z+%6*P?HN05GJS7S48QF>!-QET^O:
MXXT45Y69^,M^BA+C _V=77#$,Y011W%1]%E]SA4?V4G*BYGG_[/A@O^;W 3
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MF!!'BX$#>33<PG#)1!\MDCQLF*3APPLX>'39(A "   +(D3 D!)#"X8M+E2
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M""EV=COBZ]_['M@(@[[,%GC5KQT"CC0(U4AZ,9"$N&II>YR%DA<JP!@FK,3
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M!")X'?D+/OZ*PEGKO7BKGJN#0E!+LMY#-1G@KV%C1*=S-OAJC&FSM"1# B9
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M:#T1-3JN?% &@%+"0(,G?+;& @&3^Y3'FSMJ:,9EK-LB ,[FW%8C&,4I_\2
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MP+.XN0"ZE^.=0OA:4Z:YL=7%O:,!&@ Z<X02K?,")7C3Q+BU(H@U ?Y9&9
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M=/4E$WB!&FCX_^$4=,&$46IJ="\$SK-H4Y:)>(%!#RD"(W $N ( 8$"P,Z>
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M$BQC;91B)J)&X.@0Y&$?$TQ!X!F!-O)($504;ES@/["#%YA?,9V=9A$!C-V
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M6\/N3%4+:Q= Q:41K:SD:$7)!9B1E!PF3X-4B"O(^V5^'Q-$LWK<B(Y8@ -
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M21.?^]'57LJY16B3+CQ%Q4JMTK;I"6M-,.*#X/A@!Z3;@A"ZF,4;+*8+/*@
M!BIPQL_5#WZV"9P%%@%(.T*+CGWL+[1H,<?]]O>_R%+6+6Y1BTR,S1A,,->N
M:E.@0V)5*%IM:ZT,>U7:=.Y=(@*0!"3\7F]*;,(4QMS]O-".99"2I_]BV+U
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M-;D,%WIJ)"$="4G"E:VG6[+1E53*YRZ)29*8"-V<#9"'H K2<:'>*)S(AJG
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MW1 @77AEKHAOI4Y+=U9,WY[032KD+*AA&9RP"30 "JC C!ZD7V+$PVPD1!J
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MB+)'N.0I)^A7GK)\T,D@-*0 TFD9MO^!#_OP"8F!&###FW 1,]QD&][ "$*
MK_R-X0A+1SA(DD2DQR:C1^Z-AM3$FZ3H,UPN7Y 1%!^&<C)-HU[/)I( JCXN
M+W"@<%)%)![J,I6O"_*"J5I'JP)J,V@K:"RC249H(%Q.E5JR8R)E9PZFB1(B
MS*XNNI+(*(UR1#)&AX3KL8RDG!H"/A)"!BJR<X3BG( ,EV(L9\33D-2(*$ZJ
M>BZ$2,.EO@H)-X83<X:E6>;('KFT2Z\E$[H!CJ"*5OA#,GY+('AD( Y)';/J
MD1)27%"N>EZ'K>3N5L2E5AZD0>SM.O2-#Y6 KBRO/XQ3U+Y.1"P@YB2(*)=1
M1VI""35JYFK_,1@_,8&*H OB#[P" P@E@J*<CRK^(B-89DIJ!\B,0 -"X 1"
M(%4U0#8,  K2  [HH!F< 0U.8 RHH%#0U"#0!0$HP*]",<90H^9L<6A$J1=V
M@=,$PC.J S,"Y^M*;* JP&^*!WD X]"01RRF\,[VJ2[&AEO58FW^3&W^0BB#
M\"HD@BK:"+[V(@+^+S"0QRJN0AENJX(@U26#,#!RS0?D:2J2HC1L$?8F*X$(
M@E5NX'2(J8N(B6 A8#%\0RPC  )4;30KX3-9$#1)<PO&H1WN @03\[R0Z?].
MA<J8@IXPB:YD0!GHP@^]P!B6@2[BPCY0@GGD3NXFS%#=)\)VA0L]_T?"2HQZ
MD*.DMA!!,$]#AI8!FG*2UE#=)JA+RA0#].=&4HP:\JW,UC,]K;;,.*4/1>DL
MCL$/4Y6OIL 0F^!"IDI>"&3@1@1S)&8YB.\I(&(N,@/UED%$,ZJZ'*6G.JUG
M;'$VA1(X4,7Y9!, J8\J +!K\B(%\L(!WH716BZC7,D"51)4:"()$*5(M(\8
M+5=&#6A(Y&5S(BE]O 2X9JL872(:EB$: E$066),OJH *  -BJ$7XF *9@/E
M,$ 7@ '4GK1B)*"-&*DL,41^LN0UB)(O2I 1Y,@S4] 2F-<26BT6MK3 O+19
MBB4<:L$N.H1+R&HR"&7<TNT-RVK;DK-V-__HKZ03Y=8%'/EE2&F%JZX1 "Y(
M8-KA'_ZA'0(1&-@3&'2A:_=P]>X'C:I#*/S%031T80G63 DBI'#D*2?ITFC.
M^X#5AR*+/"I5*O"5, +C-TC&IIZD!X0 *@A%%_J!E#121=),*=E*-DQ  W8D
M>'U" D;PI)3(%@EHXV:8@HGPWH@-PI##-YK/AS&@6]E2+"RH,*;U+-5&>10*
M+KM5;<)U>9: 30IG,J[-N@1B<::*G-""SS)#S"Z)V*[$^RIP2,[J)CS-,2.5
M$XE@O1:#BPHV97*@BU*&8--.9,LN3EI@#Q!!>2>68E%0+$X0UMJ!4YYBIYBL
M0J$"F 9P"NU#%[S_IV49@3?1(@DT@ZF\("C^HZK<CKYP;'P]QW_ $3FW[3F?
M,T/2" MK%UW 49&$ CS%9\B&K"?H2@*80!7*S'[=9#V)P0FI5I?+S)MR^0FS
M]FI_&<C:H1=..">:P%!N"4!X9*I&Y)!0[P*3HI>6P(<K= DJ9&Y/R883)AE/
MZ*(XCLLDZ#*8PV];$0(@0"EPH-'R<BN0IRNV@*RZ>8&"3N.*((26Y%.*2R:*
M"^ADPK%P:#WFAWY\A$8NY+>8X F>P O>8!GJE]A*E""8,+8<JU)NU9N:H1B*
M(1B" 0TX8"$W1/+<E"BB]*361T!*)%WRXC%D@"H*;(Z<M]4L81&8MQ(L_P&G
M<7HTF3<3FK>GH5=ZHP60RB$6"B&&&J1&%'4E0DLJ5:-+X#"J%R?#1-"0VD=
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M  &H5" ]3',ZLCJ&1/8>=88W#A1IF$VH9ADB(Y2&;S>2@B_6 JI4Q2JPXB\
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M=2$A[1 -YL$7[)<6A^)S^)=U!"J?G&(0OB$^<'4^T1$^/=@H:3E$!0%0#(I
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M1'F^'L, C(95H&+)+/B2]N>T_Y)2CQDI)#YDH==B6KS()U[Q0%PZ=%Y3!!2
M (FF<0B$ 9(Z!6^ !!* !M7P!M>"!,H"7<HJ4!^L-6QA!&&)JL:1&^'3%=YQ
M-H/!B.[V@W3UNS@ .MN#/5W0:<W&'LGR%@B!T!O<J5<D7.X5-M2[@BT) DI
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MEY(J3M<X_R<VL(2#C,(8E3$06S=$_U_=R42J*!IA7-C@/7410A)  5+1!$X
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M=QO\RQX2<QNA+T?JX8F=<EU,U,&#26R+AEV1)O$^#$C<HC$ G8PR4KEQC9D
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M&[34M;3,72@=,O];9F@7*F:\T02-<KQQI!PY&&F*)[(@IB6%DDRR+-\,*,
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MPJ./\\1:G[/2QSV8B/_%+&K1C4P(H0(,V-#@*">#['$/7M_3*U]W(S7>**<
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MCZSN$&G*98 15U"&!"R;F2A!.@"23) B-Q8MQ5P+^@QF,"W# 'V'$8"'?X5
M)G-AQC!!'TG B-",??UD.-+>=;Y42EXT\.P+2LS)G#RPOF"$>VC(4NR+<ASP
M4R@$-:"!$ UN(K4#-[P(<Z1J)D]'K.;=SI+2P18(_8#(=(B>"4@8PY@P4[S(
MR>#(23D3J,J@MLP;SD*&&V"#PEQ*4@38ZU3'_]#;TI#53#"!=([:1>!=66V)
M/?_H0@-<[-OB*LS:AA<P@ 5DP:NX"J-80/E1:]K@\#OQQ?OAV3BXPE@JVA)<
M0&432PXI21<E2J*<ZZ-4=A>L*UDJE!=T$;#L2@OX"OG]4[O6G^!XE"XD 01
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M@P'LE@'_"UYC)Q[#J3B"H@P8,@0$@2%C&1*8@'D57M]&*4R@*/J!V7X'T+)
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MDQSI]9%+Q:)&+YA$N^Y9IY(GLRH:2GG) U$ "V@H!FG\!8_K!8<^"O+2,MX
MN]ZE1F&%U 4U0D2-5#IG.<1 @D:0]+D%#D0A(.B(0F#TI1JMY@U8:!5WIO B
M$F$$!!;\D(1,HL&.)#,HL&K_PA/P)8$*ZN(?>2(.%I#P!!.<$%5F+)4;A(*0
M]7S59]MY VAT1]B73<5T0?)%^S;Z-24ND0D30F)UE[B4E2$J9E!4QA2IJ MC
M&,,+>7,I7(B6&$VU8PFD"15K%K33X!;C'TQ8W6U@M5=4MN-?0<G0EIQ',H5&
MI))E3&IR7$/&TJBB*RTZR/485,*S^<<LMX62KF*U(&+LJ#0/^A(P",M)49KX
MQ"A.<;GHY<=5NEB5S4%/:([E2]*\L#2B(=5@@T)8*M6W5 [*7F-UL9!RWH0!
MI*(/FMABS?3>\W#5/$P/>L"XED+ !S<H0:<\5!*2'(J@_DR44UK2$28$!R;(
M*T+N_XH -:@)-)VMZ )@ M,%5W0!(CP0C ^(0 0AH&2?!WD*/U42Z*Q]>4\$
MX4)\O' H'*['+#T12D\(@RFT)02CG E$W=CR-DQ=P*(6;4'B%(?EE").4R2X
M@0U>>CA[6C0""X# 7.*V"'O88R# Y:4*(Z0JN&*  A[*4(L6Z!PXO2%*IE/.
M8E^EW&+1YC0ZTBN#=$&E#I[("-79(6]V@EH,X! _\"D6*H.[FK2")K01^/&N
MCN-;(YB@L>$SLL%D_(8:F> )<'H?F%"WO*!L9X%(\()CA;6,>Y KLDB0#9JY
M (*WP<@+;DKD?)!0/$E[]<\;,0%]N.>*+22A9V4Q A*,H/\!D^Q'0<"0-FO^
MM:V>H6&Q[4 #%HJS#12"@ /C(_>65I4%:!V71+FYKM"OLB>"W:D(65&*T*M+
M1#X%\6,VH]H2HMBH\0K$O$?S 0\ 9S?"_!H'1[B.6TU38^OT=#7_,(%^6U/6
M8?]X&>-H!Q->U)XBP&D_NP')P$2D"Q;=0U4@.8@7&/'.S] 86;'!HW\D@"S>
M#9:L\WE#%AYH0%W0Z_*8S[SF-\_YSGO^\Z /O>A!CZOH#1S&_UU&@OY;(Q&_
MB$<]\I(J^_6/;3QH15G  @EUSKUI X-%3"A !# 6D0@P  1+"+0U(9#J]$*@
M!#=P::>@_](;Z$!3*(V^2UNV36W_=K.[4]L*3_@3E*/T["A=:5-FKTAGP0BF
MG>UW'J,](A64(*%J2/<8!J/>Q$%?T&I,0!I!L1,_H00*Y0,7P&325 $UQ0GN
MM!8XX#9O,X%JH742Y1BBEH"',5-NTUXM< ,\D$4BR!8CA0$M8 %_4%.,8 _8
MH L8\'8Z%TRD,5OE1AHAHAS-T2^.]1S1H1\^F!PA$EHZ1@S^AD@'AGAJER\>
M=(,M@BWF%H/$DE;4H"O"$A:F0@U&T"^8HR++8 2#@TQDXRLNE! 14$+ZA5H$
MP1T6I'& ] _S4!K-,P5'$ARW800AT%L65$!>8 %,0'A<4 1=D5\_8R;9)%H,
M@00F('E!__(>BL4<4^@E.<(]R!(=6X(&544!30@,%",EQ/$$RW E$L ! @:%
M8*(ZB;007U5)"V%FXQ$<K*@G07$11\$$&((%N?,G*O$UW-==1+<2^O0R3P<S
M7/ <461UYO4B[]1>BY,8:(,$"3@YH[@EP+1KJB%,0A$GIO0<FK,]I4%&6Z +
M6  S(?(&#P:( L$%BB8?S\%FP*0+[_1.3>@E&\8@5%6'(():K<(Q.18:N9$D
M7F4G61 ?_6$"Y0$"H\(?S2-_"ND\-=0?#0&(^X$$O9)9MU$$]7&1%\F(%PEQ
M)F 6)Y,?C/8B"XD&)+,0$3!WNG)R&'F1UN-?CH5*]Z%8FB,QO?^4'(YX/3="
M#;ZS/5)" 0('A;BBB<OAA</'$^0$$14Q&A8#9=-W.%H&?8D#92953=54 A>
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M2PX,":S)$RH@0$B0,(5:.YKMJ%';=A/GMFTU>=YL1U#74&!%APXD!LP+&EW
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MI<@"7=  LB*K8MFI7",HL<"\*# 8&?"GZI,!_UU0!:G F8!!H0&9 B4@!A
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MOS):LN3>O65%(GBI3>PV;IRZ=0$#QGL9\.#"%6#!MDR7C.0/ES^D0 $$3"7
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M."6#GT"\T [J!4@@#=Q1^R@#@C>,J1WS,!""D*6J#'KO5,IBSY:6Q9[@W,H
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M,"V#92N' <C(K<QB @,:3(%<)&2NA"0C+F6EJ-,R',,Z52$5%Z-PD @:) 0
M9%L?A0 (,( &3+(][FCH71:+0IENG,O8&2/I90W7?8:,4.V8Z 2Y:@NVYAW$
M>7 ]_<AQA..S.+,B*>Z\HDJ0K PPM,B;S%%&*,%W-5'H3H%G% &A8O^$;QI:
MEG RSR+!?"T-"%S&Z3!1:,0.]!GOZLHDU/29G'H$GCF?]LV7HE0.2JW)Y1"@
M#WP:5 &%%Q!JHC'&H@ )<-GG?#U42*3$HCR-H^ $0P OU9&?5FU5Y8QT(?1E
MILH4(A!%IL3B3UI4G[IL5^[ RX;-[@H.!/R$4-E41@D@'^A-(5@.2C44%D0
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MV5!3@@E-#^J4TX-6.^A32(WPBM)-.TTUU$U)+96UV5#SPIA66XW5BR(PB
M]<[T8JPI9-@.M4?SD@" 8P%0<D0PP1RN+A_6@M8'\UJX88DMKHT$SFU+,263
M!7WP@8<6#NM"K2VZP(&X!0VL( (&6H"3CR)X6 0R)'3_H:8^&8%!0Z>;F#7"
MQXN8*. ?)I1)2!DFP+R@!3 AP!//XRHH#D_BZ,+!*O\2T99;.#GYHP4(2+X
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MP$9%"-?<UK*%)&S!1A>(034_YJWP,8&;^"P"76B',1_<X +_%;,=7=P%@0M
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M,J)S-U4DJ1@"&V 4B_+"-%#CZO#DO"P@,5V/QQAA&5PA'/F.,2U)@4  3"Q
M=$9$"5#$JBS,JKKHVZ!F+$!EP2X%5-IQ2A4L2Y\4[D1GOUJL[3;L'D,EC2!L
MC1#22M?(5!"BCTICC,@"&*A*'M^."_1N-8;B&,BB'?CG/F^%,=72.[P #6YQ
MP5A%[VJ4\Q)B'(R!84!#?2X!IAX#.'C4/S*A)4NA$S*!_-0%![J !9",9&Y
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M]PX?_AOC!>-[?V\__OC\Q'0A,4%!@/\!:H5!$;I@\T^""OX30041M*#3$A4
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M%DJ12: # =&($$0@N@BY&"/)QT0 91CP#C6HX9UCS*\(QV"42"C30:(\CR"
MR00!<:8A3OR!(S?IB UN( 0-Q: +DO&+,;Q#L;\(;SBJB8!VF% %D'%LG2 #
MG/B ,1_ ^1(\<V0"_OYQL);(+"D1,4G26O ':$:%$XLX20L@4P2D%"&"W>*6
M1%[T.^!IR2!+R(C_T5B4M*?II&D^V0U+GE45H>F"$5M 2@OD5=&,\"1L%YF6
M2O*YDRV0S7\>1>DRR9F$VM 2 ELA&$@@!*$E\,%NRA0*5EIP.Q,P3EG*,MRU
MPA(GR,&%D(X9U9) %<E<A>Y<DBI"5:=8!##=D8UDS:HC[6F8RY7N,J;XC0%;
MP-(&.I K;S,8[%*H+=IML:[1ZD)!_&HM1F1I(!KJ!#F#0ASD*-9W!2&C5N1J
M$AQD)T%H^*8_$K2,L-Q'/._L+'O*4Q#Q[<<]Z],8>=PSVOCHP@A?Y,H/L9$_
M[6S#*D3K@D(^!-<N9$(3 BW%'W9P49:\!($@<J#<4(2#!Z5()Q[1S4,>_])
MN4:F,I(9U*[&H8LB$!&,VT)AGAJ$@2VXT!B,Z,*8F! :.WH!O=C*(5)7XSHN
M!?0WL7"%%Y:0-_JH:T^UVE:7YN(IT_1G%UY(XNT6-ZM*F2FO&# C#5G3Q&P1
MLG989"(8P;A@*VY1!F^Y:Q/M5 !O1:"[2SQAB<.8(Z\R:@J'DA-KTE(CVM0&
M1UZT(HTQQ4:I(LHQG-H4K);J2+H &9*/T@4UVL$-;F1VN?@5)6DB&"W./! W
MT.&*2XQA,)/P#U-3? R7_%J$"!AAB"?<2A&F8 (L+ -9N$37G SDBA8   !-
MY!*-MX"03'SBF;T=:.HJ)#R_5*QBT/O2/["A6?]V;NQ\NL /,9A0 -9&8%=[
M:=E%X@JBDWQ$)G!5"1_XO"%.!&<DD]%%$F)"LR MC8$7B(F_+,(PXDTT8JX8
M444PVB*6K,0C$$E14T"J/()("0(0RAI34)(1"W6T(41(2E.2EA&_ F]YR6F!
M@[1", 80; '8O@#E0L2#H?XF$T45C"XP8 *YF&#=:YE+=XOP!C<8Y\>S8IP$
MR/HYMU!Q<%2<8E2][(5T7%)<RV!55<TZ!>.4IUAYP0J7+E>9TGU#0W^(K ^,
M5!O1+#&]%-Y*=[=5YNC8E=/RZD)&0Q)1763";A)E&[6=I[RAB*0+$."VW$R2
MG;U,X9OWP.P/O2-:]9W_)WVCC=^BXR>N"0_HA"#P C%BFZ#% J5Y/7%F;QN1
MF.1 ::06:DY/DO*2Z,IM*W)]3@26BQ+>N.0B=/W(S_LR;[0N:UEX,I8]<W=F
M%B=<)-_4A=M6$QK6,'GM%4"J29=V@?EJ9A&N8*T)&+4M":3);ZS]BE[X(C]@
M4",=[9A'.Z@QA246($U,I%60WX)" (28BWB:<9YH9R80P.9/95KPA#=>IV\Q
M<<8FSM,2,YQ7VRB)Q4;@0EEJ%<<B>"4M-M91:_>TJE#!*9(]3K"8$ DG*2IN
MWXV+I.1VTI0(K=(''+E@4W"3E(/MK MHZ8(R7.(3K_)X3#CXX9RQY0K_AD45
M_PE7:CO232B@XE60(Q( P  @, 54  9@@ 9H0 5-H"M^YP5<$!_'@!"HH6=M
MU6>E,&J"1C$^H77K-6-6E!=>@ 58\ ]D!''V(4_@ W39I15>L" ) A,,]"-3
MLE$0\4 F80>@IB&F  J"5A_*8%]2HA05,1,603WH9R03(1$2@7((@5AK0Q'^
MHA(:X0,HTA$J@A0\ &Q6 3P,04%&@Q3_(B+S8C9"0#0Q<P1MF!3-,343=5]A
M=G88L !51C!5!FY:HQ)/,6XO=Q5;P!9((!:#@BU@H6_\]F/>]RH%4E:. B=6
M)2N<\D1I 3KR=W""02EH@21F(0-*P [&P 2QL2OTL?]6EM$-&B($+U-[(-==
M3*1[*,052H #!5 "R*5I:<=,P#,\5+)#FF$*@N4PB;585F%?$;  -H<;+-0"
M*[,77D 9"N)W]5$?($,>[_19I!5T\?$^(* 5 5([FC6#?'%3+D=MC&!U O4(
M/.!Q%G!0FU,HSE,069-!"_02.;0:'R(:"15!HC0;W\85"U0@5 (W1> *6#%O
MU&A/8]18E"$8"'D<JU$!HZ=%=)>/SR%XY")*(+$19M-2C: AA?!W6@$ ,H &
M+ 9T!88C1K ,"E(8;M->7+1[?D-(;B$76>6(RQ(!<S9G:<)Z&:<F-%8;KE<G
M>L(W=N(G.W(F1'1"7)1[&/;_16<B9E.P+:\21%%$=WI"@G9&($.$+7MR8(7R
M*9K";X?18HX"*PGW!L& !D80#4HR?8<B*8KR&*O2$_$"5RFA$#UA-D20-5K#
M&P>C&QC$3VBQ.:(R13+ !:LE 7[3#O< F9#9#H^" ;O")9@B*M4G%\N !A2I
M.W3B%0B860C&;R"0!,:0!,G(E Q0 3]T$,:0"9V /$+X.U[PB382 0^60RI4
MD:[Y#\"  0\I&.<Q!;8R0C.8(.\%-S]E7'6593;39Y\0"[2)D%ISE\9QE\WA
M/S)Q _[4A!F5&U7XA ^% W'(-@FA-4GSA+SF$AFU3S&8$$5!41#1(D_SEV>3
M$4* _US.)B5 (2YXLUX)]1P,L #$U@)"T!0'4P$0('(5U848%&YV$W-$Z#I@
MX6:1@SB+@BYS,290-"88L$C$EYF>XSF)@U6N4E9*X 4GN21(HA9 1!N"H0IM
MP6& DT?'(1BGJ RTH"&":';>96%,)'L/ABVJ5P#VY4 ?D4]BXQ<41!$GD01\
M9@=B,QS-4XQ"41!,8 +_88,S4P1[X7G0N!>/J0LJ,S+ZP1X%873+  PG"0)Z
MLA4RP 17$5O;L SE>%@BE8[0! @<001_2A$^L78%TF"9PHGVM38IU1$@XE^P
M8QLC!GCM=5#^R#LYY(T,A $\]1(3@!&N@R(PP:"%F!9'$/])75!2!),B^^1L
MX,<#2=!UIBI*ABD97\H=+5 (>_ (D^"#I1 #<80M8^4%P"0>H1<HC46'9>)Q
M2%0;#& @R6=Z"+"3/-F5HR=Y?L)$S;<GN(=%M:-$K\>M*+9=WAJNO_=\OV<!
MO7<F(, %ZQIC=*<[;[1QLABO#=86$N!'8^DIU%>6]99@I'D825 L<3&*KZ(,
MIAHI)*036[ $]M0%Y.*PG,$H_;@%B4)6BS$LNJ $7H$&T#<%1U9,Z3(K625(
MP#!FH6%GC:E\ER(N=Y%@D9&:A4=<A6<MO>,*3) $\0H "W !P],P8Y94R,<W
M-"0#E(*/L..;RW INX*<(S44C57_-49"5R\!4'TF:A)U@0W#"$HA,TW3'(FA
ML/+2-%>(&TF#00=S$\2&35NP [WF SD@$3(A6$75M.*"-C+3$:KZ7&@CD"YJ
M*?"%?LY&(EG3 ]$&JS\AC$Q+4G=%('F9H$WQ/Y&U$DC1 S(C$>*F&>36/./@
M!052%]/G9J;A=XN356Z#*W$YET_T.729*[C4*8EB@@Z7%J7XHLMP*%. !"?Y
M!+F+!(UQ7I3A'6N5&5<R$ZW&%05@@%XQ)@$Y/3Y594SP(TM :J[@$#J@ TE3
M93&@BD\2<P :<T5A7A\J>"95!95&#$:@#-JQ%V4J&"7#,;K !8I+(*:!G'DJ
MM\N4"1J(_S.<T <4,;A_Z;\/02-IL0244R"7$QB*VA$-)8N_JGQA](HQ^3IS
M)1,$224Z8')=XP-$  0;;"(NL3I#*9$BA%00D"(^D01"H >?MJL;N"&1T )<
M\&9;]&'7(AI;H28_0L ""7@C^!S0,5(MP"9RPI-#3,1%W!78ZI1%Z14R0'N^
M%Z]1:44F9F,S1DA]XBU%I*R6LF:7PF%M8D;)8D;?)8N?X6$X@F-5!8F2XD>3
MF"F20XEM8G!MYCB(&+)EA4=Y]"B3!"9/M!@+2XEF94ER(:<M.8Z#,CIL,;JY
M(A)H 49/X O-T R^L+$X,@5OL*\W"3KVQYH(I* '4P0.IQ5%H/\*NO +!=&
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M+1 #P!P)E=WB^*()?\ 'F2UHY#2,R>R[)V,,.C$D:)%%2O# [45'!8)Q4C+
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ME$H)Q47LCX"P!XZPGM/\$!41#E()D0^=C5+\H/^B_4V]M%$'+>$Z39AZ,8J
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M+0:\+%O@ *<2R("Y)8F;.IK_!>@)A4T!%XR@"&+I_LPC Q3JX!6!9\B'!&B
M#-E3V=S@8B;(>A@( _P' H  %:#!R4Z#GP"#*DP!".1>!,@32]B.4<(%(BK9
M>K9GIL#DL_2 O[G.0D46 _'$?E!3:&S$,?[&:M2&0@5'*6:->H;$%A#'[&!$
M),9&,,+&7 GM B4MJ$C$;[#@:AA+IP2M[. .)IY&;HSM N&.6PK(3G1*$0RB
M6OV;;@1/\9R'BK!*"7B'2$S ,3X$A@Z$5_7'^DC'?+ /8>W<?QC(!=A-6,#&
M<D )=)A' \@AXY((F#XL-LX=^EP6J7K(AS#)"J%/%%97=*RIW*U'QGH X\JC
MB<0H_X;4ST)BEW:A+G<JE[6RW9O&$)BV1U7<!4*2A&S9Z12!Y+&F&^3Y79/J
M*\06Y+["Q*F IF5L(?"R9D7EUVJB5.7\39!XSD_^49KTG[804X\5C):,R0UI
MB1%9SN6XBW%R;TB2ROD!SEDR#E\4U1.U:JY$3LO:IKO)5DAI[F(J0:R0C#A)
MX/TB8;!)W@(;E6+^79AFY@0EJ0E%\/YDIFONKK2B*V,2(?#ASQQN+@?GX(9L
M2'4YB?TT5VE>Q@9S<'0*)$..'09\$%74YF;>\&8BWMQMIG2F*>-"U/U0\,WI
M*_$43V!A6W$  S!@ 9-H $O($$5$!9:66^>&SWLD0 B 0/\"<+$)X$G)N)H)
MF <(Z)N\&2AK\%MJJ-+G\>JGG87];*W$2$0 L6UHX,X"I>*%+F(@B@0Q7BU_
MH,82S*)GI>*GH,[7GF/6[AMPS ;LP,@BV?%O/!-E"2WLC,=5,3)L-!C^5=4=
M,T@JPMSSR!Q'I$<+5 !TU!S;WM5O34?R'(#B-L=?R3)^>$]#+ !@+9?:D:[P
M;&GZ8-V(*-Y4A1:URB[6,>Z]CIUT=HG6O;!Y0.?-W<BY JH4GD>7VAPT3R1
M;BF.&%<V1P#CL1U&]N[BA:Z3%,\R#\4V_> 3K1N=%%Z%9(FZ K Z2C/L3E7T
MRNKD5!'D-;#V>EOA]*:LIINR$33_3=+DK:();J:O;=;0WZE(CG2)>?3@\>;S
M.O<S?X5E &ITI*YF&]7P!XZ=N>E%"3D)DVR(N=9$33""P*XPVA!):5JTG5:%
MEC1S3;,'-=-NCKAPAZ1K18XS!F=)@FCG3ELKF);'9O8T_\CI0,C O"C&[G9<
M3JN=07XKQ#GDC@P$R,9CR%KK!7,G!1-7:>VN$5O0DB:S!0S>%G3&"C&!@HPF
M.H6=E#3!=7[&MS[I%>,(%:2!*BP#';5LC)Z':A18ILA;>Q*8J#W+YXE::O3M
MI*2MDNU$"821<.#&[5!$V,AH[BP!*\DM3VPVVQJE;M BVZ*5;0Q<;"2M:%.=
M8X>H9,'&_RG6,<60!Z@PT%W!QNS 2-.:TM!R+4?D1]KB%:N,!SK^EO(0+<4(
M1Q%T01(\TX),!/;(<GQ$]RQ3QV><5OD4C_$0\1@GLSZ:T'^HB)12*]M)]0L'
MW39CL$[_:=G=2 $4 ;,$-WO7CFC3KH#D'&F=]4Z_:0A:Y#C'4);L4(*HGMPJ
MFEXNE8R4YJ+MB'@VWF;N+HFX-:!>4'2*X!@RRF-TY Y9R*K!-$K:EY[N\_3F
M&DSY9M\,21]9E)09SH9LL(G\]+W2\#[+3&(,#@@1CF<614:[2?[^EZS2A4:F
MB$Y+ZXYX-;56,0; $ZK)"L84"?!&+Q@S-$1RD&(6L[0>M0N#0/]2?_<8SUT\
M-S.<2JM^HRM5-S/JTFY1.R1LV1-R)F0^WG7Y;,1>]8>;JBE\B4@P5S7N2O-9
M.UKO,D#O"G4(4MM$(LC!J+4Y,T 3H &>:;@,$8]V4>YU:1TT6^4RW*:9% C3
M,!##D55ABQI,?GIB4V96>9&"\09P%ZW01L2DL*U5L6 CTP:!B#9P*52JHT8K
MH?:Q--@F,U"IY\YIC(8NNE4DI@<IWS',N55KU_%PF#(>IVCLF*++W?95K:)K
M>U5L*!#5IN(HHP;Z4*,R*@AUS[)]S#EY$.264D#='L !C'(CSGE[0/5WEW><
MGG>(V,<*E2P8/,$%%S,*J0@#:%9I0XS_1G#6[A3'[[PYSJV04%!U<XRSQ2[>
MB]>TNQDQODLD>U!(ETQT[X$)>&LG?^^/Q)];H4J("!9O@(,W29-JF7#0RN@)
M>SEGGG8DG3JP_+(S<O[I1?JWR%<DFPRGCRM1LSE1^ZH$_:[30"N;B.L*='K
MDX)\14(4=%JY4*N(M:$1F(PG@*N5@]L0&48&F&@Y=XK\W(5TAV0L8YIK=D:G
ME^9YQ(_]!.TYO9>S4L^N3:L0O)<]NK6FNP6R;$6<1+RZXT9N*5;7O&, Y9Z;
MR,:IRDM(ZY+]1!JQD$\D@+ANSJG(D%';G3]:R\A  Q#70C)).CXZB$#\6X=
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MFS2"D(V,2U8T(<B>)"(#&60$0'3R5)U&1ZL2S@I/_NLBGA#B/P,JD603TAZ
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MJ MR@(XN0$(.0LZ8@UF$Y"QV@B'*1?L8XIQ((LK( L.<PV96#7MJ+:K$ @>
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ME"Y[+L 2^Q-:$.  =& "!-2/B 4M =2H LF L@L!DH0B?PDJ_$.@2.G$4B/
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MT^4H_/!]%<0C+$)DE^ [*P**!(4)\/)5AI,Z[VJNF(!MB3 [$.(N92D)FBB
MYJ0"LM6"NVHPT\8O"W,+(L5:MU49C$$7QF<9C,$5MD DLHMDQTM-U22(VC4.
M62BY*@4%H8U,#/]VL2CN-W68AL M)WJ.4X8EXUH3/4].A>1DXH9S)C""+C'B
M5<#(M,CU@7JXN$(B7])S805KW+AHXB:@B@WK4T:N.U^8.\$0CK)%O;(0=F;+
M"P8B[UJ")HX _2*X@&<.?[N(!6%EULXR3B$@Z:1%JJ(% B; ,K^E/_;C\CZN
M?$L IKIH APP+0\P:B4YOK+G1T1R)9A D9HJ9LR" 63 ,9@@V9@ OX2$79BH
M&B'HKE8G"; 33\SEU !Y4O<,^WYBQ"34GY)B;#4$,\!1-8 ,^O06H':FZ\*N
M*1P&29$4DEI&JN3EBF)%?QRKV] OYL37^ZA#"4)#.("C-TCY.5B,'DW_EW9_
M;5C)[4S0[U=<""&2 ($N<D+:BRLE$D#TE'CBP_GVHYE8HT=IF2U.3?M2R7@Z
M V$2QCY@"=?:K"M68J#Y:&' 3Y*!-FJ9BH[X"&'^^#\'>J"5[J&5SESNP@):
M(((=&"ZRZ(.\Y9BJ&5)W(EAJB$;BV?F8M<,V0CL]928&I.$B3B8": DN(D*\
M94TTHFU70CPNP O801>04B)"='4VD!&4TEB+H.#@A%10Z(*KFB^IE1$2\R_Y
M4H>T%:R\=1S881RP,TWJ\T2YD^/<DX6NA BZ)+.>K8<RBTP4)4QHQ8G_IV/W
M*.-*]K#V55.64+%@PCFU^ H13E8 "%5P0K;P_R0)P0@[8\N)5,ZO%[:%UP14
MDNNR0T7G.@SHZJ10%(L0:WIT"B1E.<[ASI!4LBOH#I;AW XS2RM9W*1U%2Z6
MT.^W\B>QTB1:0 [S+M%UFEE0'O-5YL0CTL25FHB$<HV$Y!!J)SE7'9!]'1I[
ML'=:_/, D)9SEN3C&!A %/%<MD#F\LNI5@ESO$P_E@F8+8"4R_O'U ,=F2<"
MP#9("?=T[?F>0   O  -FN"_HC;#YH4HS9.0#$@V8ZUQF"@W)$,W:B,V]J)+
MGZS_/._%2CH"G%95"C&I+T\ !=":%<:EX[+*3 8:':HS!K<Y\$N-C-> , ##
M@:29H0F_Y.RJ,I%,N__/TUQ:Z@3->+MW(C"Z05_-+/GDD:4%(2BY ;F'U0!9
MGH]C*R>B!0PB-^,D"<8W@H:ST'Q J$]U;8D00%[BUY"+?UK KO+$KFQZ)05E
M4@PKB!&M)4H +D1E?,7S;#.,+D"DB91O5&!B"0(E8#VP?*P:T#5X@P&S6CG0
M@@]3,;M5?,1*&<KGTL1U?8 HLU)S3. JTMEZ7(\K8(K+L7X+,]DV4(S3'3N3
M;3MV!CLLLN]200*%M$HV!JF(A9J38UDRBV?PB%8J,\F0H=3DM& E8 :+2IQV
M=DZ4@8IX398EBX+.Y&:"@' @4"+(-H$+$1T+=D 65S#SX&[M / D6LJ/VH'_
M"UY"!>"4"-^4BXE;(H(W4T695XT.B2&9RS!M)#ETG)*)U@'%@Z'.12 Z(D^X
MG+@+E"F>RL4A],_B)F]P1 EV2D,@2C6N@EIX:L:::4-8$1H!("E,8JG\B %&
MK#]E\BOBR6?[1.9R[B561&R?53)R0R33ILX5@G%S1GI?)E@KXEJ^\J7-)9*E
M!53X"+.EBEN.[L-=NE^@)V^-5WOF; 7!J DCH$#.LEBHJ@2X!:+MO>.IWNH1
MAC>AFVBQ/GN6:HUFHF4GH$'RT^G^5&6<[\N#OKCA&-V<-B\?" ?^!"[JUEZC
M>DYL*#?;EB4-F89V/53T>(DK+KGJ,]QI8E<UM61Z_XE47))&!BHGCF=AZ&18
MBQLN+'B$Q^>"[Y$+ CUMHF0P@RTP-="JP8>$2U\7 G.N>$#UG>U*GDTR2W R
MX2=,A(#V:;]3?C41QVO6*1OH]C5?'D@+>VMDUP2]G'"-<_C>[$?U\8YD;2BP
MJSBS;9U</Q/Y4 6,G%CD,E;G1'O89T+Y>\OWE]M0]"I@%VLIV78C] =9F+U=
M@R[O?&5VE/\&5-]2IB1*>, TVP3Y'(MU]"ZQ\@X@EI18$N&"P0L8BN!8LJ1%
MA @8"N(H4@2#18@1+%2H\) APRXX%GIALB3DD24^+CQ<6>!A 0D@6!:8V9+F
M3)8($$0 P'.E3XP_?UJTB/^PQ="A%RHDA;!@P4H(-VVV7&DA H.5#+)>M<J@
M@=<&$L)*L&"1H@RQ%BQ(",IV9<2V8,7*?:AVK%RU5L5J+<# [EP 5@%<X G
M N&Q9#&  %%$QMN'B-UB0&BQQ1**%)54](F9B9'/G[V(%EW$B&<,63,6B>D3
M0U6Z05VWI8FQ@,Z"@R?<,.@#@N\#!QX^?@A8)86VR)-GC# 3\$,&A*-+YUF
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M:HE6+!R:NJ"@#HD0<QBX01=:X0, , !1/AF4;T!4@6LE(0DHPE8&\[2V&Y2
M0SP8E[O_C.*UV+$D(Z4+WE-P$Q2$16!PZOK)5+1B2-SXT2?':Q!FEF"Z"'#D
M+1Q12G;RXQ.MZ(5AV=G.3'3BG)4$9R6E=(^KMJ,W6D$ .#[DB7S 0TM:JO*0
MJ-2/S0)9R>QEKT!%*$J$Z*,0!X%("9]A@C*I-@6K86T)25@1)!6U*\Z]L'O
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M4I + :LA#3LD741V,OI<Y&0)6UW6PG21D(B$(2Q1R048\"'W$$XK9=J9SJ9
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MFSUC"_:81PN10\;H/:MJKS DC>_C+8IRENFK,HHXBS($F;-9CTN"E3BCBP6
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M0*9L*]Q@'T:HJ5.$%/ X+.8;C2T1S#I1DT&-3,8D(<%L%$#%+%NE+,=$@YY
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MX?B=.84,'@Z,02;!.:D&2GB42QU1!4B4WA2!!"P!H@& JT4 9KH5 !0  U1
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MPWZ:%H<:N%6":6;:PY8$ED0/<+8#^=B-$F!F6A ?!A2 $1@#-,XO.R/::D7
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M"CKV1Z_PY]PZ9P81JT6RB(]F1-6N J?XJB=;LCYH!XO.Q=>$A("88-Z"1Q>
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M1^UB.=SFI>1B<=/FI1CC]G),P%P"<>[BR](F;?@B:TRC(1&IB,BN700B^9:
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MRR0W<#D&0O]B&2&Y[A@5.]!C6L".$F(";LX[8-MJ&;2P>^F_XJ0LGO:1"P
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M I)4P#$MJ#$1KH[U'=Q@8XM0AC%<P47\BMV^F6!$++[1#C,:N&(M"!8H5P+
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M&('V-D^I3P&E$:/Q'%NI&;'Q$!JQ-O!7$:#14 E5?[QZ&MTR/4L@!, 98!>
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M8N#ORWS20"ZA,NL*4:.4(E8"#JH^S3347*/:@Z*4'1:#N6YCH/*[8A(11)-
MH ROH&H+L<,-49>IJK)(DLZZY)C_TB56\"[%(2%6)^K"JR6.B/WUBP)[[ZFZ
M= %&LYDQ:D\&#)0J3 D,_B8:<%UN>JY%""5L\"3L?F."&O=@FJ)"Y$PRGGO/
M04?1PVFC@]:DU%U<OT(D$ERQ?O7AARK!$+>]+;9E%05O3C%;D+;7(9$PKQWM
MB  "EH&%98Q)%V/R0@0N8"5CB8YO!< <")@@&#.%L "5(5IO_H8!(R2!-RUH
M$YS>U*<7RBE.,A14#>\T0QC.R86U:,$40M,990E%+F@:(640>#/N3<4JCV**
M<,[#A$MA*E:9$D*G2/4=(=S !S= 51=1E2DBQ&H)+>'(B70V%:DX)W4-8@GT
M4+@AERPK_R3+XA'?2DB!.JYI*6*!"HE"!)WRU>IS-;.:LZ;@A3<\QBQ&,%XP
MF@&-8H2D*0.T(^#X-2]^-423\=K7%H+3A20P@5_Y$LR\!,.(@>F"$09SA<-<
MN3"(+:R5#&N!QKZ#,9 9A&,<:P$N\S7%+OB !Q))&1NMQH4@Z6(B6QF+6*IS
M1"5:A75,L<[IX'?--FXH.]EI3-"&0CJA'*TW/4J:#+9Y'1!@@1K4",8;HM&.
MFF2!"H4<B68P%#:QX(IK1@"&%\Z&,ZIT)3^7PT_<T,(V8#RM+TA216 :@S?F
M_01-R:I,7#2C&0T,CG*>^<PW"164QJD&-:M9#>3^%QNB/(8W1O\3#:4X<KA$
M:8: _)M6HP29ON!$4W4I3$(7BB!,'H '(5T0@KR"F03!W&YL>,-GL]K3K)&\
MB#E(\$D1D.2%X'2E06B9DMV^TI0*M  OTCN*!?ZF!%5\3B;Q,\$4=!&6W^CO
M,!0!C!J'8P0588^1Y,..-J/CH?E%)7V!-=&N**6BPZSHFO"#48SJ9Y8:+>M_
ME2F*2B)C57B"!#G188D&?0*  KSAJC2J# I%E[BC;*D (BPB1>UHK Y&H 5;
MR 0M:N%"W.H0AS*<(0XQX:<\!0JWM(B%;6OAC=H I2NR 6)2>E0LHXQP<X2D
ME3YQE3*[0LN) ,/7IUA%5!]XJ@L56,#_!9*P!"*0R@^H2H(KS*B_J5RG=<K1
M;(74 []%+O8J4QC@CIK'M\_0R )+Z&DKNM"")7@ENX'47R"A@K]&,9,CP_%"
M,- 0&@EXX1[ 4,EM,'!079C5)SBX0 3XM<KSQDU?L?+"$X/S2WK-"U_R@F(F
M)2:862KLE:^4&,-NYQWO?(P\'+N %G> $"E^)U\DON!3MO?,E41&;65\'>NP
MV3HG5R<Y3MD6CY)B@<N*I%(B2I"C>!*[_SH7P!1%+5(@0YWJ4(0*4&B"9M 0
M#"KLHB_MV- 8LB =@(*(;$+ZU1([8I%C0.\E6+[-A0SZZ(/^Y6T+]<)#(:.W
MO0GMOR0LZUTT_].C3S- 2QT=)U*2U5P)A, (J5'-:E"#&I3B[9MSD4#?3.W<
MTC4F*=/;'.: @I2_^:@DU@36SNQ[T^< .D1%@(@/A."#2T';!\'$5+X8<;OS
M?@0N-%H+WM"R&Y*H2"O)G-@JO; N]Y3 *59BRE,MX( *5,"LTG/,W^C2G&'#
MT:H30IU>3=+/ONH7130E7Q\/1%B$"UQ_]9.J85$GH[P&A^%085X$BL!N',!V
M1\K:BA>.4<8'388R0:'+"(V !C29  QC:,+H3$TT+67)UH"SR%%8N(7BTH(6
ML^ M;N$$PY_[O(9X$M2;;-N-<2@# P4HH:%T!.J36BZ<J94  NT[L__[-C$X
M!+[4O\1S X$90QG!'!6KIKT%@9Q'7EO@(_KDYZRXSN1W9-$,LEOBDY3\QBMF
M"1Q3\=8"BP>U.]]Q]G@,<H$$D21^('IF8Q%DI*U,@1'C&(9B D,?$%  @L*3
MM;%N(!$<?/#R27#7*M?N24_&*CBD]\\H2>F0+J 280=3Y;EG/TM9XG['"+NJ
M182Y19 )>9>A<G91#[S+H,9J"SC P#*9;>A%4V0BE((03IQ%ENBO)"7%,G5E
M(LK'ZXRHX/![4,8!3]G/H*FY<KFL$1 9P?:$[@F0[,67,%>3,3P!6%8QVZ#O
M/S-S6IXP,X*(4@*TZ)=-@K0@\8O < PU&9;_B8+ B1JYSJD:S6&ZU)*YS5&S
M6\,UT7B"D7HUD;(-HL"<H? UHR$UV@@:<0*B-\*5#^FC]0DDZCJ)0*J.)+@
M"" \:$,(A/"ZBUN"[WB^H!D6N, G"?BJL"D)[%&)93 &K$(J@VDQE'FBCO@*
MBFB!"N /@VB!E7F OT$#54B9Y$""#\&/8Z 0$S% 51 ,O)H")!B?A*.?[OF<
MA),XAX,X$Y&X%"DL:\(>Z'"1(L"!MVH^T,,7LZ@ @9@^O/H-&0@2VY !9*%
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M'BBQI3@+C P+W+S4ET@)ZZM#0.M4)U/*B2H*!Y2!'C6XJ."(H0@J']"8)8"
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MBV3"4:/]TJM;MH2V#6Q-/U-C2HMVK50&40GP 0LB#\*CZA*+@ KXO!)C/HG
MC=OP /_!H 9CZB?-<!L0P(H0V)H*8<OWL@FG"(RP48N":A<3-N%',S?!L O@
MO5;(J(B@V=_.+2W\7:T0.I,;,0&S<#2#,09C\)L7]F%X;:[%.12D:((0.$;/
M2"DFOLP6Y-:N8#\"W#2AP \S<ITD&JSRJ4&9Z8CS:#'8G2(AZ*5EFB0+:!"P
M2:F_O@LI<ZR\J@NU<;+MP5$9\()TL$^WX )]61D+&! AX=0*J0VP4(_XX='O
M!,^!.Q&9R&ZW<VXR^Z,\U$.@Q4Y.Y8H.7HM<61&C$D)[M!B#$ )<&CX?L.6)
M*H A4D&_W>$((,96CH#(D*@6"-MN^.6S15L")RY>=L571%O_XF+06@B';HB%
M56H!,^&/D8OBU)J><>U*9>G?C9IB[@,-QB5GG&F=C_!:3Z,0)TR'*5GMI\@[
MDGB^9(0OM@@1F:JC-@.-::Z14]6J9I)&*)VB*"4\C/F.1:@B3T&53A&5+KJ!
M'IBB3)V5.$2.T?TK@ 2:L%$E"U""QE!$ J,(2CQ&!;V CT8]CYS3=O$/B/C(
MTMLDW!.8/4WIW&MI)&%LADD"!X2(O %*B" P#)"B8%*]CT@(+306)\4;RP ;
MEX@,K-(*T)&FRN7D3D7JX>U<5H:N;+4,,=ZB81((5F'/>I9H\D#85"12BH@+
MK9B")Y +-" &))B+*8@"M5[K7GWQ_Q.9"Y.PZP2<5MG+2Z_M#,A(96>&5^ZC
M[,(V$P2(@ E(92]0!6;'O [:%EJ>.J-88F!T.B ^%*Y,'"8&7-P((,(1=D3'
MD;T1"B- P3*;[F/#7"3BB9FP&AQP!?<@ID&<=[%H'OS($6#TLM*IM3W:%9#(
MJYZAJT,.9QSE"HRPSTN3@>,4*P;(#W)90YV@$&+3GSFTPX!UJ1*A3YUM,.;
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M:BB-TV*N0N:&Z9!B,$_H/#[RA"S * #T60?O*$[.2IHU,E=0!&404LZH2T
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M@ =JYP84#"'BZ]ZSJ<-O@(G4Z (2(B**1B'L"V*P5+4'$MP_UU'([41WR0N
MH<GA/#F7PY[F'E/L"2/N*0Z3RF>=K"6V2Q?." #0X!^6X9GPW.Q5W'CU?#1T
MY3E5)HUN(%NJ7/+)A2<IC1&X35&%\E&W1<<P8 E0HL(A  !$GTY$_R9VR3"B
M)F&XS;/'."Q X&"HP69%J-HM)CE=AV,UAGXW%G9D8,^&.F?_6-450&4+O%YW
M/E]UVR'3')U8F3]<1#H)]I&OFB1S^DLRJQ4J+LM73HUS(>HC.PML7*V1MR];
MN9\8.0B[-"*E" L<Z34D!'Q0:A-.T[6O:UTK3'-@((4#A U>5S[8%AP@="UK
M1ZW@LH/ #BK4Q7#;L@XAJ+R9,L6"A(L2,&3,"**CQX\R0$A@4(1)D9,G3:(L
M@L%+NX$K3QIAHL2(D9A%;!:I>3.G$24\;0K%2;2HT9U'91)E8E)GSYA"HPI%
M8@0)$ZM4I085ZF4*RJ<^ERSQ0=8'D2Y=A CI0:1M6[9$6N&P$($! XQX\8J\
M&"%OA+\2 .?E^]>N!1E%+%CH$JMQ_^-,D"-+AFPI<JS(F#)EMJRY<N7+CBE;
MJIPI5JU:BQ:U6,!Z@5T&$11?5*Q8AD7"=2W:_<N[-X??(?YB (&A>& +Q9,K
M-UYW-^ (B1D4*%"W@ 0ONMIIUZZP^S*&X+OKFF+$HP2I,D*86"\T?4<TNHAY
M[PZL/GV&P-H)E,& =F 9&-S@PPTM0-###0C>L ,.1>#@8%D\^,##$CS@H. .
M&&[1!0\M(*745TF%>-04V;7CA1<=$86$3SII% $(.&#@0Q=>=+$%#BTLT84/
M8CF8Q(];)('!$B])(,- V@$# @!,M#,/%SFQ))5.'TXI4TU1EJ323EB>I 1*
M)A2Q1!().O]X(E-)%)%$"RULX<46;I[H!2-ONLF$+M@Q=")X#+GB!4M%>.$*
M!!!<<$&AAC8'VWE>T.0F(\:XPD2C)80$ E0]]>21"5X<Y 5B.#$%EE!;4<GB
M4%F:BM.E1;"Z4A(SND6$#RT(N(407;3B2A<(:KB%6$L(Q,BP=,I9K)QS#LNG
M%TD F-Q%&HUD%T9WW29;7[@5)MVTTDU7P%VP]=:7MG2)^]=M(PFVZ+78FAN;
MN^8:85L$WH+@A3 '<;>,??/MVR^>(&B@ 0<A1!7"P>6!8,+!#(?@$<(%3X$&
M0GG:])$1NE"#D$(O):20QQOORY!^ZE%!Q11/2&!1<BL/)X.E'YG_1Q)-*#%A
MTY<GM<3=EE7>S!3.,MVDA,T^I0H644?K!)2'*ZGJ)=,K\9034%-*A<354]/$
MU%556?7S3Z)>=;5-&7LQ$]$KC>6#$$2PS;9;/<0=]ZQ$+%%7;WC5=5%'@?45
M[6 9H3N;M.%:L 4CCB4^RV2,8Q(+)IB0QKADCXW&66B6.+9%"Q6T0)M%H"N*
MD6+BOM87==+=K6T!Y?[&@0E[AW0M<LO19?K=?%_D;0$M4;-=O_O6)]#&"8W'
M@08=-:R\#$8P;,3"$#O<*?#$@/PQ,>!Q5T2UGT> 8(2%XH"6A .VB<,% HZU
M@X 2XDH66D)$N7111XN8%%-(WV23J$9@__"7M^VBP)B6H"&T> %8.F+$0(A#
MERGH)P(8:,<__O$[)7P+@CDYCU1 U+2HG,II2;$7([K@(#/]:@E,^%4+DG B
M&A&+3L-"UJ]H5!(ZN4)/P]D?CMC4 D/YL"X .!<+Y60,1G !.\MHE$=. BH.
M0BU0?X**%,%F,U11:8,LZA).=($&5A$G)@[*T5FZ<!99H:4+D%*& 8EUHF.U
MT5@OU 6=ML" "M".9<1YUFON KC!\,8NW^H;7[IU+GB5KF_-"4S?G',1/I;+
MD(7D#5V0D#OK3.$-UOM.)H&W$!1]1#T'BQD(#K8>4)JRE)_<RZ08,A"&3"%F
MP^,D];X#'FIX@?]@5$##$\HSNMD@)T4PBUE@M/25G@ M)P+AV4^&DJF48&J#
MICH:3<XFM* M,XLVP]]19O(4K7C0:J2J&E.\MK7]C?-J63'"Q$!@$K2=1&US
M0XNLWM*VLT" "1;832.Q)4B,_&4O?<R+!5J0+@9L81&TH$7B+C.YAF:"- R5
MS&8F!SG(..8TL=C" @#0GS7Q\*,8L%UL+.(NV*2N=.\JC"0E\!N%P:XCM$-.
M8*:S&].!8%R L4X12K2=E\C2.\! PQ3VUA'D%:Q@"VL>PYAGDZ0^;V%[P0+P
M.J4?8,12%\+KSK1D ZU:$8A-"&I!A0S%@S.214!GP5#YUK>#'N!$53S_F^9*
MO'#,G!#MFAULVE>J>%-(9@0QQ2DA#C0T%@)V 4G+\-]?IC"0)'Y'":_)"$L(
M%P%F FU_^D-,U>RW$@ Q0C\E9,2:<)#"-RT!68)"%D/<Y*?BG*@(*YS3FUB&
M 1SQ@$/L\P$.?! ! '3(1B=RA3+\U*A6@:!X?WI9$UG$69P,#4L^ZV:JB@9=
MS)I*!DCP@E7-%I/:^D@72Y@G$3C4 @S(@!%X0JUZ7Z@*]#*""1BH@'Q?%M*^
MA LPBB'.'WG32\(@<E$8"2)?9GH72#I'I8D<,-X:R:W;[9=TT.GK760P,: >
MXZ?]>D/_.M*\43ILE*A47L,^XCKS2.!.&4N(_[ZPX 4TE,=A',"8QI9!#/D
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M^H@0OJ,+= =D$E $/,@FWN4@/  G!61NXN4'7<!!15<4=94_($047[)V:U<
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MF;P($2\P"8T<FHW\%:]PIOII(!DH-&JZ@!:(LFN2F>7CLI@Q&I$(K>^(FIH
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M5K>&""Z9_M<$R\GF:!WC># 0V0I&X(* 0LF4=::BT0AM*N.0"*<B*(&M"%[
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M(0$(*D Q_ 3ZTP(&#$#W\J7)08*%P$ C,"A<.((1)49X%MFYN#'DQDJ*T,0
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MA&[]SAD<"/3R-:>[GROW[MB,Q!"#_R'=J:[Z=ZNS#AYXM'03BR$M++#>@!&
MT()]X.9'7WQ%[+WW[_(=]C.#"QJ(((+_ ?!N@W865H!Z!2BQS#_9<U2VM$3V
M"/9 )!HA0XH@+#;<0AD;-! %7+9T]C+$C,01C=U77*073#8)9!-[FH\A"+"
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M"2E?^(SP-1#\A4Z,ZDC5MD>VD\4/-#FS'PB8XC4K+N,-7L!&1Y:!!6G] PU
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MA&4TA.\,3WRLTH'(28,(" +$!_+81,-M33ND0XY C$A '$OH"D%\UL:!@ :
MC,8-!4/H11%(RSM9R)GH@BIH"<SDF(] T6(X5CV9Q53(#,L9P7  B9,83CL=
M1>>U4Y1<DSVE13M(@/]L*5/W?-^4T,04^.$\;(.G0: (:DA7P!)0R%4D'D-
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M0]Q2J*V$5Z!,G&G$A;Q<4H+&!:G%X7G!S>U2_&5$4D00+S60I(&?HDW)VF#
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M([D&MXQDY54>#5WCW^ G2]Q&9G !<J%!.T2#Z9HN- 1#?%U&%V08:UP !%S
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M6**++GQP!4POB@!A/.-,L$B"]*B\LJH<F5 2JQR54"(\+'WL<\GO7'&%B1;
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M#UJ J3?Z &M55 K9&!(V%J7&*6'C3*\B0"S26,9PYE$3%;) J8T49#_PBIU
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M,H4W_%1AV[A'6+LWA0"2MCA.8>69B3&%D YK(\ES%_]^?M(.8,@$"SY+W<&
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MVZTE[NM<@A^7&Y#HXG'N542^)#WMZ$YWRE/49"#AC##J!C\$HA%Q< -9-4K
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M@U_";_4\Z2"29R27P0@HH#EXSU<N"0L3"3_ CQ]-XN3 KQ>NY3<&RR>^XPG
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MD;V\05V37F Q14@B?81>1QB@08TN3V!A G/+! @"!T8X&&*9 ]'GA4@@1,
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M4[X6>&\A$CFR3/E1: S30!_F(/DT!470(RVE1G=")=4!-N:4@./D$3(@45O
M=E[0!5>A:XX!:EM0!!3%:7[3!79'389S:IR1@ $H4D<C4DK1&1ZA! L!;+-1
M@BNQ!$WD,[GA$0YU..EQ'":T5-1!2]T!;Q:!(OWG6&*!!$C0',S1A:LCAJO#
M.]IG)>4& E$U0O_T\C68,3JB@D<Q%S[Z8V7$8!!30 S\)RIE-7\F$!L-<3W4
MDS1P00$8D 4_M@S10 W%@ 94D!X<AT?ALE<Z1F)AL3I@-5F(&"+5T1W7=AYO
M$1L7UTD5LB%(DD))1E?0)G))4B3%D'WQUS"X\1% ,C/;TQ!80"; ($$1A ;B
M$B(, C]>$'$O,7DN@PT6)Q!H0A=@4W6O@D8#U$(1L 6&,(V" G9H)W9C%RB'
M BD]%"F&0 .84CJJ4CI>T *,(7<8546N8'=3Y I\Q8;XQ@B=YSEO4H^'-UQZ
MXCEV 0 %$!6S4R;'(&$D5A#Q XCA=CW1 E?1DI $5F!K<C9H@&$N!SO_T?,]
M-D$,MP,R*/%Y$C9A5+A?$L&) ',BXD(OM>-^F3(?=U019^$0-^,0W[(Q!%$B
M!Z4A#W)'(]<QWI%/"[%5V?)X\L$B.A:2681'&6@>WW<]',%!TC).R486\ 9O
M#@%NQ =TIP6)3Y=ORR S+]1Y:O$A<$-[<+9JXY0T $,-7" 0RA=K)^%FW31.
M<C8WCG8U)&$2BN,J5'(S6.8:;S$%9O$6*^%.#*,*!F&!!0%_A18!=28GP;,F
M+H0P?*85YK04GX:"78 IRV ,I-88DZ8W,N@8%[ $$+4$-:@+3) W3H$X/,@X
MIP$U4=,TC0.4IQEXM<D:/9($7) A*)$W%H %_^FA)JP3>Q(FE12&A7I%>1P1
MAM&1!2)D!$W0.N,AAKPS?(*)91PQ0B:V#//DE?-D/.^&5U$R3W/C?NYB EHU
M6$\$'[N%!H%7<R2V6]MQ1[+Q$2P1 34A$*Z8G&_S/=<UE#IV.TAP0E0% C-9
M+%$&BP;#=(54?1:W+2TQ!;T@<B*7G\! #!/:,05!'3OC(3\C&IS73-A9/Q;G
M<KZD0F] ?&'! 1U"-.P'>U&9DJ9"=:A#HWDF$IE@"+'@=88"*3Q$*-D(I-TH
M*(9 :M)%CL&A75VP-X1#2%-D17>7;_5B2/^@"Q= %H=VC^M%7%BG7F[R*P5@
M%Y/$'=AQ#.:"B-_AD/_.DH9>,6 $!E<<D:; XR86\)<E$@W@ C +]@8B8H?R
M(F,'V3O_L7R-%'M4AAWP 6^]Z!W^DB%!:1\.VC'4\ 21-1<2 ";?LRT2HR*Q
M 0P'9Q,/I*%-8I@662+Y94F<I"(J(Y^99"$^]A(R4B+QLQ66UQ724AY>,05Q
MI3]2N2WH,T(6(4)7R34N2COI(#,44#8-V";"L@0B6)<Z$10YX7MX5!4"B&:3
M"11NF6J0$TX'*((GH4\@$3;5PC!PI0'GJ@'?]F\D,5!0"9;C=$9J]"9/@ 9Q
ML*%8A@93D:TH\1-:(5$+@9D@8@Q>X I15$6/4P0XP ,115$XX ,019J,,##_
M'.5JDM.:.;B:3-@31C.:<Z$3&5@5&' !L+$M\600(B0>P8A7O$1+XW<D1B(N
MT581X2,>8M@ZS[E44S >3;4>+Q<6VV,$;YA51G G6#8%2( N3Q"GMM@717%?
M^I*,49LI'O.7]B%:O9"*X9(@(Q<A7O418#%R$8$3S((_V^(&N(<\E\0=WOHL
M.+.)+Y2@S9(?F@@1PH*'(G>AKEA!NYA/F1I_QG$<&*! U.0SIQ6R5+(>Z<98
MK!=S=%LFW]$<8=(0M>>+QM0U"V$, L$$]@4V,P0L + %.+I#V.BCS_6C?B)$
M0]1<SQ4<1+0/I"-%TB6[C, $#M4"?,,:A,0I[#AW_YO2#J&R,1:"55S@=\%Q
M.O@X7,2E"XOY1C@SE"$9$9^$?-C4$'%J!'$J TLK+9-%KO=52'AZ('QW)!+7
M9W.(3MT# K5DJ,A7MKS:BS81GZ)B#[7C2\ 0#,6P)AX1//]QGCZV+1=!'6^0
M)+TJJH[$+=$CD=QB$-SR!EB05WNJML2RB3N8/>#'$>5!)1?\(:1E66_P'P?#
M5;QJ<R,B(E0@'5D05HWDN!%!,O01)<@ZF($G*QC0%-BZ%"I1J9_;)B"0:FE6
M->#$FM_$KT&Q$%;50EZ1>6E(+=2"KCTR!2Q8%1$ - R!O!'W;=2Q"UE<#+W@
M"Q?$!"I"?RMQ-4N3!*.6*?]=T 5 5FFU05/H4F:D69I+< ,^0,>=A@-LEX.G
M9CC#DB5&HYIYK!L+L:2XBSH#]6L?(6=><(>DU!YX.GXV5YS&>209.B(5T01N
ME1)1P&W1"9W\ABZD5 1"JR*A;"<2X,"I&"$'YR+ ,%62E<';PQ(@8G'M0$VA
MH2P*A$G<(<"7%1$7P;74  R0YA$14'0307G,\F,#F;:R]'%'AP2GA3,4-Q X
MTA$%-AX@;"9,@ 19X* ;^CJC*EJT5(A J<W+8 _G; \?1T!6,D_40R2N:!#%
M:":FEVPG1%N'-;E,LJ>6FRE1Y'[QDP5E4P"&T7E]8G:&8G:1PHU&%$1D1RA"
M-+K_@*)V7"0#H8:D3JI=LTMJHPFQA(,!6Z ,W$5W[>B[)RFE,-$"3=0"A$<7
ME=%KMW(KY0:F * +R#([H;3"A HMW_>FYW&K54(PO $;U;$3_OL&VL%[]%(T
MM;:1Z"0U'M&?.:W" U$=%>%+%O<2187.YXQ'PF*A.\F()E"(^HLS*4R3W<&W
MG&@FK\<Q__NT=OBJ$2S-+-P?N22;".E68,(:2#$Z9Y5"_J) YBL!)"K"P/!M
MU.,<Q -T.2?5+:,=Q(!EN_&5RUB7C08Y+:46M]*,;\$ <;FO6<$5%(RM+,BO
M/6PY#!-@:WJN:1@"# -6(0#*1>#7FB,P[<%.[_.SPUP _S87#-0P/B5"'4B
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MI'0(BO"GHL$&5*F6:'N3#Z&"?',E<(D7<5D&>YF7IDM'Y#HFAP&U4>.!)?#
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MEJC](]@.BO5(IYEZ"MW^8S[T;:B@YU^I,#*I%2<S0Y7]K0SKHQ$Q$<FQJO2
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M"D8XTC:H $8"!&&*3S#P#\;T[2Y,3%>:$)*JZ @.! +ZC1$LT)VM_/,G#"A
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M3Y2+.RI:T+!$+PS$,H# :V#%&\P)4]0.O$@ CY7<,NQBZ+$+$WC&%(@'=&"
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MMF5U8+R!*<\6.P)#:_V(/1G!$F6$1I-P+U96.]"4!"@! .2?G_H$9PA.BI1
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M3\PYM\Y/8D3X'+H+?TH%(4WN&.$%DS4)1,!$!D^$S"+I4H0-C=AU$SWZYTN
MI&O\[8,D$Q=Z9= &=/R-Z/83%J-B3990/?W($RR#V2QU+Y)[92U##F6:T =J
M@*6*$JA"")I]:?1"@.>%)7,.:"2YKO64;(-_DM/S2MT@W#X$M%0[Y)%CBL3*
M%$*AY9W8MZ\=ITAF>7G>5E);OI!F, !$,('+H%'S L(+!A"ZB"US^/ AL(>Z
M=$%<=@RCLF7*C'4T1I$B,(D6I_^ , G"2+M__Z9(.&G2B!$03"1ZH;:,6$.'
M!XV8D/#3XK*#((J\Q* &Z4JE2Y4R :!KJ5, 3Y>BFPK &M-_3J%JC7 5;%:M
M3/D!B/"O[%FM5L^F'?L6+ERD:M[H D:L6-YBRWI)I$8-F!$/+F4J-&%2@A=B
M=GOU%9D%23LODW5Y4!(48LZ<F"LN:Z<+PT_1/POHDDR!0>H"!2)$D# EYA0O
M#M'H\B+;2Y'6NUU'"/TSM00&/V/&9**D2/$BR6,J*6YD^7,FT)<?-MU.93I7
MMI?I@CE;%Y/E19B4/XZ$>5$02&@NQ?[OLQ<CK2T4L2!!1GX9X\<C3S[^N>BH
MHXZ_ 0?_Y*\_Y8HK[[G.=%$"0B7,FX(+(_;;8HDE%N"A"Q\ZO&"'4D0<L90_
M(L!ABRVZP+"+)7Q80L4E<,"A"R%PN&!&'UH0@L01S?%'%_(J H8AS8P\$C.'
MJ"@.!#1*XN G)I;9YDB&=)D""XAN*@D$EU[RXHW)=,)IL<9T>0,-Q;;!;AEA
M&/+,"RPJPHZ8R28#X3?%CAP3)Z$<HB8::M#X::ZX##T4T40579311>=R")LU
ML9NT'31B,@%*"33X"03]7KKO/M)6PT BD8#9*ZC LFCGB2Q<14(7#D((@8G.
M(++5(3XC\NRSU? T:S0+0'U)-".8P !9#$I L,#H:I//0/*<_S.."?:.*V_:
MYXK+EKSG(%2N""4JTD495Q@YUY5TC>&HA192Q %9''C@\%@F<% )A"DBVBS)
M?A_B "+Y7EKHKX>*&>B-(DP(#82;_+4()%N5488BCW0Y!B*,(>)R,BX>\D("
MA4Z2"243T&C"H;S&A$VFT1X25 (*B)*/T*3@DHJJE;Z"2A>S5BJ"JIZ+:.JJ
MKICZ2JR? 6!"4;?6\KG11N>JJU1=>HFHB9A1TO:Y+D%XPZ%>(KX2C33O['17
MG$9J2-=<WY2L @"$%:VWW3B=C+Q:*6V'FRN-F,+2UEQRR34,[/[)-0EB*H(]
M)*#CFFOF"#1V<3R-66:?S[@@SPN0=/^++KV\'<^[" DBF"E?RL(K%K_4+)!!
MB2GT"YU9R0T$%\'%!=Q].?\$9-#8Z72_S"$E9"COO^5NF/$"#);HHHL;MNA1
MQ$ ,OR#%+G#P$/H5NX=>"!YPJ."""VZ(( ;J2V'G,R,4(W-/(Q]6<HHI/%B&
M2^)RS74SN]+L3A<^*8!H3&*"SMVD&&.K2V>(%+%E,*%SUYF44&8SF2S<AE-%
MT@S\-,.0*?2"3[HH5-1(6$(3GE!J2'D(I6ZR&(. @ -06HV71I.LWX@& 128
M3<I,I1<3X$H7$FB'JUPU!>_,R@0CN15%'M*VD6 '#0@H@&Y<@Q@)> !/7@+!
MIB10@)F(IW;_8;2=[980/ F)!PEI-,\:UYBMX"%/0002UT;*A:YT;><C26@!
MO"[0KCVZZ (06(YGC("&^1W2(0+8WU!.0@$T;&,;Q1A), I2C)A(@ ,8V(:_
MCB&2BT#,"[4!B4<L!I);30$)H2P"%N)$,H6X#PM(> D#E>B0)URR6!9)2+*6
M,\*Q% $J0#.:,/\A-+1 [1]?><<_@,G,G!T-*TLA9C*C^0^V'+,M4.L96'SF
MM*]PDVG%Y"8RXS(U$#90/O5[PM8@5YS#@( "&!A22$QEF_IY(0L@\("^DD0,
M4[5M&4_T @ *$*K1M*9)O%*"! "  6K<XQZ4$HKP"B.!!C1@-,()_P[BAL/.
M<.G.=I +G1FA@X$B8 !VG;'0?AYG! @QISQI5*,1YJ8X$*2& :=##$[QXU(9
M6&"'N1&C@ B4/-H%"'2/JUUSIL#&:[TT0ERPRV*,8$,(0, '-UC"#5K@ QY1
MCQ,V[((7?#"C>=U@!T* WA:VYX- 5@ #YSO1']3'/F(4X7T<E!\BE_&WEBP#
M#58$FUZ)T0Z' *-L+0G9:QJX#+TD\$QE0T-= LJGQKI)& [!#C8Z%]#P0- +
M/ODA2/9DD;M"S)<H5.UJ61NUN:B)3;69%$2]HQ ))""CN?W)%"02C4"1R53
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MS4@HXN[LK8)2#4\0PL[,#61"9C:((4TX12$PP(L8B(&L3M1>#$\H CXFQ2Z
M@1'!#8!(2W[VZE;<1Q=8Z2#6<M(F+69XK,> DS6^1#YJK"?B22&L<S(R+N-0
M26$0@RMU"SNQLS7<QT[ \ W<P$[P)I5"B\4*R'!: _^T5 <?\:8_$3%D9B*"
MZB<-^XD8"B95'.LAT&2R[.(-C, A<:MD3*#&3,*0*H6(2N(-<FX*CNMAZ$F)
M5(()6*,! $VG9/$D# H)6.9%Q8LZCR5D?-$V *0BH.5QV(CIA#&F@O$LKX6B
MDN/KEL.4T.Z.&,$V=+!\^BC !*P%(D H/@,#W(U?OA$S_L%+3( [D6 ;  ,:
M!&(O>@$E;B,=NB-"^Z7ZM"B&>&L91HPR/&,GS6U*ZNPS',(#\.D)P(882.8D
M7&(*.TP#>(P<'5()CN$?)M)F*(Y1&W4LC&GX8/(D#L.58*+YD(48IFLA(Z*!
MTN2"**(N2J*0Y.."+LCA*NO_&^^"&OX!!*;"H.+2"](A@/!$<MYK+4/F-R!M
M<%*C;NC#THK*=WBG2"-G+-]HTRAG '&*IPK0< I4.$S' BZ@ HZ.6HW.Z+#+
MI'(GI/32O+25TR#G6\(U-G8(#2K$6&P(71>S/F9$1EI 6@%-$\"*1J"'!V0$
M!V[@!GA P(3 V/ U!\EG>5HR GI@!]P* GR#!]2'$KP@W/#*W=R&2.[B2D<4
M.Q1+BY3P(;HDNU(-5Y'%/652G8ZC^8Q(@IJ332A"&(3A->^N.[R 6EDMMV[(
MTDZ*@%XC(5S"@"#4;.XS0G56LEC,3FJLJ2CBI SJ-P1'T5C#-?"*(LIF#4.)
ME2I"_SS$9&S$TP02A\0$ICU%PX@FKSN (4X,[[!L11?THHE J"]ZP4E"R38D
M  $(R&LPU 2JXYVP8Q[0@.9\4CXZ40,&RU\>UOLT2S*\J $VED5;]&YN PL6
MP^LZAPD*U("N)#H4XS8>)[U<S*F*D4<7!'FZ!5P(9%R4P8Z0U NL\5[QE:NN
MRC?"Y!^(P02P%)':@4(+" 1"0!71X+'VXD--)C$V;")Z+B%8= HPYAC&!N#V
MBDT<HGB]@QU/ DMRDV%483EQPI1NXE()]2?XKLXHTE&[5[6:[)D,92X*U 3_
M=&#0@!$/*R]Z 4TFPS/>P'&2RR&B81<"2LZRH!W[96(QH_\AVH$:3G2 #"K0
M<FI;8^)5.Y;^0B,T$B=9O"4]0*TL16I;O<M8BF(M>96&5@V+3F(P:O2_DN"D
MD*5=< "$"U#0^.];FH4_J))W*CC3IL6IBD,VF&@*LFL_T!4'GN>/V.H"ED "
M3E-$.&$W(  #>OA[+),%H;0"( !%<("):?#:>H#;FJ<(IH=Z+D$U#ZP;,V-_
MYV<QP&T<)>"=*J*T@LAKNB2>Z*:*+!4FZJ>(W!@V:A,+3FQOJ"1B$HX.34LD
M#L)P.T4&3L)P.2 V] 483"(_=RA,)):>&D-L[M%J=L%J0()]92D"'/(*;2A[
M%08GNJA6)@^/[6)*[ TV.F?P)"7_2)# 4EXT LIF'(G"/0FC:P>O.P#(#0H/
M"R8QSS9#92(+GSZ5X)*E?+/+G>060SMQ(2CL'[P@;[&$9$P&=LT-.VX*;@^W
M^43#<ZDS/-0#;WQ#(6H#\VJQJ:2#ZX#1Z](26<4.>-;(_ZB#"3YB8I 4[7R
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MP 2%TP4:0M2:NU @6M?RP@])QRRN?*L=\"D7;Q@0 0FE97,V@1<$2A#*GD"
M!2SP206(PA$ ;.U,/DC4@AC6LB>%\)8R&TA!U *]SA4.#49 @D!V63U5+$,9
MKIB)#V;2L45T00)%P$$+ND"$BRAA(0+YV<!^M+"%K2QF#!M8P0A6!"Z\!758
M@D@10$ N$,C  AB0048N_\(3D-3D D7@2".85@HA$$UD))&FU"*P-:P5E"D%
MC=<-C@(!$L2K3#A9@$0AP FUN<E22%C=_^H4%^N0SR(4\)/HN..G\.C-4F=Y
M@^#60@$DJ+$KQ>BAH\YW'LF,)BQBF1&-]C21 F1A-//Q6[9&MU$?OF89#<0
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ME\ VE*8NV@,W>[AY79&18_$FMK,\GK=A@;(,P'0@P$,?R58X"V("T2@:&8$
MDH%7D(55?5)5C?D5OU94OW9$3J<EK/*"**(+R*$BRX <912(A %,&1$YD1$?
MLND9$ )D1D!6P/9V3- 9BG5KBE2;$B ?NL!OC%",$F%(+(5VG&,AA<$$C9,8
MC$=6@+,-</\A*KK0"]ZI2+3A<\00#6C04OVU#,KQ!/?S;A(71 Y(5I!E+;GY
M&9@I&3B#B/A9.(,#'_\"38[3(P'38SEIDSXF<E#") _A92#D)Z[ B2O$"%_B
M0F=37/CG9Q!@)";@:936<^_Y%>TP&.13 % W12ABBS)5=0YY.\" %E2"%Q@
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M5W_&E9;OY0/#Y2[!%7^<$0/\E E^:2VLN%'$T)MQ<5>'F9VI@0W!XA78T [
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M8)A 2D0<84J$!__"(ZAQ%F1UNGH%-\)25HKYL].KI- !O'%:2>?+%<O2!$U
M!5X%(,"0J!H8-YD7%F\Q'F@P.VL!3^42 9PT7)9*>E\3:(?V8BL)JF5R SD0
M%%U0NT%VDUPF0K846#\9H.'DE &*,^NTN_, #!@2 8V(,+6%2PM!,+O$<AE,
MH!C\$%SPPM>D$3'"=N-7 6KB XC 3WR0)L%E$]GJ%&D9Q$$! 0O $XH& ='T
M%"*S!/7'?%[@"E[ "&)R0E_B)97 3W_[#SB2'2R2(GNX+>Y99HZB"UU\:J#F
M*PW6-MD[N1I!)^"1O5EP<%SQ!B8@;13@1(CA-\0PD3RB:9?+6:;3&@C_B1=*
MY+&L85),\ 0WHAJ8@5.'V82*0B,808X91SX9(7%$Q\83H0&6)!:&@P$NQ960
M.04>4,J1T:K-J"70%H20 577$9"@@YUFC+17H2.8=Q<SBQYH$,B^HKT^5#__
M@ 940 6.TXRG)SL<2II7L6:=(U>AQ1M94J:\02YKP;^; 4T%FG(!:G*8N*H)
M@22RJJL"81<6JPN >\XMM'\WL&[2= $CHZ/&4@1,%%9%)2J'V17_D!\#.Q')
M/#?VP:/9X04XL074 A_$@8^%95X.2:,780%;<!=<H+/1/&_6E2B. T^<H9M
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M8_-"_[*\5WYU1,6]T N%B$$;B?C8VZS9RJE@BZUYE;-Z71Z CNC@A+/J"=@
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MU5LG2SC"$=HIYG;HT[H>\E_@-0\71C&* ^ZU7UNNWR&Z($I!O4 #%3A0=@F
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M21.2[!.81:&XF2&T8:&O?908+<2']=J7)!T82E&6E<YP@%M'<6U#C$UH>,_
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MV)"AY!>B+P.A)Q P. V,(%-46RR1%,!W9" 2"%/R#,LAYQUW(V!TR:YFA'+
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MP+V)'T["!0" :\E R@;XZM#88S+2#0+&6Q?;7JVZ:2^'7SS,;&"+5HI028-
M7&:FK7NF9A3 K(B*F!78O"]_(BVZF)4P(?58F![&-Q%DTI/K4=C\>6<7U(D)
MI)8=^("Z]C%-U)G+9U[2>8;&%+QQ1":73:V%=5S30;+9XLD*$F2!?> / C1
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MKYA>'.0-F"<8Y%SR!>>BV<%9B<EYF6-!N' D@=H]K-"KH4,Q^X.IM+6:.$V
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MQB!CF3W)(H<#4WB"+M!%F'90PW.P 2?K/AQBB&SC6T:(E@D&ZY]BS2^9!=
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M58PV)&E99@K[%,4+H PN_.-5< ,8O( 8_H%PWD);\ 9 V,,+)JY6HF0KT@4
M.X*)?L:/] ?3 F]D.(M%EL)I2([D$&A&4$[F4@()TH4E/D+37F(*YF-(YBFZ
MA CI?*X%;N &7%&-KHA/W@1.W@1/O@A1OB(P<$"(!H'IH.X7?W&'_\0DB):@
MZGP(A%H 4+JN1P0% +THBH8BC+!K*"@H1Z((O13EBC!%!AXOBBR BLSBZS#%
MW7Z" ?Y ACBA"T:"C=JE96""P.B1D.Q1(A ,L4KD0[+O./XG<[JO-XS   Q
MRG2O!P=QU1K$HBRO\^[ACWZ"/"3I=.('#9" EWXBJ(AC/K"@UR!G0 CI#4@N
M7Q!GHSS@)%$2(F*)-[P@!+  "^QC"JB "K:IUNSH#7M!%XBI>+PIE\2C_I)B
M:11E:BP+4C0O. +#QWI%(1("!+3I(IX@"Z02"QH@ 4" _.X&_8@C_<;)&(8P
MEA2&:?+%TU)#&8(CT# H@R2%LAI-Z_+.M/\:+3E P@).B.8P4>30,IXX@@E
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MJ]<$" P6E.AB9%2DXI!+,"1Y7 0'#@PE<"Q95O%?NS>ZEGG^##JTZ-&@O43
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MJ*46"+WX%@TURZ#!7D''@@5;03']IB^VV8:T##"@6:?+&Z.M2.);1NC22R_
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M04J;"8D=[S$/+P L=V3Q C%X!V )(,%A&-GT<H[_JB#FJ6M!ZC*E^EMR.F]
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MI(H&3W!];[ ;H2$2IXN6K.A0!>66%;!M7K %23"V,,N415#_C&"&$@#5G[H
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M;^56A*?% YWYT]A*CLR&%QZR$\H*)5:R$\/'!3>)%ZTR3S^!C^ET:_ZF)GJ
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MQ6NZ/NLTXM")92A.8$B"KDR7HDP[8"@B!CB;74"#$$@:"T5 HE%+YZ( 'XE
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MR%3TX0J@ !IQ*M(S48NYG58)4$L0* IJQ9]2K%RB85S290AQU0_B0T3X%$S
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M.2WSQ#+[0.A%AD0AY7E429GH$Y8(_0,, $@@9*P11[N$HVTZ C" ,7H( B2
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M,02CVV!\X#$?Z,$^*!.0*Z8IH)3]9YJ]8=WX!.*%@D0P.M0 QC\D0($82<
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MH,DGBS!0!EI'5UA2F;2#4.J@675&$AP"6=)%R\D4$V#!9: *9J"2 F$#=9A
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MFF6:*V(CR=I)YSXST:S@("] , &)U<8$9@H09/"( 0O0J- Q#(K 8;D*-(K
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M)?I)^I OC.!B^2ID8]8')U6R))-,&93!IJ+##FBN*2KLFG1B2WR& Z\IV%K
M-TZDLUJ+PO:(_6Y@Q3@AGKHF)O3%8GRBDJ("IZYI)I9AI.R!$9PL,.;!)&4&
MH80E'!M'H0K*H&J#-]X@TLH.6][@ 2.P/4R+":0PV]"" R<, +8IG+K $'PN
M.@(A!FC_0KE(L 2QH@BH @5CI;F"<9&N0KF8HQT8(0@9 LU"QB%^3=@\"B7%
M)JDN!-D.:^($156JP >.< GT(#H.X2@)TA@B9]D8*[!>Y'L.92)NC S-9)A6
M4GNR) W#4'PF!S308SE#ACG!D$-P<D4&R-S42K%F9$A0!DN$!'Z"I ]I)!')
MRH#89W^8!$<*B#LCZZST1R46@K&69-^V)!B"H1A8 QC$T_J\P W<0!>VP2:%
M[T1D0%XH0@:^DCS(Y0(8QI,0Y9P292]]TV,PP$PP)*R\@T+"R!6B#BQ\8 L>
M(1)JT1:+#E6RHNHX<&F:"P*(L9,L;P=J8@>D+0EBZ_B2#YZT_X8:_Z%WW*#L
MTB[M.(-:,LJ-H*6@**,@  A,_D&/S*+$[ N/RJ4%\BN0..$0O. G"JW4DFLK
M\E$?&<8?IV)33"56.M':"'()&@E+MX+]:N7 P"E6B("'./0?.3 JN 9?N/+T
MV"]6H @'5HSU!B+)NFL+ZBD"N"#V0. &R*=""$A/OF=EA,PE&?4D3&![4 92
M56+N+A2:VB021V(+R$TD>/,1):,G1]48H@,1BL "$L7D4K4%M@0*\T)K@BU]
M.I,AVI _<FUJ;@"2[K&'5JP3")).*V8BZ]052+!?QN("#J((+)"[?%*?<+0(
M_H0MPQ$!K:4M$=!Q:L,Q=FP;D25;)__C#8P@ B)0A"(" [  HB0D5BB,+*2B
MF@"@!;I@$1"3+?[ FL3&DVBBB#;G7:2"/'B )E;E!9LK4SYL.0!J&<;"V<RL
MY#2M3PY")ZY)1V1 )5K S!*5.42B".;$!' U(5(L3#%@"9'"#D0M*'RB0HYJ
M>TBB.2-B(M#PQGK-E[;0>S($.'1I#&''K4#C-T'37$\$@XIDW]!*>^"0.Z<D
M. J4X?AM#XUD#VE$?F2$$<4JL503/8%$>T@B @J@ .AJ4L?D#7JA%[)%0TSR
M1MI002:1.#TB(T0&+)8@]/25<X:K07U3(S[&8WZ'-W1"63/D(W! &3XQ>0YL
M)DY0*!;A$>C_-=7X0 A(L!=))2L63"V4L7 7Z0*BC2T"50;I,<EL5,F$Q3AT
M06,8)QN]U7&B):#@1DA1ES*Z+0 % U^A0D^==&!410A $%TB00A4983L8O).
M=BZ>YG%?4&E^$2I:Y0:DHNCNSQBODC>6%"=8[1XWZ5*>"))X*QA[44^3X DE
MKUC+Y9,RLERJ$I8(8AS.:6-5(MY*TC\F%7Q^+WM^[$-6,B%@A%%!)")IP@MZ
M\BV6SQBRC&^;A$K:ETA01D>&@QU$=527H1N ,K5:@&*=[=E,"RJ*($;7#3ML
M!SO0UE9O-0FH-/DL9 LP-RD #ROMHE^< V%^@@FVX$W2<0G,T3AD_P!MTL8D
M]8:@WB:A6)=:Y*8M*6TWS"YO6.);-\,_>:,IT18B0.!/BH-89H(#!6SJ+,43
M&6&V LE>RR)5Y6MJ6D"YAJLQ33 8+05BP$(7V('YP(-+=($L/EA$VD,&;C#F
M^./7*''8)K0^2L3Z;-7Z!H6^8J@%2!@I/N'!_#3ZY.3B>H1G)V(B/A,B>M:T
M4 9(/!5$YBUG.\H"-"T-UTT,=^U?C& 90F1_S"U%]NUJ5=-]I,0"^K!I\Z<[
M'4X\#ZB75F1C0ZM(^+!H[8UHLQ8T4CDDLF!LHT$7S&K'+B0PD  +WD!;3H)B
MBP )-\>9D=!>[.^GM&RU$L7,$H4)CL$/1?\"9DC"12Y$;PM"(+R "YA)%P3"
M SMP$29!<4.'$QBW5'A &9610P'65DKE J **?HHR0;25V@T+I;,)_;/7]I&
M&,"KHCS#+=WR6B9CQS"@!$#J,&16+817'TOL'34A2@^!!]KC^7  13[(^^CC
MGWW&"TC45(RK,M%BP/21*MYEZG" )5ZB2M/9/*A.P+275TEE)G#B>.Z. ]4"
M*]214'0.)L8/*D)18$IL"\A7DM+A*Q>$H7RCEM-J?DM"I(%)0XA$@EX&27P,
M9D# .[TY0XA6)YBI7Q""X1:($8ND9>)C5.>Z@8EGBE!,@O<2(UH5(62NM Z%
M/8A&@[2,;8"7.=[_ BXR(3I,&&'H3UB=PR<\DCS0XE+F;I_:00F48?_L 4>/
M@&\,32YT>'7?Y@!)6^W2JQLMI&TFPR0WT9*5(*0BY!Z6@9-B#BH@*1_A,9!T
M]SSXXG<&QHZ2%PE9S00C1GJ78!D]*50EPQ@HFC-!L2(^TIJ:BK 9X9CHXT:0
MH I,H%R=IQ0]*=A"L06BHQ.R\K/& :>RY"$BH&<[*V2"T#F7\V56TA%Y.0?5
M+;!MYR$V%CC3[)Q8XB/TY+$FN:L;+@A?QH!&PP@R!B,X)#<QKH 02!$[9.+.
MC^8.? R_9S24 #WK&R0@3@ZS-FO9FB6@8=LJQ);0=D%V+)HSCU RU#J<__DF
M1FTKN@!-+. @,F<B@(==+X";MCI&8(XE@H/L>B6%;6H9?)<)ND#4ZC03.N&=
MT46'-@4KZ%EZ>S$>CT(36L 5X.*F^Y>Y@64FXV)GO(!88LPN=6.@YL8R<H,W
M,H*Q.JUVC9IV7^I1HG00@&=0JK (8J4I+( )F X'N"Z>2#2(F*N)>JB/2JD7
M":7.V"6=?0@SFV97Z=F2^NCNE$A5O#082;")IB*VY(\KQZ(L-,)6(C+3MPFJ
M/<=:A!-M.S9+*"M[F)DX-U9/](2HHH2R\LU]Q?K@@B1(ZK?@#&X0L>0CE($=
MYGHR:"$ZA* %]"C%1#&Z8R[%-"P+78NT+("MR__R+2QDT E2L=DB%GIB9U)X
M(H=U+CSRG/!O"0ZC'2Q;,.PA+0EM;G28M.W&WMO2;IZ%=2WM;#O*OP?-B2G$
M8G" $< CN@BE"WB !>Y@MU%E;F\  LP"AD11VE5JTYW&Q4\/BI(GSHF4):3L
M/#Y&#'\'L#$8I.^CN6^D!/8#/3)+$V.("@.V*<;[MLI9,4QV&92@8PJ@9-J3
M@Q4"!)Z B($A9QFEF5=68T<"-,>05C'B*5L+(VZ0"<*U   @NC.K#8D*#18(
M]U0+- K H[+P9T'@:I&$#Z\0?VR]/3 .9C)M4?NG.%W$?L!SUX,O:P5N)+
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MC) ) S+R(09&M!$;[HA*0 3!4&12IU/=9$LCF=/2F-;!I<P$(B9@BD)TD00
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M,!XC85N03NFT,%IQ!.WT3LKR,J-66=_3&&ID''5A.#VC:2W(3\B3/TR0-%C
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M6_%GE*,7L,>"KCF"_<(R[90$X<%4.-@%(UAHUI$5U=$Q+TA&/L!J[00QBZ&
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MIREV \$+58(!!AIH@D$C+U5TP> SIYR2@*; 9 #! A!J>K(FPXIPY2<OH,(
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M&]X<:"%&>P@Q,L8T>M:3:4MC1"ZGQHD]=*V06V.)#W*@M:"<I(NDDF;_!"9
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MHI&8^4#-;!,C(A5<"3:+210^\#K.G9I ^ ,[D"TPPI,+&(S"8"$H88H8<:C
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M47LP($IDKLK37N AAHTP-71CP0OD',IKSOV;+8!/%^N3*UV] %X2&<,+9Y,
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MXVPG1Q.G_SNE-,V<=+5<7,-B3G0! I^$O,S6'S-4&,"5R3%R+\'<YSKQYA0
ML"N?2 ,HVK9OE47_[&Q]R<N9.!M/2WLP,5=9DYG*]#2]&+0@'R6E;%E&::A&
MH0T&VLQ?53R:9@3*X023G]1&@5V&XH3.+VT.28'.P9C5*!F!#^B8ZU0)[;%.
ME;C"((T#.X#(,F1+L(T$>)S%#<P2$71@K8G*1.!8L^72'4W$M%&;O<E MK4
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M^SW-N\6&3=07*YH(,@92"IZ;O*6->W6?N/E-$:!$NOU&-1I';YC2?U!B9X"
MO7&43&!@08#'#51!?I!H1US \FQ!"YR*6A 56ES 5A&9 !*'2IQ;6:::A[98
MXV2&0:Q(OGP85!J!B$@B5/:<65Q *W1!*Q"!#;REK-D>+7''J*S<0PH3$S1,
MG>0C$W#1%?6A:J">E2D%3Y +6IS%2>3$-DEG!#!=N*D+'8E3N$5 ]?^=I/71
MY)L AIKHA(75#WST1-'@Q9H\A4YTDYH01IK<#Z)F5E[\&:.)5J(E(=W,A4!U
M!5**5E9D9=SHJ=QP98I)8&?8RU\P*N28R5*>6=IPAFLI1,&LW 2Z4#"!FJ29
M5$F=)>80DZHJ 7XLR:E074*LTA2@S[VMQW?H$@X @0[8@ U,A$ 2 1#HV!;X
M +/)6A=\1)30C%,=B R@XV<Z)@I G0-4P($LP2DA$SGM#:F)3LT5!Q*<FV2
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M)2^/!=+JRAF90_J>OH3H:X@2&MZ,HH+)$EQ ='>36=!1W;2'GEH )S1"$H!
M#L6/AMS1%FQ!<(S#11.;<"\#B.37++<>1#""#]B;PZJ1B^3R?69+%R_#)8*%
M-V&%(=I-H;T?AOM))5)FD*)EGC35JD$SZ@B'+[866J8<_1J*Y*7;"UEAP/12
M.4X=D%5$#<9@ D4IL[Y.0B[T0W1!4T$T/8-X9:06O51ABQ/.J=US-9<CYP((
ME$S$#6QNK1;._\JX9UBS*%%*6JB%?2P0I2Q!?E"11]NN4K@3]04?&.W'E 6?
M?/\DQ3"V4T6J:<B)6389+TS'&0)T%5!P!;;1C43(1205'Z'*1_624YKP#5?4
M9L=YKV81]9LS[_U=FA^BGT#%$Z1':@=9@&A_>N8%LP$"]6;%-FZA$G%\F,O
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MPK7*54:  F7Y)<,&9C*-H2L"^2I8,Z'F&Z(DY&'](HK<3'"")IP@?!XP&$-
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MO7# Z)+@3AAA*+PB\O3+CM[-"XX!-J!Q.UI+%[A N[KBO_2D>9RG] #+O[9
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M8QGFH1W L!W00 *F8$Y:H!G!1X..@2WT2>7@37M4Q:J:K^):@/2P48Q0(@?
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M%FV2YTRT.'+@)$K/HIA'_'!E<_\0;0VKLB2(,0YH9\@N_^NH*+B LDN+]77
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M4L*R S<<Q_@B O<*8[WC-L(\YYF)-7OQJ55@FCO8TS;]8QI#-/I:C$\+45$
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MX!)"EN"B&_]]*0+!LY%TO\,U3:[E?T][[= *=D**0,>#.VQK3M1F 2&518<
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M77Y=[?"GA%O^23=2 E:$@CP1)0(BXWB2#1L9L!%?BB4)Q>CX__T;"5'! !F
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M9K7/(]4=8I$('KG/2&   Y7_$9@$';;\SJIIRR'>Q'8! .\ #R8JFK>$!(2
MWI1,0!HY12/VGL@T0%2U#%4LQU:DGA=(@!<0@Q>D5'18 ,HY&0:\!%$=3_V
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M/)JME !O/A%)6$K)==$+N=!J/4F'0-&EE(A$=:?-Z- %</\*'D71 0G5!4S
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MO&5/WMJ"/./<',;I&@5<?!W/J,SO01^JZ<35\%AE> WF,:I!:( )X/]M"'!
M"&A 3>$&:_#*" .)@T&5=8XP<+/5C_7&7?P%,/]%7NS%W'"&8D25+AXS(](8
M"RT81]M,_0"W?-=$?UISFDX-E\%R+*,M4FS&5*A-%=*C2R*9!*CJX*R&!%
M0C=X2R8H5OKGG95R3K%1K3I&=8JXBNL4A+0VHKWV&B7OZEK6!E:N<I+E3%@$
MB>&&3$1TN" 72LBFS2CX^&Y$(U)<P UG<*&L/55)DBP+_^4:4?4*<YAG2X1(
MY0X/$[3=A#8,1X,;";T0_-QTFNO%7OYE7U95_]XT <?("G:5,HSK;HV<QJKK
M"3=)1^U5$47U^92/$1+)DF"*!$-5!%''GDO_9A67^<"X%<0^4C%RW@X;#!8R
MZ<I>H60!=JC$-=1L.K[&=05QH?$ %YXSS BY(1)="I*D#]J40&'KCY<@"R@]
M$FL\NKDYT14EC.$4.(B,Q!M5GZB#"I88C[9E8G!Q"WT"@ X< "=51UY12Y+T
M"JDE.453$0X83JS<A'%MXAPK]R<"SW^XD_\%4KF@4@&0B*)IGC;=:O5=$TK\
MVA*4'$HHN,3XU&.TLIWI6:-"K4-*@"[@:64(B/#]9 ,\I"T='L!C18 L?!,X
M!!2< $,E<I/ CKE@@ Q0"[P]FMS5X'7P>*[BD^I(Z=?AA=C<-Q/LHT%D!EFH
MCH_''B5+0 FC')#H_T )',&'M*53B7.OO$Y;+19X/;M^CG@W4^-R]+O6.*A9
M@)-%)#TFL\J8R<Y&+LCN\EWHO3C+45G56TA4@B+1P7:@?+T=SSC1>4OR II-
M)'=8 DL) +?V3M<1= I;27D$M55N:%.@="JW00Z0&,X3J9 0EJ$UV?U)=/DU
MR<0*7U-S8$"-@'59'HDK(/!<C@ASGG0/8X"::S[_P/F;^S2;VS28KSE0!_4R
M0%RK2UR7D*MS@A< 5$N.\)5GDH_YC ^09&'&?A"^!I&<>"RXP=;"SM6GM*5M
M\A"7U _N;TD6.LI]XJ?"=N9LU<\@FE $.Q$S9Z'')O7:Y2"'?*4#H9ND2/_G
M$^, LFQAKZAW=QZQ;4**I63H4IF0_2 G9><KHK2$GY/$ 9%$>E#*[3  21@(
M40)$ERT7(E0H4@1#A @7,.# T0)#!88.,224N(0)A@L;;T!8L ! A (C$90\
M4   2@ K6;94R'(DS)$%&"A4*$&DR)HV7VYLB*-B4(T$;2Z(@&%)4J!$>3*8
M&;.F! D6I%:U6A4$U:L@LEZ5X"5A5:U6%7J@&H$!@ZHWI4;@ZA5NU09QK8*0
M  ( %2I-3H"( ,!I2)XV+?!L401'D8T;*_"LB! #XH0*N594PH1)$2-*IES&
M_-F+%R9&$J:-8,$"AJE>"Q\M@O/"D@LE+AQTZ+#_8)+)@WEOG'#A=X0#"A'P
M-F[<:X2V5VE>/:M<M7*K<Z^JEC 7+=L+4C4.WFFS9EJ:Q24@>&ISJE8,%'8?
M1X]3X=.14E6F)%G2_<H"Q=F7^#M2H0.&LZFX"(I3"< "#22N .12DP&AFU3K
M3B&ABE **)X8$@D^''SR<*/$<)@@HO9XJJ "H"IHX0BE*G+HAMMN(,BA)68L
M@:(+<*"-(1P5 BJR)1I"B" (4A+ON"!QL.F@"!?ZJ:+#%*LHM"JMO!++++7<
M,DM&O'#%%2^U[(+,+JPT4Q==E%ESS6786<PAAG0$$8<;;N#1MPANV.&&'GSX
MTP<A  6T!SM[Z"$'.P>]_P "M$ DB* 5%WKTM@M::.$"B4)D%%*-*EI,H8T@
M@* %"$#]<,F(&DTQ"4P]''6Q%N)D=(+?0L3!U%N'6DPCVF"=[='%%LM56%Z%
MC<!468N-\[9F[X1S3AP]3 @IA1@0$5-E&34U1AY<%974"Y)8HHB%,I7()D8E
M\D%6ARZ]#=/&6%+(R&V-7&G.OR+ 02 A*ZQHL(;F7"*)) YJX2B%4IL*!QVJ
M**$E^^1#D"21 /PK)0E4.B#BEB[&."0&4@* J(8@HK92FR#  *(*3 3/J?,:
ME,XIC:>SRBROLJ+* JY **(PUMI*JRNX3).  ;M8H\HZZNAJ"SJ<  AM"B/\
M2O\I.X4::^TFZ'1$Z+L*@0(20H!M"JJ(RY0P@FTC1E,";B6L-,(JGI7&">JN
M,9@ !]F"ZLT]GAILM%'A:D6 8P4##QR^NJSKFBV<$%@K J?A<T^ED@!0L#T
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MWD(E**9"81I2T.;%Z<#C LC*D7Z5)Q2-K;P6Z_+1D@8C.,(/8/Q(3ZH@WVX
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M&ULR9&J+X8&%EI25WJB$)63!"E6$LO2FM(5DLO]$LJZ'[<V_)F$+6T!-;Y;
M7H,D1 (HN3(&$BI$XO"E"RO!@0+;M3.Z?:8G?1H(:GEF<(5D*4>L!"#7QQ2D
M$O3K,'!;2 J5;Z6L^ \I?IG99P3?;AQL;@="V +TDN =8^CBZ$J Z'@<C>CT
M>"%RY(_.YCRW_O"DWSJF6P8[EC&.<<@NJ:H;6>YX_KM4?XE_#W(?+9 A!;0@
M-V4@3G$?W#,\]=$"55(D-[4A]P2 .J4?<---]^<N*;)<\\$]-35?.V,4,M)*
MUW5,]<$#9'4#S59 "6(A!G(!1M(_80<495,V-70L-4054W$0"Q(H/3@<OO9
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M!(RP".DA!'V'@BS0:V;2AE[0!<C!"$SPFMQ1DC+YIHBV.5X DS$)I^?W'L8
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M @8,&"M<O$@08X2+&'CX6$(11\B5%PH6O!CAQH4)&C-*X)B38PL,&7LRV,@
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M[].[#@**7_\C*Z(B*KTSJKV,@(*1P1B\@$A"JA*2,Q^ 0B8(0E.!3,BTC"7
ME%&)3%.1""=KR/00H(LQ0_> B@XLB:BH14P+I$]3DKHZ3%.S@($AJ3?*G?$3
M.39L%J;J#IO:(JLX/+ZX/Q:""'BABM^$B$$T,1/AG/!K%83H#'51LGV!$XG
M0KCZD?]:0Y2!BH+A2Q7Y'%@:--_YB:1*$^_#1%/T%A8IDI$;(;:@H/-[K"BY
MI4MZN>O9I1H9MI9A$YZH !]P'A-J&>G;/Y"(M&+2N%2AE?#)":[[HK6 B*L
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M-001I95 P,'80(EKSHJ9%9O67:.0'Y&QH%*R,# J-.)YP7#S$+#HI*%(>H*
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M*$5,Q$4 0@S2,!U3%$%"C""L&*N$04ND.5)I6TF@C02\9/*ZF <@J8?"0,K
M6H5%:>5P:(H7'(.B/G,T]Q6D0BHU6[,KJ(SQZAL0 ,'P^D .,&_R/A)>KE@2
MF2;U_(Y,V43RD#.L+>M\TPJ0X$?_ 'UF\]P5 +P'0E =WWRMS=U(ON#*8N*5
M!/ZAQB@)I'F);M:'22/$M34A&.U.?5,:'A%(*?K$7/6EPFSDRVV25LT=)X?2
MV.EF31RI)-4(0AH:NV#DM"R1^'3+$\+&=)-.I/BT#U8!WY;;".^%#J'>CR>Y
M41?U.WJHQ9(H&I!HF>E9$6''68A.UB29$%SY1EW&5YM>6/.%82#&5K,3"]P
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<L+:4Z'.3A+$6+0_3I$]Y99DQ93?79<\F(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>fiveyearchart2017a.jpg
<TEXT>
begin 644 fiveyearchart2017a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %^ L,# 2(  A$! Q$!_\0
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MS320%Y)9'9F9V)9F8DDDDU[9_P .G?V6?^C:?V?_ /PWFD?_ "/1_P $G?\
ME%E^S3_V2KPO_P"FBUKZ H ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^
MRS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT
M[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_
M (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y
M'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_
M )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#A
MO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^
M&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[
M/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_
ML_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_
M $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+
M/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT
M[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\
MAT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G
M_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@**
M/G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH
M"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>
MOH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_
M )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\
MTC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^
M&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L_
M_P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_
ML_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\
M1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+
M/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O
M[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\
MAT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>
MC_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_]&T_L_\ _AO-(_\
MD>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O[+/_ $;3^S__ .&\
MTC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'3O[+/_1M/[/_ /X;
MS2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_ /AT[^RS_P!&T_L_
M_P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^?_\ AT[^RS_T;3^S
M_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@** /G_P#X=._LL_\
M1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^@** /G__ (=._LL_
M]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\ D>OH"B@#Y_\ ^'3O
M[+/_ $;3^S__ .&\TC_Y'H_X=._LL_\ 1M/[/_\ X;S2/_D>OH"B@#Y__P"'
M3O[+/_1M/[/_ /X;S2/_ )'H_P"'3O[+/_1M/[/_ /X;S2/_ )'KZ HH ^?_
M /AT[^RS_P!&T_L__P#AO-(_^1Z/^'3O[+/_ $;3^S__ .&\TC_Y'KZ HH ^
M?_\ AT[^RS_T;3^S_P#^&\TC_P"1Z/\ AT[^RS_T;3^S_P#^&\TC_P"1Z^@*
M* /G_P#X=._LL_\ 1M/[/_\ X;S2/_D>C_AT[^RS_P!&T_L__P#AO-(_^1Z^
M@** /G__ (=._LL_]&T_L_\ _AO-(_\ D>C_ (=._LL_]&T_L_\ _AO-(_\
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MNV[TVUTXZ6(52-.27QPC/T4G-)>;]S7;?RU^NJ***R.D**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH+!2,G[QP/>B@ HH
MHH **** /Y O^#H[_E.O\<_^X!_ZC^F44?\ !T=_RG7^.?\ W /_ %'],HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%G_A+:G_ /(]'_"Z='_Y\_%G_A+:G_\ (] '645R?_"Z='_Y\_%G_A+:G_\
M(]'_  NG1_\ GS\6?^$MJ?\ \CT =917)_\ "Z='_P"?/Q9_X2VI_P#R/1_P
MNG1_^?/Q9_X2VI__ "/0!UE%<G_PNG1_^?/Q9_X2VI__ "/1_P +IT?_ )\_
M%G_A+:G_ /(] '645R?_  NG1_\ GS\6?^$MJ?\ \CT?\+IT?_GS\6?^$MJ?
M_P CT =917)_\+IT?_GS\6?^$MJ?_P CT?\ "Z='_P"?/Q9_X2VI_P#R/0!U
ME%<G_P +IT?_ )\_%G_A+:G_ /(]'_"Z='_Y\_%G_A+:G_\ (] '645R?_"Z
M='_Y\_%G_A+:G_\ (]'_  NG1_\ GS\6?^$MJ?\ \CT =917)_\ "Z='_P"?
M/Q9_X2VI_P#R/1_PNG1_^?/Q9_X2VI__ "/0!UE%<G_PNG1_^?/Q9_X2VI__
M "/1_P +IT?_ )\_%G_A+:G_ /(] '645R?_  NG1_\ GS\6?^$MJ?\ \CT?
M\+IT?_GS\6?^$MJ?_P CT =917)_\+IT?_GS\6?^$MJ?_P CT?\ "Z='_P"?
M/Q9_X2VI_P#R/0!UE%<G_P +IT?_ )\_%G_A+:G_ /(]'_"Z='_Y\_%G_A+:
MG_\ (] '645R?_"Z='_Y\_%G_A+:G_\ (]'_  NG1_\ GS\6?^$MJ?\ \CT
M=917)_\ "Z='_P"?/Q9_X2VI_P#R/1_PNG1_^?/Q9_X2VI__ "/0!UE%<G_P
MNG1_^?/Q9_X2VI__ "/1_P +IT?_ )\_%G_A+:G_ /(] '645R?_  NG1_\
MGS\6?^$MJ?\ \CT?\+IT?_GS\6?^$MJ?_P CT =917)_\+IT?_GS\6?^$MJ?
M_P CT?\ "Z='_P"?/Q9_X2VI_P#R/0!UE%<G_P +IT?_ )\_%G_A+:G_ /(]
M'_"Z='_Y\_%G_A+:G_\ (] '645R?_"Z='_Y\_%G_A+:G_\ (]'_  NG1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB*T*--X7#N]_BDOM>2_NI_\ @3]Y[12****[CS HHHH **** "BBB@ HHHH
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MJTEVUNK:7>%.IS*+_FBI+T;DM?.\7WTL[ZV17S__ ,$G?^467[-/_9*O"_\
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M0?%G_@1IG_R91_PL;6/^A!\6?^!&F?\ R90!UE%<G_PL;6/^A!\6?^!&F?\
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M# /.< [E !1110 4444 ?R!?\'1W_*=?XY_]P#_U'],HH_X.CO\ E.O\<_\
MN ?^H_IE% ']/O\ P2=_Y19?LT_]DJ\+_P#IHM:]<^+WP[D^*_P[U+0(?$7B
M3PC<7P0PZQH%REOJ.GR)(LBR1-(DD9.Y0"DD;QNI971E9E/D?_!)W_E%E^S3
M_P!DJ\+_ /IHM:^@*35U8:=G<^9=;_X)8^"OB;H_C+_A9?BSX@?%;Q!XRTB+
M09/$6OW=G9ZCI%E#<+=0Q6*Z;:VEO;M'=HEQYJP^:TD<>]W6-%7:\&_\$[?#
M,/B/Q-K7Q \6>-OC/KGBKPS-X,N+[Q@^GH;719R6N+&"'3K2S@C29L-))Y9E
M<I&#(0B ?0%%'*FK-:6:MTUO?39<UWS/>5W>]V"DT[IZWOYW5K:^7+&W;E5K
M61\[?!+_ ()QZ'\)/'O@O7M7^(/Q,^) ^&-C+I_@JP\575A):^%4DA%NSP_9
M;.WEN)OLX\D3WDEQ*$9\.&DD9OHFBBKE*3^)W]=7J[MM[MMN[;U9"BEM_7DN
MR\EH%?/_ /P2=_Y19?LT_P#9*O"__IHM:^@*^?\ _@D[_P HLOV:?^R5>%__
M $T6M24?0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445'>7D.GVDMQ<2Q
MP6\"&2221@J1J!DL2>  .231>VK&DV[(AUK6K3PYI%UJ%_<PV=C9Q--//,X6
M.)%&2S$\  5Q_AC1KOXE:];>)=;MIK/3[-O,T/2IU*/"2"/M=PIZ3,"0B'_5
M*><.S!(M&LYOC3J]MK5]%)#X5L95GTBQE4JVIR+RM[,IYV \PQGT$K#=Y8C[
M^O/C?%24W_#6J7\S[OR71==^QZU1K!1=*/\ %>DG_*GO%?WGM)]%[O\ ,%%%
M%>@>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_(%_P='?\IU_
MCG_W /\ U'],HH_X.CO^4Z_QS_[@'_J/Z910!_3[_P $G?\ E%E^S3_V2KPO
M_P"FBUKZ KY__P""3O\ RBR_9I_[)5X7_P#31:UU'[</QT\0?LX_LN>+/%GA
M+PMKGC+Q59VZ6VCZ7I>CW>K2/=SR+#%++;VD<D[6\32"68QHSB*.3:K-A3,Y
M<JO_ %Y+6RU\VD53CS243KM'^.W@?Q%XH\4Z'I_C+PK?:UX&6-_$FGV^K6\M
MUX?61#)&;R)7+6X=%9E,H7*J2,@9K/\ @=^U'\,_VG++4+GX:_$7P+\0K?27
M2*^E\,Z_:ZLED[@E%E-O(X0L%8@-C.TXZ5^*'B/4_!OP_P#'WQQ\ Z+;?$2^
MTWQ@/A3:>+]4\4>!=;T&37Q/XENFUJZU)[RT@$ NVNG_ ->4699)$CWK&X7Z
MU_X+97M[\,_C'-JW@'=IWBR3]G?XAP:D^GDP3)IULFG/:,Y0 [89Y9C$2P"-
M(Y4@DAJJ>Y#FW^)=M84^=O57Y7LM$UJWM9U1I^UK^QCIK'?M-Q23[25W==7R
MK[5U]Y_"W]K3X5_'+QMK'AGP3\3/A]XP\2>'PYU32M$\16>H7VFA)/+?SX89
M&>+;)\AW@8;@\\5Z#7PS^T/X,\-?#SQ%^P3'X)L=-TVZTOQC#H^B1Z: FS1)
M?#>H&\BC* DVY2&W=@/E8QQLQX##[FK6I3Y>9?RR<7TNTD[I:V34EI=V::NS
MFIU.90E_-%37DFY*S?5IQ>MEHUH%?/\ _P $G?\ E%E^S3_V2KPO_P"FBUKM
M/C;\=_%/PJU^TL]!^"WQ,^)EO<6_G27WAN^\/6]O:ON(\IQJ6J6<I? #91&3
M##YLY \E_P""5OCW5;/_ ()@?LWPQ^"?$]U'%\+O#*+/%/IPCF TFU 90UTK
M8/4;E!P>0#Q61J?4U%<G_P +&UC_ *$'Q9_X$:9_\F4?\+&UC_H0?%G_ ($:
M9_\ )E '645R?_"QM8_Z$'Q9_P"!&F?_ "91_P +&UC_ *$'Q9_X$:9_\F4
M=917)_\ "QM8_P"A!\6?^!&F?_)E'_"QM8_Z$'Q9_P"!&F?_ "90!UE%<G_P
ML;6/^A!\6?\ @1IG_P F4?\ "QM8_P"A!\6?^!&F?_)E '645R?_  L;6/\
MH0?%G_@1IG_R91_PL;6/^A!\6?\ @1IG_P F4 =917)_\+&UC_H0?%G_ ($:
M9_\ )E'_  L;6/\ H0?%G_@1IG_R90!UE%<G_P +&UC_ *$'Q9_X$:9_\F4?
M\+&UC_H0?%G_ ($:9_\ )E '645R?_"QM8_Z$'Q9_P"!&F?_ "91_P +&UC_
M *$'Q9_X$:9_\F4 =917)_\ "QM8_P"A!\6?^!&F?_)E'_"QM8_Z$'Q9_P"!
M&F?_ "90!UE%<G_PL;6/^A!\6?\ @1IG_P F4?\ "QM8_P"A!\6?^!&F?_)E
M '645R?_  L;6/\ H0?%G_@1IG_R91_PL;6/^A!\6?\ @1IG_P F4 =917)_
M\+&UC_H0?%G_ ($:9_\ )E'_  L;6/\ H0?%G_@1IG_R90!UE%<G_P +&UC_
M *$'Q9_X$:9_\F4?\+&UC_H0?%G_ ($:9_\ )E '645R?_"QM8_Z$'Q9_P"!
M&F?_ "91_P +&UC_ *$'Q9_X$:9_\F4 =917)_\ "QM8_P"A!\6?^!&F?_)E
M'_"QM8_Z$'Q9_P"!&F?_ "90!UE%<G_PL;6/^A!\6?\ @1IG_P F4?\ "QM8
M_P"A!\6?^!&F?_)E '645R?_  L;6/\ H0?%G_@1IG_R91_PL;6/^A!\6?\
M@1IG_P F4 =917)_\+&UC_H0?%G_ ($:9_\ )E'_  L;6/\ H0?%G_@1IG_R
M90!UE%<G_P +&UC_ *$'Q9_X$:9_\F4?\+&UC_H0?%G_ ($:9_\ )E '645R
M?_"QM8_Z$'Q9_P"!&F?_ "91_P +&UC_ *$'Q9_X$:9_\F4 =917)_\ "QM8
M_P"A!\6?^!&F?_)E'_"QM8_Z$'Q9_P"!&F?_ "90!UE%<G_PL;6/^A!\6?\
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M%55GTL  =A_IE>?_ +T[?\NU_P"3?_:K_P F_P /Q>Q_N$;_ /+Y_P#DB_\
MDW_Y(O[[]SKJ*Y/_ (6-K'_0@^+/_ C3/_DRC_A8VL?]"#XL_P# C3/_ ),K
MT#QSK**Y/_A8VL?]"#XL_P# C3/_ ),H_P"%C:Q_T(/BS_P(TS_Y,H ZRBN3
M_P"%C:Q_T(/BS_P(TS_Y,H_X6-K'_0@^+/\ P(TS_P"3* .LHKD_^%C:Q_T(
M/BS_ ,"-,_\ DRC_ (6-K'_0@^+/_ C3/_DR@#K**Y/_ (6-K'_0@^+/_ C3
M/_DRC_A8VL?]"#XL_P# C3/_ ),H ZRBN3_X6-K'_0@^+/\ P(TS_P"3*/\
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1%4%F9B  "20*\-_X)._\HLOV:?^R5>%_P#TT6M>P?%+PPGB_P"'^J61\/\
MA_Q1/Y7VBSTO6V\O3[NZB(EMQ,_DS&-1,D;>8(I&C*AE1BH!F3:5T5%)R2?^
M7XF'\(OVI?AC^T#X4U37O ?Q&\!^-M#T1S'J.HZ!K]IJ5I8,$\PK-+#(R1D)
M\Q#$?+STIWP._:C^&?[3EEJ%S\-?B+X%^(5OI+I%?2^&=?M=62R=P2BRFWD<
M(6"L0&QG:<=*_+O_ (*!77B>W^.7Q&@^+'A_1?"_B+XH6'@#3[K3/#NH'4O#
M=YX5M_%EM;7_ -IU*6.TN)[EGU$Q21R6D,:6TD:J\VY]GI7_  6RO;WX9_&.
M;5O .[3O%DG[._Q#@U)]/)@F33K9-.>T9R@!VPSRS&(E@$:1RI!)#'-^Z5;H
M^=)7ZTX.3=^SLE_=?->_+9W3I<]=4$];QUMTFXJWDU=O^][MK<]U]Y_"W]K3
MX5_'+QMK'AGP3\3/A]XP\2>'PYU32M$\16>H7VFA)/+?SX89&>+;)\AW@8;@
M\\5Z#7PS^T/X,\-?#SQ%^P3'X)L=-TVZTOQC#H^B1Z: FS1)?#>H&\BC* DV
MY2&W=@/E8QQLQX##[FK>I3Y>9?RR<7TNTD[I:V34EI=V::NSEIU.90E_-%37
MDFY*S?5IQ>MEHUH%?/\ _P $G?\ E%E^S3_V2KPO_P"FBUKM/C;XJ^,>@Z_:
M1_#CP'\,_%>EO;[KFX\2>.[[P_<0S;B-B10:1?*Z;=IWF1#DD;,#<?)?^"5N
MK>,X_P#@F!^S>MKH/AB:U7X7>&1#)+KT\<CI_9-KM+*+-@I(P2 S 'C)ZUD:
MGU-17)_VSXZ_Z%SPG_X4=Q_\@T?VSXZ_Z%SPG_X4=Q_\@T =917)_P!L^.O^
MA<\)_P#A1W'_ ,@T?VSXZ_Z%SPG_ .%'<?\ R#0!UE%<G_;/CK_H7/"?_A1W
M'_R#1_;/CK_H7/"?_A1W'_R#0!UE%<G_ &SXZ_Z%SPG_ .%'<?\ R#1_;/CK
M_H7/"?\ X4=Q_P#(- '645R?]L^.O^A<\)_^%'<?_(-']L^.O^A<\)_^%'<?
M_(- '645R?\ ;/CK_H7/"?\ X4=Q_P#(-']L^.O^A<\)_P#A1W'_ ,@T =91
M7)_VSXZ_Z%SPG_X4=Q_\@T?VSXZ_Z%SPG_X4=Q_\@T =917)_P!L^.O^A<\)
M_P#A1W'_ ,@T?VSXZ_Z%SPG_ .%'<?\ R#0!UE%<G_;/CK_H7/"?_A1W'_R#
M1_;/CK_H7/"?_A1W'_R#0!UE%<G_ &SXZ_Z%SPG_ .%'<?\ R#1_;/CK_H7/
M"?\ X4=Q_P#(- '645R?]L^.O^A<\)_^%'<?_(-']L^.O^A<\)_^%'<?_(-
M'645R?\ ;/CK_H7/"?\ X4=Q_P#(-']L^.O^A<\)_P#A1W'_ ,@T =917)_V
MSXZ_Z%SPG_X4=Q_\@T?VSXZ_Z%SPG_X4=Q_\@T =917)_P!L^.O^A<\)_P#A
M1W'_ ,@T?VSXZ_Z%SPG_ .%'<?\ R#0!UE%<G_;/CK_H7/"?_A1W'_R#1_;/
MCK_H7/"?_A1W'_R#0!UE%<G_ &SXZ_Z%SPG_ .%'<?\ R#1_;/CK_H7/"?\
MX4=Q_P#(- '645R?]L^.O^A<\)_^%'<?_(-']L^.O^A<\)_^%'<?_(- '645
MR?\ ;/CK_H7/"?\ X4=Q_P#(-']L^.O^A<\)_P#A1W'_ ,@T =917)_VSXZ_
MZ%SPG_X4=Q_\@T?VSXZ_Z%SPG_X4=Q_\@T =917)_P!L^.O^A<\)_P#A1W'_
M ,@T?VSXZ_Z%SPG_ .%'<?\ R#0!UE%<G_;/CK_H7/"?_A1W'_R#1_;/CK_H
M7/"?_A1W'_R#0!UE%<G_ &SXZ_Z%SPG_ .%'<?\ R#1_;/CK_H7/"?\ X4=Q
M_P#(- '645R?]L^.O^A<\)_^%'<?_(-']L^.O^A<\)_^%'<?_(- '645R?\
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M:)S:2YYM?%)[Z)6BDEUE%<G_ &SXZ_Z%SPG_ .%'<?\ R#1_;/CK_H7/"?\
MX4=Q_P#(->L?GIUE%<G_ &SXZ_Z%SPG_ .%'<?\ R#1_;/CK_H7/"?\ X4=Q
M_P#(- '645R?]L^.O^A<\)_^%'<?_(-']L^.O^A<\)_^%'<?_(- '645R?\
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M#_U'],HH_P"#H[_E.O\ '/\ [@'_ *C^F44 ?T^_\$G?^467[-/_ &2KPO\
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M  H[C_Y!H_MGQU_T+GA/_P *.X_^0:VC%15HHT22V.LHKD_[9\=?]"YX3_\
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M._T'P[9Z;=:EERY\Z2&-6D^<EOF)Y)/6O0***6R45LMA]6^K"OG_ /X)._\
M*++]FG_LE7A?_P!-%K7T!7S_ /\ !)W_ )19?LT_]DJ\+_\ IHM: /H"BBB@
M HHHH **** "BBB@ HHHH **** "BN9\2?&CPEX1O/LNH>(]'M[SM:_:D:Y;
MZ1*2Y_ 5F_\ "[1JG_($\*^,-:S]UQIW]GQGWW7C0@K[KG(Z9KGEBJ2?+S*_
M9:O[EJ9NM!.USN**X?\ M7XA:Y_Q[Z1X7\/QGI)>WTNH3#ZPQI&OY3'\*/\
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MQ]12FDKN+]U^CE&,K]]M2.'>)L-F>"CB5*2W336NG7W;O7U[F]_PKCQ3J_\
MR%/'NH1*?O1:-IMO91M[9E$\@'T<'WH_X9Y\,WO.J1ZIX@8_>&KZI<WT3?\
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M^*[H>5;_ (1QEW#UPSAA]" ?4"O5Z*/;8?I3?SE_P$'L<4]ZJ^4?\VS\Y_\
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M2@DO.R@KM]6[M]6SRCR/CE<?+]J^%%GG_EK]EU"YV_\  /,CSG_>&/?I2_\
M"-_'&[_YG/X4Z?M_ZDS4+SS/_*I%MQ_P+.>V.?5J*Z/KDE\,8K_MU/\ -,Y?
M[/B_BG)_]O-?DT>4_P#" ?&:X^:;XF^!XY.ZVO@2:./\!)J4C?\ CWY4G_"H
MOBA-_K/B^T8;[_V?PM9HRYZ[-Y<#VW!L<9W=_5Z*/KU3M'_P"'_R(?V=2[R_
M\#G_ /)'E/\ PH7QU<_+-\</'42==UIH^A1R9^LEA(N/^ Y]Z/\ AF[Q%/\
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M'X3_ /"<N/\ Y.K>/UA*T*BCY1A"W_D\9O\ $U7U**M[#F_Q5*B?_E.=./\
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M8_"?_A.7'_R=1_8_CK_H8_"?_A.7'_R=0!UE%<G_ &/XZ_Z&/PG_ .$Y<?\
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M(!N94WOM!)"[VQC)J_12LGN5&I**:B[7T?FKWL_FD_5!1113)"BBB@ HHHH
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M*47]P4445W'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNV98(FGT*68QQ@A5,LDDA"C<[MEB ?=]%?/_ /PQM\1?^CL?V@/_  4>"/\
MYGJ/^&-OB+_T=C^T!_X*/!'_ ,SU 'T!17S_ /\ #&WQ%_Z.Q_: _P#!1X(_
M^9ZC_AC;XB_]'8_M ?\ @H\$?_,]0!] 45\__P##&WQ%_P"CL?V@/_!1X(_^
M9ZC_ (8V^(O_ $=C^T!_X*/!'_S/4 ?0%%?/_P#PQM\1?^CL?V@/_!1X(_\
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M/6RTVR&^:9\-<ZA.0 \\SX&^1L#G@  *H"@ <'_PQM\1?^CL?V@/_!1X(_\
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M  4>"/\ YGJ/^&-OB+_T=C^T!_X*/!'_ ,SU 'T!17S_ /\ #&WQ%_Z.Q_:
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M9ZC_ (8V^(O_ $=C^T!_X*/!'_S/4 ?0%%?/_P#PQM\1?^CL?V@/_!1X(_\
MF>H_X8V^(O\ T=C^T!_X*/!'_P SU 'T!17S_P#\,;?$7_H[']H#_P %'@C_
M .9ZC_AC;XB_]'8_M ?^"CP1_P#,]0!] 45\_P#_  QM\1?^CL?V@/\ P4>"
M/_F>H_X8V^(O_1V/[0'_ (*/!'_S/4 ?0%%?/_\ PQM\1?\ H[']H#_P4>"/
M_F>H_P"&-OB+_P!'8_M ?^"CP1_\SU 'T!17QA^Q%\(?BU^TI^Q?\(?B-KO[
M5/QPM-;\?^"M&\2:A!8:)X*CM8;B\L8;B5(E?0'=8P\C!0SL0 ,L3R?3_P#A
MC;XB_P#1V/[0'_@H\$?_ #/4 ?0%%?/_ /PQM\1?^CL?V@/_  4>"/\ YGJ/
M^&-OB+_T=C^T!_X*/!'_ ,SU 'T!17S_ /\ #&WQ%_Z.Q_: _P#!1X(_^9ZC
M_AC;XB_]'8_M ?\ @H\$?_,]0!] 45\__P##&WQ%_P"CL?V@/_!1X(_^9ZC_
M (8V^(O_ $=C^T!_X*/!'_S/4 ?0%%?/_P#PQM\1?^CL?V@/_!1X(_\ F>H_
MX8V^(O\ T=C^T!_X*/!'_P SU 'T!17S_P#\,;?$7_H[']H#_P %'@C_ .9Z
MC_AC;XB_]'8_M ?^"CP1_P#,]0!] 45\H^*?"WQ(_9I_:0^ D,WQ[^)WQ T7
MX@>-+SPWK&C^)-*\,QVLENOAG7=21T>PTFTG21;C3K<@B7:5W@J<\?5U !11
M10 4444 ?R!?\'1W_*=?XY_]P#_U'],HH_X.CO\ E.O\<_\ N ?^H_IE% ']
M/O\ P2=_Y19?LT_]DJ\+_P#IHM:^@*^?_P#@D[_RBR_9I_[)5X7_ /31:U]
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M%% !1110!_(%_P '1W_*=?XY_P#< _\ 4?TRBC_@Z._Y3K_'/_N ?^H_IE%
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MU[P?\$==\9VWQRFL/%>AF+7M&M3X7U;^RK>PN+/6//O5VQH]K#)YE@+P%7E
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M6DZ5;27E[>WDZP6]G!&I>2621B%1%4%F9B  "20!7AG_  ]B_99_Z.6_9_\
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M_K5?>'G_ %_6C/%?^'L7[+/_ $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\
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M_9__ /#AZ1_\D4?\/8OV6?\ HY;]G_\ \.'I'_R17M0\?:$?'7_"+_VUI/\
MPDPL?[4_LC[9']N^R>9Y7VCR<[_*\SY-^-N[C.>*UJ.E_P"NWYZ!UM_7?\CY
M_P#^'L7[+/\ T<M^S_\ ^'#TC_Y(H_X>Q?LL_P#1RW[/_P#X</2/_DBOH"N7
M\+_&7PWXS^)GBKP?INI?:?$?@I+.36K3[/*GV-;N-Y+<[V4(^]$8_(S;<8;!
M(% 'D_\ P]B_99_Z.6_9_P#_  X>D?\ R11_P]B_99_Z.6_9_P#_  X>D?\
MR17T!10!\_\ _#V+]EG_ *.6_9__ /#AZ1_\D4?\/8OV6?\ HY;]G_\ \.'I
M'_R17K7B'XU^#?"7Q)T+P;JOB[PSIGC#Q1'-+HVAW>J00ZEJZ1*6E:WMV823
M!%!+%%(4 DX%.^)OQB\(_!31K74O&7BKPWX1T^^O8M.MKK6M2AL(;BZE)$4"
M/*RJTKD$*@)9L' -'9]]%]]OST]= VT?K\M[_<>1_P##V+]EG_HY;]G_ /\
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M_#V+]EG_ *.6_9__ /#AZ1_\D5] 44 ?/_\ P]B_99_Z.6_9_P#_  X>D?\
MR11_P]B_99_Z.6_9_P#_  X>D?\ R17T!10!\_\ _#V+]EG_ *.6_9__ /#A
MZ1_\D4?\/8OV6?\ HY;]G_\ \.'I'_R17T!10!\__P##V+]EG_HY;]G_ /\
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M<^?_ /A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(KZ
MHH&?/_\ P]B_99_Z.6_9_P#_  X>D?\ R11_P]B_99_Z.6_9_P#_  X>D?\
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M_P""3O\ RBR_9I_[)5X7_P#31:U] 5\__P#!)W_E%E^S3_V2KPO_ .FBUKZ
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MOK/[ /P=\0_&CQY\0K[P+I=WXM^*'AP>$_%5W+-,T>N:8%"B": OY)^557S
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M^7P;=2-IUA?36\-A:SVDD=W+;3OYRQNT2N[)&K"(?3/[ ?QN\3?M,^&O'WQ
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MX(_^9ZO@'_B-6_99_P"A!_: _P#!'I'_ ,LZ/^(U;]EG_H0?V@/_  1Z1_\
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M%'@C_P"9ZO@'_B-6_99_Z$']H#_P1Z1_\LZ/^(U;]EG_ *$']H#_ ,$>D?\
MRSH ^_O^&-OB+_T=C^T!_P""CP1_\SU'_#&WQ%_Z.Q_: _\ !1X(_P#F>KX!
M_P"(U;]EG_H0?V@/_!'I'_RSH_XC5OV6?^A!_: _\$>D?_+.@#[^_P"&-OB+
M_P!'8_M ?^"CP1_\SU'_  QM\1?^CL?V@/\ P4>"/_F>KX!_XC5OV6?^A!_:
M _\ !'I'_P LZ/\ B-6_99_Z$']H#_P1Z1_\LZ /O[_AC;XB_P#1V/[0'_@H
M\$?_ #/4?\,;?$7_ *.Q_: _\%'@C_YGJ^ ?^(U;]EG_ *$']H#_ ,$>D?\
MRSH_XC5OV6?^A!_: _\ !'I'_P LZ /O[_AC;XB_]'8_M ?^"CP1_P#,]1_P
MQM\1?^CL?V@/_!1X(_\ F>KX!_XC5OV6?^A!_: _\$>D?_+.C_B-6_99_P"A
M!_: _P#!'I'_ ,LZ /O[_AC;XB_]'8_M ?\ @H\$?_,]1_PQM\1?^CL?V@/_
M  4>"/\ YGJ^ ?\ B-6_99_Z$']H#_P1Z1_\LZ/^(U;]EG_H0?V@/_!'I'_R
MSH ^_O\ AC;XB_\ 1V/[0'_@H\$?_,]1_P ,;?$7_H[']H#_ ,%'@C_YGJ^
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MZ$']H#_P1Z1_\LZ /O[_ (8V^(O_ $=C^T!_X*/!'_S/4?\ #&WQ%_Z.Q_:
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M_: _\%'@C_YGJ^ ?^(U;]EG_ *$']H#_ ,$>D?\ RSH_XC5OV6?^A!_: _\
M!'I'_P LZ /O[_AC;XB_]'8_M ?^"CP1_P#,]1_PQM\1?^CL?V@/_!1X(_\
MF>KX!_XC5OV6?^A!_: _\$>D?_+.C_B-6_99_P"A!_: _P#!'I'_ ,LZ /O[
M_AC;XB_]'8_M ?\ @H\$?_,]1_PQM\1?^CL?V@/_  4>"/\ YGJ^ ?\ B-6_
M99_Z$']H#_P1Z1_\LZ/^(U;]EG_H0?V@/_!'I'_RSH ^_O\ AC;XB_\ 1V/[
M0'_@H\$?_,]1_P ,;?$7_H[']H#_ ,%'@C_YGJ^ ?^(U;]EG_H0?V@/_  1Z
M1_\ +.C_ (C5OV6?^A!_: _\$>D?_+.@#[^_X8V^(O\ T=C^T!_X*/!'_P S
MU'_#&WQ%_P"CL?V@/_!1X(_^9ZO@'_B-6_99_P"A!_: _P#!'I'_ ,LZ/^(U
M;]EG_H0?V@/_  1Z1_\ +.@#[^_X8V^(O_1V/[0'_@H\$?\ S/4?\,;?$7_H
M[']H#_P4>"/_ )GJ^ ?^(U;]EG_H0?V@/_!'I'_RSH_XC5OV6?\ H0?V@/\
MP1Z1_P#+.@#[^_X8V^(O_1V/[0'_ (*/!'_S/4?\,;?$7_H[']H#_P %'@C_
M .9ZO@'_ (C5OV6?^A!_: _\$>D?_+.C_B-6_99_Z$']H#_P1Z1_\LZ /O[_
M (8V^(O_ $=C^T!_X*/!'_S/4?\ #&WQ%_Z.Q_: _P#!1X(_^9ZO@'_B-6_9
M9_Z$']H#_P $>D?_ "SH_P"(U;]EG_H0?V@/_!'I'_RSH ^_O^&-OB+_ -'8
M_M ?^"CP1_\ ,]1_PQM\1?\ H[']H#_P4>"/_F>KX!_XC5OV6?\ H0?V@/\
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MX(_^9ZO@'_B-6_99_P"A!_: _P#!'I'_ ,LZ/^(U;]EG_H0?V@/_  1Z1_\
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<H1?9=,M+.3S$ADEC&9+=RNV1LJ5)P20"@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792682608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Feb. 12, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 29,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">exel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,307,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,116,352,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793202512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 183,164<span></span>
</td>
<td class="nump">$ 151,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">204,607<span></span>
</td>
<td class="nump">268,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Short-term restricted cash and investments</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">81,192<span></span>
</td>
<td class="nump">40,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">6,657<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="nump">5,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">484,874<span></span>
</td>
<td class="nump">469,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">64,255<span></span>
</td>
<td class="nump">55,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">4,646<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">25,743<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">12,092<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">655,294<span></span>
</td>
<td class="nump">595,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,575<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">21,073<span></span>
</td>
<td class="nump">20,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">19,849<span></span>
</td>
<td class="nump">14,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">8,974<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">7,565<span></span>
</td>
<td class="nump">3,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">31,984<span></span>
</td>
<td class="nump">19,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term loan payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">16,150<span></span>
</td>
<td class="nump">13,503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">115,170<span></span>
</td>
<td class="nump">268,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">238,520<span></span>
</td>
<td class="nump">237,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">16,643<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">370,333<span></span>
</td>
<td class="nump">506,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,114,184<span></span>
</td>
<td class="nump">2,072,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(347)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,829,172)<span></span>
</td>
<td class="num">(1,983,147)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">284,961<span></span>
</td>
<td class="nump">89,318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 655,294<span></span>
</td>
<td class="nump">$ 595,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793284304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="nump">289,923,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="nump">289,923,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793030384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">$ 349,008<span></span>
</td>
<td class="nump">$ 135,375<span></span>
</td>
<td class="nump">$ 34,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">103,469<span></span>
</td>
<td class="nump">56,079<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">452,477<span></span>
</td>
<td class="nump">191,454<span></span>
</td>
<td class="nump">37,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">15,066<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">112,171<span></span>
</td>
<td class="nump">95,967<span></span>
</td>
<td class="nump">96,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">159,362<span></span>
</td>
<td class="nump">116,145<span></span>
</td>
<td class="nump">57,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (recovery) charge</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">286,567<span></span>
</td>
<td class="nump">219,578<span></span>
</td>
<td class="nump">158,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">165,910<span></span>
</td>
<td class="num">(28,124)<span></span>
</td>
<td class="num">(121,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">4,883<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,679)<span></span>
</td>
<td class="num">(33,060)<span></span>
</td>
<td class="num">(40,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3,537)<span></span>
</td>
<td class="num">(11,616)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(7,333)<span></span>
</td>
<td class="num">(42,098)<span></span>
</td>
<td class="num">(40,268)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">158,577<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
<td class="num">(161,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income (loss) per share, basic (in shares)</a></td>
<td class="nump">293,588<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
<td class="nump">209,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income (loss) per share, diluted (in shares)</a></td>
<td class="nump">312,003<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
<td class="nump">209,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6943788992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">69<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 154,296<span></span>
</td>
<td class="num">$ (70,406)<span></span>
</td>
<td class="num">$ (161,855)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Other comprehensive income (loss) consisted solely of unrealized gains or losses, net, on available-for-sale securities arising during the periods presented. There were nominal or no reclassification adjustments to net income (loss) resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income (loss) during the periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6658253216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustments to net loss resulting from realized gains or losses on sale of securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive income, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790869328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Jan. 02, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,895,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jan. 02, 2015</a></td>
<td class="num">$ (159,324)<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 1,591,782<span></span>
</td>
<td class="num">$ (121)<span></span>
</td>
<td class="num">$ (1,751,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(161,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(161,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of shares of common stock, net</a></td>
<td class="nump">145,649<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">145,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,315,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">11,277<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">11,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">21,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants transferred from other long-term liabilities</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Jan. 01, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,960,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Jan. 01, 2016</a></td>
<td class="num">(140,806)<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">1,772,123<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="num">(1,912,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(70,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,009,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes</a></td>
<td class="nump">253,080<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">253,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,953,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">24,538<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">24,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 22,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 30, 2016</a></td>
<td class="nump">289,923,798<span></span>
</td>
<td class="nump">289,923,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 30, 2016</a></td>
<td class="nump">$ 89,318<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">2,072,591<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(1,983,147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No. 2016-09</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">154,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,408,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,409<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">17,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock on warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock on warrant exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 29, 2017</a></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="nump">296,209,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 29, 2017</a></td>
<td class="nump">$ 284,961<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 2,114,184<span></span>
</td>
<td class="num">$ (347)<span></span>
</td>
<td class="num">$ (1,829,172)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794209680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">23,938<span></span>
</td>
<td class="nump">22,912<span></span>
</td>
<td class="nump">21,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">6,239<span></span>
</td>
<td class="nump">13,901<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and debt issuance costs</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">8,432<span></span>
</td>
<td class="nump">17,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="num">(11,825)<span></span>
</td>
<td class="nump">8,008<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other equity investments</a></td>
<td class="num">(2,980)<span></span>
</td>
<td class="num">(2,494)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in warrant fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="num">(40,839)<span></span>
</td>
<td class="num">(35,318)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(3,319)<span></span>
</td>
<td class="num">(722)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,268)<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">16,705<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseAccruedClinicalLiabilities', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">5,718<span></span>
</td>
<td class="num">(3,940)<span></span>
</td>
<td class="num">(23,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseinAccruedCollaborationLiability', window );">Accrued collaboration liabilities</a></td>
<td class="nump">6,928<span></span>
</td>
<td class="num">(10,938)<span></span>
</td>
<td class="nump">10,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">13,745<span></span>
</td>
<td class="nump">256,759<span></span>
</td>
<td class="num">(2,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="nump">9,910<span></span>
</td>
<td class="nump">5,090<span></span>
</td>
<td class="num">(10,502)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">165,611<span></span>
</td>
<td class="nump">210,404<span></span>
</td>
<td class="num">(141,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(21,143)<span></span>
</td>
<td class="num">(1,703)<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(319,090)<span></span>
</td>
<td class="num">(369,187)<span></span>
</td>
<td class="num">(143,992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">336,590<span></span>
</td>
<td class="nump">151,485<span></span>
</td>
<td class="nump">178,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sale of investments</a></td>
<td class="nump">37,294<span></span>
</td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchase of restricted cash and investments</a></td>
<td class="num">(15,650)<span></span>
</td>
<td class="num">(8,650)<span></span>
</td>
<td class="num">(5,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments', window );">Proceeds from maturities of restricted cash and investments</a></td>
<td class="nump">14,650<span></span>
</td>
<td class="nump">7,150<span></span>
</td>
<td class="nump">19,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from other equity investments</a></td>
<td class="nump">2,980<span></span>
</td>
<td class="nump">2,494<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">35,795<span></span>
</td>
<td class="num">(216,048)<span></span>
</td>
<td class="nump">50,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of debt</a></td>
<td class="num">(185,788)<span></span>
</td>
<td class="num">(575)<span></span>
</td>
<td class="num">(4,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentsforConversionofConvertibleDebt', window );">Payments on conversion of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,135)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">17,555<span></span>
</td>
<td class="nump">25,327<span></span>
</td>
<td class="nump">10,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(6,563)<span></span>
</td>
<td class="num">(4,108)<span></span>
</td>
<td class="num">(534)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(169,928)<span></span>
</td>
<td class="nump">15,696<span></span>
</td>
<td class="nump">152,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">31,478<span></span>
</td>
<td class="nump">10,052<span></span>
</td>
<td class="nump">61,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">151,686<span></span>
</td>
<td class="nump">141,634<span></span>
</td>
<td class="nump">80,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">183,164<span></span>
</td>
<td class="nump">151,686<span></span>
</td>
<td class="nump">141,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">20,460<span></span>
</td>
<td class="nump">21,044<span></span>
</td>
<td class="nump">19,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CIPdeemedacquiredinBuildtoSuitLease', window );">Construction in progress deemed to have been acquired under build-to-suit lease</a></td>
<td class="nump">14,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Issuance of common stock in settlement of convertible notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 286,925<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CIPdeemedacquiredinBuildtoSuitLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CIP deemed acquired in Build-to-Suit Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CIPdeemedacquiredinBuildtoSuitLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseAccruedClinicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) accrued clinical liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseAccruedClinicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseinAccruedCollaborationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseinAccruedCollaborationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentsforConversionofConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Conversion of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentsforConversionofConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with funds and investments that are not available for withdrawal or use (such as assets held in escrow or contractually limited as to use or disposition) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783709344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (&#8220;Exelixis,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products discovered at&#160;Exelixis&#160;have progressed through clinical development, received regulatory approval, and entered the marketplace. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX&#174;&#160;(cabozantinib) tablets approved for advanced renal cell carcinoma (&#8220;RCC&#8221;) and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC&#174; (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc. (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts on the accompanying Consolidated Financial Statements have been reclassified to conform to current period presentation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net on the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments on the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were insignificant. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory related costs are recognized as Cost of goods sold on the accompanying Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets on the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. Only once regulatory approval is obtained, would we begin capitalization of these inventory related costs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:200px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value. We continue to operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018. For information on our adoption of ASU 2014-09, see &#8220;- Recent Accounting Pronouncements,&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> below</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and title has transferred or services have been performed; the price is fixed or determinable; and collectability of the resulting receivable is reasonably assured. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize net product revenues upon delivery of the product and when there are no remaining customer acceptance requirements which is frequently referred to as the &#8220;sell-in&#8221; revenue recognition model. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations generally purchase the product at a discounted price. The specialty pharmacy or distributor, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The specialty pharmacies and distributors in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect the specialty pharmacies and distributors will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> pay fees to our customers for account management, data management and other administrative services.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty pharmacies and distributors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarter&#8217;s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also includes the Medicare Part&#160;D Coverage Gap</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap are based in part on historical utilization rates, specialty pharmacy and distributor customer and payer data and third-party market research data. We also estimate when eligible patients who are prescribed our product enter and exit the insurance coverage gap. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarters&#8217; shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and discounts for prompt payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other customer credits/fees and co-pay assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Rebates and fees due to customers on the accompanying Consolidated Balance Sheets. Balances as of December 31, 2016 have been reclassified to reflect that presentation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration agreements under which we may obtain upfront license fees, milestone, royalty, development cost reimbursements, and/or product supply payments. These arrangements have multiple elements, and our deliverables may include intellectual property rights, distribution rights, delivery of manufactured product, commercial and development activities and participation on joint steering, commercial and development committees. In order to account for these arrangements, we identify the deliverables and evaluate whether the delivered elements have value to our collaboration partner on a stand-alone basis and represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver future goods or services, a right or license to use an asset, or another performance obligation. If we determine that multiple deliverables exist, the consideration is allocated to one or more units of accounting based upon the best estimate of the selling price of each deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement will be combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue then will be determined for those combined deliverables as a single unit of accounting. For a combined unit of accounting, non-refundable upfront fees are recognized in a manner consistent with the final deliverable, which has generally been ratably over the period of our continued involvement. Amounts received in advance of performance are recorded as deferred revenue.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Historically, adjustments have not been material when compared to actual amounts paid by licensees. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases in revenue are generally considered to be changes in estimates and will be reflected in the period they become known. If we are unable to reasonably estimate royalty revenue, we record royalty revenues when they are received. We consider sales-based contingent payments to be royalty revenue which is generally recognized at the date the contingency is achieved. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our product supply revenues are recognized upon delivery of the product. See &#8220;Note 2. Collaboration Agreements&#8221; for a description of our product supply agreements with our collaboration partners.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For certain milestone payments under collaboration agreements, we have made a policy election to recognize revenue using the milestone method. A milestone is an event: (i)&#160;that can be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&#160;that would result in additional payments being due to us. The determination that a milestone is substantive requires estimation and judgment and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is: (i)&#160;commensurate with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from our performance to achieve the milestone, (ii)&#160;relates solely to past performance and (iii)&#160;reasonable relative to all deliverables and payment terms in the arrangement. In making the determination as to whether a milestone is substantive or not, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. A substantive milestone is recognized as revenue in its entirety in the period in which the milestone is achieved. A non-substantive milestone is recognized as revenues over the estimated period of our continued involvement. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are also entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are entitled to low double-digit royalties on ex-U.S. net sales. See &#8220;Note 2. Collaboration Agreements&#8221; for additional information about our collaboration agreement with Genentech. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. As of December 31, 2017, we have not recognized a profit for any year to date period from the commercialization of cobimetinib in the U.S. Until we have recognized a profit under the agreement, losses are recognized as Selling, general and administrative expenses on the accompanying Consolidated Statements of Operations. In connection with our agreement to co-promote with Genentech, we were responsible for providing up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the sales force necessary to assist with the promotion of cobimetinib. Genentech reimburses us for these costs which we include as a reduction of our Selling, general and administrative costs when the obligations are incurred or we become entitled to the cost recovery.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patient Assistance Programs</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We provide CABOMETYX and COMETRIQ at no cost to eligible patients who have no insurance and meet certain financial and clinical criteria through our patient assistance programs. We record the cost of the product as a selling, general and administrative expense at the time the product is shipped to the specialty pharmacy for patient assistance use.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty on sales of any product incorporating cabozantinib payable to GlaxoSmithKline (&#8220;GSK&#8221;), indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. A portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ and CABOMETYX and therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. See &#8220;Note 2. Collaboration Agreements&#8221; for additional information on the royalty payable to GSK on sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other expenses, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The expense for stock-based compensation is based on the grant date fair value of the award; the grant date fair value of Restricted Stock Units (&#8220;RSUs&#8221;) is estimated as the value of the underlying shares of our common stock and the grant date fair value of stock-options is estimated using the Black-Scholes Merton option pricing model. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on a straight-line basis over the requisite service period. Compensation expense relating to awards subject to performance conditions is recognized if it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-09&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences and classification on the statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, with a cumulative adjustment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to accumulated deficit and additional paid-in capital as of January 1, 2017. No prior periods were restated as a result of this change in accounting principle. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on the accompanying Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in operating cash flows of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> along with a corresponding decrease in financing cash flows on the accompanying Consolidated Statement of Cash Flows for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax provision is computed under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">together with assessing carry-forwards </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an unrecognized tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2014-09,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2014-09&#8221;).&#160;In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which delayed the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, which is when we will adopt the standard. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of net product revenues. ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration agreements with Ipsen Pharma SAS (&#8220;Ipsen&#8221;) and Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;). We will record a net adjustment of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$260 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accumulated deficit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(a concept known as &#8220;lost revenue&#8221;) for amounts associated with these collaboration agreements upon recording our transition adjustment in the first quarter of 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration agreements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No.&#160;2016-02,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Leases (Topic 842),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-02&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require both types of leases to be recognized on the balance sheet. The ASU also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 is effective for us for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. We are in the process of assessing the impact of ASU No. 2016-02 on our Consolidated Financial Statements and are considering early adoption of this standard in the first half of 2018. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU No.&#160;2016-15,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-15&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-15 addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing and contingent consideration payments made after a business combination. ASU 2016-15 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-15 to have a material impact on our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2016, the FASB issued ASU No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-18&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-18 to have a material impact on our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2017-04&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU No.&#160;2017-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2017-09&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-09 streamlines the application of modification accounting by stating that when making a change to the terms or conditions of a share-based payment award, a company should apply modification accounting to the award, unless each of the following conditions is met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, and 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2017-09 to have a material impact on our Consolidated Financial Statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949252704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COLLABORATION AGREEMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Ipsen for all development and commercial activities, research and development services, and participation on the joint steering, development and commercialization committees (as defined in the collaboration agreement). We determined that these deliverables do not have stand-alone value and accordingly, combined these deliverables into a single unit of accounting and allocated the entire arrangement consideration to that combined unit of accounting. As a result, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aggregate </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> has been recognized ratably over the term of the collaboration agreement, through early 2030, which is the current estimated patent expiration of cabozantinib in the European Union (&#8220;EU&#8221;). At the time we entered into the collaboration agreement, we determined that the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> milestone we achieved in September 2016 upon the approval of cabozantinib by the European Commission in previously treated advanced RCC was not substantive due to the relatively low degree of uncertainty and relatively low amount of effort required on our part to achieve the milestone as of the date of the collaboration agreement; the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was deferred and has been recognized ratably over the remainder of the term of the Ipsen collaboration agreement. We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018, which will materially impact the timing of recognition of revenue for our collaboration </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> with Ipsen. For information on our adoption of ASU 2014-09, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the time we entered into the collaboration agreement we determined that the remaining development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. We have achieved additional milestones of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$45.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also eligible to receive future development and regulatory milestone payments, totaling up to an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$209.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including milestone payments of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$40.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upon </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">European Medicines Agency (&#8220;EMA&#8221;) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">filing and the approval of cabozantinib </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as a treatment for patients with previously treated advanced hepatocellular carcinoma (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">HCC&#8221;) and additional milestone payments for other future indications and/or jurisdictions. The collaboration agreement also provides that we will be eligible to receive contingent payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$546.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with the achievement of specified levels of Ipsen sales to end users. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Excluding Ipsen sales in Canada, we </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">received a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was achieved in the fourth quarter of 2017, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and are entitled to receive a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty on the next </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">following this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales. These tiers will reset each calendar year. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In Canada, we are entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of annual net sales and a tiered royalty thereafter, up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these tiers will also reset each calendar year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are primarily responsible for funding cabozantinib-related development costs for those trials in existence at the time we entered into the collaboration agreement with Ipsen; global development costs for additional trials are shared between the parties, with Ipsen reimbursing us for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of such costs, provided Ipsen chooses to opt into such trials. In accordance with the collaboration agreement, Ipsen has opted into and is co-funding</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib with nivolumab versus sunitinib in patients with previously untreated, advanced or metastatic RCC being conducted in collaboration with Bristol-Myers Squibb Company (&#8220;BMS&#8221;); CheckMate 040, the phase 1/2 study evaluating the combination of cabozantinib with nivolumab in patients with both previously treated and previously untreated advanced HCC being conducted in collaboration with BMS (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab); and the phase 1b trial evaluating cabozantinib in combination with atezolizumab in locally advanced or metastatic solid tumors being conducted in collaboration with Roche. We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">s a result of a change in operational responsibilities for certain clinical programs, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in March </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017, we reclassified </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of deferred revenue to Accrued collaboration liabilities and accordingly adjusted our amortization of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aggregate </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had paid </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> toward the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of reimbursements due to Ipsen for these clinical programs.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We remain responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration agreement. In connection with the collaboration agreement, we entered into a supply agreement with Ipsen in February 2016,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which, pursuant to its amended terms, effective October 2017, we will supply finished, labeled drug product to Ipsen for distribution in the territories outside of the U.S. and Japan, indefinitely. The product will be supplied</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">at our cost, as defined in the agreement, which excludes the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GSK on Ipsen&#8217;s net sales of any product incorporating cabozantinib.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless terminated earlier, the collaboration agreement has a term that continues, on a product-by-product and country-by-country basis, until the latter of (i) the expiration of patent claims related to cabozantinib, (ii) the expiration of regulatory exclusivity covering cabozantinib or (iii) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after the first commercial sale of cabozantinib, other than COMETRIQ. The supply agreement will continue in effect until expiration or termination of the collaboration agreement. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach of either the collaboration agreement or the supply agreement by the other party, bankruptcy of the other party or for safety reasons. We may terminate the collaboration agreement if Ipsen challenges or opposes any patent covered by the collaboration agreement. Ipsen may terminate the collaboration agreement if the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">U.S. Food and Drug Administration (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">FDA&#8221;) or EMA orders or requires substantially all cabozantinib clinical trials to be terminated. Ipsen also has the right to terminate the collaboration agreement on a region-by-region basis after the first commercial sale of cabozantinib in advanced RCC in the given region. Upon termination by either party, all licenses granted by us to Ipsen will automatically terminate, and, except in the event of a termination by Ipsen for our material breach, the licenses granted by Ipsen to us shall survive such termination and shall automatically become worldwide, or, if Ipsen terminated only for a particular region, then for the terminated region. Following termination by us for Ipsen&#8217;s material breach, or termination by Ipsen without cause or because we undergo a change of control by a party engaged in a competing program, Ipsen is prohibited from competing with us for a period of time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestones achieved</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of upfront payments and deferred milestone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,531</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,417</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of supplied product</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,390</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty payable to GSK on net sales by Ipsen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues under the collaboration agreement with Ipsen</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> such revenues for the year ended December 31, 2015. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the collaboration agreement was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$19.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further clinical development of cabozantinib in Japan. Pursuant to the terms of the collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan. The parties have also agreed to collaborate on the future clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In consideration for the exclusive license and other rights contained in the collaboration agreement, we received a&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upfront nonrefundable payment from Takeda. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement contains multiple deliverables consisting of intellectual property licenses, delivery of products and/or materials containing cabozantinib to Takeda for all development and commercial activities, research and development services, and participation on the joint executive, development and commercialization committees (as defined in the collaboration agreement). We determined that these deliverables, other than the commercial supply and joint commercialization committee participation, are non-contingent in nature. The commercial supply deliverable was deemed contingent, primarily due to the fact that there is uncertainty around approval in Japan, which is dependent on successful clinical trial results from a study in Japanese patients. We also determined that the non-contingent deliverables do not have stand-alone value, because each one of them has value only if we meet our obligation as a whole to provide Takeda with research and development services, including clinical supply of cabozantinib under the collaboration agreement. Accordingly, we combined the non-contingent deliverables into a single unit of accounting and allocated the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> upfront fee to that combined unit of accounting. We also determined that the level of effort required of us to meet our obligations under the collaboration agreement is not expected to vary significantly over the development period of the collaboration agreement. As a result, the upfront payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, received in the first quarter of 2017, has been recognized ratably over the development period of the collaboration agreement of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018, which will materially impact the timing of recognition of revenue for our collaboration </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> with Takeda. For information on our adoption of ASU 2014-09, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Consolidated Financial Statements&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> contained in Part II, Item 8 of this Annual Report on Form 10-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive development, regulatory and first-sale milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$95.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> related to second-line RCC, first-line RCC and second-line HCC, as well as additional development, regulatory and first-sale milestones payments for potential future indications. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We determined that the development and regulatory milestones are substantive and will be recognized as revenue in the periods in which they are achieved. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement also provides that we are eligible to receive pre-specified payments of up to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$83.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> associated with potential sales milestones. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider the contingent payments due to us upon the achievement of specified sales volumes to be similar to royalty payments. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will also receive royalties on net sales of cabozantinib in Japan. We are entitled to receive a tiered royalty of&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, and after the initial </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$300.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales, we are then entitled to receive a tiered royalty of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;on annual net sales. These tiers will reset each calendar year. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Takeda is responsible for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts into such trials, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan. Pursuant to the terms of the collaboration agreement, we are responsible for the manufacture and supply of cabozantinib for all development and commercialization activities under the collaboration, and consequently, we entered into a clinical supply agreement covering the manufacture and supply of cabozantinib to Takeda, as well as a quality agreement setting forth, in detail, the quality assurance arrangements and procedures for our manufacture of cabozantinib. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will record reimbursements for development costs as revenue as the development services represent a part of our ongoing major or central operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues, on a product-by-product basis, until the earlier of (i) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> after first generic entry with respect to such product in Japan or (ii) the later of (A) the expiration of patent claims related to cabozantinib and (B) the expiration of regulatory exclusivity covering cabozantinib in Japan. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party, bankruptcy of the other party or for safety reasons. For clarity, Takeda&#8217;s failure to achieve specified levels of commercial performance, based upon sales volume and/or promotional effort, during the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> years of the collaboration shall constitute a material breach of the collaboration agreement. We may terminate the agreement if Takeda challenges or opposes any patent covered by the collaboration agreement. At any time prior to August 1, 2023, the parties may mutually agree to terminate the collaboration agreement if Japan&#8217;s Pharmaceuticals and Medical Devices Agency is unlikely to grant any approval of the marketing authorization application in any cancer indication in Japan. After the commercial launch of cabozantinib in Japan, Takeda may terminate the collaboration agreement upon twelve months&#8217; prior written notice following the third anniversary of the first commercial sale of cabozantinib in Japan. Upon termination by either party, all licenses granted by us to Takeda will automatically terminate, and the licenses granted by Takeda to us shall survive such termination and shall automatically become worldwide.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of upfront payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues under the collaboration agreement with Takeda</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> such revenues for the year ended December 31, 2016 or 2015. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, short-term and long-term deferred revenue relating to the collaboration agreement was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$28.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cobimetinib Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genentech Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the further development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we were responsible for developing cobimetinib through the determination of the maximum-tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, which Genentech could exercise after receipt of certain phase 1 data from us. In March&#160;2008, Genentech exercised its option to co-develop cobimetinib, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and subsequent clinical development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On&#160;November&#160;10, 2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Zelboraf as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in Switzerland, the EU, Canada, Australia, Brazil and multiple additional countries for use in the same indication. Prior to the FDA&#8217;s approval of COTELLIC, in November 2013, we exercised an option under the collaboration agreement to co-promote COTELLIC in the U.S., which allowed us to provide up to 25% of the total sales force for approved cobimentinib indications in the U.S. Between November 2015 and December 2017, we fielded </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;of the sales force promoting COTELLIC in combination with Zelboraf as a treatment for patients with BRAF mutation-positive advanced melanoma in the U.S. However, following a recent commercial review, commencing in January 2018, we and Genentech scaled back the personal promotion of COTELLIC in this indication in the U.S. This decision is not indicative of any change in our intention to promote COTELLIC for other therapeutic indications for which it may be approved in the future. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement, as amended in July 2017, we share in the profits and losses received or incurred in connection with COTELLIC&#8217;s commercialization in the U.S. This profit and loss share has multiple tiers: we receive </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$200.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of U.S. actual sales, decreasing to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of profits and losses from U.S. actual sales in excess of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$400.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These tiers will reset each calendar year. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The revenue for each sale of COTELLIC applied to the profit and loss statement for the collaboration agreement (the &#8220;Genentech Collaboration P&amp;L&#8221;) is calculated using the average of the quarterly net selling prices of COTELLIC and any additional branded Genentech product(s) prescribed with COTELLIC in such sale. U.S. commercialization costs for COTELLIC are then applied to the Genentech Collaboration P&amp;L, subject to reduction based on the number of Genentech products in any given combination including COTELLIC. In addition to our profit share in the U.S., under the terms of the collaboration agreement, we are entitled to low double-digit royalties on net sales of COTELLIC outside the U.S. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Unless earlier terminated, the collaboration agreement has a term that continues until the expiration of the last payment obligation with respect to the licensed products under the collaboration. Genentech has the right to terminate the collaboration agreement without cause at any time. If Genentech terminates the collaboration agreement without cause, all licenses that were granted to Genentech under the agreement terminate and revert to us. Additionally, if Genentech terminates the collaboration agreement without cause, or we terminate the collaboration agreement for cause, we would receive, subject to certain conditions, licenses from Genentech to research, develop and commercialize reverted product candidates. The collaboration agreement may be terminated for cause by&#160;either party based on uncured material breach by the other party.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales of COTELLIC</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,771</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2016 Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay certain disputed costs that had been accrued by us; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the year ended December 31, 2016, we offset Selling, general and administrative expenses with a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> recovery of disputed losses that we had recognized and recorded prior to 2016 and also recognized a loss under the collaboration agreement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for 2016 activities, resulting in a net cost recovery of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Collaborations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with other leading pharmaceutical and biotechnology companies, including BMS, Daiichi Sankyo Company Limited (&#8220;Daiichi Sankyo&#8221;), Roche, Merck (known as MSD outside of the U.S. and Canada) and Sanofi, for various compounds and programs in our portfolio. Pursuant to these collaborations, we have fully out-licensed compounds or programs to a partner for further development and commercialization.&#160;Under each of our collaborations, we are entitled to receive milestones and royalties. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to our partnered compounds, other than cabozantinib and cobimetinib, we are eligible to receive potential contingent payments totaling approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.9 billion</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the aggregate on a non-risk adjusted basis, of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are related to clinical development milestones, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are related to regulatory milestones and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are related to commercial milestones, all to be achieved by the various licensees, which may not be paid, if at all, until certain conditions are met.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Daiichi Sankyo</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo for the discovery, development and commercialization of novel therapies targeted against the mineralocorticoid receptor (&#8220;MR&#8221;), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic diseases. Under the terms of the agreement, we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including CS-3150/esaxerenone (a specific rotational isomer of XL550). Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds and we do not have rights to reacquire such compounds, except as described below. In September 2017, Daiichi Sankyo reported positive top-line results from the phase 3 pivotal trial of CS-3150/esaxerenone and communicated its intention to submit a Japanese regulatory application for CS-3150/esaxerenone for an essential hypertension indication in the first quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive additional development, regulatory and commercialization milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$130.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. In addition, we are entitled to receive royalties on any sales of certain products commercialized under the collaboration. Daiichi Sankyo may terminate the agreement upon ninety days&#8217; written notice in which case Daiichi Sankyo&#8217;s payment obligations would cease, its license relating to compounds that modulate MR would terminate and revert to us and we would receive, subject to certain terms and conditions, licenses from Daiichi Sankyo to research, develop and commercialize compounds that were discovered under the collaboration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognized contract revenues of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for milestone payments during the year ended December 31, 2016 under our collaboration agreement with Daiichi Sankyo. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any such revenue during the years ended December 31, 2017 or 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">The Roche Group Collaboration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we established a clinical trial collaboration with The Roche Group (&#8220;Roche&#8221;) for the purpose of evaluating the safety and tolerability of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors. Each party is responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the clinical supply agreement entered into by the parties in February 2017. Based on the dose-escalation results, the trial has the potential to enroll up to four expansion cohorts, including a cohort of patients with previously untreated advanced clear cell RCC and three cohorts of urothelial carcinoma, namely platinum eligible first-line patients, first or second-line platinum ineligible patients and patients previously treated with platinum-containing chemotherapy. The trial was initiated in June 2017 and is open for enrollment. We are the sponsor of the trial, and Roche is responsible for supplying atezolizumab to us. Ipsen has opted to participate in the study and will have access to the results to support potential future development in its territories.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Merck</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December&#160;2011, we entered into an agreement with Merck pursuant to which we granted Merck an exclusive worldwide license to our phosphoinositide-3 kinase-delta (&#8220;PI3K-d&#8221;) program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck has sole responsibility to research, develop, and commercialize compounds from our PI3K-d program.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible to receive additional payments associated with the successful achievement of potential development and regulatory milestones for multiple indications of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$231.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We will also be eligible to receive payments for combined sales performance milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$375.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and royalties on net-sales of products emerging from the agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Merck may at any time, upon specified prior notice to us, terminate the license. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by Merck at will or by us for Merck&#8217;s uncured material breach, the license granted to Merck would terminate. In the event of a termination by us for Merck&#8217;s uncured material breach, we would receive a royalty-free license from Merck to develop and commercialize certain joint products. In the event of termination by Merck for our uncured material breach, Merck would retain the licenses from us, and we would receive reduced royalties from Merck on commercial sales of products. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognized contract revenues of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for milestone payments during the years ended December 31, 2016 and 2015, respectively, under our collaboration agreement with Merck. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any such revenue during the year ended December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Bristol-Myers Squibb</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Previously Untreated Advanced RCC, Bladder Cancer and Previously Treated HCC Combination Studies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2017, we entered into a clinical trial collaboration agreement with BMS for the purpose of evaluating the combination of cabozantinib and nivolumab with or without ipilimumab in various tumor types, including, in RCC, HCC and bladder cancer. To date, CheckMate 9ER, a phase 3 pivotal trial in previously untreated, advanced or metastatic RCC, and CheckMate 040, a phase 1/2 trial in both previously treated and previously untreated advanced HCC evaluating these combinations has been initiated. Pursuant to the terms of the collaboration agreement, each party will grant to the other a non-exclusive, worldwide (within the collaboration territory as defined in the collaboration agreement), non-transferable, royalty-free license to use the other party&#8217;s compounds in the conduct of each clinical trial. The parties&#8217; efforts are governed through a joint development committee established to guide and oversee the collaboration&#8217;s operation. Each trial will be conducted under a combination Investigational New Drug Application, unless otherwise required by a regulatory authority. Each party will be responsible for supplying drug product for the applicable clinical trial in accordance with the terms of the supply agreement entered into between the parties in April 2017, and costs for each such trial will be shared equally between the parties, unless two BMS compounds will be utilized in such trial, in which case BMS will bear </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two-thirds</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs and we will bear </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one-third</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the costs for such study treatment arms. Unless earlier terminated, the BMS collaboration agreement will remain in effect until the completion of all clinical trials under the collaboration, all related trial data has been delivered to both parties and the completion of any then agreed upon analysis. Ipsen has opted in to participate in both trials (though Ipsen will not be co-funding the triplet arm of the study evaluating cabozantinib with nivolumab and ipilimumab) and will have access to the results to support potential future regulatory submissions. Ipsen may also participate in future studies at its choosing.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">ROR Collaboration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2010, we entered into a worldwide collaboration with BMS pursuant to which each party granted to the other certain intellectual property licenses to enable the parties to discover, optimize and characterize ROR antagonists that may subsequently be developed and commercialized by BMS. Under the terms of the collaboration agreement, we were responsible for activities related to the discovery, optimization and characterization of the ROR antagonists during the collaborative research period which began on October&#160;8, 2010 and ended on&#160;July 8, 2013. Since the end of the collaborative research period, BMS has and will continue to have sole responsibility for any further research, development, manufacture and commercialization of products developed under the collaboration and will bear all costs and expenses associated with those activities.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are eligible for additional development and regulatory milestone payments of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$240.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the aggregate and commercialization milestones of up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$150.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the aggregate, as well as royalties on commercial net sales, depending on the advancement of the product candidate and eventual product.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The collaboration agreement was amended and restated in April 2011 in connection with an assignment of patents to a wholly-owned subsidiary. BMS may, at any time, terminate the collaboration agreement upon certain prior notice to us on a product-by-product and country-by-country basis. In addition, either party may terminate the agreement for the other party&#8217;s uncured material breach. In the event of termination by BMS at will or by us for BMS&#8217;s uncured material breach, the license granted to BMS would terminate, the right to such product would revert to us and we would receive a royalty-bearing license for late-stage reverted compounds and a royalty-free license for early-stage reverted compounds from BMS to develop and commercialize such product in the related country. In the event of termination by BMS for our uncured material breach, BMS would retain the right to such product, subject to continued payment of milestones and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognized contract revenues of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for milestone payments during the year ended December 31, 2017 under our collaboration agreement with BMS. We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any such revenue during the years ended December 31, 2016 or 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sanofi</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2009, we entered into a global license agreement with Sanofi for SAR245408 (XL147) and SAR245409 (XL765), leading inhibitors of phosphoinositide-3 kinase (&#8220;PI3K&#8221;), and a broad collaboration for the discovery of inhibitors of PI3K for the treatment of cancer. The license agreement and collaboration agreement became effective on July&#160;7, 2009. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Under the license agreement, Sanofi received a worldwide exclusive license to SAR245408 (XL147) and SAR245409 (XL765), which entered into a series of phase 1, phase 1b/2 or phase 2 clinical trials, and has sole responsibility, including funding, for all subsequent clinical, regulatory, commercial and manufacturing activities. We were notified by Sanofi that the initial clinical trials involving XL147 or XL765 have been terminated or are in the process of concluding, and that Sanofi is still considering whether to initiate any further trials. We are eligible to receive contingent payments associated with development, regulatory and commercial milestones under the license agreement of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$745.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the aggregate, as well as royalties on sales of any products commercialized under the license. Sanofi may, upon certain prior notice to us, terminate the license as to products containing SAR245408 (XL147) and SAR245409 (XL765). In the event of such termination election, Sanofi&#8217;s license relating to such product would terminate and revert to us, and we would receive, subject to certain terms, conditions and potential payment obligations, licenses from Sanofi to research, develop and commercialize such products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any revenue under our collaboration agreement with Sanofi during the three years ended December 31, 2017, 2016 and 2015.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GlaxoSmithKline</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a collaboration with GSK to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Under the terms of the product development and commercialization agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. As a result, we retained the rights to develop, commercialize, and license cabozantinib, subject to payment to GSK of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty on net sales of any product incorporating cabozantinib. The product development and commercialization agreement was terminated during 2014, although GSK will continue to be entitled to a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty on net sales by us or our collaboration partners of any product incorporating cabozantinib, including COMETRIQ and CABOMETYX. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Consolidated Statements of Operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783774896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INVESTMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investments Available-for-Sale</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash equivalents and investments by security type were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">460,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were nominal or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">zero</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses of investments available-for-sale in an unrealized loss position were as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">169,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">172,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross unrealized losses on commercial paper were less than </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$1</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> thousand.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">134</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">86</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">404,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash is excluded from the table above. The classification of certain restricted investments was dependent upon the term of the underlying restriction on the asset and not the maturity date of the investment. As a result, certain investments with contractual maturities within one year were classified as long-term restricted cash and investments.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we were required to maintain compensating balances of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$81.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in connection with our term loan payable to Silicon Valley Bank, which was included in short-term investments on the accompanying Consolidated Balance Sheet; as a result of our repayment of the term loan, the compensating balance requirement was terminated in March 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Cost Method Equity Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we recognized gains of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, related to the August 2016 sale of our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> interest in Akarna Therapeutics, Ltd. (&#8220;Akarna&#8221;) to Allergan Holdco UK Limited (&#8220;Allergan&#8221;). We acquired our interest in Akarna in 2015 in exchange for intellectual property rights related to the Exelixis discovered compound XL335. The gain on sale was included in Other expenses, net on the accompanying Consolidated Statements of Operations. We are eligible to earn additional such gains in the future as Allergan continues its development of XL335. The gain on sale of other cost method equity investments was nominal during the year ended December&#160;31, 2015.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments, including all tables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 6<br> -Section 10<br> -Paragraph (c)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949298400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INVENTORY</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A portion of the manufacturing costs for inventory was incurred prior to regulatory approval of CABOMETYX and COMETRIQ and therefore was expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. Write-downs related to excess and expiring inventory are charged to either Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and 2015, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory expected to be used or sold in periods more than 12 months from the date presented is classified as Other long-term assets on the accompanying Consolidated Balance Sheets. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the non-current portion of inventory consisted of finished goods. As of December 31, 2016, the non-current portion of inventory consisted of raw materials and a portion of the active pharmaceutical ingredient that was included in work in process inventories.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783774896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(24,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Build-to-Suit Lease </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease Agreement (the &#8220;Lease&#8221;) with Ascentris 105, LLC (&#8220;Ascentris&#8221;), to lease </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space in office and research facilities located at 1751, 1801, and 1851 Harbor Bay Parkway, Alameda, California (the &#8220;Premises&#8221;). On October 16, 2017, we executed an amendment to the Lease for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19,778</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of additional space located at the Premises with terms consistent with the original Lease. See &#8220;Note 12. Commitments&#8221; for a description of the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with the Lease, we received a tenant improvement allowance of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from Ascentris, for the costs associated with the design, development and construction of tenant improvements for the Premises. We are obligated to fund all costs incurred in excess of the tenant improvement allowance and to certain indemnification obligations related to the construction activities. We evaluated our involvement during the construction period and determined the scope of the tenant improvements on portions of the Premises including the building shells did not qualify as &#8220;normal tenant improvements&#8221; under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 840, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Accordingly, for accounting purposes, we are the deemed owner of such portions of the Premises during the construction period. As such, we will capitalize the construction costs as a build-to-suit property within property and equipment, net, including the estimated fair value of the building shells that we are deemed to own at the lease inception date, as determined using a third-party appraisal. The capitalized construction costs will also include the estimated tenant improvements incurred by Ascentris. Accordingly, we capitalized </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs related to the Lease in construction in progress as of May 2, 2017, with a corresponding build-to-suit lease obligation in Other long-term liabilities. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have capitalized an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of construction in progress for tenant improvements related to the Premises. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have also prepaid an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for future constructions costs which is included in Other long-term assets on the accompanying Consolidated Balance Sheets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Once the construction is complete, we will consider the requirements for sale-leaseback accounting treatment, including evaluating whether all risks of ownership have been transferred back to Ascentris, as evidenced by a lack of continuing involvement in the leased property. If the arrangement does not qualify for sale-leaseback accounting treatment, the building assets will remain on the accompanying Consolidated Balance Sheets at their historical cost.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783709344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DEBT</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The amortized carrying amount of our debt was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">189,122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance of unamortized fees and costs was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which was recorded as a reduction of the carrying amount of the Convertible notes on the accompanying Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Convertible notes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Secured Convertible Notes due 2018 (&#8220;Deerfield Notes&#8221;)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On June 28, 2017, we repaid all amounts outstanding under the Deerfield Notes. The repayment amount totaled </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$123.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which comprised </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$113.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in principal, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of interest paid in kind paid through the repayment date, a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> prepayment penalty associated with the early repayment of the notes and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in accrued and unpaid interest. As a result of the early repayment, there was a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> loss on the extinguishment of the debt which comprised the prepayment penalty and the unamortized fees and costs on the date of the repayment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to our early repayment of the Deerfield Notes, the outstanding principal amount of the notes bore interest at the rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per annum to be paid in cash, quarterly in arrears, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per annum to be paid in kind, quarterly in arrears, for a total interest rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per annum.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">4.25% Convertible Senior Subordinated Notes due 2019 (&#8220;2019 Notes&#8221;)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Between August and November 2016, all </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$287.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> aggregate principal amount outstanding under the 2019 Notes was either converted into </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54,009,279</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of common stock or redeemed for </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash. In addition, certain holders received inducements of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which included an aggregate cash payment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in accrued interest payments which would have been payable if the notes had not been exchanged. Under the terms of the indenture for the 2019 Notes, certain holders who exchanged their notes on August 9, 2016 would have been required to repay the interest payment they received as holders of record on August 1. The exchange transactions were structured such that the holders were not required to repay this interest. We have included those payments as an additional inducement and as financing activities on the accompanying Consolidated Statement of Cash Flows. A summary of loss on extinguishment of debt for the conversion and redemption of the 2019 Notes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash inducements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Waiver of requirement to repay interest, described above</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unamortized discount on redeemed notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third-party costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The stock issuance on the conversion of the notes resulted in an increase to common stock and additional paid-in capital of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$592.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. A portion of the settlement consideration transferred to the holders of the notes was allocated to the reacquisition of the conversion option embedded in the notes, which resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$342.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> reduction of additional paid-in capital. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to the extinguishment of the 2019 Notes, the outstanding principal amount of the notes bore interest at a rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;per annum, payable semi-annually in arrears on February&#160;15 and August&#160;15 of each year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term loan payable</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On March 29, 2017, we repaid all amounts outstanding under our term loan payable to Silicon Valley Bank. The repayment included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$80.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in principal plus </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in accrued and unpaid interest. There was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> gain or loss on the extinguishment of debt as a result of the repayment of the term loan. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Prior to our early repayment of the term loan payable, the outstanding principal amount of the loan bore interest at the rate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;per annum, which was due and payable monthly. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we were required to maintain compensating balances of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$81.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in connection with our term loan payable to Silicon Valley Bank, which was included in short-term investments on the accompanying Consolidated Balance Sheet; as a result of our repayment of the term loan, the compensating balance requirement was terminated in March 2017.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783721200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock and Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COMMON STOCK AND WARRANTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Conversion of Debt into Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Between August and November 2016, we issued </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54,009,279</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock pursuant to the conversion of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$286.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of aggregate principal amount of the 2019 Notes. The conversions resulted in a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$253.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase to shareholder&#8217;s equity and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> loss on extinguishment of debt. See &#8220;Note 6. Debt&#8221; for more information on the conversion of the 2019 Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Sale of Shares of Common Stock</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2015, we completed a registered underwritten public offering of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28,750,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3,750,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares issued under the underwriters&#8217; 30-day option to buy shares, at a price of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.40</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission, which was filed and automatically became effective on July 1, 2015. We received </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$145.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in net proceeds from the offering after deducting the underwriting discount and other expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2014 Warrants</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with an amendment to the note purchase agreement for the Secured Convertible Notes due 2015, (the &#8220;Original Deerfield Notes&#8221;), in January 2014 we issued </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year warrants to purchase an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1,000,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of our common stock at an exercise price of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.70</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share (the &#8220;2014 Warrants&#8221;). Subsequent to our March 2015 notification of our election to extend the maturity date of the Deerfield Notes, the exercise price of the 2014 Warrants was reset to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.445</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, the term was extended by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to January 22, 2018, and the 2014 Warrants were transferred to Additional paid-in capital as of that date at their then estimated fair value of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as their terms had become fixed.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On September 11, 2017, we issued an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">877,451</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares of common stock pursuant to the cashless exercises of the 2014 Warrants issued to an accredited investor transferee. The number of shares issued upon exercise was net of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">122,549</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares withheld to effect the cashless exercise of the 2014 Warrants in accordance with their terms. As of December 31, 2017, there are </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> remaining warrants outstanding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783671408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The allocation of stock-based compensation for our equity incentive plans and our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was as</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and RSUs to employees, directors and consultants. At </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">20,328,545</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans. The Board of Directors or a designated Committee of the Board is responsible for administration of our equity incentive plans and determines the term, exercise price and vesting terms of each grant. Stock options have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year vesting term, an exercise price equal to the fair market value on the date of grant, and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seven</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year life from the date of grant. Stock options issued prior to May 2011 have a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ten</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year life from the date of grant. RSUs granted to our employees generally vest annually over a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">four</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year term.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a Change in Control and Severance Benefit Plan for executives and certain non-executives. Eligible Change in Control and Severance Benefit Plan participants include employees with the title of vice president and above. If a participant&#8217;s employment is terminated without cause during a period commencing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one month</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> before and ending </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">thirteen months</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> following a change in control, as defined in the plan document, then the Change in Control and Severance Benefit Plan participant is entitled to have the vesting of all of such participant&#8217;s stock options accelerated with the exercise period being extended to no more than </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one year</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">We have an ESPP that allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the beginning of the offering period or</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">85%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">of the closing price at the end of each</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">six</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">month purchase period. Compensation expense related to our ESPP was</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">for the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively. As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, we had</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">5,052,500</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares available for issuance under our ESPP. Pursuant to the ESPP, we issued</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">434,523</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">559,936</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares, and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">324,315</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares of common stock at an average price per share of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$11.20</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$3.91</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$1.75</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">during the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Cash received</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from purchases under the ESPP in the years ended December 31, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We use the Black-Scholes Merton option pricing model to value our stock options. The weighted average grant-date fair value of our stock option grants and ESPP purchases were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered implied volatility as well as our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock option activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,999,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,166,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,469,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(229,793</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(258,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.05 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">523,448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,158,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.46 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$39.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to stock options will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.57 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between our closing stock price on the last trading day of fiscal </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the exercise prices, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total intrinsic value of options exercised was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$85.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. Cash received from option exercises during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$25.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The total estimated fair value of employee options vested and recorded as expense during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2016, March 2016 and July 2015, the Compensation Committee of the Board of Directors of Exelixis convened to determine we had met certain performance objectives for performance-based stock options granted to employees in 2013, 2014 and 2015. As a result of these determinations, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5,870,303</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6,982,613</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> performance-based stock options vested during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">, respectively</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">the years ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">we recognized</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">and</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">$13.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">in stock-based compensation for those</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock option grants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">. We did</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">t have any</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock options outstanding during the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and therefore, did </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">no</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">stock-based compensation for</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance-based stock </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">options during the year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was determined based on the value of the underlying common stock on the date of grant. The expenses relating to RSUs are recognized over their vesting period. A summary of all RSU activity were as follows (dollars in thousands, except per share amounts):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,469,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,137,817</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(708,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(136,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.95 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">114,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$61.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to employee RSUs will be recognized over a weighted-average period of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.20 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">401(k) Retirement Plan</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We sponsor the Exelixis, Inc. 401(k) Plan (the &#8220;401(k) Plan&#8221;) whereby eligible employees may elect to contribute up to the lesser of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of their annual compensation or the statutorily prescribed annual limit allowable under Internal Revenue Service regulations. We make matching contributions in the form of our common stock of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of each participant&#8217;s contributions into the 401(k) Plan. We recorded compensation expense related to the stock match of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">As of</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">231,090</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">shares were available for issuance under the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;background-color:#ffffff;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">401(k) Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783663616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">INCOME TAXES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was based on the following income (loss) before income taxes (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(150,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,843</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes for the year ended December&#160;31, 2017 primarily relates to state taxes in jurisdictions outside of California, for which we do not have net operating loss carry-forwards due to a limited operating history. Our historical losses are sufficient to fully offset any federal taxable income. The Provision for income taxes for the year ended December 31, 2016 related to state minimum and franchise taxes and were nominal. The Provision for income taxes for the year ended December 31, 2015 relates to state minimum and franchise tax expenses as well as true ups related to prior year tax returns. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of income taxes at the statutory federal income tax rate to our Provision for income taxes included on the accompanying Consolidated Statements of Operations was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax provision (benefit) at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Debt extinguishment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,726</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(20,548</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carry-forwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carry-forwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">471,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Book over tax depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit and charitable contribution carry-forwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of deferred stock compensation &#8211; non-qualified</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">629,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(629,062</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unrealized gains on derivatives and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law. The Tax Cuts and Jobs Act contains significant changes to corporate taxation, including among other items, a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%. As a result of the signing of the Tax Cuts and Jobs Act, we recorded a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$184.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> reduction of our deferred tax assets along with a corresponding reduction of our valuation allowance. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2017, or are expected to be recorded in future periods.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, further guidance may be forthcoming from the FASB and the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Securities and Exchange Commission</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC Topic 740 (&#8220;ASC 740&#8221;) requires that the tax benefit of net operating losses, temporary differences and credit carry forwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry forward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely (as defined in ASC 740) to be realized and, accordingly, has provided a valuation allowance. The valuation allowance decreased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$210.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during 2017 and increased by </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$92.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.9 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during 2016 and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At December&#160;31, 2017, we had federal net operating loss carry-forwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1,105 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2024</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and federal business tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$83 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2037</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also had state net operating loss carry-forwards of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$424 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which expire in the years </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2028</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2036</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and California research and development tax credits of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$28 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which have no expiration.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the Internal Revenue Code and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss and credit carry-forwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carry-forwards before utilization. We completed a Section 382 study through December 31, 2017, and concluded that an ownership change, as defined under Section 382, had not occurred. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASC 740 clarifies the accounting for uncertainty in income taxes by prescribing the recognition threshold a tax position is required to meet before being recognized in the financial statements. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(29,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not anticipate that the amount of unrecognized tax benefits existing as of December&#160;31, 2017 will significantly decrease over the next 12 months.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We file U.S. and state income tax returns in jurisdictions with varying statues of limitations during which such tax returns may be audited and adjusted by the relevant tax authorities. The 1999 through 2016 tax years generally remain subject to examination by federal and most state tax authorities to the extent net operating losses and credits generated during these periods are being utilized in the open tax periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783706880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NET INCOME (LOSS) PER SHARE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The 2014 Warrants were participating securities and the warrant holders did not have a contractual obligation to share in our losses. See &#8220;Note 7. Common Stock and Warrants&#8221; for a description of the 2014 Warrants.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potentially dilutive shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deerfield Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2014 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">117,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Deerfield Notes were repaid in June 2017. The 2014 Warrants were exercised in September 2017. The 2019 Notes were converted or redeemed between August and November 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949309920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">FAIR VALUE MEASUREMENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">388,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and there were no transfers of financial assets or liabilities classified as Level 3 during the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or 2016.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The estimated fair value of our financial instruments that are carried at amortized cost was as follows (in thousands)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">121,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying amounts of cash, trade and other receivables, accounts payable, accrued collaboration liability, accrued compensation and benefits, accrued clinical trial liabilities, rebates fees due customers, and other liabilities approximate their fair values and are excluded from the tables above. We had no additional financial instruments carried at amortized cost as of December 31, 2017. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following methods and assumptions were used to estimate the fair value of each class of financial instrument: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We estimated the fair value of our debt instruments using the net present value of estimated future cash flows through maturity. For the Deerfield Notes, we used a discount rate of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we estimated as our current borrowing rate for similar debt as of December&#160;31, 2016, which is a Level 3 input.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For the term loan payable, we used an interest rate that is consistent with money-market rates that would have been earned on our non-interest-bearing compensating balances as our discount rate, which is a Level 2 input.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Financial Assets, Liabilities and Equity Measured on a Nonrecurring Basis</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with the conversions of our 2019 Notes during 2016, we were required to determine the fair value of the settlement consideration received by the holders and the fair value of the liability component of the 2019 Notes, as of the various settlement dates of the conversions. The following methods and assumptions were used to estimate the fair value of those financial instruments:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The settlement consideration comprises, in part, shares of our Common Stock. The fair value of our Common Stock was determined based on the closing market price of our Common Stock on the various settlement dates of the conversions, which are level 1 inputs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of the remaining settlement consideration, which includes cash and the forgiveness of the repayment of certain prior interest payments, approximates fair value; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We estimated the fair value of the liability component of the 2019 Notes using the net present value of estimated future cash flows through maturity. We used a discount rate of </font><font style="font-family:Calibri;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which we estimated as our current borrowing rate for straight debt as of September 30, 2016, which is a Level 3 input.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663059872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COMMITMENTS</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On May 2, 2017, we entered into a Lease with Ascentris for an aggregate of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">110,783</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space in office and research facilities located at the Premises in Alameda, California. We also have the right to make certain tenant improvements to the space leased on the Premises. The Lease has an initial term of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10 years</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> with a target commencement date of February 1, 2018, and, subject to a partial twelve-month rent abatement period, rent payments will begin upon the target commencement date. We have </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">five</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-year options to extend the Lease and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-time option to terminate the Lease without cause on the last day of the 8</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term. The Lease further provides that we are obligated to pay to Ascentris certain costs, including taxes and operating expenses. We also have a right of first offer to lease certain additional space, in the aggregate of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">170,000</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space, as that additional space becomes available over the remainder of the initial term at 1601, 1701, 1751, and 1801 Harbor Bay Parkway, Alameda, California at a market rate determined according to the Lease. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are deemed, for accounting purposes only, to be the owner of portions of the Premises, including </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> building shells, even though we are not the legal owner. See &#8220;Note 5. Property and Equipment - Build-to-Suit Lease&#8221; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for a further description of the accounting for that portion of the Premises.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On May 2, 2017, we also entered into an Agreement for Conditional Option to Amend Lease (the &#8220;Optional Amendment Agreement&#8221;) with Ascentris. Under the terms of the Optional Amendment Agreement, a current tenant (the &#8220;Tenant&#8221;) occupying approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16,343</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of the facility located at 1801 Harbor Bay Parkway was given the option to relocate to another building on the premises or terminate their current lease early, requiring them to relocate within </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from the termination date. Under the terms of the Optional Amendment Agreement, we would reimburse Ascentris for the first </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of costs incurred to induce the Tenant to relocate. In August 2017, the Tenant communicated to Ascentris that they were terminating their lease early. During </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recorded a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> expense for our anticipated reimbursement of costs to Ascentris for the Tenant&#8217;s relocation of which </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> remains payable as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. On October 16, 2017, we executed an amendment to the Lease for an additional </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19,778</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of space located on the Premises, which includes the space vacated by the Tenant, with terms consistent with the original Lease. Including the amendment, we are obligated to make lease payments totaling $</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> over the Lease term. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also lease </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> buildings in South San Francisco, California with a total area of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">116,063</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet, the lease for which expires in July 2018.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the aggregate future minimum lease payments under our leases were as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other financing obligations</font><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Year ending December&#160;31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,282</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other financing obligations includes payments related to our build-to-suit lease.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Rent expense and sublease income were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross rental expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">less: Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,553</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,205</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net rental expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Letters of Credit and Restricted Cash</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We obtained a standby letter of credit related to our South San Francisco lease with a credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We obtained two standby letters of credit related to a workers compensation insurance policy with a combined credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We obtained </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">two</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> standby letters of credit related to the Lease with Ascentris for a combined credit limit of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. All of the letters of credit are fully collateralized by certificates of deposit. As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">none</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our letters of credit have been drawn upon. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of a purchasing card program we initiated during 2007, we were required to provide collateral in the form of certificates of deposit. The collateral requirement at both </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The certificate of deposit used to collateralize the standby letter of credit related to our South San Francisco lease was included in short-term restricted cash and investments. The certificates of deposit used to collateralize all other letters of credit and the purchase card program were included in long-term restricted cash and investments.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606060976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SEGMENT INFORMATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment which focuses on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Enterprise-wide disclosures about product sales, revenues from major customers, revenues and long-lived assets by geographic area are presented below.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues earned by geographic region were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">367,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to regions based on ship-to location and Collaboration revenues are attributed to regions based on the location of the collaboration partner.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> loss, a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> loss and a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> gain relating to foreign exchange fluctuations for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783707968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">QUARTERLY FINANCIAL DATA (UNAUDITED)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2017:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,510</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">84,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,414</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(59,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as Net product revenues less Cost of goods sold. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2016 Genentech stated that it changed, both retroactively and prospectively, the manner in which it allocates promotional expenses of the COTELLIC plus Zelboraf combination therapy. As a result of Genentech&#8217;s decision to change its cost allocation approach, we were relieved of our obligation to pay </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$18.7 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of disputed costs that had been accrued by us as of September 30, 2016; we were also able to invoice Genentech for certain expenses, with interest, that we had previously paid. Accordingly, during the quarter ended December 31, 2016, we offset Selling, general and administrative expenses for a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$23.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> recovery of net losses which had been recorded from 2013 through September 30, 2016, which included </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.8 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of losses that we had recognized and recorded during the three quarters ended September 30, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779329280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December&#160;31st. Fiscal year 2015 ended on January 1, 2016; fiscal year 2016 ended on December 30, 2016; fiscal year 2017 ended on December 29, 2017; and fiscal year 2018 will end on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2016, December 30, 2016 and December 29, 2017 are indicated as being as of and for the years ended December&#160;31, 2015, 2016 and 2017, respectively. All annual periods presented are 52-week fiscal years and all interim periods presented are 13-week fiscal quarters.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including deductions from revenues (such as rebates, chargebacks, sales returns and sales allowances), the period of performance, identification of deliverables and evaluation of milestones with respect to our collaborations; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liability; and valuations of awards used to determine stock-based compensation. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts on the accompanying Consolidated Financial Statements have been reclassified to conform to current period presentation. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents include high-grade, short-term investments in money market funds and marketable debt securities which are subject to minimal credit and market risk.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have designated all investments in marketable debt securities as available-for-sale and therefore, such investments are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are included in Interest and other income, net on the accompanying Consolidated Statements of Operations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We classify those investments that we do not require for use in current operations and that mature in more than 12 months as Long-term investments on the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our investments are subject to a quarterly impairment review. We recognize an impairment charge when a decline in the fair value of an investment below its cost basis is judged to be other-than-temporary. Factors considered in determining whether a loss is temporary include the length of time and extent to which the investments fair value has been less than their cost basis, the financial condition and near-term prospects of the issuer, extent of the loss related to credit of the issuer, the expected cash flows from the security, our intent to sell the security and whether or not we will be required to sell the security before we are able to recover our carrying value.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade accounts receivable are recorded net of allowances for chargebacks and cash discounts for prompt payment, as described further below. Estimates of our allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances, an analysis of days sales outstanding by geographic region and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Historically, the amounts of uncollectible accounts receivable that have been written off were insignificant. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. For those financial instruments measured and recorded at fair value on a recurring basis, we also provide fair value hierarchy information in these Notes to Consolidated Financial Statements. The fair value hierarchy has the following three levels:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quoted prices (unadjusted) in active markets for identical assets and liabilities that the reporting entity can access at the measurement date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">observable inputs that are observable either directly or indirectly, other than quoted prices in active markets for identical assets and liabilities. These inputs include using prices from independent pricing services based on quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 &#8211; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair values are determined utilizing </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">inputs that are both significant to the fair value measurement and unobservable.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain investments within the fair value hierarchy.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inventory</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We value inventory at the lower of cost or net realizable value. We determine the cost of inventory using the standard-cost method, which approximates actual cost based on a first-in, first-out method. We analyze our inventory levels quarterly and write down inventory subject to expiry in excess of expected requirements, or that has a cost basis in excess of its expected net realizable value. These inventory related costs are recognized as Cost of goods sold on the accompanying Consolidated Statements of Operations.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On a quarterly basis, we analyze our estimated production levels for the following twelve month period, which is our normal operating cycle, and reclassify inventory we expect to use or sell in periods beyond the next twelve months into Other long-term assets on the accompanying Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We consider regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory but are expensed as research and development costs. Only once regulatory approval is obtained, would we begin capitalization of these inventory related costs. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Property and Equipment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:200px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements are depreciated over the lesser of their estimated useful lives or the remainder of the lease term. Capitalized software includes certain internal use computer software costs. Repairs and maintenance costs are charged to expense as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Goodwill amounts have been recorded as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. Goodwill is not subject to amortization. We assess the recoverability of our goodwill annually, or more frequently whenever events or changes in circumstances indicate that the carrying amount of a reporting unit may exceed its fair value. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the carrying amount of the reporting unit&#8217;s goodwill exceeds its implied fair value. We continue to operate in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">one</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> segment, which is also considered to be our sole reporting unit and therefore, goodwill was tested for impairment at the enterprise level as of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-Lived Assets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying value of our long-lived assets, which includes property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will adopt ASU 2014-09 using the modified retrospective method in the first quarter of fiscal year 2018. For information on our adoption of ASU 2014-09, see &#8220;- Recent Accounting Pronouncements,&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> below</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenue is recognized when the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred and title has transferred or services have been performed; the price is fixed or determinable; and collectability of the resulting receivable is reasonably assured. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize net product revenues upon delivery of the product and when there are no remaining customer acceptance requirements which is frequently referred to as the &#8220;sell-in&#8221; revenue recognition model. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Discounts and Allowances</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We calculate gross product revenues based on the price that we charge to the specialty pharmacies and distributors in the U.S. We estimate our domestic net product revenues by deducting from our gross product revenues: (a)&#160;trade allowances, such as discounts for prompt payment; (b)&#160;estimated government rebates and chargebacks; (c) certain other fees paid to specialty pharmacies and distributors; and (d) returns. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We initially record estimates for these deductions at the time we recognize the gross revenue. We update our estimates on a recurring basis as new information becomes available. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Chargebacks: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks are discounts that occur when contracted customers purchase directly from a specialty pharmacy or distributor. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, Federal government entities purchasing via the Federal Supply Schedule and Group Purchasing Organizations, and health maintenance organizations generally purchase the product at a discounted price. The specialty pharmacy or distributor, in turn, charges back to us the difference between the price initially paid by the specialty pharmacy or distributor and the discounted price paid to the specialty pharmacy or distributor by the customer. The allowance for chargebacks is based on an estimate of sales to contracted customers.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Discounts for Prompt Payment: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The specialty pharmacies and distributors in the U.S. receive a discount of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for prompt payment. We expect the specialty pharmacies and distributors will earn </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of its prompt payment discounts and, therefore, we deduct the full amount of these discounts from total product sales when revenues are recognized.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Other Customer Credits: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> pay fees to our customers for account management, data management and other administrative services.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Co-payment Assistance: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. We accrue a liability for co-payment assistance based on actual program participation and estimates of program redemption using customer data provided by the specialty pharmacies and distributors.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Rebates: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and other government programs. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory discount rates and expected utilization. Our estimates for the expected utilization of rebates are based on customer and payer data received from the specialty pharmacies and distributors and historical utilization rates as well as third-party market research data. Rebates are generally invoiced by the payer and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#8217;s shipments to our customers, plus an accrual balance for known prior quarter&#8217;s unpaid rebates. If actual future rebates vary from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Allowances for rebates also includes the Medicare Part&#160;D Coverage Gap</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the U.S., the</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund 50% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients. Our estimates for expected Medicare Part&#160;D coverage gap are based in part on historical utilization rates, specialty pharmacy and distributor customer and payer data and third-party market research data. We also estimate when eligible patients who are prescribed our product enter and exit the insurance coverage gap. Funding of the coverage gap is invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarters&#8217; shipments to patients, plus an accrual balance for prior sales. If actual future funding varies from estimates, we may need to adjust our accruals, which would affect net revenue in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and discounts for prompt payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other customer credits/fees and co-pay assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Rebates and fees due to customers on the accompanying Consolidated Balance Sheets. Balances as of December 31, 2016 have been reclassified to reflect that presentation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration agreements under which we may obtain upfront license fees, milestone, royalty, development cost reimbursements, and/or product supply payments. These arrangements have multiple elements, and our deliverables may include intellectual property rights, distribution rights, delivery of manufactured product, commercial and development activities and participation on joint steering, commercial and development committees. In order to account for these arrangements, we identify the deliverables and evaluate whether the delivered elements have value to our collaboration partner on a stand-alone basis and represent separate units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver future goods or services, a right or license to use an asset, or another performance obligation. If we determine that multiple deliverables exist, the consideration is allocated to one or more units of accounting based upon the best estimate of the selling price of each deliverable. The selling price used for each deliverable will be based on vendor-specific objective evidence, if available, third-party evidence if vendor-specific objective evidence is not available, or estimated selling price if neither vendor-specific or third-party evidence is available. A delivered item or items that do not qualify as a separate unit of accounting within the arrangement will be combined with the other applicable undelivered items within the arrangement. The allocation of arrangement consideration and the recognition of revenue then will be determined for those combined deliverables as a single unit of accounting. For a combined unit of accounting, non-refundable upfront fees are recognized in a manner consistent with the final deliverable, which has generally been ratably over the period of our continued involvement. Amounts received in advance of performance are recorded as deferred revenue.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record royalty revenues based on estimates of the sales that occurred during the period. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Historically, adjustments have not been material when compared to actual amounts paid by licensees. However, additional information may subsequently become available to us, which may allow us to make a more accurate estimate in future periods. In this event, we are required to record adjustments in future periods when the actual level of activity becomes more certain. Such increases or decreases in revenue are generally considered to be changes in estimates and will be reflected in the period they become known. If we are unable to reasonably estimate royalty revenue, we record royalty revenues when they are received. We consider sales-based contingent payments to be royalty revenue which is generally recognized at the date the contingency is achieved. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our product supply revenues are recognized upon delivery of the product. See &#8220;Note 2. Collaboration Agreements&#8221; for a description of our product supply agreements with our collaboration partners.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For certain milestone payments under collaboration agreements, we have made a policy election to recognize revenue using the milestone method. A milestone is an event: (i)&#160;that can be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii)&#160;for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii)&#160;that would result in additional payments being due to us. The determination that a milestone is substantive requires estimation and judgment and is made at the inception of the arrangement. Milestones are considered substantive when the consideration earned from the achievement of the milestone is: (i)&#160;commensurate with either our performance to achieve the milestone or the enhancement of value of the item delivered as a result of a specific outcome resulting from our performance to achieve the milestone, (ii)&#160;relates solely to past performance and (iii)&#160;reasonable relative to all deliverables and payment terms in the arrangement. In making the determination as to whether a milestone is substantive or not, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether any portion of the milestone consideration is related to future performance or deliverables. A substantive milestone is recognized as revenue in its entirety in the period in which the milestone is achieved. A non-substantive milestone is recognized as revenues over the estimated period of our continued involvement. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are also entitled to a share of U.S. profits and losses received in connection with commercialization of cobimetinib. We are entitled to low double-digit royalties on ex-U.S. net sales. See &#8220;Note 2. Collaboration Agreements&#8221; for additional information about our collaboration agreement with Genentech. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record U.S. profits and losses under the collaboration agreement in the period earned based on our estimate of those amounts. As of December 31, 2017, we have not recognized a profit for any year to date period from the commercialization of cobimetinib in the U.S. Until we have recognized a profit under the agreement, losses are recognized as Selling, general and administrative expenses on the accompanying Consolidated Statements of Operations. In connection with our agreement to co-promote with Genentech, we were responsible for providing up to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the sales force necessary to assist with the promotion of cobimetinib. Genentech reimburses us for these costs which we include as a reduction of our Selling, general and administrative costs when the obligations are incurred or we become entitled to the cost recovery.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patient Assistance Programs</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We provide CABOMETYX and COMETRIQ at no cost to eligible patients who have no insurance and meet certain financial and clinical criteria through our patient assistance programs. We record the cost of the product as a selling, general and administrative expense at the time the product is shipped to the specialty pharmacy for patient assistance use.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost of Goods Sold</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty on sales of any product incorporating cabozantinib payable to GlaxoSmithKline (&#8220;GSK&#8221;), indirect labor costs, the cost of manufacturing, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product. A portion of the manufacturing costs for product sales were incurred prior to regulatory approval of COMETRIQ and CABOMETYX and therefore, were expensed as research and development costs when those costs were incurred, rather than capitalized as inventory. See &#8220;Note 2. Collaboration Agreements&#8221; for additional information on the royalty payable to GSK on sales of any product incorporating cabozantinib.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred and include costs associated with research performed pursuant to collaborative agreements. Research and development costs consist of direct and indirect internal costs related to specific projects as well as fees paid to other entities that conduct certain research activities on our behalf.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Substantial portions of our preclinical studies and all of our clinical trials have been executed with support from third-party contract research organizations and other vendors. We accrue expenses for preclinical studies performed by our vendors based on certain estimates over the term of the service period and adjust our estimates as required. We accrue expenses for clinical trial activities performed by contract research organizations based upon the estimated amount of work completed on each trial. For clinical trial expenses, the significant factors used in estimating accruals include the number of patients enrolled, the number of active clinical sites, and the duration for which the patients will be enrolled in the trial. We monitor patient enrollment levels and related activities to the extent possible through internal reviews, correspondence with contract research organizations and review of contractual terms. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Remeasurement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Foreign Currency Translation and Remeasurement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured using exchange rates in effect at the end of the period and related gains or losses are recorded in Other expenses, net. Gains and losses on the remeasurement of monetary assets and liabilities were not material for any of the years presented. We do not have any nonmonetary assets or liabilities denominated in currencies other than the U.S. dollar.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The expense for stock-based compensation is based on the grant date fair value of the award; the grant date fair value of Restricted Stock Units (&#8220;RSUs&#8221;) is estimated as the value of the underlying shares of our common stock and the grant date fair value of stock-options is estimated using the Black-Scholes Merton option pricing model. Because there is a market for options on our common stock, we have considered implied volatilities as well as our historical realized volatilities when developing an estimate of expected volatility. We estimate the term using historical data. We recognize compensation expense on a straight-line basis over the requisite service period. Compensation expense relating to awards subject to performance conditions is recognized if it is probable that the performance goals will be achieved; the probability of achievement is assessed on a quarterly basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we adopted Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2016-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-09&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-09 is aimed at the simplification of several aspects of the accounting for employee share-based payment transactions, including accounting for forfeitures, income tax consequences and classification on the statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the adoption of ASU 2016-09, we have made an election to record forfeitures when they occur. Previously, stock-based compensation was based on the number of awards expected to vest after considering estimated forfeitures. The change in accounting principle with regards to forfeitures was adopted using a modified retrospective approach, with a cumulative adjustment of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to accumulated deficit and additional paid-in capital as of January 1, 2017. No prior periods were restated as a result of this change in accounting principle. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-09 also requires that cash paid to taxing authorities when directly withholding shares for tax withholding purposes be classified as a financing activity on the accompanying Consolidated Statement of Cash Flows. Previously, we classified such payments as operating cash flows. The change in accounting principle with regards to such cash flows was adopted using a retrospective approach. Accordingly, we recorded a reclassification that resulted in an increase in operating cash flows of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> along with a corresponding decrease in financing cash flows on the accompanying Consolidated Statement of Cash Flows for the years ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2016</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2015</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our income tax provision is computed under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">together with assessing carry-forwards </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">using enacted tax rates in effect for the year in which the differences are expected to reverse. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. We record a valuation allowance to reduce our deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We record </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an unrecognized tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the tax authorities.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">An adverse resolution of one or more of these uncertain tax positions in any period could have a material impact on the results of operations for that period.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2014-09,&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2014-09&#8221;).&#160;In August 2015, the FASB issued ASU No. 2015-14, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which delayed the effective date of ASU 2014-09 by one year. ASU 2014-09, as amended, becomes effective for us in the first quarter of fiscal year 2018, which is when we will adopt the standard. ASU 2014-09 also permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). We will adopt ASU 2014-09 using the modified retrospective method. The core principle of ASU 2014-09 is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, has created the possibility that more judgment and estimates may be required within the revenue recognition process than required under existing U.S. generally accepted accounting pronouncements. We have completed our analysis on the adoption of ASU 2014-09 and have determined the adoption will not have a material impact on the recognition of net product revenues. ASU 2014-09 will materially impact the timing of recognition of revenue for our collaboration agreements with Ipsen Pharma SAS (&#8220;Ipsen&#8221;) and Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;). We will record a net adjustment of approximately </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$260 million</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accumulated deficit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(a concept known as &#8220;lost revenue&#8221;) for amounts associated with these collaboration agreements upon recording our transition adjustment in the first quarter of 2018, primarily due to the timing of recognition of revenue related to intellectual property licenses that we have transferred for development and commercialization of our products. Additionally, for all of our collaboration agreements, the timing of recognition of certain of our development and regulatory milestones could change as a result of the variable consideration guidance included in ASU 2014-09. ASU 2014-09 will also require additional disclosures regarding our revenue transactions.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No.&#160;2016-02,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Leases (Topic 842),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-02&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for leases with lease terms of more than 12 months. Recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. ASU 2016-02 will require both types of leases to be recognized on the balance sheet. The ASU also will require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 is effective for us for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. We are in the process of assessing the impact of ASU No. 2016-02 on our Consolidated Financial Statements and are considering early adoption of this standard in the first half of 2018. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU No.&#160;2016-15,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-15&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-15 addresses eight specific cash flow issues including debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing and contingent consideration payments made after a business combination. ASU 2016-15 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-15 to have a material impact on our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2016, the FASB issued ASU No.&#160;2016-18,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force),</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2016-18&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2016-18 to have a material impact on our Consolidated Statements of Cash Flows.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2017-04&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Consolidated Financial Statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU No.&#160;2017-09,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (&#8220;ASU 2017-09&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-09 streamlines the application of modification accounting by stating that when making a change to the terms or conditions of a share-based payment award, a company should apply modification accounting to the award, unless each of the following conditions is met: 1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, and 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all interim and annual reporting periods beginning after December 15, 2017. Early adoption is permitted. We do not expect the adoption of ASU 2017-09 to have a material impact on our Consolidated Financial Statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792702896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives once it is placed into service:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:405px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:200px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:200px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Estimated Useful Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Buildings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7 to 15 years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAllowances', window );">Reserve Balances for Discounts and Allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discount and allowance were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Chargebacks and discounts for prompt payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other customer credits/fees and co-pay assistance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Rebates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,747</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(313</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,802</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">794</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,627</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">351</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,574</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(817</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32,367</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,623</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for sales allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68073604&amp;loc=d3e63113-111658<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783747040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestones achieved</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of upfront payments and deferred milestone</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,531</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,417</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of supplied product</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(6,390</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty payable to GSK on net sales by Ipsen</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues under the collaboration agreement with Ipsen</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues and U.S. (loss) net cost recovery under the collaboration agreement were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales of COTELLIC</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(2,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,771</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(16,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of upfront payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development cost reimbursements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,320</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Product supply agreement revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues under the collaboration agreement with Takeda</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663239632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of Cash Equivalents and Investments by Security Type</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">460,274</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses on Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses of investments available-for-sale in an unrealized loss position were as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,746</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">160,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,651</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">177,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br clear="none"/>Unrealized<br clear="none"/>Losses</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">143,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">998</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">169,214</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">172,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(322</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross unrealized losses on commercial paper were less than </font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">$1</font><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> thousand.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">fair value of cash equivalents and investments by contractual maturity were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">377,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">404,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793221936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">692</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,944</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783689216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,146</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5,959</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">48,543</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(22,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(24,882</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,071</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793293632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The amortized carrying amount of our debt was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">189,122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock', window );">Summary of Loss on Extinguishment of Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A summary of loss on extinguishment of debt for the conversion and redemption of the 2019 Notes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Cash inducements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Waiver of requirement to repay interest, described above</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,572</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unamortized discount on redeemed notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Third-party costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7516071&amp;loc=d3e13374-112631<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779360976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The allocation of stock-based compensation for our equity incentive plans and our </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was as</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,369</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,546</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,977</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The weighted average grant-date fair value of our stock option grants and ESPP purchases were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.00</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of employee stock option grants and ESPP purchases was estimated using the following assumptions:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6 months</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of All Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock option activity for the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">year ended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24,999,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,166,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.43</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,469,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(229,793</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(258,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22,208,446</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.05 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">523,448</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,158,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.46 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of All RSU Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A summary of all RSU activity were as follows (dollars in thousands, except per share amounts):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Weighted&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Contractual&#160;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,469,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,137,817</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(708,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(136,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,762,990</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.95 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">114,395</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949233296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Consolidated Net Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was based on the following income (loss) before income taxes (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(150,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(10,843</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) before income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,689</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total current tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The reconciliation of income taxes at the statutory federal income tax rate to our Provision for income taxes included on the accompanying Consolidated Statements of Operations was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. federal income tax provision (benefit) at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(54,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">State tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Debt extinguishment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,726</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Non-deductible interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(20,548</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(4,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our deferred tax assets and liabilities were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net operating loss carry-forwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">244,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">471,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Book over tax depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tax credit and charitable contribution carry-forwards</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">66,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">64,367</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">53,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of deferred stock compensation &#8211; non-qualified</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,780</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accruals and reserves not currently deductible</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">418,958</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">629,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(418,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(629,062</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unrealized gains on derivatives and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(252</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:68px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net deferred taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes the activity related to our unrecognized tax benefits (in thousands): </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">58,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to prior year provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(29,110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Change relating to current year provision</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Reductions based on the lapse of the applicable statutes of limitations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">61,809</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">88,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=96868398&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783595728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The computation of basic and diluted net income (loss) per share was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">154,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustment to net income allocated to participating securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income allocable to common stock for diluted net income (loss) per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">153,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(70,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(161,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">293,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">312,003</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">250,531</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">209,227</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Potentially dilutive shares of common stock not included in the computation of diluted net income (loss) per share because to do so would be anti-dilutive were as follows (in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Outstanding stock options, unvested RSUs and ESPP contributions</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">28,470</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Deerfield Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,890</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2014 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">54,118</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total potentially dilutive shares</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">117,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783618848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis were as follows. The amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">199,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">179,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,263</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">45,478</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">394,932</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">440,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">165,375</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">70,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">71,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">388,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">459,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Estimated Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The estimated fair value of our financial instruments that are carried at amortized cost was as follows (in thousands)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">109,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">121,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term loan payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">79,784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720737296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Aggregate Future Minimum Lease Payments Under Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the aggregate future minimum lease payments under our leases were as follows (in thousands):&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other financing obligations</font><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Year ending December&#160;31,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">684</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2,282</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other financing obligations includes payments related to our build-to-suit lease.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRentExpenseTableTextBlock', window );">Schedule of Rent Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Rent expense and sublease income were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross rental expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">less: Sublease income </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(1,225</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(3,553</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(5,205</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net rental expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4,935</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,737</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals.  Rental payments under leases with terms of a month or less that were not renewed need not be included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949283520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Net Product Revenue by Product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">324,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">93,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">41,894</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">349,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135,375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">34,158</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Revenue Concentration Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues recognized by customer that represent 10% or more of total revenues was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue Earned from Geographic Region</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues earned by geographic region were as follows (dollars in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">367,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">140,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">33,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">69,792</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3,303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rest of the world</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949288224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quarter Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">March&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2017:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">120,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">152,510</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">91,758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">84,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">65,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">37,431</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,180</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27,113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">81,382</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2016:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">77,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">36,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Gross profit </font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50,064</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">40,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">30,058</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8,414</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Income (loss) from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(25,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(49,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">35,123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(11,284</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(34,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(59,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">0.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Gross profit is computed as Net product revenues less Cost of goods sold. </font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794906016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Oct. 31, 2008</div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge on goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenuePercentDiscountForPromptPayment', window );">Percent discount for prompt payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent', window );">Discount expected to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No. 2016-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,611,000<span></span>
</td>
<td class="nump">210,404,000<span></span>
</td>
<td class="num">(141,051,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,928,000<span></span>
</td>
<td class="num">(15,696,000)<span></span>
</td>
<td class="num">(152,213,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,829,172,000<span></span>
</td>
<td class="nump">1,983,147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GlaxoSmithKline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce', window );">Percentage of share of the Company in promotions</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce', window );">Percentage of share of the Company in promotions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember', window );">Products Derived from Cabozantinib [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No. 2016-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member] | Accounting Standards Update 2016-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No. 2016-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No. 2016-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (252,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital [Member] | Accounting Standards Update 2016-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No. 2016-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member] | Pro Forma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Optional Percent of Total Sales Force</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenueDiscountExpectedtobeEarnedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Discount Expected to be Earned, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenueDiscountExpectedtobeEarnedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SalesRevenuePercentDiscountForPromptPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue, Percent Discount for Prompt Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SalesRevenuePercentDiscountForPromptPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_ProductsDerivedfromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780040016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 29, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_EquipmentAndFurnitureMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794990208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Allowance Reserve) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReserveRollforwardRollForward', window );"><strong>Reserve Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">$ 5,574<span></span>
</td>
<td class="nump">$ 1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Current period</a></td>
<td class="nump">55,001<span></span>
</td>
<td class="nump">16,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment', window );">Prior periods</a></td>
<td class="num">(1,441)<span></span>
</td>
<td class="num">(358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentandCreditsIssued', window );">Payment and Credits Issued</a></td>
<td class="num">(49,641)<span></span>
</td>
<td class="num">(11,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">9,493<span></span>
</td>
<td class="nump">5,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksandPromptPaymentMember', window );">Chargebacks and Prompt Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReserveRollforwardRollForward', window );"><strong>Reserve Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Current period</a></td>
<td class="nump">33,310<span></span>
</td>
<td class="nump">8,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment', window );">Prior periods</a></td>
<td class="num">(817)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentandCreditsIssued', window );">Payment and Credits Issued</a></td>
<td class="num">(32,367)<span></span>
</td>
<td class="num">(6,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">1,928<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_OtherDiscountsMember', window );">Other Discounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReserveRollforwardRollForward', window );"><strong>Reserve Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Current period</a></td>
<td class="nump">7,301<span></span>
</td>
<td class="nump">2,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment', window );">Prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentandCreditsIssued', window );">Payment and Credits Issued</a></td>
<td class="num">(6,300)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_RebatesMember', window );">Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReserveRollforwardRollForward', window );"><strong>Reserve Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Current period</a></td>
<td class="nump">14,390<span></span>
</td>
<td class="nump">5,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment', window );">Prior periods</a></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentandCreditsIssued', window );">Payment and Credits Issued</a></td>
<td class="num">(10,623)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">5,770<span></span>
</td>
<td class="nump">2,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReserveRollforwardRollForward', window );"><strong>Reserve Rollforward [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Current period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment', window );">Prior periods</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentandCreditsIssued', window );">Payment and Credits Issued</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DiscountsandAllowances', window );">Discounts and Allowances</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Doubtful Accounts Receivable, Prior Period Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AllowanceForDoubtfulAccountsReceivablePriorPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DiscountsandAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounts and Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DiscountsandAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentandCreditsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment and Credits Issued on Discounts and Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentandCreditsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReserveRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reserve Rollforward [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReserveRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksandPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksandPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_OtherDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_OtherDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_RebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_RebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795825600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2008</div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Accrued collaboration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,643,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,643,000<span></span>
</td>
<td class="nump">$ 541,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984,000<span></span>
</td>
<td class="nump">19,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,520,000<span></span>
</td>
<td class="nump">237,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GlaxoSmithKline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentOfReimbursementsFromCollaborationArrangement', window );">Payment of reimbursements from collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | Initial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">CAD 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | Second [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | Final tier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | Final tier [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | Final tier [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | HCC Filing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member] | HCC Acceptance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember', window );">Collaborative arrangement with Ipsen, approval of product by EC in Second-Line RCC [Member] | Cabometyx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember', window );">Restatement adjustment [Member] | Collaborative arrangement with Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Upfront payment reclassified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Accrued collaboration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentOfReimbursementsFromCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Reimbursements From Collaboration Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentOfReimbursementsFromCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_SecondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_SecondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_HCCFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_HCCFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestoneObjectiveAxis=exel_HCCAcceptanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestoneObjectiveAxis=exel_HCCAcceptanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenApprovalofCabozantinibbyECinSecondLineRCCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793990128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Ipsen) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product supply agreement revenue</a></td>
<td class="nump">$ 349,008,000<span></span>
</td>
<td class="nump">$ 135,375,000<span></span>
</td>
<td class="nump">$ 34,158,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of supplied product</a></td>
<td class="num">(15,066,000)<span></span>
</td>
<td class="num">(6,552,000)<span></span>
</td>
<td class="num">(3,895,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues under the Ipsen Collaboration Agreement</a></td>
<td class="nump">103,469,000<span></span>
</td>
<td class="nump">56,079,000<span></span>
</td>
<td class="nump">3,014,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative arrangement with Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestones achieved</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Amortization of upfront payments and deferred milestone</a></td>
<td class="nump">18,531,000<span></span>
</td>
<td class="nump">13,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="nump">3,831,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementDevelopmentCostReimbursements', window );">Development cost reimbursements</a></td>
<td class="nump">4,417,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product supply agreement revenue</a></td>
<td class="nump">6,390,000<span></span>
</td>
<td class="nump">1,612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of supplied product</a></td>
<td class="num">(6,390,000)<span></span>
</td>
<td class="num">(1,555,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable to GSK on net sales by Ipsen</a></td>
<td class="num">(1,987,000)<span></span>
</td>
<td class="num">(264,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues under the Ipsen Collaboration Agreement</a></td>
<td class="nump">$ 69,792,000<span></span>
</td>
<td class="nump">$ 33,252,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementDevelopmentCostReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementDevelopmentCostReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780268160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Takeda Collaboration, Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,469,000<span></span>
</td>
<td class="nump">$ 56,079,000<span></span>
</td>
<td class="nump">$ 3,014,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,984,000<span></span>
</td>
<td class="nump">19,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,520,000<span></span>
</td>
<td class="nump">237,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredRevenueRecognitionPeriod', window );">Deferred revenue, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,779,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PeriodOfSpecificSalesVolumeThreshold', window );">Period for specific commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_InitialMember', window );">Initial [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltyTier', window );">Royalty tier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_InitialMember', window );">Initial [Member] | Minimum [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_InitialMember', window );">Initial [Member] | Maximum [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_FinalTierMember', window );">Final tier [Member] | Minimum [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RoyaltytierAxis=exel_FinalTierMember', window );">Final tier [Member] | Maximum [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_GlobalMember', window );">Global [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_JP', window );">Japan [Member] | Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent', window );">Research and development arrangement performed for others, reimbursement for costs incurred, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod', window );">Collaboration period to achieve specified levels of commercial performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Achievement Levels of Commercial Performance, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for commercial milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PeriodOfSpecificSalesVolumeThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Specific Sales Volume, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PeriodOfSpecificSalesVolumeThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltyTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltyTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_InitialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_InitialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RoyaltytierAxis=exel_FinalTierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RoyaltytierAxis=exel_FinalTierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779472464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenue - Takeda) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product supply agreement revenue</a></td>
<td class="nump">$ 349,008<span></span>
</td>
<td class="nump">$ 135,375<span></span>
</td>
<td class="nump">$ 34,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">103,469<span></span>
</td>
<td class="nump">56,079<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative arrangement with Takeda [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfDeferredRevenue', window );">Amortization of upfront payments and deferred milestone</a></td>
<td class="nump">10,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementDevelopmentCostReimbursements', window );">Development cost reimbursements</a></td>
<td class="nump">4,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product supply agreement revenue</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaboration revenues</a></td>
<td class="nump">$ 14,779<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementDevelopmentCostReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Development Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementDevelopmentCostReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794197920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Genentech Collaboration, Narrative) (Details) - Genentech [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce', window );">Percentage of share of the Company in promotions</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear', window );">Recovery (loss) of expenses, expenses prior to current fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear', window );">Recovery (loss) of expenses, expenses prior to current fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Contract revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear', window );">Recovery (loss) of expenses, expenses prior to current fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Profit Sharing Tier One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Profit Sharing Tier Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementPercentOfProfits', window );">Percent of profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Profit Sharing Tier Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce', window );">Percentage of share of the Company in promotions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Profit Sharing Tier Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ProfitSharingAgreementProfitThreshold', window );">Profit threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Optional Percent of Total Sales Force</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementOptionalPercentOfTotalSalesForce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementPercentOfProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Percent of Profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementPercentOfProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingAgreementProfitThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit Sharing Agreement, Profit Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingAgreementProfitThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery of Expenses, Expenses Prior to Current Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RecoveryofExpensesExpensesPriortoCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=exel_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=exel_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ProfitSharingTiersAxis=exel_ProfitSharingTierTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720602256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - Genentech) (Details) - Genentech [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossfromAgreement', window );">U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses</a></td>
<td class="num">$ (2,140)<span></span>
</td>
<td class="nump">$ 8,771<span></span>
</td>
<td class="num">$ (16,600)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">COTELLIC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues on ex-U.S. sales of COTELLIC</a></td>
<td class="nump">$ 6,398<span></span>
</td>
<td class="nump">$ 2,827<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossfromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossfromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780495504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Other Collaborations) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2008</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment', window );">Percentage of maximum potential milestone payments - clinical development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory', window );">Percentage of maximum potential milestone payments - regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial', window );">Percentage of maximum potential milestone payments - commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GlaxoSmithKline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember', window );">Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementShareinCostsPercentage', window );">Percentage of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember', window );">Daiichi Sankyo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember', window );">Merck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement', window );">Maximum amount eligible for royalties on sales under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember', window );">Collaborative Arrangement with BMS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement', window );">Maximum amount eligible for royalties on sales under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_SanofiAventisMember', window );">Sanofi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 745,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=exel_BristolMyersSquibbMember', window );">Bristol Myers Squibb [Member] | Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementShareinCostsPercentage', window );">Percentage of costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementShareinCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Share in Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementShareinCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumAmountEligibleForRoyaltiesOnSalesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of royalty on net sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Maximum Potential Milestone Payments - Clinical Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentageofMaximumPotentialMilestonePaymentsClinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentageofMaximumPotentialMilestonePaymentsCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Maximum Potential Milestone Payments - Commercial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentageofMaximumPotentialMilestonePaymentsCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Maximum Potential Milestone Payments - Regulatory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PercentageofMaximumPotentialMilestonePaymentsRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTwoBristolMyersSquibbCompoundUtilizedMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithMerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithBMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_SanofiAventisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_SanofiAventisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=exel_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=exel_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6698448560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Collaboration Revenues - GSK) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaborative Arrangements with Glaxo Smith Kline [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 12,413<span></span>
</td>
<td class="nump">$ 4,334<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780326160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 01, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Gain (loss) on sale of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | investment</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Other-than-temporary impairment charges on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentAxis=exel_AkarnaTherapeuticsLtd.Member', window );">Akarna Therapeutics, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMethodInvestmentsRealizedGainLoss', window );">Realized gain on sale of cost method investment</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CostMethodInvestmentOwnershipPercentage', window );">Cost method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember', window );">Silicon Valley Bank Term Loan and Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensatingBalanceAmount', window );">Collateral balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CostMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Method Investment, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CostMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 12<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMethodInvestmentsRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gain (loss) realized during the period from the sale of investments accounted for under the cost method of accounting and any losses recognized thereon for impairments of other than a temporary nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMethodInvestmentsRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentAxis=exel_AkarnaTherapeuticsLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentAxis=exel_AkarnaTherapeuticsLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792656496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Summary by Security Type) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 440,756<span></span>
</td>
<td class="nump">$ 460,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">440,410<span></span>
</td>
<td class="nump">459,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">45,478<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">45,478<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">199,647<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">199,647<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">179,336<span></span>
</td>
<td class="nump">152,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(332)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">179,022<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">16,295<span></span>
</td>
<td class="nump">70,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 16,263<span></span>
</td>
<td class="nump">$ 70,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 12<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792648160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Gross Unrealized Losses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, fair value, less than 12 months</a></td>
<td class="nump">$ 154,357<span></span>
</td>
<td class="nump">$ 169,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Unrealized loss position, fair value,12 months or greater</a></td>
<td class="nump">22,698<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses', window );">Gross unrealized losses, 12 months or greater</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Unrealized loss position, fair value</a></td>
<td class="nump">177,055<span></span>
</td>
<td class="nump">172,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses', window );">Gross unrealized losses</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, fair value, less than 12 months</a></td>
<td class="nump">140,746<span></span>
</td>
<td class="nump">140,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(296)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Unrealized loss position, fair value,12 months or greater</a></td>
<td class="nump">20,047<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses', window );">Gross unrealized losses, 12 months or greater</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Unrealized loss position, fair value</a></td>
<td class="nump">160,793<span></span>
</td>
<td class="nump">143,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses', window );">Gross unrealized losses</a></td>
<td class="num">(332)<span></span>
</td>
<td class="num">(308)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, fair value, less than 12 months</a></td>
<td class="nump">13,611<span></span>
</td>
<td class="nump">27,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Unrealized loss position, fair value,12 months or greater</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses', window );">Gross unrealized losses, 12 months or greater</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Unrealized loss position, fair value</a></td>
<td class="nump">16,262<span></span>
</td>
<td class="nump">27,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses', window );">Gross unrealized losses</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Unrealized loss position, fair value, less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Unrealized loss position, fair value,12 months or greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses', window );">Gross unrealized losses, 12 months or greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Unrealized loss position, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on securities classified as available-for-sale that have been in a loss position for twelve months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investments in available-for-sale securities that have been in a loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663059872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Summary by Contractual Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 377,155<span></span>
</td>
<td class="nump">$ 404,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">63,255<span></span>
</td>
<td class="nump">55,601<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 440,410<span></span>
</td>
<td class="nump">$ 459,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780989536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,854<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">7,349<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Inventory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">6,657<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Other long-term assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794612816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 48,543<span></span>
</td>
<td class="nump">$ 26,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(22,800)<span></span>
</td>
<td class="num">(24,882)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">25,743<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,146<span></span>
</td>
<td class="nump">13,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,959<span></span>
</td>
<td class="nump">4,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,715<span></span>
</td>
<td class="nump">6,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">2,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 22,114<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795465024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 16, 2017 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Construction in process costs capitalized</a></td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember', window );">Capital lease and other financing lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvements allowance</a></td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California [Member] | Operating lease and other financing lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">110,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California [Member] | Optional amendment agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">16,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_CapitalLeaseandOtherFinancingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_OptionalAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_OptionalAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780665104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Schedule of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 189,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses', window );">Balance of unamortized closing fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term loans payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instruments, unamortized closing fees and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentsUnamortizedClosingFeesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781271520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Secured Convertible Notes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Jun. 27, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,825)<span></span>
</td>
<td class="nump">$ 8,008<span></span>
</td>
<td class="nump">$ 3,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,460<span></span>
</td>
<td class="nump">21,044<span></span>
</td>
<td class="nump">19,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,239<span></span>
</td>
<td class="nump">$ 13,901<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible notes [Member] | Secured Convertible Notes due June 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ExtinguishmentofDebtIncludingPaidinKindInterest', window );">Repayment of principal</a></td>
<td class="nump">$ 123,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt amount</a></td>
<td class="nump">113,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentPrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued and unpaid interest</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection', window );">Stated interest after extension option election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InterestPaymentTypeAxis=exel_CouponInterestMember', window );">Coupon interest [Member] | Convertible notes [Member] | Secured Convertible Notes due June 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection', window );">Stated interest after extension option election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InterestPaymentTypeAxis=exel_PaymentinKindInterestMember', window );">Payment-in-kind interest [Member] | Convertible notes [Member] | Secured Convertible Notes due June 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection', window );">Stated interest after extension option election</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentInterestRateStatedPercentageafterExtensionOptionElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ExtinguishmentofDebtIncludingPaidinKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of Debt, Including Paid in Kind Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ExtinguishmentofDebtIncludingPaidinKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InterestPaymentTypeAxis=exel_CouponInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InterestPaymentTypeAxis=exel_CouponInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InterestPaymentTypeAxis=exel_PaymentinKindInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InterestPaymentTypeAxis=exel_PaymentinKindInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781404944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (2019 Notes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal amount of debt converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,122<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember', window );">Senior subordinated notes [Member] | 2019 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate principal amount of debt converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued pursuant to conversion (in shares)</a></td>
<td class="nump">54,009,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentRedemptionofConvertibleDebtAmount', window );">Redemption of convertible debt</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Inducements in conversion</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentsforInducementsofDebtConversion', window );">Cash inducements</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness', window );">Repayments of interest required upon a conversion under the terms of the indenture that were not repaid under the terms of the exchange agreements</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock in settlement of convertible notes</a></td>
<td class="nump">592,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Reduction of additional paid-in capital resulting from conversion</a></td>
<td class="nump">$ 342,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentRedemptionofConvertibleDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption of Convertible Debt, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentRedemptionofConvertibleDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Induced Conversion of Convertible Debt Expense, Interest Repayment Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentsforInducementsofDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Inducements of Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentsforInducementsofDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=77886427&amp;loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780626944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Summary of Loss on Extinguishment of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,239<span></span>
</td>
<td class="nump">$ 13,901<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember', window );">Senior subordinated notes [Member] | 2019 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_PaymentsforInducementsofDebtConversion', window );">Cash inducements</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness', window );">Waiver of requirement to repay interest, described above</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue', window );">Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts', window );">Unamortized discount on redeemed notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LossonExtinguishmentofDebtTransactionCosts', window );">Third-party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of Debt, Difference Between Settlement Consideration and Net Carrying Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ExtinguishmentofDebtDifferenceBetweenSettlementConsiderationandNetCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of Debt, Write-off of Unamortized Debt Discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ExtinguishmentofDebtWriteoffofUnamortizedDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Induced Conversion of Convertible Debt Expense, Interest Repayment Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InducedConversionofConvertibleDebtExpenseInterestRepaymentForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LossonExtinguishmentofDebtTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on Extinguishment of Debt, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LossonExtinguishmentofDebtTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_PaymentsforInducementsofDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Inducements of Debt Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_PaymentsforInducementsofDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780932592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Term Loan Payable) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InducedConversionofConvertibleDebtExpenseAbstract', window );"><strong>Term loan payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,460<span></span>
</td>
<td class="nump">$ 21,044<span></span>
</td>
<td class="nump">$ 19,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember', window );">Silicon Valley Bank Loan And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InducedConversionofConvertibleDebtExpenseAbstract', window );"><strong>Term loan payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensatingBalanceAmount', window );">Compensating balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term loans payable [Member] | Silicon Valley Bank Loan And Security Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_InducedConversionofConvertibleDebtExpenseAbstract', window );"><strong>Term loan payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt amount</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued and unpaid interest</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_InducedConversionofConvertibleDebtExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Induced Conversion of Convertible Debt Expense [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_InducedConversionofConvertibleDebtExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensatingBalanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensatingBalanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SiliconValleyBankLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780349968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 11, 2017</div></th>
<th class="th"><div>Mar. 18, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Increase to shareholder's equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,239<span></span>
</td>
<td class="nump">13,901<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 145,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember', window );">2014 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ClassofWarrantorRightPeriod', window );">Warrant period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair Value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock on warrant exercise (in shares)</a></td>
<td class="nump">877,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharesWithheldforConversionofWarrants', window );">Shares withheld for exercise of warrants (in shares)</a></td>
<td class="nump">122,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember', window );">Senior subordinated notes [Member] | 2019 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares issued pursuant to conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,009,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Aggregate principal amount of debt converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Increase to shareholder's equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ClassofWarrantorRightPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ClassofWarrantorRightPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharesWithheldforConversionofWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Withheld for Conversion of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharesWithheldforConversionofWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795675536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="nump">20,328,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 23,938,000<span></span>
</td>
<td class="nump">$ 22,912,000<span></span>
</td>
<td class="nump">$ 21,977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">4,868,000<span></span>
</td>
<td class="nump">2,187,000<span></span>
</td>
<td class="nump">568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="nump">$ 17,555,000<span></span>
</td>
<td class="nump">$ 25,327,000<span></span>
</td>
<td class="nump">10,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">22,208,446<span></span>
</td>
<td class="nump">24,999,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Retirement Plan, employee contribution (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contributions for first 3% of participant contributions (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of participant contributions into the 401(k) Retirement Plan (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses relating to stock match</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DefinedContributionPlanNumberofSharesAvailableforGrant', window );">Number of shares available for issuance under 401(k) Retirement Plan (in shares)</a></td>
<td class="nump">231,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exel_ChangeinControlandSeveranceBenefitPlanMember', window );">Change in Control and Severance Benefit Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl', window );">Termination period prior to change in control</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl', window );">Termination period subsequent to change in control</a></td>
<td class="text">13 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exel_ChangeinControlandSeveranceBenefitPlanMember', window );">Change in Control and Severance Benefit Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension', window );">Extension of exercise period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Life of stock options granted</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">2 years 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 85,200,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from option exercises and purchases under the ESPP</a></td>
<td class="nump">17,600,000<span></span>
</td>
<td class="nump">25,300,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue', window );">Fair value of employee options vested and expensed</a></td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="nump">$ 61,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognition</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="nump">5,052,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount rate from market value on purchase date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Discount rate from market value on offering date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued (in shares)</a></td>
<td class="nump">434,523<span></span>
</td>
<td class="nump">559,936<span></span>
</td>
<td class="nump">324,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 11.20<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceStockOptionsMember', window );">Performance Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of options in vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,870,303<span></span>
</td>
<td class="nump">6,982,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DefinedContributionPlanNumberofSharesAvailableforGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Number of Shares Available for Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DefinedContributionPlanNumberofSharesAvailableforGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, vested and expensed, fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpensedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardDiscountfromMarketPriceOfferingDatePurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period Extension</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardExercisePeriodExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Prior to Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodPriortoChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Subsequent to Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardTerminationPeriodSubsequenttoChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average of per share prices paid for shares purchased on the open market for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exel_ChangeinControlandSeveranceBenefitPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exel_ChangeinControlandSeveranceBenefitPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780096352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 23,938<span></span>
</td>
<td class="nump">$ 22,912<span></span>
</td>
<td class="nump">$ 21,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">7,569<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
<td class="nump">11,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 16,369<span></span>
</td>
<td class="nump">$ 13,546<span></span>
</td>
<td class="nump">$ 10,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774618528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 11.42<span></span>
</td>
<td class="nump">$ 4.77<span></span>
</td>
<td class="nump">$ 2.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774469008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 5 months 23 days<span></span>
</td>
<td class="text">4 years 4 months 9 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.09%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected volatility rate of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781949792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Summary of All Stock Option Activity) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of the year (in shares) | shares</a></td>
<td class="nump">24,999,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,166,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(4,469,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(229,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(258,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending of the year (in shares) | shares</a></td>
<td class="nump">22,208,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2017 (in shares) | shares</a></td>
<td class="nump">16,158,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">23.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">3.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">8.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">9.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at ending of the year (in dollars per share) | $ / shares</a></td>
<td class="nump">6.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2017 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding at December 31, 2017</a></td>
<td class="text">4 years 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2017</a></td>
<td class="text">3 years 5 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding at December 31, 2017 | $</a></td>
<td class="nump">$ 523,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2017 | $</a></td>
<td class="nump">$ 418,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949257792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Summary of All RSU Activity) (Details) - RSUs [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">2,469,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">2,137,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(708,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(136,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards outstanding at end of period (in shares) | shares</a></td>
<td class="nump">3,762,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">24.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">7.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">11.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Awards outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term, Awards outstanding at December 31, 2017</a></td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Awards outstanding at December 31, 2017 | $</a></td>
<td class="nump">$ 114,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedandReleasedinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6949318496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Consolidated Net Income (Loss)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 158,577<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (150,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,843)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">$ 158,577<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,689)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6660430800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Income Tax Expense (Benefit)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774577712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax provision (benefit) at statutory rate</a></td>
<td class="nump">$ 53,916<span></span>
</td>
<td class="num">$ (23,876)<span></span>
</td>
<td class="num">$ (54,974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(34,266)<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
<td class="nump">51,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax expense</a></td>
<td class="nump">8,282<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount', window );">Debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible interest</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">2,680<span></span>
</td>
<td class="nump">3,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(20,548)<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(4,401)<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EffectiveIncomeTaxRateReconciliationExtinguishmentofDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779702304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 244,205<span></span>
</td>
<td class="nump">$ 471,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Book over tax depreciation and amortization</a></td>
<td class="nump">39,472<span></span>
</td>
<td class="nump">70,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit and charitable contribution carry-forwards</a></td>
<td class="nump">66,770<span></span>
</td>
<td class="nump">64,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">53,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified', window );">Amortization of deferred stock compensation &#8211; non-qualified</a></td>
<td class="nump">8,966<span></span>
</td>
<td class="nump">14,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves not currently deductible</a></td>
<td class="nump">4,914<span></span>
</td>
<td class="nump">8,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">418,958<span></span>
</td>
<td class="nump">629,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(418,958)<span></span>
</td>
<td class="num">(629,062)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Unrealized gains on derivatives and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortization of deferred stock compensation - non-qualified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780238288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross', window );">Tax Cuts and Jobs Act of 2017, reduction in deferred tax asset</a></td>
<td class="nump">$ 184.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance', window );">Tax Cuts and Jobs Act of 2017, change in valuation allowance</a></td>
<td class="nump">184.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">(210.1)<span></span>
</td>
<td class="nump">$ 92.7<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,105.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">83.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">424.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credits</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TaxCutsandJobsActof2017ChangeinTaxRateEffectOnDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662735408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 61,809<span></span>
</td>
<td class="nump">$ 88,638<span></span>
</td>
<td class="nump">$ 58,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions', window );">Change relating to prior year provision</a></td>
<td class="nump">247<span></span>
</td>
<td class="num">(29,110)<span></span>
</td>
<td class="nump">21,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Change relating to current year provision</a></td>
<td class="nump">17,378<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on the lapse of the applicable statutes of limitations</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 79,342<span></span>
</td>
<td class="nump">$ 61,809<span></span>
</td>
<td class="nump">$ 88,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780614000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jul. 01, 2016</div></th>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 38,489<span></span>
</td>
<td class="nump">$ 81,382<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 35,123<span></span>
</td>
<td class="num">$ (11,284)<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="num">$ (59,223)<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Net income allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income allocable to common stock for basic net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,860<span></span>
</td>
<td class="num">(70,222)<span></span>
</td>
<td class="num">(161,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Adjustment to net income allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income allocable to common stock for diluted net income (loss) per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,882<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,588<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
<td class="nump">209,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Outstanding stock options, unvested RSUs and ESPP contributions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,415<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,003<span></span>
</td>
<td class="nump">250,531<span></span>
</td>
<td class="nump">209,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774753648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">62,458<span></span>
</td>
<td class="nump">117,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Outstanding stock options, unvested RSUs and ESPP contributions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">27,568<span></span>
</td>
<td class="nump">28,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember', window );">2014 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member', window );">Deerfield Notes [Member] | Convertible debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member', window );">2019 Notes [Member] | Convertible debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=exel_WarrantsIssuedOnJanuaryTwentySecondTwoThousandAndFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781211056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">$ 440,410<span></span>
</td>
<td class="nump">$ 459,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">45,478<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">199,647<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">179,022<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">16,263<span></span>
</td>
<td class="nump">70,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">45,478<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">45,478<span></span>
</td>
<td class="nump">71,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">394,932<span></span>
</td>
<td class="nump">388,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Commercial paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">199,647<span></span>
</td>
<td class="nump">165,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Corporate bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">179,022<span></span>
</td>
<td class="nump">152,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Total financial assets</a></td>
<td class="nump">$ 16,263<span></span>
</td>
<td class="nump">$ 70,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701092368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Schedule of Estimated Fair Value of Outstanding Debt) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount [Member] | Convertible notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of financial instruments</a></td>
<td class="nump">$ 109,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount [Member] | Term loans payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of financial instruments</a></td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value [Member] | Convertible notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of financial instruments</a></td>
<td class="nump">121,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value [Member] | Term loans payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of financial instruments</a></td>
<td class="nump">$ 79,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6699251648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Narrative) (Details) - Level 3 [Member] - Senior subordinated notes [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 30, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Deerfield Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair value inputs, discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">2019 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair value inputs, discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorSubordinatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_SecuredConvertibleNotesDueJune2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_ConvertibleSeniorSubordinatedNotesDueAugust152019425Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774549088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Schedule of Aggregate Future Minimum Lease Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 2,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">3,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments, operating leases</a></td>
<td class="nump">9,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Other financing obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">2,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">2,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">12,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments, capital leases</a></td>
<td class="nump">$ 21,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720142944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Schedule of Rent Expense and Sublease Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Gross rental expense</a></td>
<td class="nump">$ 6,160<span></span>
</td>
<td class="nump">$ 9,676<span></span>
</td>
<td class="nump">$ 13,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">less: Sublease income</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(3,553)<span></span>
</td>
<td class="num">(5,205)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Net rental expense</a></td>
<td class="nump">$ 4,935<span></span>
</td>
<td class="nump">$ 6,123<span></span>
</td>
<td class="nump">$ 8,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782510464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>property </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>debt_instrument </div>
<div>option</div>
</th>
<th class="th">
<div>Oct. 16, 2017 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_DebtInstrumentNumberofInstruments', window );">Number of letters of credit entered into (in debt instruments) | debt_instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollateralProvidedForPurchasingCardProgram', window );">Collateral provided for purchasing card program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember', window );">Building lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember', window );">Workers Compensation Insurance Policy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_BuildingShellsMember', window );">Building shells [Member] | Operating lease and other financing lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of properties | property</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby letters of credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California [Member] | Operating lease and other financing lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">110,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract', window );">Term of lease contract</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalandOperatingLeasesNumberofRenewalOptions', window );">Number of renewal options | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm', window );">Renewal option term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate', window );">Number of options to terminate | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty', window );">Option for additional area of lease (sq ft) | ft&#178;</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California [Member] | Optional amendment agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="nump">16,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract', window );">Term of lease contract</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Reimbursement cost for contract termination</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Accrual for contract termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue', window );">Capital and operating leases, Minimum lease payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=exel_SouthSanFranciscoCaliforniaMember', window );">South San Francisco, California [Member] | Leasing Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CapitalandOperatingLeasesNumberofRenewalOptions', window );">Number of renewal options | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalandOperatingLeasesNumberofOptionstoTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital and Operating Leases, Number of Options to Terminate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalandOperatingLeasesNumberofOptionstoTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalandOperatingLeasesNumberofRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital and Operating Leases, Number of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalandOperatingLeasesNumberofRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital and Operating Leases, Option, Additional Area of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CapitalandOperatingLeasesOptionAdditionalAreaofRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollateralProvidedForPurchasingCardProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collateral Provided For Purchasing Card Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollateralProvidedForPurchasingCardProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_DebtInstrumentNumberofInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_DebtInstrumentNumberofInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Capital and Operating Leases, Minimum Lease Payments Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeLeasingArrangementsCapitalandOperatingLeasesMinimumLeasePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Capital and Operating Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeLeasingArrangementsCapitalandOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Capital and Operating Leases, Term of Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeLeasingArrangementsCapitalandOperatingLeasesTermofContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfRealEstateProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of real estate properties owned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfRealEstateProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToBuildingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exel_StandbyLetterOfCreditRelatedToWorkersCompensationInsurancePolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_BuildingShellsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_BuildingShellsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseandOtherFinancingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_OptionalAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_OptionalAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_SouthSanFranciscoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_SouthSanFranciscoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=exel_OperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794191248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (loss) on foreign exchange | $</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774405808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Schedule of Revenues by Customer) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">$ 349,008<span></span>
</td>
<td class="nump">$ 135,375<span></span>
</td>
<td class="nump">$ 34,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_CabometyxMember', window );">Cabometyx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">324,000<span></span>
</td>
<td class="nump">93,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=exel_CometriqMember', window );">Cometriq [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net product revenues</a></td>
<td class="nump">$ 25,008<span></span>
</td>
<td class="nump">$ 41,894<span></span>
</td>
<td class="nump">$ 34,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6780201392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Concentration Risk by Customer) (Details) - Sales revenue, net [Member] - Customer concentration risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781237104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenues from Geographic Regions) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jul. 01, 2016</div></th>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 77,581<span></span>
</td>
<td class="nump">$ 62,194<span></span>
</td>
<td class="nump">$ 36,252<span></span>
</td>
<td class="nump">$ 15,427<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
<td class="nump">$ 37,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic concentration risk [Member] | Sales revenue, net [Member] | U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,906<span></span>
</td>
<td class="nump">140,709<span></span>
</td>
<td class="nump">33,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic concentration risk [Member] | Sales revenue, net [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,792<span></span>
</td>
<td class="nump">35,745<span></span>
</td>
<td class="nump">3,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic concentration risk [Member] | Sales revenue, net [Member] | Rest of the world [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,779<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=exel_RestofWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=exel_RestofWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781346832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Sep. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jul. 01, 2016</div></th>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Jan. 01, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 120,072<span></span>
</td>
<td class="nump">$ 152,510<span></span>
</td>
<td class="nump">$ 99,008<span></span>
</td>
<td class="nump">$ 80,887<span></span>
</td>
<td class="nump">$ 77,581<span></span>
</td>
<td class="nump">$ 62,194<span></span>
</td>
<td class="nump">$ 36,252<span></span>
</td>
<td class="nump">$ 15,427<span></span>
</td>
<td class="nump">$ 452,477<span></span>
</td>
<td class="nump">$ 191,454<span></span>
</td>
<td class="nump">$ 37,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">91,520<span></span>
</td>
<td class="nump">91,758<span></span>
</td>
<td class="nump">84,990<span></span>
</td>
<td class="nump">65,674<span></span>
</td>
<td class="nump">50,064<span></span>
</td>
<td class="nump">40,287<span></span>
</td>
<td class="nump">30,058<span></span>
</td>
<td class="nump">8,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">81,180<span></span>
</td>
<td class="nump">27,113<span></span>
</td>
<td class="nump">20,186<span></span>
</td>
<td class="nump">38,883<span></span>
</td>
<td class="nump">7,264<span></span>
</td>
<td class="num">(25,136)<span></span>
</td>
<td class="num">(49,135)<span></span>
</td>
<td class="nump">165,910<span></span>
</td>
<td class="num">(28,124)<span></span>
</td>
<td class="num">(121,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 38,489<span></span>
</td>
<td class="nump">$ 81,382<span></span>
</td>
<td class="nump">$ 17,656<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="nump">$ 35,123<span></span>
</td>
<td class="num">$ (11,284)<span></span>
</td>
<td class="num">$ (34,838)<span></span>
</td>
<td class="num">$ (59,223)<span></span>
</td>
<td class="nump">$ 154,227<span></span>
</td>
<td class="num">$ (70,222)<span></span>
</td>
<td class="num">$ (161,744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794940784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">$ 14,131<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">$ 19,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Recovery of net losses</a></td>
<td class="nump">$ 23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear', window );">Recovery of net losses, recognized in current fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RecoveryOfExpensesExpensesInCurrentFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery Of Expenses, Expenses In Current Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RecoveryOfExpensesExpensesInCurrentFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^;L/7:',P_-KX*]AW\NHO^"U!+ P04    " "5@5I,F5R<(Q &  "<)P
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M2KIQ4JA."NFD9$X*V2NY,\R)%#D+B3%;JDY*X<2R2E:E[/G"%CD?*(K,E\:
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ME*V9,H,INYO)HGR#"<RN+O64_$#L4K?<.5 A;T%]5YTI%5A&]38R8"5?KVE
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M:/_>M%4Y]A*DE/F/X?=T[G^O8_^?87R ' /D+0#L+P/4&*!^!NA?!N@Q0*.
M9$BEGYM=WN;K95U=HWIXO)>\6T7PJ,/L[[O&?K+[_X7I:4+KQSH3R^2CZV=$
M-@,B)PC<B"1T?AM!<B-L) F7]P-L*:$0LJ-(-B-"L6FJ/EY-XR4?K]EXW<?K
M:;Q"TS0@MD?.0Q;:"9&A9"D&RJC4H(2YWL!DO&;#:C94LT::!\1,Q0BEK4.:
M*6:L2!&UHY02H'G%EE5LJ6(T+QM+!M%&ZC1%BBD&#K1!^>\HIE)(9U9&RFI.
MZ<JR?'S&QF<T9Y3,)J/)&&$M2IE2UAC\'E%(9<[P>AVKUU&]:(EO'-4+$E)
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MS;N6I*X% MO6"-W+UK@*,A0KF\5F9?..)>D'5?CRP+(UM1*G#-YO;CG."*,
M*V<XX:8K[UXZ;Y626F78)6'IS,<02(%3W#(<+YWA..G)Y+N_]/5;?Z;21/OJ
M_=QVW\^3UMNYS9/LS@U0^P8>=\/IR\]NAL.@/_/Z[71NHI>J;:NR/SMXK:K6
M!YGA78BCH\\/MYO"O[;=91JNZ^$09KAIJ\MXP)3<3KG6_P-02P,$%     @
ME8%:3.';"N-; @  4 <  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R-
M55UOFS 4_2N(]]9@/AL1I(9DVJ1-JCIM>W:($U -9K83NG\_VQ!*C-OM);:O
MS[D^QY=<9SUE+[S"6#BO#6GYVJV$Z%8 \++"#>+WM,.MW#E2UB AE^P$>,<P
M.FA20P#TO!@TJ&[=/-.Q)Y9G]"Q(W>(GYO!STR#V9X,)[=>N[UX#S_6I$BH
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M-)%S-C3Y82%H-[Y?8'I$\[]02P,$%     @ E8%:3)?0\&[Y 0  >P4  !@
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M39ATQ'A+S(Q 2GTNX6V52+T;NG==X'"+\%>0[!;R_!\3_F:?ON'[RQZ<W;9
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M\0^W%5()FTF_I@[4 :.=?@+MA-%. .TRY:6,D1U5*):0YN@'HLFE*C2,P4\
M_-%:1#'2A5;$";"ZK@LM8?@3VLIS'E,,_]3RV?.A)K2"EP;ZS!Z=8IS[=2@3
M0_M+B7DN/[-)EV!K;53"OV!DO$EG[_-R(-+ .BWQNB#!NB#Y%X.,:9X9H_3
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M9(D@^V^+6SG9JR)L-5,-KDW;Y$EE!Y,V>15=%O:!ISOYDSYM^Q?A6FD\N=B
M-YOFWU@; *7L[G"%.GQ@BZ.@"=%\A[:;UFQR@NWG%\269US^!E!+ P04
M" "5@5I,PZ)R4K$!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q]4]MNVS ,_15!'U E2MH5@6V@Z5!TP 8$';8]*S9M"]7%D^2X^_M1LN-Y
MG;$7BZ1Y#@\I*ANL>_4M0"!O6AF?TS:$[L"8+UO0PM_8#@S^J:W3(J#K&N8[
M!Z)*(*T8WVSNF!;2T")+L9,K,ML')0V<'/&]UL+].H*R0TZW]!IXD4T;8H 5
M62<:^ KA6W=RZ+&9I9(:C)?6$ =U3A^VA^,^YJ>$[Q(&O[!)[.1L[6MT/E4Y
MW41!H* ,D4'@<8%'4"H2H8R?$R>=2T;@TKZR/Z7>L9>S\/!HU0]9A3:G]Y14
M4(M>A1<[/,/4SRTE4_.?X0(*TZ,2K%%:Y=.7E+T/5D\L*$6+M_&4)IW#Q'^%
MK0/X!.#O &PLE)1_%$$4F;,#<>/L.Q&O>'O@.)LR!M,HTC\4[S%Z*;;WMQF[
M1*(IYSCF\&7.G,&0?2[!UTH<^3]PO@[?K2K<)?CN+X6[=8+]*L$^$>S_V^):
MSMV[(FPQ4PVN2=OD26E[DS9Y$9T7]H&G._F3/F[[%^$::3PYVX WF^9?6QL
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M=[)HL9FE$@JT$T83"W5.;Y/#<1?B8\!/ 8-;G$FHY&S,<S#NJYQN@B"04/K
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M^-&?S31FD^&PGW\06[YQ^1M02P,$%     @ E8%:3.J>;)^T 0  T@,  !D
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M:&5E=#$Y+GAM;'U388^<(!#]*X0?<*QHV\M&36ZO:=JD33;7M/>9U5')@5C
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M86_<( S]*X@?4')<VE6G)%*OT]1*FW3JM/4SES@)*L0ID$OW[P<DS;(MVQ?
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MT>WU]):GP*I^'E.R_%<4?P!02P,$%     @ E8%:3(JJB ^R 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL;5-M;YLP$/XKEG] G3A95T6
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M.O^RL?\5H@.?RN;"CU#C/]AL**A<.%[ZLQG';#0<=M,/8O,WSO\#4$L#!!0
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M^9>-_:\1'?A4=E=^A%K_P19#0>W"\=:?S31FD^&PGW\06[YQ\0=02P,$%
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M;K*.@8"+]=NMV^M^OO2!5<TP.NDXO_._4$L#!!0    ( )6!6DP=)0IOZ@$
M &8%   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;'54ZVZ;,!1^%>0'
MJ+DEH1$@-9VJ3=JDJ-.ZWPX<+JJ-J6U"]_:S#6&,NG]B^_!=SK%S3CIR\2H;
M .6],]K)##5*]4>,9=$ (_*.]]#I+Q47C"A]%#66O0!26A*C./3]/6:D[5">
MVMA9Y"D?%&T[. M/#HP1\><$E(\9"M M\-S6C3(!G*<]J>$GJ%_]6>@37E3*
MED$G6]YY JH,/03'4V+P%O#2PBA7>\]4<N'\U1R^E1GR34) H5!&@>CE"H]
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MZYY/N.1&*0O.2G+CO'1NBI> 0V/]]L[M]?26I\"J?AY3LOQ7E'\!4$L#!!0
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MA%:"5OZ.4(0BF:# JY]$'U"+US]9S%&+@583<? V(5@/K"<H\"8@\0?4XFU
MDCEJ$5 R\5$A>+<0I!62J53Q7B#K^6HIW@PTG*$6 R7OO\'!:&)4("]N5BHO
M%]?:#>J1=9C'.^HFSE]X-\R_,7DI:^4=A39SRTV7LQ :3"[A@RF2PMP?A@V'
ML[;+Q*QE-T2[C19-?T$(AEM*]@=02P,$%     @ E8%:3$AQP641!   QQ,
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M12D.RKPF^KWM9\A^H60SS,?1.*2O_@-02P,$%     @ E8%:3*H\E%C  P
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M)AD[*#,<ZK&HFL=JHGA9-\9!TYW/_P%02P,$%     @ E8%:3'7M#;8M @
M408  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULC571CILP$/P5Q'O/
M8 B0") NB:I6:J7HJFN?';()Z RFMA.N?U_;$(Z"[]07;"\SX]G%7M*.\1=1
M DCGM::-R-Q2RG:#D"A*J(EX8"TTZLV9\9I(M>07)%H.Y&1(-478\R)4DZIQ
M\]3$#CQ/V572JH$#=\2UK@G_LP7*NLSUW7O@J;J44@=0GK;D C] /K<'KE9H
M5#E5-32B8HW#X9RYC_YFGVB\ ?RLH!.3N:,S.3+VHA=?3YGK:4- H9!:@:CA
M!CN@5 LI&[\'37?<4A.G\[OZ9Y.[RN5(!.P8_56=9)FYB>N<X$RN5#ZQ[@L,
M^:Q<9TC^&]R *KAVHO8H&!7FZ117(5D]J"@K-7GMQZHQ8S?HWVEV AX(>"3X
MT8>$8" $;X3P0T(X$,(9 ?6IF-KLB21YREGG\/[KMD0?(G\3JNH7.FB*;=ZI
M\@@5O>7A*D[130L-F&V/P1.,/R*04A^WP+8MMGA!Q_]NL%LB@AEDOX0D[Y@(
MK'D&AA].\PQCNT!H%0B-0##UN/;L BNKP&KI8)7,*MUC(H-I#.83]D-O5JXE
M*HEC?U8PBY0?1=X[EB.KY<AB>6T7B*T"\?\7+;$*)$L'T:P<VV21:12L9Y7=
M+4$XP;.#OE^"_'#F%DTN5@W\8IJ6< IV;:0^GY/HV!<?L;Z8L_A6]<N^O;W)
M],WV.^&7JA'.D4EU[<WE/#,F03GT'M1G+55_'Q<4SE)/8S7G?9?K%Y*U0P-'
MXU\D_PM02P,$%     @ E8%:3%E6/&VR P  CA(  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&ULE5CM;ILP%'T5Q ,,;/.15$FDMFFT29M4;=KVFR9.
M@@8X Z?9WGX&W!3L R/]4< Y]]YS[7L/V(N+*']51\ZE\R?/BFKI'J4\W7E>
MM3WR/*D^B!,OU"][4>:)5(_EP:M.)4]VC5&>>=3W(R]/TL)=+9JQYW*U$&>9
MI05_+IWJG.=)^?>!9^*R=(G[-O U/1QE/>"M%J?DP+]Q^?WT7*HG[^IEE^:\
MJ%)1."7?+]U[<K=A06W0('ZD_%)U[ITZE1<A?M4/GW9+UZ\9\8QO9>TB49=7
M_LBSK/:D>/S63MUKS-JP>__F?=,DKY)Y22K^*+*?Z4X>E^[,=79\GYPS^55<
M/G*=4.@Z.OO/_)5G"EXS43&V(JN:_\[V7$F1:R^*2I[\::]IT5POVO^;&3:@
MVH!>#53L,0.F#=B[031J$&B#X-T@&#4(M4$XU2#2!I%!R6LGJYG]=2*3U:(4
M%Z=L"^B4U'5*[B*UOMMZL%G.YC>U )4:?5T%$5EXK[4CC7EH,;2#8<S /-H8
M [&Q$4%$KQA/L;Q2I8CJ P4TF$'#QM ^8@V\&) G&S(SDQF+TTN%P5EGC3GK
MDIC[V$$ '02-@Z WF>9<M)BHP13MDLQ]_6>D,PG:HQ5"6B&@%1BT$"8T^(QC
M>D0B2"0"#B*#",+$!I%Q3(](#(G$P,',(((P<X/(.*9'9 :)S"P'+!C(9 X=
MS*?7+/&QUOAV$K%OBHT-8L% IF1 TPB(0P9<0*VY)_2&;'&/$P984%,V$8@-
MQ,%20( 6Q,& "]RV)+PA6]QP!'0*G9O91K;.,*Q(DZ!]8K@!B=TY;&Y*I0:%
MG6@&H;6&] B%B/H30 Y1QJU*[%X-X@'Y([A9R0W=2G&W4M"MUHIJ4'?B*"-P
M12=!^\1P>U.[O>T5U:"Q%040O*  R$9Y8TVA%"RK^5+2H%ZL&-+:3(+VB6&E
MHDB$!MX-%(L0#6ZH-RQ"%+ST[7H+[2(*L(),@O:)86FCMK2!>HNL:(2&@-<:
M(*V"&X/T*6/1H^!SP2XU6_3>%,V:RRG0/C$L;11)VVS !98V>H.T,2QM;(JT
M:5!7QN, =R*SI<V&]HEA:6,3I&VM0?C]TA;0_R&;44B?*Y8SAN1LX$.-#6R#
M;M@',2P\#'W]F%]9"#0SXWB=+7/.RT-SX%$Y6W$N9+W5ZXQ>#U7N:;WE-L8?
MR=U3>S3R[J8]J?F2E(>TJ)P7(=6&OMEV[X607''T/ZCJ.?)D=WW(^%[6M[&Z
M+]L3DO9!BI,^_?&N1U"K?U!+ P04    " "5@5I,7BM^&OD!   ?!0  &0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;)58VVZ;0!#]%<1[PEZ
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M4--4SEG?O_N%H.WP-@G&!]+R'U!+ P04    " "5@5I,/-YF,:<"  !/"@
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M,J(#=P/LMP-*TQ$*N$1Q.KW$,%RD>#8E6@@TTJTQ7,L8*N9LA (N4YQ/CY;
M!4C\ O2C!4%NM-'5+*+GU>^LW1=U%[P*J<8:,WSLA)!<$:([==,'-2(/FY+O
MI%[.U+KMY\1^(T5C9^!H&,27_P!02P,$%     @ E8%:3 Q"^^S* @  5PH
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MUT]*L37-,+5CU;8Z[<3(0]?&17TON?@'4$L#!!0    ( )6!6DSM,M3'C@(
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M3.\<C&!C0T .CFNY($I#VY(^!@V3&7%9#"3#;)O%_YJ;>P""$1I?U1CV)4R
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M(=D=J#B"_$$?81CR!S[#JP/ VD.@YW"K9#6")FLBHT5Q/2(GM%C# 0!D<FT
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MV\> P%GJ[5KM>3_A^D"R=AC>:/P'*?X!4$L#!!0    ( )6!6DR9+(V/FP(
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MB8(@"H R#T07H ^$4([3#"85(*D 2,0C%4L2QKS@ 1 #00P Y1Z( :"<95D
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MXEU>&%/!1UTU<A5>E&H7<2P/%U93&?&6-?K)B8N:*CT5YUBV@M&C=:JK& &
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M##<*;)72TJ1#]Z:IO9D.SXM:;K6]Y>:^'T>D<:%5-XU_R7D&7?T#4$L#!!0
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MVDU!CU(O$[7F=M[:C61U\RWAM1\TR[]02P,$%     @ E8%:3$I]C)AJ @
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M[22G!ZF'D1KSNIFH)Y)53:/DM-W:XA]02P,$%     @ E8%:3.:TX5., P
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MS*+="GM/%R_UZK5,TC1'5P.:8G9C#%G$A&$TQR#-GT6(4X18P.8?D<P-")V
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;'U578^;,!#\*XCW'F#
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MA^SIIE=G\P5"-'^+L?T/4$L#!!0    ( )6!6DS2B/HP  (  $8%   9
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M(Z6,)E@&@+#? VTAI:#W5]@!H%'7$/AG6",/V&>D*A%<U\C_A&]P92,\Q3<
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M\ #:!M N0/?]58#7!G@? >S+ -8&L*$!?AO@#PW@;0 ?&B#: #$T0+8!<FA
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M.9!H;LKLTIZU.-V!S_1_4$L#!!0    ( )6!6DRF00IO)P(  #T&   9
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MED_^UGL&VLPT'O;G\7@XI5\.S^;Q?#B*9_.S*-E&(//3]35LSVC BAT_!!=
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MMU+V4&7&$:/(>CN?544;+)7K]#;+<]Q'H![SGQ69^ AK5>R^GCQRJ$.OPZ*
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MXSZV\0'F;G@6)0KZ:AS1\O0^@FV'#<A34OFR-1Y@4)7P_$OD$PWHBIAQDQ;
M\M%]MKV#)T"NE3W85I)ONQ*>V%'P!_EJ,)^/8YA2"9)(XBN5FUU**K)2B!E.
M&1'7<E<6N]L[GVQ@EA*+6D.ZRRVZ/ K@KF2#LTY6,5_C=+#(4P<77/DYW8+P
M6Z2]Z--]$>&Z@)EI!!*8B^2Z^"U!7LRN\7V8_5UVG<&X2* U.KIPS=N'LJB
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M*Z&R+P8CT/C?&D$-V+04Y^A:FYYEX3KA&\4]YKC@\ ZBW<8E\2I"V"071.=
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M(Q32O"-R0+Z41V]0Z"@ZV])!A,TV!V/(SGG0F2A0),GU>!8YT]/5X"_#^OB
MN^L]I0,[',;B;$HO!V!U8 ]U@"J7 2E0!3Q #>D[OO7!1[649<:,'6/J^7]U
ML,C<X"3'ROB\_AU*7/D&H@>]6;@M[PL2JQ<&'Y_\\&HR$/I>!Y!^ [7ZECI5
MDO$?HG,07R).__/]SWWT'02Y5?8OE +CNA5=_1+TM3)W #M3@P^2@V!%QKMO
MM,QN(-/M5<5NYYQX]=(\+_RJCQZ]6"7PT-4"XSY8%U-N4>_@,(-"'TIM](MT
MD>RX-)+#,XG#84==7KXC:DO8]$_=(1:^6< ROA1X9%<.-5UU*!S$AN45-SQX
MGF2'R!FV10(OD<L8=R\]A*743GM@@ICON11['WH+.$C93)+.++84IYTY[82D
M)EZ5-=VD%_*N#LB1!-R=0CM$&& ?ZVIVP-)5S:N;W2A255E<>SQ<$33N_=L"
M=8%Z0$RA!?!-AQE@XT%4X%QQQ[)VW,77OKN0\\)IPZ-]O9/UM)Q?_>(.B^FG
M' <$DV1=/FT!)4\^ 3,LHMG@[.FSZ+7%M ("7FJ;R"L\62)$/FB)HLGG,9/1
M";A)]2+S4R)(MO;Q[XI8VV)&5GBC$RQI /AM\JTH?\UUL*2IL8!R<2/3<<I&
M9FICP/]N4D(.XZ<HOI)\I8-'.1[:P:H.;"G@^^H>) W'X9#TL,#:&5LT]28J
M!V]1&,O.&U'L<FGG:%(5*(B,&'"@816["E-B.L4WPML$\MOHJ'QD;*W(%^H4
M0#6**G]"H#<S(8[ERKW-?10:#8S4(KVE+V$8R"X(?5O"ZRQ4DBZ$%/)+).0\
MI>X:D;1LH-\YO0H7]:3?&V$,9R6$M-T=EBELHD !!<'J;'GJ0?@DN3OL@C7K
MP?$*&I94SHF[U=O)AEM)+=Q/G/!H4!3'9,@FVBQ5J]"3KT2BW?:N**U(5Q@#
MI QBTYF[4)J#!K_:[,H-MD"C[)P@83YI:0[Z"#<Y^8Q<:_*0/>^#;U%HU*4(
M(+D]L*8Y2-_ 7C2R 05J8[%VSF)X_1)))!/VF7PFF7]A<A9XLR4C,'>Y4E'0
MU-I,!KESW!LX[D0V!':=^!\@>)/C<&=V<:<J/[C?)3OX-^[343W97#>V251O
MQ_::!2>W"7Z_*ZTDW;C*&4(@)C3"I8WI."PF7V2NB3FN_3@.U*%Y=_4/( N[
M'2K">^Z]_";M$+YRK6T(NZ#!BUL.@O,.T<7.NU"6#]BX1IM4,6@X S?@P'6C
MQI(\C%+[67L7H >UPA[3:2]HDFN\-#8YL-;P0YS'LAG<6%AWB6*Q^'>'I!".
M&>:*@A6S]6VY7*,&7.4JN2>C1=S)KDF,FK\&0]I7S]&ZECOI#KMLV72]19T#
M2&QBVC&IEF4\P2XP0>W"M6*<!S.EG)H$.670#LF@,+F!OR6.5HRP J%>G?*X
M'\0P>%%UR KNK(0SI#>DTB8N@T7*P8D&7MH34EJR)![ ,UBL=BX>9^H)W"ZV
M3]RAS8D9S:V\V SU!JQO1B%)(=J8S/3JN5% :571#^&*H:[[-B$]=\SN,M]!
MH%75?5' 'TZY?'5^]<+8A53JAO>G:+T,=*909;1[BM8C68D7KNY+M-YI?_JT
MKKN.C>Y*VOGY[A8]HMR8DB8-\VCY_N045_7H[S\30<<A%QS_DF0$7DTO4='7
M=&(P*Y.'E,W8U#VR%.O-PLVA5SAGX=(+8>#P,ER3A(^=H\B/Q:V9CD:A,T",
MI(?<!_AWHB'33@:SD!X4*)KP<-\7(O%9\(JJ_"R\I#F[C-R\K(%Y:,>PE1O0
MYX3 8=KP]9[&+)W"@5WDW&B4(J81I,9A"F&YQH-Z FYW<*DRT%IK1J]_4\L\
MV-JB4-T^#$#N/_)].(*B.!54QJZ*4HU',FU)D&MWB^I.LCGKV;.TN=G60>XQ
M:D^&ET*CZBHLKV2U2 2W:$RF,TR8+19TE)(Y\>VG"=8N,8 !ZUDQ]-4JC<F$
M;(>Z/R5\ B,C[,XVW>!"%M)_SR?!D:H2T([ B/!&I6:E51%3<0GJ8ULYD.Q%
M9P6&$_=PA"!!U5^J=0^QJ?5I0]MSD\1[Q;W$2I2[?\GGU](K-E":K3#V^4\F
ME((Y+*[2(^\R7OD4Y\N6]"GS//&P=W%VWRU!<5(;1%^XCS2NZ3DIPTE00! 7
M.DJ>-([>64M+PN#U!D1)](%2(J*K\RMW1= O@D[JGY+/Z3*19Q?ICCNJ7$@;
M[#=;.(OZ,C_JKQ8]YDX[PJ6'IJQI-0$+?3*<]@\9MB=H-E#JLZ"O )_*]U><
M1D.$<&L@1[54Q-3#R)H3U%5VO"D4XELU3)(0TK[-+R3[XX_;G_[X8Y7]]$?\
MW_:GKD!][;GHZWKUK(+-3?_Y#QLI]_[#3Q?OW[PY?_'^X_FGU^_?1><_?[R\
M?'OY[M,56#0F#R3X1"4[&GX7KO97Z76IGK<IF7Q!-GR]>3R; UQ)6DLKY \X
M<(U&#AR5H$NS-!OJ(<^1S1NH^XY<FNB>=,!8/N]2.D$XKG95]J5M)EPQS2%;
MP2R@E&O7A\P!ZQIR"J0O:_V[+4IMG1-CVUR V%@R%LN_),#[>@5U9&(F55A(
M)4H)REC?5!RMSJW#V^E>"KS$G_<BC50,^MXRS'A([7:IH=B]'X?)9"C#:Z;J
M\=3AJ7#VM0 _$488R4D.M2:UTG)?/LX>*E\ A^3RM>5XER37JZRZX_6A-B(-
MC,DZ2)O<XH"7G )/SU/R6'H+NBA[D>#GSUT9(%QS&E_5Q%@T_L0!@7G["[(G
M3R457VV5AT:+:DM3/Q-I_FWHKYF51BWP8&#*T^X(FH1Y8@2,,K-%E>7[SXMW
M"1_F*CU=Y(9#%)S;6_0W;7W9JG-DH7]G..CWO)C>?PYDPE5'.;GDV\B5UHZ*
M(,2H02#(#5HI;(->EXY&C<0YV"0OP[@HPP D4+Z>KU1PN01Q=Q#;U.&W82K@
M]M1Q%;H_J7MCCL )E]<>L=U/P^9/2V>75S5ZVY"LA4;@("&=2.LA=!7.+4/)
M_=%9)>T@A!9.A>0:ACWEW%J?M:>RFI*[U0DMK2"[V+6%6UW#5F/5-&JF;0)1
MYP%3"0>\L<+K==0WUB(;6RQ43?U$LI7DAZSTB>/A+<3V\0Z9'W3A7W*RJ42_
MN?S%ZU;G(5IQK<9MS[SO6QDE>C*U9/(%(O>F-@YF=X4ZM[^\7!:33:H,5B2.
M'K>B"^3OBAVFJ/BK_QPT*[8UI.Y\&7V\N*!K5'J9N.(5*;1CS9JM66Q7CK49
M*2X3IQ!4!VH6A7_0.]JD=,C9'!*NIEK'SCJUQ*DK:@GOH?CS%O+>V\)Y-C..
M8,M&[QS+IRS:.N;P.UC<C_:9_#L:,4;#^:X^ 916.^@%&-&T'5>[]3KA>\8Z
MHJW;#XMR10G"S%NACAGXN&:B^GYPL1/BX.O7<"UCM>.9"[6=4R\>;&U4<"DN
MK'T=#?JG?XZ^62!TR0,/0U6_LTPJ]3HL,K6G-*Q_[RAL\[E.51 CX PJ7\'F
ME%Y7I>LCFV8.%'R:F'-&T:>A/7D&4V)?,,@T.JD'@WZU!6E:7,'1;((;%JWY
M&*HYM2IF*&=?%I,$E<:PA+E9@U7N6LK+D0K!G4=4&-N?D-AV(IF0+LEQ=,[%
M^>Z^>7ONS>ALI9?Z7GE/,5:2Y;1T4VRAH+Q[1/Y="L\6"U "=]@E=0%J5Y87
MZ\3-*/K3Q47@G6AC!$\*DB.D/S=M&54<_PX<4<%/C8'3=51L:V'M]NQAA=J8
MH0U* :\GVN0GD_'4;E/3.5$OO)8L<WA"\E_A9RSX'9XZ9A'NJK2L=4049V1C
M,JYJW5SE7=_D;WPI5KMUJ@Y+;6B+:_:E!=[]QI<.A_V9)$'-I*N5;-,;Q(1M
M&N/6"+_\JD?!$L*8-O>F$W>"<.^F]@8'5"?VDXD](>*GX]'<E994@3)$]V&!
M/@][(7*.$S%GK7[4(] /FO.@_IAP<+MFP4/:SM($L2J3'W3.WI70;@D.MG4Z
ML!T$X:,S@D7 !+$\;_H#@_?3Q6,J6S^108#O5>KCPS@WQ2] '4@Q*"+AF=?!
M7G33I'T2A54[+LY?1D]&M976)\>DKP]'68J4]1-KZ6'[VIZ+L6/6)OS;M4"Y
M$7R55[WH40%B+8.?:F)OLPC%^_NE.(." =J++OG6>][I3,^CVU5QG:PZ/FU$
MJGR?[O8[0AD*6E*P'RBV#B>MNZ2KC,<;<8DGIZUP]9E#81*M]:Z@;!UJB+;E
MI3 :.'V?6(CMTL1EYQ_A+*3>2INM\W4RA,:B.-7]0,#:=/'Y+2KQ\\N/;$UN
MJ-_'*-ID7PA>5@HL)+ ON@,;J.TV'$TOSTA.)M<1NJMVZ S$HRHV7N>-"-HE
MWXFQOQ31N9%N$\SER!9D%3'@B&]WG=45?QKV18GIJZO3MP_(R%=@X%Q?.[^]
M7J@OWE[I??K<4*,_[EMJ#'X<4FG.PW?0H;%L:A/>I@WDRU:2>(K\Z7@:O+W"
MB"09ZLP4+F9#L'6.%;9<>()1(F!W7SY47_2^%1*#;4!/6N,_GSYWRI(0\;K)
M2W7CW]*3,W"VZ6]@0/RF)$1W"D6_VKF#C(UHNUM3K=11)/I8+.[21JPF!$>E
M<]Q2P.>5><E;;W./11YM,Q$0(4Y?5^_H.OD[ZFF(F83)!"N3@4%X&36(%Y\N
MYYZCA'"1N9K)9#NRNQ(EK4JF6.=;\NJYE.0 S?;)/+QDZC!W**O.J49L62-J
MO:VK<:AYG#BR4$U35I<"_ A75B?,021IMP*Z_F34FYN@&B9PL4NBML3:EHMF
M&(1]JK1)2DDV6DO=8G#QD5?!8]6R/Y[QM-K"$/N=LLY ]W5>!V$D6G$,#KG'
M:A&R.@"8O>ZR9H0--<4XJ$8E[ L)_U"P*S89*>\7VT+<:<R&= KEFS=8_'Z'
MMP%,-D6-B1HHF/8I?GN"FFHMI0.>Q0HZTK;WZ=%4)HZNYFQ+1NZG.U]4[[.Y
M-ERBD2@("2+!-GW4EIBD-E-<0]M)F.+W%K0_!'R7>F07B:9(2F H'%NA_ NW
M85?DI)1P1& )9;Q74[IC&Q:=:UJ=2T WL&]4X""?/KU^.+4-#,DW5#[@C^6O
MG&T9XQ66K>B3H/*)E<#8:VG-&2P>8A!$V3JH+[8+$VRJYMO&QZ"QI(Q*=;](
M[,T>.& 9P3D#!F)?B&W<PVV374 $:5\_L[&MRM)*>H'D;9Z9U<H1TJ2),FGL
M,DJW7T8N=A[O?>:Z)*&8[:<[@8J6P+P4=#(N9W89H#LL0D^7/I?CNB2='WW%
MV?9NO[A1!+/&\L4+7O@OQO#)_'.YVVP7KHC._#KBX@V@^TU*@(L(+<:R%I?E
MUK1W-MF-4[!!M*8$4DFE69P<3\=(&*Y@/#5M\-8I36FX1\W "9M7A90T4INI
M<X/L84(<T:N7WN<$<[U\>\X0XY)V*Z4#E:]^7U%Y:\C;]>IV]E5X1M"%D&%W
M)[H+0VFC%774T@IN]7B+T6$X\OPWQ1A_W$$R<+L<]A!)>@L71"[? &E&#AIS
M-FH\'!,=-%K*=8"\I5SX:_3?9+<MT%W.NJ1;;\QI8 CNL7$(3(R32)I7[>/^
M[L'KH'9@!**M93;\&CN=*F1,V$W0%#$B23:?Q;E#?8$>"6<L!<_W1;E:WL.E
MAEF/L6=W<^(IAYDQ/CE 2XY%)FG,+A%55,Q;2O)7WML2+EU,V_".:E"@)LO<
MVE&!0"@O%D74FHS_>B_%GK>%UW.UMKQ8X0")B <XS,FME&5P,90FP*%2IA8P
MU_S=@5),T@\3=OVSI,;(0A*#[4:>A3K6B._C>Q"YRZA'C;XQM7XQ?\.@T66'
M!YZ\[Q;&4CUO3Z(Q]A?!%AW#/OWEO*9*-](6.'0O*KQW% _.XLEH$ U&\?!L
M#)90B&X[BL_PE[-)@&[2TCLB&L=CF+#V"_G0@1SK!IY2LY1!/!T,';R0TZY4
MI3CAI["Q23R93. O'SNQ6[QVY'@,WIJ?48.4X13[K/P>V_DDFL[CV7R(/72
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M!EB!&=)\4U(^4E+>$NQ^0NU+.441,Q9!NA<+C(LMBHPUU0TV^E6Y\?:CEQ7
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M 8(,SOH#:8UR-AE$?TK*:XP:PU(_).7G>PRWGZ^2-37AN(";#$1ZGB7!XCZ
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M>Y2YJ05'>*PRYRXGYMYO4>9&:(^K,C?N#TX^/X6-W&K>%+E'?_6]5LFQ(I=
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MPK9-%W>Y0.J4)2?_QPXR U_5.G:RTE4:8X^,Q=;!B)66 BUNHIB21TL3<&:
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M(:^S=TW#\2*%+8%X4I*2Q4PJJ?3JF-ZUKJ!9L8BE_/J:^AU?TLV1\^2!J\_
M[[:A<,B<ED617X!EVI@,E(0B!4"6.<'CG)P,2H['R"^$\L+\K9L9G; 3@7Q]
M);07Z/ 8C?O,+!1FDI"XA/JW0D77J?X*FG+.L-+!G I"Z]1C$+4@ROH!E>,
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MP4G9/F!=YL'[# <#+-"F8C_0V&8DMH^:<S!2.,UP_G"SVYAN^9<XI8F!7/,
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M8<GH;W?+*0L$"F0:,V->6ATJ(56<%##<X3P E<XIV XY%]2K%%'P4B*G9;!
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MV:M,!8"(HFMGEK1N7@9KZ*N74S"&-_-<Z0MF:&] *):[',/$!7@_^88!EQY
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MILBK8YXL4?G#''E5/:]\JWJJ\!KDZC:R!.KJK?UP/3]EABFS2Y-.(<18\;7
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M6=.F<\&X-&_]27_7N4O3A>X<W +\:FD[J=+G'=>H[;DOCG ^$!4W,AL4FU;
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MM250UL+"[;K0*60PK):%2ZM1,R!9^.BQD=WFH3^Y=D8H'K\MW?ZTT1AT,LS
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M4?[&GO\FWH!_+,OM__[_4$L#!!0    ( )6!6DR[2%219P(  %H-   -
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M;',O+G)E;'-02P$"% ,4    " "5@5I,9O,+8((   "Q    $
M    @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )6!6DRXR[IM
M[@   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( )6!6DR97)PC$ 8  )PG   3              "  ;8"  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ E8%:3*E3<>>P @  "0H
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M965T-2YX;6Q02P$"% ,4    " "5@5I,E]#P;OD!  ![!0  &
M    @ $5&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
ME8%:3%:6,LS@!   _1<  !@              ( !1!P  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )6!6DSN&9_NL@8  $ D   8
M          "  5HA  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " "5@5I,1C:,%K !  #2 P  &               @ %"*   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ E8%:3,.B<E*Q 0  T@,
M !D              ( !*"H  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " "5@5I,[V'/2+4!  #2 P  &0              @ $0+
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( )6!6DSO02I5
ML@$  -(#   9              "  ?PM  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ E8%:3-3)-$.T 0  T@,  !D
M ( !Y2\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "5
M@5I,ZIYLG[0!  #2 P  &0              @ '0,0  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )6!6DRTM=C&M0$  -(#   9
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M970Q.2YX;6Q02P$"% ,4    " "5@5I,Q[W2!K0!  #2 P  &0
M    @ %4/0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M )6!6DR4,_$NM0$  -(#   9              "  3\_  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ E8%:3(K"^,BS 0  T@,  !D
M             ( !*T$  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " "5@5I,,UXRK[ "   3"P  &0              @ $50P  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( )6!6DRRV5[XPP$
M #<$   9              "  ?Q%  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ E8%:3(JJB ^R 0  T@,  !D              ( !
M]D<  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "5@5I,
M2A4;D]4!  "<!   &0              @ '?20  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( )6!6DQ.*G]<MP$  -(#   9
M      "  >M+  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ E8%:3.K\*]:W 0  T@,  !D              ( !V4T  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "5@5I,0<HI <<!   W!
M&0              @ ''3P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( )6!6DPH@M&F]0$  ,L%   9              "  <51  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ E8%:3!TE"F_J
M 0  9@4  !D              ( !\5,  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " "5@5I,7_TYU\(!   W!   &0
M@ $25@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( )6!
M6DSQD09ZQ $  #<$   9              "  0M8  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ E8%:3&FC!X;' 0  -P0  !D
M         ( !!EH  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " "5@5I,Y1U\D-$!  "<!   &0              @ $$7   >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )6!6DPCXSC@MP$  -(#
M   9              "  0Q>  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ E8%:3#)SP88*!   \Q,  !D              ( !^E\
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "5@5I,?>+C
M]4H"  "Q"   &0              @ $[9   >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( )6!6DQ(<<%E$00  ,<3   9
M  "  ;QF  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
ME8%:3+6DDRB7!   21@  !D              ( !!&L  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " "5@5I,)6"S(@0#  "P"P  &0
M            @ '2;P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( )6!6DRJ/)18P ,  )@1   9              "  0US  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ E8%:3"MZHT-P @
M^@<  !D              ( !!'<  'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " "5@5I,0W 8!=8"  "I"P  &0              @ &K
M>0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( )6!6DQU
M[0VV+0(  %$&   9              "  ;A\  !X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ E8%:3%E6/&VR P  CA(  !D
M     ( !''\  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )6!6DSS]5DTZ $  /($   9              "
M ::/  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ E8%:
M3)FZ+DB@ @  + D  !D              ( !Q9$  'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " "5@5I,/-YF,:<"  !/"@  &0
M        @ &<E   >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( )6!6DSBGJ/OA@(  %\)   9              "  7J7  !X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ E8%:3#OYE/0' @  4@8
M !D              ( !-YH  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " "5@5I,L/7[$=<"  "4"P  &0              @ %UG
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( )6!6DP,0OOL
MR@(  %<*   9              "  8.?  !X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ E8%:3.TRU,>. @  LP@  !D
M ( !A*(  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "5
M@5I,26>J<#("  !#!P  &0              @ %)I0  >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( )6!6DS^R;@67P,  ,,.   9
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M970V-"YX;6Q02P$"% ,4    " "5@5I,7 %K/_,"   D"P  &0
M    @ $EN   >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M )6!6DR%SRE]D0(  *,(   9              "  4^[  !X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ E8%:3)KB)20M @  1@8  !D
M             ( !%[X  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"
M% ,4    " "5@5I,$4%,@7("   5"0  &0              @ %[P   >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( )6!6DSASOPJP (
M +$)   9              "  23#  !X;"]W;W)K<VAE971S+W-H965T-CDN
M>&UL4$L! A0#%     @ E8%:3)^ MQK  @  CPH  !D              ( !
M&\8  'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " "5@5I,
M"5Q\]HD"  #<"   &0              @ $2R0  >&PO=V]R:W-H965T<R]S
M:&5E=#<Q+GAM;%!+ 0(4 Q0    ( )6!6DQ*?8R8:@(  *$'   9
M      "  =++  !X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%
M  @ E8%:3*!M.^'> P  !A(  !D              ( !<\X  'AL+W=O<FMS
M:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " "5@5I,Y8R@WY$"  "Y"0
M&0              @ &(T@  >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+
M 0(4 Q0    ( )6!6DSFM.%3C ,  /,2   9              "  5#5  !X
M;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ E8%:3/:_GQD-
M @  908  !D              ( !$]D  'AL+W=O<FMS:&5E=',O<VAE970W
M-BYX;6Q02P$"% ,4    " "5@5I,Y'/[(MP!  #[!   &0
M@ %7VP  >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( )6!
M6DPV%"V39@(  .D(   9              "  6K=  !X;"]W;W)K<VAE971S
M+W-H965T-S@N>&UL4$L! A0#%     @ E8%:3)YF.-(R @  008  !D
M         ( !!^   'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
M    " "5@5I,TRH!]X$#  #1$   &0              @ %PX@  >&PO=V]R
M:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( )6!6DS2B/HP  (  $8%
M   9              "  2CF  !X;"]W;W)K<VAE971S+W-H965T.#$N>&UL
M4$L! A0#%     @ E8%:3,XI22]. @  3 <  !D              ( !7^@
M 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " "5@5I,[3("
M9(@"  #Q"0  &0              @ 'DZ@  >&PO=V]R:W-H965T<R]S:&5E
M=#@S+GAM;%!+ 0(4 Q0    ( )6!6DR<B:>_*0,  +$,   9
M  "  :/M  !X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @
ME8%:3'%/W>@,!   _!$  !D              ( ! _$  'AL+W=O<FMS:&5E
M=',O<VAE970X-2YX;6Q02P$"% ,4    " "5@5I,ID$*;R<"   ]!@  &0
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9>&UL4$L%!@    !? %\ "QH  "+8 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>315</ContextCount>
  <ElementCount>424</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Common Stock and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommonStockAndWarrants</Role>
      <ShortName>Common Stock and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Investments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Commitments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SegmentInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Organization and Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Estimated Useful Lives of Property Plant And Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2401405 - Disclosure - Organization and Summary of Significant Accounting Policies (Allowance Reserve) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAllowanceReserveDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Allowance Reserve) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesIpsenDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Ipsen) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Takeda Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Collaboration Agreements (Collaboration Revenue - Takeda) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenueTakedaDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenue - Takeda) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Collaboration Agreements (Genentech Collaboration, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsGenentechCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements (Genentech Collaboration, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGenentechDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - Genentech) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Collaboration Agreements (Other Collaborations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsOtherCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements (Other Collaborations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Collaboration Agreements (Collaboration Revenues - GSK) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesGskDetails</Role>
      <ShortName>Collaboration Agreements (Collaboration Revenues - GSK) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InvestmentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Investments (Summary by Security Type) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InvestmentsSummaryBySecurityTypeDetails</Role>
      <ShortName>Investments (Summary by Security Type) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InvestmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Investments (Gross Unrealized Losses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InvestmentsGrossUnrealizedLossesDetails</Role>
      <ShortName>Investments (Gross Unrealized Losses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InvestmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Investments (Summary by Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InvestmentsSummaryByContractualMaturityDetails</Role>
      <ShortName>Investments (Summary by Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InvestmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Inventory (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryScheduleOfInventoryDetails</Role>
      <ShortName>Inventory (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Debt (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtScheduleOfDebtDetails</Role>
      <ShortName>Debt (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Debt (Secured Convertible Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exelixis.com/role/DebtSecuredConvertibleNotesDetails</Role>
      <ShortName>Debt (Secured Convertible Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Debt (2019 Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.exelixis.com/role/Debt2019NotesDetails</Role>
      <ShortName>Debt (2019 Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Debt (Summary of Loss on Extinguishment of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtSummaryOfLossOnExtinguishmentOfDebtDetails</Role>
      <ShortName>Debt (Summary of Loss on Extinguishment of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Debt (Term Loan Payable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/DebtTermLoanPayableDetails</Role>
      <ShortName>Debt (Term Loan Payable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/DebtTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Common Stock and Warrants (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommonStockAndWarrantsNarrativeDetails</Role>
      <ShortName>Common Stock and Warrants (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommonStockAndWarrants</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Stock-based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleOfAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation (Schedule of Allocated Employee Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueDetails</Role>
      <ShortName>Stock-based Compensation (Weighted Average Grant Date Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationScheduleOfFairValueOfEmployeeShareBasedPaymentsAwardsEsppAssumptionsAndWeightedAverageFairValuesDetails</Role>
      <ShortName>Stock-based Compensation (Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Stock-based Compensation (Summary of All Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation (Summary of All Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Stock-based Compensation (Summary of All RSU Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationSummaryOfAllRsuActivityDetails</Role>
      <ShortName>Stock-based Compensation (Summary of All RSU Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Income Taxes (Schedule of Consolidated Net Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfConsolidatedNetIncomeLossDetails</Role>
      <ShortName>Income Taxes (Schedule of Consolidated Net Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes (Components of Income Tax Expense (Benefit)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfReconciliationOfIncomeTaxesAtStatutoryFederalIncomeTaxRateToNetIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to Net Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfDeferredAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerShareComputationOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Computation of Basic and Diluted Net Income (Loss) Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomeLossPerSharePotentiallyDilutiveSharesOfCommonStockDetails</Role>
      <ShortName>Net Income (Loss) Per Share (Potentially Dilutive Shares of Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Schedule of Fair Value of Financial Assets Measured on A Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Fair Value Measurements (Schedule of Estimated Fair Value of Outstanding Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueOfOutstandingDebtDetails</Role>
      <ShortName>Fair Value Measurements (Schedule of Estimated Fair Value of Outstanding Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Fair Value Measurements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Commitments (Schedule of Aggregate Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsScheduleOfAggregateFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments (Schedule of Aggregate Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Commitments (Schedule of Rent Expense and Sublease Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsScheduleOfRentExpenseAndSubleaseIncomeDetails</Role>
      <ShortName>Commitments (Schedule of Rent Expense and Sublease Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsNarrativeDetails</Role>
      <ShortName>Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Segment Information Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SegmentInformationSegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Segment Information (Schedule of Revenues by Customer) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SegmentInformationScheduleOfRevenuesByCustomerDetails</Role>
      <ShortName>Segment Information (Schedule of Revenues by Customer) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SegmentInformationTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Segment Information (Concentration Risk by Customer) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SegmentInformationConcentrationRiskByCustomerDetails</Role>
      <ShortName>Segment Information (Concentration Risk by Customer) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SegmentInformationTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Segment Information (Revenues from Geographic Regions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SegmentInformationRevenuesFromGeographicRegionsDetails</Role>
      <ShortName>Segment Information (Revenues from Geographic Regions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SegmentInformationTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedSummaryOfUnauditedQuarterlyFinancialDataDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Summary of Unaudited Quarterly Financial Data) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="exel-20171229.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Quarterly Financial Data (Unaudited) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedNarrativeDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>exel-20171229.xml</File>
    <File>exel-20171229.xsd</File>
    <File>exel-20171229_cal.xml</File>
    <File>exel-20171229_def.xml</File>
    <File>exel-20171229_lab.xml</File>
    <File>exel-20171229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0000939767-18-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-18-000023-xbrl.zip
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M6UGWSSPKPT@WK_-UBIAQS&EJB4).&>Z=FGS=&L.^__G5)(!\ZE.3H?BB5<W
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M*8$9*2=$D=F!S7Q]?E@?\L\=L$=9;_!;=KN6U''B/!**<J,$M4GVT)3YA9'
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M>%.T1EF3N>1(WNV"QY+VR95@&L ,MB'(J<HNTCC"M[N\UY^D2G:]^7"I=(M
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MM0IJENP-1*7"<$2D!CV-IC5S0JJ:9T>JJK,&ZO6\PD=82ZL(T1)<$1Y(VE'
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MD7'M]*+6CD<^%^.UK"4MA%>[#4[QH+1GRD@<I.3*<R\=YMPA2Q?5AE:QQX:
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MGK&$IX/-@^9>1)H:B!,,P:_'!MQM7(]9SESI[F%)RD:(5[BW$=A1*R*2+YH
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M]2 OW_7RCS=E,?Q\$SM?\C_SK'Q.@LM130CB,6URHT11&E,]:W32H<AIO2"
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MKLZD57@ 3VVU39^Z8%SR+=^I5_,X@3D,ZW0ZAB-;ZQTZYIXGBUI2FU**;,E
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MM\];+;('([P*)AGF4RQ;MUC&0['3LQ$QZ([Y0DMIB]%!)^6<"5SQ;;B=RZ&
M9#P1YQ.DHE2F1C;K0?OL34*UT\+G&*P< ?\"N =%)Z/?:Q7+'&4'39222FUA
M8Q!>E94\#^Q!81$&(!<PGL=4DN:!/X0?&)<<"C]&P.XK "IK-Q?J%-M[U%^3
MY6S127NNVJ\_Y/LZ*OK,3T,[3]M&%5-L\;Y(D$:R(-</= ">]27O7?=IM\.+
M VP:'<XXC&.*DFBLG4ZTC<=*O9VZ*'@]#-OI3E#0CV0$UN'Y\#1OT39/N['@
M'4+VYA:K$;I^*@=GY66Q/H<<89@FDHC219MT5LR6M,[2V1*EJ'=!P9 <?7NR
M]U;?/:;;*DZCZC(&K)"-91BPKG<=H.]#VU KNJ&;Y7XRW3\MYE=C;Y(VW(-2
M(F5=4+^#EH*U,YM0O]:;-81A[J!X/J 9!WGP0H6L@1E!01)S@OOH-Y)%%TJF
MZM&7"ZOX01:?"_)SW"N#3H-T5A06"E=&2^M]>Z^L+SU+>1@_+& OA?JCKE>.
M49@,"BRZ2C)S:=?)Z,8\I50ONK$#U^LP]3L9N_.Y@!8E&&&CY<(+A[$1*+--
M* ;DZ!%.R3'(SD;1H'.(Q@T@99Z35^AJ!2GY-JY0SA_C'#XK08-NHXN")AHX
MB"EF9$".D%J",'PZ)MH;2Q!^R*]6T[O5KO_Y=-U>! \9C TE6%Y$]("'(D*6
M/ENCZBK%'AKV8#D%]J!^Y])@((1AD:<14-D'E_(&-N>.UP]E0DG1>\7'H&\6
M^XWP2"&5H@5JH1 MO=?0:+=&7FAVC*K4LD9O /KMZ"Z4$6"/V*_*G;(*G5*>
MH)F?5S8OJ A>F@JL!.N4/15LFWF?3:L]CL=5@JN,EDQ978I*5-[%N6]1HY0<
MHV/V8#D%]B"S==:)HS #H@SH#>K@3 L;\L%J^U-@CV*Q+EZI9(5#IS $1%U2
M::78)%'OHN^4T/2A.(CRS>?ILAE[2>6^S?*>F\7R=RI1>3KXD)B4UFA=0 KI
M\1IJUH+GKH[TI0'!S6'\^_&=BZPC]HLQKF06R3";#1Z(+'HK/V#K#>IH>UE_
ML'LR67<?>S:D#1Z,,N@;!.5$0(W'O7/>^/9@\*@J;P<Z SO[<8Q .KSQTEE.
M +52V:!+AE(C6UZ[6*]Q F8'U.(PU+?+!9[&W=>WMQ/TE.?75'?U^=.H8"YG
MAZ)>'"O6Z:(D"TYLKZ\,55FO81H&+L!>=&>B:?A(F#+6(@69TJ10T "(]DAD
MABK5(YPT TII'$WXAXC_/;L[44TI0[D096BC'O>"1[,I,D>">(J5FL*(7 \<
M4C^T<U SO-I1Y2RYE2JPQ'FDLINMW\/Q+RMJM#']\=B)U+1_M_&OWTU7T^67
M*>UTH2$V]XB\_:NG'YE06KN4T,-SM)A >%E,2Z3K&99L8>A:/0GP!4D?WKR*
M]C1C7!TY3RRP*&6.V^NG8EWZXH:\VO.13D/"FQ$0_O9V\3M-S1[A\2 /<F$8
M8)3,2T[<6]O2%TNIFJ#1;V=Z0+_4N$XE8[A()EF6148B"EI;PR67N970['B5
MQCO&HS^:C$=>Z=,/ " B:MIQ)K0J0@9T\UOD!4K=2;O?Y7R$8P3284>^<,D*
MK1*-)4;I@WRP1-Z[*BX] \B1#E?0(D,V7C&N,T,^FDUG?^/&\,KA.HZGAUR9
M0<S#65V(FFEKLD7_D),;$WB+6?M\3$IL&"ZU$S3-[;-?[TFRR0.@5J9WTZO%
MAWFU%6E_,N]Q2A*2%LQ%G:64PF>?G-G(!<]H%.N[5R<DAW&=3DAO#F\GLYR%
M9)+&W,J,7B^>F=$M'=+40SD O@TAO;F[G4(VKZCI@Y)'4**VP)G<'DA)=;QA
M+D1(_O3Y=O%UNOQQ<G?U$:.MG:^OJU>.HJY3*^8TZ481DD$GTCB#UJLE3UCV
MV,M_5%DC!LD[ NUY:'YSTWQQ!.G6"JXA1J:-] D5,FL+<7GVMG? )IR#[@WB
M7?(_+VG>6-6Y<YS24&B5065&0Y8B1O0Q.1KOK8QWW+)2*0VHM<;#[S\:UZ .
M8+2#/BI'\WQ!"V'PYJSK$#4Z&'5]4+4S<Q2LP1OM%7?TNA4P$C+*,QLW[_U4
MUI]9W35</WD-P\(_WTX;?P?]T$^+Y=WLOYYRNCONF$PHIS3(1,:8BF &!&T6
MLJ*@4DUU'J&[H^087"?3,3R1"G0LZ.<4=/XS<5](LR8C:V9"3SJ$=1V)9R!C
M^"T''7:-(A.$MR+Z&%5B&S*R!E4Y;@"V&[X]C8RV8[%=)ADFJ]G5<6+T>$Y>
MH56U2AI*$3@A@45'L^<XL(#FV'7LV,.VRU?LK^;1:-M>-$^'JW^&\J^?81_8
ME!/+%G4S7DP027DG-A-XM?,A[UT$C6 ?[](Z&UB.8/G>V8].9RM4-!P*"K9Q
M?E,&B6!1A-4!L(_G$)X-K/C'_2WCK]Y//^]Z];O2((I$P2W10\9(*6?K6\S1
M=BW&#F8F+X"YOG0[>T1\E$DE5!A2&R518[--U9,O0C!^2!SL)="^N;IC\*J*
MFW:6 KDL6.31H]_+8^8>?<>6P[1G;1]F% I^=LCF9R"P\.K'R5+LO74:W=D
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M.'^_GUU3 N?U?/WM@<:V4[&/O[F;+G]9?)Y=H</>P7)X%P^2C%SXU!>[/5X
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MV0SS*0WGO].%=BA-CNOXB!*P$TTDF$*HH#2!VZ#K!FRZL376@O]5M[:?./F
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M-#5,C<MQC>/:P(M9A\]1'-PXN V$%3FX<7#CX,;!K4MPX_C5:5> <_ KSP6
M3B2I@$]@&4@+!74DZ[R1U1&4T9DIZXL0#][(BHL(%Q$N(EQ$N(AP(VL(GLJ
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MO)N3V/8B(C<3$3I] 6W%UN\K#*WG+43Q?9CEV$DN@Y]A1YLB*RR2+,*A;4(
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MD^4,_C /\F)GJ%IP0W5]A R-?RLW066*[0.6]0#Z:)Z@X1A]!V1CIB-N@GX
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M?LZM!]X^8V@,C&%V@<;9.;YRACT!AJ7-YW$Q;5FB*X-BVR=^H7<7G-<YKY\
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M/?;0\YJFT:R,WCWIG/?LE6"0C[KU%$_0,<+(*I49ZDD\Y?W?A?#9!,L3 (#
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MUSVSFV2R8V>S>?54BVQ9W%"DPHL]VD__ &B2HFZV;),2+]@Z9V))O'2C 32
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M2&JWTG^P3=1O]Y&C&A)39Z*Y^ /_"<V93>#_,;6ILX*MT/^QZ0,.U(O\C>X
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MK-?*=3AQ, U?%'2M&DORT08K0%: %5& .9\JL09\D09D_)&#Z'DE76]NNXQ
M4HI=ISSL5SK",<<QQS''E9]P50$9V7C@8..=^/E(6_!OF\TTXWX5WG2CM5P4
M!J%P<8A:%$@+>]$IK'C\AI.+7YH%,N[J_=$H+TW*H=/F;0RU%H]^6^]W#18/
M%@\6CQWBT1XS.-1QHRYUR@2^PAP%^T%FTGLY_,+.<'D)QQS'',<<5W["O3W\
MTMT,A51YG_V4B9G$490%-7#7M<A]D 'F"7Z^_36@_GK7M[_\LM[FO0BK]\3-
MC8I-9AOIO<-;!+PU [@N1C/[E"Q=)4VR9Q%C$6,18Q$[;>CG.'4LU3X13!M$
MKT>5=IP4YEL?\TJUL:LR(4\_+J_^6H5JFZ[1T=OM;C&:YB44+DT6(%>_ULHX
M8"F_S_TDE:6<I9REO'Q2GN^!,$MYP6'NDTCX3'54I:/L\DC[<P<LISE'*16M
MF*^8KYBOF*\J02LN?7M=_\]5_$M7Z?1',^9>9167 ?^H=)7$S[)QQ?J#M5O]
M(V+#E(&E.#A0SN  :SC6<(7@)+1;G=RJL-Y.O<: =K,N9%W(NK!TNG!8@A!R
MXW1A1<+)97",X^R14BO+$M*T5%A:951][59O?#0:-<6?95.-M0]KG](YH8VS
MKUA/L9YB/54Y![%Q>BKC!WX=8H.)7=>_<3"OLODR-'-L5Y[%A\U&I_VWS378
MA,DP.CL*%];T13NYP'9!%8;?]$:O.,)^?O9QC"$QP?&!=S.I==I&3_M-^+YP
MPT![E+[<VP&/BAQ"N.=17:[-/ <X. "GU-)<#SZ+!ZD)5<,KS# 2CN9-8-8"
MJWFQ60@YL5@.X46^AKZM#%K:K91:4OC3:7_[LQ=*;=C2+E6IQ2V56N";DT&F
MUQK?4L,1H5DR,'V;*HNQ2"/<G%:KB8O["]#1#6WA.,M,9<KN2A9</-LUG<A2
MU2I(056Q(A*B'E"VHDVD*:* VL)8L-B>]NA%C@5?P_J%]EDZ"N(R$<#J.6 #
M!-I[>J47P?RLX,,V$DNN=#G0/'@#5[37F<*$99#^WD7?40*UDW/P<W8DKN?/
MA;/.CGA-^F#2H)HI'2>^YOMW[7?T&;8$,_F\@ZQW]AQXY&?YJ'WVYF++.)L+
M_]YVU2!%%'K)%VJ;HF\>;2N<P=5 JWB7@X5PQ"*0WR1_;(G-:MS9$&"Z@8UW
M)@0='D140^J/__;\#KES#X^GU'GC_:>]G4=_^.UO"DH7;J"-WKQOC+;4H_H-
M'Y,H%_KF4>F;"6SV2F@M:7H^;0S?H/V41T[AJ-Q%SULJO'3D_QW,6>W:Q?W[
M2IIR/H%-N6OHK["\F=F+9O:\*OR;PMM@R^?F='.HB_GP#7PX8#ZL)!_F5<-8
M$)-N,6'";P>#>7'10<D Z8Y'^,JUYC+T02\_E+I&%^)62,)+M_^PA.ZOIA_J
M_4%^!_(LHBRB+*(YB^A([PW;+*)YB"CG'V<?<25!"]C2L30\BLW-YCUBCDS5
M,"KK(D?E$YEJ[6AU$9%N5Q^-<]N;6#I8.E@ZZBX=', \$.<ND]=62D^JC")7
M!*YX&2J".6Y1P7VL]M)FZ.UV\9$)EC.6,Y8SEC,.\KW2CAQS?(_C>QS!X @&
MBPB+"(M(OB+2[^F&D5L&15VD@_O3'\8]=UXH'&VQOX(S-ZN_I)U$2B+%^68J
M<D^1TKCS3=I26<:?E/%!1^_U2X" RT+.0LY"7M1&;@SUWI"E_.AF/N/XY,W/
M>W!\-K(V%<:*+Q?")D27?T0N@>(,6]H>U!_Y1?JF';<KOI6+4!61K]TSSC[<
M]%R4#KC!\^%-EI1SB6 OX:.4KG8>W4=!2'54/X,J39XU>!J+)_G[NZ^CX.Q>
MB,4WU\)W@<3!+]*_1=?G#BA\X7CF'S_\]2_?)1?="-O_MW B>1X$,@Q^DB*(
M8$2?W,\(7N3#_1<BL(/T7JKJ@@^?Y?3[=U<XQ7_U;G[__>[JG69;W[^[$69X
M-KJ\[)WWQC>]Z\MVKW_='E^.C(O!1?_ZHMOKC8S^NQ\V."J[C,] J.P2Z+HQ
MI.F((+"GH#P3""$$?9K:KG!-\&DU04NE/=KA+$8<FL(J:@^XC-K,EK[PS=D2
M?A"AXK=YO*K$4SX6Z"+: ?R:N0]>)/ WM>C41BC8A!M2W"SFH)WA_0OPIK&H
MTP(!(  DS13!3-<F40J)!/_%TL"YQ.N3:>&K [I6DW]&-KR>?GX.RH@AALH+
M,61TRH$Q],;;3XS2PY-OR.0K<J!>.C]N-5R# 3A>!,"1(!NMR-XU=.TE\##,
MLP4W_V2676?9'^6#=#0CK\ #LR*SXIM8<47RW/I:,D\R3[Z6)^F@N]#-NT0G
M"D=*'O@)J+O4P&/^0X;:%"9^TA3/\D?"C]X<X0U=\RIW\-+KYWKN4GIFXL/3
M<N[0K-=8KY4\!;K\',7*K>G*C?57=5+0CV1ZU44!520T?"2IPNY+F ^":>AB
M(?W7!$.>PW5^<ZU'O?;_N@A2^62F=!MV(T3$&(_U02^WS@TL'BP>+!ZU%P\.
M\A]HG_D+/$Z1VL1[683_8.$J#C^E7G9;[3VC"DE?=;>R6DJ;,1SK[4YNF08L
M:2QI+&DL:1SMRYE[?FW=MK0[GPILEE1?<X_R[6+)BQ8L/#?PL/"&THD6OAV\
M"(#B<,$\;9/7RMF=SY"K+J):/JFL\-Y78Q$S!GIGT&7I8NEBZ6+I*H=T,>#9
M8=RE ,\VB\.+X;8=<!V<(Y,7)3F)IACRU44A<H2KH#0_UG&G%]**ZKCNN*>/
MN_G%#EG)L9)C)<=*KE1*KM=KZSTCOW8IC5=R!X'\,=P5PUWME:PJ@AZ5[/9J
MC[Y2DZ_(B7'I##J&NZ+'Y EW-2@T_,P\RW@NKV59AKMB5BP3*S+<%?-DB7B2
MX:X:"W=50LHQ<L(>P@P-O=?/K3*O%"S!QQWEW$I9 ;$".DZV>!GX@K40:R'6
M0E710FP&<4G9JYF' :080(I+4DY>DE)E$3$&?;T[S*W_-HL'BP>+1^W%@\/F
M#"!5+;NM]IY1A:2ONEM9+:7-Z'?T7IMC$"QI+&DL:662-([V,8!4U>W.AH!P
ME$\J*[SWU5C$AFU]V,EO!V3I8NEBZ6+I*FTTDP&D7L=MC#M0("4YB:88\M5%
M(7*$JZ T/]9QIQ?2BNJX[FBD]]OCT]./E1PK.59RK.0* 9#JC_7QX&#H!59R
MN0-()7]_]W44G-T+L?CF1MC^OX43R7-R]WZB\P=I?7(_2S/R?>"J"Q'8P1U0
MX<+QS#]^^.M?OMNZ]\H.3,?#&U<7 EE=I-UG.?W^W56G;0S_U;OY_?>[JW>:
M;7W_[D:8X9DQ/A\,>I>=SG7O_&IT?CXVKL87@XO^]46WU^]?#M[]L+$86<(^
M@PBU:RWW@F814!6*S>9JKRFS7>A7^8M*CL72-^<?/VO_/O_QUVOMI^OSVU\_
M7_]T_?/=K?8D?[T!9.SE).R-CD!#%=Z821 T$03V%%0)$DKSIIH7^5LA#^W1
M#F>VJX5PQQ187'M 'M=FMO2%;\Z6\(,(M4?I2VT>BPN=U_FX!!9^"+/WP8L$
M_J:D29N@.*F[1:!-/0=V_J"EX?#$''05O'\!<H3G?)8FOYA.9,' 13#3M4D4
M:K:KOK'=!QF$>#@8I-/"5P=TK2;_C&QX/?W\GN;B14 N*_CP35&+SPASC#"W
M[_9JHZ3QY*LR^8JDE)3.XV.$N=>:6'L1Y@X.6#//,H02(\PQ*S:6%1EACGFR
M1#S)"'.-19B+18&""B?-AZH2[DH11*M20[+2,Q,?LY9SAV:]QGJM[/4MI><H
M5FY-5VZLOZJ4 7(4TZLN"J@BH6'&PRM%>1#CX7&\,(=X89U%Q!B/]4$OMUH2
M%@\6#Q:/VHL'!_D9#Z]:=EOM/:,*25]UM[):2ILQ'.OM3FZ9!BQI+&DL:2QI
M'.UC/+R*R2?CX7' I Q[7XU%S!CHG4&7I8NEBZ6+I:L<TL5X>(=Q%^/A521'
MIGDP*KDFT30>184C7 6E^;&..[V05E3'=<<]?=S-+W;(2HZ5'"LY5G*E4G*]
M7EOO&>W3TZ\N2N[%>'@,=\5P5SONKQ;H4<ENK_;H*S7YBIP8E\Z@8[@K>DR>
M<%<'H_HRSS*>"\-=,2LVEA49[HIYLD0\R7!7C86[*B'E&#GA.$W0RL 2?-Q1
MSJV4%1 KH.-DBY>!+U@+L19B+505+<1F$)>4O9IY&$"* :2X).7D)2E5%A%C
MT->[PSZ+!XL'BP>+1Y%F6(F<0P:0*K74<6B&0S.EW,IJ*6U&OZ/WVAR#8$EC
M26-)*Y.D<;2/ :2J;G<V!(2C?%)9X;VOQB(V;.O#3GX[($L72Q=+%TM7::.9
M#"#U.FYCW($"*<E)-,60KRX*D2-<!:7YL8X[O9!65,=U1R.]WQZ?GGZLY%C)
ML9)C)5<(@%1_K(\'!T,OL)++!4#JK5'SUXSQ#4!5!G+O)M'7=,HF"%5O!%_D
MS[+K1<OTP-^D9MF6YGJA-A,/4A/N,N,P.[:8V(X=VC+0YG2.(RTZR/&QD-G"
M#Z$V%;:O/0@GDIKG:@)_BWP?YJ9-1& 'X'5KWE0+9UX [Q*A#%K:TV]5;KKF
M^6OO-QWXWI[:^-) 4Y@27<UVX<DR.X:9+7WAF[-E_.*M5<V+?J_ :-EV^7)=
M3"19F::[K1?SG2YR(JR^+[5'_,?UM-"'!TRE3RO_.HZR(N)=Y*HE*(A DRXR
M>K%3.27'X$*UFJC[[F")91#:<U!*UIH:FVI>Y&?XQW:#T(_PW#H Q@"=)X#=
M3 %:3JE ,?=@._^?Q*A^$&J/@K3>U'/ !@ZT]Z2DO @&9P4?BEW0;XI:2$9;
M+ !M<90+V.*PVR3(O9+=SGB#5?#_T^$.RWW86A!:$7W*HA&]U&ZK=KY;>=GQ
M"%A9\2-H*WWZ1+Q$K'D)MM42)G*H-7.J<9[/O0@&EU/XAR6#)>,YCKM!-^7?
MZ*84JJ1+=)APM-HWETB!_H7KA2]*1LY=JDL1YV6HE+<1QFB/=8/;;^=W3E<>
MG52Z?9,U$&N@'1JH8^B=3G[];<K $Z5+K*VM170G_;GF>,+5%F))9[$GU$<E
MI$]N:J>BVF74UL%3RHL(==$AY5,7]3=66#F43CD,Q_IPU&/EL-? X/2F(QWQ
MFW$L&4_I(SS!]Z;P73#3,5O$DI1%XF$:"68N2?L!ER70-6&:ZO+8^*%O_(C.
M^!U'3.(\F#2C9)F]8+Z0;J!^Q\=/I"NG=AAD+@$J(YO#&#82K708Q@33I+2I
MA'^L"&80!4!XZ>/]Z6"SF2QBL?"]+Y3(@(DKMI_)9@CH'DQ8D%],)\)<EJGO
MS2G!A5@0+IC %D%963.!65D:+AX.?JUZ*IL$L3_W025=)4=+6I+&TMI.H&D(
M^ZDL$.2_N0QGGA6O1Q!$\P72.%#)2U$ % R]-"%E,ZT-B"J%.5-)2^O93:N%
M^>9I*K\H>6*+QCO6(4N@S00+;1^%]R<RT,*\\#2]J+-SF/9+-ITMKMV8_;I5
MT\NFM.3*<0DB1&?P=H,,2/"BC7>+!L6;6KLR6F<2E.Z#L!VEM1]E+$&V^P#"
MI?371*"X@7;^,_(P^6OAVR9J7,^/$U5WJCUXV,P&&<2DUCA?T(#?%U'8TCY%
MN'_,!:AU$/7LNU#UT@@L$'*56FC[UME"^.&27HS?!5[DFS)] V@#S9O E&DW
M2AK9J%'J\/005 8H6Y_V"=0G2ULZH($C']Z;O1,4-.Q&<\]UELE<Z6X8D)IN
M8 .IA9^D2(JUNVENZKIXH#M(T(E)\&8;Z-7JJ<?:B;531;13-N5T>XO'M%-+
M3L(U8RO1&E)S20G(  &45F;!*H4U"B-*3 UFVI123\.9[T7W,U @\ O8J"WM
MAE2<! M-^E-2&C_C82?I2;)!A&;9 9F^I%Y>DT)_ !W&K?[?7OK8EU$ZT52/
M68JC>@,28X$"TA",>%_99C35K#ZD55@W9K?SI'9HP^X^;9CKY I.1T^8)-R,
M &?8Q%W?AE1>-!#"!)/6#D(D[Z,= NMA*[:S> =3&Q9=^NA%P'Q4_C&1L&6#
MM^JJ/1E7"-S6L^3Y9Q/X#1=IY5=1<8D#.[0,DC5=X]HBMZE#?)77.2;M(_@E
MZD=\SBM:%=ZD5M$YF0NZ]F/6"P4[Y/K/"-2,]E-2+$0503][[JHHZ *+@IKH
M#'YT439<:5)8@&0#9<RDO). /,%X!P#5,E9J.:E&B95-7.CB2Z"RK_Q%2Z*0
M IEV[";X#2Q3Z$B"W"/)M&0<MU#!#GC(9$D7SF#IL7 F+JK9\:@TTD&""$P!
MSXQ_6HU83^N]T.KU;2\*LF.@ K#D]\S46UJ^OO(35OS3)1)LA+(16G<C].XI
MO8"R36"<Z&=JZ*7J6C #)S953Y?D4&JWH6?^$<OMEA&;O8;JH5(]9:V<;](!
MCD?F;=;%W?F0^/H7Z)3$"$ 'W,EZZ\';X_6L)EA--$%-I(<G:Y; *M"U3XVD
M!KA+9PZ!<DI3V\+S[\'V<&40K!X)+L8\-BE,()] [0.R[J_\C/@*M#%6!QY!
M1OOL\(M8L%FP6;!?%(0ZV-;/-S+U&P>@*  5^@+Y(QN!NI6+,#Y/;;\\\O3:
M7(3OOHZ"LWLA%M]@T0G5G%S!RH#!!FL9W 'G7CA@F?WPU[]\MW5A)BZ0Q (^
MN9^3( #% -('X,Z!<O!93K]_=X6GQ?_JW?S^^]W5.\VVOG]W(\SP[,JX&?9[
MPXO^9?^J>WTU&EV/KB\&%_WKBV[O<GS5>_?#AJ0]I7?W"5E- P^,<\ X!XQS
M4+52_Y+=SC@'.V2^=)FUC'/ . =E9$>NYM[-FHQSP)+!DK&+XQCG('_?4*D<
MQCG@*F/&.7B+PG<8YZ VI8.EX#;60&_40(QSP#@'K^8>QCG@4F;&.6"<@_(;
M*ZP<2J<<&.?@U3@'N_[>D7/PDE2"G;D(GZ9IW<+'U0'W+YYCF\M#<@^,GG'=
MZUUT1J/>L MFYD7?N*#<@^&-T>F>&T?+/:AK54D:ZDOJ1FB!GN2UFJ9JW*R2
M,WPY=:1)B1@RA:[(5$Y-Y*J$(UIXKA8(AU(ZP(ZE8E[L[;$0-E5*)'U1-)')
M[+(1G$*CX+"S5)<(59PRD>$CUF0E2=D"=94-J@@KA$,:T7RU4I2 K;V77^PX
M?_M#W.&'<H5V56?LSCC![*>D#-FUU@ N\">5\*1RP*F>.X"WX8!-RI7(U(,D
M58Y[2T!>W<R(:G"$$WCP:N_!MO9T'K+=*4H!T5)U*(*1J)0Y&.:EYU(,GM)Q
M5B55MR%\0</;2JI?/7DF@CB#-JF4"6>^C//;GREMJ:G,)(7X25ZG811>'ID%
M5_%EMK8A"H%E_X?K4NP0UG$+WD>NL/X;!?#5!Q)KD(J'!#9 28^-JT*(,WM$
MC%1+G(F-65XP!;P#,T!1HY@F)FOO$?Y&M@]*RDH;Q7?;X!!IGF#F)VD31)%E
M@_H,86^A)/[DDQX#&,&-F_@;KV-=4I=!.J"XY"!.3DZ0/1#R"%ED(8E/5L ;
M,&:Z8@\DR.XA)57BV3T%OB9U;X$<^DMM[EF@D>-1@)"(>'RZ%D18E!3L@O&(
M7THT1;&;R P1B;XX1C#,,6^8(*@(T&-CB,T$6TJRH!LECYM"".LV ^Z\=^TI
M2 R\"(V_=6,BJ[R1YR)W);F-5.3GL.4]V."AQ04..PVOI%F@&5MU!'1@16:8
M%+G_&8&53)8T68HM[1+TV[W2(/C4A,C*]H97X1L2$Y$6<2Z6,)(@<D(2:;0]
MUU\*-RD[CW104B25Q1K"JO(G6F(^4QNPWP=_RH5>\[D]'WC"O:3R!G-YM_(I
M@G/7HH\.S26^]T4U (/KFZN;T>7%\/R\,[[HCWKM]C#QPR_/C7/VP]_HAZO%
MTY+5TS+K19KBL\SHCB9JBI^ 5J'PE_ML:!B.!_H_V955E8^)OV1,'A+.R#5C
M@$4SH;8@9(?4,U6&@_QBDAJ);01XJ)Q.P1Y(+'&)>)!*;2U@$E[BT3HTAGO0
M#ZKMJ0<##N)7Q-XN/.L3C4I^0505+/B&V;6TO]---#5U5UQY[6=7'U\Z?X8:
M<5/6$&N\),%<DH?O+I,1J_ZJ<=F8M%34P%MO"PSLN?F>C3:N!Q/]U]9M"Y[O
M@.'V]GVNICK@I1O$:_5]=M/XN^=9C[;CP!T?W1"X'7/3%,!,\M/AP=JK<;=]
M?7[5O33.AQ>C]M6@<SU*-HGS7ON"-XFW,4BR(DU4_\G<TW#L"KUJ%4-4\3G0
MVQ@O641@=H%CF>!:/* ^BCD\5F?Z.I*O2P"-ZY> >Q<#_F2A,\"\VU75!PH\
M&288J:A+@VCR7]PRP!6("_AH44G=X@N"(-;O)HXO8Z%B<>!].F?7C81#[KL/
MJA]4^Q1QB& %P.1]G$E7XN3@G]@7-E?FKVG[9C0/0H77A9$ ,T4,"[<1FBF(
MG0E#1:X=DG&,1$4E'P9K\\5@J9I'LC-M3 7OG=I^L,(H0&L=?A+D-4]!;WA^
ML(ZF!#.*=P]<3 (T4\ DF1FN3<N1PJ)GB/0IRG)2P&B$C49D<^P_),;;<5O"
MY4G)L!XCWZ* C>^@M4+LM1B$.4.VEG:.T\*8G9I7AB88*Y<^!J61?FKWS9(@
M<ZGR0%3@@P9\I@9\AN\]PP&O3P\#-%/E_^QZ7,R#Z=O5<NT;9[(^P1K]#^$/
MQ1O!!G,0AHTZ.#!1#)%R\P7\K-XV$_X]'22DXAN[RZ!>\((]+U^/DN+KTYC#
M\-M@)3+9,<%K'7M#4'\CN!IX2$3'%]Y"4A4X#+G@()Z[G>*4ZPNT0-XCA;-5
MZGAHDBRO(O1$DH8)/&>3G E0B"^!:6 14XIBQ3'8P:3QD/%6:YG:P\";A%\4
M0_ZH OIBI[NWP&Q8,)F13,6^8F>57*YO>"98N6US'FPN9FW,CRFG?/*O[&#A
M!<+Y-/W1<^]_Q!-4=?M'BAP#$VX^5SWO%2&+B]ZH<]'MC(WVQ?5-K]<=#*_3
MU(%Q^_J2K=&W6:.X@&>T@C$B91/-TMTX3:A:'22/0^1)C,T-6*:%C[L.V$BH
M2A!6<J'T-NV)&!3=UK1OL_54:@):9&@63#)FIP,[XOG:_HSQA[5L!^_>)?0)
M',*3Z#(8TJ#0+&PS<4@U;7I!V.K3S&#(YH:)T'S BL',!5 0=A+H?<;J>J'Z
M*D 3K2DZU_3F\DY\64&UO$AC&1?GUU?&==?HWO2[EQ?75\.101KK\OS2,(PA
M:ZRW::R//U]^^NE:NSO_S_5M4Y75+Y@[@Q"-2K40QX);_ 5CAB)8QX=<);K$
MU[U'K? !% *:ANLWKP/0,$1,E2!BC$XN&#']<9-@4DIV>[5'7ZG)5[Z"*Q_L
M@!P & R#H7)2U(7?I?"U:Q<C83N#&H<2F-DS+_;,"Q\D1Z*6B%]WQMBX8(VY
MKFBN.Q@ZC+F.N2XWKNL7NO^6"'?D2,6K5]X<HXCF*85Y+]4/A^TJ!S%+@4Y2
M!-&*A2[IC_3^,#<CIOS<Q,A*Y=R%6;&Q8LN3:N^';;US!%2X;3$\$36+9,%M
M-'W6@*P!60.66P,:_;8^ZN46*F 5V(S8<ZYDBRLT7A..Z3P3CBGXX*-0V4P3
M=CNY[1!-<:+84F 181%A$6$1 0L/#;QNWFSS(CNNA#9'L:;:@2[L9M9>E8VX
MC\^E/N;F8JR=L'7!+["\"-,,WW+$QF[PB\G<*#\Y[R.05Q.W-/S(9R3E-&I8
M=[+N+)?NS/N4Y<W$Y1@D*UE6LJQD:Z5DC8&A#T;C\E"7M>Q&^&!_EX&W1D%?
M8VXWMW93!''%)E=C<C4F5V/RY!LQ^<JG'.13MY G#B77=)Z4_EP(6M:5X1*K
MDBT(UZ!R-6!U6)4+5YE5*\*J7.V:;UQ-H;2'3T=B7LOA1Z1F%51#:8A57YW*
M',<<QQQW*L+EX-C7*4/S1H*!)Y[NBL'-X=],CXHUA^<2"G8O"]K164.PAF -
MP1J"-01KB*9J""X?.XR%;D,1;G=\RJ%V,U>/N"Q%G3V]VV\7'GBIBPQRY"F'
MR%,CY:R C8VEC:6-I6WG(_H'GZ8V7LC>'MKN#FID/=YY8=JF/L14_Z1A?"&R
M5T"FQ.'U+[6Q.I^A8FDJ@CA^5)$ML:EB6821RL+)PLG"62Z;EF62TR@/;1HB
MIQ)L88OS*$]]PE4BWBL=X9CCF..8X\I/.,ZC?&,>92. 9CD)@#W)(WB2+"(L
M(BPB+"+-$Q%.)>-4LDH(7.U/W]D%YQ07EC:6-I8VEK:Z21MGENW(++/B\[2B
M4\MJ>PQ>7(Y*O<^[.2R2XQ;7U!P43A!CX63A9.%LE' 6&"WMURE5;'^SA&+8
MD?OA%(0=P/UPCE2KPNT:.4"7FX'$FI,U9[DT9^$&*>M/UI^L/UE_UE1_%E7Q
MQ6ISOX?/K17S9N7U-@GJ*.SIUHKX10B7++$MD]S?EDG#9C3:PK?GPH>Q:+YT
M1 CWAQZ,%/Z*'V>[VG\CWPXLV\2V"X'F16%@6U+SIAH.'U[GVD*GUS[.;'.F
M/4J0#\WU0FTF'J3FRE#S%A*[-KCWFN,%@68*WU^>P1V/PK<"S8HDOE5HCCVW
M0QCOZO*9'82>OVQIGR(__H#R28^!P0E?:D$TG=JF38 3GC:-')B+-YT&\%KA
M+K6IJA+ V5#;146KEO9Z*FHQ\08QR:P5R>:V:\^C.;S8TJ:^<$T8<O)$_.Y1
MPH!=#RX33AY#Z&^OVMXA).>EU'CS43H._C?T@?;1(LA.!5@"WDQOQ=M\&4:^
M&[2TILJ:+TW/-6W'IKXCR/=KRR1"6B6D?H2\FG+<ZBK-)WGR0';\IU8</C@1
MKK/GTC.%"3_"IK!$4;@$X</]@Y:)<BOG0(L Q_-)R0M*)S=6Y<:JR0RYL>K)
M;Z_VZ"LU>6X?F7D"MT1].>7H4[;C&#V2NYN6C3W+T4$OKZ2&HS)S^?J/YA8A
M*5U$E/DU%WXM61-2YE?FUR?YE3N1YAO&_[5UV]H54EFD893W$^G*J1U^P%#,
M*@SCOZSZ-/]Z@#)4J!S]".H-)TRE/$3JZN/\MJ!2L 2?H)=S_SV> BK-J625
MM%/ESK_?=[KZ:%B\[MH6PQ-1LT@6_, :D#4@:\"*:<!^3Q\/>ZP!CZH!*Q_H
MSI5LES/AWF/6B?8@G$AE$ @\FQ>N69K2];+4X+WO]O3.(/>(WXODLH0\E)OQ
MP39&,^1HH'>'N9WS-"4VP<+1#.'H&WJO8[!TY&"UE<B9/2:F9>&-[>J( 3;2
M.Z,.!](YC%2>7:R6<C;0^QUN2<YRQG)6F?+"N@L91P2SC[B2DQ"L1RQOB^Q@
MAD4\[*(5#GU0%UDJG]A4=U^JLHCT]&$GMT Y"P<+1YV$@_</CO.]C8-^]MPS
M2UJ1&=H*-""4O@P*,=1JZ1T9>G>0VPE4[1VD"LE?=3>T6LI91Q^,.-K'<L9R
M5JR<=?5N>\1RQ@&_5_#.;>B9?YQ-1"!1BN9X;$QY@.RU;18LM/5^+S<IX^R_
MDPM8=3>Q*LM15S?R.YRJRY;$PL'"08&),8L&AP1?PSF?0EB"0ARFY]H$U=&A
M>M_3>^W<LG#?3$(V$LLGU]7=(!LIT3TCOP#):^E7ERV9I92EM!@I+:H95P.%
M-(<HYZA&]G%%&QB6D)+':PA3''UJU%2P+OJ*0V E5#]5@P$IE6ZJ'"+-27KZ
ME87#6+>Q;F/=5EO==LQ^>V5A+&ZK5Y]67U=R*GT?6Z")+YH( AFJGFV.+2:V
M8X>VQ"YI4T>:JN$7]K4C((CI%+ZB/EP[6MWA$_ J$YYLAYN=[^A7.5]XOO"7
MFF7#HWSIFO"FB0P?I51MP.@F?**8>U'<\FO/ -'UGMJN<$U;.#!<>#*-A5Z$
M'<7B)T28C+3NIVN+R%]X@0Q:35Q]["]H'< !U,&/&ZS5HL':*)?^:L-ND[IL
ME>QV;C'V(JNF-#V<AMQA+&T:PFW%2L&2W/:&VXI5((S#_)H+OQZ,G<#9D0>B
MVFSY3D\[0Z_EZB-2M@KJH#3$JJ\>98[CG)=],!'; ;_U"-\IK:(2TBNW$Y:*
M)JYT>CV]T^8*E)/X!)7>KE@[U%\[](:&WNUPXX8C>F!U,D8N/.\/#147^6"6
M7/C2M...0ZZ%1W] J/\5!CU0RW3Y[ECO#1FVGAW2,M6MU%'0AFU]D%\0N?:"
MQG[XVB/N5ADVN-69,P&$5[D*<+5O3R+:!E_MFS<"&F$PT(?#W,HJZB)I[)NR
M=)!T]/*$-*V+=+!O]L+C,5\^2#?BMF$'9Y5W]7ZORW8A.V#EV<9J*6A%E*;5
M7=K8"UM[Q'DFPH@U"FD^?8 (J&O8IUK*;L:W&A#^[,\(WC&UI<5VY_HC1OHX
MOX[H=1$\=LI8./ 11D\?YH=_7Q?I8*?LP/W*-'W8=E21ER_AP@<9P&X4:F8$
M^Y8;.DMMU02&+<F#T5G&1H]M2/;8RK/'U5+.1KK!)V;LJ[V.>0C-.$[4+T3B
M3EO 5W!SL_;H:%BG=9$_=ME8N X2KG9NT8ZFB%:!_EZ_3C5J=UXHG%TH'VQR
M'H[QK8_[W B-G;LR[89UE+1!9ZQW.8S"[MWKV.??PHGBU'_$J1*N64C\LLH2
M]C[GS6R;+ZI9A<7]!OD0[F6"A'M5>Y!;E4SC!(G]M\,(BM7VQ_+>CMD;)B\,
MG<KEA[V6R(W _V7?L021U.;)>:>?7[DKRW>Q'FN-]O8U_+ ,X'(A(&(%4+$*
M6K%DG%4Z^C#_G,9)J57D[5?7EW#E_T"5W0O;#33/!:?%MQ]$:&-Z(>8:>I1\
MD=%R'!;G*A5V),JF\AHO;>_S= :X!7MNAG^MHGH[LC**WAD+2)^JA&]_BAA>
M$UQY]JU8.,NUV1Y(Q!?MN:41Y5)LR(<9?(,ZN;:;YV\E[^Q>"L?NV-"WS_?.
M?(YO*P::6[A-\Q(:-L6@X9 !*SI6=*SH*J_HN,GRD=OLNEK2[E#K='0-.\?I
MU)D8(5POH[CC[C^\2:"=FR&B".$EVJ,(M  F X:G[8:>YHC'EG:W]S9$?:7#
M%[S'G@+GPQS,F7#O9:#![:;G8\_ED!H?4YZTCIV0G0AIA$CI\*\ZI+%#.0]T
M36B^ H)0R$;4E3G[#(W^F/K>'"Z%1=!4 UOLP8P_P"W=_M_PS4*;.B),O^T8
M?VMIYP$]/XB<,'DXC1L',=U/'%U[E'";B4)LP1.V^"G7E?O*&/5:(PT>X.P"
MD,_U7>O$]O:U9G9PF1[M< :3!RH !1>>2RNX=?_#=CY\JV""/<6=D6-I$^S&
M+5U<.\_7@FCR7^HL[FFA-&<N*FLU*5.QY^/,-F?QK8J3B3-6S;[M^4)@'_)P
M!OQ%;:I7O!&NI*YK)%(';Q5PE?RR@'<@:3T<4WJ3[6K3*(S@B@7,V+-V] 7/
M=]&+??PYZ#^D)*S_4H>9^23>]Y%M(3. O"YQ]E,/OC>].3(123/2^.;\]B+M
MH%[L*&^E&?FJTSB^\/I+O-27WGQN!T'ADJ=C;_-'Z3CX7U_>1PY)38#J,93^
MPI>A^D)AYD2P-]T'BE)3";8$\"'^$(2)7A3W$MA3!NL,'"L[8#&1+DO"P(UL
M/W]^>ZG=>0O;U(:]MO8^L?4Z;?H%ODN_,;[] .3[,[)]&<LZ<B62>B)=.;5I
M"W&W^I+A"L!6ACN6O]0L>PKZ%%8FYK,8.YWPT;4$'WU-&PB\4&E>TE$S5!PA
M$$F-82Y<6.DY?L9K\/_4#RH90JE>.]#>S3U0*([]AW26>(&+<$NM=]KGS&7Q
MGA<KG\S, GR")1>25@<3*U"UJZ.B)8X*>$W2SAI$4]CT;1H>;/!HTL+V[LTE
M;1? =K2!9V<;*[F6=B%-$04RV3B  /B4F1V$'ER-WV[1-3/YB71L^;":O.G!
M/IZ=U<Z-S+>#-84C)N#5GN$#X4ZX=@\I5BA5B%D5$_6]0!K!MJ!4>,P^'U+M
M'N>FP*J#K)NXNO!J5(DSN''A>P^VLB9V[IBXI^WX 5X('"0"N'&R+-H.Z1CM
MEG$D.\0"90P+0R8HR@DPT='F.>ZTAD>:)DZMX-D,6^.CK]F )@9_]'7<<=#,
ML1] 1IJYPZQLP/^7;30?&X/@2LR$E6[BVQO(1O,,U&=B ?KBBST'C>L4* Y$
M+PLW(E([WZ 'G?@DNM'N'XFOE/T"UC+LO%J\A2S!I0].,?-.N[-=&Y[O?,.9
M[T7WL]/,KKL- I.WG>NNN'T2P?X+1@OML,H6*@F#C[H-Y>YM4-<Z<?<V;%^N
MLVMIOX$1Z00>Z73EC%5$H_<ZO>-PO%XZEM]&(J@3RQ]%H>.MP,^N3?%46$M8
M8/S> I_,\1;SV"$LEX[O'"FJFG#\3#R .O 4Y]-H&FD0_PHO]$GH/V)H"R-0
MGU5S'NW2LZ2*8]GP?.''*I2\XT"%PTSIXPD#QFWA1W#4,5P;'S#8*C#A/;K2
M#V;V8COHA?_G1G"+ R\(X["'TD!B[D7NGB#.5JQFI;PIWF#"@\')CT);.?FK
M$*[2:Z$'SYUB"&<54<@$1Y1_OSTRC(VN!J]"/PGK[(LV/3'4B9QB$$B-4O$?
M[E?8'L*1(04?;E746^N..D#[R%JFRFM'')O>Y-'I#<95D!! APSU:5DHLID$
M1B):^\Q;=-HI,8SBF116L78<#S1 *.)PD68"UV,[CD#QI&DB4U*,RO.!>C'W
MATMDB#BR1@EA&!=9 *^8OCW!R_'N;!0,EE$&,\_!149%O/ ".XD-QE%-.HB8
M2QDFC#*1ZDB'GA*S]?K1!XDG*O>@I7T,E>43A[*"58A?%6*M!J/C+(. C@>3
M(T!0!#)03207$E1"2*'KS/QIOG"5/4^.173-L@,3N!X%BDX)?*"XK?@:!6KJ
M89R,J$'"%D3S.5#W?REQ0_L! YB^=$1\#H/J(W(S4UX+_;TG G@1K*P5?/BF
M,$9MK_,I!D*EOY</,R]ZDIGQ<W8DKN?/A;,N(7A-^N"XD:=TG/B:[]^UW]'G
M8"',Y/,.";BSYT#CG^6C]MF;BZW4('5$JP8IHM!+OE!Y2/3-HVV%,[@::!7G
M2H#,.&(1R&^2/[8D>37N;"[I*D6BLS/A^/!T5#6F_OAOSR=A[$P%B>?TQMO?
M>G^E;Z_VZ"LU^<JC)(S>O%>OGO"FP@O#*#>J]-;VD@_EZ-.CVFHF8'BH1_X.
M]K!V3<D7.Z/BAQ*8V3,O]GP.<Z$([MPF:EZ50D=E9G2#7D#R(_!F;J5"I<ON
M9G[-A5]SP_AG?F5^/0*_]@LU"$I43G.D,I +"9XV93A/A/-"=.K<]4$IJAR.
M7C]3L_*8@:&/VN/"J5.7PI<*J:32[:G'4T!5*[DOA78J@FC%-G(<Z8-N\4UU
M2L-,K-=8KY6$%5FO%:C7^B.]<[CGQ'JMUH'F7#GK4E7%T8DY':SC>;_M^93G
MLLK3>4V<I,Z=6CJ]W.+$=9&K\HE0Z<R"1HC&^\Y8-XSMK'/N8<1RQ'+T@BW&
MT ?CW$YWZK++\*G :\VZN,;Y"(9=+1&\C:'>'7*_9HX>E6A[JZ6@=?1NF[LU
MLYRQG!5\5J(/.[D%,6HO9QPUS#[B<X(*%V@3 G&)2^ZHCB,!Z!&+A0,TH4*=
M4(11**E,=%4.5TA+BBJ+Y/LQMW[FL,GI][M*RU"GRS+$,L0R] :&*0 @N]%V
M8(F<L".IG&N%'IQS2O)Q,?]+DPU1JX8 E<N]&8[U;J^@?E(OH6UIV)'#6>4T
M35AULNHLE^K,N9*$52>K3E:=K#J;H#ISKF1AU7F@4\^]J_)FYQW8>+])X#_"
M"$2\1]->4(^3I /'"K=Q/W";_&('E-@DZ$QI/QZ[]F@[3K9YE;-,>RQHN _1
M*UT@@V9TM#D,?=;,OBF_(0P@:(1?6[>M3.>9%22AYLLP\ET"Y?QOY-N!9<='
M@-0XZD'X2UP0.NK;.NE+>@DHW-0@@G^RCXQ[!HG(LD/54D,3UG^C(%3](13V
MH2,?1(PZ*Z)PYJGN/@H9T!B/QRFR)34LP,L45J?J9>(XB LXCY%&DPY1\@N0
MS%7XF_"B;.>=N1>$6J;]SNJ5&VU;G@'M#-)F*E9"!;@Y2)M!4>LHA<R8A1O%
M%\!3707NN*]OU)I"B__^[NLH.+L78O'-1UJ\._'E*L55O(-!7SB>^<</?_W+
M=UO7_0+JW5RFUU#W-_CP64Z_?W>%XO2OWLWOO]]=O=-LZ_MW-\(,SSHW\/7@
MJG?5'UY?W%R,A_W.U>BB/30NNOU1M]]]]\.&T&0Y]1E<P5W[R%Z9>YV M8\@
M7^I'?$X"T4C?9-$Q]H,:J[7!_F?/-(FNJ5[Z%/E9)90FKE+;'F^^B,(4A98V
M#^JKA-+GV$D_H[D$T;5:L$OLZ!B4N9)ZA?G8@R>4_IS@;=>R&U:]GD!>PT<I
M]Z*G*O12W+!$8"MP[-VOVUK17&D7>O>2FK.IUG[43@KUS :,<+&#B.B5TA6J
M-5[<X9&V$3 P40\C$FX"&8]?JTUBG>+!5H<]7\+N'<B6=IOI3"G!*IC3XP6U
M[8MQ<&WW_V?O39O;-M9$X<_W_@J4ZYPJNPI2N(J2/9DJK1G?26P?2[F9W"]O
M@4!3Q#$(,%@D*[_^?9;N1H,$)4H":2X]-3.1):#1_?2SK_I2<3/8%+9$)/R\
MV7D75L2?.8L%^'1U38T1LV/<X'FME> I(^\^P\F QNPWZL[,@\#JYT+QN8("
M>^PNF-4H94^I),V/M&)5"O"N;D38S/BJ_6S.7%[#:G$?0+Y(AY4C3N.R!W2U
MC7,2PZ6%(R=\Y";-F77Z15)XA]@<.<-5D3M.X=<SFHYZS=2D5@N+54^EQ F(
MQ!&PPWH2%7IH:2R0# F"FJ;K@9YQ2_D'J6_);O/4Y=]SD 6DY7A0)12XG7MF
MS+/#=9BEP?7(87@O5=QF%+*JTG8'1).D#S7*W3**6^_TI#OH],\NSKMGYZ"T
MG5]<#<Z.SOJ7I_V3B]/.B57<7JFX??J_EY]N/G_]<Q\9K$9.Q$10@5!FJVF4
MNHG[3/?U5<')-E]?0?/UXT9ZKP^Z^]2!>\->M^W'G^6FWIC^S@/;?5PW%+4M
MQS<")3>C)>ZF(NGF=17?ZF"]Q;IEL6[I[A$VJWFYLC?O7KL!GE.\UCA%;WZX
MWK8#7&%R2._$]CBU.7.;G#-GF9IE:L_->#MJK'!S\S%IXTK4=E9G^R-)OV%8
M9YHFOLALRX&9);KNR8EM96J-<%L'7;-$Q^WV&A-*NT(<UE>P%.Y<A7&8C47@
MW"9)L!*QLY-=J3KN<=]V?[/VZP9)L)VDL\$:QN3L"I6]WJ#J'NV09+M)<B]J
M#'E64ERY*6;^QM50[J+C: !:^AJ+S#<%MZP!O+GN;\O5+%=[O6.NUYPA9+G:
M#G@N9GF@S#SNO"05_@=FY:P1H-L&Q(T!G,7$?<9$&T&42_ _\<WW(1B]H<^+
MGG%;2^=Z+$0.\LC+,BI I0J@56#JCT'('T[)&X9O&P<?BS\_2-N;+3';4O9&
M2^A2O1])F!OA0]ZF]*Y--%F/W*.^G2BS!^K^#Q=\EO]8_E/G,NO:J.8ZC;Q=
M4H,^4Z.D*,&CB'0BV^V\1!G?Y8RXH^8F5.T*'5D[U9(&D4;+#NM>GPEN,VIL
MN_+-#DKO5?'6FG-P-AX;K>-@,S41RSDMY]PLSKGF/)^-QT8[YV%WND">.M,D
M57U8L??CQ(N+D>?GW ;?3[(\D^V75;O(>P^;L/H%M3V>IB'V44U4#V5\P)MB
MYV8OPB7/3\\^_W9Y\^?_4%_M<_SYZ\=_<?-MP"(QPIZON"+VC8ZQ;S/\G(H,
MKL8?TV.!N!-1,J6>W;R=^S&U]4XRH7X!"^DMN=B\>DR]QKW8\;TII07\S2OK
M4QPZ?P *BX,@N8_Q@Y$G>U:+[UB#3%^&+84$A?+LV%[:'WOIK7PXI"^=XQP"
M."S5D2%A!H[LE^W+OV0%3EHG>"4XEQUW&Q4!][T^QP:/0]F>E)IFQP7UN,89
M#/?&-NF<<UC:*#[\HWW8<>#U"+:RVB^YJSY)Z["_GI,0LNS*M51:O0-9QHBD
M*_ODXMZ\B^?%;#=:UO;\:AX=X3-]%QDI=N,/@8,^[&<;^;++L3F88"B<@F8$
MI,RML?F$'/5"3<A)=.AA0]P'GH8=X*B9*8JG&%?"^18RLXS%2WV$0O4A]WR<
MAN'%-(3G/(E)@R.Y4\E6 \Y_2LW*]XKJ:,93$A^0$(>5#;4DK.]4/:J4;RN@
MJ1,X<N-'+UDZ-;O(\:RC63W)([)RIJ ,3#Q?%*3JPWJW.%$(OT*]Y:6NI$7]
M?;75B?Y^;6__IQK0+VXN7]N$_@63@[J=R];%<;]_?'K2NNB>]D\[W0XUH!]<
MM:\NSR]L WHS__0EDX.62>S:4=;\AZ#Y*L)4KWE81I2 IHN$QNIS2O.[>!P*
M=6BGUVA2BYX#5-&VRP5YL@W^+<N!C+T4C6IXB.<-N7*.#1DLW]4$&;!]@)+I
M,3U)Q@-NDV8()%?^E!2YGEH$&_%B+WKXFV?"E)^/T';)G+\*+X5]1@_$2DBC
M=U"C-YZL##P#L^.!AN^P+4)C:Z3PDO-RT!K*7$>-L!@#F_'TEL.L^C)/XY,+
MU(/RAD9NE-M1!A';5SRH1X](@8_563Q/";EK-7J)-O593^+8RUE^GQ&G2KR@
M6P-TK"*2&FNDS4:4/Q*GE)I>SFK([T4$$HET%JG.* 3' 5>P'C,H8Q*>_^!'
MPB6LA/ME5>;!-/75/"?$RR*C*2V9B")381J*AX2M>9[1:&X#$1'>;$@MVD<\
M^4.P9H+#TQ:X6)1+P8=K),!E2L75$W3P@M5CI8/G*?<-CGS$(48XJ0@IO(@C
MY"AUCR*"#7F6$2EB.#[2?=2?5+/KY9Q*R(QP5XL\.\X0.+.:1+:<1^G0^8RC
MG!+$M2=.!Q1%$X?N<<#<;6@XF#Q#.US,2Y^PPAY1\YZ8,Y3EQ%K/M3UR]@"T
ME*<LSG[S\ +RAPO8R0TR_N>I@2=71[WVU46W!3K?X.+T].1<SB'JGERTCT[7
MI@9N(0&/O#"5>@XJ-%XV=E"$PV]($B(^AN7UX=POO[PV-$+HWMCUYV62W6=/
M#N9I] Q+QO%><8-V ) = +3@]>V>X+-5A]_ZHM*-F;9B!P#9 4 ;AI)V%(L=
M /2BC Z+=:O$.CL J-ED+;9T*6F#Y@K3Q/(D=:+G=99?7_GBQJ1U;5-MX_;E
M$ X&;KO?7SGL-@:;;'KU9DIFR]@L8VL2:KU6S^T>6<:V*07?NZC*>:,<\P&4
M-I>/ 4%NQ\X($W H3?$EELF3/>5_K(MFM86P7;?3H#+R!*1VA3HWCQ W3KNP
MU 5+]/ON4:MMJ<M6HMM*],W4X6P]Y0\U&7HMM]=N_7C@;@P^6F?)9JHSEG=:
MWKEAO+-_XIX<-=;&R/+.9772Q=7H3^=OOC0WT\SQ_,U+OPG:P[7P\?E09)P2
MNDP&YU6_WST:=#IGEYV+;O_\ZN2T-U"%/(/C;M=F<#Z:@CWV[K#6)(.M42JO
M1RGP9=9F&#L3?3_PX!"^KF\)TS:].R^,\(\'HR0]R+Q(5$O@7<J8KJS)11=8
M=88?S)TRD=1U[L-\[!0QUW%@!9P7QIQ+&B59)C*JUDAES9GG^\6DX!SDA#+Q
M,=\^%6,19^A!PU<.G2M*[==[IH1OG8>MTE#=:E'[S.-A5A;,4,G-5/C8=!_0
M$$ZDV^_KLIFO"[>O%D XR7H>$RQF1=U'#-?#7^EU/A[\.9D E+#4Y>55*7M9
M+HOE!JH,A#LLF+#GDD:L7:(,?%F+1.G\!3WJJ!++1,-1XKF7,Q+14W4UMD D
MO^H"$?.CMDKDZ6L[C:@21!6?F;1B%):9!4<AP#),J00B%7>AN*<J-EWD!;=F
M/L(M+[CQA@?\S4?@.2'?3#7#W8N-+3A# >H\%:"9Q6F9\^\BN-6EV$2U!X@/
M</L3X'@>]N= N96DF2Y_87)7!7^(!; =HG>/V 8NJU]7+(++"45\"_P22S-
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M-Z1)9/#!S.K\X( 0$'<JCU)F7&KWG=PA\UU<VI# \I-R^(&,6$2)KP)$,A'
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M8?*H2(D*B&\=EJYPQ5WUY[@]7U(,\U$1E;OEU!C= %2K0[HO*>::RC$^NJZ
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MAS^BL24I4<I,.,;].(G(9 GY;DEFLPI.^&':3JERNDG!+?4DT!FUEE[DQ./
M$D0["G8.^M]D=B47-FCN$+&3&0Q^E\Z"H@G$)]D212QA#OQHEM.8.C)*%]0
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M@9B+&E,1H"($V',? W 3.45DX2T_CE3P^8P6H"_0%"O?FQ(0_A;S+RF:IM'
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M_Y:O6;[6*%_KNH/N?!,<R]=V=Z#6NL:<>$/4L)/TX47Y@_H,NSQ'J.^>].W
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MX8VH:R*$,B[*D3?U>!?/'=53*D )#*"PH/)2S:9).03V4Z2I)$K)B]2C698
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MC2M</Q-1!' R.+O:JSH)R0Z042*R-/$<FK@  8URE(N?2E5VSV"HZ *4%;_
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M9W@V$^=^C!8>*O:B^><&MB*/*X59.!8\$-A>!%4T'],H*Y."/9P(<*5G?J@
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M_9APH,NFZP_5AV]9XQ+]?"\09V,AX=:T&C\\9_+G%=$F<OUSHJ\ 56-V@1<
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MX>M#"67BP*=I+ )*#:A0:D!7269 QZ[3^;!F/Z?#\3*8F?/E=NALG,[&R\S
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M*8Y8Q?_L.[S-##WE)\O%$W)!+I@JD;0U/J*5106L.M#_J%6O$W"M?4$"49Q
M;*WMRDE/M5UJ=XL*;D^0A$!,?G0FUZQ*M^)\3(6XIRO$G6&(/B<31XJH#_H7
M7WZ[NOOS_PX6]0/,//W3[X]V/K$K(U:IEL.VF@:L3=GAA/;<1(>O>NIH C8"
M-J6UM[;1[%*1&N$:X1KA6H5PK8C1$MISE#[E$AH&U-7ZI.B1?OWTC[=$5[:6
M*A48)=2E5,EJ@1MUM,&859$]BEV2=.TV<];H]IHD721=)%T%Q ";AMDBW74,
MNW%'3_EY)F:9+<I-R;3*/#\JRC@6):M6E&$W>\59['6LRJ @84%!0@(Y KDW
M4LZT6X;=.>+ 1AVXBD".0(Y KCX@5Z3[6D>,4UM>J[;R=4MY[?<$^#3UXC'.
ML?@RO!3WR5[%LAWSZLHT&RW;O+[H6(-!OW71D+-G^X..W>DWJ%AV>QUJG\7I
M9,*C)QP[ZX=QS,* B94=P6]<V!,Y?!:'N,*6@/3%.(\6.[Q&PA63Z6QT+5X
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M5\8\-,6(IA@="&5@I1\Q+507WB('6-_P-Z$:H=KA@;EF07.'ZXIJ98]</,?
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MX.0#U(5+ON0S):FLVV3MA([",21"%- D"2()TM VK)TL44!S-]MP./1\3PX
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M.DW&8,4N&<APO9. ?8:<#(:^N^19R!8*@+K+7TW3:!IBY2N8A3/PG6W9T O
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MV29C/H',-0*S(\J22?JOI2G(4UG)8UD&E">50K"<;K*20UNTW7:\ \QX]KK
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M&@]>G&;!J2 KC1=YT]"DEM'L= LGG3;,1&.3]-2XA&N$:RJIMM2*DL"-P(W
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M@*VJJ039$HJF0([K=,3(26IUPFJ=J%['5.S$->_<(<'I#OX\?YY1KFB?>X,
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MLCJ;[]</_7R EE'NA$[)+W_Y?U!+ P04    " "5@5I,=+]]@IPJ   &QP$
M%0   &5X96PM,C Q-S$R,CE?8V%L+GAM;.U]6W,;.9+N^_X*G]YGC'&_;.S,
MAGSK<)SNEM=VG]Y]JL!5JFV*U!9)VYI??Q(4=:?((JL*17MF)L)M2T!6(O$A
M+T B\>__\>UB\N)+;.;U;/K7G\A?\$\OXM3/0CT]^^M/OW]")Y]>OW__TW_\
M[5_^_?\@]%^O/O[RXLW,+R_B=/'B=1/M(H877^O%^8L_0IS_^2(ULXL7?\R:
M/^LO%J'K3B]6?YG4TS__+?_A[#R^^#:O_VWNS^.%_67F[6+U[?/%XO+?7K[\
M^O7K7[ZY9O*767/VDF+,7M[V>K9%_A>Z:8;RCQ"AB)&_?)N'GU[ "*?SU;=;
M?.2F^;<G[;^R56MBC'FY^NUMTWF]J2&0)2__Z]=?/JW&B>KI?&&G/O[TMW]Y
M\>):',UL$C_&]"+_]_>/[Q\0B=_BI/Y6S__B9Q<O<X.7KV>3B76S9B6ND[,F
MQCP+<^!B1>R\B>FO/^5N( "B"*4F#_]?=W1;7%W&O_XTKR\N)S#VESTS]^#'
M'^.7.%W&S_;/&.R;N+#UY%#N6],M/[SYSW$*OXO^O/\A/DM[C&'._QQB@$^H
MCC"T]Y?S.!U@<)OH#CN\6[P\^/UOMLE_^1*[C7$_XL,.="7:(0;9GO"P SQ=
MG,?FP>_FW0:VF^"P _ILW20>ROS#SD,SFNW*$-C:@W)O0[RXJ!<M_88G3?MG
M8G]![NS:/Y/9@0O+23Q-)V<P=V?@]+Y;+I9-_+6>UA?+BU\B^(T?[-6J\?X#
MZ4)^R,%^A'^^_789I_-X,@V?EK#B@)'W$!Q<'#!=!]'M?WAMM<XS'7ID:#;]
MM)CY/T$$?V0DMUR1S_<:E+5#UFE[*KVQ/IW/)G7(0>DK.\G!UJ?S&-L(=D?'
MH1G\8!O VGE<U-Y.#N9V(Y4!6/^T@#^O?8CTVL[/WTUF7_>2\58"0S,\N[AL
MXCEH'\#AM=+Y938_G/WMY,89S,%P.I3VP,,\O8QK#_70P3RE,##+*]5W/IN$
MV,S?_N^R7ER]B:GV]>+0$>PDV-. WD2WD\?[;7K\+'S#_#9;Q+8^U+8^/;)U
MY[GD?^W!V]:.?3(8/7B+ 9#S)3:+&OR5?:78CD*?+"\O+FQS=9JR2CF=OOVV
MJ*=GRWI^GM&^OZ#WIM;C4-IYE$];]LE";"Y^F=DI! GY$WM(;GO/OEA<'QB
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MKPRQW#2&M[:9@G3F]T;VZ!7PC;>6=W6NL!3>P;++ K;(>XC<A<K)("G:I'C
MF)## 5?F3.8( #>(I$MA[%Y0TRY*KH)V3E.24"!"(!-X#G681HI)<  2]Z#1
MC]VK&C24ZR:L$29^=_+>T\95$I%R"<HR:@S#P^#_>1WS;0@CK:4A<=<ABZ!X
M1+_?3#T_XX>+IZ"#DQ_/F*\??]\]^9L[5,HJZ@383<6$1\0&CEQ@,%;C?*)!
M6BH[W"LJ#H"#)NZIZ]&/I IBH5G>%12^>8>U%2:V=*R\2BHZ29%/%J-$!'Q9
MVH@\Q(J&1&;T=V4C>L)&OQ([N#+*FI/7T+(& ;<R!.TZ5BPHR[GVR'(6D(A!
M(HZC6%?K$%)$?O11<T_S/IC$.L_[_5H3-QQ=M9SZ;7TK3B5EE%I$N3;(<4)0
M=&!"K\=B*=C1#OMM90+8(6:_9Z$5VWI=/Q?Q,:;EW;/M6Y#2KF.E&+<A\  1
MEB1("8Z1(CZG(Q"6='0<ZP[5,LN$G3T;A]XE5FY[?OHE0I@-WLZ;Z!8ML+&Q
M0Y7MF](095%+P?P);%"4BB+)</:^ XVTPU9$F5R]OC'1EZ1*8>&WV2*VCRHV
MM*Z(-C%PR9&FTB A,4,.O"(D0C21>$8P[> ^E"F8UC,*^A%3L52NO.&Z-GM[
M;3!L[UB!R##&($&5",A-&]""E',4;#)),B:"ZW ;4'^/P.A=8J4P\J@FY&YL
M;.Y0&9VX O.':" &&1,4DKGH"U-)2^\#X;'#Y2GS/6*B-TD5U1?WA)!WY]OI
MBHV=JD09-P:B*1'SC743, J"120\YYPR;U276\/%]QTZ;4KV*J:1E$,K/#S;
MIR(DFEQU' G%%$H</&AIB81UH)WD#L)C??2EC_J"0Y]2*IG\LT[E/9F&7(JV
MGI[%J=]^6+6E5X6%CIA$CIRQ!$'D'1$U22#BA%?&)6Q$A_)$Q1'1_^%5O\(K
MMH\]G\>-U9L?-JB\Q"*7#492:@'N,S= 4<!8O%") >BM:54P:,A1M-A\O]^N
MTI8K+*5#3%*-M X$<0-3'@,V-GJODN]03;#,.<PAT_-X?[VC4,J5,)J?YY4%
M_\G+]8N=K-;:XK5MFBM8:SNS'-OTK[ *E@3'$558([#J$G$J,"(I!&&$)%IT
MJ(Q5$A0'S>B3LD3#R*P49CZ=SYK%Y]A<O)]^B?.'Y9HWY>QO:%X% >P[JY$7
M'H/_KR4*U%CXE,:!.BP3[F#YRKC&_2&B)Q&5RP3S$6";;S/]%EOLLFYLGX\:
M2'22(8M31,I%DF]J411\$I+SE+#H<#Y3QOGI#P)]R:@4!C)2IS 95]MO!]]O
M5JEH'><^(1+!8_.66E!I."&((903C+/D.UR[*7,BU]^,=Q1-P9LRE[8.=]?6
MK[?Z6CJ'+7I7E!H>):!:.>L09S&@@*E'+B3%G$X6C-VQG\#U!XMA)%;.-,P7
M3>T7,:R]G'L6K8VAV-F[4IQ2IKU$QCB!HM<):4)@I7#L#02 Q*@.F7YESN;Z
M-!M#2*Q8UN=L>M;>D=S0&F(T\(EYSF(66B,EE41.2@C9-,8T.&9"Z'!&5]*/
M[!1N]B.:8U 2K?98VQ&H6/24&$V1, 2C8'-"/8\*<<F52'FC,7TG'F8G< PF
MK7(NR.PR-HNK#Q,[70#_.6I>O="UW??<UJTBAG/+-,FG#!'YR#PRA.1[%OD(
MRDM8'AT41TE?M!,V>I91*43D)SV_UI-M5REOFE2&60EJ,"*JB$4B@J'57C,D
M;$@F&4Y(EV*J)=W+3C/=01YE\S560VU_]/JX?64<5<DZ@P(W"DFJP$/VR2'I
MA!:48F=4AXN+)1W$3O/=EW"*U,AYIH3+!YN9/H^+G*[\D*WABLA\6L"?UV\"
MIFPPWTUF7\=\?&W39O&'V-0SL..^R160WL3K_^Z]3[^93!4"C:#:)2(X 5*4
MMLA9S9$CFDI H;"ZU3[-0(E]<9&' 9;K2PUS\.KJ]WD,N0+E%(!33\]._*+^
MLNL*87LB58B.&R<U\IAA\*,I1Q8L'XJ68>*M%<%U*-Q8ZAFVH:;_<8+@D'(M
MZ&_Z&,/\'<CQ_7R^S H)=,%=X8GM3N?VOE5P+HA@<F*]T"A9\*^H$@P%",@2
MM\%RWV&[JPR>AIKFI]YI[\(< T0K7D\OLV#G;[_%QM?S&%J":&/?*F >$N,<
M<14LPI12I'+BE#%.!<5,"O+H4\M& %%?PAP-1#E.VV;7-G>H$E.,A+PXN+5(
M\=4^(RP3QAW'X/A''CK I<Q.R%AP.52"Y7;3+M=ED4_3S3Y@OJ*Q=?]L<Y>*
M.D53% DQCR,*(F*DH_#(!DPT@;_JV.$RU+U=D2&+D18"2H]"//@2Y4U![#1K
MKB_HS$$\L_3HLLX&).S1NS+)P7 X1EYK\ <)2,I13A#(E@7IM:)=4KK$#P&*
M8>59S-RL!_ QKNK%?)Y]MM_^J!?G.:$39/1NUGPZAY#\%40)(1<RBM/Y2O;;
M#-*!)"L9I$H2C'(D!B-8/Q$9S@V*&%NJ;%!*]7,'[SM&W0A"+G9];[/DKH\N
M.D;Y&XA4"C-B<HY55"X@16!E:ATHQ!66RN0,8^+H'>JQH_Q^Y%I:V7V>G7B0
M5A.?/0MIH=YV$ZE2C(0Z(I!TG")8WP+12!-*"1:\,YJU? IA9]P_@D+K////
M*+1!Q#I*\&;S^Q\'(:P]E2JI&"3!$FE)P7($)Q!+@2"I5%12$ NZ_MB56"F$
M#2K6L2 &;/]J%\NF7ER=IM4)4+O4FKWH5!'<!JYES)525P&Q1EQJA:CED1$7
MM-$=TOE'W4T8&F9]"[9<NN]#]^']=%M6R=:$X'T(59C$H P%B9L4D"401G./
M#6CW%)UTR4?1(?8<=T.B;ZP-+MK1/+.[<;149ZT(5-%8*S&X#C0)#(O,"@3K
M#*(?;STQ@4KF^BG]\P. :S"1CN>-G7RQ]23?N,CQ,?SD4_19,6\/*?<A4P4&
M*MM:AX2+&B5I.9(R&L1)$B)BS8SO<..[3"K*:/Y8KW(= V5K0P\,KW+ZKVZO
M,=O)9-X#_ ZF7SENO+(0)%$#LP7!/GBURCOD/-;4>ARU[I B5::RT0BX+"GP
MT6SM\Z/8<:BT)Z6*"&:XSC4>F':(".OS89I!S&N-<T$ITZ6\EOZQK6_OLAUY
M7_?VF;\N^[H;B%2<<T?R"T*)*PL.;F0(>VN18+G$+;=.=[ES6"96'7M?MQ^Y
M%D38W;L:VT%TUZZ2G#CBP:6PU#%$(X8@G,$2)5R(E%C20G^O65F=I^\I2CH)
MKESUILLF^GHE.?C[)*XF91I.+O)3''_?=7+9IGO%E,.>D8!$ $6+A5(HI& 0
M!#[2*M#I$/U\ISNN?<-F('F6JWJQY\GW,T>ND<7HDU;(48,1%U(A;86!4 9;
M':GR6AQ]4?)"B.E-@L6N)=EZ.L]:,<Y/IV^_95$LZ_EY=MU.TP[W>6??BH%5
M%P8S^*HB*$CFD95:@RBILQ@[37 _+W*-X##W#9TAI%D*1?<5XFFZS15Y/9NO
MHLTW]?SZ78\M8&I+(N_741\203)QB$>P=$@Y(1"$(Q0[GZQ6'2XWE+D<5PA2
M \JT7+"?7SW\OW4^"-CYUO+3QI7E2@0+'AYC02*&F4!&<0$F6A "XPP@Q>]T
M/[-OM/0BO9)V*RO+T^GUUNL>)\>[NE8A*16#92!$RW-MT/R@'>-(<L%,R+7C
M18<]</7#6:V>A5D*0N]LW:P*UYV$_UE>LWN:_K!-8[?C9VN_RF+FF<<!44%S
M>4_GD?*)(9=HH)8'IW"'N]ME*JT7PD[?@BQZZ3O?4 8976\KK$L?;0'-LWT@
M?B0P&A81X3J7RF,))2$D<LQ;J8PBK%U)U9UEV'\ ;=.G%,?+0[EYY>ZF4M:]
M0GI[I:%LH5-1G$@,8*]E-M_"K6I@8 @8HJ+Y2H;GMDM16_Q#P6IHT8X'M9N*
M?=L/)[;VJUQBR2B*D;.2(15]0(+:B*(2W$JPY9WJSI!QTX"'AU(W48X'G755
MOYNR]QNK^^V%J38$*Y^?57"!(A 00YY&CP@$H2@REV*(WGG3I70!_<'!-I",
MQT/AK<6_K@9S .PV4JB,QX1[#4LO2=#D6$!0R_*3+A%S310+O,M=+<)^<)SU
M)=3QG;#UTV '.5[KOI753J8('@'7V" 70@+=GB0PP4&M>VV([)"52<J49AO=
MUSI<FN.AZ.8UXO4UQGLOB^P%J.?)5"37O>3Y[6NB%2AK;Y&QX')*(O+I$7=!
M==A/(#_4?O? @CWXSOMCOIY_U7@#:O:D4#F7GS0"<PZB,F#3?2ZB2LWZ/5Q#
ME+)=7J[X(;:\AY=I;UBIIUM?06X+F!UD*L^E341R)%FB*&7OT*F4UB.4.FG5
M(2N$C)I@.RAJ^A?L>-;LT1-G>YFP1WTK0YA1DFLDM F(.<$05UXC(F$)8>.5
M3ATN=I(?:B-\"&F.'++=BNA0E^A9*I6".-4IRB%H30;E4O,09>2"H#@Q#A8\
MDBY/T)$R#Y>.&[GU)-<[C!4IM/J@S.GLXK*)YW$ZK[_$I\FSY8N>/N4'IO@T
M?;;?ML!^2Z^*&X-)+F]"B<3(1C <6EB8>XVC]MQ+'UKMA/TS9;GGU/:^YNP[
MS5%>*9!GEM^-(#[DO".8F\6BJ=URD</ZS[/KTLB[SD@/IUPI&LBJE&:DPB,?
M/$9:.XF,#DZ#MZ52E\BG4$&<@=!57K;'9QQ&K\V]-KNSZ7AV:ER]/9@+NF8T
M7WF\?G)W"<[-G;A?Q31KUD@ H,?YK_5TEBM:W&2ZK0H-W*=R_1+PKW%Q/FM?
M)J(4%Q6.CBNB&4J"Y'1@'I"/P:(8*2<TF!ACA[SJ8E=_#D784R?WB"5?S"[?
M^/2MUO>&UI71AD=M!%(2_N"86F02SO8E2.P4RP^U'3NJCA8+C^UQ+_(OA:WU
M-L0V0-TTJ1A+2CHI@(9/R$7,80#Y&1!A(8X4G,O0Y3"L"(HZS\Z3PKL'"Z?8
M93$[B?,UG_GAG?GVEZHV-:\8T3ZZZ!%U&$1$74+6:(TP=30:XZ-/73*%BDS]
M85/U^!I8/](I-?=933;6+^:[-WX?-ZV2=LXD!LM"^%S=!,3$M ?#+9/B7L#_
MN]3?+A-T]3+G/4BFN*NPS@]JY2C<M*THLYQ3[9$5$<R>,QXEGW',;10N4F5=
M/Q>(A\R<Z5O#]R&F<LM]#@'_2B]]FDVVO>KQJ"6,R4OME$>:)(>\LQ0133AR
M,!AN# FBRZ,,A6W[83/U9-5WE5 Y'VX>X5NY+,<;T%"3V:I2Z.Z;"UO[5: 9
M<PUNBAP'']@9)9#)M3N\$I@%RHWT'?(URZC_?A'1M[R*.8!Q C3/?HY3D,8D
M5SD(%_6TGB^R;+ZTN.+2CD!%C0V<)HXH&$%D<+2(<T-1"DX)%:0$(1R.F#+5
M!/I%S&""*ZA:%LW2YU)CT[/7Y[8YVQ$J/FU>*2T,3S(B[(E%02:)I*44>2.<
M<DE(S3N\?%PFA;)W1=*'F$J!X+?9=/;0J=JM,I[M4QD'SIAU#KFD!:*:8&2"
M"3!.:HW#,-#4X:2PC%WY7O:B^IR%TG<P]X;<]HY@G[%GCB:D<LUTA6&M2NT]
M(B%H1BSU-'2Y-U=F9[V?^7SF[F5O@BN7H72]EG9CXU'+2H%6-<8Z1*U2^94]
M#WX:Q3F5+_J4I)5=WK\H=1=I$#1T%U7IZ;\>^PK%+2!PKW6URO 5DB.3I$%.
M \BQR(]V.$:]-RJ_W'GL'NNP*.@FK8*IBM=V=CWT5^!PIWK;+O<S/< +<RIH
MD<\HI40I2A"7(PDE:[VPF!.G.L0PY2XI]GH VX>81DP:6;V<F9\?B\W\VLMZ
M X/P=_@8(E/D?H6UH>C#:C"_S1:YSN["UI/G<D]Z^]XG?Q[#,A>#R?\J]=%<
M33@GX=\^7%ATR'G)-5?Y5<WY,]7;"G'R^4$9B<&^$IN+7V9VNKZR5V)L,[_,
MPLRO'$$<E2,D")VN]=R0W[VM4?-KM'- V(,LH&(?_"T7Q<E[004DO9&!NS7]
M=KZH+[+NO&UWFDZ7B_G"3O/#C86@OH/)>[RMJ][9R?4=Y77[<#K]F#5&WEIY
M9>=U"46QD>?AU^N]W85"G\GIE[/IM55]QC78+NY_1%=PH*.^Z_OY^P]W>\<J
M4(CW97X0&(/+R)S"*(\4$2:#L=S:H+Z35+&.,_KX.+!OL14[$[YF_%T,^0SB
M *0\U[-BTEE*F468RYPO[B2B@1&4*&?<4)YO&QT[5/J<ULV(Z5%\A2&SBJ'
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MBZ$@^H!V%8UT,:6 M'4*29IT?M[8(9\LL<'[(/71O])ZK CM*NGQ$7H0]*K
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M'A&HA/6$VSBK6UXB&_[Z1AT"=>G4O4/@./S_  X!I0DA07IB=# [>5CW":L
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MI4P0R%ZK]]<S$=I04-$'6 T($+$<3540[VH=WE\F-!Y2^_YV&38$$("\E=I
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M:ZP#&R:Q'4M1=!"N;E:+):2AN22([D]*3>\QD\X*8IF&G!JHG!  L%)FY>0
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M+ZGWFCDM2IF9 NDU'KK+).N&.FU#=>(9:;, _YI_6_\J8>IYUD%F%-,&$@V
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M1H@&8;F2"D#,12FU0#)]+]!=CM4@)JH4](8P+R52YJ%M!CCPDC(JN>+"$.V
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M,3^\V S3V]&.$@YHM!%"YZ#;07DPAJ32EE1IBM678E8.XU#FP,MG,VZ(=]9
MJRQP'"LNB2C'R8%L4">D;;.V+<"+=B%I&I8WF?WG9'953X-[FF0$$*D1IYS9
M8'=;!*@AY:@U!NF!EZWO3[I09'O(G,J'G')\!(--J8D4T@$K'#6<"UQ*YL/^
MJT>=]VXDM0C,N1T;4$$<P&%7K853AANJ? 45]8(.TZ!J1V'US@_2$'IK/!B4
M\34D]9_S\9%!F$O)E&2  D&=%]A6LDES/L='M954Z_CH.%C.I88#!AS8  S
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MG@&=GD_1_29F,%QK#&M?*];+@3Z792/RN]FFM-6>->W8KC(?H B+0ICAO7%
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MQL+@].R=S@R%H3.Z3;R'S^?RNRTE[6.6/O#.3 L#G/>>&08\7^>3LQ)C+?0
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MIGQ[6RR_;(KI'^>N(J_"%&?E]"HF=W]-%]LP 1_VV#.\W62UG"^_58M\WZ#
M?%^?R%0L  MY3!2QF @#!"</O;>E"@<R:G(B#8/BD[H"W19[0H'Z'CZ4,4B%
M1=XJA2$G@%ND<(DHL!VL9#U7L1^?A0X7N!\?]Z1]NUT3UH604EM-E!4(4@ "
M+*:"0I@QDV':5L$?E2/J$]Y/0_02DYR%4)AI0!SAF#HA.*056)PRGK8?N O)
MFF8[MT/H&GDA24]O"BS04ZSG[L2+YK^@AZPV\W"6?0B"[]IN\__8+O/PO*C)
M=&\X/J-(:JX,(0([IP6R&*MR/=ZP!"L&=R=-,3Q0'8)\JXE\R9?SH"=OOP9$
MY\MH/RFGIK;?MNL-I&&X)(@>9X7V;\PX$U1)CJ1E-B ++-257.<$;<\<@[E[
M^V6.T: ;S9K53:C2]V^_H$8^'?"K,?8>AA->:6.EH@A;)RN<"8/M?8T#E6M(
M3-!-AS3GW0*-I*6ZH9FDD'),B(<&0F>$CAT2]BN6GM"T)>@D>*$1?W:&_._
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M#ZR&J%RY@0ZF;97MF[PG<4\G!/]./)2DL?426*<OMWD0[[_E7R?3/Z)*_2E
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ME6O@0"7H*1R,U+VC-=:%_#Z?K//OQ6+V[O9N5?S8J:SU/N0CHS+L*=?"&P$
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M7=KJ>CO"'*!N)T0NG<Y)ZK;G(&]?7O[O\4R:QW:EF[#J2?2"_\A7\9+1^3(
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MH6OTTIT;_^1Y>I]X6"G VZ_KZ6J^6_SG@8)_:CZ9><6\4]Y!#1D"1&K&*X6
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M 0NE0<A8@BO: DS&+.DSGJFSM7*<-'%J;9W[7\<_OH89_I__]?\!4$L#!!0
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MET"=0KJ:AD*]_'.9RK'9Y*SGY]+#>*H6H/<&G"B--A_UNWK%+4>K", T!""
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M!"D-Q+40@['05=KNIVG"LIQ]VI>;W]Y<"UAB/7O I:9DNO1)K@'99TYQ]4<
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M\W%!@4:0MPRM&>- ::PAJ8\E18WWOA [?M_?-'?HO"V^9MWBPBKBXU:&8)(
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MS^7G]?>_Y_LO7\K=-B]NQ;F@+^LJ0[P7;O') Z4KDL8$< #8IZ[K13!,F3O
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MC\9\VP$BWX<)A 0G<4 PP31UTV$5B*%(]1&3Z1&J;P90?O#DS%: K/V5ZCZ
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M_(DWCDL1=VFWN%GFEZ&IIIUZNB_<!F>R"DBRZ_W;@@\8#J)R:)?O$?1#%**
M"VS"& E#C[J(I<Q-$^0%8:Q2@>M\?\)M7.^&@S,"J'-$JKDA2XM..5&SS:3^
M9J@1)%I1L1>8NB!98WA=ACZ-\J TU\KDE"?[SAM[OT&V&[%\YG^S69MG."(
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MAK[(RH7"<QR+RR@U1_I0FFQ7"N7DT5!_BW'_[[=%)VDLK[G4_6>VKE8A"T-
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M&!5W[QRJ?/\PVX,[BBQ?D$A;\5J&:EKSKIRFU5O1UGZ_0Y+$7L!1)"QAA$:
MNC[N08@3^Q:D5=:T967EO2JQHJ;2U!H54QNL6M727\3C@I^_9;NO_"?*8O]E
MXET.:KR.5T_5 /U0XJGLG)YVZG%H6#K?%I^_E:($J,7\L;#(@00D]C$@+&*#
MA .B]&21>>OV!32U(J J!!O54$O<6I+1*Z&C8NL*!]V4I,L4T".IXS54(T _
ME(SJ^*>GI-I,FA=3WB:S%DD2!3"%%"8X#"(_!A $T2#K\/_C[MV:&]>1+M&_
M@I<39W>$=P]X!7G> (+LJ1EWV:?L_75\L1\4M$3;[)9)-RE5E?O7#\";Y(MD
M  1(UG1$Q_:ME"M7@BL3%R8L$\6HE'WC@FI#4X(J0;)N237#KW%1Y;"7+:L#
ML5J$53Y,OYJT*GBH+*ZJ;&J7UX0]$BT00F$4N[[E\66&P+%\QSFL-R#L&U%7
M<?/FQ=4R)*X2%&O65C/LFI96CGK1RCK0JD-8Y6/TB^FJ@H.JLJK*I7Y5S;]W
M\NYZ;D)18KF8!!@1.[;]82D"^K[4P54#YLVKJFU*5<4IUJVJ1M@UKJJ\5<NB
M5;6G58NJ2L?H5U-5>0>555612\VJ>ON855EZSU1HQ?L\PM!S[3@*(Q=""R*O
MQV&'D8D-?PGKAC7U@,2(LLK0K%58#3%L5%<%8C&GJ![@C==4A?#\4I*JXI^:
MHBHSJ5E05Q[Q0V394>Q#CR0$Q2X<3F]%.(ED.N/KLBDEGO(M\[NG^:E[FMMW
M"9Z'9[J<XCC5Y[QKU56ME!O<\E^D@H[736'Z?RFU%/=*32,E65,Y __Y"2R$
M(DPB)_!HZ"([2.PP)#V&V$%"[6S-6#9]JO3-*U?EW39_:-YKD51$S7R+Z>)\
M5,NIXZL#]+_4T5(IAL](J)E(+4-(#?EVYG2^;@:UBFI_-,N-/.(Y+HH0]BT:
M.XF+>P@6H41JETFKX<4=)]5+JT;I-,&H0>6<^R"I#*=CM5(V-+^05$J[IJ*4
M:OQI%<JCDU<!#FW;"=PXLGT<!PE,B-VCB!-'OU9*V%[<X5'MY&I43$.\&A/-
M&4^-2O(Y5C 5(O,+:::*=RJRJ<RB;N4\'*MR?0@M:I$PLE# ;S*V$[?'@2&4
M.BNJW_KB3HH:(%BO?IKAUJR"SG5$5)I3#2HJ'Y]?2T<5_%-44E4F-6OIX2Q5
M;!,7!H%KVZ[O4YM@9/<O %B0%<8&I%3<^.*.A>JG5ZN0FF'6J([.=1Y4EM'Q
M*BH?G%]*1!7<4]-051YU2^AP<(HBFO@!#" AH>N3(+"M XS8R$Q>W/CBSH#J
MIU>OA!IAUJR$SG3X4Y91#1(J'9Q?2T+EW5.44$4>M4KHT4FI*(P"'#NQ9T%D
MAS[D1U%[% @&4D<^==M>Z(%/[11K5%%#[)H3T;E.>DJR.59 %>+R"^FGBG<J
M\JG,HE;U7.$8VXC$D/'I^I%O!XEE#>L'OA?*G._48W'>TYWK[GE7.=NIB7&-
M$JJ5;&/"N4"U'*N1PL3_0LHH[I.*'DHR)JJ"_TCYK:R[&A>;;_G#XZ[^6NXR
MFM?K;5DS',.Q)\?S44SLV(NH8Q$WI!1:)$Y"[/N());H"ILN<^:>RQYATT6\
MQ0@X2'! .=N904'VSCR<NOE?QN.IW:O2[*B5+%2V:5U?W7<@KJH&0GNY!@S\
MQ W#($:Q%R86M'R'] :I)==:<H09PY.W!AF_9J;#Q@94^V2JW> SAD_!VF,:
M*B4+#F46S909)SDZ5UN,)W89BJ7#D;=5A"YNA.\<RXJ\K&[V=XRMO$AWV8;+
M8MU=P, _.?#\B'BQQ?X#;2NV>YO(<ERIV\9&63*L3BTX4!^A P6')WG=BR9:
MQ11J.D;E1*HC\QA84WT)D&GF-K%S/)T1*CW\+D.K-/GR]NXPC0P)W1H6E<7W
MK-KE3!!/V.:O>>P?]O7.\OC96=?V.C1A3 .7^L1"7F3A. @@]'LT. [#%?O@
MNU+H'C&#*&2>RF/ 4@>*19_&:?D_+WI+(EZR9CN !J>E<;//0(L<6-X%X. O
M@/M7V_M_EA8GB1O(%A(OM1O)Q.,F%2RQV\G4F?L@H4T5BP7<7C:%E^6T(URR
MH-_?U?DF3ZN7FY1?ZGFS*]?_PC_S>@6M.$YLQ_*B&/N1!XGMAKT]EJ!MJ6)>
MV8KI0CYM+[-M ($_.239TEV=0,&R?1+N)$MV&=K,%.FG6#E7H(]F<B'%^7@_
MWA;FFI@15IV#E:_I$_ORMDJ+.EWSA$O+IS0O5E:26"ZB#H0!@8PDUT->;]CV
M(KFUA/'FIM6A%I2L$FD@55"2IN5SE#9]1J49=?J4H',RI8_=A>B51H?>"I=N
MKH1[A;$R#F^WY8Y/%*Z>N;VN3D,T3BP;6R1 ,:%Q[,0$#<L8 9(2+G4KAO6*
M _L][9&!LH&FN/@Y@DHQN9J&13F5:@@<0($K00+-]/0ZQ<\9D1K/Z3*T28,?
M;SMU:6)FU%9Q4[M%!(9LCI@DCF]%-+ PL8>MZ9#:R>B=8B$K\VT4*\SF1I Y
M8IM8.X_:=HEGF-F=9$AVCUB*U66HD08_1':(%9@9I49=)>:3&+/99(P])Z*)
M&T48=UO2"'G4EJJ,QMB93Y&4YG6C*!VA2@;8U*9+L\SJSK DJTV2W"Y8G60]
M$=$G)7:$-H3[4WU?ZGJ?;:Z*_Y46^[1ZN?W!:K67FXP1L;G]4=X^EOLZ+3:X
MV/!78G=9UI=P#DY@&+F!#6-^[13[-DYZ2#01N^QI$B"&-8X](6[_6"KM#!L/
MA,#V\))B(*>, _,M='!5@ X\:-&#%G[3C:IW # /0._"(F,FL56\I-BI[1=/
M$4.QS>.17)[:09XJ1 O81I[,U7*&1T##!. R+[(ON^RI7I$H<&)"8&(1'"$[
M3EPX&,6.)W6U]TA3\TT#.$;0@-0Q%9 @=\1LP ROVB8$(I1.-RD8R)*=%\BS
MO."I@8(S(K,#58Y$%8QF=[OVG$[-\GEW8B?;?"GJ7=7D^9O'E W25G:ME>_9
MQ(H(Q5[DV@[V8QB[/0A'LLV79M.&%>[KGN<1_CS6#2R0MY7,\[ZJ]_SQW)5@
M/7@#?LN+[@__(J=ZN@,BIH(SQD).%3E0<$!Z 0:LX #V K1PNVIS6HV4H_*,
M9AJ*R3(TU)1SY23C6K/&XJ=R7^RL%4DP##S/IBB =N@$,2*#^<CVL%9U%35J
M6%?QPT.5/:2[##Q7>;'.G],M2!MH7&LW_'%?]^ U*ZDP[9HTU 3C1M2S!;HP
MV>S8&R.8L@'X1:12VBU9D53C3?A\)#_0U"HPW3,->+C.JKS<_%>ZW6<'6%?W
MKXZ3K_GE1GE6KW"00-_R@AA3"#T[1DE_9A.AP/.)V*M+TV"1>;"57F#Z4JRK
MII\-*T:;ZO.QW++1^?_6(/OW/M^]3'PP< R9Y\X,3A*D93S\$_GZ]J3AA R/
ME(FV@/N:_6A^5:\B[)/(<@F$<8B1XR5)Z P+?3Z2FJ%J,FFX@KK>WVUS-A3O
M[[.JN8COGE5,3T]L$EHWIX)%IJ)3/O]OZ)-_T%7Y7_03K>R4V*,[CC/A9Y1;
MN:[R=;;"#D$Q#.+ PY&?.-"AH3?4"KX?2#V'XA]K^%EKD/"9RCIKGJM-N=VF
M50V>LZI]QB17>V0($YN%&.)*;I[1TM2@F%AR!N_/R8H\10N1#@7@;^5!U7=1
M";BNRG66;>J$H>=:DS+/>*' $U*C32L;>Q:U?$@B)W:A'WH1BH>3+G;DR%7L
MX^T9K\J_9CLF&2U,P*,*GE^G[&F?D4\9._/HZ&-[&4^41G]*4^-2I@4(WT(J
M^RVDLMU":@N E>U'D%@!<6S+]RSD^U8X'#!S+5?HHNK11@RGYWZK]+E!(],3
M8@QQ J>OIN),TQ;S!;B>E$&9MAD3,:G8%T.94<'6%Z>]/W4R20=A"SAUI,6-
M4O- TG!:Z&J_JW=IL6%EP,H*O2"D%$,70=]%?N)YM#=+'$_N_H*QQJ:1:O:P
M'#"I[YJ/IW;$:2%3K&H3\R. "S@O=(1&]L20"M/+*#3UN2-R:DB=IU%:%O_,
MJG5>M_/+X9=U]]O:6@5V'-,X2FPV[W3"&-G8/>@JI51NZF<&@_'I8(^P6T8:
MEHZT+"@9BLL(=9PT(-HD<PA2 _OH;^KACZ:^)DN%7%F!U1:L!:NN/A]%I%@S
MH\K7'ARG!,8DBGP/H@C[0>*'* YQ;](*H=3:_"A#AFO,),TKT&Q:\@?X1X=4
M3E#'$2FFFY-Q*">/']T4,5LI>8ZC,RJGA=IEB)D>5SZ[^4&='Z$5RG8?\A_Y
M[O$QVV[NR^IPG&"8B]<KQR81C:&'J.NZ,/8I]=!PUIV&XFN5>LQ-L:E8@Q\=
M2L!@@JRO/XZ$2WYZK)-R@57.Z=E6V):LP3^.B3Y /"[RIJ=78@ET>IK5%D,U
MT"VV*BI$R*GU4;UL+F"E5+-#I;&1)WFV9/V8;?:\ ]ZW['M6[+-F:RW^R02W
M2+?1OMZ53PP*2V279?%PF7_/-KBNLUW=7A'B6JR^#F@<QDZ<.*%%<1@20A(O
M@'Z$8"1U'L4L%-/IID//'\ >?[LMW7L !A>:TH\[\7OC!6C=4+N6R'0 Q6KM
M!<5.,GF9#YN9(SFC"#]WC&>:2"ZC^)_*V;?'A:;D6'CMF5-6[*JF&OF6U_\B
M+[?L YI&7T[D>@'[?!12DA#DV-B+>HLD)E)+&V/L&-;P5]  QP8X-+4V@&/H
M%%P8GHA)R>5?-1+-K.Z>9NC<&JX&7I>A;UH\>;L>JXT=967B]KH&7S"FF&!F
MU0^MT/4CB-RDMVAY5*X9R @[<RF36CO ,80J:I,A+C5ITSS- $]S)*-."LPN
M5)U4//E,G939$56GOV7E0Y4^/^;K=[:[+DDN<6A((^HS );G10EV!U5TD=P]
M%..M&5:J T"P?O6T5?QI4VOOKH%B,=6:EETY[3HB]@,9FZ?M^Z=\G=$Q?5PO
M0\TT^E.:&I6C9X0D*]:/3VG5WNP3QCX,/<^A$)$@IK%+D-^;]1(DU5ECM+'I
M*[ !GZX)HB2[RK-$<\2.+L>$.9UJOOB**[E)HQK-RU S?>Y\/GT<PY.ZEO5&
MN^*01-!*$NC3Q M#[-* .$-QZ(2VU!ONHXW-JF5ZII32_*JJF4%J=:K9,F:8
M;]B2TC-%HI>J9ZKN?*IGHWB2N?ZP[G8/_E:6F_IKMNN+02NT7!QBA[K,0.PC
M/W9Z@SZECNRUAXIF3.^W<F2@:J%=@"+;*4XNQS IN#DZ#8F2&Y\-?]]Z_AI<
M%^"K"(W&[CO\F*1SFY7CF5V&/.EPY(-[#;5P\YDDK7D;L^IE]<?-"H?0(1%!
M(4S<T"*8)K%_^.!$:$(H\7&&)>:/O][\55)49+@X+QZ&:) 3B3^^?KF-*;BY
MQ;?QC8H>U-GZKP_E]__1>=/*0??-6R4X>/S!$Z] Q[Q/M@K@4CGT<L5#O*_*
MYZP3@RA$* I\Z(64M[SF5WC1WD2,Q4X%*WVPX:>WQ:)8%,@Q)%8&&"-'[ID6
MY<5(EC_FX$Q>5Z)J&9E<#7JI8:A(O"_P+:MWY?T_RFJ[Z8R$OH-03!!U+,^)
M,)NK\$E*:P19CM ^NN)'&]8!#HB?[ML]9N 'AZ5R;Y$"8>=%80*NY&2AI^D?
M$U(D<3K?+%5J)_$E*1,[=?_.T0]D<B0C"SA-/P)\J654R!5,DL<T+X?K11Q(
M:.!1&U,_\",?$3_$'1P$H45EBBMC((P+L-JQZDO5*X[,14NLT%M$H&35WUR,
MC!22JAR?*3J-AVT9!:IY-\N)'P<U+5_1(* NLG%@QRBD#C,4(4*8'2^!D8NE
M^D()?^A$6JLFF)]3(B> 6ME0$[1Y5$E 982Y699JB,,^H0*2?DLTR'W.JMW+
M-1L%.R8J\;_W^3,OZ6E>K[=EO:^RV^SGCFQYCU ?!DY"$9M1>XX5!P&*8$1\
MXL6N'81NX$GWRM5G6N:)4.J3U*-M,OH 54XO])(MIBFSL2RG.SW,"]  ?<TR
M.& %?W*TH($[<>DDP^09(3,2D&6(G1G7WK<R-L6?>"G$"<FW>;/N<77_1U&Q
MGSP4^7^RS6WZDV1%=I_OZOCG>KOGK4O:&XOJ:P8[S0OV@]LR_ID^L8*-__FW
M;+>OBOI;N=TF9?4CK3:KV(\L/[9@3%V(?"?T[2 ((L<) ^1Y023U=L[L8(V7
M;L?^\76E8P\!PPQZ'WDCM<[+[E:Q&AS\Y-<4]9XV_ZSS%?S)O06=N])SZKF'
MBFCI^0N-$MF2=B$#Q%#I;#9P9TORA8R9962_Y=#Q;@JQ%&!26?8$S)43V$X<
MAI&-;.3&D-A1,EB+PB!9M?WV;W9IM1-+D:J69#3K+2AA^2+90UXT\G.7;OF]
M#7()2)E%L;PQ!75R<G]2W*?5Y1/$G)'3L50N0P5'>U'J'6 2N_LG3/776-*L
M_>^WK-YO=^R!Y,Y?LZ>Z:OOTLW]R7=8YU]AZ%1"F@2%%,<*)'T#+BZVP@X=M
M)I3"YP*F!&6X4H\>V7<9J+)MNNO*J6>.%+QD:<7O)/J>\]Y=$GOGDT9,X&#"
M4H.E24$OP'"EZV^]+W\!@S?M)ECC3W>_2/.O!Y>6&EB)XQ1+#;#:08S) RUV
ME$,CR:<.@<P1QP4<'YG%[7+FYT?+K*-'6 _0^+9LM*\J]M1]  XB2+P$0^Q0
MZKJ>A8B?]. 0"J16\":"-'WV7[=8E?+_U/$:-1V:,U3Z<_^;/-"Y,2H3&)US
M2;(O/T4S%=Y%S^B,.2TV 33+^<AL\2W;[->-W5?H+M/G.KNZQ\_/VWS-6U+>
ML()MOV,_NLR?\K9XJU>)AVT<$]^'+IOC>EZ,!Z0$DC!8%=E#NF/V1F<0HS"%
M-"IL->J=1Q*+^[T+X(Z-A@THB^;$^I;[T!]?3P=/0-VZTMRSLSUXHR7GF(WZ
MJ 0T?Z1U9Z/!H[?IZ+*/_,$KT+G%?WHI$/0ID].8R,AGJDG&P:+3UC0,B.6P
M":,Q=M,%DL".+,O''DW<$+J0Q'9O+4D2I]MTB8O-N"V7S^S(;[GTD(1%)VYO
M__QLMV7ANP:B1"[Z817W0G#70(X5T8?FZYZ_0W-U?\5&7#.YO<D>^&I<O;+#
MV/%@;-DA)8Z'$'*A14)L619RL4>D[GE0MV)X9M\"X\FU[*&!NL,F5UB-(%*L
M/)J&0[DBYT#?@ K<?$:?$?4YR<X9_1G/Z#(42(,?I>ZQ)J="25EE^4/13H'7
M+[=56M1I4U[\+<V+R[*N27;/_H;IX0I%0>2% <$^2A S[J+$[Q$XON?)Z)).
MNX:5B@,"OVT9I+_PB>)]BQQD/]?-XJ2<6&GE6TR^YJ):3M ZE*"'"8YP@C8$
M'.I?+L!=@Y;/[*85.@D>STB?B6@L0PR->%::'\L2ASVNTY=&C)F)+P6;AF7-
M=^4]S>YVAWO$5I%GAS[UJ05=IM*.Q1ML4CMT8AR%[(>)\#D.3?9,;]*D]2/(
M#_@DMNQU$2IPS&(&+N44L ?87#)X!)$7>1SDT<6#,S L<=YA!J;5CC+H8%SL
M=((8):<.'F@F= %G"G1[5)H;?A+IH36W.;Y1LOUZE]]M,VX__OF<%77VI6 R
MF]6[;]ES"Y;EM8?\>U9D=;U",8HP@@ZV73="L1T&B=4#<RR?BKTP.2$@F0=5
MZ37*?Z0,2C/9K;)_[_.JB2@_"U!QN"SUM. OP":KUU5^EVU >E=^%RS-IPR=
M0)Y:7LSDTEB'_\TUN4<NM-+:.<%/"+1N@,$/<.3(\D(HD0B7%TJU/#E12,52
MJ1923V7::2.V@$0\L</E;$^'1!J/?_*%MWU>/W)C;>% \_O[C,\Y,Y+M?F19
M<9/M=MLF$3'0=;[)VJ;D:;'YFNVBM*I>V&?\5[K=9RL;NQ[[/PUA$-+(<>S8
M13U$FUI"ZV:S #,\;SQ !W<M]N;@Q:[<I5M0#V[PJZT.?H!TMV,I?K]C>L0J
M@.;81I[>Y=M\]\+^\NFY+/B_Z0YQ,/D(P=>2G]W@S0'XCWCS\G5' _C.>>C_
M>/@<B:0S^5@1J""6/$SD:HG7GO33L@MP-'(Z=\#!'Q"]'B\L[KS3>N\3:)Q:
M<H@E*HPEAUJMUI@AY&)UAV:J3U4@<T5T ;7(;*Z7"WBB1M8G_ZCR75;>WY?W
M?Q3I4\EJJ/]DFQ9[W;0XKU<1IKZ?1 Z%D8_MQ*$)]7LD ?:$[@LP:=]PM7&$
M"VPZ4'P_K\HV&0OE!A2\3!B9%W2$03'#3QP!/8F\ ?T[0]UVV#A$J)E0#L@7
M$)6127GBZ.C-O6.CI)Y@/Z=-)H]J#,)"TZ5.#S_+BMK9%$I^?(^W+#["<[09
M')4ULY[X), 6)"BR@]A+;!H&T9!Z8PL))SR--@TGN=O'O-K\_IQ6S62XEE).
MG<P*Y+"92)7+6QPD+Q).*>/Q(95H1KXELM-,O*ME)'W\B^4@<7).Y1T#]"X@
MUYCPJC0[*&4F5/4N?^+ODOU19_?[+>^/75_=G^P9><M?KSAJ%YDXH9_P.Z+B
M, F<T$66$Y#0@P@F[,>.Q'ZM62#&]VD'^*#%#QH'^-,ZIA'N%"$2F7,M)C:2
M4Z^/@W)U%)2V>RY^U3WWS\8!(-(X=_)HR<S%%A,UQ2F9\>@)3L[&\'ARCC9)
M<!:0/B=RM)Q\X"O=!O&M?<N*/P=XNRU_\#?FZI4/D8W"A#>G1SAVPRA!5F^2
MNK;4U8BC#!F>HGW+ZJSZG@'2OBK8'CX<ILQ-@CR 5;I:0I'?\SEP<FKELEP'
M"QSANCCB$?QY76YS_E;!7(W@S_%VYG4!+70OX_T /:Y\?-.%#GZ$;X-G*;S9
M^[E99T5:Y27^F=>K,,*A:UL0>;X5>0Z;DD01A8A2&&&;S5>D+H)7LF!8MWHL
MX$^.1O;>=S7.Q"3)/%UR6B3*E)FKW3\BXXS C"-O&<HRTH>W=[EK8$182SH3
M?Q3U<[;.[_-L0\NG-"]6A&#L0>R[)$X\&D?\AL7!GNO(Z8FRE8DTY0(<00-_
MMN!D)4:=2D&9F81%-:F1)-",\ISBYYSZC.9T(0HTWH^W*J2)&?&Y6=WK'M[\
M<U_O^%?=/:\8QS%RB(5QX%/JQYZ5T,XB"9Q JB'%&#OF9V8]-) .V!0OM1_%
MI^A4;!HJ96=B!Q:Q!(N&9ETG*3H[Z1I/[#)T28LG[Z9<NM@1VIR)RBW[NN0G
M[+YGN*IXSP5N\4>^>_SR7&=%9SK&'IO:A9Z-$"0.]&S7&DQ#&!.);1A=)HUO
MN+P""M(#4L"A@@:KRO7RVC@7V%>9@VPY17O-,EX>RQ+[(7.PK;;SH8=UL=T-
M059.[6/H)G4!.Q;:72H-#D*=V00_\Y[BZ;:\C]C?_2<M=GF1W]V]Q%%>W/ [
ML3:7>9%]BZ(.H^W8#K;M*/$<*X34@Y2$/48<8%OXD-GDR Q7TR*YZ8)WV6V<
MXH<$V%>\M26X>P%Q!'+^@@?WZG?N%F!^&=%8[?'6D?+F#+7^W'@!\%&4CSWZ
MQ4.M,^_.&7)S"?IUZ*]'/^":TKDDV<IYWU10?X4"P9CO4I6$V0B(+JYU _^J
MNLFJ[_DZ:W84 L>/[1!&#D8H"OE)1M_I37F)Y<NLJBD9,%P =)C:(PT=KEII
M]U"-/K%%-./,R>53)=),W5S_CI@S:V:C>%S&8MDX%][?.#^6#TEUJ7&QZ4=,
MMU401"2,/<MR0S=,8! E21 /:F9CHB Q"E;FT1FE3<015$K)C6$6M6C.+)N(
M)_GY7'I&<+HH_1GCQ\<B-)H9L:455F ]9;N7G_U>@$=C!(D;68D54XQ\B^E=
M9R)&MBN^,B+YP:87-GHX2I-469)$EA,,\B.Y&C I-3+3;X,4*<Z>Q:D2G/2^
M=O'DG%61B25,.56AEQI&@H00_CW?9O6N++*KNW]FZV9FRHL_XKE6[#@T]*R0
M8"=(<&0->Z-6*#3?&_/YAF7Q/2JIN=XHY@1$<@+2Y+1R3KXDE',"WM0$5)X_
M,1W]V.%3<CJ2G@6HZE@/2GV#993&=H4MT^PDMB,?)B2Q(NKXMN?VMASL."-4
M5M#"##HK-=<=R9^2UAJ@;KS:3LG:*,4UP)Z:YO:4->^L32? )U< ]/"U2!&6
M]>&\#"LQ(B3$_S.*DIS]\J&KIT//3<*$7TX5$1^YE@7=_G0RH;$G=%98Z8,-
MRRZ# UH\*G-;:98$5-8D07+B.C$W$EIJDB,U"97A2DPOW_AX2B95J5B .BI#
M+S4,!3DMQ&ON#7_]M#/CHIA"*TP<Y"$<.#2Q\+#0:@>VE!Y*?_@$FGC I/CL
MRS,FIHU&R9+7QQEXDM-)HWRI:Z4,;\)Z^=;7,YJI3,LR=%,=?JEI>$CH9WL@
MI_O\!"&'4#] +H;$=1/>Y&O8H4(2E^A)?:IAQ6RQJ"B '#<"$FF,%CEMG(H1
M"3$TQHR:"HHR)*9^Q\Z=DCTE A:@=VJXR[&AESNM\_?TGV45[=G\_(GI1[,^
M"A,,88RLF'H)BCP<(U:"MH8BEQ*I8SH*'V]ZO[P#HW3T3X6M\^(W$5%R*BC*
MD9$S-^^9.'/89@1MRSAE,\:!4ML0DM.,K^E3=G7_RERWH@=#ZD?(27S;LU"4
MN*&3N(,]CTB]FJ]N93(%43K4-X(],2F9ACA519GE'-])2LY(RW@:EZ$P&OPH
M=0\PB5G8W[;IS_+F*=\]_F_V)_UTCR0X]B(801?3R&>%4(*]WA#V8" \'5/[
M>,,*\P:4RG1$D3:!F9IYQN2DI<$#&D!@:KHDIG'F:5.;SYVF[Z\CYW8?>GQJ
MDC>.G@7,]D8Z4&H;*F.;X [;M7_/=H_EYO4?_"?;K"P8!3@*$ ,2^139,!PF
MHA'T(ZGYH0'SAK6Y;^U:#8@NP%./>72'W/'DB]6(,_,NI_ ?=M,=\((6\ 5X
M\V<,\]P]=3_C]$SU:3! RRA+33KX:5=>S5R*7>NQS1_X5=+7W:W1C)&C]X7+
M(BDKRG!LRZ8#.BX8JH?]EL?H98"+UX\Y^QO^!W\4+$"O/J#&#U76_&[E^!AC
MQ_8C"FV$O3CT/#3D"NC%XI<K+@BT86'O707])?%\S(+U,=CFH-GFX&_SBEHU
M>'S( R ]^ SVW.G7'U2#M'=;YAZ+!05#Z(Z2!>$UEYV&<=.Y";B?X!5.D/"F
M^D?CAE^/<7#V*)<=N0L:?U]_4 WPKSYN9&Y+61!N\Q.QI8TCP9M8IHO1J:GC
M$H?) B:DBZ2E7/CC+3=YIME]5E597S^N/"?"5NRAB-B>CY.0%9%);X7")%D5
MV0._!$=L;BS[Z4(2%;82=0Q$6*'^>&9#C E*7R"Q*? VK>NF&[3<Q%>:.+%9
MK1'&E(J"'DD_*9UV)OJ&AS/33%7&EC&'5$9?ZADW<FIQM7O,JLL\O<NW;!*:
MU5^9DWMFELE38$<.)(EC03\.@C@@WO!*6F0CY(IU"]9@2.:)4.H1C-?K:L^>
MB]?SJNT!K)R0C.%43%,F(E-.7AI0X C5!3C@FE9K3O-S1G8TD+H,!=+A2*E]
MP$FL2G7%U]7]MRQ_NMM7=5,OU>^*L:-N=BMJ1W: 8(BLT(X3BIW8'>0QMD(J
MO+IDPKCA5:)^<E;>L_+G&/1'RT5';68EINM&0B*P7#-W-.0DL _$U3UXC?>C
M>3->3B DUC_F#HC:.H;VP(@M1"B0=6I!P23O"U@8,.I>.='XE2N]3S5FY1>=
M;LMZ7QU=-NO:, @IC2P[08[K^7Y@N<0G7FQ1@A 1:A1FPJ[I4XVOG\M^Y42R
M'M=*M%B!/A?'<NGJ='OJ T[PYVSWP4J0>*:L-Q&*9=3Y1CPKS0]D.9F,TZK(
MBX?Z.JMN'M,JPW?UKDK7NU48.-CS;.K'Q$5VX/LT<4F(+<O"ED\M+/BH*G^^
MP=V[#A)@F$ #"OS9PYKX&3S%SID';C2ARWBZQKM1:AYHLO>F/F:;_3:[NG]K
MF*1UOL;%AN;;_2[;O+G7'B4QQ:X%K22$+F:S>C:?[]%00D.Y6U7-8#!<=O2P
M^82:G[\IUODV;VL0]I,&>G/*H@,/OF8[<%G61\^K[+VLAD(EIH!+B)*<0!X'
MZ+U87GP0HC\;[//=;:_(\1F9-1VU9:BP<2_?W2D[!:OR&HZ+7;[AEED9=I.M
M]U6S#!O_7&_WFVS3SEZ?GO?MLLA[\ >@MAV%D>=&08 (#I#%"C74 [6<Q%.3
M]\G@3:C\U^6.%;IYNFU5I6YN9BJ?GE@6N-DQK.!KN0-?BM9%]@4X<I'_K?[L
M,-T@D$T<BXR_>DXY=@<<_ &]0^VZ^IMX?U2U+R;KZ J04$*:?#0L+5=-3\#)
M-#93+$0S7)+FU7^EVWUV6%"HAXD1QCZF@85=$B,'ADG@^19)/(^E6NJ32'0Q
M;I0-<X+#88$&U]%R6SW;3/\<2V>>>BWD+N/YU>-*:6#P*3Y3N*ZSYF:3HYW[
MOV<IQ["Y*KYQ-:C8P\[^X&M95/VWO-"MF\2U\KT 8P_YMA4YQ$.6#6W:XW-]
M*-0I>GI4AFO$H^>V@]WL2?!WO3JLS<SS&'Q7"$@V99@PCI)"NJ@0*JNNMNB9
MU>.Q9(N(]V0!79C23^?WJ;0P,?/2.82\#%_^SSRKV+]_?+GD)^";7CZ^ZP:^
MYSJNXT'+=BP<PW!(8+$EM2^MR>1DZG\!!G1*?;MT42RIW=.QJRK,$L2:5=ZS
M5(G(JAZN%Z:9FIPZ)8@Z.9-6N^.2X#V,KJ&01VT7TSBB(8UQB.+8\]T> ^(O
MAJB(GA;+TU6^1T^H4L,QS8Q+:N#D9"O7J!(\F]5"$<I$)%$K]0M31KV^G1)(
M PQ*Z^27XGF_JQM9MKI60!!YR$9>2-S(=HF-+(CBWJ+E4:RDB@IV#&M@@P58
MDOV\M! H*7*&N5.O[EI@%T"82K/*]IXG$1T;P>["5&N,)Z<T:C0[8Q3)[BTZ
M0>@GS%:,N%T/QA3U%BF.A!K.Z+ SB2+9&A5)F$!U13+!G2Y%$J!R,D6RE11)
MEMWE*I*T)P**I,:.<//ZLLA>_IY6_\IVR;[8U/U=2LCU/0^&'@J2P+)=#\71
M8,R'L=S;U(I&9)XFI3>I&US@J0$&[CDR15E295%,D2:@3TZ,6MY:1" 1X\U,
MH_L/F3DC/R.I7(;RC'7B;=-['9Q,N=M[F1?9EUWV5*^LR".(>!8B. H#-_8"
MZ@Q5&J5PZAU?<603KONW_C3[A$<>]?N)&U 6YW83&[_ G]PST+@VP[:P1,"G
MVQHV$VOUJG"R,"]V_WB(B.$]9/G(+R-OS.2[@;UDU0B(9JD6V@>'H094J]!U
M8A+ZMLL"82,2V([K]88#BTA6R!H,&J^6;\M=N@7W>9$6:W[./&TPRV4#'<2*
M2?S$C,KI=@ON GQXJ/+H<,^T&OPY96>$52/?RU!+G0Z5QL;F7&_HM(=Y+":W
M=D(Q=BSD0D1M[+2'K$,,:6C-\W:.$#3#];>YUS,DR^^I(RXFS@L.MIR0SQ'G
MA;][\\DASIE"OXR<,I?SQMZW48B!Z,71?!H0E04K57>\Q?'7<I?5=)_]KWV1
ML3$<=*M4GAT2A"/7#9PX9FF2.@[N;2>1+UB&Z[5IO!*G65;=Y]F6S^%WF?SB
MZ^F;A(4(^.#I-D/@ CI]Z?>I-#GD)*>YXYY^\O+Q!S1''W%,K)!03"(:8L]V
M:!RZ/6+7MX0Z7"X!I^%"\531H')$>]9P"L[*?Y%(2D[GU8)H9A)OCN%SL_\%
MQ'49)=XBF'B[WK $3!HR$[\UMSLQ&GJ6AQS73:S(LN(H(%%$>K-AXDHU!AEM
M;)X<<0$X1,43[>,)'B/XAKC5HMJBM$ZHW@>ZI"58@>DEZZB*.T)BJ,R3\-(K
M;\+#938KZD9GK]E@[*I[FT:)34)D^RXE?I)8KN_U%J/ DVMB-\*.81V[VN_J
M75IL^'YSW?0D*I^;2X8NP)Y-@&K>?NC;S1_M'G9\<WT-V%C95?G=OKUP2^UL
MUBCB!9<S)^)<<FVRH?@8%N"X9CJJ=8:C<ZN%&IA=AIYI\>3M.IXV=L2[@ \K
M%32[VQWTL[]A&R';<9 ;17;@Q6Z,(=//SBJ&U);K_#W.EF$U.X('-@R?HCR-
M9E1,HJ8D4TZFCGGDT%Y-H&>1JD^X.B-7NEA>AF1I\^9=EVZ=+$VTV'DY'#G"
M'O&IA6Q(*'7<(((!&F:\OA=*:=QDH&9:QI3>^[Q4/6<Z77@G6>DT$UD]RYI&
M@KK$Q=!+@0.ED\=Y&;EA>K?UKFFJ\CY1ML%/Y;[8K2('63"!,84,'J+8<JQA
M9SVTD=3"P#2(#.>9]@SJ<]_K>/L"!H&JF[;'DR8-T2A-DC$,!&B6='$!6D]^
MJ4S10C:7)B2#^W]%CI#U66^"4&)<]9:@U]=V# U72>*Z"8Z0[SMVB&+J^6Y(
M;2\(<0S=P(YDY%^32</Z_G7_E%5\T/Y_<D*NBU QI9Z!2SDI_J (?W,SS%)N
M:/J8NC-"JIG[92BE;J<^N<M)"V>B6O<UVWTIUN53QF^56(743XB-(AI1"Y(X
MBEQ^=K2UX3A!("-I<I]L6KFR'=@R'-,^3J\H.//4J%&UC(=#$7NI8[#(#?4_
MBDU>MQN6V:9_Z+@]O&U(S#:WY75:[?)U_LP>O>+A4)<T]_6L+#L.?0Q]%/D^
M11&!).QA68X;):LB>^ ?(_9\&(<C]$B%[2-UC%SJH<J;J(&TQPQV)7@^1@WJ
M ;9<T6 ^7&+EQ#+BI%1HO()^F,S]QM'_!>#CF+WRX-5YF\:):75S+.5GI':R
M:"Y#G:=SMYSIJ1E1[N#O:;YMKEXKV[NXFAW[QW++@M*A2*B5$ LY"8FH&T:.
M[=O.@():4DM\NFU/4#*]4G>^!<R48MU>6]8>$;HO*W#77)!8'/[\MVVC+\]L
M=E/+7U&F/41B,C]G=.14G0?F2\=TI^0]7!Z?XVOE.L2SB+@DH:+EL<;0+$.B
MC7EWKL36SN($17AW!^(J\2S;0E9,63YPL.5Z'NHGPE;BV,YD9;@H(..%.-[\
M<U_O>!-G+@#%4LMRX0 :+\RU1FZ^TKQSXY<ISCN\9LISV9@N0_VG=%A?B:[&
MM?XBO<=A^:$=DP139%M!G% _2*PA5_F1H3)=U/I2"O5-=XGP#*6Z<*!T%^LF
M8F2^7)]%V*5)U5*RRP9H&;)MT#_ELEV-25%1_D>6/SRRC\??LRI]R+[N^6'@
MJ_OV.O.C=X<Z%(>N6<TYKF$7*[01#%W;2T(_B4D81)YO]^!@B'P9I9X(DF'Y
MIEE1/N6%PK;Z5"$1T^0%1D-.J'L'0.<!:%W@YZ!:)\#Q*W(+V;'7P_H9)9\X
MK,N0]ZF=+F=]E,PD@G85B=DC!":V$X70B^,H=J)HP!#'H5PC5KVV9:1$J1-4
M#_?WM%.4]A0L5Y17Q7EYI"O[FBE07O _>-XW,_Y/U]?!;^SOVX_^BYD,(AA+
MO8E"?Q -YH-9EMBEF-2@\7(1^;6D7-(W1<5687"4,'<IXAV0PY+QRG$]:L,(
M(>S9F#@VA3[JT=#(D[ILSQ0&PS7XV-X'>@581\Q&2/'$X=(CRAWHCRKU ^X%
MJ//GY,KJM,9P+5BQ=7HIHMW:61U97I_"LX(4^Y FE"#/"Q,O\&QK*/+=Q'>U
M%-C*UA=98G,1/[R8=G@5ZGWI+;!BKKWX5H_TJ/)[DA ;+<!G63279%.^"!\=
MEP6+N@[OQ IQ32RJOD'6EOTV=&)(2>CYB>LZ89S09$@8-LLC8UX8$[,PW4[D
M6YF\Z)8QN%INRNTVK>K#+R6%4Y%=,7DT3ZR<"'[T"NX,2PT?TG)&S<;1N S-
M&NG#)Z]YJ3"BJC_#UB _N8<1@8D'XP#:KDUI;\VGB(Q1(%$;<VI07\^94"%A
MCM5TR 2]XY5HEIKK!#42:B1+YC+U2-J+3Q1)C1513;JJ'M(B_T^S71J515UN
M\TW[AFNQN6;#CDVINY?]D_X2NQOVDXS/M>O#%A?[ZYO\H<CO\W5:[/!ZS1L!
M,"^NV>>MV2SN-ONY(XRU?ZUB'!"*@I!$%%F1CX@+(^(3+[9B$E,LU81Z<>!-
M+X@>^=O,EV_V3T]I]=+,O0X>@(,+H/=!3D471ZR@/"\.MSG=/W;U KQRMAD:
MQ^[R\3$X# X>'UV@V ZG\V,(_,D=!XWG$Q^HF#JP9[+68L?8,M+A<NDI?Q&M
M4+V>LCV02++[LLK:KV_3GY3]I][E:P8S83]G2)O[QPZH(*+0BH(@IDG$7^EW
M;=]O4#D0QI1(=>8TC<5P>CV^F/ P(MC$Y-UA8=7[) V%2"PY+BDZ<KGN.#!=
M'.X:\/UW##Z;]70.-*FL<Z&[&!+,EKA&DGXF#TT5SF6DE<F\/7GMXQ0LRXL^
M[\=6%CPE]0@9JO@G[V[/L!;9?;Y[@RARX\AWW=BGB1U";,7(3GI$=B+W5HY)
M').*?0_^2&$8?M Y '[K7% 6?@-ADA7]>2.D+OCBP5F0V$N3+23TYD*X-)$W
MZ.E)@3?-KKRXQ_?WV9J?AQC@?&/UZ.MW'-Y "E'HN@Z)$LN%,+1LZD8#I(3(
M-=HW"F1">7_S4L@K%<EJ@'?@]C%KED7V;/2_@"1CXSS='FL-=Y>_%W@T$VC^
ML6H^,!%9V80P<U#5,\( _%V$WK[^LYA\(,^U4$(P&,*E9023KIY,"<;YE<\)
M-+O/JBK;,"RXKK-=S:8>EWEZQ^#PXW)OT-@^=F@0> 1:3N"[EFOYJ$<3L)F(
M6CK0BV'"3- #!RWL9J7@"+BJFFN.B:R0SQ<.=0T?(L&U^^-H+$B^I1@64FXS
M,5N::!OR\J1>FV157JK_*"J6*1Z*_#\-HFX.47\KM]NDK'ZDU>8-H 11WX51
M$$>Q%7B1$T0X&N83MI6HJ;5V&!,*]C'V1BIZ]*I2K3\FLFH]:SC4!?MD) !'
M#CKH"])L69Z%9-M8\):FW.8</2G>AKF5U^^K9WZO1EX\7&9IG6W:C-)@6%DA
MOR46Q8'CVLA"A"0P)DGD^U82VMA55.H1!B?4Y $E:&'VY5O[Z,O>-*V%;5D-
MGHAH=;55Y=BPII[F34@]-="^-)W4X=))1=3&UV?:E_UDCP_>ID_9)HW2;7Y?
M5D6>=E?+AA8,O"".'1O2A$FLZY*P-^40*M0<:I0!P]K6P;H !V"2]U*/H^^\
M>$W&G)Q8S4W:IESOG_HC6O.3]PJ.61+?2#QWL1%NR[;#1K;/.?V!3&OA:%Y9
MUN-"J7',2,CN3;G?/=ZD15+Q0X;UNGQGU$V<Q U#UZ;$H=".7<\=M#Z($Z%6
M()I,F2XS.4# $((!XEB%T4"O@$!/RZQD7;E(4B4$?%IRU:1\-,EBLOXI%:<$
M7A^'"Y!ZC<Z41L:9W(I#5&6;?)>D?$MQ]X)_YC4K[WE"H9%M)[&5Q$ESUW9O
M"$92MY@J?+QAF6\1@1X2^).#DEPX4"%-;)G ,%]RXBU)E9'Y_WM"SLSV1["W
MC+G]& =*;2-IC(+0\BG-BQ7[5&1Y?D3"(+1)3"*'_:<WE;B6NH8(&IA:15I8
MHW1$E#H5)3' VD@M^8RP"=2DA2"L)Y(<+E%19%TXJRE*? COA/!V/'<OE]F.
M/YU7]ZWIOA3R+)C$R(I<+_0MQZ9)X/4F$452ZC+*D.DI:8L-;%MP30NS]CF2
MFS?I(55PHV,J/B4GHAV5EP<J(T$JS>QKG*'IW'Z&#G:7H4QZ7'F[?Z&/'Z$%
M-++/M[QKV,UCMMW6G1TO\7R$;3_ -BNU0CO$-.CMQ$$@U&9"_=,-:U*/"=0-
M*)45'#72!%;"C/,EISD#53<34R6QOF6<,K4E+6GJQ):P/O+VU*K5*&86L% U
M#G^I:XS(E7W-9C.N*C86FF8'M^Q?-W-7WPYB%!$7)G[D1I2X."2#N012F9)/
MV8AA:6UP@2-@%X!#4UJB4B=2K,R;A$,YN56DSTAY=XJ>,Z7=:$:74=:-=Z/4
M/-+&*U WTT5V#!T[BBS?\CP'1A2BH7YT,)3JUCK"S%PJI+3$-89.=24RP*0F
M+9IEV>LT19)Z),GK<A5)UA$!35+B1FB2>=7</))N,3.UX>;P0Y4U=KM:S(E<
MZ$([H2&)^)6[#HR3WJ8/DT!XPCG:DF%MZO&!M <(TAZARO1J/+,"L]))2963
MJ8'/ 1O \_(I,76=E%>U:>PX?L7FM)_1<&I^JXV^!<QU]?E2FAA@4EI_?.RZ
MLX-])[:9"03#V'9MA\V]\6 GL*"$OBM\^@3U9G,ITR&=JDF/"G%"\FV8,UG)
M?O5VQG1422FS8<I4U5B2.E$!?N_M:=$=P<PBA'8,_E+7&)$YXGR\(]1O"'W+
MMKRYYFW9+VV^ N%8H4\(J^-#8D/;(A8^;!/A2+R:UF]ZJKV=K:JT&&!;0*+G
M)7K,1C2X&O:A.[S@M@1#')0EWD <9 Y-SQH/Q4/4!N(B>*Y:EJU3R<4<[0O(
M/ :=*R<9NMIRUC_*ZE],VWG+P*RHFU'^I:CW_.!XUG3^?NF011Z;E838(0[R
MJ$MI3.(AF\9V(/2B^)1X#&>W#B<X!@H&I.U- R_ZQ59?N$9GPEDBI3\]_O*!
MU)9*9PFHN?RJ*; ZTJXHLVJY6'O<%I^@]7LLGK4-L2U\S=5'G10N\R+[LLN>
MZE4<AABZT++=A/@>Q580ND,WA<AVI2ZE&F?*^.[-B<8B'"%H($KN+H^E5FR'
M>4)61ZT%RA%JYJZDLU2=V6W6Q/$R=IQU.?/VUB"='(FJ%ZZR].K^6Y9NXYI?
M071=E0S&[F5%7.KC(,:6'5B4?3RRXL&<PV#(Z):R$<.*Q7'Q5P6V[>/UW,%J
M;WC_][WLG0SJ7(H)U20TRDE4SR '!5I4H(<UK32=(N>,*(WF<QER--Z-4O,X
MDU@+N<R8S&7=)N'1'F$=I<_Y+F6#;?-:%^O;K'HJ[Z.RV%7I>K>",;*]* BQ
M;R$'$P\YB Y["A$6>IU]&B2&Q8RC&<0,K#M4$M-C\Z$06.%85!3DM+"%#C[8
M\*YYOXX&?M.(^DU=QW[;QRY:8M0DEC,6%3VUA8PIHBBV@C&6S%-K%Y,%:0&K
M%M/Y6L[Q&$@DVI.FO^[YXDC)\GV1_4BW[:FH>N4&GHM<VT>^14)"8RNRHQZ"
MYT?B;SGJ-FPXC;:H^&-<M;A V0*3T&3M7 LDSCEIELN3YT7TP'\'&%S-S[]$
M"IPS#FH93W<\Q+*;)$^GDIDINA>0NXRY5DXP7(U. 3M,/&FN+-?U(\LA;#KJ
MN,2AGD>&OFDD<87N')T AN&L]>U5K@+L$YZ,SB&D(F!DVF>*_,GF?'W(;A<5
M*Z.3/5,QFWRF)Q0[4[.\(Q;U3?%40K. '#F1H^,F=^K<ZIG9=;E[5W($>9'N
MLE4<P(19MHE/7"=,,"'),,&TDD3\[)@)XY/-\+J9';]]==>CTSG-4"%>QU3/
M,.=FIGM7AV#<+B48.N=]AH-B=NXG%1Q-$\#WA"E/ D=POX D9]0]J<G@:!['
M);36/-YL\N[-S2I+RX\V*H,X3%P:>IZ'@X!X&'ED..E%'"AT-^U$4(P?RFHF
MA/=E!=(!+$B/#SZ W^I_ ^'##E-%:$P>G"4X.K-BZ\ %.+@ E$Y:S!(Y'4ES
ME@B:2*&Z(CDRIXKR*9UAM0=JR?E6O[-"V=<0QZ)'!-OD_\&!H#RK5[%G$61;
MH1]"2K'OV!0=VD/'5*IQWRA#DTT:GP=,<J<#Q]%X/AU.SJ!<LCO>0WJG>>>(
M-')2\!Q)9TX+:N%V&2<&];A2&AA[DLW\RKKF9R:84F;%^H59S9^8W:O[:_:+
M_&Z;\3]8$>*$- C#V+5C+^8=7<BP9>721.B22;T6C6\&Y4]W>_;/FF8KZ[+>
M-?5_?R1P6.MBR42RVY\>OL6T;'JJ);=^F'EP!/ "]!"YT/4@ ?^SB=L!BA!W
M1NCT$K\,Q=/LT]M^@0884]1 O%Y7^W3+I/=[7O/Y5V@CZ@80XA@["7:A'WF#
M52MVI:[[&FO+L.YU>,R(G3RQ2C)GE--Q @<Z;!=@0#>KL+VE2ES2E$E>I)BI
M>W->QD:R-$[ \"Y*J^J%_?"_TNT^6WD!9!-:*T%^Z">,M C[0P'I(DOH.*I>
MB^9/].S <_K"KV37(5S2A(Z1+Y-<ZA&Q)2C7&Y:D]4N5Y26KF+)/0EHVCC%#
MIQG_GA?YT_ZI^>8Z?6G^F#)P)/((@IX?NZ$3)E;@0-_JP<$X$K^;>SI(AC7Q
M>*F]');:M]U2>P>ZV]1Z[F"#S5[F&,&$X1/8X5IFY"056/V871_1MA];[PZ@
M2XVHT<.34T1V\H.4"A$V=:SR!+_ZCEB.#> "=L9F<'K<T4L]G M/9?(BZ]L3
M]=>H_CW]R1&0LJK*'PP7@\I^LWM960XE!$,'PM!G\ZH(6X$_U!X.M5??L^JN
M%)[3Z#0M(QG'*,45@S>P.5QW>M<C!.L.HN2,1ROO@A.?N0B7S+X=TV\N:&;*
MVV(% U@0?<:]F:F1!(_G9D@FPK&0B9(1U][.E\SQ)S1MHMG=[DM1[ZJF_NC/
M&QY^4J^(&T8Q=&/DD@!Y21#C>%A]@C86:J2FR=1D9PW>WPS-\&7L*Y 7N[+I
M4[1AWK#O!O RQ_@TD"XPB9F6;SEYY-C  <KQD><C@--2*C&+F)9:M=G!2(K%
MROU/B3A5QNMC< 'EN49G2B.C3/:NQE?7?%_M=S5O!,IK_Z=R7^Q6!"&'!!&.
M8Q^%)/'BQ!NJ>"NF0BMDVHP93@J7[U)!>8 H>VGC6%X%2^0I*95=E!K8["KC
M(W07H,4W]2V.Y]DZ5_SJ(GHA!:\V=][=ZZB5)[&76<HM[U-<=1NIFVR3E-4U
M&Y:/S2I&E%8;]HN'*GU:09O@A+\0&B(W"3W/YJL4G?70\FSQMU;TV32]HC\@
MY>=J&ZC-\8WG 2Q8,[3\EQRNS(L.&GD7*')GHEQ.]8[8[E$"!A,<< (.%%S/
MRK;,^R/SL*[XHH@F]@5?!1&FYE1I;(#<!=3()KPJS0Y)N:HY3JN"&:JOL^KF
M,:VRV^SGCC#W_[6BB4L29+G8MRTW0#Z)K(B$V+(L;(=N('3SV7@KIA=/,C[;
M7)=/&?B-'P+X"V 008-1KDH>P:-8>3P-A7(9HL=T( W\R7&!!MC$W>9/$G2F
M%!Y/ZC)J8 U^E+J'FYP.)6E>-:=LVD;VN-A<YND=7UC.L_KO65KO61%^57S+
MUONJXB5XL?E:%E7_+6%R6?-_WR39VVS]6.3_WF?U+3\0MR)>A+#ON1'R XH2
M['G()@Y"=AQ[B>\(=?U:!%##:LA] XUSH/.DVY8?O&DVYH_]N0"#,^#@#9,!
M[H_D!1[SC@$Q&?YEPB^GY--%WHCVFXS*F?2QB,&PC RT#"K*!3ZLBGGP2_&\
MW]67V?=LZW0W4H70@0YRL173P+5]VXM1.%AT;:D%[#%VC*]=,RS D;RS3PN!
MDCG ,'>J$GX!6F 70)A*LZK\GB<141W![L(T<8PGIR1M-#LS5^:7PU55ED5B
MBUH>=@GQ?$R)2[T>MN^X\0*J<W&POTZ%?JEZS][L',];JIL9"[.5ZR+#X%>J
MV2\%[A=<S,A86)Z:G8YIZG?5."G6\#2OUWR_^!MO@.A@#\41#"E"[+&@;N3A
MP6(8QU+M1<;8F2)/?6\$*N]JT4T'#U3"K5JU$*I4TQOC4EGG^Y*^1P:^2315
M-5+/'W,D7L\K,;LPG1SCR?EZ?@0[XN=+[DK^TLOW[.B=F!_Y[O%O6<'/"Z\?
MN^E$XF+;=QS'=DD$'4)LGP04.C3 CF5[KB_VRHEVLS)/F]+K)@,@79?+2WA_
M=G==,X%+V5[7[=:[_74CO D];M=5>9_O^ 8:*T=N<Y9'\<^<E1V.$SA!D%@0
M);;MNV[BT]Z2AZ!0$3#F\PTG_Q85Z&"!!A?XDR,3G&F.XNY\OI^*-KD\/R]C
M$D>H)F!.[;B4"H-BZOVQRZ>$>B1!"]#DL1Z4^H;+**6EY5.:%ROB43]P$A@R
M/8<)=H+0A;TM'$/QFRF5+<RBMBVV<>HARJ"2XAH@3X?F3LG;*-TUP)^:\O:4
M-2>QIY3AUJZX$$LRMD@IEO7AO!@K,:(FQU=%UI79$%&"'6Q;T NCT.+23WIK
M-/ M=4$6MS&]) ,&3G)'>S21*KILAL/1RCP'?6/DV0R-VDIC,3H5A7GP75B:
MY=E:HC@K>'%6GE5941/HVQ]E9\UU7#?$CNU9OLOJ\=AG_QW602!%Z@(M;F,&
M@6;@M"B,!)$J FV&P_$"/0-]8P3:#(WZ!%J(3D6!'GP7%FAYMI8HT I>G!5H
M5584!9H%.1N6JMG_G,BW,$I"9/O$";W>GA6.64"6L3*'2'-X>G1&ADXEH3;$
MI :IGH?$47)MB$R-@BU&JJID'_P7%VT%SA8IVRI^G!=N968$-]G;VR2^9=^S
M8M\;H@ETL95 .TA\-\$T3JS!$+&@3+\&E8\W+-8]*%"UJ%3D19$W 7$V3YF<
M*@]L?9N<+:E^":994VV-(,N>Z#F-#_P]?2)C##D+T-F1#I3:!HIJ48P?F(KS
MT=/>>)ENKS,V7MBW][?E+MW>I-NL3DKVHU4<NSZU ]_S;0\1"X4VC7HD,8E#
MB9-,AA 8/]34(4L?FOZN=?.N/OMB]YB!J'QZ3HL7D!>\<<Y3V5S:K5H5:@R*
M;-$]3S1&E>,#Y/[J7][MI47-H]/@!@UPT"!?0%14J_AYHJ.EOM<6)87B7Y@V
MH6F!_B L()&9]O#D5,(4FR-2X8"@_76]LNT@B'WL!7$<!#;U8GZ2N+/L1ECH
MY3J=]DRO&1T>R^<6T6C)E*=4.7$995-7HCJB^'HVBD=G(:-4Z\XZ$I2/23%O
M.9%+*<J,+C:%J'OT><H8R=:8%-'\E"^!U8_E=K-R[0 12"T<!@ZRG0"'WK"Y
M3)Q0<2]!V=PTFPJ['L]X[9*E4ST[&&126W)H?W,['[WC,X-!FK4G!E&Z1Z6%
MUX1(9@5%-I>;%%0=$L@)H[@22@G?LG7Y/:M>ROOXYW-6U%G=__>ZRLMJ5T;[
MJF)0DKQ>I]O_SM)J!4E,2&3A**;432SD0=?J43B("%T);LJVX631(P:_;9O>
MH*S^RCK(%\-7;*+!T(-="=8M?G#?. !>F <2^F<B- *Y9N:HR"6>(2 L$O$0
MB?XK<-U'HL,,6M#@O^>/A$1:FCDB:CG*1&3$DI8\7:<RF$'B%Y#.3'I73C-\
MY=IPW*P?L\U^RR\J._$6<-TV#%F?^/4M^ZI.U\U^2-/S[] $U[:LQ,6$N,@B
M<4AC2FA$;2\((^11:"<R;3SFQ&DX@?:N-3>G'*/OMVYK\$?!!OWQ+\OB4.'*
MM0F9->#G4^T2()I+RZ?#?.Q8WY+J]_6I/P''WG6=9,%L#<4-QNJ##+2D$;*,
M=BN+8*)<WO,KF059(==N4MVW%QTP?'S'O\H>65)FX+J?WM7-$8Z5Y80PIDX8
M(-_U48(A#4(*$:46M'U(H*C0:39K4+QZI*UZ'4'L;X;XLT<YM0#)<7A.5 Q%
M8R%"8<J[MP^_419%'^BKW6-6?6"67U_":N]M6M?Y?;YN*BF\^>>^WG'("6,-
M7T5?DK+B^])7]S>\2U[32.]KQG>LTY\KZ%$[\MTHM+&#862%=CS@=: OU"IA
M?I3FUX1>@0?I@+[F$]PBVP&^6@389^RW_&YYP$<L^S;=YO_)-N AS5EQPV;#
M_*]8 <P^HD[;VJD>O)4K?&<<$F+9X-<8#7)YH_'IXX317B74=&-]/58.OK6#
M@GO7]$VXZ4; P<,+P.\FXL>+TI_3IAUCP3J3H.8?(,M(90O@H5S:HZLO/7*K
M,86)%<66'_BA3:( (VCW5B//%[H87I<MPZFJ5:CU*X7*&X 78'=&5<SP.CY3
MZ*94N]XO2JK5!5>&Y^7+II0W$N(GS])G$I87W[-ZM_K2_*=9+&@NFO%CC)TP
M@C8DU*).$C/-)(E+G,"!8236,$?QHPT+U &.W(5AJD2=EZ ).))3' EZSJ@+
MFU3\]:'\_C]:][BV.-W77%6<(U7YF( /1&0D4_-JQECPI9;1(G%FXR;?YLRG
M_TJWV^R%I,6_+LNTP,6F*ZE>AMV2[KTKVW$=XA,4A2B.8^BS*LMN(;@0!1A+
MO.VDV[3,LZ+TFE,'&+2( 8<,;K/J"7#@S0;$);_O@J_T-9>ZJ[QXJ3T> J<T
MY@R$Y'+J!Q%HR&=H^^GMRV&';Q$!D#B<,6<@U$YF: ^(V+$,2:).G<DPQ?<"
M#F08<ZV<8+PJ5K1-^]\(D=!+B&];L>4%/H0N@;T-5CD+7<>K]LD3UK,2S;L5
M69*L9K43I%[,2O6#U53+GFC:/8ZFA56R<MA/%;(*#$CK0-=Y-O9B%UF)!V//
M@]CR442]WHKMA(&2$@A^]H1:(-546IDK23TP0).Z(GS&D!E-.-E!>BQ9"],%
M6?2GE$&)!:$Y+OY76A7I[6-6I<_9?I>OZ\O=YJ]=31)@2)$%860G-DXL2&P;
M]?;""(N_H3;*BF&]:+&!8W 7@,-3F2&-HU-@/CH9DW*2LB 2)>:4DY&I-H$<
M0:K85/&<_Z?FA5HX6\ D4(\?I>[1I%C670XW:\+ @AY- I8=W"BD$8P#MS<4
M)TCHK;$1'S]A<7<I>X_R&-8D:SPSA*F7>2)<F2GU+L]<"ZR!MH45? H.G*KY
M5+D0/:^!OZ?YEF^==$=%#@=%_E8U1TS:8W-_8X4GWW7]FNU6E+@>A:X3AB2&
M;@0].[&&^I-0J3MT#9@WK#T<RO!"ZN'L8-H[\OM]6?W>_%3U.*&)D)P7KH5$
M0[+8?,_X\?&]!C'H(8,V;,U!D6G/B,AS>N;8B,$ +>,DB4D'R\D&NZ($LW%<
MOP+RI?BCZ \N<PS799TWKZ[\_WOVPUWS<@N_LIBIT;[*ONYYC7EU/_R5M<)6
M[/BNA["-0D0<B(.8-H!Q!)DC1$FJIX=I>N[_3DDNCJ2$-^8\^ >X@V# ?@&.
M? 0')R] ZV;3,ZK_8\4T,,.PD$P7RQX18]/*Q(/!;!;2'BJ1;#7?^%A85IN1
MB%/9;^[82!TLOWU,B]OLZ;FLTNKER]-SFE?-)*EYE><P::I/>[=B>3NBU/$3
MWW42B!#+W'B81F%?:&5D:DR&\U_CQN\[YL?ON]X1D ^>@/5C6CVTKTIIG.9,
M%E"Q9+;$6,IEKO:$/ \C&'P !R= Z\4%./+C IR=1<UPFGY\!,XDI*ECO(SL
M,[G7'YWBGYQUT;S"7R_(BCKEKXJ2E#U0ZPP_E?MBMW+YD6''P4E$(V1%<1*X
MPV(]=2W!:PO&VS%^:K?II<#R1KH%=RTR.24?0:&8-D_#G9S:'F,"'2@FIPVL
M:77S)#MGE' \H\O0-@U^E+K'FJS^U+N_9[O'<G.D@F\7GU8X)C"@H</,61BY
MEF/;PWDPSPZQ3-6JQZ+AFO3;\?OZQPOM:X8>/#7P03[@EQ4L+9R+BM?4=,L*
M6;W[O2/T56DX_]JY$'5G54XG]4M1/*T^O5,__8P)7MKWWO#5CX()QV/^?+@]
M:17%U,(46Q$,71^1R$G"80D>Q43\0@U=!@WK8/2AW(&R1PJ>!ZA2E]=I8ON\
M!,Y&M+P"@K^_5< +,* $U[.2+'5GX/1DJ]XBJ(%TT8L%A4@Y==9--Z<+./:F
MW:72X!B4GL\_Y;N^%2"_&I$5\EFQSK/ZL&I]Z/H7)@3:E+]K 5$2>!1%A+^
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M(W+81-'0E,:6'@@-R6RB@&C.9Z<"8RB3G29)-IEIH'O!^4R'=R(I31N+D@M
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MT;V &9PQU\H)AJMLYX$W5X!<G;@"9&7YD9N0"/HNFSF&Q++\,.GMQ[8KV69
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M.9-1K0F,6RIA4RQZ3<\FLS7EF- JP!#$88@"&GAID'HI\L;]N]BC:%(.)=*
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M-$V(S ORIM<9=BB=9ILJD]U73O_&J\?>WV3E+M^M2WX!<K.OV[JD07M#[.(
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MFGS[_N;G:G?[,W\MJT/R;K?>'O@-J$\AOEQ6#",WHF[@1RF!J1>E 0%C8AN
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MJ2(IF?*:)JGS(U@C=%_N\^W/1=X4>?\T6?\PS^ZV_6Z?I<'0]3,*"4 )\4!
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M_30-YN#E]'PR7ZGS\^)N'J.Y'X)7=#X]O/RD28])F)K-BK_B6>['?)DO:N^
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M=L<T&8#2P/"F4@%U>%^9A1A7%A&6)Q8S.RJ^!I#/^%(^EJ]W3?^1[/'L>-T
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M\)6-Q[%*OZ3!$T!/"X+'!,%S2ZVE" :%T<$,E$=/90 # ;C3U$O$"##<:/Y
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M(@,!2MD)FU^,^CWMA$>48FME^,=M8.E\%598'3I^F-RO5[U+)>X9DC%#&8!
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MU_B4U\#X[+T'4ULY'E<%_IE?3)Y\^'NL[HBT_NA(5P=_ F,/-54RMO[B7 $
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MDM=W#^W33 >&9IISK(51SC$NM:?.4_A@GMJD3?+T3P)Z8G/[F&SLG!M6LG5
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M,K7$,H52*L!'Z'OU )-$C@Z6K'-QL5:E0:E.IA?OYF9R.PV&YKXLG=='9$H
M&A.1$"4"",PM@]4[P! XL0JJ'A#3#6,'S/*ZN[F;Q3YY:T\PX#W(Z#J?+Z=?
M\W?S\^(FC[>7_)Z'C?OSY-O^M*\F,V52>D)Q8#"#)): ."4K[Q(S=F)%5GT
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MC8(_%Q_S\R+LJ[/\R<H_%]VIN#Z^+E-(!A]446>YT410A*0H.1L^2ZF&'&&
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MO&^$F^* 6JMKUA_%A8WK/+N-<EVZ;_GB?+H\<#O5@;$9X<99IZUV@7CJ3&!
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M]%>/'=?W)CX]/)8A&5R>L/=30#CV3 83MSHJ%C+IYMP17I[4N7Q?)#&U9NV
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M7.?UQF,[MC?[Y!,>CM2RF:'8"B_V*+_^!4AV2[)%LDGTC?1L=C.2IH'N.G4
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M4AYH8#3#T@LHN*]D503G+&,CC#SH<AEK$^?N@[$.>*[.ZR@P*J1!S (61ZC
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MZHP*I2AG<:['FG*( +(5CH2!7L-^!SY0;TRIS@[43U/&M>588(0(1J/1BRF
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M.6L\1<I:KIFF#D8*$M@H!FV$^#V%JR:B'.)'DPFO[T\)3@EMN9#:6 X-XYH
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MGM34%Y73;<%"3Y;%;:JZ&4?>%KN'':#14(ZP1<,Y^36.^^3/Z"U$DX8"3SC
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MJN<!*_'G6;'+3*3NR\5JE[5HKXR'0D9:>D70U&# '?*"0,,1E=;C&D'F<G8
MS6="N67JO/B2!+I4K@ZDD\'GRG?%6:=>L5G "A,)M>&0":(H31G,*TF!%#FQ
MX*?O/\MT0^1"N=<BRH.=_ Z<;;/;HUV++35>.$4ME%II%0WX32(H!*7#K%$N
M[[X//W)RD#TK$22X]8 YP9EGDE*N!:PD9Y#UFGEL#,>YC9G0^.#C3*A[&>C_
MN9XL(NJSQSK[HIVL)O^<3]:WT[A0#C;:?_ZN-_.[<G&_7;+K3&X-QOZ)/05@
M-&)&HI17DA/EN$3;E'# NKC%;[3W' "3)K-!LPZ"(8AXJ("#U$$D@(_#K$(
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MU?PA+KL_-N#9_N,E;K8_#G]\?@,@C[\,2@*LC>82^-0E4%GOV.."ZD>6OM:
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M6')4.5HIS[DDA2Y79KN5SB,2.^_1]EBIJTIY?E8@?5?J\Z6EVYL?#I*EZN&
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M1Q\NQ[ZO#5JTYW)D?++X'*R#T/J8 5++%7:$,I"RNIVU$E0\MB@GOL O^]7
MQ'>&N])S>CO:?%X,&HQWQ@*'0.2L4Y)*7<F=IT4I0TG$98\9G@1[K "R;EM\
MJ?#Q"E)<<JF\IDP)I!TB5FTKN" &L*]URFMIK:MZ5;MO]W?S'T7QN5A\CR;Z
MCD7_;CVY^+</-Y^*J_GM;/I_D=ZU5W+-A-^CM'5\YJ]]2UU;8P:G2-Q,%(18
M<$X0!4_X3"#.N8QT=$K>.:QT=6'Y<J4;B #/Y<Q\9$WS]2):2Y'ZG%<@&FO
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M.2YX;6Q02P$"% ,4    " "5@5I,4K? \DT;   --@$ $0
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M2P$"% ,4    " "5@5I,,._G'TK%   J)@H %0              @ %F100
K97AE;"TR,#$W,3(R.5]P<F4N>&UL4$L%!@     &  8 B@$  .,*!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
